{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# BS6201 Assignment 7\n",
    "\n",
    "Xinxin\n",
    "\n",
    "15-Jan-2021\n",
    "\n",
    "-----\n",
    "__Requirements:__\n",
    "- Find an API that gives you data\n",
    "- Tell a story that you find interesting and fun\n",
    "\n",
    "__Data API chosen:__ API to clinicaltrials.gov\n",
    "\n",
    "__Objective__: to understand the clinical trials related to COVID19 vaccines.\n",
    "\n",
    "Since Q4 2020, COVID vaccines developed by different companies with different mechanisms have been approved and launched. Since then, many countries have started to administer the vaccine to the general public. However, more daily cases have been reported in many parts of the world recently, due to the mutations in the virus as well as the colder weather. In this assignment, we would like to analyze the clinical trials related to COVID19 vaccines.\n",
    "\n",
    "The data was taken from clinicaltrials.gove, which is one of the most famous clinical trial website governed by the US National Institutes of Health.\n",
    "\n",
    "## 1. Inject the Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# retrieve data from clinicaltrials.gov for selected fields\n",
    "# return is the search result of expression = covid19 AND vaccine\n",
    "df_all = requests.get('https://clinicaltrials.gov/api/query/study_fields?expr=covid19+AND+vaccine&fields=NCTId%2CBriefTitle%2CCondition%2C+Keyword%2CStudyType%2C+Phase%2C+DesignPrimaryPurpose%2C+EnrollmentCount%2C+InterventionType%2C+InterventionName%2C+Gender%2C+StdAge%2C+LocationCountry%2COrgFullName%2C+OverallStatus%2C+StartDate%2C+CompletionDate%2C+IsFDARegulatedDrug%2C+ArmGroupType&min_rnk=1&max_rnk=500&fmt=json')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'StudyFieldsResponse': {'APIVrs': '1.01.02',\n",
       "  'DataVrs': '2021:01:14 22:30:16.698',\n",
       "  'Expression': 'covid19 AND vaccine',\n",
       "  'NStudiesAvail': 364122,\n",
       "  'NStudiesFound': 378,\n",
       "  'MinRank': 1,\n",
       "  'MaxRank': 500,\n",
       "  'NStudiesReturned': 378,\n",
       "  'FieldList': ['NCTId',\n",
       "   'BriefTitle',\n",
       "   'Condition',\n",
       "   'Keyword',\n",
       "   'StudyType',\n",
       "   'Phase',\n",
       "   'DesignPrimaryPurpose',\n",
       "   'EnrollmentCount',\n",
       "   'InterventionType',\n",
       "   'InterventionName',\n",
       "   'Gender',\n",
       "   'StdAge',\n",
       "   'LocationCountry',\n",
       "   'OrgFullName',\n",
       "   'OverallStatus',\n",
       "   'StartDate',\n",
       "   'CompletionDate',\n",
       "   'IsFDARegulatedDrug',\n",
       "   'ArmGroupType'],\n",
       "  'StudyFields': [{'Rank': 1,\n",
       "    'NCTId': ['NCT04568811'],\n",
       "    'BriefTitle': ['The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine'],\n",
       "    'Condition': ['Adenovirus Type-5 Vectored COVID-19 Vaccine'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['89'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Adenovirus Type-5 Vectored COVID-19 Vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Jiangsu Province Centers for Disease Control and Prevention'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['September 26, 2020'],\n",
       "    'CompletionDate': ['September 27, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 2,\n",
       "    'NCTId': ['NCT04497298'],\n",
       "    'BriefTitle': ['Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['SARS-CoV-2', 'Vaccine', 'Prevention'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['90'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Biological', 'Other'],\n",
       "    'InterventionName': ['Two COVID-19 vaccine candidate (TMV-083) administrations - Low dose',\n",
       "     'Two COVID-19 vaccine candidate (TMV-083) administrations - High dose',\n",
       "     'One COVID-19 vaccine candidate (TMV-083) administration - High dose',\n",
       "     'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Belgium', 'France'],\n",
       "    'OrgFullName': ['Institut Pasteur'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 10, 2020'],\n",
       "    'CompletionDate': ['October 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 3,\n",
       "    'NCTId': ['NCT04651790'],\n",
       "    'BriefTitle': ['Efficacy, Safety, and Immunogenicity of an Inactivated Vaccine Against COVID-19 in High Infection Risk Adults'],\n",
       "    'Condition': ['Covid19', 'Vaccines'],\n",
       "    'Keyword': ['Clinical trials', 'Covid19', 'Inactivated vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['2300'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['SARS-CoV-2 inactivated vaccine', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Chile'],\n",
       "    'OrgFullName': ['Pontificia Universidad Catolica de Chile'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 27, 2020'],\n",
       "    'CompletionDate': ['March 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Placebo Comparator']},\n",
       "   {'Rank': 4,\n",
       "    'NCTId': ['NCT04659941'],\n",
       "    'BriefTitle': ['Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers'],\n",
       "    'Condition': ['COVID 19 Vaccine'],\n",
       "    'Keyword': ['COVID 19', 'BCG vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1000'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['BCG vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Brazil'],\n",
       "    'OrgFullName': ['Universidade Federal do Rio de Janeiro'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 1, 2020'],\n",
       "    'CompletionDate': ['October 1, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 5,\n",
       "    'NCTId': ['NCT04510207'],\n",
       "    'BriefTitle': ['A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['SARS-CoV-2', 'SARS-CoV-2 Vaccine', 'Coronavirus'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['45000'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Biological'],\n",
       "    'InterventionName': ['Inactivated SARS-CoV-2 Vaccine (Vero cell)',\n",
       "     'Inactivated SARS-CoV-2 Vaccine (Vero cell)',\n",
       "     'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Bahrain',\n",
       "     'Egypt',\n",
       "     'Egypt',\n",
       "     'Jordan',\n",
       "     'United Arab Emirates',\n",
       "     'United Arab Emirates'],\n",
       "    'OrgFullName': ['China National Biotec Group Company Limited'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['July 16, 2020'],\n",
       "    'CompletionDate': ['September 16, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 6,\n",
       "    'NCTId': ['NCT04560881'],\n",
       "    'BriefTitle': ['Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)'],\n",
       "    'Condition': ['COVID-19 Virus Infection'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'SARS-CoV-2 infection',\n",
       "     'Inactivated SARS-CoV-2 Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['3000'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Inactivated SARS-CoV-2 vaccine (Vero cell)',\n",
       "     'Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Argentina', 'Argentina', 'Argentina', 'Argentina'],\n",
       "    'OrgFullName': ['Laboratorio Elea Phoenix S.A.'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['September 16, 2020'],\n",
       "    'CompletionDate': ['December 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 7,\n",
       "    'NCTId': ['NCT04657263'],\n",
       "    'BriefTitle': ['Impact of the COVID-19 Pandemic on Vaccination'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['People over 18 years old',\n",
       "     'vaccines',\n",
       "     'immunization schedule',\n",
       "     'Infection'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['500'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Vaccine coverage assessment'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['University Hospital, Montpellier'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 1, 2020'],\n",
       "    'CompletionDate': ['May 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 8,\n",
       "    'NCTId': ['NCT04691947'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC'],\n",
       "    'Condition': ['COVID-19 Vaccine'],\n",
       "    'Keyword': ['COVID-19', 'Inactive Vaccine', 'Phase I'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['44'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['ERUCOV-VAC', 'Placebo Vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Turkey'],\n",
       "    'OrgFullName': ['Health Institutes of Turkey'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 5, 2020'],\n",
       "    'CompletionDate': ['March 15, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 9,\n",
       "    'NCTId': ['NCT04706143'],\n",
       "    'BriefTitle': ['Immunologic Responses to Single and Double Doses of COVID-19 Vaccines in Egyptians'],\n",
       "    'Condition': ['COVID-19 Vaccines'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Safety',\n",
       "     'Efficacy',\n",
       "     'T cell responses',\n",
       "     'Cytokine responses',\n",
       "     'Antibody responses'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['COVID-19 Vaccines'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Assiut University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 15, 2021'],\n",
       "    'CompletionDate': ['August 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 10,\n",
       "    'NCTId': ['NCT04706156'],\n",
       "    'BriefTitle': ['Oral Side Effects of COVID-19 Vaccine'],\n",
       "    'Condition': ['Oral Manifestations',\n",
       "     'Covid19',\n",
       "     'Vaccine Adverse Reaction'],\n",
       "    'Keyword': ['COVID19', 'Oral Manifestations', 'Vaccine Adverse Reaction'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['1540'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['COVID-19 Vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Masaryk University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 27, 2021'],\n",
       "    'CompletionDate': ['March 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 11,\n",
       "    'NCTId': ['NCT04695652'],\n",
       "    'BriefTitle': ['A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult'],\n",
       "    'Condition': ['Covid19 Vaccine'],\n",
       "    'Keyword': ['Covid19 vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['3700'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['MVC-COV1901(S protein with adjuvant)',\n",
       "     'MVC-COV1901(Saline)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Taiwan',\n",
       "     'Taiwan',\n",
       "     'Taiwan',\n",
       "     'Taiwan',\n",
       "     'Taiwan',\n",
       "     'Taiwan',\n",
       "     'Taiwan',\n",
       "     'Taiwan',\n",
       "     'Taiwan',\n",
       "     'Taiwan',\n",
       "     'Taiwan',\n",
       "     'Vietnam'],\n",
       "    'OrgFullName': ['Medigen Vaccine Biologics Corp.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 30, 2020'],\n",
       "    'CompletionDate': ['June 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 12,\n",
       "    'NCTId': ['NCT04582344'],\n",
       "    'BriefTitle': ['Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19, SARS-CoV-2 Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['13000'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['CoronaVac', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey'],\n",
       "    'OrgFullName': ['Health Institutes of Turkey'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 14, 2020'],\n",
       "    'CompletionDate': ['April 15, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 13,\n",
       "    'NCTId': ['NCT04456595'],\n",
       "    'BriefTitle': [\"Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals\"],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['13060'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Adsorbed COVID-19 (inactivated) Vaccine', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil'],\n",
       "    'OrgFullName': ['Butantan Institute'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['July 21, 2020'],\n",
       "    'CompletionDate': ['October 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 14,\n",
       "    'NCTId': ['NCT04508075'],\n",
       "    'BriefTitle': ['Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine'],\n",
       "    'Condition': ['SARS-CoV2 Infection'],\n",
       "    'Keyword': ['vaccine', 'SARS-CoV-2', 'infection'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1620'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['SARS-CoV-2 vaccine (inactivated)', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Indonesia'],\n",
       "    'OrgFullName': ['PT Bio Farma'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 10, 2020'],\n",
       "    'CompletionDate': ['September 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 15,\n",
       "    'NCTId': ['NCT04691908'],\n",
       "    'BriefTitle': ['Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine'],\n",
       "    'Condition': ['Covid19', 'SARS-CoV Infection', 'Vaccine Adverse Reaction'],\n",
       "    'Keyword': ['QazCovid-in®, vaccine, III phase, efficiency, safety, immunogenicity'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['3000'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['QazCovid-in®-vaccine against COVID-19', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Kazakhstan'],\n",
       "    'OrgFullName': ['Research Institute for Biological Safety Problems'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['December 25, 2020'],\n",
       "    'CompletionDate': ['July 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Placebo Comparator']},\n",
       "   {'Rank': 16,\n",
       "    'NCTId': ['NCT04357028'],\n",
       "    'BriefTitle': ['Measles Vaccine in HCW'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['MMR vaccine, Respiratory failure,'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['Measles-Mumps-Rubella Vaccine', 'Placebos'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Egypt'],\n",
       "    'OrgFullName': ['Kasr El Aini Hospital'],\n",
       "    'OverallStatus': ['Suspended'],\n",
       "    'StartDate': ['July 13, 2020'],\n",
       "    'CompletionDate': ['January 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 17,\n",
       "    'NCTId': ['NCT04618796'],\n",
       "    'BriefTitle': ['Effect of COVID-19 Pandemic on Vaccination Compliance'],\n",
       "    'Condition': ['Vaccine Refusal'],\n",
       "    'Keyword': ['Covid19'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Assiut University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['April 1, 2021'],\n",
       "    'CompletionDate': ['May 1, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 18,\n",
       "    'NCTId': ['NCT04453852'],\n",
       "    'BriefTitle': ['Monovalent Recombinant COVID19 Vaccine'],\n",
       "    'Condition': ['Coronavirus Infection', 'COVID'],\n",
       "    'Keyword': ['COVID19', 'coronavirus', 'vaccine', 'adjuvant'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['40'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['COVID19 vaccine', 'Saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Australia'],\n",
       "    'OrgFullName': ['Vaxine Pty Ltd'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 30, 2020'],\n",
       "    'CompletionDate': ['July 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 19,\n",
       "    'NCTId': ['NCT04706390'],\n",
       "    'BriefTitle': ['Comparison of the Immune Response to Natural COVID-19 Infection and Vaccination'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['Covid19', 'Vaccine', 'SARS-CoV-2 antibody'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['2500'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['covid-19 vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Norway'],\n",
       "    'OrgFullName': ['University of Bergen'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['January 12, 2021'],\n",
       "    'CompletionDate': ['January 12, 2024'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 20,\n",
       "    'NCTId': ['NCT04659239'],\n",
       "    'BriefTitle': ['The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['34020'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Inactivated SARS-CoV-2 Vaccine (Vero cell)',\n",
       "     'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Brazil', 'Malaysia'],\n",
       "    'OrgFullName': ['Chinese Academy of Medical Sciences'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 2020'],\n",
       "    'CompletionDate': ['March 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 21,\n",
       "    'NCTId': ['NCT04546841'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults'],\n",
       "    'Condition': ['COVID-19 Vaccine'],\n",
       "    'Keyword': ['COVID-19 vaccine', 'COVID-19 infection', 'preemptive'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['36'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['multipeptide cocktail'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Germany'],\n",
       "    'OrgFullName': ['University Hospital Tuebingen'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 27, 2020'],\n",
       "    'CompletionDate': ['December 20, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 22,\n",
       "    'NCTId': ['NCT04414267'],\n",
       "    'BriefTitle': ['Bacillus Calmette-guérin Vaccination to Prevent COVID-19'],\n",
       "    'Condition': ['COVID-19',\n",
       "     'Virus Diseases',\n",
       "     'Corona Virus Infection',\n",
       "     'Coronary Heart Disease',\n",
       "     'Chronic Obstructive Pulmonary Disease'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'SARS-CoV-2',\n",
       "     'Vaccination',\n",
       "     'Bacillus Calmette-Guérin vaccination'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 4'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['900'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['BCG vaccine', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Greece',\n",
       "     'Greece',\n",
       "     'Greece',\n",
       "     'Greece',\n",
       "     'Greece',\n",
       "     'Greece',\n",
       "     'Greece',\n",
       "     'Greece',\n",
       "     'Greece',\n",
       "     'Greece',\n",
       "     'Greece',\n",
       "     'Greece',\n",
       "     'Greece',\n",
       "     'Greece',\n",
       "     'Greece'],\n",
       "    'OrgFullName': ['Hellenic Institute for the Study of Sepsis'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 26, 2020'],\n",
       "    'CompletionDate': ['May 25, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 23,\n",
       "    'NCTId': ['NCT04428073'],\n",
       "    'BriefTitle': ['Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection'],\n",
       "    'Condition': ['COVID'],\n",
       "    'Keyword': ['SARS-CoV-2', 'COVID-19', 'therapeutic vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['32'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Covax-19™'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['GeneCure Biotechnologies'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['July 2020'],\n",
       "    'CompletionDate': ['December 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 24,\n",
       "    'NCTId': ['NCT04632537'],\n",
       "    'BriefTitle': ['BCG Vaccination to Prevent COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19', 'BCG', 'vaccine', 'clinical trial'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['550'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine',\n",
       "     'Preservative-free saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States', 'United States', 'United States'],\n",
       "    'OrgFullName': ['Henry M. Jackson Foundation for the Advancement of Military Medicine'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 7, 2020'],\n",
       "    'CompletionDate': ['April 2023'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Placebo Comparator']},\n",
       "   {'Rank': 25,\n",
       "    'NCTId': ['NCT04639375'],\n",
       "    'BriefTitle': ['Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)'],\n",
       "    'Condition': ['SARS-CoV-2'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 4'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['25'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Vaccinated with polio vaccine (IPV)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['E-MO Biology Inc'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 15, 2020'],\n",
       "    'CompletionDate': ['January 15, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 26,\n",
       "    'NCTId': ['NCT04527575'],\n",
       "    'BriefTitle': ['Study of the Safety, Reactogenicity and Immunogenicity of \"EpiVacCorona\" Vaccine for the Prevention of COVID-19'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['Covid19', 'SARS-CoV-2', 'EpiVacCorona', 'vaccination'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)',\n",
       "     'Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Russian Federation'],\n",
       "    'OrgFullName': ['Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['July 27, 2020'],\n",
       "    'CompletionDate': ['October 4, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 27,\n",
       "    'NCTId': ['NCT04706403'],\n",
       "    'BriefTitle': ['Views on COVID-19 and Vaccination'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['Covid-19', 'Vaccination'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['3000'],\n",
       "    'InterventionType': ['Behavioral'],\n",
       "    'InterventionName': [\"Healthcare Providers' Communication about the COVID-19 Vaccine\"],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['University of Massachusetts, Worcester'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 2021'],\n",
       "    'CompletionDate': ['December 26, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'No Intervention']},\n",
       "   {'Rank': 28,\n",
       "    'NCTId': ['NCT04612972'],\n",
       "    'BriefTitle': ['Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Adult Population In Peru'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['6000'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Inactivated SARS CoV 2 vaccine (Vero cell). Wuhan'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Peru'],\n",
       "    'OrgFullName': ['Universidad Peruana Cayetano Heredia'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 10, 2020'],\n",
       "    'CompletionDate': ['September 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 29,\n",
       "    'NCTId': ['NCT04705116'],\n",
       "    'BriefTitle': ['COVID-19 Vaccines International Pregnancy Exposure Registry'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['5000'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['COVID-19 vaccine'],\n",
       "    'Gender': ['Female'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Pregistry'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 15, 2021'],\n",
       "    'CompletionDate': ['December 31, 2025'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 30,\n",
       "    'NCTId': ['NCT04299724'],\n",
       "    'BriefTitle': ['Safety and Immunity of Covid-19 aAPC Vaccine'],\n",
       "    'Condition': ['Treat and Prevent Covid-19 Infection'],\n",
       "    'Keyword': ['Lentiviral vector, Covid-19/aAPC vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Pathogen-specific aAPC'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Shenzhen Geno-Immune Medical Institute'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['February 15, 2020'],\n",
       "    'CompletionDate': ['December 31, 2024'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 31,\n",
       "    'NCTId': ['NCT04709003'],\n",
       "    'BriefTitle': ['Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI)'],\n",
       "    'Condition': ['Covid19',\n",
       "     'Corona Virus Infection',\n",
       "     'Vaccine Effectiveness'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['4504'],\n",
       "    'InterventionType': ['Diagnostic Test', 'Diagnostic Test'],\n",
       "    'InterventionName': ['Serologic test', 'Respiratory swabs'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Israel',\n",
       "     'Israel',\n",
       "     'Israel',\n",
       "     'Israel',\n",
       "     'Israel',\n",
       "     'Israel'],\n",
       "    'OrgFullName': ['Clalit Health Services'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 23, 2020'],\n",
       "    'CompletionDate': ['June 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 32,\n",
       "    'NCTId': ['NCT04475302'],\n",
       "    'BriefTitle': ['BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots'],\n",
       "    'Condition': ['COVID'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['2175'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['BCG vaccine (Freeze-dried)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['India'],\n",
       "    'OrgFullName': ['Tuberculosis Research Centre, India'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['July 1, 2020'],\n",
       "    'CompletionDate': ['May 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 33,\n",
       "    'NCTId': ['NCT04350931'],\n",
       "    'BriefTitle': ['Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19'],\n",
       "    'Condition': ['Coronavirus Disease (COVID-19)'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['900'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['intradermal injection of BCG Vaccine', 'placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Egypt'],\n",
       "    'OrgFullName': ['Ain Shams University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['April 20, 2020'],\n",
       "    'CompletionDate': ['December 1, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Placebo Comparator']},\n",
       "   {'Rank': 34,\n",
       "    'NCTId': ['NCT04530357'],\n",
       "    'BriefTitle': ['Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine'],\n",
       "    'Condition': ['Covid19', 'SARS-CoV Infection', 'Vaccine Adverse Reaction'],\n",
       "    'Keyword': ['vaccine, I/II phase, safety, immunogenicity, QazCovid-in®'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['244'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['QazCovid-in® - COVID-19 inactivated vaccine',\n",
       "     'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Kazakhstan'],\n",
       "    'OrgFullName': ['Research Institute for Biological Safety Problems'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['September 19, 2020'],\n",
       "    'CompletionDate': ['November 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 35,\n",
       "    'NCTId': ['NCT04460703'],\n",
       "    'BriefTitle': ['COVID-19 Vaccine Messaging, Part 1'],\n",
       "    'Condition': ['Vaccination', 'COVID-19'],\n",
       "    'Keyword': ['messaging'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Other'],\n",
       "    'EnrollmentCount': ['4000'],\n",
       "    'InterventionType': ['Other',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Other'],\n",
       "    'InterventionName': ['Control message',\n",
       "     'Baseline message',\n",
       "     'Personal freedom message',\n",
       "     'Economic freedom message',\n",
       "     'Self-interest message',\n",
       "     'Community interest message',\n",
       "     'Economic benefit message',\n",
       "     'Guilt message',\n",
       "     'Embarrassment message',\n",
       "     'Anger message',\n",
       "     'Trust in science message',\n",
       "     'Not bravery message'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Yale University'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['July 3, 2020'],\n",
       "    'CompletionDate': ['July 8, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Sham Comparator',\n",
       "     'Active Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 36,\n",
       "    'NCTId': ['NCT04583995'],\n",
       "    'BriefTitle': ['A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom'],\n",
       "    'Condition': ['SARS-CoV-2 Infection', 'COVID-19'],\n",
       "    'Keyword': ['Coronavirus'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['15000'],\n",
       "    'InterventionType': ['Biological', 'Other', 'Biological'],\n",
       "    'InterventionName': ['SARS-CoV-2 rS/Matrix M1-Adjuvant',\n",
       "     'Placebo',\n",
       "     'Licensed seasonal influenza vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom'],\n",
       "    'OrgFullName': ['Novavax'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 28, 2020'],\n",
       "    'CompletionDate': ['January 14, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 37,\n",
       "    'NCTId': ['NCT04564716'],\n",
       "    'BriefTitle': ['Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'vector vaccine',\n",
       "     'SARS-CoV-2',\n",
       "     'adenoviral vector'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['Gam-COVID-Vac', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Belarus',\n",
       "     'Belarus',\n",
       "     'Belarus',\n",
       "     'Belarus',\n",
       "     'Belarus',\n",
       "     'Belarus',\n",
       "     'Belarus',\n",
       "     'Belarus'],\n",
       "    'OrgFullName': ['Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['September 28, 2020'],\n",
       "    'CompletionDate': ['April 10, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 38,\n",
       "    'NCTId': ['NCT04369794'],\n",
       "    'BriefTitle': ['COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement'],\n",
       "    'Condition': ['COVID-19',\n",
       "     'Therapeutic Vaccine',\n",
       "     'BCG',\n",
       "     'SARS-CoV 2',\n",
       "     'Transmission'],\n",
       "    'Keyword': ['BCG',\n",
       "     'Therapeutic Vaccine',\n",
       "     'COVID-19',\n",
       "     'SARS-CoV 2',\n",
       "     'Interferon Gamma',\n",
       "     'Immunoglobulin',\n",
       "     'Immunemodulation',\n",
       "     'Transmission'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 4'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['1000'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['BCG', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Brazil'],\n",
       "    'OrgFullName': ['University of Campinas, Brazil'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 10, 2020'],\n",
       "    'CompletionDate': ['August 2023'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Placebo Comparator']},\n",
       "   {'Rank': 39,\n",
       "    'NCTId': ['NCT04656613'],\n",
       "    'BriefTitle': ['A Phase III Clinical Trial of the Immunogenicity and Safety of the Gam-COVID-Vac Vaccine Against COVID-19 in the UAE'],\n",
       "    'Condition': ['Covid19', 'SARS-CoV Infection'],\n",
       "    'Keyword': ['vector',\n",
       "     'covid-19',\n",
       "     'adenoviral vector vaccine',\n",
       "     'Sputnik V'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1000'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['Gam-COVID-Vac', 'placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 2020'],\n",
       "    'CompletionDate': ['December 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 40,\n",
       "    'NCTId': ['NCT04551547'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['552'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Other'],\n",
       "    'InterventionName': ['Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28',\n",
       "     'Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28',\n",
       "     'Two doses of placebo at the schedule of day 0,28'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Sinovac Biotech Co., Ltd'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 31, 2020'],\n",
       "    'CompletionDate': ['September 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 41,\n",
       "    'NCTId': ['NCT04636333'],\n",
       "    'BriefTitle': ['Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Safety',\n",
       "     'Tolerability',\n",
       "     'Immunogenicity',\n",
       "     'SARS-CoV-2 Vaccine',\n",
       "     'Recombinant vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['216'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14',\n",
       "     'Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28',\n",
       "     'Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14',\n",
       "     'Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28',\n",
       "     'Two doses of placebo at the schedule of day 0, 14 #middle-dose group#',\n",
       "     'Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#',\n",
       "     'Two doses of placebo at the schedule of day 0, 14 #High-dose group#',\n",
       "     'Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Jiangsu Province Centers for Disease Control and Prevention'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 30, 2020'],\n",
       "    'CompletionDate': ['January 7, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 42,\n",
       "    'NCTId': ['NCT04530396'],\n",
       "    'BriefTitle': ['Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19'],\n",
       "    'Condition': ['Covid19 Prevention'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'vector vaccine',\n",
       "     'SARS-CoV-2',\n",
       "     'adenoviral vector'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['40000'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['Gam-COVID-Vac', 'placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation'],\n",
       "    'OrgFullName': ['Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 7, 2020'],\n",
       "    'CompletionDate': ['May 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 43,\n",
       "    'NCTId': ['NCT04470609'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['471'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule',\n",
       "     'Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule',\n",
       "     'High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule',\n",
       "     'Placebo on a 0- and 28-day schedule'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Chinese Academy of Medical Sciences'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['July 10, 2020'],\n",
       "    'CompletionDate': ['November 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 44,\n",
       "    'NCTId': ['NCT04530656'],\n",
       "    'BriefTitle': ['Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Safety',\n",
       "     'Tolerability',\n",
       "     'Immunogenicity',\n",
       "     'SARS-CoV-2 Vaccine',\n",
       "     'Recombinant vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['168'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28',\n",
       "     'Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28',\n",
       "     'Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28',\n",
       "     'Two doses of placebo at the schedule of day 0, 28（middle-dose group）',\n",
       "     'Two doses of placebo at the schedule of day 0, 28（high-dose group）',\n",
       "     'Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Jiangsu Province Centers for Disease Control and Prevention'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['August 28, 2020'],\n",
       "    'CompletionDate': ['August 28, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 45,\n",
       "    'NCTId': ['NCT04445389'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults'],\n",
       "    'Condition': ['SARS-CoV-2'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['210'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['GX-19', 'Saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Korea, Republic of'],\n",
       "    'OrgFullName': ['Genexine, Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 17, 2020'],\n",
       "    'CompletionDate': ['June 17, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 46,\n",
       "    'NCTId': ['NCT04495933'],\n",
       "    'BriefTitle': ['A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults'],\n",
       "    'Condition': ['SARS-CoV2', 'Covid19'],\n",
       "    'Keyword': ['SARS-CoV-2 infection'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['216'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Biological', 'Other'],\n",
       "    'InterventionName': ['MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg',\n",
       "     'MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg',\n",
       "     'MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg',\n",
       "     'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Australia'],\n",
       "    'OrgFullName': ['The University of Queensland'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['July 13, 2020'],\n",
       "    'CompletionDate': ['September 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 47,\n",
       "    'NCTId': ['NCT04436471'],\n",
       "    'BriefTitle': ['An Open Study of the Safety, Tolerability and Immunogenicity of the Drug \"Gam-COVID-Vac\" Vaccine Against COVID-19'],\n",
       "    'Condition': ['Preventive Immunization COVID-19'],\n",
       "    'Keyword': ['COVID-19', 'SARS-CoV-2', 'vector vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['38'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Gam-COVID-Vac'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Russian Federation'],\n",
       "    'OrgFullName': ['Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['June 17, 2020'],\n",
       "    'CompletionDate': ['August 10, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 48,\n",
       "    'NCTId': ['NCT04327206'],\n",
       "    'BriefTitle': ['BCG Vaccination to Protect Healthcare Workers Against COVID-19'],\n",
       "    'Condition': ['Coronavirus Disease 2019 (COVID-19)',\n",
       "     'Respiratory Illness',\n",
       "     'Corona Virus Infection',\n",
       "     'COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['10078'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['BCG Vaccine', '0.9%NaCl'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom'],\n",
       "    'OrgFullName': ['Murdoch Childrens Research Institute'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['March 30, 2020'],\n",
       "    'CompletionDate': ['March 30, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 49,\n",
       "    'NCTId': ['NCT04461379'],\n",
       "    'BriefTitle': ['Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers'],\n",
       "    'Condition': ['BCG', 'COVID-19', 'SARS-CoV2', 'Corona Virus Infection'],\n",
       "    'Keyword': ['Healthcare workers'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['908'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['BCG vaccine', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Mexico'],\n",
       "    'OrgFullName': ['Hospital Universitario Dr. Jose E. Gonzalez'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['July 21, 2020'],\n",
       "    'CompletionDate': ['January 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 50,\n",
       "    'NCTId': ['NCT04642339'],\n",
       "    'BriefTitle': ['Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['vaccine',\n",
       "     'COVID-19',\n",
       "     'adenoviral vector',\n",
       "     'SARS-CoV-2',\n",
       "     'Ad26',\n",
       "     'Ad5',\n",
       "     'Heterologous prime-boost vaccination'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['2000'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Gam-COVID-Vac', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['November 2020'],\n",
       "    'CompletionDate': ['December 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 51,\n",
       "    'NCTId': ['NCT04664309'],\n",
       "    'BriefTitle': ['Understanding Immunity to the COVID-19 Vaccines'],\n",
       "    'Condition': ['COVID-19', 'Immunity', 'Vaccine'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['1000'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['No intervention'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Stanford University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 2021'],\n",
       "    'CompletionDate': ['January 2023'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 52,\n",
       "    'NCTId': ['NCT04542395'],\n",
       "    'BriefTitle': ['COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents'],\n",
       "    'Condition': ['Coronavirus'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Supportive Care'],\n",
       "    'EnrollmentCount': ['310'],\n",
       "    'InterventionType': ['Behavioral'],\n",
       "    'InterventionName': ['Increasing Willingness and Uptake of COVID-19 Testing and Vaccination'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Charles Drew University of Medicine and Science'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 1, 2020'],\n",
       "    'CompletionDate': ['November 30, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 53,\n",
       "    'NCTId': ['NCT04450004'],\n",
       "    'BriefTitle': ['Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.'],\n",
       "    'Condition': ['SARS-CoV 2'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['180'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Intramuscular Vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Canada', 'Canada'],\n",
       "    'OrgFullName': ['Medicago'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['July 10, 2020'],\n",
       "    'CompletionDate': ['December 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 54,\n",
       "    'NCTId': ['NCT04383574'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['422'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Biological', 'Other'],\n",
       "    'InterventionName': ['Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28',\n",
       "     'Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28',\n",
       "     'Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28',\n",
       "     'Two doses of placebo at the schedule of day 0,28'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Sinovac Biotech Co., Ltd'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['May 22, 2020'],\n",
       "    'CompletionDate': ['May 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 55,\n",
       "    'NCTId': ['NCT04400838'],\n",
       "    'BriefTitle': ['Investigating a Vaccine Against COVID-19'],\n",
       "    'Condition': ['Coronavirus'],\n",
       "    'Keyword': ['Covid-19', 'ChAdOx1 nCov19', 'sars-cov-2', 'vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['12390'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['ChAdOx1 nCoV-19 (Abs 260)',\n",
       "     'MenACWY vaccine',\n",
       "     'ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost',\n",
       "     'Two dose MenACWY vaccine',\n",
       "     'ChAdOx1 nCoV-19 (qPCR)',\n",
       "     'ChAdOx1 nCoV-19 0.5mL prime plus boost',\n",
       "     'Two dose MenACWY vaccine min. 4 weeks apart',\n",
       "     'Two dose ChAdOx1 nCoV-19/Covishield 0.5mL',\n",
       "     'Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom'],\n",
       "    'OrgFullName': ['University of Oxford'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 28, 2020'],\n",
       "    'CompletionDate': ['September 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator']},\n",
       "   {'Rank': 56,\n",
       "    'NCTId': ['NCT04665258'],\n",
       "    'BriefTitle': ['COVID-19 Vaccine and Impact on Fertility Study'],\n",
       "    'Condition': ['Infertility, Male'],\n",
       "    'Keyword': ['COVID-19 Vaccine'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['60'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['Male'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['University of Miami'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 14, 2020'],\n",
       "    'CompletionDate': ['June 14, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 57,\n",
       "    'NCTId': ['NCT04703790'],\n",
       "    'BriefTitle': ['Acceptability of SARS-CoV-2 Vaccine'],\n",
       "    'Condition': ['Covid19', 'Vaccine Acceptability'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['1200'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Columbia University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['February 2021'],\n",
       "    'CompletionDate': ['August 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 58,\n",
       "    'NCTId': ['NCT04362124'],\n",
       "    'BriefTitle': ['Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of COVID-19 Infection.'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['coronavirus', 'BCG', 'COVID-19', 'SARS-COV-2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Supportive Care'],\n",
       "    'EnrollmentCount': ['0'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['vaccine BCG', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Colombia'],\n",
       "    'OrgFullName': ['Universidad de Antioquia'],\n",
       "    'OverallStatus': ['Withdrawn'],\n",
       "    'StartDate': ['August 2020'],\n",
       "    'CompletionDate': ['November 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 59,\n",
       "    'NCTId': ['NCT04324606'],\n",
       "    'BriefTitle': ['A Study of a Candidate COVID-19 Vaccine (COV001)'],\n",
       "    'Condition': ['Coronavirus'],\n",
       "    'Keyword': ['COVID-19, Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['1090'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Drug',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['ChAdOx1 nCoV-19',\n",
       "     'MenACWY',\n",
       "     'ChAdOx1 nCoV-19 full boost',\n",
       "     'ChAdOx1 nCoV-19 half boost',\n",
       "     'MenACWY boost',\n",
       "     'Paracetamol',\n",
       "     'ChAdOx1 nCoV-19 0.5mL boost'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom'],\n",
       "    'OrgFullName': ['University of Oxford'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['April 23, 2020'],\n",
       "    'CompletionDate': ['October 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Active Comparator',\n",
       "     'Experimental',\n",
       "     'Active Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Active Comparator',\n",
       "     'Experimental',\n",
       "     'Active Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Active Comparator',\n",
       "     'Experimental',\n",
       "     'Active Comparator']},\n",
       "   {'Rank': 60,\n",
       "    'NCTId': ['NCT04640402'],\n",
       "    'BriefTitle': ['A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Safety',\n",
       "     'Immunogenicity',\n",
       "     'COVID-19 Vaccine',\n",
       "     'Recombinant vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['960'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen',\n",
       "     'Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen',\n",
       "     'High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen',\n",
       "     'High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen',\n",
       "     'Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen',\n",
       "     'Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen',\n",
       "     'High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen',\n",
       "     'High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen',\n",
       "     'Low-dose placebo (18-59 years) & Two dose regimen',\n",
       "     'Low-dose placebo (18-59 years) & Three dose regimen',\n",
       "     'High-dose placebo (18-59 years) & Two dose regimen',\n",
       "     'High-dose placebo (18-59 years) & Three dose regimen',\n",
       "     'Low-dose placebo (60-85 years) & Two dose regimen',\n",
       "     'Low-dose placebo (60-85 years) & Three dose regimen',\n",
       "     'High-dose placebo (60-85 years) & Two dose regimen',\n",
       "     'High-dose placebo (60-85 years) & Three dose regimen'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Jiangsu Province Centers for Disease Control and Prevention'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 17, 2020'],\n",
       "    'CompletionDate': ['November 18, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 61,\n",
       "    'NCTId': ['NCT04437875'],\n",
       "    'BriefTitle': ['An Open Study of the Safety, Tolerability and Immunogenicity of \"Gam-COVID-Vac Lyo\" Vaccine Against COVID-19'],\n",
       "    'Condition': ['Preventive Immunization COVID-19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'SARS-CoV-2',\n",
       "     'vector vaccine',\n",
       "     'adenovirus vector'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['38'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Gam-COVID-Vac Lyo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Russian Federation'],\n",
       "    'OrgFullName': ['Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['June 17, 2020'],\n",
       "    'CompletionDate': ['August 10, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 62,\n",
       "    'NCTId': ['NCT04473690'],\n",
       "    'BriefTitle': ['KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['Vaccine', 'Covid19 Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['180'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Biological'],\n",
       "    'InterventionName': ['Low Dose of KBP-COVID-19',\n",
       "     'High Dose of KBP-COVID-19',\n",
       "     'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Kentucky BioProcessing, Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 30, 2020'],\n",
       "    'CompletionDate': ['March 23, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 63,\n",
       "    'NCTId': ['NCT04276896'],\n",
       "    'BriefTitle': ['Immunity and Safety of Covid-19 Synthetic Minigene Vaccine'],\n",
       "    'Condition': ['Pathogen Infection Covid-19 Infection'],\n",
       "    'Keyword': ['Lentiviral vector', 'LV-DC vaccine', 'Covid-19 CTL'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China', 'China', 'China'],\n",
       "    'OrgFullName': ['Shenzhen Geno-Immune Medical Institute'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['March 24, 2020'],\n",
       "    'CompletionDate': ['December 31, 2024'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 64,\n",
       "    'NCTId': ['NCT04537130'],\n",
       "    'BriefTitle': ['Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge'],\n",
       "    'Condition': ['Pulmonary Fibrosis', 'Covid19'],\n",
       "    'Keyword': ['EGF',\n",
       "     'Fibrosis secondary to Covid19 infection',\n",
       "     'IN01 vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['40'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['IN01 vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Spain'],\n",
       "    'OrgFullName': ['Instituto Oncológico Dr Rosell'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 1, 2020'],\n",
       "    'CompletionDate': ['June 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 65,\n",
       "    'NCTId': ['NCT04694651'],\n",
       "    'BriefTitle': ['Potential Acceptance of COVID-19 Vaccines in Healthcare Workers in Egypt'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Healthcare workers',\n",
       "     'COVID-19 vaccines',\n",
       "     'Vaccine',\n",
       "     'Acceptance'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['400'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Egypt', 'Egypt'],\n",
       "    'OrgFullName': ['Assiut University'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 15, 2020'],\n",
       "    'CompletionDate': ['February 15, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 66,\n",
       "    'NCTId': ['NCT04534803'],\n",
       "    'BriefTitle': ['BCG Against Covid-19 for Prevention and Amelioration of Severity Trial (BAC to the PAST)'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['2100'],\n",
       "    'InterventionType': ['Drug', 'Other'],\n",
       "    'InterventionName': ['BCG Vaccine', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Harvard Medical School'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['September 2020'],\n",
       "    'CompletionDate': ['November 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 67,\n",
       "    'NCTId': ['NCT04587219'],\n",
       "    'BriefTitle': ['The Study of \"Gam-COVID-Vac\" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older'],\n",
       "    'Condition': ['Coronavirus Infection'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'vaccine',\n",
       "     'vector vaccine',\n",
       "     'Immunologic Factors',\n",
       "     'SARS-CoV-2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['110'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Gam-COVID-Vac'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Russian Federation'],\n",
       "    'OrgFullName': ['Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['October 22, 2020'],\n",
       "    'CompletionDate': ['December 31, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 68,\n",
       "    'NCTId': ['NCT04648800'],\n",
       "    'BriefTitle': ['Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland'],\n",
       "    'Condition': ['Covid19', 'BCG Vaccination Reaction', 'SARS-CoV Infection'],\n",
       "    'Keyword': ['Covid19',\n",
       "     'BCG Vaccination',\n",
       "     'SARS-CoV Infection',\n",
       "     'BCG vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1000'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['BCG-10 vaccine', '0.9% saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Poland',\n",
       "     'Poland',\n",
       "     'Poland',\n",
       "     'Poland',\n",
       "     'Poland',\n",
       "     'Poland'],\n",
       "    'OrgFullName': ['University of Rzeszow'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['July 7, 2020'],\n",
       "    'CompletionDate': ['April 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['No Intervention',\n",
       "     'Active Comparator',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 69,\n",
       "    'NCTId': ['NCT04348370'],\n",
       "    'BriefTitle': ['BCG Vaccine for Health Care Workers as Defense Against COVID 19'],\n",
       "    'Condition': ['Coronavirus',\n",
       "     'Coronavirus Infection',\n",
       "     'Coronavirus as the Cause of Diseases Classified Elsewhere'],\n",
       "    'Keyword': ['BACILLUS CALMETTE-GUÉRIN VACCINATION',\n",
       "     'BCG Vaccine',\n",
       "     'Coronavirus',\n",
       "     'SARS-CoV-2',\n",
       "     'COVID19',\n",
       "     'COVID'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 4'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1800'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['BCG Vaccine', 'Placebo Vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['Texas A&M University'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 20, 2020'],\n",
       "    'CompletionDate': ['November 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 70,\n",
       "    'NCTId': ['NCT04552366'],\n",
       "    'BriefTitle': ['A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19 vaccine', 'Ad5-nCoV'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['149'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Ad5-nCoV'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['September 29, 2020'],\n",
       "    'CompletionDate': ['June 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Active Comparator',\n",
       "     'Experimental']},\n",
       "   {'Rank': 71,\n",
       "    'NCTId': ['NCT04608305'],\n",
       "    'BriefTitle': ['Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['SARS-CoV-2', 'Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1040'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Other',\n",
       "     'Other'],\n",
       "    'InterventionName': ['IIBR-100, low dose (prime)',\n",
       "     'IIBR-100 medium dose (prime)',\n",
       "     'IIBR-100 high-dose (prime)',\n",
       "     'IIBR-100 low-dose (prime-boost)',\n",
       "     'Saline Placebo',\n",
       "     'Saline Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Israel',\n",
       "     'Israel',\n",
       "     'Israel',\n",
       "     'Israel',\n",
       "     'Israel',\n",
       "     'Israel',\n",
       "     'Israel',\n",
       "     'Israel'],\n",
       "    'OrgFullName': ['Israel Institute for Biological Research (IIBR)'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 28, 2020'],\n",
       "    'CompletionDate': ['June 1, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 72,\n",
       "    'NCTId': ['NCT04352608'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['744'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule',\n",
       "     'Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule',\n",
       "     'Two doses of placebo at the emergency vaccination schedule',\n",
       "     'Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule',\n",
       "     'Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule',\n",
       "     'Two doses of placebo at the routine vaccination schedule'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Sinovac Biotech Co., Ltd'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['April 16, 2020'],\n",
       "    'CompletionDate': ['December 13, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 73,\n",
       "    'NCTId': ['NCT04591717'],\n",
       "    'BriefTitle': ['Study of the Safety of Prophylactic Vaccination With 2nd Generation E1/E2B/E3-Deleted Adenoviral-COVID-19 in Normal Healthy Volunteers'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['35'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['hAd5-S-Fusion+N-ETSD vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['ImmunityBio, Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 19, 2020'],\n",
       "    'CompletionDate': ['November 19, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 74,\n",
       "    'NCTId': ['NCT04617483'],\n",
       "    'BriefTitle': ['Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1040'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Biological'],\n",
       "    'InterventionName': ['Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14',\n",
       "     'Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14',\n",
       "     'Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Sinovac Biotech Co., Ltd'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 31, 2020'],\n",
       "    'CompletionDate': ['May 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 75,\n",
       "    'NCTId': ['NCT04328441'],\n",
       "    'BriefTitle': ['Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Health care workers'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1500'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['BCG Vaccine', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands'],\n",
       "    'OrgFullName': ['UMC Utrecht'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['March 25, 2020'],\n",
       "    'CompletionDate': ['April 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 76,\n",
       "    'NCTId': ['NCT04646590'],\n",
       "    'BriefTitle': ['A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19'],\n",
       "    'Condition': ['Prevention of COVID-19', 'Safety and Efficacy'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['29000'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Recombinant new coronavirus vaccine (CHO cell) group',\n",
       "     'Recombinant new coronavirus vaccine (CHO cells) placebo group'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 16, 2020'],\n",
       "    'CompletionDate': ['April 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 77,\n",
       "    'NCTId': ['NCT04685603'],\n",
       "    'BriefTitle': ['Dendritic Cell Vaccine to Prevent COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['covid-19', 'vaccine', 'dendritic cell'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['27'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['AV-COVID-19'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Indonesia'],\n",
       "    'OrgFullName': ['Indonesia-MoH'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 7, 2020'],\n",
       "    'CompletionDate': ['January 31, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 78,\n",
       "    'NCTId': ['NCT04686409'],\n",
       "    'BriefTitle': ['App-based Symptom Tracking After Corona Vaccination (CoCoV)'],\n",
       "    'Condition': ['Adverse Events in COVID-19 Vaccination'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['500'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['COVID-19 vaccines'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Germany'],\n",
       "    'OrgFullName': ['University of Ulm'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 11, 2021'],\n",
       "    'CompletionDate': ['August 31, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 79,\n",
       "    'NCTId': ['NCT04639466'],\n",
       "    'BriefTitle': ['A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['129'],\n",
       "    'InterventionType': ['Drug', 'Biological'],\n",
       "    'InterventionName': ['Placebo Administration', 'Vaccine Therapy'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['City of Hope Medical Center'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 11, 2020'],\n",
       "    'CompletionDate': ['November 10, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Active Comparator',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 80,\n",
       "    'NCTId': ['NCT04412538'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['942'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule',\n",
       "     'Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule',\n",
       "     'Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule',\n",
       "     'Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule',\n",
       "     'High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule',\n",
       "     'High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule',\n",
       "     'Placebo on a 0- and 28-day schedule',\n",
       "     'Placebo on a 0- and 14-day schedule'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Chinese Academy of Medical Sciences'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 15, 2020'],\n",
       "    'CompletionDate': ['September 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 81,\n",
       "    'NCTId': ['NCT04380532'],\n",
       "    'BriefTitle': ['Tableted COVID-19 Therapeutic Vaccine'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'SARS-CoV-2',\n",
       "     'coronavirus',\n",
       "     'respiratory disease',\n",
       "     'SARS',\n",
       "     'ARDS',\n",
       "     'pneumonia',\n",
       "     'pandemic'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['20'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['V-SARS'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Canada', 'Mongolia'],\n",
       "    'OrgFullName': ['Immunitor LLC'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['May 15, 2020'],\n",
       "    'CompletionDate': ['June 15, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 82,\n",
       "    'NCTId': ['NCT04379336'],\n",
       "    'BriefTitle': ['BCG Vaccination for Healthcare Workers in COVID-19 Pandemic'],\n",
       "    'Condition': ['COVID-19', 'Sars-CoV2'],\n",
       "    'Keyword': ['Blinded', 'Randomized controlled', 'SARS-CoV-2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['500'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['Bacille Calmette-Guérin (BCG)',\n",
       "     'Placebo Comparator'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['South Africa'],\n",
       "    'OrgFullName': ['TASK Applied Science'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 4, 2020'],\n",
       "    'CompletionDate': ['April 28, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 83,\n",
       "    'NCTId': ['NCT04611802'],\n",
       "    'BriefTitle': ['A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2'],\n",
       "    'Condition': ['SARS-CoV Infection', 'Covid19'],\n",
       "    'Keyword': ['Coronavirus', 'Prevent 19'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['30000'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['SARS-CoV-2 rS/Matrix-M1 Adjuvant', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Puerto Rico',\n",
       "     'Puerto Rico',\n",
       "     'Puerto Rico',\n",
       "     'Puerto Rico'],\n",
       "    'OrgFullName': ['Novavax'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 27, 2020'],\n",
       "    'CompletionDate': ['December 30, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 84,\n",
       "    'NCTId': ['NCT04710303'],\n",
       "    'BriefTitle': ['Study of a City of a Prophylactiv COVID-19 Vaccination Using a 2ndGeneration E1/E2B/E3-Deleted Adenoviral Platform in Healthy South African Adults'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['35'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['hAd5-S-Fusion+N-ETSD vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['ImmunityBio, Inc.'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['February 2021'],\n",
       "    'CompletionDate': ['April 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 85,\n",
       "    'NCTId': ['NCT04563702'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['VXA-C0V2-1', 'Vaxart oral vaccine', 'tablet vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['35'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['VXA-CoV2-1'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Vaxart'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['September 21, 2020'],\n",
       "    'CompletionDate': ['October 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 86,\n",
       "    'NCTId': ['NCT04671017'],\n",
       "    'BriefTitle': ['Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults'],\n",
       "    'Condition': ['Sars-Cov-2 Virus Infection'],\n",
       "    'Keyword': ['VLA2001',\n",
       "     'Sars-Cov-2 Virus Infection',\n",
       "     'Covid-19',\n",
       "     'inactivated-adjuvanted Sars-Cov-2 virus vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['150'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['VLA2001'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom'],\n",
       "    'OrgFullName': ['Valneva Austria GmbH'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 16, 2020'],\n",
       "    'CompletionDate': ['August 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 87,\n",
       "    'NCTId': ['NCT04604743'],\n",
       "    'BriefTitle': ['Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama'],\n",
       "    'Condition': ['Vaccine Refusal'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['4'],\n",
       "    'InterventionType': ['Behavioral'],\n",
       "    'InterventionName': ['Intervention, TBN'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['University of Alabama at Birmingham'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 1, 2021'],\n",
       "    'CompletionDate': ['June 30, 2023'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 88,\n",
       "    'NCTId': ['NCT04672395'],\n",
       "    'BriefTitle': ['A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['34000'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['AS03-adjuvanted SCB-2019 vaccine',\n",
       "     'Placebo; 0.9% saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Belgium',\n",
       "     'Belgium',\n",
       "     'Belgium',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Dominican Republic',\n",
       "     'Dominican Republic',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Nepal',\n",
       "     'Nepal',\n",
       "     'Panama',\n",
       "     'Panama',\n",
       "     'Panama',\n",
       "     'Panama',\n",
       "     'Panama',\n",
       "     'Panama',\n",
       "     'Philippines',\n",
       "     'Philippines',\n",
       "     'Philippines',\n",
       "     'Philippines',\n",
       "     'Philippines',\n",
       "     'Philippines',\n",
       "     'Philippines',\n",
       "     'Philippines',\n",
       "     'Philippines',\n",
       "     'Philippines',\n",
       "     'Poland',\n",
       "     'Poland',\n",
       "     'Poland',\n",
       "     'Poland',\n",
       "     'Poland',\n",
       "     'Poland',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa'],\n",
       "    'OrgFullName': ['Clover Biopharmaceuticals AUS Pty Ltd'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 2021'],\n",
       "    'CompletionDate': ['July 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 89,\n",
       "    'NCTId': ['NCT04540393'],\n",
       "    'BriefTitle': ['AZD1222 Vaccine for the Prevention of COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19 Prevention',\n",
       "     'AZD1222 vaccine for COVID-19 Prevention'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['AZD1222'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation'],\n",
       "    'OrgFullName': ['AstraZeneca'],\n",
       "    'OverallStatus': ['Suspended'],\n",
       "    'StartDate': ['September 2, 2020'],\n",
       "    'CompletionDate': ['March 12, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 90,\n",
       "    'NCTId': ['NCT04475081'],\n",
       "    'BriefTitle': ['Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis'],\n",
       "    'Condition': ['Sepsis Syndrome'],\n",
       "    'Keyword': ['MMR vaccine',\n",
       "     'COVID-19',\n",
       "     'Sepsis',\n",
       "     'trained innate immunity',\n",
       "     'myeloid-derived suppressor cells',\n",
       "     'inflammation'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['60'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['MMR vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Louisiana State University Health Sciences Center in New Orleans'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['August 17, 2020'],\n",
       "    'CompletionDate': ['December 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 91,\n",
       "    'NCTId': ['NCT04417335'],\n",
       "    'BriefTitle': ['Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['BCG',\n",
       "     'Bacille Calmette-Guérin',\n",
       "     'COVID-19',\n",
       "     'SARS-CoV-2',\n",
       "     'trained immunity',\n",
       "     'off-target effects'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 4'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['2014'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['BCG vaccine', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Netherlands', 'Netherlands'],\n",
       "    'OrgFullName': ['Radboud University'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['April 16, 2020'],\n",
       "    'CompletionDate': ['May 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 92,\n",
       "    'NCTId': ['NCT04368728'],\n",
       "    'BriefTitle': ['Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals'],\n",
       "    'Condition': ['SARS-CoV-2 Infection', 'COVID-19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Coronavirus',\n",
       "     'Vaccine',\n",
       "     'SARS-CoV-2',\n",
       "     'RNA Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['43998'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Other'],\n",
       "    'InterventionName': ['BNT162b1', 'BNT162b2', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Argentina',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey',\n",
       "     'Turkey'],\n",
       "    'OrgFullName': ['BioNTech SE'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 29, 2020'],\n",
       "    'CompletionDate': ['January 27, 2023'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Other',\n",
       "     'Other']},\n",
       "   {'Rank': 93,\n",
       "    'NCTId': ['NCT04569383'],\n",
       "    'BriefTitle': ['Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['MVA', 'vaccine', 'SARS-CoV-2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['30'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['MVA-SARS-2-S vaccinations (days 0 & 28)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Germany'],\n",
       "    'OrgFullName': ['Universitätsklinikum Hamburg-Eppendorf'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 5, 2020'],\n",
       "    'CompletionDate': ['May 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 94,\n",
       "    'NCTId': ['NCT04391400'],\n",
       "    'BriefTitle': ['The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines'],\n",
       "    'Condition': ['SARS-CoV-2'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['500'],\n",
       "    'InterventionType': ['Diagnostic Test', 'Diagnostic Test'],\n",
       "    'InterventionName': ['nasal pharyngeal (NP) swab samples',\n",
       "     'peripheral blood draw'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Invivoscribe, Inc.'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['June 1, 2020'],\n",
       "    'CompletionDate': ['June 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 95,\n",
       "    'NCTId': ['NCT04453488'],\n",
       "    'BriefTitle': ['Clinical Trial to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers'],\n",
       "    'Condition': ['Covid-19', 'Sars-CoV2'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['315'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['RUTI® vaccine', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Spain', 'Spain'],\n",
       "    'OrgFullName': ['Fundació Institut Germans Trias i Pujol'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['July 30, 2020'],\n",
       "    'CompletionDate': ['December 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 96,\n",
       "    'NCTId': ['NCT04579588'],\n",
       "    'BriefTitle': ['Understanding Immunity to the Flu Vaccine in COVID-19 Patients'],\n",
       "    'Condition': ['Corona Virus Infection', 'Flu Vaccine', 'Immunity'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Flu shot'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Stanford University'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['October 29, 2020'],\n",
       "    'CompletionDate': ['December 1, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 97,\n",
       "    'NCTId': ['NCT04540185'],\n",
       "    'BriefTitle': ['A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19'],\n",
       "    'Condition': ['Covid19',\n",
       "     'SARS (Severe Acute Respiratory Syndrome)',\n",
       "     'SARS-CoV Infection',\n",
       "     'SARS-CoV-2'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['3600'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Drug',\n",
       "     'Drug',\n",
       "     'Combination Product',\n",
       "     'Combination Product'],\n",
       "    'InterventionName': ['Biological: oral polio vaccine',\n",
       "     'Comparable Placebo',\n",
       "     'NA-831',\n",
       "     'Comparable Placebo of drug',\n",
       "     'Combination of oral polio vaccine and NA-831',\n",
       "     'Comparable Placebo of Oral Polio Vaccine and Placebo of drug'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'New Zealand',\n",
       "     'New Zealand'],\n",
       "    'OrgFullName': ['NeuroActiva, Inc.'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['November 1, 2020'],\n",
       "    'CompletionDate': ['December 31, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 98,\n",
       "    'NCTId': ['NCT04673149'],\n",
       "    'BriefTitle': ['GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)'],\n",
       "    'Condition': ['SARS-CoV-2'],\n",
       "    'Keyword': ['COVID-19'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['345'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['GLS-5310', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Korea, Republic of'],\n",
       "    'OrgFullName': ['GeneOne Life Science, Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 23, 2020'],\n",
       "    'CompletionDate': ['December 31, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental']},\n",
       "   {'Rank': 99,\n",
       "    'NCTId': ['NCT04373291'],\n",
       "    'BriefTitle': ['Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic'],\n",
       "    'Condition': ['COVID-19',\n",
       "     'Non-specific Effects of Vaccines',\n",
       "     'Morbidity',\n",
       "     'Absenteeism',\n",
       "     'Heterologous Immunity'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1500'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['BCG-Denmark', 'Saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Denmark'],\n",
       "    'OrgFullName': ['Bandim Health Project'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 18, 2020'],\n",
       "    'CompletionDate': ['August 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Placebo Comparator']},\n",
       "   {'Rank': 100,\n",
       "    'NCTId': ['NCT04640233'],\n",
       "    'BriefTitle': ['Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection'],\n",
       "    'Condition': ['COVID-19 Prevention'],\n",
       "    'Keyword': ['Sputnik', 'Gamaleya'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1600'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['Gam-COVID-Vac', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['India', 'India', 'India', 'India', 'India', 'India'],\n",
       "    'OrgFullName': [\"Dr. Reddy's Laboratories Limited\"],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 2020'],\n",
       "    'CompletionDate': ['September 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 101,\n",
       "    'NCTId': ['NCT04694664'],\n",
       "    'BriefTitle': ['COVID-19 Vaccine Confidence Among Pregnant Women and Mothers'],\n",
       "    'Condition': ['Pregnancy Related', 'Mothers'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['18000'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['This is an online survey with no intervention.'],\n",
       "    'Gender': ['Female'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Pregistry'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['October 1, 2020'],\n",
       "    'CompletionDate': ['December 1, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 102,\n",
       "    'NCTId': ['NCT04636697'],\n",
       "    'BriefTitle': ['Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults'],\n",
       "    'Condition': ['SARS-CoV-2 Infection'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['30612'],\n",
       "    'InterventionType': ['Drug', 'Biological'],\n",
       "    'InterventionName': ['Intramuscular injection', 'Intramuscular vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada'],\n",
       "    'OrgFullName': ['Medicago'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 19, 2020'],\n",
       "    'CompletionDate': ['April 30, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Placebo Comparator', 'Experimental']},\n",
       "   {'Rank': 103,\n",
       "    'NCTId': ['NCT04283461'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)'],\n",
       "    'Condition': ['COVID-19', 'COVID-19 Immunisation'],\n",
       "    'Keyword': ['2019-nCoV (mRNA-1273)',\n",
       "     'COVID-19',\n",
       "     'Dose-escalation',\n",
       "     'Immunogenicity',\n",
       "     'novel coronavirus',\n",
       "     'Safety',\n",
       "     'SARS-CoV-2',\n",
       "     'vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['120'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['mRNA-1273'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States', 'United States', 'United States'],\n",
       "    'OrgFullName': ['National Institute of Allergy and Infectious Diseases (NIAID)'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['March 16, 2020'],\n",
       "    'CompletionDate': ['November 22, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 104,\n",
       "    'NCTId': ['NCT04686773'],\n",
       "    'BriefTitle': ['Study in Adults to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, Given in Combination With rAd26-S, Recombinant Adenovirus Type 26 Component of Gam-COVID-Vac Vaccine, for the Prevention of COVID-19.'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['SARS-CoV-2',\n",
       "     'Severe acute respiratory syndrome coronavirus 2',\n",
       "     '2019-nCoV',\n",
       "     '2019 novel coronavirus',\n",
       "     'Respiratory disease',\n",
       "     'lung disease',\n",
       "     'COVID-19',\n",
       "     'coronavirus'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['AZD1222', 'rAd26-S'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Azerbaijan'],\n",
       "    'OrgFullName': ['R-Pharm'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['February 10, 2021'],\n",
       "    'CompletionDate': ['September 20, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 105,\n",
       "    'NCTId': ['NCT04652102'],\n",
       "    'BriefTitle': ['A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19'],\n",
       "    'Condition': ['Covid19', 'SARS-CoV-2'],\n",
       "    'Keyword': ['Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['36500'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['CVnCoV', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Belgium', 'Germany', 'Germany', 'Netherlands'],\n",
       "    'OrgFullName': ['CureVac AG'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 14, 2020'],\n",
       "    'CompletionDate': ['March 4, 2023'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 106,\n",
       "    'NCTId': ['NCT04515147'],\n",
       "    'BriefTitle': ['A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19'],\n",
       "    'Condition': ['Coronavirus',\n",
       "     'Covid19',\n",
       "     'SARS-CoV-2',\n",
       "     'Severe Acute Respiratory Syndrome'],\n",
       "    'Keyword': ['Vaccine',\n",
       "     'SARS',\n",
       "     'COVID',\n",
       "     'Safety',\n",
       "     'Reactogenicity',\n",
       "     'Immunogenicity'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['674'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['CVnCoV 6 μg',\n",
       "     'CVnCoV 12 μg',\n",
       "     'Hepatitis A vaccine',\n",
       "     'Pneumococcal vaccine',\n",
       "     'CVnCoV 12μg'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Panama', 'Peru'],\n",
       "    'OrgFullName': ['CureVac AG'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['September 28, 2020'],\n",
       "    'CompletionDate': ['November 9, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Experimental',\n",
       "     'Active Comparator',\n",
       "     'Experimental',\n",
       "     'Active Comparator']},\n",
       "   {'Rank': 107,\n",
       "    'NCTId': ['NCT04505722'],\n",
       "    'BriefTitle': ['A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants'],\n",
       "    'Condition': ['Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol'],\n",
       "    'Keyword': ['Prevention', 'Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['60000'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['Ad26.COV2.S', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa'],\n",
       "    'OrgFullName': ['Janssen Vaccines & Prevention B.V.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 7, 2020'],\n",
       "    'CompletionDate': ['March 10, 2023'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 108,\n",
       "    'NCTId': ['NCT04537949'],\n",
       "    'BriefTitle': ['A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults'],\n",
       "    'Condition': ['Covid-19', 'Protection Against COVID-19'],\n",
       "    'Keyword': ['Protection against COVID-19',\n",
       "     'Coronavirus',\n",
       "     'Vaccine',\n",
       "     'RNA Vaccine',\n",
       "     'SARS-CoV-2',\n",
       "     'Coronavirus Disease 2019',\n",
       "     'Virus Diseases',\n",
       "     'Coronavirus infection'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['120'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['BNT162b3'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Germany', 'Germany'],\n",
       "    'OrgFullName': ['BioNTech SE'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 9, 2020'],\n",
       "    'CompletionDate': ['December 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 109,\n",
       "    'NCTId': ['NCT04386252'],\n",
       "    'BriefTitle': ['Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['175'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['AV-COVID-19'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Aivita Biomedical, Inc.'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['February 2021'],\n",
       "    'CompletionDate': ['February 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 110,\n",
       "    'NCTId': ['NCT04619628'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['live attenuated',\n",
       "     'live attenuated vaccine',\n",
       "     'SARS-CoV-2',\n",
       "     'COVID-19'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['48'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['COVI-VAC', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United Kingdom'],\n",
       "    'OrgFullName': ['Codagenix, Inc'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 11, 2020'],\n",
       "    'CompletionDate': ['May 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 111,\n",
       "    'NCTId': ['NCT04674189'],\n",
       "    'BriefTitle': ['A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19'],\n",
       "    'Condition': ['Coronavirus',\n",
       "     'Covid19',\n",
       "     'SARS-CoV-2',\n",
       "     'Severe Acute Respiratory Syndrome'],\n",
       "    'Keyword': ['Vaccine', 'SARS', 'COVID', 'Safety', 'Immunogenicity'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['2520'],\n",
       "    'InterventionType': ['Biological', 'Drug'],\n",
       "    'InterventionName': ['CVnCoV Vaccine', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Germany'],\n",
       "    'OrgFullName': ['CureVac AG'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 23, 2020'],\n",
       "    'CompletionDate': ['April 30, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 112,\n",
       "    'NCTId': ['NCT04641481'],\n",
       "    'BriefTitle': ['An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers'],\n",
       "    'Condition': ['Covid19', 'SARS-CoV Infection'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['25800'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['BBV152', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['India'],\n",
       "    'OrgFullName': ['Bharat Biotech International Limited'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 25, 2020'],\n",
       "    'CompletionDate': ['March 1, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 113,\n",
       "    'NCTId': ['NCT04536051'],\n",
       "    'BriefTitle': ['A Study of a Candidate COVID-19 Vaccine (COV003)'],\n",
       "    'Condition': ['Coronavirus'],\n",
       "    'Keyword': ['Covid-19', 'ChAdOx1 nCov19', 'sars-cov-2', 'vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['10300'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['ChAdOx1 nCoV-19 single dose + paracetamol',\n",
       "     'MenACWY single dose + paracetamol',\n",
       "     'ChAdOx1 nCoV-19 two dose + paracetamol',\n",
       "     'MenACWY prime & saline placebo boost + paracetamol'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil'],\n",
       "    'OrgFullName': ['University of Oxford'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 2, 2020'],\n",
       "    'CompletionDate': ['September 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Active Comparator',\n",
       "     'Experimental',\n",
       "     'Active Comparator']},\n",
       "   {'Rank': 114,\n",
       "    'NCTId': ['NCT04545749'],\n",
       "    'BriefTitle': ['A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['60'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['UB-612'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Taiwan'],\n",
       "    'OrgFullName': ['United Biomedical Inc., Asia'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 25, 2020'],\n",
       "    'CompletionDate': ['August 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 115,\n",
       "    'NCTId': ['NCT04313127'],\n",
       "    'BriefTitle': ['Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'vaccine',\n",
       "     'Ad5',\n",
       "     'Safety',\n",
       "     'Immunogenicity',\n",
       "     'Infection',\n",
       "     'novel coronavirus',\n",
       "     'Dose-escalation'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['108'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['CanSino Biologics Inc.'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['March 16, 2020'],\n",
       "    'CompletionDate': ['December 20, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 116,\n",
       "    'NCTId': ['NCT04522089'],\n",
       "    'BriefTitle': ['A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['70'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['AdimrSC-2f'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Taiwan'],\n",
       "    'OrgFullName': ['Adimmune Corporation'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 24, 2020'],\n",
       "    'CompletionDate': ['March 20, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 117,\n",
       "    'NCTId': ['NCT04445428'],\n",
       "    'BriefTitle': ['OPV as Potential Protection Against COVID-19'],\n",
       "    'Condition': ['Poliovirus Vaccine, Oral',\n",
       "     'COVID',\n",
       "     'Mortality',\n",
       "     'Morbidity',\n",
       "     'Non-Specific Effects of Vaccines'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 4'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['3400'],\n",
       "    'InterventionType': ['Biological', 'Behavioral'],\n",
       "    'InterventionName': ['oral polio vaccine + information', 'Information'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Guinea-Bissau'],\n",
       "    'OrgFullName': ['Bandim Health Project'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['July 15, 2020'],\n",
       "    'CompletionDate': ['December 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Other']},\n",
       "   {'Rank': 118,\n",
       "    'NCTId': ['NCT04533399'],\n",
       "    'BriefTitle': ['A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults'],\n",
       "    'Condition': ['SARS-CoV-2 Infection', 'COVID-19'],\n",
       "    'Keyword': ['Coronavirus'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['4400'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['SARS-CoV-2 rS/Matrix-M1 Adjuvant', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa'],\n",
       "    'OrgFullName': ['Novavax'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 17, 2020'],\n",
       "    'CompletionDate': ['November 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 119,\n",
       "    'NCTId': ['NCT04540419'],\n",
       "    'BriefTitle': ['Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['500'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)',\n",
       "     'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation'],\n",
       "    'OrgFullName': ['NPO Petrovax'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['September 11, 2020'],\n",
       "    'CompletionDate': ['July 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 120,\n",
       "    'NCTId': ['NCT04596098'],\n",
       "    'BriefTitle': ['Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.'],\n",
       "    'Condition': ['SARS-CoV 2'],\n",
       "    'Keyword': ['Coronavirus Infection',\n",
       "     'Neutralizing monoclonal antibodies',\n",
       "     'antibodies/development',\n",
       "     'biomarkers/blood',\n",
       "     'biomarkers/immunology',\n",
       "     'SARS-CoV 2'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Blood sampling'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['University Hospital, Grenoble'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 30, 2020'],\n",
       "    'CompletionDate': ['September 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 121,\n",
       "    'NCTId': ['NCT04523246'],\n",
       "    'BriefTitle': ['Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents'],\n",
       "    'Condition': ['Herpes Zoster',\n",
       "     'Allergy and Immunology',\n",
       "     'Corona Virus Infection'],\n",
       "    'Keyword': ['Herpes Zoster',\n",
       "     'corona virus infection',\n",
       "     'allergy and immunology'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Early Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Basic Science'],\n",
       "    'EnrollmentCount': ['250'],\n",
       "    'InterventionType': ['Biological', 'Drug'],\n",
       "    'InterventionName': ['SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted)',\n",
       "     'Normal Saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['University of Oklahoma'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 1, 2020'],\n",
       "    'CompletionDate': ['September 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 122,\n",
       "    'NCTId': ['NCT04405908'],\n",
       "    'BriefTitle': ['SCB-2019 as COVID-19 Vaccine'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['150'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Biological'],\n",
       "    'InterventionName': ['SCB-2019',\n",
       "     'SCB-2019 with AS03 adjuvant',\n",
       "     'SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Australia'],\n",
       "    'OrgFullName': ['Clover Biopharmaceuticals AUS Pty Ltd'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['June 19, 2020'],\n",
       "    'CompletionDate': ['May 25, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator']},\n",
       "   {'Rank': 123,\n",
       "    'NCTId': ['NCT04384549'],\n",
       "    'BriefTitle': ['Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers'],\n",
       "    'Condition': ['Infection',\n",
       "     'Viral, Agent as Cause of Disease Classified Elsewhere'],\n",
       "    'Keyword': ['Vaccinology', 'Infectiology', 'COVID-19', 'Health Workers'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1120'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['BCG GROUP', 'PLACEBO GROUP'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['Assistance Publique - Hôpitaux de Paris'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 20, 2020'],\n",
       "    'CompletionDate': ['February 20, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 124,\n",
       "    'NCTId': ['NCT04341389'],\n",
       "    'BriefTitle': ['A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19 vaccine', 'Ad5-nCoV', 'SARS-CoV-2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['508'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)',\n",
       "     'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['April 12, 2020'],\n",
       "    'CompletionDate': ['January 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 125,\n",
       "    'NCTId': ['NCT04444674'],\n",
       "    'BriefTitle': ['COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection'],\n",
       "    'Condition': ['Coronavirus'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['2130'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['ChAdOx1 nCoV-19', 'Normal saline 0.9%'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa'],\n",
       "    'OrgFullName': ['University of Oxford'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['June 24, 2020'],\n",
       "    'CompletionDate': ['December 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 126,\n",
       "    'NCTId': ['NCT04528641'],\n",
       "    'BriefTitle': ['GRAd-COV2 Vaccine Against COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['90'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['GRAd-COV2'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Italy', 'Italy'],\n",
       "    'OrgFullName': ['ReiThera Srl'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 10, 2020'],\n",
       "    'CompletionDate': ['July 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 127,\n",
       "    'NCTId': ['NCT04405076'],\n",
       "    'BriefTitle': ['Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older'],\n",
       "    'Condition': ['SARS-CoV-2'],\n",
       "    'Keyword': ['mRNA-1273',\n",
       "     'mRNA-1273 vaccine',\n",
       "     'SARS-CoV-2',\n",
       "     'SARS-CoV-2 Vaccine',\n",
       "     'Coronavirus',\n",
       "     'Virus Diseases',\n",
       "     'Messenger RNA',\n",
       "     'COVID 19',\n",
       "     'COVID 19 Vaccine',\n",
       "     'Moderna'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['600'],\n",
       "    'InterventionType': ['Biological', 'Other', 'Biological'],\n",
       "    'InterventionName': ['Biological: mRNA-1273: 50 mcg',\n",
       "     'Placebo',\n",
       "     'Biological: mRNA-1273: 100 mcg'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['ModernaTX, Inc.'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['May 29, 2020'],\n",
       "    'CompletionDate': ['August 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 128,\n",
       "    'NCTId': ['NCT04649021'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population'],\n",
       "    'Condition': ['SARS-CoV-2'],\n",
       "    'Keyword': ['Coronavirus Disease 2019',\n",
       "     'Coronavirus infection',\n",
       "     'Vaccine',\n",
       "     'Protection against COVID-19',\n",
       "     'Covid19',\n",
       "     'SARS (Severe Acute Respiratory Syndrome)'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['960'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['BNT162b2', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['BioNTech SE'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 2020'],\n",
       "    'CompletionDate': ['December 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 129,\n",
       "    'NCTId': ['NCT04537208'],\n",
       "    'BriefTitle': ['Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older'],\n",
       "    'Condition': ['COVID-19 (Healthy Volunteers)'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['440'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['SARS-CoV-2 vaccine formulation 1 with adjuvant 1',\n",
       "     'SARS-CoV-2 vaccine formulation 1 with adjuvant 2',\n",
       "     'SARS-CoV-2 vaccine formulation 2 with adjuvant 1',\n",
       "     'SARS-CoV-2 vaccine formulation 2 with adjuvant 2',\n",
       "     'SARS-CoV-2 vaccine formulation 2 without adjuvant',\n",
       "     'Placebo (0.9% normal saline)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['Sanofi'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['September 3, 2020'],\n",
       "    'CompletionDate': ['October 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 130,\n",
       "    'NCTId': ['NCT04690387'],\n",
       "    'BriefTitle': ['Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['27'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['AV-COVID-19', 'GM-CSF'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Indonesia'],\n",
       "    'OrgFullName': ['Aivita Biomedical, Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 7, 2020'],\n",
       "    'CompletionDate': ['January 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 131,\n",
       "    'NCTId': ['NCT04568031'],\n",
       "    'BriefTitle': ['Study of AZD1222 for the Prevention of COVID-19 in Japan'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19 Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['256'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['AZD1222', '0.9% (w/v) saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Japan', 'Japan', 'Japan', 'Japan', 'Japan'],\n",
       "    'OrgFullName': ['AstraZeneca'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['August 23, 2020'],\n",
       "    'CompletionDate': ['November 10, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Placebo Comparator']},\n",
       "   {'Rank': 132,\n",
       "    'NCTId': ['NCT04662697'],\n",
       "    'BriefTitle': ['Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults (USA)'],\n",
       "    'Condition': ['SARS-CoV-2 Infection'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['918'],\n",
       "    'InterventionType': ['Drug', 'Biological'],\n",
       "    'InterventionName': ['Intramuscular injection', 'intramuscular accine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Medicago'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 11, 2020'],\n",
       "    'CompletionDate': ['March 31, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Placebo Comparator', 'Experimental']},\n",
       "   {'Rank': 133,\n",
       "    'NCTId': ['NCT04693689'],\n",
       "    'BriefTitle': ['Novelty, Conformity and Trust in Vaccines'],\n",
       "    'Condition': ['Trust'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Coronavirus',\n",
       "     'Vaccine',\n",
       "     'Trust',\n",
       "     'RNA',\n",
       "     'Global survey'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Health Services Research'],\n",
       "    'EnrollmentCount': ['32400'],\n",
       "    'InterventionType': ['Other',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Other'],\n",
       "    'InterventionName': ['RNA vaccine',\n",
       "     '20% adoption rate',\n",
       "     '40% adoption rate',\n",
       "     '60% adoption rate',\n",
       "     '80% adoption rate',\n",
       "     'Conventional vaccine',\n",
       "     '0% adoption rate'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['National University, Singapore'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 15, 2021'],\n",
       "    'CompletionDate': ['January 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 134,\n",
       "    'NCTId': ['NCT04537663'],\n",
       "    'BriefTitle': ['Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults'],\n",
       "    'Condition': ['Respiratory Tract Infections', 'Covid19'],\n",
       "    'Keyword': ['Bacillus Calmette-Guerin'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 4'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['5200'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['Bacille Calmette-Guérin (BCG)', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands'],\n",
       "    'OrgFullName': ['UMC Utrecht'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 25, 2020'],\n",
       "    'CompletionDate': ['April 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 135,\n",
       "    'NCTId': ['NCT04649151'],\n",
       "    'BriefTitle': ['A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19'],\n",
       "    'Condition': ['SARS-CoV-2'],\n",
       "    'Keyword': ['mRNA-1273',\n",
       "     'mRNA-1273 vaccine',\n",
       "     'SARS-CoV-2',\n",
       "     'SARS-CoV-2 Vaccine',\n",
       "     'Coronavirus',\n",
       "     'Virus Diseases',\n",
       "     'Messenger RNA',\n",
       "     'COVID-19',\n",
       "     'COVID-19 Vaccine',\n",
       "     'Moderna'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['3000'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['mRNA-1273', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['ModernaTX, Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 9, 2020'],\n",
       "    'CompletionDate': ['June 30, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 136,\n",
       "    'NCTId': ['NCT04470427'],\n",
       "    'BriefTitle': ['A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19'],\n",
       "    'Condition': ['SARS-CoV-2'],\n",
       "    'Keyword': ['mRNA-1273',\n",
       "     'mRNA-1273 vaccine',\n",
       "     'SARS-CoV-2',\n",
       "     'SARS-CoV-2 Vaccine',\n",
       "     'Coronavirus',\n",
       "     'Virus Diseases',\n",
       "     'Messenger RNA',\n",
       "     'COVID-19',\n",
       "     'COVID-19 Vaccine',\n",
       "     'Moderna'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['30000'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['mRNA-1273', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['ModernaTX, Inc.'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['July 27, 2020'],\n",
       "    'CompletionDate': ['October 27, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 137,\n",
       "    'NCTId': ['NCT04368988'],\n",
       "    'BriefTitle': ['Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1419'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Other',\n",
       "     'Other',\n",
       "     'Biological',\n",
       "     'Other',\n",
       "     'Biological',\n",
       "     'Other',\n",
       "     'Biological',\n",
       "     'Other',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['SARS-CoV-2 rS - Phase 1',\n",
       "     'SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1',\n",
       "     'Normal saline solution (NSS), Placebo - Phase 1',\n",
       "     'Normal saline solution (NSS), Placebo - Phase 2',\n",
       "     'SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1',\n",
       "     'Normal saline solution (NSS), Placebo, Day 21 - Phase 1',\n",
       "     'SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2',\n",
       "     'Normal saline solution (NSS), Placebo, Day 189 - Phase 2',\n",
       "     'SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2',\n",
       "     'Normal saline solution (NSS), Placebo, Day 21 - Phase 2',\n",
       "     'SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia'],\n",
       "    'OrgFullName': ['Novavax'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['May 25, 2020'],\n",
       "    'CompletionDate': ['November 18, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 138,\n",
       "    'NCTId': ['NCT04614948'],\n",
       "    'BriefTitle': ['A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults'],\n",
       "    'Condition': ['Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['30000'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['Ad26.COV2.S', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Belgium',\n",
       "     'Belgium',\n",
       "     'Belgium',\n",
       "     'Belgium',\n",
       "     'Belgium',\n",
       "     'Belgium',\n",
       "     'Belgium',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Philippines',\n",
       "     'Philippines',\n",
       "     'Philippines',\n",
       "     'Philippines',\n",
       "     'Philippines',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom'],\n",
       "    'OrgFullName': ['Janssen Vaccines & Prevention B.V.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 15, 2020'],\n",
       "    'CompletionDate': ['May 11, 2023'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 139,\n",
       "    'NCTId': ['NCT04445610'],\n",
       "    'BriefTitle': ['Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?'],\n",
       "    'Condition': ['Coronavirus (COVID-19)'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['60'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Egypt'],\n",
       "    'OrgFullName': ['Ain Shams University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['July 1, 2020'],\n",
       "    'CompletionDate': ['November 1, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 140,\n",
       "    'NCTId': ['NCT04352582'],\n",
       "    'BriefTitle': ['COVID-19 and Vaccination Attitudes'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['1194'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Survey'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United Kingdom'],\n",
       "    'OrgFullName': ['University Hospital, Geneva'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['April 14, 2020'],\n",
       "    'CompletionDate': ['April 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 141,\n",
       "    'NCTId': ['NCT04702178'],\n",
       "    'BriefTitle': ['A Clinical Trial of COVAC Vaccines in Healthy Adults'],\n",
       "    'Condition': ['Severe Acute Respiratory Syndrome Coronavirus 2'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['108'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['COVAC-2', 'Saline Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Canada'],\n",
       "    'OrgFullName': ['University of Saskatchewan'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 2021'],\n",
       "    'CompletionDate': ['February 2023'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 142,\n",
       "    'NCTId': ['NCT04588480'],\n",
       "    'BriefTitle': ['Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults'],\n",
       "    'Condition': ['SARS-CoV-2 Infection', 'COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['160'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['BNT162b2', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Japan', 'Japan'],\n",
       "    'OrgFullName': ['BioNTech SE'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['October 21, 2020'],\n",
       "    'CompletionDate': ['November 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 143,\n",
       "    'NCTId': ['NCT04396067'],\n",
       "    'BriefTitle': ['Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID 2019',\n",
       "     'Isotretinoin',\n",
       "     'Endosomal toll-like receptor 3',\n",
       "     'T Cells',\n",
       "     'IFN type1',\n",
       "     'AT1',\n",
       "     'ACE2',\n",
       "     'Alvelestat'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['360'],\n",
       "    'InterventionType': ['Drug', 'Drug', 'Other'],\n",
       "    'InterventionName': ['Aerosolized 13 cis retinoic acid',\n",
       "     'Aerosolized All trans retinoic acid',\n",
       "     'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Kafrelsheikh University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['October 2020'],\n",
       "    'CompletionDate': ['December 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 144,\n",
       "    'NCTId': ['NCT04468802'],\n",
       "    'BriefTitle': ['Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?'],\n",
       "    'Condition': ['Covid19', 'Measles Vaccine', 'Mortality'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['32'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Case fatality rate'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Turkey'],\n",
       "    'OrgFullName': ['Kanuni Sultan Suleyman Training and Research Hospital'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['February 1, 2020'],\n",
       "    'CompletionDate': ['July 1, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 145,\n",
       "    'NCTId': ['NCT04526990'],\n",
       "    'BriefTitle': ['Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'vaccine',\n",
       "     'Ad5',\n",
       "     'Safety',\n",
       "     'Immunogencity',\n",
       "     'efficacy',\n",
       "     'adaptive design',\n",
       "     'SARS-CoV-2',\n",
       "     'Adenovirus Vector'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['40000'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)',\n",
       "     'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Pakistan',\n",
       "     'Pakistan',\n",
       "     'Pakistan',\n",
       "     'Pakistan',\n",
       "     'Pakistan',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation',\n",
       "     'Russian Federation'],\n",
       "    'OrgFullName': ['CanSino Biologics Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 15, 2020'],\n",
       "    'CompletionDate': ['January 30, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 146,\n",
       "    'NCTId': ['NCT04591184'],\n",
       "    'BriefTitle': ['A Clinical Trial of a Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults'],\n",
       "    'Condition': ['SARS-CoV-2'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'SARS-CoV-2',\n",
       "     'anti-infective',\n",
       "     'prophylaxis',\n",
       "     'healthy volunteer',\n",
       "     'prevention',\n",
       "     'Covigenix VAX-001'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['72'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Covigenix VAX-001 placebo', 'Covigenix VAX-001'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Entos Pharmaceuticals Inc.'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 2020'],\n",
       "    'CompletionDate': ['June 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 147,\n",
       "    'NCTId': ['NCT04367883'],\n",
       "    'BriefTitle': ['Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection'],\n",
       "    'Condition': ['COVID19', 'Influenza Vaccination', 'ACE Inhibitors', 'ARB'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['2574'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['ACE inhibitor', 'ARB'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Spain'],\n",
       "    'OrgFullName': ['Consorci Sanitari de Terrassa'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['March 1, 2020'],\n",
       "    'CompletionDate': ['August 31, 2023'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 148,\n",
       "    'NCTId': ['NCT04668339'],\n",
       "    'BriefTitle': ['A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults'],\n",
       "    'Condition': ['Covid19', 'SARS-CoV Infection', 'Corona Virus Infection'],\n",
       "    'Keyword': ['SARS-CoV-2 Vaccine',\n",
       "     'Coronavirus Virus Diseases',\n",
       "     'RNA COVID 19',\n",
       "     'COVID 19 Vaccine Arcturus',\n",
       "     'self amplifying RNA vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['600'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['ARCT-021 single dose priming',\n",
       "     'ARCT-021 two lower dose priming',\n",
       "     'ARCT-021 two higher dose priming',\n",
       "     'Placebo (two doses), priming',\n",
       "     'Randomized booster',\n",
       "     'Placebo booster'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Singapore'],\n",
       "    'OrgFullName': ['Arcturus Therapeutics, Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['January 7, 2021'],\n",
       "    'CompletionDate': ['April 30, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 149,\n",
       "    'NCTId': ['NCT04523571'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects'],\n",
       "    'Condition': ['SARS-CoV-2'],\n",
       "    'Keyword': ['Protection against COVID-19',\n",
       "     'Coronavirus Disease 2019',\n",
       "     'Coronavirus infection',\n",
       "     'Vaccine',\n",
       "     'RNA Vaccine',\n",
       "     'Virus Diseases'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['144'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['BNT162b1', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['BioNTech SE'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['July 28, 2020'],\n",
       "    'CompletionDate': ['August 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 150,\n",
       "    'NCTId': ['NCT04566770'],\n",
       "    'BriefTitle': ['A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Vaccine',\n",
       "     'Ad5',\n",
       "     'Safety',\n",
       "     'Immunogencity',\n",
       "     'SARS-CoV-2',\n",
       "     'Adenovirus Vector'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['481'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)',\n",
       "     'Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['CanSino Biologics Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 24, 2020'],\n",
       "    'CompletionDate': ['October 20, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 151,\n",
       "    'NCTId': ['NCT04627675'],\n",
       "    'BriefTitle': ['CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)'],\n",
       "    'Condition': ['SARS-CoV-2'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['36'],\n",
       "    'InterventionType': ['Drug', 'Drug', 'Device'],\n",
       "    'InterventionName': ['CORVax', 'IL-12 plasmid', 'Cliniporator'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Providence Health & Services'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 2020'],\n",
       "    'CompletionDate': ['May 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 152,\n",
       "    'NCTId': ['NCT04542330'],\n",
       "    'BriefTitle': ['Using BCG to Protect Senior Citizens During the COVID-19 Pandemic'],\n",
       "    'Condition': ['Covid19',\n",
       "     'Non-specific Effects of Vaccines',\n",
       "     'Heterologous Immunity',\n",
       "     'Morbidity',\n",
       "     'Immunosenescence',\n",
       "     'Vaccine Preventable Disease'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1900'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['BCG-Denmark', 'Saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Older Adult'],\n",
       "    'LocationCountry': ['Denmark'],\n",
       "    'OrgFullName': ['Bandim Health Project'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 15, 2020'],\n",
       "    'CompletionDate': ['March 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Placebo Comparator']},\n",
       "   {'Rank': 153,\n",
       "    'NCTId': ['NCT04684446'],\n",
       "    'BriefTitle': ['AZD1222 Vaccine in Combination With rAd26-S (Component of Gam-COVID-Vac Vaccine) for the Prevention of COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19 Prevention',\n",
       "     'AZD1222 vaccine',\n",
       "     'rAd26-S',\n",
       "     'Sputnik V'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['AZD1222', 'rAd26-S'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['AstraZeneca'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['March 16, 2021'],\n",
       "    'CompletionDate': ['November 16, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 154,\n",
       "    'NCTId': ['NCT04471519'],\n",
       "    'BriefTitle': ['Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers'],\n",
       "    'Condition': ['COVID-19', 'SARS-CoV-2 Infection'],\n",
       "    'Keyword': ['BBV152', 'COVID-19 vaccine', 'inactivated vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['755'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['BBV152A - Phase I',\n",
       "     'BBV152B - Phase I',\n",
       "     'BBV152C - Phase I',\n",
       "     'Placebo - Phase I',\n",
       "     'BBV152A - Phase II',\n",
       "     'BBV152B - Phase II'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['India',\n",
       "     'India',\n",
       "     'India',\n",
       "     'India',\n",
       "     'India',\n",
       "     'India',\n",
       "     'India',\n",
       "     'India',\n",
       "     'India',\n",
       "     'India',\n",
       "     'India',\n",
       "     'India'],\n",
       "    'OrgFullName': ['Bharat Biotech International Limited'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['July 13, 2020'],\n",
       "    'CompletionDate': ['June 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Active Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 155,\n",
       "    'NCTId': ['NCT04334980'],\n",
       "    'BriefTitle': ['Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['24'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['bacTRL-Spike'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Australia'],\n",
       "    'OrgFullName': ['Symvivo Corporation'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 2, 2020'],\n",
       "    'CompletionDate': ['February 28, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 156,\n",
       "    'NCTId': ['NCT04666012'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['150'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['AdCLD-CoV19'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Korea, Republic of'],\n",
       "    'OrgFullName': ['Cellid Co., Ltd.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 29, 2020'],\n",
       "    'CompletionDate': ['April 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 157,\n",
       "    'NCTId': ['NCT04641858'],\n",
       "    'BriefTitle': ['BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic'],\n",
       "    'Condition': ['Covid19', 'Morbidity', 'Absenteeism'],\n",
       "    'Keyword': ['Innate immune training',\n",
       "     'Non-specific effects of BCG',\n",
       "     'Heterologous effects'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 4'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1050'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['BCG-Denmark', 'Saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Cape Verde', 'Guinea-Bissau', 'Mozambique'],\n",
       "    'OrgFullName': ['University of Southern Denmark'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 3, 2020'],\n",
       "    'CompletionDate': ['March 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Placebo Comparator']},\n",
       "   {'Rank': 158,\n",
       "    'NCTId': ['NCT04513847'],\n",
       "    'BriefTitle': ['PsoVac: Educational Needs re Vaccines for Biologic Patients With Psoriasis'],\n",
       "    'Condition': ['Psoriasis', 'Covid19'],\n",
       "    'Keyword': ['Education', 'Vaccine', 'Biologic'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['661'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Canada'],\n",
       "    'OrgFullName': ['Dermatrials Research'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['August 13, 2020'],\n",
       "    'CompletionDate': ['October 6, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 159,\n",
       "    'NCTId': ['NCT04683224'],\n",
       "    'BriefTitle': ['A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine'],\n",
       "    'Condition': ['Covid-19', 'SARS-CoV-2', 'Coronavirus'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['7320'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['UB-612', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['COVAXX'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['February 1, 2021'],\n",
       "    'CompletionDate': ['March 22, 2023'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental']},\n",
       "   {'Rank': 160,\n",
       "    'NCTId': ['NCT04655625'],\n",
       "    'BriefTitle': ['Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['vaccine', 'COVID-19', 'SARS-CoV-2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['500'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['Group A (AG0302-COVID19)',\n",
       "     'Group A (Placebo)',\n",
       "     'Group B (AG0302-COVID19)',\n",
       "     'Group B (Placebo)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Japan',\n",
       "     'Japan',\n",
       "     'Japan',\n",
       "     'Japan',\n",
       "     'Japan',\n",
       "     'Japan',\n",
       "     'Japan',\n",
       "     'Japan'],\n",
       "    'OrgFullName': ['AnGes, Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 23, 2020'],\n",
       "    'CompletionDate': ['March 31, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 161,\n",
       "    'NCTId': ['NCT04566276'],\n",
       "    'BriefTitle': ['ChulaCov19 mRNA Vaccine in Healthy Adults'],\n",
       "    'Condition': ['COVID-19 Vaccine', 'Safety Issues'],\n",
       "    'Keyword': ['tolerability',\n",
       "     'reactivity',\n",
       "     'immunogenicity',\n",
       "     'healthy adults',\n",
       "     'healthy elderlies',\n",
       "     'coronavirus disease 2019',\n",
       "     'SARS-CoV-2-specific serum neutralising antibody titer',\n",
       "     'SARS-CoV-2-surrogate viral neutralising antibody',\n",
       "     'SARS-Cov2 spike protein-binding IgG antibody titer',\n",
       "     'SARS-Cov2 spike protein-specific CD4+ and CD8+ T-cells responses',\n",
       "     'IFNγ enzyme-linked immune absorbent spot (ELISpot)',\n",
       "     'SARS-Cov2 spike protein-specific Th1/Th2 polarisation',\n",
       "     'novel lipid nanoparticles (LNPs)-encapsulated mRNA-based vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Other'],\n",
       "    'EnrollmentCount': ['96'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['ChulaCov19 mRNA vaccine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Thailand', 'Thailand'],\n",
       "    'OrgFullName': ['Chulalongkorn University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 2021'],\n",
       "    'CompletionDate': ['June 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 162,\n",
       "    'NCTId': ['NCT04347694'],\n",
       "    'BriefTitle': ['Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.'],\n",
       "    'Condition': ['SARS-CoV 2', 'Immunization; Infection'],\n",
       "    'Keyword': ['Nephrology', 'SARS-CoV-2', 'Vienna', 'Health Care Personnel'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['400'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Austria'],\n",
       "    'OrgFullName': ['Medical University of Vienna'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 11, 2020'],\n",
       "    'CompletionDate': ['April 11, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 163,\n",
       "    'NCTId': ['NCT04463472'],\n",
       "    'BriefTitle': ['Study of COVID-19 DNA Vaccine (AG0301-COVID19)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['vaccine', 'COVID-19', 'SARS-CoV-2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['30'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['AG0301-COVID19', 'AG0301-COVID19'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Japan'],\n",
       "    'OrgFullName': ['AnGes, Inc.'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['June 29, 2020'],\n",
       "    'CompletionDate': ['July 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 164,\n",
       "    'NCTId': ['NCT04527081'],\n",
       "    'BriefTitle': ['Study of COVID-19 DNA Vaccine (AG0302-COVID19)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['vaccine', 'COVID-19', 'SARS-CoV-2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['30'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Biological'],\n",
       "    'InterventionName': ['AG0302-COVID19', 'AG0302-COVID19', 'AG0302-COVID19'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Japan'],\n",
       "    'OrgFullName': ['AnGes, Inc.'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['August 31, 2020'],\n",
       "    'CompletionDate': ['September 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 165,\n",
       "    'NCTId': ['NCT04160975'],\n",
       "    'BriefTitle': ['Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects'],\n",
       "    'Condition': ['Flu, Human', 'Influenza, Human', 'Covid19'],\n",
       "    'Keyword': ['Belief Updating', 'Preventive Care', 'Racial Disparity'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Health Services Research'],\n",
       "    'EnrollmentCount': ['3350'],\n",
       "    'InterventionType': ['Behavioral', 'Behavioral'],\n",
       "    'InterventionName': ['Video about safety and effectiveness of adult seasonal flu vaccination',\n",
       "     'Message directing subjects to information on COVID-19 vaccine safety and efficacy'],\n",
       "    'Gender': ['Male'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Harvard University'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['December 20, 2019'],\n",
       "    'CompletionDate': ['February 15, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 166,\n",
       "    'NCTId': ['NCT04347876'],\n",
       "    'BriefTitle': ['Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?'],\n",
       "    'Condition': ['COVID-19', 'BCG Vaccination'],\n",
       "    'Keyword': ['Outcome',\n",
       "     'COVID-19 pneumonia',\n",
       "     'BCG',\n",
       "     'Tuberculin test positive',\n",
       "     'Egypt'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Diagnostic Test'],\n",
       "    'InterventionName': ['Tuberculin test'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Egypt'],\n",
       "    'OrgFullName': ['Assiut University'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 11, 2020'],\n",
       "    'CompletionDate': ['June 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 167,\n",
       "    'NCTId': ['NCT04516746'],\n",
       "    'BriefTitle': ['Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults'],\n",
       "    'Condition': ['COVID-19', 'SARS-CoV-2'],\n",
       "    'Keyword': ['COVID-19 Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['30000'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['AZD1222', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Chile',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru'],\n",
       "    'OrgFullName': ['AstraZeneca'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 28, 2020'],\n",
       "    'CompletionDate': ['February 21, 2023'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 168,\n",
       "    'NCTId': ['NCT04352751'],\n",
       "    'BriefTitle': ['Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020'],\n",
       "    'Condition': ['Covid-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Other'],\n",
       "    'EnrollmentCount': ['2000'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['convalescent plasma'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Pakistan'],\n",
       "    'OrgFullName': ['Hilton Pharma'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 1, 2020'],\n",
       "    'CompletionDate': ['April 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 169,\n",
       "    'NCTId': ['NCT04380701'],\n",
       "    'BriefTitle': ['A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults'],\n",
       "    'Condition': ['Infections, Respiratory',\n",
       "     'Virus Diseases',\n",
       "     'Infection Viral',\n",
       "     'Vaccine Adverse Reaction',\n",
       "     'RNA Virus Infections'],\n",
       "    'Keyword': ['SARS-CoV-2',\n",
       "     'Severe Acute Respiratory Syndrome (SARS)',\n",
       "     'Coronavirus Disease 2019',\n",
       "     'COVID-2019',\n",
       "     'Virus Diseases'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['456'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological'],\n",
       "    'InterventionName': ['BNT162a1', 'BNT162b1', 'BNT162b2', 'BNT162c2'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Germany', 'Germany'],\n",
       "    'OrgFullName': ['BioNTech SE'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 23, 2020'],\n",
       "    'CompletionDate': ['November 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 170,\n",
       "    'NCTId': ['NCT04403880'],\n",
       "    'BriefTitle': ['Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19'],\n",
       "    'Condition': ['SARS-CoV-2', 'COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['727'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Sample collection'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Malawi',\n",
       "     'Mozambique',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'Tanzania',\n",
       "     'Zambia',\n",
       "     'Zambia',\n",
       "     'Zambia',\n",
       "     'Zimbabwe',\n",
       "     'Zimbabwe',\n",
       "     'Zimbabwe'],\n",
       "    'OrgFullName': ['HIV Vaccine Trials Network'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 13, 2020'],\n",
       "    'CompletionDate': ['August 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 171,\n",
       "    'NCTId': ['NCT04702295'],\n",
       "    'BriefTitle': ['ERN ReCONNET Study on COVID-19 Vaccination in Rare and Complex Connective Tissue Disease (VACCINATE)'],\n",
       "    'Condition': ['Connective Tissue Diseases',\n",
       "     'Rare Diseases',\n",
       "     'Rheumatologic Disorder'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['250'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['University of Pisa'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['February 2021'],\n",
       "    'CompletionDate': ['August 2023'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 172,\n",
       "    'NCTId': ['NCT04346186'],\n",
       "    'BriefTitle': ['COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff'],\n",
       "    'Condition': ['COVID'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['30000'],\n",
       "    'InterventionType': ['Diagnostic Test', 'Diagnostic Test'],\n",
       "    'InterventionName': ['IgM and IgG diagnostic kits to SARS-CoV-2',\n",
       "     'Elisa-test for IgM and IgG to SARS-CoV-2'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Denmark',\n",
       "     'Denmark',\n",
       "     'Denmark',\n",
       "     'Denmark',\n",
       "     'Denmark',\n",
       "     'Denmark',\n",
       "     'Denmark',\n",
       "     'Denmark',\n",
       "     'Denmark',\n",
       "     'Denmark',\n",
       "     'Denmark',\n",
       "     'Denmark',\n",
       "     'Denmark',\n",
       "     'Denmark'],\n",
       "    'OrgFullName': ['Herlev Hospital'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['April 15, 2020'],\n",
       "    'CompletionDate': ['August 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 173,\n",
       "    'NCTId': ['NCT04681092'],\n",
       "    'BriefTitle': ['Anti-COVID19 AKS-452 - ACT Study'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['vaccine',\n",
       "     'safety',\n",
       "     'immunogenicity',\n",
       "     'dose-finding',\n",
       "     'exploratory efficacy'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['130'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['AKS-452'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Netherlands'],\n",
       "    'OrgFullName': ['University Medical Center Groningen'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 18, 2021'],\n",
       "    'CompletionDate': ['June 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 174,\n",
       "    'NCTId': ['NCT04384614'],\n",
       "    'BriefTitle': ['Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study'],\n",
       "    'Condition': ['Covid 19', 'BCG Vaccination'],\n",
       "    'Keyword': ['covid 19', 'BCG Vaccination'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['0'],\n",
       "    'InterventionType': ['Diagnostic Test', 'Genetic', 'Other'],\n",
       "    'InterventionName': ['Test PCR', 'TDR', 'Clinical Examination'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Tunisia'],\n",
       "    'OrgFullName': ['Direction des Soins de Santé de Base'],\n",
       "    'OverallStatus': ['Withdrawn'],\n",
       "    'StartDate': ['May 15, 2020'],\n",
       "    'CompletionDate': ['July 15, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 175,\n",
       "    'NCTId': ['NCT04381845'],\n",
       "    'BriefTitle': ['Immunity and Infections in the Psychiatric Population'],\n",
       "    'Condition': ['COVID', 'Psychiatric Disorders'],\n",
       "    'Keyword': ['COVID infection', 'psychiatric population'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Diagnostic'],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Diagnostic Test'],\n",
       "    'InterventionName': ['COVID19 immunization testing'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Assistance Publique - Hôpitaux de Paris'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 10, 2020'],\n",
       "    'CompletionDate': ['March 10, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Other']},\n",
       "   {'Rank': 176,\n",
       "    'NCTId': ['NCT04442048'],\n",
       "    'BriefTitle': ['Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure'],\n",
       "    'Condition': ['Cancer', 'Covid-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['1500'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['IMM-101', 'Observation'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada'],\n",
       "    'OrgFullName': ['Canadian Cancer Trials Group'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 25, 2020'],\n",
       "    'CompletionDate': ['March 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 177,\n",
       "    'NCTId': ['NCT04436276'],\n",
       "    'BriefTitle': ['A Study of Ad26.COV2.S in Adults (COVID-19)'],\n",
       "    'Condition': ['Healthy'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Ad26COVS1',\n",
       "     'Ad26.COV2.S',\n",
       "     'SARS CoV 2',\n",
       "     'Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Other'],\n",
       "    'EnrollmentCount': ['1045'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Ad26.COV2.S', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Belgium',\n",
       "     'Belgium',\n",
       "     'Belgium',\n",
       "     'Belgium',\n",
       "     'Belgium',\n",
       "     'Belgium'],\n",
       "    'OrgFullName': ['Janssen Vaccines & Prevention B.V.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['July 15, 2020'],\n",
       "    'CompletionDate': ['February 2, 2024'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 178,\n",
       "    'NCTId': ['NCT04498247'],\n",
       "    'BriefTitle': ['A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)'],\n",
       "    'Condition': ['Coronavirus Disease (COVID-19)'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['260'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['V591', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Austria',\n",
       "     'Austria',\n",
       "     'Belgium',\n",
       "     'Belgium',\n",
       "     'Belgium'],\n",
       "    'OrgFullName': ['Merck Sharp & Dohme Corp.'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['August 27, 2020'],\n",
       "    'CompletionDate': ['April 26, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 179,\n",
       "    'NCTId': ['NCT04449276'],\n",
       "    'BriefTitle': ['A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults'],\n",
       "    'Condition': ['Severe Acute Respiratory Syndrome',\n",
       "     'Coronavirus',\n",
       "     'SARS-CoV-2',\n",
       "     'COVID-19'],\n",
       "    'Keyword': ['Safety',\n",
       "     'Reactogenicity',\n",
       "     'Immunogenicity',\n",
       "     'Vaccine',\n",
       "     'CEPI'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['280'],\n",
       "    'InterventionType': ['Biological', 'Drug'],\n",
       "    'InterventionName': ['CVnCoV Vaccine', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Belgium', 'Germany', 'Germany', 'Germany'],\n",
       "    'OrgFullName': ['CureVac AG'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['June 18, 2020'],\n",
       "    'CompletionDate': ['December 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 180,\n",
       "    'NCTId': ['NCT04548557'],\n",
       "    'BriefTitle': ['Intravenous Immunoglobulins for the Treatment of Covid-19 Patients: a Clinical Trial'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['Covid 19',\n",
       "     'intravenous immunogloulin therapy',\n",
       "     'passive immunization'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['60'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['intravenous immunoglobulin therapy'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Pakistan'],\n",
       "    'OrgFullName': ['University of Health Sciences Lahore'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['September 15, 2020'],\n",
       "    'CompletionDate': ['November 15, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['No Intervention', 'Experimental']},\n",
       "   {'Rank': 181,\n",
       "    'NCTId': ['NCT04487210'],\n",
       "    'BriefTitle': ['A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19 vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['45'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['MVC-COV1901'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Taiwan'],\n",
       "    'OrgFullName': ['Medigen Vaccine Biologics Corp.'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['October 7, 2020'],\n",
       "    'CompletionDate': ['June 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 182,\n",
       "    'NCTId': ['NCT04646239'],\n",
       "    'BriefTitle': ['Biomarkers of Trained Immunity Following MMR Vaccination'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['COVID 19', 'Trained Immunity', 'Infectious Diseases'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['80'],\n",
       "    'InterventionType': ['Diagnostic Test'],\n",
       "    'InterventionName': ['Heterologous stimuli'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Washington University School of Medicine'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 2020'],\n",
       "    'CompletionDate': ['April 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 183,\n",
       "    'NCTId': ['NCT04439045'],\n",
       "    'BriefTitle': ['Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity'],\n",
       "    'Condition': ['SARS-CoV-2 Infection'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['3626'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['VPM1002', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Canada'],\n",
       "    'OrgFullName': ['University Health Network, Toronto'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 24, 2020'],\n",
       "    'CompletionDate': ['July 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 184,\n",
       "    'NCTId': ['NCT04447781'],\n",
       "    'BriefTitle': ['Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19'],\n",
       "    'Condition': ['Coronavirus Infection', 'SARS-CoV 2'],\n",
       "    'Keyword': ['Coronavirus Infection', 'SARS-CoV 2', 'INO-4800'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['160'],\n",
       "    'InterventionType': ['Biological', 'Device', 'Other'],\n",
       "    'InterventionName': ['INO-4800',\n",
       "     'CELLECTRA® 2000',\n",
       "     'Saline-sodium citrate (SSC) buffer'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Korea, Republic of', 'Korea, Republic of'],\n",
       "    'OrgFullName': ['International Vaccine Institute'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['July 15, 2020'],\n",
       "    'CompletionDate': ['February 22, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 185,\n",
       "    'NCTId': ['NCT04398147'],\n",
       "    'BriefTitle': ['Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'vaccine',\n",
       "     'Ad5',\n",
       "     'Safety',\n",
       "     'Immunogenicity',\n",
       "     'Dose-escalation',\n",
       "     'SARS-CoV-2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['696'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)',\n",
       "     'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Canada'],\n",
       "    'OrgFullName': ['CanSino Biologics Inc.'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['August 1, 2020'],\n",
       "    'CompletionDate': ['December 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 186,\n",
       "    'NCTId': ['NCT04565197'],\n",
       "    'BriefTitle': ['Convalescent Plasma Therapy for COVID-19 Patients'],\n",
       "    'Condition': ['SARS-CoV Infection'],\n",
       "    'Keyword': ['COVID-19, Convalescent plasma therapy'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Early Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['20'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['convalescent plasma'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Pakistan'],\n",
       "    'OrgFullName': ['Lahore General Hospital'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['May 1, 2020'],\n",
       "    'CompletionDate': ['December 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 187,\n",
       "    'NCTId': ['NCT04333732'],\n",
       "    'BriefTitle': ['CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION'],\n",
       "    'Condition': ['COVID 19'],\n",
       "    'Keyword': ['COVID 19', 'Health care workers', 'M-M-R II ®'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['30000'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['MR or M-M-R II ® vaccine', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'Canada',\n",
       "     'Ghana',\n",
       "     'Ireland',\n",
       "     'Netherlands',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'Uganda',\n",
       "     'United Kingdom',\n",
       "     'Zambia',\n",
       "     'Zambia',\n",
       "     'Zimbabwe'],\n",
       "    'OrgFullName': ['Washington University School of Medicine'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 4, 2020'],\n",
       "    'CompletionDate': ['August 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 188,\n",
       "    'NCTId': ['NCT04480957'],\n",
       "    'BriefTitle': ['Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects'],\n",
       "    'Condition': ['SARS-CoV-2'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['92'],\n",
       "    'InterventionType': ['Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Biological',\n",
       "     'Other'],\n",
       "    'InterventionName': ['ARCT-021 Dose 1',\n",
       "     'ARCT-021 Dose 2',\n",
       "     'ARCT-021 Dose 3',\n",
       "     'ARCT-021 Dose 4',\n",
       "     'ARCT-021 Dose Regimen 1',\n",
       "     'ARCT-021 Dose Regimen 2',\n",
       "     'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Singapore'],\n",
       "    'OrgFullName': ['Arcturus Therapeutics, Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 4, 2020'],\n",
       "    'CompletionDate': ['January 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 189,\n",
       "    'NCTId': ['NCT04441047'],\n",
       "    'BriefTitle': ['Universal Anti-Viral Vaccine for Healthy Elderly Adults'],\n",
       "    'Condition': ['Virus Diseases'],\n",
       "    'Keyword': ['vaccine', 'COVID-19', 'AlloStim'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['40'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['AlloStim'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Immunovative Therapies, Ltd.'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 6, 2021'],\n",
       "    'CompletionDate': ['December 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 190,\n",
       "    'NCTId': ['NCT04642638'],\n",
       "    'BriefTitle': ['Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure'],\n",
       "    'Condition': ['Coronavirus Infection',\n",
       "     'Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)',\n",
       "     'COVID-19 Disease'],\n",
       "    'Keyword': ['DNA vaccine', 'Electroporation', 'Healthy', 'COVID-19'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['6578'],\n",
       "    'InterventionType': ['Drug', 'Device', 'Drug', 'Device'],\n",
       "    'InterventionName': ['INO-4800',\n",
       "     'CELLECTRA® 2000',\n",
       "     'Placebo',\n",
       "     'CELLECTRA® 2000'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['Inovio Pharmaceuticals'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 30, 2020'],\n",
       "    'CompletionDate': ['September 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 191,\n",
       "    'NCTId': ['NCT04336410'],\n",
       "    'BriefTitle': ['Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers'],\n",
       "    'Condition': ['Coronavirus Infection'],\n",
       "    'Keyword': ['DNA vaccine', 'Electroporation'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['120'],\n",
       "    'InterventionType': ['Drug', 'Device'],\n",
       "    'InterventionName': ['INO-4800', 'CELLECTRA® 2000'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States', 'United States', 'United States'],\n",
       "    'OrgFullName': ['Inovio Pharmaceuticals'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['April 3, 2020'],\n",
       "    'CompletionDate': ['July 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 192,\n",
       "    'NCTId': ['NCT04550351'],\n",
       "    'BriefTitle': ['Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old)'],\n",
       "    'Condition': ['Coronavirus'],\n",
       "    'Keyword': ['Recombinant Novel Coronavirus Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['50'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Biological'],\n",
       "    'InterventionName': ['Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group',\n",
       "     'Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group',\n",
       "     'Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['August 19, 2020'],\n",
       "    'CompletionDate': ['December 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 193,\n",
       "    'NCTId': ['NCT04569786'],\n",
       "    'BriefTitle': ['Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)'],\n",
       "    'Condition': ['Coronavirus Disease (COVID-19)'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['252'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['V590', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['Merck Sharp & Dohme Corp.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 29, 2020'],\n",
       "    'CompletionDate': ['January 10, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 194,\n",
       "    'NCTId': ['NCT04679909'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)'],\n",
       "    'Condition': ['Healthy Volunteers'],\n",
       "    'Keyword': ['COVID-19', 'SARS-CoV-2', 'Intranasal Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['180'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['AdCOVID', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Altimmune, Inc.'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 2020'],\n",
       "    'CompletionDate': ['February 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 195,\n",
       "    'NCTId': ['NCT04025580'],\n",
       "    'BriefTitle': ['Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine'],\n",
       "    'Condition': ['Healthy Volunteer', 'COVID-19'],\n",
       "    'Keyword': ['Systems Biology', 'Immunology'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Basic Science'],\n",
       "    'EnrollmentCount': ['300'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Biological'],\n",
       "    'InterventionName': ['Flucelvax', 'Fluvirin', 'Fluzone High Dose'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['National Institutes of Health Clinical Center (CC)'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 2, 2019'],\n",
       "    'CompletionDate': ['December 31, 2025'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 196,\n",
       "    'NCTId': ['NCT04375124'],\n",
       "    'BriefTitle': ['Treatment of Angiotensin Peptide (1-7) for COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['20'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Biological/Vaccine: Angiotensin peptide (1-7) derived plasma'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Turkey'],\n",
       "    'OrgFullName': ['Kanuni Sultan Suleyman Training and Research Hospital'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 25, 2020'],\n",
       "    'CompletionDate': ['September 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['No Intervention', 'Active Comparator']},\n",
       "   {'Rank': 197,\n",
       "    'NCTId': ['NCT04568044'],\n",
       "    'BriefTitle': ['Evaluation of Humoral Immunity Following COVID-19 in Pregnancy'],\n",
       "    'Condition': ['COVID-19', 'Pregnancy Related', 'Influenza, Human'],\n",
       "    'Keyword': ['Pregnancy',\n",
       "     'COVID-19',\n",
       "     'Immunity',\n",
       "     'Influenza',\n",
       "     'Vaccination'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['96'],\n",
       "    'InterventionType': ['Procedure'],\n",
       "    'InterventionName': ['Blood sample'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United Kingdom', 'United Kingdom'],\n",
       "    'OrgFullName': ['Imperial College London'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 16, 2020'],\n",
       "    'CompletionDate': ['July 3, 2023'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 198,\n",
       "    'NCTId': ['NCT04387409'],\n",
       "    'BriefTitle': [\"Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic\"],\n",
       "    'Condition': ['Infection, Respiratory Tract'],\n",
       "    'Keyword': ['infectious respiratory diseases', 'COVID-19'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['59'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['VPM1002', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Germany', 'Germany', 'Germany'],\n",
       "    'OrgFullName': ['Vakzine Projekt Management GmbH'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['May 25, 2020'],\n",
       "    'CompletionDate': ['May 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Placebo Comparator']},\n",
       "   {'Rank': 199,\n",
       "    'NCTId': ['NCT04344938'],\n",
       "    'BriefTitle': ['Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality'],\n",
       "    'Condition': ['Covid 19 Pandemic From Ethical View'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['874'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Assiut University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['April 2020'],\n",
       "    'CompletionDate': ['July 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 200,\n",
       "    'NCTId': ['NCT04375176'],\n",
       "    'BriefTitle': ['Monocytes and NK Cells Activity in Covid-19 Patients'],\n",
       "    'Condition': ['COVID-19',\n",
       "     'Severe Acute Respiratory Syndrome Coronavirus 2',\n",
       "     'Immunomodulation'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['150'],\n",
       "    'InterventionType': ['Diagnostic Test'],\n",
       "    'InterventionName': ['Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Italy'],\n",
       "    'OrgFullName': [\"Università degli Studi dell'Insubria\"],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 27, 2020'],\n",
       "    'CompletionDate': ['October 31, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 201,\n",
       "    'NCTId': ['NCT04372589'],\n",
       "    'BriefTitle': ['Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)'],\n",
       "    'Condition': ['COVID-19', 'Pneumonia'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['3000'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Heparin'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Mexico'],\n",
       "    'OrgFullName': ['University of Manitoba'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 20, 2020'],\n",
       "    'CompletionDate': ['January 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 202,\n",
       "    'NCTId': ['NCT04690816'],\n",
       "    'BriefTitle': ['Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases'],\n",
       "    'Condition': ['Systemic Autoimmune Diseases'],\n",
       "    'Keyword': ['COVID-19 Study',\n",
       "     'Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Disease',\n",
       "     'An Observational Prospective Study for COVID-19'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['350'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['National Institutes of Health Clinical Center (CC)'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['January 20, 2021'],\n",
       "    'CompletionDate': ['December 31, 2024'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 203,\n",
       "    'NCTId': ['NCT04712110'],\n",
       "    'BriefTitle': ['A Study of TAK-019 in Healthy Japanese Adults (COVID-19)'],\n",
       "    'Condition': ['Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['TAK-019', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Takeda'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['February 20, 2021'],\n",
       "    'CompletionDate': ['April 4, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 204,\n",
       "    'NCTId': ['NCT04435379'],\n",
       "    'BriefTitle': ['Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic'],\n",
       "    'Condition': ['Infection, Respiratory Tract'],\n",
       "    'Keyword': ['infectious respiratory diseases'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['2038'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['VPM1002', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany'],\n",
       "    'OrgFullName': ['Vakzine Projekt Management GmbH'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 18, 2020'],\n",
       "    'CompletionDate': ['September 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 205,\n",
       "    'NCTId': ['NCT04445194'],\n",
       "    'BriefTitle': ['Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine'],\n",
       "    'Condition': ['Coronavirus'],\n",
       "    'Keyword': ['Recombinant Novel Coronavirus Vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['50'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Biological'],\n",
       "    'InterventionName': ['Recombinant new coronavirus vaccine (CHO cell) low-dose group',\n",
       "     'Recombinant new coronavirus vaccine (CHO cells) high-dose group',\n",
       "     'Recombinant new coronavirus vaccine (CHO cells) placebo group'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['June 22, 2020'],\n",
       "    'CompletionDate': ['September 20, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 206,\n",
       "    'NCTId': ['NCT04346147'],\n",
       "    'BriefTitle': ['Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19'],\n",
       "    'Condition': ['COVID-19 Pneumonia'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['165'],\n",
       "    'InterventionType': ['Drug', 'Drug', 'Other'],\n",
       "    'InterventionName': ['Imatinib tablets',\n",
       "     'Baricitinib Oral Tablet',\n",
       "     'Supportive tratment'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Spain'],\n",
       "    'OrgFullName': ['Hospital Universitario de Fuenlabrada'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 13, 2020'],\n",
       "    'CompletionDate': ['May 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 207,\n",
       "    'NCTId': ['NCT04347681'],\n",
       "    'BriefTitle': ['Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19'],\n",
       "    'Condition': ['Convalescent Plasma for COVID 19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['575'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['convalescent plasma from recovered COVID 19 donor'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Saudi Arabia',\n",
       "     'Saudi Arabia',\n",
       "     'Saudi Arabia',\n",
       "     'Saudi Arabia',\n",
       "     'Saudi Arabia',\n",
       "     'Saudi Arabia',\n",
       "     'Saudi Arabia',\n",
       "     'Saudi Arabia',\n",
       "     'Saudi Arabia',\n",
       "     'Saudi Arabia',\n",
       "     'Saudi Arabia',\n",
       "     'Saudi Arabia',\n",
       "     'Saudi Arabia',\n",
       "     'Saudi Arabia'],\n",
       "    'OrgFullName': ['King Fahad Specialist Hospital Dammam'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 18, 2020'],\n",
       "    'CompletionDate': ['April 11, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 208,\n",
       "    'NCTId': ['NCT04569019'],\n",
       "    'BriefTitle': ['Attitudes Towards Influenza Vaccinations Among the Healthcare Workers of Medical University of Warsaw'],\n",
       "    'Condition': ['Vaccnation in HCW'],\n",
       "    'Keyword': ['Medicine Vaccinations among healthcare professionals ,Vaccinations against influenza ,COVID19 pandemic and its impact on influenza vaccination coverage'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['1000'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Vacciantion status in health care workers'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Poland'],\n",
       "    'OrgFullName': ['Medical University of Warsaw'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 1, 2020'],\n",
       "    'CompletionDate': ['July 1, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 209,\n",
       "    'NCTId': ['NCT03209713'],\n",
       "    'BriefTitle': ['Edtech-HPV: A Community Approach Using Education and Technology to Increase HPV Vaccination'],\n",
       "    'Condition': ['Parents'],\n",
       "    'Keyword': ['Mexican', 'Mexican-American', '17-336'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['800'],\n",
       "    'InterventionType': ['Behavioral', 'Behavioral'],\n",
       "    'InterventionName': ['HPV Vaccine Education', 'Text Messaging Reminder'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['Memorial Sloan Kettering Cancer Center'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 28, 2017'],\n",
       "    'CompletionDate': ['June 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Experimental']},\n",
       "   {'Rank': 210,\n",
       "    'NCTId': ['NCT04061382'],\n",
       "    'BriefTitle': ['Sero-epidemiological Survey of England in 2019/2020'],\n",
       "    'Condition': ['Serogroup C Meningococcal Meningitis',\n",
       "     'Diphtheria',\n",
       "     'COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['3800'],\n",
       "    'InterventionType': ['Procedure', 'Procedure'],\n",
       "    'InterventionName': ['Venepuncture', 'Oral fluid swab'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult'],\n",
       "    'LocationCountry': ['United Kingdom'],\n",
       "    'OrgFullName': ['University of Oxford'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 15, 2019'],\n",
       "    'CompletionDate': ['June 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 211,\n",
       "    'NCTId': ['NCT04431414'],\n",
       "    'BriefTitle': ['A Study of Immune Responses to the Virus That Causes COVID-19'],\n",
       "    'Condition': ['SARS-CoV-2', 'COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['800'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Sample collection'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Argentina',\n",
       "     'Argentina',\n",
       "     'Botswana',\n",
       "     'Brazil',\n",
       "     'Brazil',\n",
       "     'Kenya',\n",
       "     'Malawi',\n",
       "     'Mexico',\n",
       "     'Mozambique',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'Peru',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'South Africa',\n",
       "     'Tanzania',\n",
       "     'Zambia',\n",
       "     'Zambia',\n",
       "     'Zambia',\n",
       "     'Zimbabwe',\n",
       "     'Zimbabwe',\n",
       "     'Zimbabwe'],\n",
       "    'OrgFullName': ['COVID-19 Prevention Network'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['July 20, 2020'],\n",
       "    'CompletionDate': ['January 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 212,\n",
       "    'NCTId': ['NCT04332380'],\n",
       "    'BriefTitle': ['Convalescent Plasma for Patients With COVID-19: A Pilot Study'],\n",
       "    'Condition': ['Coronavirus', 'Coronavirus Infection'],\n",
       "    'Keyword': ['COVID-19', 'Coronavirus Disease 2019'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['10'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Plasma'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Colombia'],\n",
       "    'OrgFullName': ['Universidad del Rosario'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['May 1, 2020'],\n",
       "    'CompletionDate': ['July 28, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 213,\n",
       "    'NCTId': ['NCT04476940'],\n",
       "    'BriefTitle': ['COVID-19 Breastfeeding Guideline for African-Americans'],\n",
       "    'Condition': ['Covid19', 'Exclusive Breastfeeding'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Exclusive Breastfeeding',\n",
       "     'Breastfeeding Guidelines',\n",
       "     'African American'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Behavioral'],\n",
       "    'InterventionName': ['COVID-19 Breastfeeding Support'],\n",
       "    'Gender': ['Female'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Meharry Medical College'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['September 2020'],\n",
       "    'CompletionDate': ['June 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 214,\n",
       "    'NCTId': ['NCT04332835'],\n",
       "    'BriefTitle': ['Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study'],\n",
       "    'Condition': ['Coronavirus', 'Coronavirus Infection'],\n",
       "    'Keyword': ['COVID-19', 'Coronavirus Disease 2019'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['92'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['Plasma', 'Standard Therapy'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Colombia'],\n",
       "    'OrgFullName': ['Universidad del Rosario'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['August 8, 2020'],\n",
       "    'CompletionDate': ['November 15, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 215,\n",
       "    'NCTId': ['NCT04388436'],\n",
       "    'BriefTitle': ['Post Covid-19 Cardiopulmonary and Immunological Changes'],\n",
       "    'Condition': ['COVID'],\n",
       "    'Keyword': ['covid-19 cardiopulmonary immunological impact'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Egypt'],\n",
       "    'OrgFullName': ['Mansoura University'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['May 11, 2020'],\n",
       "    'CompletionDate': ['October 10, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 216,\n",
       "    'NCTId': ['NCT04702945'],\n",
       "    'BriefTitle': ['Canadian COVID-19 Emergency Department Registry'],\n",
       "    'Condition': ['Covid-19'],\n",
       "    'Keyword': ['Coronavirus', 'Infectious diseases', 'Registry'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['200000'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada'],\n",
       "    'OrgFullName': ['University of British Columbia'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['March 1, 2020'],\n",
       "    'CompletionDate': ['December 31, 2023'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 217,\n",
       "    'NCTId': ['NCT04510233'],\n",
       "    'BriefTitle': ['Ivermectin Nasal Spray for COVID19 Patients'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['COVID19'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['60'],\n",
       "    'InterventionType': ['Drug', 'Drug', 'Other'],\n",
       "    'InterventionName': ['Ivermectin nasal',\n",
       "     'Ivermectin oral',\n",
       "     'standard care'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Tanta University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['September 2020'],\n",
       "    'CompletionDate': ['December 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 218,\n",
       "    'NCTId': ['NCT04530435'],\n",
       "    'BriefTitle': ['PEP Flute-selfcare in COVID-19'],\n",
       "    'Condition': ['COVID-19', 'SARS-CoV-2'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'SARS-CoV-2',\n",
       "     'Respiratory symptoms',\n",
       "     'Positive expiratory pressure',\n",
       "     'Positive expiratory pressure flute',\n",
       "     'Airway clearance techniques'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['400'],\n",
       "    'InterventionType': ['Device'],\n",
       "    'InterventionName': ['PEP flute'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Denmark'],\n",
       "    'OrgFullName': ['Bispebjerg Hospital'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 6, 2020'],\n",
       "    'CompletionDate': ['April 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 219,\n",
       "    'NCTId': ['NCT04397900'],\n",
       "    'BriefTitle': ['Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes'],\n",
       "    'Condition': ['Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection',\n",
       "     'Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['80'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States', 'United States'],\n",
       "    'OrgFullName': ['TScan Therapeutics, Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 9, 2020'],\n",
       "    'CompletionDate': ['July 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 220,\n",
       "    'NCTId': ['NCT04370288'],\n",
       "    'BriefTitle': ['Clinical Application of Methylene Blue for Treatment of Covid-19 Patients'],\n",
       "    'Condition': ['Covid-19'],\n",
       "    'Keyword': ['Covid-19', 'Coronavirus'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['20'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['MCN (Methylene blue, vitamin C, N-acetyl cysteine)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Iran, Islamic Republic of'],\n",
       "    'OrgFullName': ['Mashhad University of Medical Sciences'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 19, 2020'],\n",
       "    'CompletionDate': ['September 21, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['No Intervention', 'Experimental']},\n",
       "   {'Rank': 221,\n",
       "    'NCTId': ['NCT04360278'],\n",
       "    'BriefTitle': ['Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Titer', 'Antibodies'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['1500'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['National Institutes of Health Clinical Center (CC)'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 21, 2020'],\n",
       "    'CompletionDate': ['April 14, 2030'],\n",
       "    'IsFDARegulatedDrug': [],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 222,\n",
       "    'NCTId': ['NCT04530422'],\n",
       "    'BriefTitle': ['Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['SARS-COV-2',\n",
       "     'Covid-19',\n",
       "     'Sofosbuvir- Ledipasvir',\n",
       "     'Hydroxychloroquine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['250'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Sofosbuvir plus Ledipasvir'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Egypt'],\n",
       "    'OrgFullName': ['Almaza Military Fever Hospital'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['April 15, 2020'],\n",
       "    'CompletionDate': ['July 23, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 223,\n",
       "    'NCTId': ['NCT04467047'],\n",
       "    'BriefTitle': ['Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19'],\n",
       "    'Condition': ['COVID-19', 'Sars-CoV2'],\n",
       "    'Keyword': ['Mesenchymal Stromal Cells', 'COVID-19', 'Sars-CoV2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['10'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Mesenchymal Stromal Cells infusion'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Hospital de Clinicas de Porto Alegre'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['July 25, 2020'],\n",
       "    'CompletionDate': ['December 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 224,\n",
       "    'NCTId': ['NCT04606563'],\n",
       "    'BriefTitle': ['Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?'],\n",
       "    'Condition': ['Covid19', 'SARS-CoV Infection'],\n",
       "    'Keyword': ['ARBs',\n",
       "     'angiotensin II type 1 receptor blocker',\n",
       "     'ACEi',\n",
       "     'acute respiratory distress syndrome',\n",
       "     'COVID-19',\n",
       "     'coronavirus',\n",
       "     'multisite',\n",
       "     'Global',\n",
       "     'Canada',\n",
       "     'Acute kidney injury',\n",
       "     'acute cardiac injury',\n",
       "     'shock'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['1372'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Losartan'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Belgium',\n",
       "     'Belgium',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'France',\n",
       "     'Japan',\n",
       "     'Spain'],\n",
       "    'OrgFullName': ['University of British Columbia'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 9, 2020'],\n",
       "    'CompletionDate': ['June 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 225,\n",
       "    'NCTId': ['NCT04542967'],\n",
       "    'BriefTitle': ['Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease'],\n",
       "    'Condition': ['Severe COVID-19 Disease'],\n",
       "    'Keyword': ['SARS-CoV2',\n",
       "     'Convalescent Plasma',\n",
       "     'Severe Acute Respiratory Syndrome'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['150'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Biological'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Mexico'],\n",
       "    'OrgFullName': ['Hospital Central Militar'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 23, 2020'],\n",
       "    'CompletionDate': ['September 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['No Intervention', 'Experimental']},\n",
       "   {'Rank': 226,\n",
       "    'NCTId': ['NCT04466657'],\n",
       "    'BriefTitle': ['Antioxidant Therapy for COVID-19 Study'],\n",
       "    'Condition': ['Covid-19'],\n",
       "    'Keyword': ['SARS-CoV infection', 'COVID-19', 'coronavirus'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Supportive Care'],\n",
       "    'EnrollmentCount': ['90'],\n",
       "    'InterventionType': ['Dietary Supplement', 'Other'],\n",
       "    'InterventionName': ['Antioxidation Therapy', 'Standard of Care'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Nigeria',\n",
       "     'Nigeria',\n",
       "     'Nigeria',\n",
       "     'Nigeria',\n",
       "     'Nigeria',\n",
       "     'Nigeria',\n",
       "     'Nigeria',\n",
       "     'Nigeria',\n",
       "     'Nigeria',\n",
       "     'Nigeria',\n",
       "     'Nigeria'],\n",
       "    'OrgFullName': ['Obafemi Awolowo University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['November 1, 2020'],\n",
       "    'CompletionDate': ['April 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Experimental']},\n",
       "   {'Rank': 227,\n",
       "    'NCTId': ['NCT04459286'],\n",
       "    'BriefTitle': ['The Nitazoxanide Plus Atazanavir for COVID-19 Study'],\n",
       "    'Condition': ['Covid-19'],\n",
       "    'Keyword': ['SARS-CoV infection', 'COVID-19', 'coronavirus'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['98'],\n",
       "    'InterventionType': ['Drug', 'Other'],\n",
       "    'InterventionName': ['Nitazoxanide and atazanavir/ritonavir',\n",
       "     'Standard of Care'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Nigeria', 'Nigeria', 'Nigeria', 'Nigeria'],\n",
       "    'OrgFullName': ['Obafemi Awolowo University'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 9, 2020'],\n",
       "    'CompletionDate': ['March 21, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Experimental']},\n",
       "   {'Rank': 228,\n",
       "    'NCTId': ['NCT04621071'],\n",
       "    'BriefTitle': ['Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['covid', 'sars-cov-2', 'coronavirus'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['84'],\n",
       "    'InterventionType': ['Dietary Supplement', 'Dietary Supplement'],\n",
       "    'InterventionName': ['Probiotics (2 strains 10x10^9 UFC)',\n",
       "     'Placebo (potato starch and magnesium stearate)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Canada'],\n",
       "    'OrgFullName': ['Centre de recherche du Centre hospitalier universitaire de Sherbrooke'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['November 16, 2020'],\n",
       "    'CompletionDate': ['March 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 229,\n",
       "    'NCTId': ['NCT04333355'],\n",
       "    'BriefTitle': ['Safety in Convalescent Plasma Transfusion to COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19', 'SARS-CoV-2', 'Convalescent plasma'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['20'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Convalescent Plasma'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Mexico'],\n",
       "    'OrgFullName': ['Hospital San Jose Tec de Monterrey'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 8, 2020'],\n",
       "    'CompletionDate': ['April 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 230,\n",
       "    'NCTId': ['NCT04359602'],\n",
       "    'BriefTitle': ['COVID-19 Recovered Volunteer Research Participant Pool Registry'],\n",
       "    'Condition': ['Recovered From COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['10000'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['University of California, Los Angeles'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 8, 2020'],\n",
       "    'CompletionDate': ['April 20, 2042'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 231,\n",
       "    'NCTId': ['NCT04379466'],\n",
       "    'BriefTitle': ['Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'T cell receptor',\n",
       "     'Effector T cells',\n",
       "     'Regulatory T cells',\n",
       "     'Single cell sequencing',\n",
       "     'Modelisation',\n",
       "     'Pathophysiology',\n",
       "     'Biomarkers'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['60'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['Assistance Publique - Hôpitaux de Paris'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 5, 2020'],\n",
       "    'CompletionDate': ['April 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 232,\n",
       "    'NCTId': ['NCT04627233'],\n",
       "    'BriefTitle': ['Ezrin Peptide (HEP-1) for Treatment of Coronavirus Disease (COVID-19) Infection'],\n",
       "    'Condition': ['Covid19', 'Treatment', 'Corona Virus Infection'],\n",
       "    'Keyword': ['COVID19', 'Treatment', 'Ezrin peptide', 'HEP-1'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['20'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['Human Ezrin Peptide 1 (HEP1)', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Iran, Islamic Republic of'],\n",
       "    'OrgFullName': ['Shahid Beheshti University of Medical Sciences'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 20, 2020'],\n",
       "    'CompletionDate': ['April 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Placebo Comparator', 'Experimental']},\n",
       "   {'Rank': 233,\n",
       "    'NCTId': ['NCT04634370'],\n",
       "    'BriefTitle': ['Fase I Clinical Trial on NK Cells for COVID-19'],\n",
       "    'Condition': ['Covid19', 'Sars-cov 2'],\n",
       "    'Keyword': ['Natural Killer Cells', 'COVID-19', 'Sars-CoV2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['24'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Natural Killer Cells infusion'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Brazil'],\n",
       "    'OrgFullName': ['Hospital de Clinicas de Porto Alegre'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 2, 2021'],\n",
       "    'CompletionDate': ['March 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 234,\n",
       "    'NCTId': ['NCT04452812'],\n",
       "    'BriefTitle': ['Statistical and Epidemiological Study Based on the Use of Convalescent Plasma for the Management of Patients With COVID-19'],\n",
       "    'Condition': ['COVID-19 Pneumonia', 'Convalescent Plasma'],\n",
       "    'Keyword': ['COVID-19', 'Convalescent plasma', 'plasmapheresis'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['15'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Convalescent plasma'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Mexico'],\n",
       "    'OrgFullName': ['Universidad Autonoma de Coahuila'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['July 6, 2020'],\n",
       "    'CompletionDate': ['April 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 235,\n",
       "    'NCTId': ['NCT04312243'],\n",
       "    'BriefTitle': ['NO Prevention of COVID-19 for Healthcare Providers'],\n",
       "    'Condition': ['Coronavirus Infections', 'Healthcare Associated Infection'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['470'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Inhaled nitric oxide gas'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Massachusetts General Hospital'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 7, 2020'],\n",
       "    'CompletionDate': ['April 7, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 236,\n",
       "    'NCTId': ['NCT04590365'],\n",
       "    'BriefTitle': ['Iota-carrageenan Nasal Spray COVID-19 Prophylaxis for Healthcare Professionals'],\n",
       "    'Condition': ['COVID-19', 'SARS-CoV 2'],\n",
       "    'Keyword': ['Carrageenan', 'Nasal spray', 'Anti-viral', 'Prevention'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['480'],\n",
       "    'InterventionType': ['Device', 'Device'],\n",
       "    'InterventionName': ['Carrageenan nasal and throat spray',\n",
       "     'Saline nasal and throat spray'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Swansea University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 20, 2020'],\n",
       "    'CompletionDate': ['December 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 237,\n",
       "    'NCTId': ['NCT04644198'],\n",
       "    'BriefTitle': ['Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica'],\n",
       "    'Condition': ['COVID-19, Convalescent Plasma Treatment'],\n",
       "    'Keyword': ['Donor',\n",
       "     'Recipients',\n",
       "     'Transfusion',\n",
       "     'Convalescent plasma',\n",
       "     'COVID Viral Load'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['30'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Convalescent Plasma Infusion'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Jamaica'],\n",
       "    'OrgFullName': ['The University of The West Indies'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['February 1, 2021'],\n",
       "    'CompletionDate': ['December 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'No Intervention']},\n",
       "   {'Rank': 238,\n",
       "    'NCTId': ['NCT04650035'],\n",
       "    'BriefTitle': ['The Impact of COVID-19 on Surgical Practice in Jordan During the Second Outbreak'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['60'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Jordan'],\n",
       "    'OrgFullName': ['Yarmouk University'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['November 1, 2020'],\n",
       "    'CompletionDate': ['November 10, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 239,\n",
       "    'NCTId': ['NCT04546854'],\n",
       "    'BriefTitle': ['Influenza 2020/2021'],\n",
       "    'Condition': ['Influenza Vaccine'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Other'],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Behavioral'],\n",
       "    'InterventionName': ['Appeals'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United Kingdom'],\n",
       "    'OrgFullName': ['University of Warwick'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['September 21, 2020'],\n",
       "    'CompletionDate': ['September 21, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 240,\n",
       "    'NCTId': ['NCT04345653'],\n",
       "    'BriefTitle': ['Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers'],\n",
       "    'Condition': ['COVID19'],\n",
       "    'Keyword': ['covid-19', 'workers', 'prevention'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['44'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Hydroxychloroquine Sulfate (HCQ)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Hackensack Meridian Health'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['April 14, 2020'],\n",
       "    'CompletionDate': ['April 8, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 241,\n",
       "    'NCTId': ['NCT04494204'],\n",
       "    'BriefTitle': ['Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients'],\n",
       "    'Condition': ['Treatment of Covid-19 Virus Infection'],\n",
       "    'Keyword': ['coronavirus',\n",
       "     'covid-19',\n",
       "     'covid',\n",
       "     'corona',\n",
       "     'coagulation',\n",
       "     'immunofree',\n",
       "     'mgcts',\n",
       "     'biogetica'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Combination Product'],\n",
       "    'InterventionName': ['Immunofree tablets and Reginmune capsule'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['India', 'India', 'India'],\n",
       "    'OrgFullName': ['Nutrin GmbH'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['August 7, 2020'],\n",
       "    'CompletionDate': ['December 20, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 242,\n",
       "    'NCTId': ['NCT04581148'],\n",
       "    'BriefTitle': ['SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)'],\n",
       "    'Condition': ['SARS-Cov2'],\n",
       "    'Keyword': ['SARS-Cov2', 'Pediatrics'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['2000'],\n",
       "    'InterventionType': ['Diagnostic Test'],\n",
       "    'InterventionName': ['Blood test for IgG antibodies against SARS-CoV-2'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['University of Erlangen-Nürnberg Medical School'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['October 5, 2020'],\n",
       "    'CompletionDate': ['May 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 243,\n",
       "    'NCTId': ['NCT04542941'],\n",
       "    'BriefTitle': ['Assessment of Safety and Efficacy of CCP'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['136'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['COVID Convalescent Plasma'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Uganda'],\n",
       "    'OrgFullName': ['Makerere University'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['June 16, 2020'],\n",
       "    'CompletionDate': ['December 31, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'No Intervention']},\n",
       "   {'Rank': 244,\n",
       "    'NCTId': ['NCT04332094'],\n",
       "    'BriefTitle': ['Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Tocilizumab'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['276'],\n",
       "    'InterventionType': ['Drug', 'Drug', 'Drug'],\n",
       "    'InterventionName': ['Tocilizumab', 'Hydroxychloroquine', 'Azithromycin'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Spain'],\n",
       "    'OrgFullName': [\"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau\"],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 2, 2020'],\n",
       "    'CompletionDate': ['October 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 245,\n",
       "    'NCTId': ['NCT04383652'],\n",
       "    'BriefTitle': ['Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales'],\n",
       "    'Condition': ['COVID'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Biological sample and clinical data collection'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia',\n",
       "     'Australia'],\n",
       "    'OrgFullName': ['Kirby Institute'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 6, 2020'],\n",
       "    'CompletionDate': ['June 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 246,\n",
       "    'NCTId': ['NCT04428008'],\n",
       "    'BriefTitle': ['Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Thymalfasin',\n",
       "     'Thymosin alpha 1',\n",
       "     'ZADAXIN',\n",
       "     'Hemodialysis'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['240'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Thymalfasin'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Inova Health System'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['January 12, 2021'],\n",
       "    'CompletionDate': ['January 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 247,\n",
       "    'NCTId': ['NCT04668469'],\n",
       "    'BriefTitle': ['Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['Ivermectin', 'COVID-19', 'Hydroxychloroquine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['600'],\n",
       "    'InterventionType': ['Drug', 'Drug', 'Behavioral'],\n",
       "    'InterventionName': ['Ivermectin',\n",
       "     'Hydroxychloroquine',\n",
       "     'personal protective Measures'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Egypt'],\n",
       "    'OrgFullName': ['Benha University'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['June 8, 2020'],\n",
       "    'CompletionDate': ['October 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Active Comparator',\n",
       "     'Experimental',\n",
       "     'Active Comparator',\n",
       "     'Experimental',\n",
       "     'Active Comparator']},\n",
       "   {'Rank': 248,\n",
       "    'NCTId': ['NCT04320277'],\n",
       "    'BriefTitle': ['Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.'],\n",
       "    'Condition': ['Pharmacological Action'],\n",
       "    'Keyword': ['COVID-19', 'Baricitinib', 'Moderate disease', 'Infection'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Baricitinib'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Italy'],\n",
       "    'OrgFullName': ['Hospital of Prato'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['May 16, 2020'],\n",
       "    'CompletionDate': ['July 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 249,\n",
       "    'NCTId': ['NCT04362865'],\n",
       "    'BriefTitle': ['Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Pandemic', 'Coronavirus', 'SARS-CoV-2'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['180'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['National Institutes of Health Clinical Center (CC)'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 27, 2020'],\n",
       "    'CompletionDate': ['December 1, 2024'],\n",
       "    'IsFDARegulatedDrug': [],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 250,\n",
       "    'NCTId': ['NCT04328493'],\n",
       "    'BriefTitle': ['The Vietnam Chloroquine Treatment on COVID-19'],\n",
       "    'Condition': ['SARS-CoV-2 Infection', 'COVID-19'],\n",
       "    'Keyword': ['SARS-CoV-2', 'COVID-19', 'chloroquine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['250'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Chloroquine phosphate'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Vietnam', 'Vietnam', 'Vietnam', 'Vietnam', 'Vietnam'],\n",
       "    'OrgFullName': ['Oxford University Clinical Research Unit, Vietnam'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 7, 2020'],\n",
       "    'CompletionDate': ['April 1, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['No Intervention', 'Experimental']},\n",
       "   {'Rank': 251,\n",
       "    'NCTId': ['NCT04433039'],\n",
       "    'BriefTitle': ['COVID19 Versus H1N1: Radiological Challenge During Next Influenza Season Rising'],\n",
       "    'Condition': ['COVID'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['130'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Egypt'],\n",
       "    'OrgFullName': ['Alexandria University'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['May 22, 2020'],\n",
       "    'CompletionDate': ['June 14, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 252,\n",
       "    'NCTId': ['NCT04392427'],\n",
       "    'BriefTitle': ['New Antiviral Drugs for Treatment of COVID-19'],\n",
       "    'Condition': ['COVID', 'Drug Effect'],\n",
       "    'Keyword': ['COVID-19;', 'clinical trial', 'corona virus'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Egypt'],\n",
       "    'OrgFullName': ['Mansoura University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['October 2020'],\n",
       "    'CompletionDate': ['May 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'No Intervention']},\n",
       "   {'Rank': 253,\n",
       "    'NCTId': ['NCT04412382'],\n",
       "    'BriefTitle': ['Covid-19: Possible Role of Neutrophil Extracellular Traps'],\n",
       "    'Condition': ['Covid-19'],\n",
       "    'Keyword': ['Covid-19', 'neutrophil extracellular traps'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Diagnostic Test'],\n",
       "    'InterventionName': ['NETosis markers'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Italy'],\n",
       "    'OrgFullName': ['Azienda Ospedaliera Universitaria Integrata Verona'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 1, 2020'],\n",
       "    'CompletionDate': ['December 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 254,\n",
       "    'NCTId': ['NCT04431466'],\n",
       "    'BriefTitle': ['A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19'],\n",
       "    'Condition': ['Coronavirus Infection'],\n",
       "    'Keyword': ['coronavirus infections',\n",
       "     'SARS-CoV-2',\n",
       "     'COVID-19',\n",
       "     'ivermectin',\n",
       "     'clinical trial'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['64'],\n",
       "    'InterventionType': ['Drug', 'Other'],\n",
       "    'InterventionName': ['Ivermectin', 'Standard treatment for COVID-19'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Brazil', 'Brazil'],\n",
       "    'OrgFullName': ['Universidade Federal de Sao Carlos'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['July 1, 2020'],\n",
       "    'CompletionDate': ['July 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 255,\n",
       "    'NCTId': ['NCT04318314'],\n",
       "    'BriefTitle': ['COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2'],\n",
       "    'Condition': ['Health Care Worker Patient Transmission',\n",
       "     'Coronavirus',\n",
       "     'Coronavirus Infections',\n",
       "     'Immunological Abnormality'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['400'],\n",
       "    'InterventionType': ['Diagnostic Test'],\n",
       "    'InterventionName': ['COPAN swabbing and blood sample collection'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United Kingdom', 'United Kingdom'],\n",
       "    'OrgFullName': ['University College, London'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['March 18, 2020'],\n",
       "    'CompletionDate': ['December 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 256,\n",
       "    'NCTId': ['NCT04358783'],\n",
       "    'BriefTitle': ['Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia'],\n",
       "    'Condition': ['Coronavirus Infection'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Plasma from patients cured',\n",
       "     'SARS-CoV-2 pneumonia'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['30'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['Plasma', 'Best Available Therapy'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Mexico'],\n",
       "    'OrgFullName': ['Hospital Universitario Dr. Jose E. Gonzalez'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 27, 2020'],\n",
       "    'CompletionDate': ['May 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 257,\n",
       "    'NCTId': ['NCT04385186'],\n",
       "    'BriefTitle': ['Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19'],\n",
       "    'Condition': ['Infections, Coronavirus'],\n",
       "    'Keyword': ['CoViD-19',\n",
       "     'Pathogen inactivation',\n",
       "     'Apheresis',\n",
       "     'Convalescent plasma'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['60'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['Inactivated convalescent plasma',\n",
       "     'Support treatment'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia',\n",
       "     'Colombia'],\n",
       "    'OrgFullName': ['National Blood Center Foundation, Hemolife'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['June 20, 2020'],\n",
       "    'CompletionDate': ['December 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 258,\n",
       "    'NCTId': ['NCT04385108'],\n",
       "    'BriefTitle': ['Predictive Immune Biomarkers for COVID-19 Pathogenesis'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['SARS-CoV-2',\n",
       "     'COVID-19',\n",
       "     'predictive medicine',\n",
       "     'pathophysiology',\n",
       "     'immune responses'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Basic Science'],\n",
       "    'EnrollmentCount': ['400'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Blood collection on admission and longitudinally',\n",
       "     'Blood collection on their first consultation and 10 to 14 days later'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['University Hospital, Toulouse'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['March 4, 2020'],\n",
       "    'CompletionDate': ['December 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 259,\n",
       "    'NCTId': ['NCT04565067'],\n",
       "    'BriefTitle': ['Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['CD8 T Cell',\n",
       "     'COVID-19',\n",
       "     'Immune Response',\n",
       "     'Epitope',\n",
       "     'Aging'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['120'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['National Institutes of Health Clinical Center (CC)'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['January 20, 2021'],\n",
       "    'CompletionDate': ['September 1, 2022'],\n",
       "    'IsFDARegulatedDrug': [],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 260,\n",
       "    'NCTId': ['NCT04292340'],\n",
       "    'BriefTitle': ['Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19'],\n",
       "    'Condition': ['Coronavirus'],\n",
       "    'Keyword': ['Plasma transfusion', 'Coronavirus'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['15'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Shanghai Public Health Clinical Center'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['February 1, 2020'],\n",
       "    'CompletionDate': ['December 31, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 261,\n",
       "    'NCTId': ['NCT04563650'],\n",
       "    'BriefTitle': ['COVID-19 Serology and Immunosenescence'],\n",
       "    'Condition': ['Covid19',\n",
       "     'Geriatric Medicine',\n",
       "     'Seroconversion',\n",
       "     'Immunosenescence'],\n",
       "    'Keyword': ['Covid19',\n",
       "     'geriatric medicine',\n",
       "     'seroconversion',\n",
       "     'immunosenescence'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Screening'],\n",
       "    'EnrollmentCount': ['330'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['blood sample'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['Centre Hospitalier Universitaire, Amiens'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 18, 2020'],\n",
       "    'CompletionDate': ['November 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 262,\n",
       "    'NCTId': ['NCT04328285'],\n",
       "    'BriefTitle': ['Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['SARS-CoV-2',\n",
       "     'COVID-19',\n",
       "     'nasopharyngeal swab',\n",
       "     'pneumonia',\n",
       "     'Hydroxychloroquine',\n",
       "     'Lopinavir/ritonavir',\n",
       "     'Healthcare Workers'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1200'],\n",
       "    'InterventionType': ['Drug', 'Drug', 'Drug', 'Drug'],\n",
       "    'InterventionName': ['Hydroxychloroquine',\n",
       "     'Placebo of Hydroxychloroquine',\n",
       "     'Lopinavir and ritonavir',\n",
       "     'Placebo of LPV/r Tablets'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France'],\n",
       "    'OrgFullName': ['Centre Hospitalier Universitaire de Saint Etienne'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['April 14, 2020'],\n",
       "    'CompletionDate': ['March 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 263,\n",
       "    'NCTId': ['NCT04363268'],\n",
       "    'BriefTitle': ['ACCESS A Master Digital Surveillance Protocol for COVID-19'],\n",
       "    'Condition': ['Coronavirus',\n",
       "     'COVID',\n",
       "     'COVID-19',\n",
       "     'COVID19',\n",
       "     'Corona Virus Infection',\n",
       "     'Coronavirus Infection'],\n",
       "    'Keyword': ['COVID',\n",
       "     'COVID-19',\n",
       "     'Corona',\n",
       "     'Coronavirus',\n",
       "     'COVID19',\n",
       "     'Coronavirus Infection'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['1000000'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Medable Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 20, 2020'],\n",
       "    'CompletionDate': ['October 1, 2031'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 264,\n",
       "    'NCTId': ['NCT04444310'],\n",
       "    'BriefTitle': ['Antibody Responses in Contacts of COVID-19 Patients'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19', 'antibodies', 'IgG', 'IgM', 'SARs-CoV-2'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Egypt'],\n",
       "    'OrgFullName': ['Assiut University'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['June 15, 2020'],\n",
       "    'CompletionDate': ['September 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 265,\n",
       "    'NCTId': ['NCT04700462'],\n",
       "    'BriefTitle': ['COVID-19 Preventive Behavior in African Americans'],\n",
       "    'Condition': ['Covid19', 'Health Behavior'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Smartphone App',\n",
       "     'Preventative Behavior',\n",
       "     'Self-Management',\n",
       "     'Health Disparities'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['250'],\n",
       "    'InterventionType': ['Behavioral'],\n",
       "    'InterventionName': ['Sm-EMA'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Johns Hopkins University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 20, 2021'],\n",
       "    'CompletionDate': ['October 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 266,\n",
       "    'NCTId': ['NCT04548895'],\n",
       "    'BriefTitle': ['Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19'],\n",
       "    'Condition': ['Covid19', 'Community-Acquired Respiratory Tract Infection'],\n",
       "    'Keyword': ['COVID-19', 'wearables', 'biometric data'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['30'],\n",
       "    'InterventionType': ['Device'],\n",
       "    'InterventionName': ['Observational measurement of biometric data. No change to health care provided.'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Health Stream Analytics, LLC'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 30, 2020'],\n",
       "    'CompletionDate': ['October 26, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 267,\n",
       "    'NCTId': ['NCT04468139'],\n",
       "    'BriefTitle': ['The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19'],\n",
       "    'Condition': ['Covid-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 4'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['60'],\n",
       "    'InterventionType': ['Drug', 'Dietary Supplement', 'Drug', 'Drug'],\n",
       "    'InterventionName': ['Quercetin', 'bromelain', 'Zinc', 'Vitamin C'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Saudi Arabia'],\n",
       "    'OrgFullName': ['Ministry of Health, Saudi Arabia'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 20, 2020'],\n",
       "    'CompletionDate': ['July 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 268,\n",
       "    'NCTId': ['NCT04363541'],\n",
       "    'BriefTitle': ['Local Thermotherapy for Patients With Mild-to-moderate COVID-19'],\n",
       "    'Condition': ['COVID-19', 'Thermotherapy'],\n",
       "    'Keyword': ['SARS-CoV-2', 'Hyperthermia'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['274'],\n",
       "    'InterventionType': ['Device'],\n",
       "    'InterventionName': ['Electric pad for human external pain therapy'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Mexico', 'Mexico', 'Mexico'],\n",
       "    'OrgFullName': ['Instituto Nacional de Perinatologia'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 27, 2020'],\n",
       "    'CompletionDate': ['June 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 269,\n",
       "    'NCTId': ['NCT04649515'],\n",
       "    'BriefTitle': ['Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans'],\n",
       "    'Condition': ['Coronavirus Disease-2019 (COVID-19)'],\n",
       "    'Keyword': ['Coronavirus Disease-2019',\n",
       "     'COVID-19',\n",
       "     'SARS-CoV-2',\n",
       "     'Monoclonal Antibody',\n",
       "     'Infectious diseases',\n",
       "     'Phase 3 study',\n",
       "     'Singapore'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['1305'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Other'],\n",
       "    'InterventionName': ['TY027', 'TY027', '0.9% saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Singapore'],\n",
       "    'OrgFullName': ['Tychan Pte Ltd.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 4, 2020'],\n",
       "    'CompletionDate': ['December 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 270,\n",
       "    'NCTId': ['NCT04520880'],\n",
       "    'BriefTitle': ['Antibodies Responses to COVID-19 Infection in Hospitalized Patients'],\n",
       "    'Condition': ['Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection)',\n",
       "     'Hospitalized Patients',\n",
       "     'Laboratory-confirmed SARS-CoV 2 Infection'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['158'],\n",
       "    'InterventionType': ['Diagnostic Test', 'Diagnostic Test'],\n",
       "    'InterventionName': ['Testing procedure for Binding antibodies',\n",
       "     'Neutralizing antibodies'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Saudi Arabia'],\n",
       "    'OrgFullName': ['Dammam University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['August 2020'],\n",
       "    'CompletionDate': ['February 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 271,\n",
       "    'NCTId': ['NCT04480398'],\n",
       "    'BriefTitle': ['Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients'],\n",
       "    'Condition': ['Covid19', 'Asymptomatic Condition'],\n",
       "    'Keyword': ['Ayurveda', 'Guduchi Ghan Vati'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['91'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Guduchi Ghan Vati'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['India'],\n",
       "    'OrgFullName': ['Aarogyam UK'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['May 12, 2020'],\n",
       "    'CompletionDate': ['July 3, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 272,\n",
       "    'NCTId': ['NCT04523831'],\n",
       "    'BriefTitle': ['Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['Covid-19, Ivermectin'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['400'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['Ivermectin and Doxycycline', 'Standard of care'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Bangladesh'],\n",
       "    'OrgFullName': ['Dhaka Medical College'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['June 1, 2020'],\n",
       "    'CompletionDate': ['September 10, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Placebo Comparator']},\n",
       "   {'Rank': 273,\n",
       "    'NCTId': ['NCT04668625'],\n",
       "    'BriefTitle': ['Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures'],\n",
       "    'Condition': ['COVID-19 (SARS-CoV-2)'],\n",
       "    'Keyword': ['SARS-CoV-2',\n",
       "     'COVID-19',\n",
       "     'Coronavirus',\n",
       "     'Superspreading event',\n",
       "     'Concert'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1000'],\n",
       "    'InterventionType': ['Behavioral'],\n",
       "    'InterventionName': ['Participate in a massive musical event'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Spain'],\n",
       "    'OrgFullName': ['Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['November 30, 2020'],\n",
       "    'CompletionDate': ['December 22, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 274,\n",
       "    'NCTId': ['NCT04416113'],\n",
       "    'BriefTitle': ['Photodynamic Therapy for the Treatment of COVID-19'],\n",
       "    'Condition': ['Photodynamic Therapy& Low Level Laser in Management of COVID 19'],\n",
       "    'Keyword': ['photodynamic therapy',\n",
       "     'low level laser therapy',\n",
       "     'COVID 19 virus'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['60'],\n",
       "    'InterventionType': ['Procedure'],\n",
       "    'InterventionName': ['photobiomodulation and photodynamic therapy'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Cairo University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['August 2020'],\n",
       "    'CompletionDate': ['February 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator']},\n",
       "   {'Rank': 275,\n",
       "    'NCTId': ['NCT04371965'],\n",
       "    'BriefTitle': ['Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['SARS-CoV-2', 'Povidone Iodine decolonization'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['24'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Povidone-Iodine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['Poitiers University Hospital'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['September 1, 2020'],\n",
       "    'CompletionDate': ['October 23, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 276,\n",
       "    'NCTId': ['NCT04339660'],\n",
       "    'BriefTitle': ['Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'UC-MSCs',\n",
       "     'critically ill',\n",
       "     'cell transplantation'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['30'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['UC-MSCs', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Puren Hospital Affiliated to Wuhan University of Science and Technology'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['February 1, 2020'],\n",
       "    'CompletionDate': ['June 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 277,\n",
       "    'NCTId': ['NCT04387240'],\n",
       "    'BriefTitle': ['Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19'],\n",
       "    'Condition': ['Covid 19 Positive', 'Corona Virus Infection'],\n",
       "    'Keyword': ['artemisinin', 'Artesunate'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['22'],\n",
       "    'InterventionType': ['Drug', 'Other'],\n",
       "    'InterventionName': ['Artemisinin / Artesunate', 'placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Saudi Arabia'],\n",
       "    'OrgFullName': ['Princess Nourah Bint Abdulrahman University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 2020'],\n",
       "    'CompletionDate': ['April 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 278,\n",
       "    'NCTId': ['NCT04344977'],\n",
       "    'BriefTitle': ['Collection of Anti-SARS-CoV-2 Immune Plasma'],\n",
       "    'Condition': ['Coronavirus Disease 2019 (COVID-19)'],\n",
       "    'Keyword': ['Coronavirus',\n",
       "     'COVID-19',\n",
       "     'IVIG',\n",
       "     'Convalescent plasma',\n",
       "     'Severe acute respiratory syndrome coronavirus 2'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['1500'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States', 'United States', 'United States'],\n",
       "    'OrgFullName': ['National Institutes of Health Clinical Center (CC)'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['June 1, 2020'],\n",
       "    'CompletionDate': ['April 1, 2025'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 279,\n",
       "    'NCTId': ['NCT04326036'],\n",
       "    'BriefTitle': ['Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection'],\n",
       "    'Condition': ['Pulmonary Alveolar Proteinosis',\n",
       "     'COPD',\n",
       "     'Idiopathic Pulmonary Fibrosis',\n",
       "     'Viral Pneumonia',\n",
       "     'Coronavirus Infection',\n",
       "     'Interstitial Lung Disease'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Early Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['10'],\n",
       "    'InterventionType': ['Procedure', 'Device', 'Procedure', 'Drug', 'Drug'],\n",
       "    'InterventionName': ['Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)',\n",
       "     'Centricyte 1000',\n",
       "     'IV Deployment Of cSVF In Sterile Normal Saline IV Solution',\n",
       "     'Liberase Enzyme (Roche)',\n",
       "     'Sterile Normal Saline for Intravenous Use'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Black Tie Medical, Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['March 25, 2020'],\n",
       "    'CompletionDate': ['December 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Other',\n",
       "     'Other']},\n",
       "   {'Rank': 280,\n",
       "    'NCTId': ['NCT04694612'],\n",
       "    'BriefTitle': ['Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['676'],\n",
       "    'InterventionType': ['Drug', 'Drug', 'Drug'],\n",
       "    'InterventionName': ['Favipiravir', 'Placebo', 'Remdesivir'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Nepal', 'Nepal'],\n",
       "    'OrgFullName': ['Nepal Health Research Council'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['January 1, 2021'],\n",
       "    'CompletionDate': ['May 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Placebo Comparator', 'Active Comparator']},\n",
       "   {'Rank': 281,\n",
       "    'NCTId': ['NCT04344756'],\n",
       "    'BriefTitle': ['Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort'],\n",
       "    'Condition': ['COVID19 Pneumonia'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['808'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Tinzaparin or unfractionated heparin'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France', 'France', 'France'],\n",
       "    'OrgFullName': ['Assistance Publique - Hôpitaux de Paris'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['April 20, 2020'],\n",
       "    'CompletionDate': ['September 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 282,\n",
       "    'NCTId': ['NCT04476888'],\n",
       "    'BriefTitle': ['Convalescent Plasma Treatment in COVID-19'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['Convalescent plasma', 'Covid 19'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['Convalescent Plasma (CP)',\n",
       "     'Drugs and supportive care'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Pakistan'],\n",
       "    'OrgFullName': ['Aga Khan University'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 26, 2020'],\n",
       "    'CompletionDate': ['September 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Other']},\n",
       "   {'Rank': 283,\n",
       "    'NCTId': ['NCT04699227'],\n",
       "    'BriefTitle': ['Can RIC Prevent Deterioration to Critical Care in Covid19'],\n",
       "    'Condition': ['Covid19', 'Ischemia'],\n",
       "    'Keyword': ['Covid19', 'Ischemia'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['20'],\n",
       "    'InterventionType': ['Procedure', 'Other'],\n",
       "    'InterventionName': ['Cuff application with inflation', 'Sham inflation'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United Kingdom', 'United Kingdom'],\n",
       "    'OrgFullName': ['University College London Hospitals'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 23, 2020'],\n",
       "    'CompletionDate': ['April 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Sham Comparator', 'Experimental']},\n",
       "   {'Rank': 284,\n",
       "    'NCTId': ['NCT04636203'],\n",
       "    'BriefTitle': ['Burden of COVID-19 Infection in Populations With High or Low Risk of Infection'],\n",
       "    'Condition': ['SARS-CoV-2 Infection', 'Covid19'],\n",
       "    'Keyword': ['SARS-CoV-2', 'Healthcare workers', 'General population'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['3500'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Neuromed IRCCS'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['December 15, 2020'],\n",
       "    'CompletionDate': ['June 15, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 285,\n",
       "    'NCTId': ['NCT04321174'],\n",
       "    'BriefTitle': ['COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir'],\n",
       "    'Condition': ['Coronavirus Infections', 'Post-exposure Prophylaxis'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1220'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Lopinavir/ritonavir'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Canada', 'Canada', 'Canada', 'Canada'],\n",
       "    'OrgFullName': [\"St. Michael's Hospital, Toronto\"],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 17, 2020'],\n",
       "    'CompletionDate': ['March 31, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 286,\n",
       "    'NCTId': ['NCT04408456'],\n",
       "    'BriefTitle': ['Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19'],\n",
       "    'Condition': ['CoVID-19'],\n",
       "    'Keyword': ['CoVID-19',\n",
       "     'SARS-CoV-2',\n",
       "     'Hydroxychloroquine (HCQ)',\n",
       "     'post exposure prophylaxis (PEP)'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['325'],\n",
       "    'InterventionType': ['Drug', 'Other'],\n",
       "    'InterventionName': ['HCQ', 'Standard therapy'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['India', 'India'],\n",
       "    'OrgFullName': ['Postgraduate Institute of Medical Education and Research'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['March 1, 2020'],\n",
       "    'CompletionDate': ['July 31, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Other']},\n",
       "   {'Rank': 287,\n",
       "    'NCTId': ['NCT04346368'],\n",
       "    'BriefTitle': ['Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)'],\n",
       "    'Condition': ['Coronavirus Disease 2019 (COVID-19)'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['20'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['BM-MSCs', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['China'],\n",
       "    'OrgFullName': ['Guangzhou Institute of Respiratory Disease'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['April 2020'],\n",
       "    'CompletionDate': ['December 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 288,\n",
       "    'NCTId': ['NCT04376944'],\n",
       "    'BriefTitle': ['Barrier Measures to Limit Covid-19.Nosocomial Transmission: a Cross-sectional Evaluation'],\n",
       "    'Condition': ['Caregivers', 'COVID-19'],\n",
       "    'Keyword': ['barrier measures'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['300'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Survey'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['University Hospital, Montpellier'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 1, 2020'],\n",
       "    'CompletionDate': ['December 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 289,\n",
       "    'NCTId': ['NCT04602507'],\n",
       "    'BriefTitle': ['Ivermectin in Adults With Severe COVID-19.'],\n",
       "    'Condition': ['Covid19', 'Severe Acute Respiratory Syndrome'],\n",
       "    'Keyword': ['COVID19 drug treatment',\n",
       "     'Randomized Clinical Trial',\n",
       "     'Ivermectin',\n",
       "     'Hospitalized',\n",
       "     'Intensive Care Unit',\n",
       "     'SARS-CoV-2',\n",
       "     'Pneumonia, Viral'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Drug', 'Other'],\n",
       "    'InterventionName': ['Ivermectin', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Colombia'],\n",
       "    'OrgFullName': ['CES University'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 7, 2020'],\n",
       "    'CompletionDate': ['March 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 290,\n",
       "    'NCTId': ['NCT04492410'],\n",
       "    'BriefTitle': ['COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID)'],\n",
       "    'Condition': ['Cancer'],\n",
       "    'Keyword': ['Covid-19', 'Screening'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Screening'],\n",
       "    'EnrollmentCount': ['500'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['rapid serological test'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['Centre Antoine Lacassagne'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['July 21, 2020'],\n",
       "    'CompletionDate': ['March 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 291,\n",
       "    'NCTId': ['NCT04393727'],\n",
       "    'BriefTitle': ['Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19'],\n",
       "    'Condition': ['COVID', 'SARS-CoV 2'],\n",
       "    'Keyword': ['covid-19', 'SARS-CoV2', 'pneumonia', 'convalescent plasma'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['1'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['CONVALESCENT PLASMA'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Italy'],\n",
       "    'OrgFullName': ['Azienda Ospedaliero, Universitaria Pisana'],\n",
       "    'OverallStatus': ['Terminated'],\n",
       "    'StartDate': ['May 1, 2020'],\n",
       "    'CompletionDate': ['September 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 292,\n",
       "    'NCTId': ['NCT04424940'],\n",
       "    'BriefTitle': ['COVID-19 Lessons Learned: the Outcome of TOMEKA® Project is to Teach'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['TOMEKA®', 'Treatment', 'COVID-19', 'Education'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['800'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Congo, The Democratic Republic of the'],\n",
       "    'OrgFullName': ['University of Kinshasa'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['September 1, 2020'],\n",
       "    'CompletionDate': ['September 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 293,\n",
       "    'NCTId': ['NCT04403477'],\n",
       "    'BriefTitle': ['Convalescent Plasma Therapy in Severe COVID-19 Infection'],\n",
       "    'Condition': ['Covid19', 'Convalescence'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['20'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Convalescent plasma'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Bangladesh'],\n",
       "    'OrgFullName': ['Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 20, 2020'],\n",
       "    'CompletionDate': ['October 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['No Intervention', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 294,\n",
       "    'NCTId': ['NCT04380987'],\n",
       "    'BriefTitle': ['Luxembourg Cohort of Positive Patients for COVID-19: a Stratification Study to Predict Patient Prognosis'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['Severity factors', 'Patient stratification', 'Digital'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Biological sampling'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Luxembourg'],\n",
       "    'OrgFullName': ['Luxembourg Institute of Health'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 4, 2020'],\n",
       "    'CompletionDate': ['December 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 295,\n",
       "    'NCTId': ['NCT04348240'],\n",
       "    'BriefTitle': ['Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Saliva', 'Coronavirus', 'SARS-CoV-2', 'Symptoms', 'COVID19'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['90'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['National Institutes of Health Clinical Center (CC)'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 16, 2020'],\n",
       "    'CompletionDate': ['July 1, 2021'],\n",
       "    'IsFDARegulatedDrug': [],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 296,\n",
       "    'NCTId': ['NCT04400006'],\n",
       "    'BriefTitle': ['Ozone Therapy in the Prevention of COVID-19 Infection'],\n",
       "    'Condition': ['Corona Virus Infection'],\n",
       "    'Keyword': ['Coronavirus', 'Ozone', 'Preventive Medicine'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['71'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Turkey'],\n",
       "    'OrgFullName': ['Marmara University'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['May 6, 2020'],\n",
       "    'CompletionDate': ['May 17, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 297,\n",
       "    'NCTId': ['NCT04613817'],\n",
       "    'BriefTitle': ['Sero-prevalence COVID-19 Among Belgian Children'],\n",
       "    'Condition': ['SARS-CoV-2', 'SARS-CoV Infection', 'Covid19'],\n",
       "    'Keyword': ['SARS-CoV-2',\n",
       "     'COVID-19',\n",
       "     'Children',\n",
       "     'Belgium',\n",
       "     'Pandemic 2020'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['1640'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Sciensano'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['November 20, 2020'],\n",
       "    'CompletionDate': ['August 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 298,\n",
       "    'NCTId': ['NCT04620798'],\n",
       "    'BriefTitle': ['Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students'],\n",
       "    'Condition': ['SARS-CoV-2', 'Serology', 'Students'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Screening'],\n",
       "    'EnrollmentCount': ['1700'],\n",
       "    'InterventionType': ['Behavioral'],\n",
       "    'InterventionName': ['Immediate vs. delayed provision of antibody test results'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Indiana University'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['September 14, 2020'],\n",
       "    'CompletionDate': ['December 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 299,\n",
       "    'NCTId': ['NCT04530682'],\n",
       "    'BriefTitle': ['COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs'],\n",
       "    'Condition': ['Rheumatoid Arthritis'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'SARS-CoV2',\n",
       "     'Rheumatoid arthritis',\n",
       "     'Spondyloarthritis',\n",
       "     'Seroprevalence',\n",
       "     'Seropersistence'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['5000'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['University Hospital, Montpellier'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['February 1, 2021'],\n",
       "    'CompletionDate': ['July 2024'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 300,\n",
       "    'NCTId': ['NCT04429529'],\n",
       "    'BriefTitle': ['Safety of TY027, a Treatment for COVID-19, in Humans'],\n",
       "    'Condition': ['Coronavirus Disease-2019 (COVID-19)'],\n",
       "    'Keyword': ['Coronavirus Disease-2019',\n",
       "     'COVID-19',\n",
       "     'SARS-CoV-2',\n",
       "     'Monoclonal Antibody',\n",
       "     'Infectious diseases',\n",
       "     'Phase 1 first in human study',\n",
       "     'Singapore'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['32'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['TY027', '0.9% Saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Singapore'],\n",
       "    'OrgFullName': ['Tychan Pte Ltd.'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['June 9, 2020'],\n",
       "    'CompletionDate': ['February 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 301,\n",
       "    'NCTId': ['NCT04442789'],\n",
       "    'BriefTitle': ['Sequelae of Sars-CoV-2 Infections'],\n",
       "    'Condition': ['Lung Diseases', 'Cardiac Disease', 'Inflammatory Reaction'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['30'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Germany'],\n",
       "    'OrgFullName': ['University of Giessen'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 20, 2020'],\n",
       "    'CompletionDate': ['December 31, 2023'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 302,\n",
       "    'NCTId': ['NCT04332666'],\n",
       "    'BriefTitle': ['Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial'],\n",
       "    'Condition': ['Coronavirus',\n",
       "     'Respiratory Failure',\n",
       "     'Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere',\n",
       "     'SARS-CoV-2'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['60'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['Angiotensin 1-7', 'Placebos'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Erasme University Hospital'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['September 30, 2020'],\n",
       "    'CompletionDate': ['June 15, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Placebo Comparator', 'Experimental']},\n",
       "   {'Rank': 303,\n",
       "    'NCTId': ['NCT04441814'],\n",
       "    'BriefTitle': ['FOUND - Ancillary Study to Smile Protocol NCT03654105'],\n",
       "    'Condition': ['COVID 19', 'Inflammatory Status'],\n",
       "    'Keyword': ['COVID',\n",
       "     'Lung cancer screening',\n",
       "     'Subsolid pulmonary nodules',\n",
       "     'Low dose CT screening',\n",
       "     'Blood biomarkers'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['960'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Italy'],\n",
       "    'OrgFullName': ['Fondazione IRCCS Istituto Nazionale dei Tumori, Milano'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['July 23, 2019'],\n",
       "    'CompletionDate': ['July 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 304,\n",
       "    'NCTId': ['NCT04529460'],\n",
       "    'BriefTitle': ['Healthy Volunteer COVID-19 Antibody Testing Study'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Diagnostic Test'],\n",
       "    'InterventionName': ['COVID-19 antibody point of care test kit'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Royal Free Hospital NHS Foundation Trust'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['September 1, 2020'],\n",
       "    'CompletionDate': ['April 30, 2021'],\n",
       "    'IsFDARegulatedDrug': [],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 305,\n",
       "    'NCTId': ['NCT04363047'],\n",
       "    'BriefTitle': ['Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19'],\n",
       "    'Condition': ['SARS Virus'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['125'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['40ml blood sample'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United Kingdom'],\n",
       "    'OrgFullName': ['University of Manchester'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['October 1, 2020'],\n",
       "    'CompletionDate': ['May 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 306,\n",
       "    'NCTId': ['NCT04390152'],\n",
       "    'BriefTitle': [\"Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19\"],\n",
       "    'Condition': ['Acute Respiratory Distress Syndrome'],\n",
       "    'Keyword': ['coronavirus', 'stem cell research', 'mesenchymal stem cell'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['40'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': [\"Wharton's jelly derived Mesenchymal stem cells.\",\n",
       "     'Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Colombia', 'Colombia'],\n",
       "    'OrgFullName': ['BioXcellerator'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['January 13, 2020'],\n",
       "    'CompletionDate': ['April 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 307,\n",
       "    'NCTId': ['NCT04355767'],\n",
       "    'BriefTitle': ['Convalescent Plasma in Outpatients With COVID-19'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['600'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Convalescent Plasma', 'Saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['Stanford University'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['August 11, 2020'],\n",
       "    'CompletionDate': ['December 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 308,\n",
       "    'NCTId': ['NCT04402892'],\n",
       "    'BriefTitle': ['COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells'],\n",
       "    'Condition': ['COVID-19', 'SARS-CoV-2 Infection'],\n",
       "    'Keyword': ['COVID-19', 'Immunity'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Basic Science'],\n",
       "    'EnrollmentCount': ['60'],\n",
       "    'InterventionType': ['Other', 'Other'],\n",
       "    'InterventionName': ['35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )',\n",
       "     '35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Assistance Publique - Hôpitaux de Paris'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['June 1, 2020'],\n",
       "    'CompletionDate': ['March 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Active Comparator']},\n",
       "   {'Rank': 309,\n",
       "    'NCTId': ['NCT04646616'],\n",
       "    'BriefTitle': ['CRISOL Contigo: a Multi-level Intervention to Reduce the Disproportionate Toll of COVID-19 Among Latino Communities in Philadelphia.'],\n",
       "    'Condition': ['Covid19', 'Mental Health Issue', 'Violence'],\n",
       "    'Keyword': ['Latino health', 'Immigrant health', 'Syndemic'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['800'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Community popular opinion leader (POL) based intervention'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Drexel University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 6, 2021'],\n",
       "    'CompletionDate': ['October 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 310,\n",
       "    'NCTId': ['NCT04523012'],\n",
       "    'BriefTitle': ['COVID-19 and HIV Patients'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['2200'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Seroprevalence of SARS-CoV-2 infection in patients with HIV infection'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': [\"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida\"],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['July 1, 2020'],\n",
       "    'CompletionDate': ['June 30, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 311,\n",
       "    'NCTId': ['NCT04425915'],\n",
       "    'BriefTitle': ['Efficacy of Convalescent Plasma Therapy in Patients With COVID-19'],\n",
       "    'Condition': ['COVID'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['400'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['Convalescent Plasma', 'Standard of Care'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['India', 'India', 'India'],\n",
       "    'OrgFullName': ['Institute of Liver and Biliary Sciences, India'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 14, 2020'],\n",
       "    'CompletionDate': ['May 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 312,\n",
       "    'NCTId': ['NCT04534595'],\n",
       "    'BriefTitle': ['Data Collection on the Model Schools Pediatric Health Initiative at 5 SBHC Sites: COVID-19 Questionnaire'],\n",
       "    'Condition': ['COVID-19 Experience'],\n",
       "    'Keyword': ['COVID-19', 'School-based health center', 'mental health'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['1500'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['COVID-19'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child'],\n",
       "    'LocationCountry': ['Canada'],\n",
       "    'OrgFullName': [\"St. Michael's Hospital, Toronto\"],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 30, 2019'],\n",
       "    'CompletionDate': ['March 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 313,\n",
       "    'NCTId': ['NCT04610502'],\n",
       "    'BriefTitle': ['Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Anti-SARS-CoV-2 Equine Immunoglobulin',\n",
       "     'Passive Immunotherapy',\n",
       "     'Neutralizing Equine Antibodies.'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['26'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Administration of Equine immunoglobulin anti SARS-CoV-2'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Costa Rica',\n",
       "     'Costa Rica',\n",
       "     'Costa Rica',\n",
       "     'Costa Rica'],\n",
       "    'OrgFullName': ['Caja Costarricense de Seguro Social'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['September 6, 2020'],\n",
       "    'CompletionDate': ['December 6, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 314,\n",
       "    'NCTId': ['NCT04483752'],\n",
       "    'BriefTitle': ['Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images'],\n",
       "    'Condition': ['CoV2 SARS Pneumonia'],\n",
       "    'Keyword': ['SARS CoV2', 'COVID-19', 'fibrosis'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Diagnostic'],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['CHEST CT SCAN'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France', 'France', 'France'],\n",
       "    'OrgFullName': ['Centre Chirurgical Marie Lannelongue'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 8, 2020'],\n",
       "    'CompletionDate': ['November 8, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Other']},\n",
       "   {'Rank': 315,\n",
       "    'NCTId': ['NCT04416308'],\n",
       "    'BriefTitle': ['COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB)'],\n",
       "    'Condition': ['Coronavirus'],\n",
       "    'Keyword': ['Covid 19, SRAS-CoV-2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Diagnostic'],\n",
       "    'EnrollmentCount': ['13000'],\n",
       "    'InterventionType': ['Diagnostic Test', 'Diagnostic Test', 'Behavioral'],\n",
       "    'InterventionName': ['NG test', 'Blood test', 'Self-questionnary'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France'],\n",
       "    'OrgFullName': ['Rennes University Hospital'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 29, 2020'],\n",
       "    'CompletionDate': ['October 10, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Other', 'Other', 'Other', 'Other']},\n",
       "   {'Rank': 316,\n",
       "    'NCTId': ['NCT04342182'],\n",
       "    'BriefTitle': ['Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['426'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Convalescent plasma'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands'],\n",
       "    'OrgFullName': ['Erasmus Medical Center'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['April 8, 2020'],\n",
       "    'CompletionDate': ['July 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 317,\n",
       "    'NCTId': ['NCT04565509'],\n",
       "    'BriefTitle': ['Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic'],\n",
       "    'Condition': ['Covid19',\n",
       "     'Intellectual Disability',\n",
       "     'Developmental Disability',\n",
       "     'Child Development Disorder'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Health Services Research'],\n",
       "    'EnrollmentCount': ['2500'],\n",
       "    'InterventionType': ['Behavioral',\n",
       "     'Behavioral',\n",
       "     'Behavioral',\n",
       "     'Behavioral'],\n",
       "    'InterventionName': ['General Communication Message',\n",
       "     'Focused/Targeted Message',\n",
       "     'Best Message Alone',\n",
       "     'Best Message + Augmented Message or Implementation Strategy'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States', 'United States', 'United States'],\n",
       "    'OrgFullName': ['Washington University School of Medicine'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 20, 2020'],\n",
       "    'CompletionDate': ['September 21, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator']},\n",
       "   {'Rank': 318,\n",
       "    'NCTId': ['NCT04346446'],\n",
       "    'BriefTitle': ['Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients'],\n",
       "    'Condition': ['COVID'],\n",
       "    'Keyword': ['convalescent plasma,COVID,SARS-COV -2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['29'],\n",
       "    'InterventionType': ['Drug', 'Other', 'Drug'],\n",
       "    'InterventionName': ['Convalescent Plasma Transfusion',\n",
       "     'Supportive Care',\n",
       "     'Random Donor Plasma'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['India', 'India'],\n",
       "    'OrgFullName': ['Institute of Liver and Biliary Sciences, India'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['April 20, 2020'],\n",
       "    'CompletionDate': ['May 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 319,\n",
       "    'NCTId': ['NCT04553705'],\n",
       "    'BriefTitle': ['Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)'],\n",
       "    'Condition': ['Covid19', 'Immunodeficiency'],\n",
       "    'Keyword': ['COVID-19', 'omega3', 'thymoquinone'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug'],\n",
       "    'InterventionName': ['Omega 3/Nigella Sativa Oil',\n",
       "     'Omega 3/Nigella Sativa Oil/Indian Costus',\n",
       "     'Omega 3/Nigella Sativa Oil/Quinine pills',\n",
       "     'Omega 3/Nigella Sativa Oil/Anise seed capsule',\n",
       "     'Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice',\n",
       "     'Active Comparator'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Saudi Arabia'],\n",
       "    'OrgFullName': ['Beni-Suef University'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 20, 2020'],\n",
       "    'CompletionDate': ['December 4, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Active Comparator']},\n",
       "   {'Rank': 320,\n",
       "    'NCTId': ['NCT04615000'],\n",
       "    'BriefTitle': ['SeroCovid<19: A Prospective Covid-19 Seroconversion Study in a Tertiary Pediatric Patient Cohort'],\n",
       "    'Condition': ['Covid19', 'Children, Only'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['1000'],\n",
       "    'InterventionType': ['Diagnostic Test'],\n",
       "    'InterventionName': ['SARS-CoV-2 serological assessment (IgG)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult'],\n",
       "    'LocationCountry': ['Belgium'],\n",
       "    'OrgFullName': ['University Hospital, Ghent'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 29, 2020'],\n",
       "    'CompletionDate': ['November 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 321,\n",
       "    'NCTId': ['NCT04387253'],\n",
       "    'BriefTitle': ['Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID'],\n",
       "    'Condition': ['Identification of the Mother or Fetus Contamination by SARS Cov-2',\n",
       "     'Research the Presence of Viruses at Different Sites of the Mother and the Fetus or Father',\n",
       "     'The Survey Builds on a Network Work Already Organized Around the CPDPN of Poitou-Charentes',\n",
       "     'Analysis Laboratories of the Poitiers CHU'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Diagnostic'],\n",
       "    'EnrollmentCount': ['80'],\n",
       "    'InterventionType': ['Diagnostic Test'],\n",
       "    'InterventionName': ['Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['Poitiers University Hospital'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 23, 2020'],\n",
       "    'CompletionDate': ['July 23, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 322,\n",
       "    'NCTId': ['NCT04377802'],\n",
       "    'BriefTitle': ['Safe Return to Regular Clinical Operation After COVID-19 Pandemic'],\n",
       "    'Condition': ['COVID 19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['400'],\n",
       "    'InterventionType': ['Diagnostic Test'],\n",
       "    'InterventionName': ['molecular testing for virus RNA using RT-PCR'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Saudi Arabia'],\n",
       "    'OrgFullName': ['King Fahad Specialist Hospital Dammam'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['May 17, 2020'],\n",
       "    'CompletionDate': ['December 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 323,\n",
       "    'NCTId': ['NCT04329611'],\n",
       "    'BriefTitle': ['ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['SARS-Cov2', 'viral pneumonia'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['148'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Hydroxychloroquine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Canada', 'Canada'],\n",
       "    'OrgFullName': ['University of Calgary'],\n",
       "    'OverallStatus': ['Terminated'],\n",
       "    'StartDate': ['April 13, 2020'],\n",
       "    'CompletionDate': ['July 20, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Placebo Comparator']},\n",
       "   {'Rank': 324,\n",
       "    'NCTId': ['NCT04547660'],\n",
       "    'BriefTitle': ['Convalescent Plasma for Severe COVID-19 Patients'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['160'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['Convalescent Plasma', 'Best Supportive Care'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Brazil'],\n",
       "    'OrgFullName': ['Hospital de Clinicas de Porto Alegre'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['July 16, 2020'],\n",
       "    'CompletionDate': ['October 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 325,\n",
       "    'NCTId': ['NCT04516512'],\n",
       "    'BriefTitle': ['Assessment of SARS-CoV-2 Seroprevalence in Detention'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19', 'SARS-CoV-2', 'inmates', 'seroprevalence'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Screening'],\n",
       "    'EnrollmentCount': ['2500'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Blood draw'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Assistance Publique - Hôpitaux de Paris'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['September 1, 2020'],\n",
       "    'CompletionDate': ['January 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 326,\n",
       "    'NCTId': ['NCT04542343'],\n",
       "    'BriefTitle': ['COVID-19 Risk Reduction Among African American Parishioners'],\n",
       "    'Condition': ['Coronavirus'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Supportive Care'],\n",
       "    'EnrollmentCount': ['265'],\n",
       "    'InterventionType': ['Behavioral'],\n",
       "    'InterventionName': ['Change in knowledge, motivation, skills, resources'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Charles Drew University of Medicine and Science'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['October 1, 2020'],\n",
       "    'CompletionDate': ['September 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 327,\n",
       "    'NCTId': ['NCT04377308'],\n",
       "    'BriefTitle': ['Fluoxetine to Reduce Intubation and Death After COVID19 Infection'],\n",
       "    'Condition': ['COVID-19', 'Cytokine Storm'],\n",
       "    'Keyword': ['IL-6', 'fluoxetine', 'cytokine storm', 'NF-KB', 'COVID-19'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 4'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['2000'],\n",
       "    'InterventionType': ['Drug'],\n",
       "    'InterventionName': ['Fluoxetine'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['University of Toledo Health Science Campus'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 1, 2020'],\n",
       "    'CompletionDate': ['October 20, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['No Intervention', 'Active Comparator']},\n",
       "   {'Rank': 328,\n",
       "    'NCTId': ['NCT03734237'],\n",
       "    'BriefTitle': ['A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD'],\n",
       "    'Condition': ['Influenza', 'Influenza-like Illness'],\n",
       "    'Keyword': ['Influenza vaccine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 4'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['15000'],\n",
       "    'InterventionType': ['Biological', 'Biological', 'Biological'],\n",
       "    'InterventionName': ['Egg based influenza vaccines',\n",
       "     'Recombinant influenza vaccines',\n",
       "     'Cell-culture based influenza vaccines'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['Henry M. Jackson Foundation for the Advancement of Military Medicine'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 6, 2018'],\n",
       "    'CompletionDate': ['May 31, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Active Comparator',\n",
       "     'Active Comparator',\n",
       "     'Active Comparator']},\n",
       "   {'Rank': 329,\n",
       "    'NCTId': ['NCT04606069'],\n",
       "    'BriefTitle': ['Treat COVID-19 Patients With Regadenoson'],\n",
       "    'Condition': ['COVID-19', 'Lung Inflammation'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['40'],\n",
       "    'InterventionType': ['Drug', 'Other'],\n",
       "    'InterventionName': ['Regadenoson', 'Placebo Control'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['University of Maryland, Baltimore'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['November 1, 2020'],\n",
       "    'CompletionDate': ['January 31, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 330,\n",
       "    'NCTId': ['NCT04460690'],\n",
       "    'BriefTitle': ['Rapid, Onsite COVID-19 Detection'],\n",
       "    'Condition': ['COVID-19', 'Sars-CoV2'],\n",
       "    'Keyword': ['rapid detection', 'assay', 'saliva', 'coronavirus'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Diagnostic'],\n",
       "    'EnrollmentCount': ['10000'],\n",
       "    'InterventionType': ['Device'],\n",
       "    'InterventionName': ['Rapid Onsite COVID-19 Detection'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['University of Wisconsin, Madison'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['July 13, 2020'],\n",
       "    'CompletionDate': ['July 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 331,\n",
       "    'NCTId': ['NCT04469179'],\n",
       "    'BriefTitle': ['Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19'],\n",
       "    'Condition': ['COVID-19', 'SARS-CoV2'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['21'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['SAB-185', 'Normal Saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States', 'United States', 'United States'],\n",
       "    'OrgFullName': ['SAb Biotherapeutics, Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 20, 2020'],\n",
       "    'CompletionDate': ['December 2020'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 332,\n",
       "    'NCTId': ['NCT04344548'],\n",
       "    'BriefTitle': ['Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia'],\n",
       "    'Condition': ['COVID'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['10'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Allogeneic NK transfer'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Colombia', 'Colombia'],\n",
       "    'OrgFullName': ['Universidad Nacional de Colombia'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['April 13, 2020'],\n",
       "    'CompletionDate': ['November 10, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 333,\n",
       "    'NCTId': ['NCT04371367'],\n",
       "    'BriefTitle': ['Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )'],\n",
       "    'Condition': ['COVID'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['208'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['avdoralimab', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['Assistance Publique Hopitaux De Marseille'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['April 27, 2020'],\n",
       "    'CompletionDate': ['March 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 334,\n",
       "    'NCTId': ['NCT04355052'],\n",
       "    'BriefTitle': ['Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to \"no Treatment\" in SARS CoV 2 Virus'],\n",
       "    'Condition': ['COVID - 19'],\n",
       "    'Keyword': ['COVID - 19', 'hydroxychloroquine', 'camostat mesylate'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['250'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['hydroxychloroquine in combination with camostat mesylate',\n",
       "     'Hydroxychloroquine in combination of Azithromycin'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Israel', 'Israel'],\n",
       "    'OrgFullName': ['Sheba Medical Center'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 11, 2020'],\n",
       "    'CompletionDate': ['December 11, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Experimental', 'No Intervention']},\n",
       "   {'Rank': 335,\n",
       "    'NCTId': ['NCT04420338'],\n",
       "    'BriefTitle': ['SeroCOVIDial Study: Assessment of COVID-19 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study'],\n",
       "    'Condition': ['Chronic Hemodialysis Patients',\n",
       "     'Caregivers of Chronic Hemodialysis Patients'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Diagnostic'],\n",
       "    'EnrollmentCount': ['800'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Blood sample', 'Serum tube collection'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['Assistance Publique Hopitaux De Marseille'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 5, 2020'],\n",
       "    'CompletionDate': ['December 15, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 336,\n",
       "    'NCTId': ['NCT03885232'],\n",
       "    'BriefTitle': ['Presumptively Initiating Vaccines and Optimizing Talk With Motivational Interviewing (PIVOT With MI)'],\n",
       "    'Condition': ['Preventive Health Services (PREV HEALTH SERV)'],\n",
       "    'Keyword': ['Communication', 'Immunization'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Health Services Research'],\n",
       "    'EnrollmentCount': ['1000'],\n",
       "    'InterventionType': ['Behavioral', 'Other'],\n",
       "    'InterventionName': ['Experimental: PIVOT with MI',\n",
       "     'Active Comparator: Control'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child'],\n",
       "    'LocationCountry': ['United States', 'United States'],\n",
       "    'OrgFullName': ['University of Colorado, Denver'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['September 1, 2019'],\n",
       "    'CompletionDate': ['July 31, 2023'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 337,\n",
       "    'NCTId': ['NCT04683484'],\n",
       "    'BriefTitle': ['A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['620'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Nanocovax', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Vietnam'],\n",
       "    'OrgFullName': ['Nanogen Pharmaceutical Biotechnology Joint Stock Company'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 10, 2020'],\n",
       "    'CompletionDate': ['August 10, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 338,\n",
       "    'NCTId': ['NCT04334876'],\n",
       "    'BriefTitle': ['Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers'],\n",
       "    'Condition': ['SARS-CoV-2'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['340'],\n",
       "    'InterventionType': ['Diagnostic Test'],\n",
       "    'InterventionName': ['SARS-CoV-2 IgG Antibody Testing Kit'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['Indiana University'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['April 1, 2020'],\n",
       "    'CompletionDate': ['January 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 339,\n",
       "    'NCTId': ['NCT04664075'],\n",
       "    'BriefTitle': ['Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)'],\n",
       "    'Condition': ['Influenza',\n",
       "     'SARS (Severe Acute Respiratory Syndrome)',\n",
       "     'Respiratory Viral Infection',\n",
       "     'Respiratory Tract Infections',\n",
       "     'Infection, Bacterial',\n",
       "     'Infection Viral',\n",
       "     'Covid19',\n",
       "     'RNA Virus Infections'],\n",
       "    'Keyword': ['Flu',\n",
       "     'Influenza',\n",
       "     'SARS-CoV-2',\n",
       "     'Covid19',\n",
       "     'Respiratory',\n",
       "     'Predict',\n",
       "     'Infection',\n",
       "     'RNA'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Respiratory infections'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United Kingdom'],\n",
       "    'OrgFullName': ['Imperial College London'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 2021'],\n",
       "    'CompletionDate': ['June 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 340,\n",
       "    'NCTId': ['NCT04514302'],\n",
       "    'BriefTitle': ['Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody Fragments (INOSARS) for Hospitalized Patients With COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19', 'SARS-CoV-2', 'Immunoglobulin fragments'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['51'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['Placebo',\n",
       "     'Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS)'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Mexico'],\n",
       "    'OrgFullName': ['Hospital San Jose Tec de Monterrey'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['October 20, 2020'],\n",
       "    'CompletionDate': ['June 20, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Placebo Comparator', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 341,\n",
       "    'NCTId': ['NCT04468958'],\n",
       "    'BriefTitle': ['Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants'],\n",
       "    'Condition': ['COVID-19', 'SARS-CoV2'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['28'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['SAB-185', 'Normal saline'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States', 'United States', 'United States'],\n",
       "    'OrgFullName': ['SAb Biotherapeutics, Inc.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 5, 2020'],\n",
       "    'CompletionDate': ['December 2020'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 342,\n",
       "    'NCTId': ['NCT04348656'],\n",
       "    'BriefTitle': ['CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Convalescent plasma',\n",
       "     'Transfusion',\n",
       "     'SARS-CoV-2',\n",
       "     'Passive immunization'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['1200'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Convalescent plasma'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada',\n",
       "     'Canada'],\n",
       "    'OrgFullName': ['McMaster University'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 14, 2020'],\n",
       "    'CompletionDate': ['December 31, 2020'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 343,\n",
       "    'NCTId': ['NCT04418518'],\n",
       "    'BriefTitle': ['A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Convalescent plasma',\n",
       "     'Transfusion',\n",
       "     'SARS-CoV-2',\n",
       "     'Passive immunization'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['1200'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['Convalescent plasma'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States', 'United States', 'United States'],\n",
       "    'OrgFullName': ['Weill Medical College of Cornell University'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 24, 2020'],\n",
       "    'CompletionDate': ['December 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 344,\n",
       "    'NCTId': ['NCT04387929'],\n",
       "    'BriefTitle': ['Detection of Anti-COVID-19 Antibody Levels in an Hospital Population'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Antibody titer',\n",
       "     'Serological tests',\n",
       "     'Hospital personnel'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['6000'],\n",
       "    'InterventionType': ['Diagnostic Test'],\n",
       "    'InterventionName': ['Detection of anti-COVID-19 antibody level'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Italy'],\n",
       "    'OrgFullName': ['Istituto Clinico Humanitas'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['May 4, 2020'],\n",
       "    'CompletionDate': ['May 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 345,\n",
       "    'NCTId': ['NCT04535453'],\n",
       "    'BriefTitle': ['A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents'],\n",
       "    'Condition': ['Healthy'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['1210'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['Ad26.COV2.S', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Canada',\n",
       "     'Canada',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom'],\n",
       "    'OrgFullName': ['Janssen Vaccines & Prevention B.V.'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 28, 2020'],\n",
       "    'CompletionDate': ['December 15, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 346,\n",
       "    'NCTId': ['NCT04497441'],\n",
       "    'BriefTitle': [\"Netizens' Perception of COVID-19 Information & Information Sources.\"],\n",
       "    'Condition': ['Covid19',\n",
       "     'Information Seeking Behavior',\n",
       "     'Social Media',\n",
       "     'Perception, Self'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Information',\n",
       "     'Information sources',\n",
       "     'Netizens',\n",
       "     'Perception',\n",
       "     'Social media'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['385'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Electronic Survey questionnaire'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Saudi Arabia'],\n",
       "    'OrgFullName': ['Qassim University'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 10, 2020'],\n",
       "    'CompletionDate': ['August 15, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 347,\n",
       "    'NCTId': ['NCT04677660'],\n",
       "    'BriefTitle': ['A Placebo-Controlled Study of TAK-919 in Healthy Japanese Adults (COVID-19)'],\n",
       "    'Condition': ['Prevention of Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1', 'Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['TAK-919', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Japan', 'Japan'],\n",
       "    'OrgFullName': ['Takeda'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 20, 2021'],\n",
       "    'CompletionDate': ['March 11, 2022'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 348,\n",
       "    'NCTId': ['NCT04590066'],\n",
       "    'BriefTitle': ['Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy'],\n",
       "    'Condition': ['Influenza, Human'],\n",
       "    'Keyword': ['Influenza vaccination',\n",
       "     'behavioral science interventions',\n",
       "     'vaccination promotion'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Health Services Research'],\n",
       "    'EnrollmentCount': ['1200000'],\n",
       "    'InterventionType': ['Behavioral'],\n",
       "    'InterventionName': ['Flu shot text messages'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['University of Pennsylvania'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['September 25, 2020'],\n",
       "    'CompletionDate': ['December 31, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['No Intervention',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 349,\n",
       "    'NCTId': ['NCT04509947'],\n",
       "    'BriefTitle': ['A Study of Ad26.COV2.S in Adults (COVID-19)'],\n",
       "    'Condition': ['Healthy'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['250'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['Ad26.COV2.S', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Japan', 'Japan', 'Japan'],\n",
       "    'OrgFullName': ['Janssen Pharmaceutical K.K.'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['August 11, 2020'],\n",
       "    'CompletionDate': ['December 8, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 350,\n",
       "    'NCTId': ['NCT04447209'],\n",
       "    'BriefTitle': ['Dietary Diversity of Young Children During CoVID-19 Outbreak: A Longitudinal Study'],\n",
       "    'Condition': ['Dietary Diversity'],\n",
       "    'Keyword': ['Dietary diversity',\n",
       "     'micro-nutrient adequacy',\n",
       "     'young children',\n",
       "     'urban settings'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['300'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Dietary counselling on Food Groups according to IYC Feeding practices, WHO'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child'],\n",
       "    'LocationCountry': ['Malaysia'],\n",
       "    'OrgFullName': ['University of Malaya'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 6, 2020'],\n",
       "    'CompletionDate': ['May 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 351,\n",
       "    'NCTId': ['NCT04477902'],\n",
       "    'BriefTitle': ['Long-Term Experience and Health Effects of COVID-19'],\n",
       "    'Condition': ['Covid19',\n",
       "     'Corona Virus Infection',\n",
       "     'Quality of Life',\n",
       "     'Risk Reduction'],\n",
       "    'Keyword': ['covid-19',\n",
       "     'corona virus',\n",
       "     'covid19',\n",
       "     'coronavirus',\n",
       "     'SARS-CoV-2',\n",
       "     'infection',\n",
       "     'household',\n",
       "     'transmission',\n",
       "     'vaccine',\n",
       "     'clinical trials',\n",
       "     'online',\n",
       "     'Altura',\n",
       "     'outpatient',\n",
       "     'telemedicine'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['50000'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['none - observational'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Altura'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['July 1, 2020'],\n",
       "    'CompletionDate': ['July 1, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 352,\n",
       "    'NCTId': ['NCT04494893'],\n",
       "    'BriefTitle': ['ImmuneRACE - Immune Response Action to COVID-19 Events'],\n",
       "    'Condition': ['Covid19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['1000'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Adaptive Biotechnologies'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 24, 2020'],\n",
       "    'CompletionDate': ['January 31, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 353,\n",
       "    'NCTId': ['NCT04280705'],\n",
       "    'BriefTitle': ['Adaptive COVID-19 Treatment Trial (ACTT)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Adaptive',\n",
       "     'COVID-19',\n",
       "     'Efficacy',\n",
       "     'Multicenter',\n",
       "     'novel coronavirus',\n",
       "     'Safety'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['1062'],\n",
       "    'InterventionType': ['Other', 'Drug'],\n",
       "    'InterventionName': ['Placebo', 'Remdesivir'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Denmark',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Greece',\n",
       "     'Greece',\n",
       "     'Japan',\n",
       "     'Korea, Republic of',\n",
       "     'Korea, Republic of',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Singapore',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom'],\n",
       "    'OrgFullName': ['National Institute of Allergy and Infectious Diseases (NIAID)'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['February 21, 2020'],\n",
       "    'CompletionDate': ['May 21, 2020'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Placebo Comparator', 'Experimental']},\n",
       "   {'Rank': 354,\n",
       "    'NCTId': ['NCT04565782'],\n",
       "    'BriefTitle': ['Corona Virus Infection Among Liver Transplant Recipients'],\n",
       "    'Condition': ['SARS-CoV Infection',\n",
       "     'Corona Virus Infection',\n",
       "     'Liver Transplant Recipient',\n",
       "     'COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['150'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Egypt'],\n",
       "    'OrgFullName': ['Assiut University'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 15, 2020'],\n",
       "    'CompletionDate': ['December 31, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 355,\n",
       "    'NCTId': ['NCT04199169'],\n",
       "    'BriefTitle': ['Safety and Immunogenicity of a Nipah Virus Vaccine'],\n",
       "    'Condition': ['Nipah Virus Infection'],\n",
       "    'Keyword': ['Nipah, Vaccine, Henipah'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['274'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['HeV-sG-V', 'Normal Saline Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Auro Vaccines LLC'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['February 18, 2020'],\n",
       "    'CompletionDate': ['October 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Placebo Comparator']},\n",
       "   {'Rank': 356,\n",
       "    'NCTId': ['NCT04401579'],\n",
       "    'BriefTitle': ['Adaptive COVID-19 Treatment Trial 2 (ACTT-2)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Adaptive',\n",
       "     'COVID-19',\n",
       "     'Efficacy',\n",
       "     'Multicenter',\n",
       "     'novel coronavirus',\n",
       "     'Safety'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['1034'],\n",
       "    'InterventionType': ['Other', 'Drug', 'Drug'],\n",
       "    'InterventionName': ['Placebo', 'Remdesivir', 'Baricitinib'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Denmark',\n",
       "     'Japan',\n",
       "     'Korea, Republic of',\n",
       "     'Korea, Republic of',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Singapore',\n",
       "     'Singapore',\n",
       "     'Singapore',\n",
       "     'Singapore',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom'],\n",
       "    'OrgFullName': ['National Institute of Allergy and Infectious Diseases (NIAID)'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['May 8, 2020'],\n",
       "    'CompletionDate': ['July 31, 2020'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 357,\n",
       "    'NCTId': ['NCT04492475'],\n",
       "    'BriefTitle': ['Adaptive COVID-19 Treatment Trial 3 (ACTT-3)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Adaptive',\n",
       "     'COVID-19',\n",
       "     'Efficacy',\n",
       "     'Multicenter',\n",
       "     'novel coronavirus',\n",
       "     'Safety'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['969'],\n",
       "    'InterventionType': ['Drug', 'Other', 'Drug'],\n",
       "    'InterventionName': ['Interferon beta-1a', 'Placebo', 'Remdesivir'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Japan',\n",
       "     'Korea, Republic of',\n",
       "     'Korea, Republic of',\n",
       "     'Mexico',\n",
       "     'Mexico',\n",
       "     'Singapore',\n",
       "     'Singapore',\n",
       "     'Singapore',\n",
       "     'Singapore'],\n",
       "    'OrgFullName': ['National Institute of Allergy and Infectious Diseases (NIAID)'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['August 4, 2020'],\n",
       "    'CompletionDate': ['December 30, 2020'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 358,\n",
       "    'NCTId': ['NCT04640168'],\n",
       "    'BriefTitle': ['Adaptive COVID-19 Treatment Trial 4 (ACTT-4)'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['ACTT',\n",
       "     'Adaptive',\n",
       "     'COVID-19',\n",
       "     'Efficacy',\n",
       "     'Multicenter',\n",
       "     'novel coronavirus',\n",
       "     'Safety'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['1500'],\n",
       "    'InterventionType': ['Drug', 'Drug', 'Other', 'Drug'],\n",
       "    'InterventionName': ['Baricitinib',\n",
       "     'Dexamethasone',\n",
       "     'Placebo',\n",
       "     'Remdesivir'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Japan',\n",
       "     'Korea, Republic of',\n",
       "     'Korea, Republic of',\n",
       "     'Singapore',\n",
       "     'Singapore',\n",
       "     'Singapore',\n",
       "     'Singapore',\n",
       "     'Singapore'],\n",
       "    'OrgFullName': ['National Institute of Allergy and Infectious Diseases (NIAID)'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['November 24, 2020'],\n",
       "    'CompletionDate': ['June 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Experimental']},\n",
       "   {'Rank': 359,\n",
       "    'NCTId': ['NCT04521309'],\n",
       "    'BriefTitle': ['SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['COVID19 ( Corona Virus Disease -2019)',\n",
       "     'SARS-CoV-2 (Severe Acute respiratory syndrome Coronavirus 2)',\n",
       "     'Passive Immunization',\n",
       "     'Intravenous Immunoglobulin (IVIG)',\n",
       "     'Pooled convalescent Plasma',\n",
       "     'Critically ill COVID-19 patients',\n",
       "     'Severe COVID-19 patients',\n",
       "     'Antibody'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['50'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['SARS-CoV-2 antibody based IVIG therapy'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Pakistan'],\n",
       "    'OrgFullName': ['Dow University of Health Sciences'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['June 19, 2020'],\n",
       "    'CompletionDate': ['March 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['No Intervention',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 360,\n",
       "    'NCTId': ['NCT03102034'],\n",
       "    'BriefTitle': ['Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age'],\n",
       "    'Condition': ['Respiratory Syncytial Virus Infections'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['32'],\n",
       "    'InterventionType': ['Biological', 'Biological'],\n",
       "    'InterventionName': ['D46/NS2/N/ΔM2-2-HindIII', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['National Institute of Allergy and Infectious Diseases (NIAID)'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['April 6, 2017'],\n",
       "    'CompletionDate': ['May 25, 2018'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 361,\n",
       "    'NCTId': ['NCT04545047'],\n",
       "    'BriefTitle': ['Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19'],\n",
       "    'Condition': ['Novel Coronavirus Disease 2019 (COVID-19)'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Antibodies, viral/blood',\n",
       "     'adult',\n",
       "     'Human',\n",
       "     'Retrospective Studies',\n",
       "     'Immunization, Passive',\n",
       "     'Pandemics',\n",
       "     'Antibodies, Neutralizing',\n",
       "     'COVID-19 serotherapy',\n",
       "     'Severe acute respiratory syndrome coronavirus 2',\n",
       "     'Coronavirus Infections / therapy'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['4000'],\n",
       "    'InterventionType': ['Biological'],\n",
       "    'InterventionName': ['COVID-19 convalescent plasma'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States', 'United States'],\n",
       "    'OrgFullName': ['VA Office of Research and Development'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['August 7, 2020'],\n",
       "    'CompletionDate': ['June 30, 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 362,\n",
       "    'NCTId': ['NCT04525521'],\n",
       "    'BriefTitle': ['Hand Sanitizer Effects on the Skin Barrier'],\n",
       "    'Condition': ['Dermatitis Hand',\n",
       "     'Skin Abnormalities',\n",
       "     'Atopic Dermatitis',\n",
       "     'Atopic Dermatitis Eczema'],\n",
       "    'Keyword': ['Hand dermatitis',\n",
       "     'Skin barrier',\n",
       "     'Hand washing',\n",
       "     'Hand sanitizer',\n",
       "     'Eczema',\n",
       "     'Atopic dermatitis'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['40'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Hand sanitizer and hand washing'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['National Jewish Health'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 8, 2020'],\n",
       "    'CompletionDate': ['August 20, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 363,\n",
       "    'NCTId': ['NCT04659486'],\n",
       "    'BriefTitle': ['Adolescents With COVID-19/MIS-C at HCFMUSP'],\n",
       "    'Condition': ['Covid19',\n",
       "     'Corona Virus Infection',\n",
       "     'SARS (Severe Acute Respiratory Syndrome)',\n",
       "     'SARS-CoV Infection'],\n",
       "    'Keyword': ['Covid19', 'Children', 'Adolescents'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['100'],\n",
       "    'InterventionType': ['Behavioral'],\n",
       "    'InterventionName': ['Home-based exercise training'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult'],\n",
       "    'LocationCountry': ['Brazil'],\n",
       "    'OrgFullName': ['University of Sao Paulo'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['September 24, 2020'],\n",
       "    'CompletionDate': ['April 30, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 364,\n",
       "    'NCTId': ['NCT04583969'],\n",
       "    'BriefTitle': ['ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Adults',\n",
       "     'COVID-19',\n",
       "     'Multicenter',\n",
       "     'Putative',\n",
       "     'Therapeutics'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Biological', 'Other', 'Drug'],\n",
       "    'InterventionName': ['Lenzilumab', 'Placebo', 'Remdesivir'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['National Institute of Allergy and Infectious Diseases (NIAID)'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 19, 2020'],\n",
       "    'CompletionDate': ['July 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Active Comparator']},\n",
       "   {'Rank': 365,\n",
       "    'NCTId': ['NCT04583956'],\n",
       "    'BriefTitle': ['ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Adults',\n",
       "     'COVID-19',\n",
       "     'Multicenter',\n",
       "     'Platform',\n",
       "     'Putative',\n",
       "     'Therapeutics'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Other', 'Drug', 'Biological'],\n",
       "    'InterventionName': ['Placebo', 'Remdesivir', 'Risankizumab'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States'],\n",
       "    'OrgFullName': ['National Institute of Allergy and Infectious Diseases (NIAID)'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 14, 2020'],\n",
       "    'CompletionDate': ['July 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Experimental']},\n",
       "   {'Rank': 366,\n",
       "    'NCTId': ['NCT04518410'],\n",
       "    'BriefTitle': ['ACTIV-2: A Study for Outpatients With COVID-19'],\n",
       "    'Condition': ['Coronavirus', 'Covid19'],\n",
       "    'Keyword': ['COVID-19',\n",
       "     'Coronavirus',\n",
       "     'COVID 19',\n",
       "     'Coronaviridae Infections',\n",
       "     'Coronavirus Infections',\n",
       "     'RNA Virus Infections',\n",
       "     'Virus Diseases',\n",
       "     'Nidovirales Infections',\n",
       "     'SARS-CoV-2',\n",
       "     'SARS Coronavirus',\n",
       "     'ACTIV-2',\n",
       "     'ACTIV2'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 2', 'Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['2000'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['LY3819253', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'Puerto Rico'],\n",
       "    'OrgFullName': ['National Institute of Allergy and Infectious Diseases (NIAID)'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['August 19, 2020'],\n",
       "    'CompletionDate': ['December 2021'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 367,\n",
       "    'NCTId': ['NCT04292730'],\n",
       "    'BriefTitle': ['Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 3'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['1113'],\n",
       "    'InterventionType': ['Drug', 'Drug'],\n",
       "    'InterventionName': ['Remdesivir', 'Standard of Care'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'United States',\n",
       "     'China',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'France',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Germany',\n",
       "     'Hong Kong',\n",
       "     'Hong Kong',\n",
       "     'Hong Kong',\n",
       "     'Italy',\n",
       "     'Italy',\n",
       "     'Italy',\n",
       "     'Italy',\n",
       "     'Italy',\n",
       "     'Italy',\n",
       "     'Italy',\n",
       "     'Italy',\n",
       "     'Italy',\n",
       "     'Italy',\n",
       "     'Italy',\n",
       "     'Italy',\n",
       "     'Japan',\n",
       "     'Japan',\n",
       "     'Japan',\n",
       "     'Korea, Republic of',\n",
       "     'Korea, Republic of',\n",
       "     'Korea, Republic of',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Netherlands',\n",
       "     'Singapore',\n",
       "     'Singapore',\n",
       "     'Singapore',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Spain',\n",
       "     'Sweden',\n",
       "     'Sweden',\n",
       "     'Sweden',\n",
       "     'Switzerland',\n",
       "     'Switzerland',\n",
       "     'Switzerland',\n",
       "     'Taiwan',\n",
       "     'Taiwan',\n",
       "     'Taiwan',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom',\n",
       "     'United Kingdom'],\n",
       "    'OrgFullName': ['Gilead Sciences'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['March 15, 2020'],\n",
       "    'CompletionDate': ['June 26, 2020'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental',\n",
       "     'Experimental',\n",
       "     'Active Comparator',\n",
       "     'Experimental']},\n",
       "   {'Rank': 368,\n",
       "    'NCTId': ['NCT04576377'],\n",
       "    'BriefTitle': ['Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures'],\n",
       "    'Condition': ['Influenza, Human'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 4'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['820'],\n",
       "    'InterventionType': ['Biological', 'Other'],\n",
       "    'InterventionName': ['FluBlok', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult'],\n",
       "    'LocationCountry': ['Hong Kong'],\n",
       "    'OrgFullName': ['The University of Hong Kong'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['October 5, 2020'],\n",
       "    'CompletionDate': ['December 31, 2024'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Experimental', 'Placebo Comparator']},\n",
       "   {'Rank': 369,\n",
       "    'NCTId': ['NCT04631367'],\n",
       "    'BriefTitle': ['mHealth Intervention for Increasing COVID-19 Prevention Practices With Urban Refugee and Displaced Youth in Uganda'],\n",
       "    'Condition': ['Knowledge, Attitudes, Practice', 'Covid19'],\n",
       "    'Keyword': ['Uganda',\n",
       "     'Forcibly displaced youth',\n",
       "     'mHealth',\n",
       "     'Water, Sanitation and Hygiene',\n",
       "     'RANAS (Risks, Attitudes, Norms, Abilities, Self-Regulation)',\n",
       "     'COVID-19'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['404'],\n",
       "    'InterventionType': ['Behavioral', 'Device'],\n",
       "    'InterventionName': ['Kukaa Salama: mHealth intervention',\n",
       "     'Face Mask + Soap'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Child', 'Adult'],\n",
       "    'LocationCountry': [],\n",
       "    'OrgFullName': ['University of Toronto'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['February 1, 2021'],\n",
       "    'CompletionDate': ['September 20, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental']},\n",
       "   {'Rank': 370,\n",
       "    'NCTId': ['NCT04474496'],\n",
       "    'BriefTitle': ['Impact of COVID-19 on Marshallese Communities in the U.S.'],\n",
       "    'Condition': ['COVID-19'],\n",
       "    'Keyword': ['Marshallese',\n",
       "     'Pacific Islanders',\n",
       "     'Type 2 Diabetes',\n",
       "     'COVID-19'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['2000'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['Assessing impact of COVID19'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['University of Arkansas'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['July 27, 2020'],\n",
       "    'CompletionDate': ['December 15, 2020'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 371,\n",
       "    'NCTId': ['NCT04443257'],\n",
       "    'BriefTitle': ['REassessement After Hospitalization for Sars-COV-2 disordER'],\n",
       "    'Condition': ['Sars-CoV2'],\n",
       "    'Keyword': ['comorbidities',\n",
       "     'Sars-CoV2',\n",
       "     'sequelae',\n",
       "     'patient outcome assessment',\n",
       "     'Covid19',\n",
       "     'quality of life'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['200'],\n",
       "    'InterventionType': ['Other'],\n",
       "    'InterventionName': ['assessment of the sequelae after hospitalization for Sars-COV-2'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['France'],\n",
       "    'OrgFullName': ['University Hospital, Montpellier'],\n",
       "    'OverallStatus': ['Enrolling by invitation'],\n",
       "    'StartDate': ['July 8, 2020'],\n",
       "    'CompletionDate': ['July 25, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 372,\n",
       "    'NCTId': ['NCT04565353'],\n",
       "    'BriefTitle': ['Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates'],\n",
       "    'Condition': ['Influenza, Human'],\n",
       "    'Keyword': ['Influenza vaccination',\n",
       "     'behavioral science interventions',\n",
       "     'vaccination promotion'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Health Services Research'],\n",
       "    'EnrollmentCount': ['80000'],\n",
       "    'InterventionType': ['Behavioral'],\n",
       "    'InterventionName': ['Flu shot text messages'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States', 'United States'],\n",
       "    'OrgFullName': ['University of Pennsylvania'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['September 20, 2020'],\n",
       "    'CompletionDate': ['March 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['No Intervention',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental',\n",
       "     'Experimental']},\n",
       "   {'Rank': 373,\n",
       "    'NCTId': ['NCT04370119'],\n",
       "    'BriefTitle': ['Screening for COVID-19 and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers'],\n",
       "    'Condition': ['SARS-Cov-2'],\n",
       "    'Keyword': ['Serology', 'antibody formation', 'epidemiology', 'immunity'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['4000'],\n",
       "    'InterventionType': ['Diagnostic Test', 'Diagnostic Test'],\n",
       "    'InterventionName': ['Nasal swab', 'Serum testing'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Germany'],\n",
       "    'OrgFullName': ['University Medicine Greifswald'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['April 27, 2020'],\n",
       "    'CompletionDate': ['May 2025'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': []},\n",
       "   {'Rank': 374,\n",
       "    'NCTId': ['NCT04652596'],\n",
       "    'BriefTitle': ['Reducing Food Insecurity During COVID-19'],\n",
       "    'Condition': ['Food Insecurity'],\n",
       "    'Keyword': ['Produce prescription program',\n",
       "     'Mobile markets',\n",
       "     'Grocery store gift cards',\n",
       "     'Fruit and vegetable consumption',\n",
       "     'Low-income families',\n",
       "     'Social determinants of health'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Prevention'],\n",
       "    'EnrollmentCount': ['250'],\n",
       "    'InterventionType': ['Other', 'Other'],\n",
       "    'InterventionName': ['Produce prescription program',\n",
       "     'Grocery store gift cards'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Boston Medical Center'],\n",
       "    'OverallStatus': ['Not yet recruiting'],\n",
       "    'StartDate': ['January 2021'],\n",
       "    'CompletionDate': ['October 2022'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Active Comparator']},\n",
       "   {'Rank': 375,\n",
       "    'NCTId': ['NCT04461353'],\n",
       "    'BriefTitle': ['A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers'],\n",
       "    'Condition': ['Severe Acute Respiratory Syndrome Coronavirus 2'],\n",
       "    'Keyword': ['coronavirus',\n",
       "     'COVID-19',\n",
       "     'Hydroxychloroquine Sulfate',\n",
       "     'Hydroxychloroquine'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Phase 1'],\n",
       "    'DesignPrimaryPurpose': ['Treatment'],\n",
       "    'EnrollmentCount': ['12'],\n",
       "    'InterventionType': ['Drug', 'Other'],\n",
       "    'InterventionName': ['Aerolized Hydroxychloroquine Sulfate', 'Placebo'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Pulmoquine Therapeutics, Inc'],\n",
       "    'OverallStatus': ['Completed'],\n",
       "    'StartDate': ['June 25, 2020'],\n",
       "    'CompletionDate': ['August 17, 2020'],\n",
       "    'IsFDARegulatedDrug': ['Yes'],\n",
       "    'ArmGroupType': ['Active Comparator', 'Placebo Comparator']},\n",
       "   {'Rank': 376,\n",
       "    'NCTId': ['NCT03922334'],\n",
       "    'BriefTitle': ['Navigating New Motherhood 2'],\n",
       "    'Condition': ['Postpartum Health',\n",
       "     'Breastfeeding',\n",
       "     'Contraception',\n",
       "     'Preventive Care / Anticipatory Guidance',\n",
       "     'Retention in Care'],\n",
       "    'Keyword': [],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Supportive Care'],\n",
       "    'EnrollmentCount': ['400'],\n",
       "    'InterventionType': ['Behavioral'],\n",
       "    'InterventionName': ['Patient Navigation Program'],\n",
       "    'Gender': ['Female'],\n",
       "    'StdAge': ['Child', 'Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['Northwestern University'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['January 21, 2020'],\n",
       "    'CompletionDate': ['December 2024'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Experimental', 'No Intervention']},\n",
       "   {'Rank': 377,\n",
       "    'NCTId': ['NCT04237883'],\n",
       "    'BriefTitle': ['Primary Care Clinical Excellence Incentive Study'],\n",
       "    'Condition': ['Behavioral Economics',\n",
       "     'Primary Health Care',\n",
       "     'Health Maintenance',\n",
       "     'Diabetes',\n",
       "     'Colorectal Cancer Screening',\n",
       "     'Cervical Cancer Screening',\n",
       "     'Chlamydia Screening',\n",
       "     'HPV Screening'],\n",
       "    'Keyword': ['Behavioral Economics',\n",
       "     'Primary Health Care',\n",
       "     'Health Maintenance',\n",
       "     'Physician Reimbursement'],\n",
       "    'StudyType': ['Interventional'],\n",
       "    'Phase': ['Not Applicable'],\n",
       "    'DesignPrimaryPurpose': ['Health Services Research'],\n",
       "    'EnrollmentCount': ['225'],\n",
       "    'InterventionType': ['Behavioral', 'Behavioral', 'Behavioral'],\n",
       "    'InterventionName': ['Standard communication email',\n",
       "     'Social comparison Intervention',\n",
       "     'Leadership Training'],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['United States'],\n",
       "    'OrgFullName': ['University of California, Los Angeles'],\n",
       "    'OverallStatus': ['Active, not recruiting'],\n",
       "    'StartDate': ['November 1, 2019'],\n",
       "    'CompletionDate': ['July 1, 2021'],\n",
       "    'IsFDARegulatedDrug': ['No'],\n",
       "    'ArmGroupType': ['Placebo Comparator', 'Experimental', 'Experimental']},\n",
       "   {'Rank': 378,\n",
       "    'NCTId': ['NCT04709263'],\n",
       "    'BriefTitle': ['Heart Failure Patients Registry'],\n",
       "    'Condition': ['Heart Failure'],\n",
       "    'Keyword': ['Heart Failure'],\n",
       "    'StudyType': ['Observational'],\n",
       "    'Phase': [],\n",
       "    'DesignPrimaryPurpose': [],\n",
       "    'EnrollmentCount': ['20000'],\n",
       "    'InterventionType': [],\n",
       "    'InterventionName': [],\n",
       "    'Gender': ['All'],\n",
       "    'StdAge': ['Adult', 'Older Adult'],\n",
       "    'LocationCountry': ['Russian Federation', 'Russian Federation'],\n",
       "    'OrgFullName': ['AstraZeneca'],\n",
       "    'OverallStatus': ['Recruiting'],\n",
       "    'StartDate': ['December 23, 2020'],\n",
       "    'CompletionDate': ['December 31, 2023'],\n",
       "    'IsFDARegulatedDrug': [],\n",
       "    'ArmGroupType': []}]}}"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_all = df_all.json()\n",
    "df_all"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>NCTId</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Keyword</th>\n",
       "      <th>StudyType</th>\n",
       "      <th>Phase</th>\n",
       "      <th>DesignPrimaryPurpose</th>\n",
       "      <th>EnrollmentCount</th>\n",
       "      <th>InterventionType</th>\n",
       "      <th>InterventionName</th>\n",
       "      <th>Gender</th>\n",
       "      <th>StdAge</th>\n",
       "      <th>LocationCountry</th>\n",
       "      <th>OrgFullName</th>\n",
       "      <th>OverallStatus</th>\n",
       "      <th>StartDate</th>\n",
       "      <th>CompletionDate</th>\n",
       "      <th>IsFDARegulatedDrug</th>\n",
       "      <th>ArmGroupType</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>[NCT04568811]</td>\n",
       "      <td>[The Phase I Clinical Trial of Booster Vaccina...</td>\n",
       "      <td>[Adenovirus Type-5 Vectored COVID-19 Vaccine]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[Phase 1]</td>\n",
       "      <td>[Prevention]</td>\n",
       "      <td>[89]</td>\n",
       "      <td>[Biological]</td>\n",
       "      <td>[Adenovirus Type-5 Vectored COVID-19 Vaccine]</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[Child, Adult, Older Adult]</td>\n",
       "      <td>[China]</td>\n",
       "      <td>[Jiangsu Province Centers for Disease Control ...</td>\n",
       "      <td>[Active, not recruiting]</td>\n",
       "      <td>[September 26, 2020]</td>\n",
       "      <td>[September 27, 2021]</td>\n",
       "      <td>[No]</td>\n",
       "      <td>[Experimental]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>[NCT04497298]</td>\n",
       "      <td>[Clinical Trial to Evaluate the Safety and Imm...</td>\n",
       "      <td>[COVID-19]</td>\n",
       "      <td>[SARS-CoV-2, Vaccine, Prevention]</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[Phase 1]</td>\n",
       "      <td>[Prevention]</td>\n",
       "      <td>[90]</td>\n",
       "      <td>[Biological, Biological, Biological, Other]</td>\n",
       "      <td>[Two COVID-19 vaccine candidate (TMV-083) admi...</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[Adult]</td>\n",
       "      <td>[Belgium, France]</td>\n",
       "      <td>[Institut Pasteur]</td>\n",
       "      <td>[Recruiting]</td>\n",
       "      <td>[August 10, 2020]</td>\n",
       "      <td>[October 2021]</td>\n",
       "      <td>[No]</td>\n",
       "      <td>[Experimental, Experimental, Experimental, Pla...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>[NCT04651790]</td>\n",
       "      <td>[Efficacy, Safety, and Immunogenicity of an In...</td>\n",
       "      <td>[Covid19, Vaccines]</td>\n",
       "      <td>[Clinical trials, Covid19, Inactivated vaccine]</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[Phase 3]</td>\n",
       "      <td>[Prevention]</td>\n",
       "      <td>[2300]</td>\n",
       "      <td>[Biological, Other]</td>\n",
       "      <td>[SARS-CoV-2 inactivated vaccine, Placebo]</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[Chile]</td>\n",
       "      <td>[Pontificia Universidad Catolica de Chile]</td>\n",
       "      <td>[Recruiting]</td>\n",
       "      <td>[November 27, 2020]</td>\n",
       "      <td>[March 2022]</td>\n",
       "      <td>[No]</td>\n",
       "      <td>[Active Comparator, Placebo Comparator]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>[NCT04659941]</td>\n",
       "      <td>[Use of BCG Vaccine as a Preventive Measure fo...</td>\n",
       "      <td>[COVID 19 Vaccine]</td>\n",
       "      <td>[COVID 19, BCG vaccine]</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[Phase 2]</td>\n",
       "      <td>[Prevention]</td>\n",
       "      <td>[1000]</td>\n",
       "      <td>[Biological]</td>\n",
       "      <td>[BCG vaccine]</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[Brazil]</td>\n",
       "      <td>[Universidade Federal do Rio de Janeiro]</td>\n",
       "      <td>[Recruiting]</td>\n",
       "      <td>[October 1, 2020]</td>\n",
       "      <td>[October 1, 2022]</td>\n",
       "      <td>[No]</td>\n",
       "      <td>[Experimental, Placebo Comparator]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>[NCT04510207]</td>\n",
       "      <td>[A Study to Evaluate The Efficacy, Safety and ...</td>\n",
       "      <td>[COVID-19]</td>\n",
       "      <td>[SARS-CoV-2, SARS-CoV-2 Vaccine, Coronavirus]</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[Phase 3]</td>\n",
       "      <td>[Prevention]</td>\n",
       "      <td>[45000]</td>\n",
       "      <td>[Biological, Biological, Biological]</td>\n",
       "      <td>[Inactivated SARS-CoV-2 Vaccine (Vero cell), I...</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[Bahrain, Egypt, Egypt, Jordan, United Arab Em...</td>\n",
       "      <td>[China National Biotec Group Company Limited]</td>\n",
       "      <td>[Recruiting]</td>\n",
       "      <td>[July 16, 2020]</td>\n",
       "      <td>[September 16, 2021]</td>\n",
       "      <td>[No]</td>\n",
       "      <td>[Experimental, Experimental, Placebo Comparator]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>373</th>\n",
       "      <td>374</td>\n",
       "      <td>[NCT04652596]</td>\n",
       "      <td>[Reducing Food Insecurity During COVID-19]</td>\n",
       "      <td>[Food Insecurity]</td>\n",
       "      <td>[Produce prescription program, Mobile markets,...</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[Not Applicable]</td>\n",
       "      <td>[Prevention]</td>\n",
       "      <td>[250]</td>\n",
       "      <td>[Other, Other]</td>\n",
       "      <td>[Produce prescription program, Grocery store g...</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[United States]</td>\n",
       "      <td>[Boston Medical Center]</td>\n",
       "      <td>[Not yet recruiting]</td>\n",
       "      <td>[January 2021]</td>\n",
       "      <td>[October 2022]</td>\n",
       "      <td>[No]</td>\n",
       "      <td>[Active Comparator, Active Comparator]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>374</th>\n",
       "      <td>375</td>\n",
       "      <td>[NCT04461353]</td>\n",
       "      <td>[A Study to Evaluate the Safety, Tolerability ...</td>\n",
       "      <td>[Severe Acute Respiratory Syndrome Coronavirus 2]</td>\n",
       "      <td>[coronavirus, COVID-19, Hydroxychloroquine Sul...</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[Phase 1]</td>\n",
       "      <td>[Treatment]</td>\n",
       "      <td>[12]</td>\n",
       "      <td>[Drug, Other]</td>\n",
       "      <td>[Aerolized Hydroxychloroquine Sulfate, Placebo]</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[United States]</td>\n",
       "      <td>[Pulmoquine Therapeutics, Inc]</td>\n",
       "      <td>[Completed]</td>\n",
       "      <td>[June 25, 2020]</td>\n",
       "      <td>[August 17, 2020]</td>\n",
       "      <td>[Yes]</td>\n",
       "      <td>[Active Comparator, Placebo Comparator]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>375</th>\n",
       "      <td>376</td>\n",
       "      <td>[NCT03922334]</td>\n",
       "      <td>[Navigating New Motherhood 2]</td>\n",
       "      <td>[Postpartum Health, Breastfeeding, Contracepti...</td>\n",
       "      <td>[]</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[Not Applicable]</td>\n",
       "      <td>[Supportive Care]</td>\n",
       "      <td>[400]</td>\n",
       "      <td>[Behavioral]</td>\n",
       "      <td>[Patient Navigation Program]</td>\n",
       "      <td>[Female]</td>\n",
       "      <td>[Child, Adult]</td>\n",
       "      <td>[United States]</td>\n",
       "      <td>[Northwestern University]</td>\n",
       "      <td>[Recruiting]</td>\n",
       "      <td>[January 21, 2020]</td>\n",
       "      <td>[December 2024]</td>\n",
       "      <td>[No]</td>\n",
       "      <td>[Experimental, No Intervention]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>376</th>\n",
       "      <td>377</td>\n",
       "      <td>[NCT04237883]</td>\n",
       "      <td>[Primary Care Clinical Excellence Incentive St...</td>\n",
       "      <td>[Behavioral Economics, Primary Health Care, He...</td>\n",
       "      <td>[Behavioral Economics, Primary Health Care, He...</td>\n",
       "      <td>[Interventional]</td>\n",
       "      <td>[Not Applicable]</td>\n",
       "      <td>[Health Services Research]</td>\n",
       "      <td>[225]</td>\n",
       "      <td>[Behavioral, Behavioral, Behavioral]</td>\n",
       "      <td>[Standard communication email, Social comparis...</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[United States]</td>\n",
       "      <td>[University of California, Los Angeles]</td>\n",
       "      <td>[Active, not recruiting]</td>\n",
       "      <td>[November 1, 2019]</td>\n",
       "      <td>[July 1, 2021]</td>\n",
       "      <td>[No]</td>\n",
       "      <td>[Placebo Comparator, Experimental, Experimental]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>377</th>\n",
       "      <td>378</td>\n",
       "      <td>[NCT04709263]</td>\n",
       "      <td>[Heart Failure Patients Registry]</td>\n",
       "      <td>[Heart Failure]</td>\n",
       "      <td>[Heart Failure]</td>\n",
       "      <td>[Observational]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[20000]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[All]</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[Russian Federation, Russian Federation]</td>\n",
       "      <td>[AstraZeneca]</td>\n",
       "      <td>[Recruiting]</td>\n",
       "      <td>[December 23, 2020]</td>\n",
       "      <td>[December 31, 2023]</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>378 rows × 20 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Rank          NCTId                                         BriefTitle  \\\n",
       "0       1  [NCT04568811]  [The Phase I Clinical Trial of Booster Vaccina...   \n",
       "1       2  [NCT04497298]  [Clinical Trial to Evaluate the Safety and Imm...   \n",
       "2       3  [NCT04651790]  [Efficacy, Safety, and Immunogenicity of an In...   \n",
       "3       4  [NCT04659941]  [Use of BCG Vaccine as a Preventive Measure fo...   \n",
       "4       5  [NCT04510207]  [A Study to Evaluate The Efficacy, Safety and ...   \n",
       "..    ...            ...                                                ...   \n",
       "373   374  [NCT04652596]         [Reducing Food Insecurity During COVID-19]   \n",
       "374   375  [NCT04461353]  [A Study to Evaluate the Safety, Tolerability ...   \n",
       "375   376  [NCT03922334]                      [Navigating New Motherhood 2]   \n",
       "376   377  [NCT04237883]  [Primary Care Clinical Excellence Incentive St...   \n",
       "377   378  [NCT04709263]                  [Heart Failure Patients Registry]   \n",
       "\n",
       "                                             Condition  \\\n",
       "0        [Adenovirus Type-5 Vectored COVID-19 Vaccine]   \n",
       "1                                           [COVID-19]   \n",
       "2                                  [Covid19, Vaccines]   \n",
       "3                                   [COVID 19 Vaccine]   \n",
       "4                                           [COVID-19]   \n",
       "..                                                 ...   \n",
       "373                                  [Food Insecurity]   \n",
       "374  [Severe Acute Respiratory Syndrome Coronavirus 2]   \n",
       "375  [Postpartum Health, Breastfeeding, Contracepti...   \n",
       "376  [Behavioral Economics, Primary Health Care, He...   \n",
       "377                                    [Heart Failure]   \n",
       "\n",
       "                                               Keyword         StudyType  \\\n",
       "0                                                   []  [Interventional]   \n",
       "1                    [SARS-CoV-2, Vaccine, Prevention]  [Interventional]   \n",
       "2      [Clinical trials, Covid19, Inactivated vaccine]  [Interventional]   \n",
       "3                              [COVID 19, BCG vaccine]  [Interventional]   \n",
       "4        [SARS-CoV-2, SARS-CoV-2 Vaccine, Coronavirus]  [Interventional]   \n",
       "..                                                 ...               ...   \n",
       "373  [Produce prescription program, Mobile markets,...  [Interventional]   \n",
       "374  [coronavirus, COVID-19, Hydroxychloroquine Sul...  [Interventional]   \n",
       "375                                                 []  [Interventional]   \n",
       "376  [Behavioral Economics, Primary Health Care, He...  [Interventional]   \n",
       "377                                    [Heart Failure]   [Observational]   \n",
       "\n",
       "                Phase        DesignPrimaryPurpose EnrollmentCount  \\\n",
       "0           [Phase 1]                [Prevention]            [89]   \n",
       "1           [Phase 1]                [Prevention]            [90]   \n",
       "2           [Phase 3]                [Prevention]          [2300]   \n",
       "3           [Phase 2]                [Prevention]          [1000]   \n",
       "4           [Phase 3]                [Prevention]         [45000]   \n",
       "..                ...                         ...             ...   \n",
       "373  [Not Applicable]                [Prevention]           [250]   \n",
       "374         [Phase 1]                 [Treatment]            [12]   \n",
       "375  [Not Applicable]           [Supportive Care]           [400]   \n",
       "376  [Not Applicable]  [Health Services Research]           [225]   \n",
       "377                []                          []         [20000]   \n",
       "\n",
       "                                InterventionType  \\\n",
       "0                                   [Biological]   \n",
       "1    [Biological, Biological, Biological, Other]   \n",
       "2                            [Biological, Other]   \n",
       "3                                   [Biological]   \n",
       "4           [Biological, Biological, Biological]   \n",
       "..                                           ...   \n",
       "373                               [Other, Other]   \n",
       "374                                [Drug, Other]   \n",
       "375                                 [Behavioral]   \n",
       "376         [Behavioral, Behavioral, Behavioral]   \n",
       "377                                           []   \n",
       "\n",
       "                                      InterventionName    Gender  \\\n",
       "0        [Adenovirus Type-5 Vectored COVID-19 Vaccine]     [All]   \n",
       "1    [Two COVID-19 vaccine candidate (TMV-083) admi...     [All]   \n",
       "2            [SARS-CoV-2 inactivated vaccine, Placebo]     [All]   \n",
       "3                                        [BCG vaccine]     [All]   \n",
       "4    [Inactivated SARS-CoV-2 Vaccine (Vero cell), I...     [All]   \n",
       "..                                                 ...       ...   \n",
       "373  [Produce prescription program, Grocery store g...     [All]   \n",
       "374    [Aerolized Hydroxychloroquine Sulfate, Placebo]     [All]   \n",
       "375                       [Patient Navigation Program]  [Female]   \n",
       "376  [Standard communication email, Social comparis...     [All]   \n",
       "377                                                 []     [All]   \n",
       "\n",
       "                          StdAge  \\\n",
       "0    [Child, Adult, Older Adult]   \n",
       "1                        [Adult]   \n",
       "2           [Adult, Older Adult]   \n",
       "3           [Adult, Older Adult]   \n",
       "4           [Adult, Older Adult]   \n",
       "..                           ...   \n",
       "373         [Adult, Older Adult]   \n",
       "374         [Adult, Older Adult]   \n",
       "375               [Child, Adult]   \n",
       "376         [Adult, Older Adult]   \n",
       "377         [Adult, Older Adult]   \n",
       "\n",
       "                                       LocationCountry  \\\n",
       "0                                              [China]   \n",
       "1                                    [Belgium, France]   \n",
       "2                                              [Chile]   \n",
       "3                                             [Brazil]   \n",
       "4    [Bahrain, Egypt, Egypt, Jordan, United Arab Em...   \n",
       "..                                                 ...   \n",
       "373                                    [United States]   \n",
       "374                                    [United States]   \n",
       "375                                    [United States]   \n",
       "376                                    [United States]   \n",
       "377           [Russian Federation, Russian Federation]   \n",
       "\n",
       "                                           OrgFullName  \\\n",
       "0    [Jiangsu Province Centers for Disease Control ...   \n",
       "1                                   [Institut Pasteur]   \n",
       "2           [Pontificia Universidad Catolica de Chile]   \n",
       "3             [Universidade Federal do Rio de Janeiro]   \n",
       "4        [China National Biotec Group Company Limited]   \n",
       "..                                                 ...   \n",
       "373                            [Boston Medical Center]   \n",
       "374                     [Pulmoquine Therapeutics, Inc]   \n",
       "375                          [Northwestern University]   \n",
       "376            [University of California, Los Angeles]   \n",
       "377                                      [AstraZeneca]   \n",
       "\n",
       "                OverallStatus             StartDate        CompletionDate  \\\n",
       "0    [Active, not recruiting]  [September 26, 2020]  [September 27, 2021]   \n",
       "1                [Recruiting]     [August 10, 2020]        [October 2021]   \n",
       "2                [Recruiting]   [November 27, 2020]          [March 2022]   \n",
       "3                [Recruiting]     [October 1, 2020]     [October 1, 2022]   \n",
       "4                [Recruiting]       [July 16, 2020]  [September 16, 2021]   \n",
       "..                        ...                   ...                   ...   \n",
       "373      [Not yet recruiting]        [January 2021]        [October 2022]   \n",
       "374               [Completed]       [June 25, 2020]     [August 17, 2020]   \n",
       "375              [Recruiting]    [January 21, 2020]       [December 2024]   \n",
       "376  [Active, not recruiting]    [November 1, 2019]        [July 1, 2021]   \n",
       "377              [Recruiting]   [December 23, 2020]   [December 31, 2023]   \n",
       "\n",
       "    IsFDARegulatedDrug                                       ArmGroupType  \n",
       "0                 [No]                                     [Experimental]  \n",
       "1                 [No]  [Experimental, Experimental, Experimental, Pla...  \n",
       "2                 [No]            [Active Comparator, Placebo Comparator]  \n",
       "3                 [No]                 [Experimental, Placebo Comparator]  \n",
       "4                 [No]   [Experimental, Experimental, Placebo Comparator]  \n",
       "..                 ...                                                ...  \n",
       "373               [No]             [Active Comparator, Active Comparator]  \n",
       "374              [Yes]            [Active Comparator, Placebo Comparator]  \n",
       "375               [No]                    [Experimental, No Intervention]  \n",
       "376               [No]   [Placebo Comparator, Experimental, Experimental]  \n",
       "377                 []                                                 []  \n",
       "\n",
       "[378 rows x 20 columns]"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# convert json into a dataframe\n",
    "df_detail = pd.json_normalize(df_all['StudyFieldsResponse']['StudyFields']) \n",
    "df_detail"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 2. Data Cleaning\n",
    "\n",
    "Cleaning the format of the dataframe\n",
    "\n",
    "For columns with only one single value, flatten the list inside each cell:\n",
    "- `NCTId`\n",
    "- `BriefTitle`\n",
    "- `StudyType`\n",
    "- `DesignPrimaryPurpose`\n",
    "- `EnrollmentCount`\n",
    "- `Gender`\n",
    "- `OrgFullName`\n",
    "- `OverallStatus`\n",
    "- `StartDate`\n",
    "- `CompletionDate`\n",
    "- `IsFDARegulatedDrug`"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/iris.xx/opt/anaconda3/lib/python3.8/site-packages/pandas/core/indexing.py:671: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  self._setitem_with_indexer(indexer, value)\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(df_detail)):\n",
    "    if len(df_detail.NCTId.iloc[i]) == 0:\n",
    "        df_detail.NCTId.iloc[i] = 'Unknown'\n",
    "    else:\n",
    "        df_detail.NCTId.iloc[i] = df_detail.NCTId.iloc[i][0]\n",
    "        \n",
    "    if len(df_detail.BriefTitle.iloc[i]) == 0:\n",
    "        df_detail.BriefTitle.iloc[i] = 'Unknown'\n",
    "    else:\n",
    "        df_detail.BriefTitle.iloc[i] = df_detail.BriefTitle.iloc[i][0]\n",
    "        \n",
    "    if len(df_detail.StudyType.iloc[i]) == 0:\n",
    "        df_detail.StudyType.iloc[i] = 'Unknown'\n",
    "    else:\n",
    "        df_detail.StudyType.iloc[i] = df_detail.StudyType.iloc[i][0]\n",
    "        \n",
    "    if len(df_detail.DesignPrimaryPurpose.iloc[i]) == 0:\n",
    "        df_detail.DesignPrimaryPurpose.iloc[i] = 'Unknown'\n",
    "    else:\n",
    "        df_detail.DesignPrimaryPurpose.iloc[i] = df_detail.DesignPrimaryPurpose.iloc[i][0]\n",
    "    \n",
    "    if len(df_detail.EnrollmentCount.iloc[i]) == 0:\n",
    "        df_detail.EnrollmentCount.iloc[i] = 'Unknown'\n",
    "    else:\n",
    "        df_detail.EnrollmentCount.iloc[i] = df_detail.EnrollmentCount.iloc[i][0]\n",
    "    \n",
    "    if len(df_detail.Gender.iloc[i]) == 0:\n",
    "        df_detail.Gender.iloc[i] = 'Unknown'\n",
    "    else:\n",
    "        df_detail.Gender.iloc[i] = df_detail.Gender.iloc[i][0]\n",
    "    \n",
    "    if len(df_detail.OrgFullName.iloc[i]) == 0:\n",
    "        df_detail.OrgFullName.iloc[i] = 'Unknown'\n",
    "    else:\n",
    "        df_detail.OrgFullName.iloc[i] = df_detail.OrgFullName.iloc[i][0]\n",
    "    \n",
    "    if len(df_detail.OverallStatus.iloc[i]) == 0:\n",
    "        df_detail.OverallStatus.iloc[i] = 'Unknown'\n",
    "    else:\n",
    "        df_detail.OverallStatus.iloc[i] = df_detail.OverallStatus.iloc[i][0]\n",
    "    \n",
    "    if len(df_detail.StartDate.iloc[i]) == 0:\n",
    "        df_detail.StartDate.iloc[i] = 'Unknown'\n",
    "    else:\n",
    "        df_detail.StartDate.iloc[i] = df_detail.StartDate.iloc[i][0]\n",
    "    \n",
    "    if len(df_detail.CompletionDate.iloc[i]) == 0:\n",
    "        df_detail.CompletionDate.iloc[i] = 'Unknown'\n",
    "    else:\n",
    "        df_detail.CompletionDate.iloc[i] = df_detail.CompletionDate.iloc[i][0]\n",
    "    \n",
    "    if len(df_detail.IsFDARegulatedDrug.iloc[i]) == 0:\n",
    "        df_detail.IsFDARegulatedDrug.iloc[i] = 'Unknown'\n",
    "    else:\n",
    "        df_detail.IsFDARegulatedDrug.iloc[i] = df_detail.IsFDARegulatedDrug.iloc[i][0]\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>NCTId</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Keyword</th>\n",
       "      <th>StudyType</th>\n",
       "      <th>Phase</th>\n",
       "      <th>DesignPrimaryPurpose</th>\n",
       "      <th>EnrollmentCount</th>\n",
       "      <th>InterventionType</th>\n",
       "      <th>InterventionName</th>\n",
       "      <th>Gender</th>\n",
       "      <th>StdAge</th>\n",
       "      <th>LocationCountry</th>\n",
       "      <th>OrgFullName</th>\n",
       "      <th>OverallStatus</th>\n",
       "      <th>StartDate</th>\n",
       "      <th>CompletionDate</th>\n",
       "      <th>IsFDARegulatedDrug</th>\n",
       "      <th>ArmGroupType</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT04568811</td>\n",
       "      <td>The Phase I Clinical Trial of Booster Vaccinat...</td>\n",
       "      <td>[Adenovirus Type-5 Vectored COVID-19 Vaccine]</td>\n",
       "      <td>[]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Phase 1]</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>89</td>\n",
       "      <td>[Biological]</td>\n",
       "      <td>[Adenovirus Type-5 Vectored COVID-19 Vaccine]</td>\n",
       "      <td>All</td>\n",
       "      <td>[Child, Adult, Older Adult]</td>\n",
       "      <td>[China]</td>\n",
       "      <td>Jiangsu Province Centers for Disease Control a...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>September 26, 2020</td>\n",
       "      <td>September 27, 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT04497298</td>\n",
       "      <td>Clinical Trial to Evaluate the Safety and Immu...</td>\n",
       "      <td>[COVID-19]</td>\n",
       "      <td>[SARS-CoV-2, Vaccine, Prevention]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Phase 1]</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>90</td>\n",
       "      <td>[Biological, Biological, Biological, Other]</td>\n",
       "      <td>[Two COVID-19 vaccine candidate (TMV-083) admi...</td>\n",
       "      <td>All</td>\n",
       "      <td>[Adult]</td>\n",
       "      <td>[Belgium, France]</td>\n",
       "      <td>Institut Pasteur</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>August 10, 2020</td>\n",
       "      <td>October 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental, Experimental, Experimental, Pla...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT04651790</td>\n",
       "      <td>Efficacy, Safety, and Immunogenicity of an Ina...</td>\n",
       "      <td>[Covid19, Vaccines]</td>\n",
       "      <td>[Clinical trials, Covid19, Inactivated vaccine]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Phase 3]</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>2300</td>\n",
       "      <td>[Biological, Other]</td>\n",
       "      <td>[SARS-CoV-2 inactivated vaccine, Placebo]</td>\n",
       "      <td>All</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[Chile]</td>\n",
       "      <td>Pontificia Universidad Catolica de Chile</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>November 27, 2020</td>\n",
       "      <td>March 2022</td>\n",
       "      <td>No</td>\n",
       "      <td>[Active Comparator, Placebo Comparator]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT04659941</td>\n",
       "      <td>Use of BCG Vaccine as a Preventive Measure for...</td>\n",
       "      <td>[COVID 19 Vaccine]</td>\n",
       "      <td>[COVID 19, BCG vaccine]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Phase 2]</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>1000</td>\n",
       "      <td>[Biological]</td>\n",
       "      <td>[BCG vaccine]</td>\n",
       "      <td>All</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[Brazil]</td>\n",
       "      <td>Universidade Federal do Rio de Janeiro</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>October 1, 2020</td>\n",
       "      <td>October 1, 2022</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental, Placebo Comparator]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>NCT04510207</td>\n",
       "      <td>A Study to Evaluate The Efficacy, Safety and I...</td>\n",
       "      <td>[COVID-19]</td>\n",
       "      <td>[SARS-CoV-2, SARS-CoV-2 Vaccine, Coronavirus]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Phase 3]</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>45000</td>\n",
       "      <td>[Biological, Biological, Biological]</td>\n",
       "      <td>[Inactivated SARS-CoV-2 Vaccine (Vero cell), I...</td>\n",
       "      <td>All</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[Bahrain, Egypt, Egypt, Jordan, United Arab Em...</td>\n",
       "      <td>China National Biotec Group Company Limited</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>July 16, 2020</td>\n",
       "      <td>September 16, 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental, Experimental, Placebo Comparator]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>373</th>\n",
       "      <td>374</td>\n",
       "      <td>NCT04652596</td>\n",
       "      <td>Reducing Food Insecurity During COVID-19</td>\n",
       "      <td>[Food Insecurity]</td>\n",
       "      <td>[Produce prescription program, Mobile markets,...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Not Applicable]</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>250</td>\n",
       "      <td>[Other, Other]</td>\n",
       "      <td>[Produce prescription program, Grocery store g...</td>\n",
       "      <td>All</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[United States]</td>\n",
       "      <td>Boston Medical Center</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>January 2021</td>\n",
       "      <td>October 2022</td>\n",
       "      <td>No</td>\n",
       "      <td>[Active Comparator, Active Comparator]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>374</th>\n",
       "      <td>375</td>\n",
       "      <td>NCT04461353</td>\n",
       "      <td>A Study to Evaluate the Safety, Tolerability a...</td>\n",
       "      <td>[Severe Acute Respiratory Syndrome Coronavirus 2]</td>\n",
       "      <td>[coronavirus, COVID-19, Hydroxychloroquine Sul...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Phase 1]</td>\n",
       "      <td>Treatment</td>\n",
       "      <td>12</td>\n",
       "      <td>[Drug, Other]</td>\n",
       "      <td>[Aerolized Hydroxychloroquine Sulfate, Placebo]</td>\n",
       "      <td>All</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[United States]</td>\n",
       "      <td>Pulmoquine Therapeutics, Inc</td>\n",
       "      <td>Completed</td>\n",
       "      <td>June 25, 2020</td>\n",
       "      <td>August 17, 2020</td>\n",
       "      <td>Yes</td>\n",
       "      <td>[Active Comparator, Placebo Comparator]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>375</th>\n",
       "      <td>376</td>\n",
       "      <td>NCT03922334</td>\n",
       "      <td>Navigating New Motherhood 2</td>\n",
       "      <td>[Postpartum Health, Breastfeeding, Contracepti...</td>\n",
       "      <td>[]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Not Applicable]</td>\n",
       "      <td>Supportive Care</td>\n",
       "      <td>400</td>\n",
       "      <td>[Behavioral]</td>\n",
       "      <td>[Patient Navigation Program]</td>\n",
       "      <td>Female</td>\n",
       "      <td>[Child, Adult]</td>\n",
       "      <td>[United States]</td>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>January 21, 2020</td>\n",
       "      <td>December 2024</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental, No Intervention]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>376</th>\n",
       "      <td>377</td>\n",
       "      <td>NCT04237883</td>\n",
       "      <td>Primary Care Clinical Excellence Incentive Study</td>\n",
       "      <td>[Behavioral Economics, Primary Health Care, He...</td>\n",
       "      <td>[Behavioral Economics, Primary Health Care, He...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Not Applicable]</td>\n",
       "      <td>Health Services Research</td>\n",
       "      <td>225</td>\n",
       "      <td>[Behavioral, Behavioral, Behavioral]</td>\n",
       "      <td>[Standard communication email, Social comparis...</td>\n",
       "      <td>All</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[United States]</td>\n",
       "      <td>University of California, Los Angeles</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>November 1, 2019</td>\n",
       "      <td>July 1, 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[Placebo Comparator, Experimental, Experimental]</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>377</th>\n",
       "      <td>378</td>\n",
       "      <td>NCT04709263</td>\n",
       "      <td>Heart Failure Patients Registry</td>\n",
       "      <td>[Heart Failure]</td>\n",
       "      <td>[Heart Failure]</td>\n",
       "      <td>Observational</td>\n",
       "      <td>[]</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>20000</td>\n",
       "      <td>[]</td>\n",
       "      <td>[]</td>\n",
       "      <td>All</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[Russian Federation, Russian Federation]</td>\n",
       "      <td>AstraZeneca</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>December 23, 2020</td>\n",
       "      <td>December 31, 2023</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>[]</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>378 rows × 20 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Rank        NCTId                                         BriefTitle  \\\n",
       "0       1  NCT04568811  The Phase I Clinical Trial of Booster Vaccinat...   \n",
       "1       2  NCT04497298  Clinical Trial to Evaluate the Safety and Immu...   \n",
       "2       3  NCT04651790  Efficacy, Safety, and Immunogenicity of an Ina...   \n",
       "3       4  NCT04659941  Use of BCG Vaccine as a Preventive Measure for...   \n",
       "4       5  NCT04510207  A Study to Evaluate The Efficacy, Safety and I...   \n",
       "..    ...          ...                                                ...   \n",
       "373   374  NCT04652596           Reducing Food Insecurity During COVID-19   \n",
       "374   375  NCT04461353  A Study to Evaluate the Safety, Tolerability a...   \n",
       "375   376  NCT03922334                        Navigating New Motherhood 2   \n",
       "376   377  NCT04237883   Primary Care Clinical Excellence Incentive Study   \n",
       "377   378  NCT04709263                    Heart Failure Patients Registry   \n",
       "\n",
       "                                             Condition  \\\n",
       "0        [Adenovirus Type-5 Vectored COVID-19 Vaccine]   \n",
       "1                                           [COVID-19]   \n",
       "2                                  [Covid19, Vaccines]   \n",
       "3                                   [COVID 19 Vaccine]   \n",
       "4                                           [COVID-19]   \n",
       "..                                                 ...   \n",
       "373                                  [Food Insecurity]   \n",
       "374  [Severe Acute Respiratory Syndrome Coronavirus 2]   \n",
       "375  [Postpartum Health, Breastfeeding, Contracepti...   \n",
       "376  [Behavioral Economics, Primary Health Care, He...   \n",
       "377                                    [Heart Failure]   \n",
       "\n",
       "                                               Keyword       StudyType  \\\n",
       "0                                                   []  Interventional   \n",
       "1                    [SARS-CoV-2, Vaccine, Prevention]  Interventional   \n",
       "2      [Clinical trials, Covid19, Inactivated vaccine]  Interventional   \n",
       "3                              [COVID 19, BCG vaccine]  Interventional   \n",
       "4        [SARS-CoV-2, SARS-CoV-2 Vaccine, Coronavirus]  Interventional   \n",
       "..                                                 ...             ...   \n",
       "373  [Produce prescription program, Mobile markets,...  Interventional   \n",
       "374  [coronavirus, COVID-19, Hydroxychloroquine Sul...  Interventional   \n",
       "375                                                 []  Interventional   \n",
       "376  [Behavioral Economics, Primary Health Care, He...  Interventional   \n",
       "377                                    [Heart Failure]   Observational   \n",
       "\n",
       "                Phase      DesignPrimaryPurpose EnrollmentCount  \\\n",
       "0           [Phase 1]                Prevention              89   \n",
       "1           [Phase 1]                Prevention              90   \n",
       "2           [Phase 3]                Prevention            2300   \n",
       "3           [Phase 2]                Prevention            1000   \n",
       "4           [Phase 3]                Prevention           45000   \n",
       "..                ...                       ...             ...   \n",
       "373  [Not Applicable]                Prevention             250   \n",
       "374         [Phase 1]                 Treatment              12   \n",
       "375  [Not Applicable]           Supportive Care             400   \n",
       "376  [Not Applicable]  Health Services Research             225   \n",
       "377                []                   Unknown           20000   \n",
       "\n",
       "                                InterventionType  \\\n",
       "0                                   [Biological]   \n",
       "1    [Biological, Biological, Biological, Other]   \n",
       "2                            [Biological, Other]   \n",
       "3                                   [Biological]   \n",
       "4           [Biological, Biological, Biological]   \n",
       "..                                           ...   \n",
       "373                               [Other, Other]   \n",
       "374                                [Drug, Other]   \n",
       "375                                 [Behavioral]   \n",
       "376         [Behavioral, Behavioral, Behavioral]   \n",
       "377                                           []   \n",
       "\n",
       "                                      InterventionName  Gender  \\\n",
       "0        [Adenovirus Type-5 Vectored COVID-19 Vaccine]     All   \n",
       "1    [Two COVID-19 vaccine candidate (TMV-083) admi...     All   \n",
       "2            [SARS-CoV-2 inactivated vaccine, Placebo]     All   \n",
       "3                                        [BCG vaccine]     All   \n",
       "4    [Inactivated SARS-CoV-2 Vaccine (Vero cell), I...     All   \n",
       "..                                                 ...     ...   \n",
       "373  [Produce prescription program, Grocery store g...     All   \n",
       "374    [Aerolized Hydroxychloroquine Sulfate, Placebo]     All   \n",
       "375                       [Patient Navigation Program]  Female   \n",
       "376  [Standard communication email, Social comparis...     All   \n",
       "377                                                 []     All   \n",
       "\n",
       "                          StdAge  \\\n",
       "0    [Child, Adult, Older Adult]   \n",
       "1                        [Adult]   \n",
       "2           [Adult, Older Adult]   \n",
       "3           [Adult, Older Adult]   \n",
       "4           [Adult, Older Adult]   \n",
       "..                           ...   \n",
       "373         [Adult, Older Adult]   \n",
       "374         [Adult, Older Adult]   \n",
       "375               [Child, Adult]   \n",
       "376         [Adult, Older Adult]   \n",
       "377         [Adult, Older Adult]   \n",
       "\n",
       "                                       LocationCountry  \\\n",
       "0                                              [China]   \n",
       "1                                    [Belgium, France]   \n",
       "2                                              [Chile]   \n",
       "3                                             [Brazil]   \n",
       "4    [Bahrain, Egypt, Egypt, Jordan, United Arab Em...   \n",
       "..                                                 ...   \n",
       "373                                    [United States]   \n",
       "374                                    [United States]   \n",
       "375                                    [United States]   \n",
       "376                                    [United States]   \n",
       "377           [Russian Federation, Russian Federation]   \n",
       "\n",
       "                                           OrgFullName  \\\n",
       "0    Jiangsu Province Centers for Disease Control a...   \n",
       "1                                     Institut Pasteur   \n",
       "2             Pontificia Universidad Catolica de Chile   \n",
       "3               Universidade Federal do Rio de Janeiro   \n",
       "4          China National Biotec Group Company Limited   \n",
       "..                                                 ...   \n",
       "373                              Boston Medical Center   \n",
       "374                       Pulmoquine Therapeutics, Inc   \n",
       "375                            Northwestern University   \n",
       "376              University of California, Los Angeles   \n",
       "377                                        AstraZeneca   \n",
       "\n",
       "              OverallStatus           StartDate      CompletionDate  \\\n",
       "0    Active, not recruiting  September 26, 2020  September 27, 2021   \n",
       "1                Recruiting     August 10, 2020        October 2021   \n",
       "2                Recruiting   November 27, 2020          March 2022   \n",
       "3                Recruiting     October 1, 2020     October 1, 2022   \n",
       "4                Recruiting       July 16, 2020  September 16, 2021   \n",
       "..                      ...                 ...                 ...   \n",
       "373      Not yet recruiting        January 2021        October 2022   \n",
       "374               Completed       June 25, 2020     August 17, 2020   \n",
       "375              Recruiting    January 21, 2020       December 2024   \n",
       "376  Active, not recruiting    November 1, 2019        July 1, 2021   \n",
       "377              Recruiting   December 23, 2020   December 31, 2023   \n",
       "\n",
       "    IsFDARegulatedDrug                                       ArmGroupType  \n",
       "0                   No                                     [Experimental]  \n",
       "1                   No  [Experimental, Experimental, Experimental, Pla...  \n",
       "2                   No            [Active Comparator, Placebo Comparator]  \n",
       "3                   No                 [Experimental, Placebo Comparator]  \n",
       "4                   No   [Experimental, Experimental, Placebo Comparator]  \n",
       "..                 ...                                                ...  \n",
       "373                 No             [Active Comparator, Active Comparator]  \n",
       "374                Yes            [Active Comparator, Placebo Comparator]  \n",
       "375                 No                    [Experimental, No Intervention]  \n",
       "376                 No   [Placebo Comparator, Experimental, Experimental]  \n",
       "377            Unknown                                                 []  \n",
       "\n",
       "[378 rows x 20 columns]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_detail"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 3. Exploratory Data Analysis\n",
    "\n",
    "### 3.1 Clinical trials status and phases\n",
    "\n",
    "To visualize phase of clinical trials and their status."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "import seaborn as sns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x7fedd732b370>"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x576 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# split the StartDate by Month - Day - Year\n",
    "df_detail['StartDate_Month'] = [date.split()[0] for date in df_detail.StartDate]\n",
    "df_detail['StartDate_Year'] = [int(date.split()[-1]) for date in df_detail.StartDate]\n",
    "\n",
    "# plot the distribution of start date in year and month\n",
    "plt.rcParams['figure.figsize'] = [12, 8]\n",
    "\n",
    "sns.countplot(df_detail.StartDate_Month, hue = df_detail.StartDate_Year,\n",
    "             order = ['January', 'February', 'March', 'April', 'May', 'June', 'July', 'August',\n",
    "                     'September', 'October', 'November', 'December'], palette = 'Set2')\n",
    "plt.legend(loc='upper left')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>NCTId</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Keyword</th>\n",
       "      <th>StudyType</th>\n",
       "      <th>Phase</th>\n",
       "      <th>DesignPrimaryPurpose</th>\n",
       "      <th>EnrollmentCount</th>\n",
       "      <th>InterventionType</th>\n",
       "      <th>...</th>\n",
       "      <th>StdAge</th>\n",
       "      <th>LocationCountry</th>\n",
       "      <th>OrgFullName</th>\n",
       "      <th>OverallStatus</th>\n",
       "      <th>StartDate</th>\n",
       "      <th>CompletionDate</th>\n",
       "      <th>IsFDARegulatedDrug</th>\n",
       "      <th>ArmGroupType</th>\n",
       "      <th>StartDate_Month</th>\n",
       "      <th>StartDate_Year</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>164</th>\n",
       "      <td>165</td>\n",
       "      <td>NCT04160975</td>\n",
       "      <td>Persuasion in Medicine: Experimental Evidence ...</td>\n",
       "      <td>[Flu, Human, Influenza, Human, Covid19]</td>\n",
       "      <td>[Belief Updating, Preventive Care, Racial Disp...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Not Applicable]</td>\n",
       "      <td>Health Services Research</td>\n",
       "      <td>3350</td>\n",
       "      <td>[Behavioral, Behavioral]</td>\n",
       "      <td>...</td>\n",
       "      <td>[Adult]</td>\n",
       "      <td>[United States]</td>\n",
       "      <td>Harvard University</td>\n",
       "      <td>Enrolling by invitation</td>\n",
       "      <td>December 20, 2019</td>\n",
       "      <td>February 15, 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental, Experimental, Experimental, Exp...</td>\n",
       "      <td>December</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>194</th>\n",
       "      <td>195</td>\n",
       "      <td>NCT04025580</td>\n",
       "      <td>Systems Analyses of the Immune Response to the...</td>\n",
       "      <td>[Healthy Volunteer, COVID-19]</td>\n",
       "      <td>[Systems Biology, Immunology]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Phase 2]</td>\n",
       "      <td>Basic Science</td>\n",
       "      <td>300</td>\n",
       "      <td>[Biological, Biological, Biological]</td>\n",
       "      <td>...</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[United States]</td>\n",
       "      <td>National Institutes of Health Clinical Center ...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>October 2, 2019</td>\n",
       "      <td>December 31, 2025</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental]</td>\n",
       "      <td>October</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>208</th>\n",
       "      <td>209</td>\n",
       "      <td>NCT03209713</td>\n",
       "      <td>Edtech-HPV: A Community Approach Using Educati...</td>\n",
       "      <td>[Parents]</td>\n",
       "      <td>[Mexican, Mexican-American, 17-336]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Not Applicable]</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>800</td>\n",
       "      <td>[Behavioral, Behavioral]</td>\n",
       "      <td>...</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[United States, United States, United States, ...</td>\n",
       "      <td>Memorial Sloan Kettering Cancer Center</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>June 28, 2017</td>\n",
       "      <td>June 2022</td>\n",
       "      <td>No</td>\n",
       "      <td>[Active Comparator, Experimental]</td>\n",
       "      <td>June</td>\n",
       "      <td>2017</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>209</th>\n",
       "      <td>210</td>\n",
       "      <td>NCT04061382</td>\n",
       "      <td>Sero-epidemiological Survey of England in 2019...</td>\n",
       "      <td>[Serogroup C Meningococcal Meningitis, Diphthe...</td>\n",
       "      <td>[]</td>\n",
       "      <td>Observational</td>\n",
       "      <td>[]</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>3800</td>\n",
       "      <td>[Procedure, Procedure]</td>\n",
       "      <td>...</td>\n",
       "      <td>[Child, Adult]</td>\n",
       "      <td>[United Kingdom]</td>\n",
       "      <td>University of Oxford</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>October 15, 2019</td>\n",
       "      <td>June 30, 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[]</td>\n",
       "      <td>October</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>302</th>\n",
       "      <td>303</td>\n",
       "      <td>NCT04441814</td>\n",
       "      <td>FOUND - Ancillary Study to Smile Protocol NCT0...</td>\n",
       "      <td>[COVID 19, Inflammatory Status]</td>\n",
       "      <td>[COVID, Lung cancer screening, Subsolid pulmon...</td>\n",
       "      <td>Observational</td>\n",
       "      <td>[]</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>960</td>\n",
       "      <td>[]</td>\n",
       "      <td>...</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[Italy]</td>\n",
       "      <td>Fondazione IRCCS Istituto Nazionale dei Tumori...</td>\n",
       "      <td>Enrolling by invitation</td>\n",
       "      <td>July 23, 2019</td>\n",
       "      <td>July 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[]</td>\n",
       "      <td>July</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>311</th>\n",
       "      <td>312</td>\n",
       "      <td>NCT04534595</td>\n",
       "      <td>Data Collection on the Model Schools Pediatric...</td>\n",
       "      <td>[COVID-19 Experience]</td>\n",
       "      <td>[COVID-19, School-based health center, mental ...</td>\n",
       "      <td>Observational</td>\n",
       "      <td>[]</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>1500</td>\n",
       "      <td>[Other]</td>\n",
       "      <td>...</td>\n",
       "      <td>[Child]</td>\n",
       "      <td>[Canada]</td>\n",
       "      <td>St. Michael's Hospital, Toronto</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>April 30, 2019</td>\n",
       "      <td>March 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[]</td>\n",
       "      <td>April</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>327</th>\n",
       "      <td>328</td>\n",
       "      <td>NCT03734237</td>\n",
       "      <td>A Pragmatic Assessment of Influenza Vaccine Ef...</td>\n",
       "      <td>[Influenza, Influenza-like Illness]</td>\n",
       "      <td>[Influenza vaccine]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Phase 4]</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>15000</td>\n",
       "      <td>[Biological, Biological, Biological]</td>\n",
       "      <td>...</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[United States, United States, United States, ...</td>\n",
       "      <td>Henry M. Jackson Foundation for the Advancemen...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>November 6, 2018</td>\n",
       "      <td>May 31, 2022</td>\n",
       "      <td>Yes</td>\n",
       "      <td>[Active Comparator, Active Comparator, Active ...</td>\n",
       "      <td>November</td>\n",
       "      <td>2018</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>335</th>\n",
       "      <td>336</td>\n",
       "      <td>NCT03885232</td>\n",
       "      <td>Presumptively Initiating Vaccines and Optimizi...</td>\n",
       "      <td>[Preventive Health Services (PREV HEALTH SERV)]</td>\n",
       "      <td>[Communication, Immunization]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Not Applicable]</td>\n",
       "      <td>Health Services Research</td>\n",
       "      <td>1000</td>\n",
       "      <td>[Behavioral, Other]</td>\n",
       "      <td>...</td>\n",
       "      <td>[Child]</td>\n",
       "      <td>[United States, United States]</td>\n",
       "      <td>University of Colorado, Denver</td>\n",
       "      <td>Enrolling by invitation</td>\n",
       "      <td>September 1, 2019</td>\n",
       "      <td>July 31, 2023</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental, Active Comparator]</td>\n",
       "      <td>September</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>359</th>\n",
       "      <td>360</td>\n",
       "      <td>NCT03102034</td>\n",
       "      <td>Evaluating the Infectivity, Safety, and Immuno...</td>\n",
       "      <td>[Respiratory Syncytial Virus Infections]</td>\n",
       "      <td>[]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Phase 1]</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>32</td>\n",
       "      <td>[Biological, Biological]</td>\n",
       "      <td>...</td>\n",
       "      <td>[Child]</td>\n",
       "      <td>[United States, United States, United States, ...</td>\n",
       "      <td>National Institute of Allergy and Infectious D...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>April 6, 2017</td>\n",
       "      <td>May 25, 2018</td>\n",
       "      <td>Yes</td>\n",
       "      <td>[Experimental, Placebo Comparator]</td>\n",
       "      <td>April</td>\n",
       "      <td>2017</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>376</th>\n",
       "      <td>377</td>\n",
       "      <td>NCT04237883</td>\n",
       "      <td>Primary Care Clinical Excellence Incentive Study</td>\n",
       "      <td>[Behavioral Economics, Primary Health Care, He...</td>\n",
       "      <td>[Behavioral Economics, Primary Health Care, He...</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>[Not Applicable]</td>\n",
       "      <td>Health Services Research</td>\n",
       "      <td>225</td>\n",
       "      <td>[Behavioral, Behavioral, Behavioral]</td>\n",
       "      <td>...</td>\n",
       "      <td>[Adult, Older Adult]</td>\n",
       "      <td>[United States]</td>\n",
       "      <td>University of California, Los Angeles</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>November 1, 2019</td>\n",
       "      <td>July 1, 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[Placebo Comparator, Experimental, Experimental]</td>\n",
       "      <td>November</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10 rows × 22 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Rank        NCTId                                         BriefTitle  \\\n",
       "164   165  NCT04160975  Persuasion in Medicine: Experimental Evidence ...   \n",
       "194   195  NCT04025580  Systems Analyses of the Immune Response to the...   \n",
       "208   209  NCT03209713  Edtech-HPV: A Community Approach Using Educati...   \n",
       "209   210  NCT04061382  Sero-epidemiological Survey of England in 2019...   \n",
       "302   303  NCT04441814  FOUND - Ancillary Study to Smile Protocol NCT0...   \n",
       "311   312  NCT04534595  Data Collection on the Model Schools Pediatric...   \n",
       "327   328  NCT03734237  A Pragmatic Assessment of Influenza Vaccine Ef...   \n",
       "335   336  NCT03885232  Presumptively Initiating Vaccines and Optimizi...   \n",
       "359   360  NCT03102034  Evaluating the Infectivity, Safety, and Immuno...   \n",
       "376   377  NCT04237883   Primary Care Clinical Excellence Incentive Study   \n",
       "\n",
       "                                             Condition  \\\n",
       "164            [Flu, Human, Influenza, Human, Covid19]   \n",
       "194                      [Healthy Volunteer, COVID-19]   \n",
       "208                                          [Parents]   \n",
       "209  [Serogroup C Meningococcal Meningitis, Diphthe...   \n",
       "302                    [COVID 19, Inflammatory Status]   \n",
       "311                              [COVID-19 Experience]   \n",
       "327                [Influenza, Influenza-like Illness]   \n",
       "335    [Preventive Health Services (PREV HEALTH SERV)]   \n",
       "359           [Respiratory Syncytial Virus Infections]   \n",
       "376  [Behavioral Economics, Primary Health Care, He...   \n",
       "\n",
       "                                               Keyword       StudyType  \\\n",
       "164  [Belief Updating, Preventive Care, Racial Disp...  Interventional   \n",
       "194                      [Systems Biology, Immunology]  Interventional   \n",
       "208                [Mexican, Mexican-American, 17-336]  Interventional   \n",
       "209                                                 []   Observational   \n",
       "302  [COVID, Lung cancer screening, Subsolid pulmon...   Observational   \n",
       "311  [COVID-19, School-based health center, mental ...   Observational   \n",
       "327                                [Influenza vaccine]  Interventional   \n",
       "335                      [Communication, Immunization]  Interventional   \n",
       "359                                                 []  Interventional   \n",
       "376  [Behavioral Economics, Primary Health Care, He...  Interventional   \n",
       "\n",
       "                Phase      DesignPrimaryPurpose EnrollmentCount  \\\n",
       "164  [Not Applicable]  Health Services Research            3350   \n",
       "194         [Phase 2]             Basic Science             300   \n",
       "208  [Not Applicable]                Prevention             800   \n",
       "209                []                   Unknown            3800   \n",
       "302                []                   Unknown             960   \n",
       "311                []                   Unknown            1500   \n",
       "327         [Phase 4]                Prevention           15000   \n",
       "335  [Not Applicable]  Health Services Research            1000   \n",
       "359         [Phase 1]                Prevention              32   \n",
       "376  [Not Applicable]  Health Services Research             225   \n",
       "\n",
       "                         InterventionType  ...                StdAge  \\\n",
       "164              [Behavioral, Behavioral]  ...               [Adult]   \n",
       "194  [Biological, Biological, Biological]  ...  [Adult, Older Adult]   \n",
       "208              [Behavioral, Behavioral]  ...  [Adult, Older Adult]   \n",
       "209                [Procedure, Procedure]  ...        [Child, Adult]   \n",
       "302                                    []  ...  [Adult, Older Adult]   \n",
       "311                               [Other]  ...               [Child]   \n",
       "327  [Biological, Biological, Biological]  ...  [Adult, Older Adult]   \n",
       "335                   [Behavioral, Other]  ...               [Child]   \n",
       "359              [Biological, Biological]  ...               [Child]   \n",
       "376  [Behavioral, Behavioral, Behavioral]  ...  [Adult, Older Adult]   \n",
       "\n",
       "                                       LocationCountry  \\\n",
       "164                                    [United States]   \n",
       "194                                    [United States]   \n",
       "208  [United States, United States, United States, ...   \n",
       "209                                   [United Kingdom]   \n",
       "302                                            [Italy]   \n",
       "311                                           [Canada]   \n",
       "327  [United States, United States, United States, ...   \n",
       "335                     [United States, United States]   \n",
       "359  [United States, United States, United States, ...   \n",
       "376                                    [United States]   \n",
       "\n",
       "                                           OrgFullName  \\\n",
       "164                                 Harvard University   \n",
       "194  National Institutes of Health Clinical Center ...   \n",
       "208             Memorial Sloan Kettering Cancer Center   \n",
       "209                               University of Oxford   \n",
       "302  Fondazione IRCCS Istituto Nazionale dei Tumori...   \n",
       "311                    St. Michael's Hospital, Toronto   \n",
       "327  Henry M. Jackson Foundation for the Advancemen...   \n",
       "335                     University of Colorado, Denver   \n",
       "359  National Institute of Allergy and Infectious D...   \n",
       "376              University of California, Los Angeles   \n",
       "\n",
       "               OverallStatus          StartDate     CompletionDate  \\\n",
       "164  Enrolling by invitation  December 20, 2019  February 15, 2021   \n",
       "194               Recruiting    October 2, 2019  December 31, 2025   \n",
       "208               Recruiting      June 28, 2017          June 2022   \n",
       "209               Recruiting   October 15, 2019      June 30, 2021   \n",
       "302  Enrolling by invitation      July 23, 2019          July 2021   \n",
       "311               Recruiting     April 30, 2019         March 2021   \n",
       "327               Recruiting   November 6, 2018       May 31, 2022   \n",
       "335  Enrolling by invitation  September 1, 2019      July 31, 2023   \n",
       "359                Completed      April 6, 2017       May 25, 2018   \n",
       "376   Active, not recruiting   November 1, 2019       July 1, 2021   \n",
       "\n",
       "    IsFDARegulatedDrug                                       ArmGroupType  \\\n",
       "164                 No  [Experimental, Experimental, Experimental, Exp...   \n",
       "194                 No                                     [Experimental]   \n",
       "208                 No                  [Active Comparator, Experimental]   \n",
       "209                 No                                                 []   \n",
       "302                 No                                                 []   \n",
       "311                 No                                                 []   \n",
       "327                Yes  [Active Comparator, Active Comparator, Active ...   \n",
       "335                 No                  [Experimental, Active Comparator]   \n",
       "359                Yes                 [Experimental, Placebo Comparator]   \n",
       "376                 No   [Placebo Comparator, Experimental, Experimental]   \n",
       "\n",
       "    StartDate_Month StartDate_Year  \n",
       "164        December           2019  \n",
       "194         October           2019  \n",
       "208            June           2017  \n",
       "209         October           2019  \n",
       "302            July           2019  \n",
       "311           April           2019  \n",
       "327        November           2018  \n",
       "335       September           2019  \n",
       "359           April           2017  \n",
       "376        November           2019  \n",
       "\n",
       "[10 rows x 22 columns]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# check those clinical trials started before 2020, before the pandemic started\n",
    "df_detail[df_detail.StartDate_Year <= 2019]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "After searching more details of the trials above on clinicaltrials.gov, it has been confirmed that:\n",
    "- All 3 studies started in 2018 & 2017 are not relevant to COVID19\n",
    "- Other than NCT03885232 & NCT04237883, studies started in 2019 are indeed relevant to COVID19."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "# remove trials irrelevant to COVID19\n",
    "df_detail = df_detail[df_detail.StartDate_Year > 2018]\n",
    "df_detail = df_detail[~df_detail.NCTId.isin(['NCT03885232', 'NCT04237883'])]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x7feddb13ba60>"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x576 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# verify the new set of start date after dropping any records before 2019\n",
    "sns.countplot(df_detail.StartDate_Month, hue = df_detail.StartDate_Year,\n",
    "             order = ['January', 'February', 'March', 'April', 'May', 'June', 'July', 'August',\n",
    "                     'September', 'October', 'November', 'December'], palette = 'Set2')\n",
    "plt.legend(loc='upper left')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(array([0, 1, 2, 3, 4, 5, 6, 7, 8]),\n",
       " <a list of 9 Text major ticklabel objects>)"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x576 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Plot the various primary purpose of design\n",
    "sns.countplot(df_detail.DesignPrimaryPurpose)\n",
    "plt.xticks(rotation = 45)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Most of the trials are focusing on preventions (i.e. Vaccines), while some others are focusing on screening, treatment or other areas."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "# filter the trials with objective of preventions (i.e. vaccines)\n",
    "df_detail = df_detail[df_detail.DesignPrimaryPurpose == 'Prevention']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Next, examine the distribution of clinical trials by phases."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>NCTId</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Keyword</th>\n",
       "      <th>StudyType</th>\n",
       "      <th>DesignPrimaryPurpose</th>\n",
       "      <th>EnrollmentCount</th>\n",
       "      <th>InterventionType</th>\n",
       "      <th>InterventionName</th>\n",
       "      <th>...</th>\n",
       "      <th>LocationCountry</th>\n",
       "      <th>OrgFullName</th>\n",
       "      <th>OverallStatus</th>\n",
       "      <th>StartDate</th>\n",
       "      <th>CompletionDate</th>\n",
       "      <th>IsFDARegulatedDrug</th>\n",
       "      <th>ArmGroupType</th>\n",
       "      <th>StartDate_Month</th>\n",
       "      <th>StartDate_Year</th>\n",
       "      <th>Phase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT04568811</td>\n",
       "      <td>The Phase I Clinical Trial of Booster Vaccinat...</td>\n",
       "      <td>[Adenovirus Type-5 Vectored COVID-19 Vaccine]</td>\n",
       "      <td>[]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>89</td>\n",
       "      <td>[Biological]</td>\n",
       "      <td>[Adenovirus Type-5 Vectored COVID-19 Vaccine]</td>\n",
       "      <td>...</td>\n",
       "      <td>[China]</td>\n",
       "      <td>Jiangsu Province Centers for Disease Control a...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>September 26, 2020</td>\n",
       "      <td>September 27, 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental]</td>\n",
       "      <td>September</td>\n",
       "      <td>2020</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT04497298</td>\n",
       "      <td>Clinical Trial to Evaluate the Safety and Immu...</td>\n",
       "      <td>[COVID-19]</td>\n",
       "      <td>[SARS-CoV-2, Vaccine, Prevention]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>90</td>\n",
       "      <td>[Biological, Biological, Biological, Other]</td>\n",
       "      <td>[Two COVID-19 vaccine candidate (TMV-083) admi...</td>\n",
       "      <td>...</td>\n",
       "      <td>[Belgium, France]</td>\n",
       "      <td>Institut Pasteur</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>August 10, 2020</td>\n",
       "      <td>October 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental, Experimental, Experimental, Pla...</td>\n",
       "      <td>August</td>\n",
       "      <td>2020</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT04651790</td>\n",
       "      <td>Efficacy, Safety, and Immunogenicity of an Ina...</td>\n",
       "      <td>[Covid19, Vaccines]</td>\n",
       "      <td>[Clinical trials, Covid19, Inactivated vaccine]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>2300</td>\n",
       "      <td>[Biological, Other]</td>\n",
       "      <td>[SARS-CoV-2 inactivated vaccine, Placebo]</td>\n",
       "      <td>...</td>\n",
       "      <td>[Chile]</td>\n",
       "      <td>Pontificia Universidad Catolica de Chile</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>November 27, 2020</td>\n",
       "      <td>March 2022</td>\n",
       "      <td>No</td>\n",
       "      <td>[Active Comparator, Placebo Comparator]</td>\n",
       "      <td>November</td>\n",
       "      <td>2020</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT04659941</td>\n",
       "      <td>Use of BCG Vaccine as a Preventive Measure for...</td>\n",
       "      <td>[COVID 19 Vaccine]</td>\n",
       "      <td>[COVID 19, BCG vaccine]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>1000</td>\n",
       "      <td>[Biological]</td>\n",
       "      <td>[BCG vaccine]</td>\n",
       "      <td>...</td>\n",
       "      <td>[Brazil]</td>\n",
       "      <td>Universidade Federal do Rio de Janeiro</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>October 1, 2020</td>\n",
       "      <td>October 1, 2022</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental, Placebo Comparator]</td>\n",
       "      <td>October</td>\n",
       "      <td>2020</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>NCT04510207</td>\n",
       "      <td>A Study to Evaluate The Efficacy, Safety and I...</td>\n",
       "      <td>[COVID-19]</td>\n",
       "      <td>[SARS-CoV-2, SARS-CoV-2 Vaccine, Coronavirus]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>45000</td>\n",
       "      <td>[Biological, Biological, Biological]</td>\n",
       "      <td>[Inactivated SARS-CoV-2 Vaccine (Vero cell), I...</td>\n",
       "      <td>...</td>\n",
       "      <td>[Bahrain, Egypt, Egypt, Jordan, United Arab Em...</td>\n",
       "      <td>China National Biotec Group Company Limited</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>July 16, 2020</td>\n",
       "      <td>September 16, 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental, Experimental, Placebo Comparator]</td>\n",
       "      <td>July</td>\n",
       "      <td>2020</td>\n",
       "      <td>Phase 3</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 22 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   Rank        NCTId                                         BriefTitle  \\\n",
       "0     1  NCT04568811  The Phase I Clinical Trial of Booster Vaccinat...   \n",
       "1     2  NCT04497298  Clinical Trial to Evaluate the Safety and Immu...   \n",
       "2     3  NCT04651790  Efficacy, Safety, and Immunogenicity of an Ina...   \n",
       "3     4  NCT04659941  Use of BCG Vaccine as a Preventive Measure for...   \n",
       "4     5  NCT04510207  A Study to Evaluate The Efficacy, Safety and I...   \n",
       "\n",
       "                                       Condition  \\\n",
       "0  [Adenovirus Type-5 Vectored COVID-19 Vaccine]   \n",
       "1                                     [COVID-19]   \n",
       "2                            [Covid19, Vaccines]   \n",
       "3                             [COVID 19 Vaccine]   \n",
       "4                                     [COVID-19]   \n",
       "\n",
       "                                           Keyword       StudyType  \\\n",
       "0                                               []  Interventional   \n",
       "1                [SARS-CoV-2, Vaccine, Prevention]  Interventional   \n",
       "2  [Clinical trials, Covid19, Inactivated vaccine]  Interventional   \n",
       "3                          [COVID 19, BCG vaccine]  Interventional   \n",
       "4    [SARS-CoV-2, SARS-CoV-2 Vaccine, Coronavirus]  Interventional   \n",
       "\n",
       "  DesignPrimaryPurpose EnrollmentCount  \\\n",
       "0           Prevention              89   \n",
       "1           Prevention              90   \n",
       "2           Prevention            2300   \n",
       "3           Prevention            1000   \n",
       "4           Prevention           45000   \n",
       "\n",
       "                              InterventionType  \\\n",
       "0                                 [Biological]   \n",
       "1  [Biological, Biological, Biological, Other]   \n",
       "2                          [Biological, Other]   \n",
       "3                                 [Biological]   \n",
       "4         [Biological, Biological, Biological]   \n",
       "\n",
       "                                    InterventionName  ...  \\\n",
       "0      [Adenovirus Type-5 Vectored COVID-19 Vaccine]  ...   \n",
       "1  [Two COVID-19 vaccine candidate (TMV-083) admi...  ...   \n",
       "2          [SARS-CoV-2 inactivated vaccine, Placebo]  ...   \n",
       "3                                      [BCG vaccine]  ...   \n",
       "4  [Inactivated SARS-CoV-2 Vaccine (Vero cell), I...  ...   \n",
       "\n",
       "                                     LocationCountry  \\\n",
       "0                                            [China]   \n",
       "1                                  [Belgium, France]   \n",
       "2                                            [Chile]   \n",
       "3                                           [Brazil]   \n",
       "4  [Bahrain, Egypt, Egypt, Jordan, United Arab Em...   \n",
       "\n",
       "                                         OrgFullName           OverallStatus  \\\n",
       "0  Jiangsu Province Centers for Disease Control a...  Active, not recruiting   \n",
       "1                                   Institut Pasteur              Recruiting   \n",
       "2           Pontificia Universidad Catolica de Chile              Recruiting   \n",
       "3             Universidade Federal do Rio de Janeiro              Recruiting   \n",
       "4        China National Biotec Group Company Limited              Recruiting   \n",
       "\n",
       "            StartDate      CompletionDate IsFDARegulatedDrug  \\\n",
       "0  September 26, 2020  September 27, 2021                 No   \n",
       "1     August 10, 2020        October 2021                 No   \n",
       "2   November 27, 2020          March 2022                 No   \n",
       "3     October 1, 2020     October 1, 2022                 No   \n",
       "4       July 16, 2020  September 16, 2021                 No   \n",
       "\n",
       "                                        ArmGroupType StartDate_Month  \\\n",
       "0                                     [Experimental]       September   \n",
       "1  [Experimental, Experimental, Experimental, Pla...          August   \n",
       "2            [Active Comparator, Placebo Comparator]        November   \n",
       "3                 [Experimental, Placebo Comparator]         October   \n",
       "4   [Experimental, Experimental, Placebo Comparator]            July   \n",
       "\n",
       "  StartDate_Year    Phase  \n",
       "0           2020  Phase 1  \n",
       "1           2020  Phase 1  \n",
       "2           2020  Phase 3  \n",
       "3           2020  Phase 2  \n",
       "4           2020  Phase 3  \n",
       "\n",
       "[5 rows x 22 columns]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# flatten the list by phase - \n",
    "# for the same clinical trials with multiple phase, it will be shown as multiple records\n",
    "flattened_col = pd.DataFrame([(index, value) \n",
    "                              for (index, values) in df_detail['Phase'].iteritems() for value in values],\n",
    "                             columns=['index', 'Phase']).set_index('index')\n",
    "df_flat = df_detail.drop('Phase', axis=1).join(flattened_col)\n",
    "df_flat = df_flat.reset_index(drop = True)\n",
    "df_flat.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x7feddb429eb0>"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x576 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot the clinical trials by phase and status\n",
    "sns.countplot(df_flat.Phase, hue = df_flat.OverallStatus,\n",
    "              order = ['Early Phase 1', 'Phase 1', 'Phase 2', 'Phase 3', 'Phase 4', 'Not Applicable'],\n",
    "             palette = 'Set1')\n",
    "plt.legend(loc='upper right')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "As shown in the plots above:\n",
    "- There's a large number of the clinical trials in Phase 3, which means they are close to getting approval and subsequently drug launches (provided if Phase 3 result is good).\n",
    "- Majority of the Phase 3 trials are ongoing or to be kick started (e.g. recruiting / active, not recruiting / not yet recruiting / enrolling by invitation), which indicates that either new vaccines are in late-stage clinical trials, or those vaccines approved are close to be approved and launched in more countries. Phase 3 clinical trials are usually conducted on large scale of patients (in the scale of hundreds or thousands) to study if the vaccine is safe and effective, as well as its common side effect.\n",
    "- Around 10~20 Phase 4 trials can be found, which are to monitor the vaccine performance in real-world setting on patients after launch. This is important as almost all of the trials were started in 2020, leading to a very short duration to complete, comparing to the duration of normal clinical trials. Hence, it's essential to monitor if there's any severe adverse effect in real-world setting.\n",
    "- Other than the large number of trials found in Phase 3, there are still many trials ongoing/planned in Phase 1 and Phase 2, which might yield promising result in vaccines in the future."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3.2 Clinical trial patients\n",
    " \n",
    "To visualize the demographics of the patients enrolled."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x7feddbb94250>"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x576 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot the distribution of patients gender covered per trial\n",
    "sns.countplot(df_flat.Gender)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Most of the vaccince trials are not gender-specific, and are open to recruit patients of both genders."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "# count the unique number of trials per age group\n",
    "\n",
    "child_id = []\n",
    "adult_id = []\n",
    "oldAdult_id = []\n",
    "\n",
    "for i in range(len(df_flat)):\n",
    "    # count the number of trials including children\n",
    "    if any(x == 'Child' for x in df_flat.StdAge[i]) :\n",
    "        child_id.append(df_flat.NCTId.iloc[i])\n",
    "    else: \n",
    "        pass\n",
    "    \n",
    "    # count the number of trials including adult\n",
    "    if any(x == 'Adult' for x in df_flat.StdAge[i]):\n",
    "        adult_id.append(df_flat.NCTId.iloc[i])\n",
    "    else: \n",
    "        pass\n",
    "    \n",
    "    # count the number of trials including older adult\n",
    "    if any(x == 'Older Adult' for x in df_flat.StdAge[i]) :\n",
    "        oldAdult_id.append(df_flat.NCTId.iloc[i])\n",
    "    else: \n",
    "        pass"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Age_Grp</th>\n",
       "      <th>Count</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Child</td>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Adult</td>\n",
       "      <td>159</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Older Adult</td>\n",
       "      <td>128</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       Age_Grp  Count\n",
       "0        Child     11\n",
       "1        Adult    159\n",
       "2  Older Adult    128"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# find the unique count of NCT Id per list\n",
    "child_id = pd.unique(child_id)\n",
    "adult_id = pd.unique(adult_id)\n",
    "oldAdult_id = pd.unique(oldAdult_id)\n",
    "\n",
    "# consolidate the result\n",
    "temp1 = pd.DataFrame({'Age_Grp': ['Child', 'Adult', 'Older Adult'], \n",
    "                     'Count': [int(len(child_id)), int(len(adult_id)), int(len(oldAdult_id))]})\n",
    "temp1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.axes._subplots.AxesSubplot at 0x7feddbec5550>"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x576 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot the count of clinical trials per age group\n",
    "temp1.plot.bar(y = 'Count', x = 'Age_Grp')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "As shown, most of the trials are focusing on adults and older adults. However, very few are focusing on children. This can be shown by the launched COVID19 vaccines both the vaccines by Pfizer and AstraZenaca does not cover Children under 16, indicating the lack of research in COVID19 prevention in the age group of children."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3.3 Location of Clinical Trials"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "For columns like `LocationCountry`, there are more than one values in the list. Besides, further cleaning is required to remove the duplicate values in the same list, such as listed below. Such duplicates could be due to the same clinical trials conducted in multiple cities in the same country."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Belgium', 'France']\n",
      "['Bahrain', 'Egypt', 'Egypt', 'Jordan', 'United Arab Emirates', 'United Arab Emirates']\n",
      "['Argentina', 'Argentina', 'Argentina', 'Argentina']\n",
      "['Taiwan', 'Taiwan', 'Taiwan', 'Taiwan', 'Taiwan', 'Taiwan', 'Taiwan', 'Taiwan', 'Taiwan', 'Taiwan', 'Taiwan', 'Vietnam']\n",
      "['Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey']\n",
      "['Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil']\n",
      "['Brazil', 'Malaysia']\n",
      "['Greece', 'Greece', 'Greece', 'Greece', 'Greece', 'Greece', 'Greece', 'Greece', 'Greece', 'Greece', 'Greece', 'Greece', 'Greece', 'Greece', 'Greece']\n",
      "['United States', 'United States', 'United States']\n",
      "['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom']\n",
      "['Belarus', 'Belarus', 'Belarus', 'Belarus', 'Belarus', 'Belarus', 'Belarus', 'Belarus']\n",
      "['Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation']\n",
      "['Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'United Kingdom', 'United Kingdom', 'United Kingdom']\n",
      "['Canada', 'Canada']\n",
      "['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom']\n",
      "['Poland', 'Poland', 'Poland', 'Poland', 'Poland', 'Poland']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States']\n",
      "['Israel', 'Israel', 'Israel', 'Israel', 'Israel', 'Israel', 'Israel', 'Israel']\n",
      "['Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Puerto Rico', 'Puerto Rico', 'Puerto Rico', 'Puerto Rico']\n",
      "['United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom']\n",
      "['Belgium', 'Belgium', 'Belgium', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Dominican Republic', 'Dominican Republic', 'Germany', 'Germany', 'Germany', 'Germany', 'Nepal', 'Nepal', 'Panama', 'Panama', 'Panama', 'Panama', 'Panama', 'Panama', 'Philippines', 'Philippines', 'Philippines', 'Philippines', 'Philippines', 'Philippines', 'Philippines', 'Philippines', 'Philippines', 'Philippines', 'Poland', 'Poland', 'Poland', 'Poland', 'Poland', 'Poland', 'South Africa', 'South Africa', 'South Africa', 'South Africa']\n",
      "['Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation']\n",
      "['Netherlands', 'Netherlands']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'Argentina', 'Brazil', 'Brazil', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey', 'Turkey']\n",
      "['Spain', 'Spain']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'New Zealand', 'New Zealand']\n",
      "['India', 'India', 'India', 'India', 'India', 'India']\n",
      "['Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada', 'Canada']\n",
      "['United States', 'United States', 'United States']\n",
      "['Belgium', 'Germany', 'Germany', 'Netherlands']\n",
      "['Panama', 'Peru']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Chile', 'Chile', 'Chile', 'Chile', 'Chile', 'Chile', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Peru', 'Peru', 'Peru', 'Peru', 'Peru', 'Peru', 'Peru', 'Peru', 'Peru', 'Peru', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa']\n",
      "['Germany', 'Germany']\n",
      "['Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil', 'Brazil']\n",
      "['South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa']\n",
      "['Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation']\n",
      "['South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa']\n",
      "['Italy', 'Italy']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States']\n",
      "['Japan', 'Japan', 'Japan', 'Japan', 'Japan']\n",
      "['Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands', 'Netherlands']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia', 'Australia']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'Belgium', 'Belgium', 'Belgium', 'Belgium', 'Belgium', 'Belgium', 'Belgium', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'Colombia', 'France', 'France', 'France', 'France', 'France', 'France', 'France', 'France', 'France', 'France', 'Germany', 'Germany', 'Philippines', 'Philippines', 'Philippines', 'Philippines', 'Philippines', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'Spain', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom']\n",
      "['Japan', 'Japan']\n",
      "['Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Argentina', 'Chile', 'Chile', 'Chile', 'Chile', 'Chile', 'Chile', 'Chile', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Mexico', 'Pakistan', 'Pakistan', 'Pakistan', 'Pakistan', 'Pakistan', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation', 'Russian Federation']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'Singapore']\n",
      "['India', 'India', 'India', 'India', 'India', 'India', 'India', 'India', 'India', 'India', 'India', 'India']\n",
      "['Cape Verde', 'Guinea-Bissau', 'Mozambique']\n",
      "['Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan', 'Japan']\n",
      "['United States', 'United States', 'United States', 'United States', 'Austria', 'Austria', 'Belgium', 'Belgium', 'Belgium']\n",
      "['Belgium', 'Germany', 'Germany', 'Germany']\n",
      "['Korea, Republic of', 'Korea, Republic of']\n",
      "['United States', 'Canada', 'Ghana', 'Ireland', 'Netherlands', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'South Africa', 'Uganda', 'United Kingdom', 'Zambia', 'Zambia', 'Zimbabwe']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States']\n",
      "['United States', 'United States', 'United States']\n",
      "['United States', 'United States', 'United States', 'United States', 'United States', 'United States', 'United States']\n",
      "['Germany', 'Germany', 'Germany']\n",
      "['Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany', 'Germany']\n",
      "['France', 'France', 'France', 'France', 'France', 'France', 'France', 'France', 'France', 'France']\n",
      "['United Kingdom', 'United Kingdom']\n",
      "['Canada', 'Canada', 'Canada', 'Canada']\n",
      "['India', 'India']\n",
      "['Canada', 'Canada', 'Germany', 'Germany', 'Germany', 'Netherlands', 'Netherlands', 'Netherlands', 'Spain', 'Spain', 'Spain', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom', 'United Kingdom']\n",
      "['Japan', 'Japan']\n",
      "['Japan', 'Japan', 'Japan']\n"
     ]
    }
   ],
   "source": [
    "# print all LocationCountry with more than 1 elements -> mostly are duplicate values\n",
    "for country in df_detail.LocationCountry:\n",
    "    if len(country) > 1:\n",
    "        print(country)\n",
    "    else:\n",
    "        pass"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/iris.xx/opt/anaconda3/lib/python3.8/site-packages/pandas/core/indexing.py:671: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  self._setitem_with_indexer(indexer, value)\n"
     ]
    }
   ],
   "source": [
    "# get the unique value of LocationCountry per clinical trial (defined by unique NCT ID)\n",
    "\n",
    "for i in range(len(df_flat.LocationCountry)):\n",
    "    temp = pd.unique(df_flat.LocationCountry.iloc[i])\n",
    "    df_flat.LocationCountry.iloc[i] = temp"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCTId</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Keyword</th>\n",
       "      <th>StudyType</th>\n",
       "      <th>DesignPrimaryPurpose</th>\n",
       "      <th>EnrollmentCount</th>\n",
       "      <th>InterventionType</th>\n",
       "      <th>InterventionName</th>\n",
       "      <th>Gender</th>\n",
       "      <th>...</th>\n",
       "      <th>OrgFullName</th>\n",
       "      <th>OverallStatus</th>\n",
       "      <th>StartDate</th>\n",
       "      <th>CompletionDate</th>\n",
       "      <th>IsFDARegulatedDrug</th>\n",
       "      <th>ArmGroupType</th>\n",
       "      <th>StartDate_Month</th>\n",
       "      <th>StartDate_Year</th>\n",
       "      <th>Phase</th>\n",
       "      <th>LocationCountry</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT04568811</td>\n",
       "      <td>The Phase I Clinical Trial of Booster Vaccinat...</td>\n",
       "      <td>[Adenovirus Type-5 Vectored COVID-19 Vaccine]</td>\n",
       "      <td>[]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>89</td>\n",
       "      <td>[Biological]</td>\n",
       "      <td>[Adenovirus Type-5 Vectored COVID-19 Vaccine]</td>\n",
       "      <td>All</td>\n",
       "      <td>...</td>\n",
       "      <td>Jiangsu Province Centers for Disease Control a...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>September 26, 2020</td>\n",
       "      <td>September 27, 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental]</td>\n",
       "      <td>September</td>\n",
       "      <td>2020</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04497298</td>\n",
       "      <td>Clinical Trial to Evaluate the Safety and Immu...</td>\n",
       "      <td>[COVID-19]</td>\n",
       "      <td>[SARS-CoV-2, Vaccine, Prevention]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>90</td>\n",
       "      <td>[Biological, Biological, Biological, Other]</td>\n",
       "      <td>[Two COVID-19 vaccine candidate (TMV-083) admi...</td>\n",
       "      <td>All</td>\n",
       "      <td>...</td>\n",
       "      <td>Institut Pasteur</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>August 10, 2020</td>\n",
       "      <td>October 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental, Experimental, Experimental, Pla...</td>\n",
       "      <td>August</td>\n",
       "      <td>2020</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>Belgium</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT04497298</td>\n",
       "      <td>Clinical Trial to Evaluate the Safety and Immu...</td>\n",
       "      <td>[COVID-19]</td>\n",
       "      <td>[SARS-CoV-2, Vaccine, Prevention]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>90</td>\n",
       "      <td>[Biological, Biological, Biological, Other]</td>\n",
       "      <td>[Two COVID-19 vaccine candidate (TMV-083) admi...</td>\n",
       "      <td>All</td>\n",
       "      <td>...</td>\n",
       "      <td>Institut Pasteur</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>August 10, 2020</td>\n",
       "      <td>October 2021</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental, Experimental, Experimental, Pla...</td>\n",
       "      <td>August</td>\n",
       "      <td>2020</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>France</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04651790</td>\n",
       "      <td>Efficacy, Safety, and Immunogenicity of an Ina...</td>\n",
       "      <td>[Covid19, Vaccines]</td>\n",
       "      <td>[Clinical trials, Covid19, Inactivated vaccine]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>2300</td>\n",
       "      <td>[Biological, Other]</td>\n",
       "      <td>[SARS-CoV-2 inactivated vaccine, Placebo]</td>\n",
       "      <td>All</td>\n",
       "      <td>...</td>\n",
       "      <td>Pontificia Universidad Catolica de Chile</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>November 27, 2020</td>\n",
       "      <td>March 2022</td>\n",
       "      <td>No</td>\n",
       "      <td>[Active Comparator, Placebo Comparator]</td>\n",
       "      <td>November</td>\n",
       "      <td>2020</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Chile</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT04659941</td>\n",
       "      <td>Use of BCG Vaccine as a Preventive Measure for...</td>\n",
       "      <td>[COVID 19 Vaccine]</td>\n",
       "      <td>[COVID 19, BCG vaccine]</td>\n",
       "      <td>Interventional</td>\n",
       "      <td>Prevention</td>\n",
       "      <td>1000</td>\n",
       "      <td>[Biological]</td>\n",
       "      <td>[BCG vaccine]</td>\n",
       "      <td>All</td>\n",
       "      <td>...</td>\n",
       "      <td>Universidade Federal do Rio de Janeiro</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>October 1, 2020</td>\n",
       "      <td>October 1, 2022</td>\n",
       "      <td>No</td>\n",
       "      <td>[Experimental, Placebo Comparator]</td>\n",
       "      <td>October</td>\n",
       "      <td>2020</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Brazil</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 21 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         NCTId                                         BriefTitle  \\\n",
       "0  NCT04568811  The Phase I Clinical Trial of Booster Vaccinat...   \n",
       "1  NCT04497298  Clinical Trial to Evaluate the Safety and Immu...   \n",
       "2  NCT04497298  Clinical Trial to Evaluate the Safety and Immu...   \n",
       "3  NCT04651790  Efficacy, Safety, and Immunogenicity of an Ina...   \n",
       "4  NCT04659941  Use of BCG Vaccine as a Preventive Measure for...   \n",
       "\n",
       "                                       Condition  \\\n",
       "0  [Adenovirus Type-5 Vectored COVID-19 Vaccine]   \n",
       "1                                     [COVID-19]   \n",
       "2                                     [COVID-19]   \n",
       "3                            [Covid19, Vaccines]   \n",
       "4                             [COVID 19 Vaccine]   \n",
       "\n",
       "                                           Keyword       StudyType  \\\n",
       "0                                               []  Interventional   \n",
       "1                [SARS-CoV-2, Vaccine, Prevention]  Interventional   \n",
       "2                [SARS-CoV-2, Vaccine, Prevention]  Interventional   \n",
       "3  [Clinical trials, Covid19, Inactivated vaccine]  Interventional   \n",
       "4                          [COVID 19, BCG vaccine]  Interventional   \n",
       "\n",
       "  DesignPrimaryPurpose EnrollmentCount  \\\n",
       "0           Prevention              89   \n",
       "1           Prevention              90   \n",
       "2           Prevention              90   \n",
       "3           Prevention            2300   \n",
       "4           Prevention            1000   \n",
       "\n",
       "                              InterventionType  \\\n",
       "0                                 [Biological]   \n",
       "1  [Biological, Biological, Biological, Other]   \n",
       "2  [Biological, Biological, Biological, Other]   \n",
       "3                          [Biological, Other]   \n",
       "4                                 [Biological]   \n",
       "\n",
       "                                    InterventionName Gender  ...  \\\n",
       "0      [Adenovirus Type-5 Vectored COVID-19 Vaccine]    All  ...   \n",
       "1  [Two COVID-19 vaccine candidate (TMV-083) admi...    All  ...   \n",
       "2  [Two COVID-19 vaccine candidate (TMV-083) admi...    All  ...   \n",
       "3          [SARS-CoV-2 inactivated vaccine, Placebo]    All  ...   \n",
       "4                                      [BCG vaccine]    All  ...   \n",
       "\n",
       "                                         OrgFullName           OverallStatus  \\\n",
       "0  Jiangsu Province Centers for Disease Control a...  Active, not recruiting   \n",
       "1                                   Institut Pasteur              Recruiting   \n",
       "2                                   Institut Pasteur              Recruiting   \n",
       "3           Pontificia Universidad Catolica de Chile              Recruiting   \n",
       "4             Universidade Federal do Rio de Janeiro              Recruiting   \n",
       "\n",
       "            StartDate      CompletionDate IsFDARegulatedDrug  \\\n",
       "0  September 26, 2020  September 27, 2021                 No   \n",
       "1     August 10, 2020        October 2021                 No   \n",
       "2     August 10, 2020        October 2021                 No   \n",
       "3   November 27, 2020          March 2022                 No   \n",
       "4     October 1, 2020     October 1, 2022                 No   \n",
       "\n",
       "                                        ArmGroupType StartDate_Month  \\\n",
       "0                                     [Experimental]       September   \n",
       "1  [Experimental, Experimental, Experimental, Pla...          August   \n",
       "2  [Experimental, Experimental, Experimental, Pla...          August   \n",
       "3            [Active Comparator, Placebo Comparator]        November   \n",
       "4                 [Experimental, Placebo Comparator]         October   \n",
       "\n",
       "  StartDate_Year    Phase LocationCountry  \n",
       "0           2020  Phase 1           China  \n",
       "1           2020  Phase 1         Belgium  \n",
       "2           2020  Phase 1          France  \n",
       "3           2020  Phase 3           Chile  \n",
       "4           2020  Phase 2          Brazil  \n",
       "\n",
       "[5 rows x 21 columns]"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# flatten the list by country -\n",
    "# for the same clinical trial with multiple locations, it will be shown by multiple records\n",
    "flattened_col = pd.DataFrame([(index, value) \n",
    "                              for (index, values) in df_flat['LocationCountry'].iteritems() for value in values],\n",
    "                             columns=['index', 'LocationCountry']).set_index('index')\n",
    "df_flat2 = df_flat.drop('LocationCountry', axis=1).join(flattened_col)\n",
    "df_flat2 = df_flat2.reset_index(drop = True)\n",
    "df_flat2 = df_flat2.drop(['Rank'], axis = 1)\n",
    "df_flat2.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(array([ 0,  1,  2,  3,  4,  5,  6,  7,  8,  9, 10, 11, 12, 13, 14, 15, 16,\n",
       "        17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,\n",
       "        34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50,\n",
       "        51, 52, 53, 54, 55, 56]),\n",
       " <a list of 57 Text major ticklabel objects>)"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x576 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# plot the trials per country\n",
    "sns.countplot(df_flat2.LocationCountry)\n",
    "plt.xticks(rotation=90)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>LocationCountry</th>\n",
       "      <th>Count</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Argentina</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Australia</td>\n",
       "      <td>7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Austria</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Azerbaijan</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Bahrain</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  LocationCountry  Count\n",
       "0       Argentina      4\n",
       "1       Australia      7\n",
       "2         Austria      2\n",
       "3      Azerbaijan      1\n",
       "4         Bahrain      1"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# consolidate the country-level count into a dataframe\n",
    "country_count = pd.DataFrame(df_flat2.groupby('LocationCountry').count()['NCTId'])\n",
    "country_count.columns = ['Count']\n",
    "country_count = country_count.reset_index()\n",
    "country_count.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "import folium\n",
    "from folium import Circle\n",
    "import branca.colormap as cm"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "with open('world_countries.json') as f:\n",
    "    wc = json.load(f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "# match the country name to world_countries.json\n",
    "country_count.LocationCountry = country_count.LocationCountry.replace(['Congo, The Democratic Republic of the', \n",
    "                                                                       'Iran, Islamic Republic of', \n",
    "                                                                       'Korea, Republic of', 'Russian Federation', \n",
    "                                                                       'United States'], \n",
    "                                                                      ['Democratic Republic of the Congo', 'Iran', \n",
    "                                                                       'South Korea', 'Russia', 'United States of America'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div style=\"width:100%;\"><div style=\"position:relative;width:100%;height:0;padding-bottom:60%;\"><span style=\"color:#565656\">Make this Notebook Trusted to load map: File -> Trust Notebook</span><iframe src=\"about:blank\" style=\"position:absolute;width:100%;height:100%;left:0;top:0;border:none !important;\" data-html=%3C%21DOCTYPE%20html%3E%0A%3Chead%3E%20%20%20%20%0A%20%20%20%20%3Cmeta%20http-equiv%3D%22content-type%22%20content%3D%22text/html%3B%20charset%3DUTF-8%22%20/%3E%0A%20%20%20%20%0A%20%20%20%20%20%20%20%20%3Cscript%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20L_NO_TOUCH%20%3D%20false%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20L_DISABLE_3D%20%3D%20false%3B%0A%20%20%20%20%20%20%20%20%3C/script%3E%0A%20%20%20%20%0A%20%20%20%20%3Cstyle%3Ehtml%2C%20body%20%7Bwidth%3A%20100%25%3Bheight%3A%20100%25%3Bmargin%3A%200%3Bpadding%3A%200%3B%7D%3C/style%3E%0A%20%20%20%20%3Cstyle%3E%23map%20%7Bposition%3Aabsolute%3Btop%3A0%3Bbottom%3A0%3Bright%3A0%3Bleft%3A0%3B%7D%3C/style%3E%0A%20%20%20%20%3Cscript%20src%3D%22https%3A//cdn.jsdelivr.net/npm/leaflet%401.6.0/dist/leaflet.js%22%3E%3C/script%3E%0A%20%20%20%20%3Cscript%20src%3D%22https%3A//code.jquery.com/jquery-1.12.4.min.js%22%3E%3C/script%3E%0A%20%20%20%20%3Cscript%20src%3D%22https%3A//maxcdn.bootstrapcdn.com/bootstrap/3.2.0/js/bootstrap.min.js%22%3E%3C/script%3E%0A%20%20%20%20%3Cscript%20src%3D%22https%3A//cdnjs.cloudflare.com/ajax/libs/Leaflet.awesome-markers/2.0.2/leaflet.awesome-markers.js%22%3E%3C/script%3E%0A%20%20%20%20%3Clink%20rel%3D%22stylesheet%22%20href%3D%22https%3A//cdn.jsdelivr.net/npm/leaflet%401.6.0/dist/leaflet.css%22/%3E%0A%20%20%20%20%3Clink%20rel%3D%22stylesheet%22%20href%3D%22https%3A//maxcdn.bootstrapcdn.com/bootstrap/3.2.0/css/bootstrap.min.css%22/%3E%0A%20%20%20%20%3Clink%20rel%3D%22stylesheet%22%20href%3D%22https%3A//maxcdn.bootstrapcdn.com/bootstrap/3.2.0/css/bootstrap-theme.min.css%22/%3E%0A%20%20%20%20%3Clink%20rel%3D%22stylesheet%22%20href%3D%22https%3A//maxcdn.bootstrapcdn.com/font-awesome/4.6.3/css/font-awesome.min.css%22/%3E%0A%20%20%20%20%3Clink%20rel%3D%22stylesheet%22%20href%3D%22https%3A//cdnjs.cloudflare.com/ajax/libs/Leaflet.awesome-markers/2.0.2/leaflet.awesome-markers.css%22/%3E%0A%20%20%20%20%3Clink%20rel%3D%22stylesheet%22%20href%3D%22https%3A//cdn.jsdelivr.net/gh/python-visualization/folium/folium/templates/leaflet.awesome.rotate.min.css%22/%3E%0A%20%20%20%20%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cmeta%20name%3D%22viewport%22%20content%3D%22width%3Ddevice-width%2C%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20initial-scale%3D1.0%2C%20maximum-scale%3D1.0%2C%20user-scalable%3Dno%22%20/%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cstyle%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%23map_aa62a99e890e45728843666414ba6b9f%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20position%3A%20relative%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20width%3A%20100.0%25%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20height%3A%20100.0%25%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20left%3A%200.0%25%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20top%3A%200.0%25%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20%20%20%20%20%3C/style%3E%0A%20%20%20%20%20%20%20%20%0A%20%20%20%20%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3Cstyle%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.foliumtooltip%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.foliumtooltip%20table%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20margin%3A%20auto%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.foliumtooltip%20tr%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20text-align%3A%20left%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.foliumtooltip%20th%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20padding%3A%202px%3B%20padding-right%3A%208px%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%3C/style%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%0A%20%20%20%20%3Cscript%20src%3D%22https%3A//cdnjs.cloudflare.com/ajax/libs/d3/3.5.5/d3.min.js%22%3E%3C/script%3E%0A%3C/head%3E%0A%3Cbody%3E%20%20%20%20%0A%20%20%20%20%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Cdiv%20class%3D%22folium-map%22%20id%3D%22map_aa62a99e890e45728843666414ba6b9f%22%20%3E%3C/div%3E%0A%20%20%20%20%20%20%20%20%0A%3C/body%3E%0A%3Cscript%3E%20%20%20%20%0A%20%20%20%20%0A%20%20%20%20%20%20%20%20%20%20%20%20var%20map_aa62a99e890e45728843666414ba6b9f%20%3D%20L.map%28%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%22map_aa62a99e890e45728843666414ba6b9f%22%2C%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20center%3A%20%5B30.0%2C%200.0%5D%2C%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20crs%3A%20L.CRS.EPSG3857%2C%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20zoom%3A%201.5%2C%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20zoomControl%3A%20true%2C%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20preferCanvas%3A%20false%2C%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20%20%20%20%20%29%3B%0A%0A%20%20%20%20%20%20%20%20%20%20%20%20%0A%0A%20%20%20%20%20%20%20%20%0A%20%20%20%20%0A%20%20%20%20%20%20%20%20%20%20%20%20var%20tile_layer_36e2c744832a4e7d908fff833dbbd09a%20%3D%20L.tileLayer%28%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%22https%3A//cartodb-basemaps-%7Bs%7D.global.ssl.fastly.net/light_all/%7Bz%7D/%7Bx%7D/%7By%7D.png%22%2C%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%7B%22attribution%22%3A%20%22%5Cu0026copy%3B%20%5Cu003ca%20href%3D%5C%22http%3A//www.openstreetmap.org/copyright%5C%22%5Cu003eOpenStreetMap%5Cu003c/a%5Cu003e%20contributors%20%5Cu0026copy%3B%20%5Cu003ca%20href%3D%5C%22http%3A//cartodb.com/attributions%5C%22%5Cu003eCartoDB%5Cu003c/a%5Cu003e%2C%20CartoDB%20%5Cu003ca%20href%20%3D%5C%22http%3A//cartodb.com/attributions%5C%22%5Cu003eattributions%5Cu003c/a%5Cu003e%22%2C%20%22detectRetina%22%3A%20false%2C%20%22maxNativeZoom%22%3A%2018%2C%20%22maxZoom%22%3A%2018%2C%20%22minZoom%22%3A%200%2C%20%22noWrap%22%3A%20false%2C%20%22opacity%22%3A%201%2C%20%22subdomains%22%3A%20%22abc%22%2C%20%22tms%22%3A%20false%7D%0A%20%20%20%20%20%20%20%20%20%20%20%20%29.addTo%28map_aa62a99e890e45728843666414ba6b9f%29%3B%0A%20%20%20%20%20%20%20%20%0A%20%20%20%20%0A%20%20%20%20%20%20%20%20%20%20%20%20var%20choropleth_8cfe1a1e6955456380449b5135e92e6e%20%3D%20L.featureGroup%28%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%7B%7D%0A%20%20%20%20%20%20%20%20%20%20%20%20%29.addTo%28map_aa62a99e890e45728843666414ba6b9f%29%3B%0A%20%20%20%20%20%20%20%20%0A%20%20%20%20%0A%20%20%20%20%20%20%20%20function%20geo_json_70014295e18e4bfc98d118a4cf48986b_styler%28feature%29%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20switch%28feature.properties.name%29%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20case%20%22United%20Arab%20Emirates%22%3A%20case%20%22Argentina%22%3A%20case%20%22Australia%22%3A%20case%20%22Austria%22%3A%20case%20%22Azerbaijan%22%3A%20case%20%22Belarus%22%3A%20case%20%22Chile%22%3A%20case%20%22Colombia%22%3A%20case%20%22Denmark%22%3A%20case%20%22Dominican%20Republic%22%3A%20case%20%22Egypt%22%3A%20case%20%22Spain%22%3A%20case%20%22France%22%3A%20case%20%22Ghana%22%3A%20case%20%22Greece%22%3A%20case%20%22Indonesia%22%3A%20case%20%22India%22%3A%20case%20%22Ireland%22%3A%20case%20%22Israel%22%3A%20case%20%22Italy%22%3A%20case%20%22Jordan%22%3A%20case%20%22Kazakhstan%22%3A%20case%20%22Mexico%22%3A%20case%20%22Mozambique%22%3A%20case%20%22Malaysia%22%3A%20case%20%22Nepal%22%3A%20case%20%22New%20Zealand%22%3A%20case%20%22Pakistan%22%3A%20case%20%22Panama%22%3A%20case%20%22Peru%22%3A%20case%20%22Philippines%22%3A%20case%20%22Poland%22%3A%20case%20%22Puerto%20Rico%22%3A%20case%20%22Saudi%20Arabia%22%3A%20case%20%22Turkey%22%3A%20case%20%22Taiwan%22%3A%20case%20%22Uganda%22%3A%20case%20%22Vietnam%22%3A%20case%20%22Zambia%22%3A%20case%20%22Zimbabwe%22%3A%20%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return%20%7B%22color%22%3A%20%22black%22%2C%20%22fillColor%22%3A%20%22%23ffffb2%22%2C%20%22fillOpacity%22%3A%200.8%2C%20%22opacity%22%3A%200.2%2C%20%22weight%22%3A%201%7D%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20case%20%22Belgium%22%3A%20case%20%22Brazil%22%3A%20case%20%22Canada%22%3A%20case%20%22United%20Kingdom%22%3A%20case%20%22Japan%22%3A%20case%20%22South%20Korea%22%3A%20case%20%22Netherlands%22%3A%20case%20%22Russia%22%3A%20case%20%22South%20Africa%22%3A%20%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return%20%7B%22color%22%3A%20%22black%22%2C%20%22fillColor%22%3A%20%22%23fed976%22%2C%20%22fillOpacity%22%3A%200.8%2C%20%22opacity%22%3A%200.2%2C%20%22weight%22%3A%201%7D%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20case%20%22China%22%3A%20%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return%20%7B%22color%22%3A%20%22black%22%2C%20%22fillColor%22%3A%20%22%23fd8d3c%22%2C%20%22fillOpacity%22%3A%200.8%2C%20%22opacity%22%3A%200.2%2C%20%22weight%22%3A%201%7D%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20case%20%22Germany%22%3A%20%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return%20%7B%22color%22%3A%20%22black%22%2C%20%22fillColor%22%3A%20%22%23feb24c%22%2C%20%22fillOpacity%22%3A%200.8%2C%20%22opacity%22%3A%200.2%2C%20%22weight%22%3A%201%7D%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20case%20%22United%20States%20of%20America%22%3A%20%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return%20%7B%22color%22%3A%20%22black%22%2C%20%22fillColor%22%3A%20%22%23bd0026%22%2C%20%22fillOpacity%22%3A%200.8%2C%20%22opacity%22%3A%200.2%2C%20%22weight%22%3A%201%7D%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20default%3A%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return%20%7B%22color%22%3A%20%22black%22%2C%20%22fillColor%22%3A%20%22black%22%2C%20%22fillOpacity%22%3A%200%2C%20%22opacity%22%3A%200.2%2C%20%22weight%22%3A%201%7D%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20%7D%0A%0A%20%20%20%20%20%20%20%20function%20geo_json_70014295e18e4bfc98d118a4cf48986b_onEachFeature%28feature%2C%20layer%29%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20layer.on%28%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20%7D%29%3B%0A%20%20%20%20%20%20%20%20%7D%3B%0A%20%20%20%20%20%20%20%20var%20geo_json_70014295e18e4bfc98d118a4cf48986b%20%3D%20L.geoJson%28null%2C%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20onEachFeature%3A%20geo_json_70014295e18e4bfc98d118a4cf48986b_onEachFeature%2C%0A%20%20%20%20%20%20%20%20%20%20%20%20%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20style%3A%20geo_json_70014295e18e4bfc98d118a4cf48986b_styler%2C%0A%20%20%20%20%20%20%20%20%7D%29%3B%0A%0A%20%20%20%20%20%20%20%20function%20geo_json_70014295e18e4bfc98d118a4cf48986b_add%20%28data%29%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20geo_json_70014295e18e4bfc98d118a4cf48986b%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.addData%28data%29%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20.addTo%28choropleth_8cfe1a1e6955456380449b5135e92e6e%29%3B%0A%20%20%20%20%20%20%20%20%7D%0A%20%20%20%20%20%20%20%20%20%20%20%20geo_json_70014295e18e4bfc98d118a4cf48986b_add%28%7B%22features%22%3A%20%5B%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B61.210817%2C%2035.650072%5D%2C%20%5B62.230651%2C%2035.270664%5D%2C%20%5B62.984662%2C%2035.404041%5D%2C%20%5B63.193538%2C%2035.857166%5D%2C%20%5B63.982896%2C%2036.007957%5D%2C%20%5B64.546479%2C%2036.312073%5D%2C%20%5B64.746105%2C%2037.111818%5D%2C%20%5B65.588948%2C%2037.305217%5D%2C%20%5B65.745631%2C%2037.661164%5D%2C%20%5B66.217385%2C%2037.39379%5D%2C%20%5B66.518607%2C%2037.362784%5D%2C%20%5B67.075782%2C%2037.356144%5D%2C%20%5B67.83%2C%2037.144994%5D%2C%20%5B68.135562%2C%2037.023115%5D%2C%20%5B68.859446%2C%2037.344336%5D%2C%20%5B69.196273%2C%2037.151144%5D%2C%20%5B69.518785%2C%2037.608997%5D%2C%20%5B70.116578%2C%2037.588223%5D%2C%20%5B70.270574%2C%2037.735165%5D%2C%20%5B70.376304%2C%2038.138396%5D%2C%20%5B70.806821%2C%2038.486282%5D%2C%20%5B71.348131%2C%2038.258905%5D%2C%20%5B71.239404%2C%2037.953265%5D%2C%20%5B71.541918%2C%2037.905774%5D%2C%20%5B71.448693%2C%2037.065645%5D%2C%20%5B71.844638%2C%2036.738171%5D%2C%20%5B72.193041%2C%2036.948288%5D%2C%20%5B72.63689%2C%2037.047558%5D%2C%20%5B73.260056%2C%2037.495257%5D%2C%20%5B73.948696%2C%2037.421566%5D%2C%20%5B74.980002%2C%2037.41999%5D%2C%20%5B75.158028%2C%2037.133031%5D%2C%20%5B74.575893%2C%2037.020841%5D%2C%20%5B74.067552%2C%2036.836176%5D%2C%20%5B72.920025%2C%2036.720007%5D%2C%20%5B71.846292%2C%2036.509942%5D%2C%20%5B71.262348%2C%2036.074388%5D%2C%20%5B71.498768%2C%2035.650563%5D%2C%20%5B71.613076%2C%2035.153203%5D%2C%20%5B71.115019%2C%2034.733126%5D%2C%20%5B71.156773%2C%2034.348911%5D%2C%20%5B70.881803%2C%2033.988856%5D%2C%20%5B69.930543%2C%2034.02012%5D%2C%20%5B70.323594%2C%2033.358533%5D%2C%20%5B69.687147%2C%2033.105499%5D%2C%20%5B69.262522%2C%2032.501944%5D%2C%20%5B69.317764%2C%2031.901412%5D%2C%20%5B68.926677%2C%2031.620189%5D%2C%20%5B68.556932%2C%2031.71331%5D%2C%20%5B67.792689%2C%2031.58293%5D%2C%20%5B67.683394%2C%2031.303154%5D%2C%20%5B66.938891%2C%2031.304911%5D%2C%20%5B66.381458%2C%2030.738899%5D%2C%20%5B66.346473%2C%2029.887943%5D%2C%20%5B65.046862%2C%2029.472181%5D%2C%20%5B64.350419%2C%2029.560031%5D%2C%20%5B64.148002%2C%2029.340819%5D%2C%20%5B63.550261%2C%2029.468331%5D%2C%20%5B62.549857%2C%2029.318572%5D%2C%20%5B60.874248%2C%2029.829239%5D%2C%20%5B61.781222%2C%2030.73585%5D%2C%20%5B61.699314%2C%2031.379506%5D%2C%20%5B60.941945%2C%2031.548075%5D%2C%20%5B60.863655%2C%2032.18292%5D%2C%20%5B60.536078%2C%2032.981269%5D%2C%20%5B60.9637%2C%2033.528832%5D%2C%20%5B60.52843%2C%2033.676446%5D%2C%20%5B60.803193%2C%2034.404102%5D%2C%20%5B61.210817%2C%2035.650072%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22AFG%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Afghanistan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B16.326528%2C%20-5.87747%5D%2C%20%5B16.57318%2C%20-6.622645%5D%2C%20%5B16.860191%2C%20-7.222298%5D%2C%20%5B17.089996%2C%20-7.545689%5D%2C%20%5B17.47297%2C%20-8.068551%5D%2C%20%5B18.134222%2C%20-7.987678%5D%2C%20%5B18.464176%2C%20-7.847014%5D%2C%20%5B19.016752%2C%20-7.988246%5D%2C%20%5B19.166613%2C%20-7.738184%5D%2C%20%5B19.417502%2C%20-7.155429%5D%2C%20%5B20.037723%2C%20-7.116361%5D%2C%20%5B20.091622%2C%20-6.94309%5D%2C%20%5B20.601823%2C%20-6.939318%5D%2C%20%5B20.514748%2C%20-7.299606%5D%2C%20%5B21.728111%2C%20-7.290872%5D%2C%20%5B21.746456%2C%20-7.920085%5D%2C%20%5B21.949131%2C%20-8.305901%5D%2C%20%5B21.801801%2C%20-8.908707%5D%2C%20%5B21.875182%2C%20-9.523708%5D%2C%20%5B22.208753%2C%20-9.894796%5D%2C%20%5B22.155268%2C%20-11.084801%5D%2C%20%5B22.402798%2C%20-10.993075%5D%2C%20%5B22.837345%2C%20-11.017622%5D%2C%20%5B23.456791%2C%20-10.867863%5D%2C%20%5B23.912215%2C%20-10.926826%5D%2C%20%5B24.017894%2C%20-11.237298%5D%2C%20%5B23.904154%2C%20-11.722282%5D%2C%20%5B24.079905%2C%20-12.191297%5D%2C%20%5B23.930922%2C%20-12.565848%5D%2C%20%5B24.016137%2C%20-12.911046%5D%2C%20%5B21.933886%2C%20-12.898437%5D%2C%20%5B21.887843%2C%20-16.08031%5D%2C%20%5B22.562478%2C%20-16.898451%5D%2C%20%5B23.215048%2C%20-17.523116%5D%2C%20%5B21.377176%2C%20-17.930636%5D%2C%20%5B18.956187%2C%20-17.789095%5D%2C%20%5B18.263309%2C%20-17.309951%5D%2C%20%5B14.209707%2C%20-17.353101%5D%2C%20%5B14.058501%2C%20-17.423381%5D%2C%20%5B13.462362%2C%20-16.971212%5D%2C%20%5B12.814081%2C%20-16.941343%5D%2C%20%5B12.215461%2C%20-17.111668%5D%2C%20%5B11.734199%2C%20-17.301889%5D%2C%20%5B11.640096%2C%20-16.673142%5D%2C%20%5B11.778537%2C%20-15.793816%5D%2C%20%5B12.123581%2C%20-14.878316%5D%2C%20%5B12.175619%2C%20-14.449144%5D%2C%20%5B12.500095%2C%20-13.5477%5D%2C%20%5B12.738479%2C%20-13.137906%5D%2C%20%5B13.312914%2C%20-12.48363%5D%2C%20%5B13.633721%2C%20-12.038645%5D%2C%20%5B13.738728%2C%20-11.297863%5D%2C%20%5B13.686379%2C%20-10.731076%5D%2C%20%5B13.387328%2C%20-10.373578%5D%2C%20%5B13.120988%2C%20-9.766897%5D%2C%20%5B12.87537%2C%20-9.166934%5D%2C%20%5B12.929061%2C%20-8.959091%5D%2C%20%5B13.236433%2C%20-8.562629%5D%2C%20%5B12.93304%2C%20-7.596539%5D%2C%20%5B12.728298%2C%20-6.927122%5D%2C%20%5B12.227347%2C%20-6.294448%5D%2C%20%5B12.322432%2C%20-6.100092%5D%2C%20%5B12.735171%2C%20-5.965682%5D%2C%20%5B13.024869%2C%20-5.984389%5D%2C%20%5B13.375597%2C%20-5.864241%5D%2C%20%5B16.326528%2C%20-5.87747%5D%5D%5D%2C%20%5B%5B%5B12.436688%2C%20-5.684304%5D%2C%20%5B12.182337%2C%20-5.789931%5D%2C%20%5B11.914963%2C%20-5.037987%5D%2C%20%5B12.318608%2C%20-4.60623%5D%2C%20%5B12.62076%2C%20-4.438023%5D%2C%20%5B12.995517%2C%20-4.781103%5D%2C%20%5B12.631612%2C%20-4.991271%5D%2C%20%5B12.468004%2C%20-5.248362%5D%2C%20%5B12.436688%2C%20-5.684304%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22AGO%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Angola%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B20.590247%2C%2041.855404%5D%2C%20%5B20.463175%2C%2041.515089%5D%2C%20%5B20.605182%2C%2041.086226%5D%2C%20%5B21.02004%2C%2040.842727%5D%2C%20%5B20.99999%2C%2040.580004%5D%2C%20%5B20.674997%2C%2040.435%5D%2C%20%5B20.615%2C%2040.110007%5D%2C%20%5B20.150016%2C%2039.624998%5D%2C%20%5B19.98%2C%2039.694993%5D%2C%20%5B19.960002%2C%2039.915006%5D%2C%20%5B19.406082%2C%2040.250773%5D%2C%20%5B19.319059%2C%2040.72723%5D%2C%20%5B19.40355%2C%2041.409566%5D%2C%20%5B19.540027%2C%2041.719986%5D%2C%20%5B19.371769%2C%2041.877548%5D%2C%20%5B19.304486%2C%2042.195745%5D%2C%20%5B19.738051%2C%2042.688247%5D%2C%20%5B19.801613%2C%2042.500093%5D%2C%20%5B20.0707%2C%2042.58863%5D%2C%20%5B20.283755%2C%2042.32026%5D%2C%20%5B20.52295%2C%2042.21787%5D%2C%20%5B20.590247%2C%2041.855404%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ALB%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Albania%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B51.579519%2C%2024.245497%5D%2C%20%5B51.757441%2C%2024.294073%5D%2C%20%5B51.794389%2C%2024.019826%5D%2C%20%5B52.577081%2C%2024.177439%5D%2C%20%5B53.404007%2C%2024.151317%5D%2C%20%5B54.008001%2C%2024.121758%5D%2C%20%5B54.693024%2C%2024.797892%5D%2C%20%5B55.439025%2C%2025.439145%5D%2C%20%5B56.070821%2C%2026.055464%5D%2C%20%5B56.261042%2C%2025.714606%5D%2C%20%5B56.396847%2C%2024.924732%5D%2C%20%5B55.886233%2C%2024.920831%5D%2C%20%5B55.804119%2C%2024.269604%5D%2C%20%5B55.981214%2C%2024.130543%5D%2C%20%5B55.528632%2C%2023.933604%5D%2C%20%5B55.525841%2C%2023.524869%5D%2C%20%5B55.234489%2C%2023.110993%5D%2C%20%5B55.208341%2C%2022.70833%5D%2C%20%5B55.006803%2C%2022.496948%5D%2C%20%5B52.000733%2C%2023.001154%5D%2C%20%5B51.617708%2C%2024.014219%5D%2C%20%5B51.579519%2C%2024.245497%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ARE%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22United%20Arab%20Emirates%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B-65.5%2C%20-55.2%5D%2C%20%5B-66.45%2C%20-55.25%5D%2C%20%5B-66.95992%2C%20-54.89681%5D%2C%20%5B-67.56244%2C%20-54.87001%5D%2C%20%5B-68.63335%2C%20-54.8695%5D%2C%20%5B-68.63401%2C%20-52.63637%5D%2C%20%5B-68.25%2C%20-53.1%5D%2C%20%5B-67.75%2C%20-53.85%5D%2C%20%5B-66.45%2C%20-54.45%5D%2C%20%5B-65.05%2C%20-54.7%5D%2C%20%5B-65.5%2C%20-55.2%5D%5D%5D%2C%20%5B%5B%5B-64.964892%2C%20-22.075862%5D%2C%20%5B-64.377021%2C%20-22.798091%5D%2C%20%5B-63.986838%2C%20-21.993644%5D%2C%20%5B-62.846468%2C%20-22.034985%5D%2C%20%5B-62.685057%2C%20-22.249029%5D%2C%20%5B-60.846565%2C%20-23.880713%5D%2C%20%5B-60.028966%2C%20-24.032796%5D%2C%20%5B-58.807128%2C%20-24.771459%5D%2C%20%5B-57.777217%2C%20-25.16234%5D%2C%20%5B-57.63366%2C%20-25.603657%5D%2C%20%5B-58.618174%2C%20-27.123719%5D%2C%20%5B-57.60976%2C%20-27.395899%5D%2C%20%5B-56.486702%2C%20-27.548499%5D%2C%20%5B-55.695846%2C%20-27.387837%5D%2C%20%5B-54.788795%2C%20-26.621786%5D%2C%20%5B-54.625291%2C%20-25.739255%5D%2C%20%5B-54.13005%2C%20-25.547639%5D%2C%20%5B-53.628349%2C%20-26.124865%5D%2C%20%5B-53.648735%2C%20-26.923473%5D%2C%20%5B-54.490725%2C%20-27.474757%5D%2C%20%5B-55.162286%2C%20-27.881915%5D%2C%20%5B-56.2909%2C%20-28.852761%5D%2C%20%5B-57.625133%2C%20-30.216295%5D%2C%20%5B-57.874937%2C%20-31.016556%5D%2C%20%5B-58.14244%2C%20-32.044504%5D%2C%20%5B-58.132648%2C%20-33.040567%5D%2C%20%5B-58.349611%2C%20-33.263189%5D%2C%20%5B-58.427074%2C%20-33.909454%5D%2C%20%5B-58.495442%2C%20-34.43149%5D%2C%20%5B-57.22583%2C%20-35.288027%5D%2C%20%5B-57.362359%2C%20-35.97739%5D%2C%20%5B-56.737487%2C%20-36.413126%5D%2C%20%5B-56.788285%2C%20-36.901572%5D%2C%20%5B-57.749157%2C%20-38.183871%5D%2C%20%5B-59.231857%2C%20-38.72022%5D%2C%20%5B-61.237445%2C%20-38.928425%5D%2C%20%5B-62.335957%2C%20-38.827707%5D%2C%20%5B-62.125763%2C%20-39.424105%5D%2C%20%5B-62.330531%2C%20-40.172586%5D%2C%20%5B-62.145994%2C%20-40.676897%5D%2C%20%5B-62.745803%2C%20-41.028761%5D%2C%20%5B-63.770495%2C%20-41.166789%5D%2C%20%5B-64.73209%2C%20-40.802677%5D%2C%20%5B-65.118035%2C%20-41.064315%5D%2C%20%5B-64.978561%2C%20-42.058001%5D%2C%20%5B-64.303408%2C%20-42.359016%5D%2C%20%5B-63.755948%2C%20-42.043687%5D%2C%20%5B-63.458059%2C%20-42.563138%5D%2C%20%5B-64.378804%2C%20-42.873558%5D%2C%20%5B-65.181804%2C%20-43.495381%5D%2C%20%5B-65.328823%2C%20-44.501366%5D%2C%20%5B-65.565269%2C%20-45.036786%5D%2C%20%5B-66.509966%2C%20-45.039628%5D%2C%20%5B-67.293794%2C%20-45.551896%5D%2C%20%5B-67.580546%2C%20-46.301773%5D%2C%20%5B-66.597066%2C%20-47.033925%5D%2C%20%5B-65.641027%2C%20-47.236135%5D%2C%20%5B-65.985088%2C%20-48.133289%5D%2C%20%5B-67.166179%2C%20-48.697337%5D%2C%20%5B-67.816088%2C%20-49.869669%5D%2C%20%5B-68.728745%2C%20-50.264218%5D%2C%20%5B-69.138539%2C%20-50.73251%5D%2C%20%5B-68.815561%2C%20-51.771104%5D%2C%20%5B-68.149995%2C%20-52.349983%5D%2C%20%5B-68.571545%2C%20-52.299444%5D%2C%20%5B-69.498362%2C%20-52.142761%5D%2C%20%5B-71.914804%2C%20-52.009022%5D%2C%20%5B-72.329404%2C%20-51.425956%5D%2C%20%5B-72.309974%2C%20-50.67701%5D%2C%20%5B-72.975747%2C%20-50.74145%5D%2C%20%5B-73.328051%2C%20-50.378785%5D%2C%20%5B-73.415436%2C%20-49.318436%5D%2C%20%5B-72.648247%2C%20-48.878618%5D%2C%20%5B-72.331161%2C%20-48.244238%5D%2C%20%5B-72.447355%2C%20-47.738533%5D%2C%20%5B-71.917258%2C%20-46.884838%5D%2C%20%5B-71.552009%2C%20-45.560733%5D%2C%20%5B-71.659316%2C%20-44.973689%5D%2C%20%5B-71.222779%2C%20-44.784243%5D%2C%20%5B-71.329801%2C%20-44.407522%5D%2C%20%5B-71.793623%2C%20-44.207172%5D%2C%20%5B-71.464056%2C%20-43.787611%5D%2C%20%5B-71.915424%2C%20-43.408565%5D%2C%20%5B-72.148898%2C%20-42.254888%5D%2C%20%5B-71.746804%2C%20-42.051386%5D%2C%20%5B-71.915734%2C%20-40.832339%5D%2C%20%5B-71.680761%2C%20-39.808164%5D%2C%20%5B-71.413517%2C%20-38.916022%5D%2C%20%5B-70.814664%2C%20-38.552995%5D%2C%20%5B-71.118625%2C%20-37.576827%5D%2C%20%5B-71.121881%2C%20-36.658124%5D%2C%20%5B-70.364769%2C%20-36.005089%5D%2C%20%5B-70.388049%2C%20-35.169688%5D%2C%20%5B-69.817309%2C%20-34.193571%5D%2C%20%5B-69.814777%2C%20-33.273886%5D%2C%20%5B-70.074399%2C%20-33.09121%5D%2C%20%5B-70.535069%2C%20-31.36501%5D%2C%20%5B-69.919008%2C%20-30.336339%5D%2C%20%5B-70.01355%2C%20-29.367923%5D%2C%20%5B-69.65613%2C%20-28.459141%5D%2C%20%5B-69.001235%2C%20-27.521214%5D%2C%20%5B-68.295542%2C%20-26.89934%5D%2C%20%5B-68.5948%2C%20-26.506909%5D%2C%20%5B-68.386001%2C%20-26.185016%5D%2C%20%5B-68.417653%2C%20-24.518555%5D%2C%20%5B-67.328443%2C%20-24.025303%5D%2C%20%5B-66.985234%2C%20-22.986349%5D%2C%20%5B-67.106674%2C%20-22.735925%5D%2C%20%5B-66.273339%2C%20-21.83231%5D%2C%20%5B-64.964892%2C%20-22.075862%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22ARG%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Argentina%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B43.582746%2C%2041.092143%5D%2C%20%5B44.97248%2C%2041.248129%5D%2C%20%5B45.179496%2C%2040.985354%5D%2C%20%5B45.560351%2C%2040.81229%5D%2C%20%5B45.359175%2C%2040.561504%5D%2C%20%5B45.891907%2C%2040.218476%5D%2C%20%5B45.610012%2C%2039.899994%5D%2C%20%5B46.034534%2C%2039.628021%5D%2C%20%5B46.483499%2C%2039.464155%5D%2C%20%5B46.50572%2C%2038.770605%5D%2C%20%5B46.143623%2C%2038.741201%5D%2C%20%5B45.735379%2C%2039.319719%5D%2C%20%5B45.739978%2C%2039.473999%5D%2C%20%5B45.298145%2C%2039.471751%5D%2C%20%5B45.001987%2C%2039.740004%5D%2C%20%5B44.79399%2C%2039.713003%5D%2C%20%5B44.400009%2C%2040.005%5D%2C%20%5B43.656436%2C%2040.253564%5D%2C%20%5B43.752658%2C%2040.740201%5D%2C%20%5B43.582746%2C%2041.092143%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ARM%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Armenia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B-59.572095%2C%20-80.040179%5D%2C%20%5B-59.865849%2C%20-80.549657%5D%2C%20%5B-60.159656%2C%20-81.000327%5D%2C%20%5B-62.255393%2C%20-80.863178%5D%2C%20%5B-64.488125%2C%20-80.921934%5D%2C%20%5B-65.741666%2C%20-80.588827%5D%2C%20%5B-65.741666%2C%20-80.549657%5D%2C%20%5B-66.290031%2C%20-80.255773%5D%2C%20%5B-64.037688%2C%20-80.294944%5D%2C%20%5B-61.883246%2C%20-80.39287%5D%2C%20%5B-61.138976%2C%20-79.981371%5D%2C%20%5B-60.610119%2C%20-79.628679%5D%2C%20%5B-59.572095%2C%20-80.040179%5D%5D%5D%2C%20%5B%5B%5B-159.208184%2C%20-79.497059%5D%2C%20%5B-161.127601%2C%20-79.634209%5D%2C%20%5B-162.439847%2C%20-79.281465%5D%2C%20%5B-163.027408%2C%20-78.928774%5D%2C%20%5B-163.066604%2C%20-78.869966%5D%2C%20%5B-163.712896%2C%20-78.595667%5D%2C%20%5B-163.712896%2C%20-78.595667%5D%2C%20%5B-163.105801%2C%20-78.223338%5D%2C%20%5B-161.245113%2C%20-78.380176%5D%2C%20%5B-160.246208%2C%20-78.693645%5D%2C%20%5B-159.482405%2C%20-79.046338%5D%2C%20%5B-159.208184%2C%20-79.497059%5D%5D%5D%2C%20%5B%5B%5B-45.154758%2C%20-78.04707%5D%2C%20%5B-43.920828%2C%20-78.478103%5D%2C%20%5B-43.48995%2C%20-79.08556%5D%2C%20%5B-43.372438%2C%20-79.516645%5D%2C%20%5B-43.333267%2C%20-80.026123%5D%2C%20%5B-44.880537%2C%20-80.339644%5D%2C%20%5B-46.506174%2C%20-80.594357%5D%2C%20%5B-48.386421%2C%20-80.829485%5D%2C%20%5B-50.482107%2C%20-81.025442%5D%2C%20%5B-52.851988%2C%20-80.966685%5D%2C%20%5B-54.164259%2C%20-80.633528%5D%2C%20%5B-53.987991%2C%20-80.222028%5D%2C%20%5B-51.853134%2C%20-79.94773%5D%2C%20%5B-50.991326%2C%20-79.614623%5D%2C%20%5B-50.364595%2C%20-79.183487%5D%2C%20%5B-49.914131%2C%20-78.811209%5D%2C%20%5B-49.306959%2C%20-78.458569%5D%2C%20%5B-48.660616%2C%20-78.047018%5D%2C%20%5B-48.660616%2C%20-78.047019%5D%2C%20%5B-48.151396%2C%20-78.04707%5D%2C%20%5B-46.662857%2C%20-77.831476%5D%2C%20%5B-45.154758%2C%20-78.04707%5D%5D%5D%2C%20%5B%5B%5B-121.211511%2C%20-73.50099%5D%2C%20%5B-119.918851%2C%20-73.657725%5D%2C%20%5B-118.724143%2C%20-73.481353%5D%2C%20%5B-119.292119%2C%20-73.834097%5D%2C%20%5B-120.232217%2C%20-74.08881%5D%2C%20%5B-121.62283%2C%20-74.010468%5D%2C%20%5B-122.621735%2C%20-73.657778%5D%2C%20%5B-122.621735%2C%20-73.657777%5D%2C%20%5B-122.406245%2C%20-73.324619%5D%2C%20%5B-121.211511%2C%20-73.50099%5D%5D%5D%2C%20%5B%5B%5B-125.559566%2C%20-73.481353%5D%2C%20%5B-124.031882%2C%20-73.873268%5D%2C%20%5B-124.619469%2C%20-73.834097%5D%2C%20%5B-125.912181%2C%20-73.736118%5D%2C%20%5B-127.28313%2C%20-73.461769%5D%2C%20%5B-127.28313%2C%20-73.461768%5D%2C%20%5B-126.558472%2C%20-73.246226%5D%2C%20%5B-125.559566%2C%20-73.481353%5D%5D%5D%2C%20%5B%5B%5B-98.98155%2C%20-71.933334%5D%2C%20%5B-97.884743%2C%20-72.070535%5D%2C%20%5B-96.787937%2C%20-71.952971%5D%2C%20%5B-96.20035%2C%20-72.521205%5D%2C%20%5B-96.983765%2C%20-72.442864%5D%2C%20%5B-98.198083%2C%20-72.482035%5D%2C%20%5B-99.432013%2C%20-72.442864%5D%2C%20%5B-100.783455%2C%20-72.50162%5D%2C%20%5B-101.801868%2C%20-72.305663%5D%2C%20%5B-102.330725%2C%20-71.894164%5D%2C%20%5B-102.330725%2C%20-71.894164%5D%2C%20%5B-101.703967%2C%20-71.717792%5D%2C%20%5B-100.430919%2C%20-71.854993%5D%2C%20%5B-98.98155%2C%20-71.933334%5D%5D%5D%2C%20%5B%5B%5B-68.451346%2C%20-70.955823%5D%2C%20%5B-68.333834%2C%20-71.406493%5D%2C%20%5B-68.510128%2C%20-71.798407%5D%2C%20%5B-68.784297%2C%20-72.170736%5D%2C%20%5B-69.959471%2C%20-72.307885%5D%2C%20%5B-71.075889%2C%20-72.503842%5D%2C%20%5B-72.388134%2C%20-72.484257%5D%2C%20%5B-71.8985%2C%20-72.092343%5D%2C%20%5B-73.073622%2C%20-72.229492%5D%2C%20%5B-74.19004%2C%20-72.366693%5D%2C%20%5B-74.953895%2C%20-72.072757%5D%2C%20%5B-75.012625%2C%20-71.661258%5D%2C%20%5B-73.915819%2C%20-71.269345%5D%2C%20%5B-73.915819%2C%20-71.269344%5D%2C%20%5B-73.230331%2C%20-71.15178%5D%2C%20%5B-72.074717%2C%20-71.190951%5D%2C%20%5B-71.780962%2C%20-70.681473%5D%2C%20%5B-71.72218%2C%20-70.309196%5D%2C%20%5B-71.741791%2C%20-69.505782%5D%2C%20%5B-71.173815%2C%20-69.035475%5D%2C%20%5B-70.253252%2C%20-68.87874%5D%2C%20%5B-69.724447%2C%20-69.251017%5D%2C%20%5B-69.489422%2C%20-69.623346%5D%2C%20%5B-69.058518%2C%20-70.074016%5D%2C%20%5B-68.725541%2C%20-70.505153%5D%2C%20%5B-68.451346%2C%20-70.955823%5D%5D%5D%2C%20%5B%5B%5B-58.614143%2C%20-64.152467%5D%2C%20%5B-59.045073%2C%20-64.36801%5D%2C%20%5B-59.789342%2C%20-64.211223%5D%2C%20%5B-60.611928%2C%20-64.309202%5D%2C%20%5B-61.297416%2C%20-64.54433%5D%2C%20%5B-62.0221%2C%20-64.799094%5D%2C%20%5B-62.51176%2C%20-65.09303%5D%2C%20%5B-62.648858%2C%20-65.484942%5D%2C%20%5B-62.590128%2C%20-65.857219%5D%2C%20%5B-62.120079%2C%20-66.190326%5D%2C%20%5B-62.805567%2C%20-66.425505%5D%2C%20%5B-63.74569%2C%20-66.503847%5D%2C%20%5B-64.294106%2C%20-66.837004%5D%2C%20%5B-64.881693%2C%20-67.150474%5D%2C%20%5B-65.508425%2C%20-67.58161%5D%2C%20%5B-65.665082%2C%20-67.953887%5D%2C%20%5B-65.312545%2C%20-68.365335%5D%2C%20%5B-64.783715%2C%20-68.678908%5D%2C%20%5B-63.961103%2C%20-68.913984%5D%2C%20%5B-63.1973%2C%20-69.227556%5D%2C%20%5B-62.785955%2C%20-69.619419%5D%2C%20%5B-62.570516%2C%20-69.991747%5D%2C%20%5B-62.276736%2C%20-70.383661%5D%2C%20%5B-61.806661%2C%20-70.716768%5D%2C%20%5B-61.512906%2C%20-71.089045%5D%2C%20%5B-61.375809%2C%20-72.010074%5D%2C%20%5B-61.081977%2C%20-72.382351%5D%2C%20%5B-61.003661%2C%20-72.774265%5D%2C%20%5B-60.690269%2C%20-73.166179%5D%2C%20%5B-60.827367%2C%20-73.695242%5D%2C%20%5B-61.375809%2C%20-74.106742%5D%2C%20%5B-61.96337%2C%20-74.439848%5D%2C%20%5B-63.295201%2C%20-74.576997%5D%2C%20%5B-63.74569%2C%20-74.92974%5D%2C%20%5B-64.352836%2C%20-75.262847%5D%2C%20%5B-65.860987%2C%20-75.635124%5D%2C%20%5B-67.192818%2C%20-75.79191%5D%2C%20%5B-68.446282%2C%20-76.007452%5D%2C%20%5B-69.797724%2C%20-76.222995%5D%2C%20%5B-70.600724%2C%20-76.634494%5D%2C%20%5B-72.206776%2C%20-76.673665%5D%2C%20%5B-73.969536%2C%20-76.634494%5D%2C%20%5B-75.555977%2C%20-76.712887%5D%2C%20%5B-77.24037%2C%20-76.712887%5D%2C%20%5B-76.926979%2C%20-77.104802%5D%2C%20%5B-75.399294%2C%20-77.28107%5D%2C%20%5B-74.282876%2C%20-77.55542%5D%2C%20%5B-73.656119%2C%20-77.908112%5D%2C%20%5B-74.772536%2C%20-78.221633%5D%2C%20%5B-76.4961%2C%20-78.123654%5D%2C%20%5B-77.925858%2C%20-78.378419%5D%2C%20%5B-77.984666%2C%20-78.789918%5D%2C%20%5B-78.023785%2C%20-79.181833%5D%2C%20%5B-76.848637%2C%20-79.514939%5D%2C%20%5B-76.633224%2C%20-79.887216%5D%2C%20%5B-75.360097%2C%20-80.259545%5D%2C%20%5B-73.244852%2C%20-80.416331%5D%2C%20%5B-71.442946%2C%20-80.69063%5D%2C%20%5B-70.013163%2C%20-81.004151%5D%2C%20%5B-68.191646%2C%20-81.317672%5D%2C%20%5B-65.704279%2C%20-81.474458%5D%2C%20%5B-63.25603%2C%20-81.748757%5D%2C%20%5B-61.552026%2C%20-82.042692%5D%2C%20%5B-59.691416%2C%20-82.37585%5D%2C%20%5B-58.712121%2C%20-82.846106%5D%2C%20%5B-58.222487%2C%20-83.218434%5D%2C%20%5B-57.008117%2C%20-82.865691%5D%2C%20%5B-55.362894%2C%20-82.571755%5D%2C%20%5B-53.619771%2C%20-82.258235%5D%2C%20%5B-51.543644%2C%20-82.003521%5D%2C%20%5B-49.76135%2C%20-81.729171%5D%2C%20%5B-47.273931%2C%20-81.709586%5D%2C%20%5B-44.825708%2C%20-81.846735%5D%2C%20%5B-42.808363%2C%20-82.081915%5D%2C%20%5B-42.16202%2C%20-81.65083%5D%2C%20%5B-40.771433%2C%20-81.356894%5D%2C%20%5B-38.244818%2C%20-81.337309%5D%2C%20%5B-36.26667%2C%20-81.121715%5D%2C%20%5B-34.386397%2C%20-80.906172%5D%2C%20%5B-32.310296%2C%20-80.769023%5D%2C%20%5B-30.097098%2C%20-80.592651%5D%2C%20%5B-28.549802%2C%20-80.337938%5D%2C%20%5B-29.254901%2C%20-79.985195%5D%2C%20%5B-29.685805%2C%20-79.632503%5D%2C%20%5B-29.685805%2C%20-79.260226%5D%2C%20%5B-31.624808%2C%20-79.299397%5D%2C%20%5B-33.681324%2C%20-79.456132%5D%2C%20%5B-35.639912%2C%20-79.456132%5D%2C%20%5B-35.914107%2C%20-79.083855%5D%2C%20%5B-35.77701%2C%20-78.339248%5D%2C%20%5B-35.326546%2C%20-78.123654%5D%2C%20%5B-33.896763%2C%20-77.888526%5D%2C%20%5B-32.212369%2C%20-77.65345%5D%2C%20%5B-30.998051%2C%20-77.359515%5D%2C%20%5B-29.783732%2C%20-77.065579%5D%2C%20%5B-28.882779%2C%20-76.673665%5D%2C%20%5B-27.511752%2C%20-76.497345%5D%2C%20%5B-26.160336%2C%20-76.360144%5D%2C%20%5B-25.474822%2C%20-76.281803%5D%2C%20%5B-23.927552%2C%20-76.24258%5D%2C%20%5B-22.458598%2C%20-76.105431%5D%2C%20%5B-21.224694%2C%20-75.909474%5D%2C%20%5B-20.010375%2C%20-75.674346%5D%2C%20%5B-18.913543%2C%20-75.439218%5D%2C%20%5B-17.522982%2C%20-75.125698%5D%2C%20%5B-16.641589%2C%20-74.79254%5D%2C%20%5B-15.701491%2C%20-74.498604%5D%2C%20%5B-15.40771%2C%20-74.106742%5D%2C%20%5B-16.46532%2C%20-73.871614%5D%2C%20%5B-16.112784%2C%20-73.460114%5D%2C%20%5B-15.446855%2C%20-73.146542%5D%2C%20%5B-14.408805%2C%20-72.950585%5D%2C%20%5B-13.311973%2C%20-72.715457%5D%2C%20%5B-12.293508%2C%20-72.401936%5D%2C%20%5B-11.510067%2C%20-72.010074%5D%2C%20%5B-11.020433%2C%20-71.539767%5D%2C%20%5B-10.295774%2C%20-71.265416%5D%2C%20%5B-9.101015%2C%20-71.324224%5D%2C%20%5B-8.611381%2C%20-71.65733%5D%2C%20%5B-7.416622%2C%20-71.696501%5D%2C%20%5B-7.377451%2C%20-71.324224%5D%2C%20%5B-6.868232%2C%20-70.93231%5D%2C%20%5B-5.790985%2C%20-71.030289%5D%2C%20%5B-5.536375%2C%20-71.402617%5D%2C%20%5B-4.341667%2C%20-71.461373%5D%2C%20%5B-3.048981%2C%20-71.285053%5D%2C%20%5B-1.795492%2C%20-71.167438%5D%2C%20%5B-0.659489%2C%20-71.226246%5D%2C%20%5B-0.228637%2C%20-71.637745%5D%2C%20%5B0.868195%2C%20-71.304639%5D%2C%20%5B1.886686%2C%20-71.128267%5D%2C%20%5B3.022638%2C%20-70.991118%5D%2C%20%5B4.139055%2C%20-70.853917%5D%2C%20%5B5.157546%2C%20-70.618789%5D%2C%20%5B6.273912%2C%20-70.462055%5D%2C%20%5B7.13572%2C%20-70.246512%5D%2C%20%5B7.742866%2C%20-69.893769%5D%2C%20%5B8.48711%2C%20-70.148534%5D%2C%20%5B9.525135%2C%20-70.011333%5D%2C%20%5B10.249845%2C%20-70.48164%5D%2C%20%5B10.817821%2C%20-70.834332%5D%2C%20%5B11.953824%2C%20-70.638375%5D%2C%20%5B12.404287%2C%20-70.246512%5D%2C%20%5B13.422778%2C%20-69.972162%5D%2C%20%5B14.734998%2C%20-70.030918%5D%2C%20%5B15.126757%2C%20-70.403247%5D%2C%20%5B15.949342%2C%20-70.030918%5D%2C%20%5B17.026589%2C%20-69.913354%5D%2C%20%5B18.201711%2C%20-69.874183%5D%2C%20%5B19.259373%2C%20-69.893769%5D%2C%20%5B20.375739%2C%20-70.011333%5D%2C%20%5B21.452985%2C%20-70.07014%5D%2C%20%5B21.923034%2C%20-70.403247%5D%2C%20%5B22.569403%2C%20-70.697182%5D%2C%20%5B23.666184%2C%20-70.520811%5D%2C%20%5B24.841357%2C%20-70.48164%5D%2C%20%5B25.977309%2C%20-70.48164%5D%2C%20%5B27.093726%2C%20-70.462055%5D%2C%20%5B28.09258%2C%20-70.324854%5D%2C%20%5B29.150242%2C%20-70.20729%5D%2C%20%5B30.031583%2C%20-69.93294%5D%2C%20%5B30.971733%2C%20-69.75662%5D%2C%20%5B31.990172%2C%20-69.658641%5D%2C%20%5B32.754053%2C%20-69.384291%5D%2C%20%5B33.302443%2C%20-68.835642%5D%2C%20%5B33.870419%2C%20-68.502588%5D%2C%20%5B34.908495%2C%20-68.659271%5D%2C%20%5B35.300202%2C%20-69.012014%5D%2C%20%5B36.16201%2C%20-69.247142%5D%2C%20%5B37.200035%2C%20-69.168748%5D%2C%20%5B37.905108%2C%20-69.52144%5D%2C%20%5B38.649404%2C%20-69.776205%5D%2C%20%5B39.667894%2C%20-69.541077%5D%2C%20%5B40.020431%2C%20-69.109941%5D%2C%20%5B40.921358%2C%20-68.933621%5D%2C%20%5B41.959434%2C%20-68.600514%5D%2C%20%5B42.938702%2C%20-68.463313%5D%2C%20%5B44.113876%2C%20-68.267408%5D%2C%20%5B44.897291%2C%20-68.051866%5D%2C%20%5B45.719928%2C%20-67.816738%5D%2C%20%5B46.503343%2C%20-67.601196%5D%2C%20%5B47.44344%2C%20-67.718759%5D%2C%20%5B48.344419%2C%20-67.366068%5D%2C%20%5B48.990736%2C%20-67.091718%5D%2C%20%5B49.930885%2C%20-67.111303%5D%2C%20%5B50.753471%2C%20-66.876175%5D%2C%20%5B50.949325%2C%20-66.523484%5D%2C%20%5B51.791547%2C%20-66.249133%5D%2C%20%5B52.614133%2C%20-66.053176%5D%2C%20%5B53.613038%2C%20-65.89639%5D%2C%20%5B54.53355%2C%20-65.818049%5D%2C%20%5B55.414943%2C%20-65.876805%5D%2C%20%5B56.355041%2C%20-65.974783%5D%2C%20%5B57.158093%2C%20-66.249133%5D%2C%20%5B57.255968%2C%20-66.680218%5D%2C%20%5B58.137361%2C%20-67.013324%5D%2C%20%5B58.744508%2C%20-67.287675%5D%2C%20%5B59.939318%2C%20-67.405239%5D%2C%20%5B60.605221%2C%20-67.679589%5D%2C%20%5B61.427806%2C%20-67.953887%5D%2C%20%5B62.387489%2C%20-68.012695%5D%2C%20%5B63.19049%2C%20-67.816738%5D%2C%20%5B64.052349%2C%20-67.405239%5D%2C%20%5B64.992447%2C%20-67.620729%5D%2C%20%5B65.971715%2C%20-67.738345%5D%2C%20%5B66.911864%2C%20-67.855909%5D%2C%20%5B67.891133%2C%20-67.934302%5D%2C%20%5B68.890038%2C%20-67.934302%5D%2C%20%5B69.712624%2C%20-68.972791%5D%2C%20%5B69.673453%2C%20-69.227556%5D%2C%20%5B69.555941%2C%20-69.678226%5D%2C%20%5B68.596258%2C%20-69.93294%5D%2C%20%5B67.81274%2C%20-70.305268%5D%2C%20%5B67.949889%2C%20-70.697182%5D%2C%20%5B69.066307%2C%20-70.677545%5D%2C%20%5B68.929157%2C%20-71.069459%5D%2C%20%5B68.419989%2C%20-71.441788%5D%2C%20%5B67.949889%2C%20-71.853287%5D%2C%20%5B68.71377%2C%20-72.166808%5D%2C%20%5B69.869307%2C%20-72.264787%5D%2C%20%5B71.024895%2C%20-72.088415%5D%2C%20%5B71.573285%2C%20-71.696501%5D%2C%20%5B71.906288%2C%20-71.324224%5D%2C%20%5B72.454627%2C%20-71.010703%5D%2C%20%5B73.08141%2C%20-70.716768%5D%2C%20%5B73.33602%2C%20-70.364024%5D%2C%20%5B73.864877%2C%20-69.874183%5D%2C%20%5B74.491557%2C%20-69.776205%5D%2C%20%5B75.62756%2C%20-69.737034%5D%2C%20%5B76.626465%2C%20-69.619419%5D%2C%20%5B77.644904%2C%20-69.462684%5D%2C%20%5B78.134539%2C%20-69.07077%5D%2C%20%5B78.428371%2C%20-68.698441%5D%2C%20%5B79.113859%2C%20-68.326216%5D%2C%20%5B80.093127%2C%20-68.071503%5D%2C%20%5B80.93535%2C%20-67.875546%5D%2C%20%5B81.483792%2C%20-67.542388%5D%2C%20%5B82.051767%2C%20-67.366068%5D%2C%20%5B82.776426%2C%20-67.209282%5D%2C%20%5B83.775331%2C%20-67.30726%5D%2C%20%5B84.676206%2C%20-67.209282%5D%2C%20%5B85.655527%2C%20-67.091718%5D%2C%20%5B86.752359%2C%20-67.150474%5D%2C%20%5B87.477017%2C%20-66.876175%5D%2C%20%5B87.986289%2C%20-66.209911%5D%2C%20%5B88.358411%2C%20-66.484261%5D%2C%20%5B88.828408%2C%20-66.954568%5D%2C%20%5B89.67063%2C%20-67.150474%5D%2C%20%5B90.630365%2C%20-67.228867%5D%2C%20%5B91.5901%2C%20-67.111303%5D%2C%20%5B92.608539%2C%20-67.189696%5D%2C%20%5B93.548637%2C%20-67.209282%5D%2C%20%5B94.17542%2C%20-67.111303%5D%2C%20%5B95.017591%2C%20-67.170111%5D%2C%20%5B95.781472%2C%20-67.385653%5D%2C%20%5B96.682399%2C%20-67.248504%5D%2C%20%5B97.759646%2C%20-67.248504%5D%2C%20%5B98.68021%2C%20-67.111303%5D%2C%20%5B99.718182%2C%20-67.248504%5D%2C%20%5B100.384188%2C%20-66.915346%5D%2C%20%5B100.893356%2C%20-66.58224%5D%2C%20%5B101.578896%2C%20-66.30789%5D%2C%20%5B102.832411%2C%20-65.563284%5D%2C%20%5B103.478676%2C%20-65.700485%5D%2C%20%5B104.242557%2C%20-65.974783%5D%2C%20%5B104.90846%2C%20-66.327527%5D%2C%20%5B106.181561%2C%20-66.934931%5D%2C%20%5B107.160881%2C%20-66.954568%5D%2C%20%5B108.081393%2C%20-66.954568%5D%2C%20%5B109.15864%2C%20-66.837004%5D%2C%20%5B110.235835%2C%20-66.699804%5D%2C%20%5B111.058472%2C%20-66.425505%5D%2C%20%5B111.74396%2C%20-66.13157%5D%2C%20%5B112.860378%2C%20-66.092347%5D%2C%20%5B113.604673%2C%20-65.876805%5D%2C%20%5B114.388088%2C%20-66.072762%5D%2C%20%5B114.897308%2C%20-66.386283%5D%2C%20%5B115.602381%2C%20-66.699804%5D%2C%20%5B116.699161%2C%20-66.660633%5D%2C%20%5B117.384701%2C%20-66.915346%5D%2C%20%5B118.57946%2C%20-67.170111%5D%2C%20%5B119.832924%2C%20-67.268089%5D%2C%20%5B120.871%2C%20-67.189696%5D%2C%20%5B121.654415%2C%20-66.876175%5D%2C%20%5B122.320369%2C%20-66.562654%5D%2C%20%5B123.221296%2C%20-66.484261%5D%2C%20%5B124.122274%2C%20-66.621462%5D%2C%20%5B125.160247%2C%20-66.719389%5D%2C%20%5B126.100396%2C%20-66.562654%5D%2C%20%5B127.001427%2C%20-66.562654%5D%2C%20%5B127.882768%2C%20-66.660633%5D%2C%20%5B128.80328%2C%20-66.758611%5D%2C%20%5B129.704259%2C%20-66.58224%5D%2C%20%5B130.781454%2C%20-66.425505%5D%2C%20%5B131.799945%2C%20-66.386283%5D%2C%20%5B132.935896%2C%20-66.386283%5D%2C%20%5B133.85646%2C%20-66.288304%5D%2C%20%5B134.757387%2C%20-66.209963%5D%2C%20%5B135.031582%2C%20-65.72007%5D%2C%20%5B135.070753%2C%20-65.308571%5D%2C%20%5B135.697485%2C%20-65.582869%5D%2C%20%5B135.873805%2C%20-66.033591%5D%2C%20%5B136.206705%2C%20-66.44509%5D%2C%20%5B136.618049%2C%20-66.778197%5D%2C%20%5B137.460271%2C%20-66.954568%5D%2C%20%5B138.596223%2C%20-66.895761%5D%2C%20%5B139.908442%2C%20-66.876175%5D%2C%20%5B140.809421%2C%20-66.817367%5D%2C%20%5B142.121692%2C%20-66.817367%5D%2C%20%5B143.061842%2C%20-66.797782%5D%2C%20%5B144.374061%2C%20-66.837004%5D%2C%20%5B145.490427%2C%20-66.915346%5D%2C%20%5B146.195552%2C%20-67.228867%5D%2C%20%5B145.999699%2C%20-67.601196%5D%2C%20%5B146.646067%2C%20-67.895131%5D%2C%20%5B147.723263%2C%20-68.130259%5D%2C%20%5B148.839629%2C%20-68.385024%5D%2C%20%5B150.132314%2C%20-68.561292%5D%2C%20%5B151.483705%2C%20-68.71813%5D%2C%20%5B152.502247%2C%20-68.874813%5D%2C%20%5B153.638199%2C%20-68.894502%5D%2C%20%5B154.284567%2C%20-68.561292%5D%2C%20%5B155.165857%2C%20-68.835642%5D%2C%20%5B155.92979%2C%20-69.149215%5D%2C%20%5B156.811132%2C%20-69.384291%5D%2C%20%5B158.025528%2C%20-69.482269%5D%2C%20%5B159.181013%2C%20-69.599833%5D%2C%20%5B159.670699%2C%20-69.991747%5D%2C%20%5B160.80665%2C%20-70.226875%5D%2C%20%5B161.570479%2C%20-70.579618%5D%2C%20%5B162.686897%2C%20-70.736353%5D%2C%20%5B163.842434%2C%20-70.716768%5D%2C%20%5B164.919681%2C%20-70.775524%5D%2C%20%5B166.11444%2C%20-70.755938%5D%2C%20%5B167.309095%2C%20-70.834332%5D%2C%20%5B168.425616%2C%20-70.971481%5D%2C%20%5B169.463589%2C%20-71.20666%5D%2C%20%5B170.501665%2C%20-71.402617%5D%2C%20%5B171.20679%2C%20-71.696501%5D%2C%20%5B171.089227%2C%20-72.088415%5D%2C%20%5B170.560422%2C%20-72.441159%5D%2C%20%5B170.109958%2C%20-72.891829%5D%2C%20%5B169.75737%2C%20-73.24452%5D%2C%20%5B169.287321%2C%20-73.65602%5D%2C%20%5B167.975101%2C%20-73.812806%5D%2C%20%5B167.387489%2C%20-74.165498%5D%2C%20%5B166.094803%2C%20-74.38104%5D%2C%20%5B165.644391%2C%20-74.772954%5D%2C%20%5B164.958851%2C%20-75.145283%5D%2C%20%5B164.234193%2C%20-75.458804%5D%2C%20%5B163.822797%2C%20-75.870303%5D%2C%20%5B163.568239%2C%20-76.24258%5D%2C%20%5B163.47026%2C%20-76.693302%5D%2C%20%5B163.489897%2C%20-77.065579%5D%2C%20%5B164.057873%2C%20-77.457442%5D%2C%20%5B164.273363%2C%20-77.82977%5D%2C%20%5B164.743464%2C%20-78.182514%5D%2C%20%5B166.604126%2C%20-78.319611%5D%2C%20%5B166.995781%2C%20-78.750748%5D%2C%20%5B165.193876%2C%20-78.907483%5D%2C%20%5B163.666217%2C%20-79.123025%5D%2C%20%5B161.766385%2C%20-79.162248%5D%2C%20%5B160.924162%2C%20-79.730482%5D%2C%20%5B160.747894%2C%20-80.200737%5D%2C%20%5B160.316964%2C%20-80.573066%5D%2C%20%5B159.788211%2C%20-80.945395%5D%2C%20%5B161.120016%2C%20-81.278501%5D%2C%20%5B161.629287%2C%20-81.690001%5D%2C%20%5B162.490992%2C%20-82.062278%5D%2C%20%5B163.705336%2C%20-82.395435%5D%2C%20%5B165.095949%2C%20-82.708956%5D%2C%20%5B166.604126%2C%20-83.022477%5D%2C%20%5B168.895665%2C%20-83.335998%5D%2C%20%5B169.404782%2C%20-83.825891%5D%2C%20%5B172.283934%2C%20-84.041433%5D%2C%20%5B172.477049%2C%20-84.117914%5D%2C%20%5B173.224083%2C%20-84.41371%5D%2C%20%5B175.985672%2C%20-84.158997%5D%2C%20%5B178.277212%2C%20-84.472518%5D%2C%20%5B180%2C%20-84.71338%5D%2C%20%5B-179.942499%2C%20-84.721443%5D%2C%20%5B-179.058677%2C%20-84.139412%5D%2C%20%5B-177.256772%2C%20-84.452933%5D%2C%20%5B-177.140807%2C%20-84.417941%5D%2C%20%5B-176.084673%2C%20-84.099259%5D%2C%20%5B-175.947235%2C%20-84.110449%5D%2C%20%5B-175.829882%2C%20-84.117914%5D%2C%20%5B-174.382503%2C%20-84.534323%5D%2C%20%5B-173.116559%2C%20-84.117914%5D%2C%20%5B-172.889106%2C%20-84.061019%5D%2C%20%5B-169.951223%2C%20-83.884647%5D%2C%20%5B-168.999989%2C%20-84.117914%5D%2C%20%5B-168.530199%2C%20-84.23739%5D%2C%20%5B-167.022099%2C%20-84.570497%5D%2C%20%5B-164.182144%2C%20-84.82521%5D%2C%20%5B-161.929775%2C%20-85.138731%5D%2C%20%5B-158.07138%2C%20-85.37391%5D%2C%20%5B-155.192253%2C%20-85.09956%5D%2C%20%5B-150.942099%2C%20-85.295517%5D%2C%20%5B-148.533073%2C%20-85.609038%5D%2C%20%5B-145.888918%2C%20-85.315102%5D%2C%20%5B-143.107718%2C%20-85.040752%5D%2C%20%5B-142.892279%2C%20-84.570497%5D%2C%20%5B-146.829068%2C%20-84.531274%5D%2C%20%5B-150.060732%2C%20-84.296146%5D%2C%20%5B-150.902928%2C%20-83.904232%5D%2C%20%5B-153.586201%2C%20-83.68869%5D%2C%20%5B-153.409907%2C%20-83.23802%5D%2C%20%5B-153.037759%2C%20-82.82652%5D%2C%20%5B-152.665637%2C%20-82.454192%5D%2C%20%5B-152.861517%2C%20-82.042692%5D%2C%20%5B-154.526299%2C%20-81.768394%5D%2C%20%5B-155.29018%2C%20-81.41565%5D%2C%20%5B-156.83745%2C%20-81.102129%5D%2C%20%5B-154.408787%2C%20-81.160937%5D%2C%20%5B-152.097662%2C%20-81.004151%5D%2C%20%5B-150.648293%2C%20-81.337309%5D%2C%20%5B-148.865998%2C%20-81.043373%5D%2C%20%5B-147.22075%2C%20-80.671045%5D%2C%20%5B-146.417749%2C%20-80.337938%5D%2C%20%5B-146.770286%2C%20-79.926439%5D%2C%20%5B-148.062947%2C%20-79.652089%5D%2C%20%5B-149.531901%2C%20-79.358205%5D%2C%20%5B-151.588416%2C%20-79.299397%5D%2C%20%5B-153.390322%2C%20-79.162248%5D%2C%20%5B-155.329376%2C%20-79.064269%5D%2C%20%5B-155.975668%2C%20-78.69194%5D%2C%20%5B-157.268302%2C%20-78.378419%5D%2C%20%5B-158.051768%2C%20-78.025676%5D%2C%20%5B-158.365134%2C%20-76.889207%5D%2C%20%5B-157.875474%2C%20-76.987238%5D%2C%20%5B-156.974573%2C%20-77.300759%5D%2C%20%5B-155.329376%2C%20-77.202728%5D%2C%20%5B-153.742832%2C%20-77.065579%5D%2C%20%5B-152.920247%2C%20-77.496664%5D%2C%20%5B-151.33378%2C%20-77.398737%5D%2C%20%5B-150.00195%2C%20-77.183143%5D%2C%20%5B-148.748486%2C%20-76.908845%5D%2C%20%5B-147.612483%2C%20-76.575738%5D%2C%20%5B-146.104409%2C%20-76.47776%5D%2C%20%5B-146.143528%2C%20-76.105431%5D%2C%20%5B-146.496091%2C%20-75.733154%5D%2C%20%5B-146.20231%2C%20-75.380411%5D%2C%20%5B-144.909624%2C%20-75.204039%5D%2C%20%5B-144.322037%2C%20-75.537197%5D%2C%20%5B-142.794353%2C%20-75.34124%5D%2C%20%5B-141.638764%2C%20-75.086475%5D%2C%20%5B-140.209007%2C%20-75.06689%5D%2C%20%5B-138.85759%2C%20-74.968911%5D%2C%20%5B-137.5062%2C%20-74.733783%5D%2C%20%5B-136.428901%2C%20-74.518241%5D%2C%20%5B-135.214583%2C%20-74.302699%5D%2C%20%5B-134.431194%2C%20-74.361455%5D%2C%20%5B-133.745654%2C%20-74.439848%5D%2C%20%5B-132.257168%2C%20-74.302699%5D%2C%20%5B-130.925311%2C%20-74.479019%5D%2C%20%5B-129.554284%2C%20-74.459433%5D%2C%20%5B-128.242038%2C%20-74.322284%5D%2C%20%5B-126.890622%2C%20-74.420263%5D%2C%20%5B-125.402082%2C%20-74.518241%5D%2C%20%5B-124.011496%2C%20-74.479019%5D%2C%20%5B-122.562152%2C%20-74.498604%5D%2C%20%5B-121.073613%2C%20-74.518241%5D%2C%20%5B-119.70256%2C%20-74.479019%5D%2C%20%5B-118.684145%2C%20-74.185083%5D%2C%20%5B-117.469801%2C%20-74.028348%5D%2C%20%5B-116.216312%2C%20-74.243891%5D%2C%20%5B-115.021552%2C%20-74.067519%5D%2C%20%5B-113.944331%2C%20-73.714828%5D%2C%20%5B-113.297988%2C%20-74.028348%5D%2C%20%5B-112.945452%2C%20-74.38104%5D%2C%20%5B-112.299083%2C%20-74.714198%5D%2C%20%5B-111.261059%2C%20-74.420263%5D%2C%20%5B-110.066325%2C%20-74.79254%5D%2C%20%5B-108.714909%2C%20-74.910103%5D%2C%20%5B-107.559346%2C%20-75.184454%5D%2C%20%5B-106.149148%2C%20-75.125698%5D%2C%20%5B-104.876074%2C%20-74.949326%5D%2C%20%5B-103.367949%2C%20-74.988497%5D%2C%20%5B-102.016507%2C%20-75.125698%5D%2C%20%5B-100.645531%2C%20-75.302018%5D%2C%20%5B-100.1167%2C%20-74.870933%5D%2C%20%5B-100.763043%2C%20-74.537826%5D%2C%20%5B-101.252703%2C%20-74.185083%5D%2C%20%5B-102.545337%2C%20-74.106742%5D%2C%20%5B-103.113313%2C%20-73.734413%5D%2C%20%5B-103.328752%2C%20-73.362084%5D%2C%20%5B-103.681289%2C%20-72.61753%5D%2C%20%5B-102.917485%2C%20-72.754679%5D%2C%20%5B-101.60524%2C%20-72.813436%5D%2C%20%5B-100.312528%2C%20-72.754679%5D%2C%20%5B-99.13738%2C%20-72.911414%5D%2C%20%5B-98.118889%2C%20-73.20535%5D%2C%20%5B-97.688037%2C%20-73.558041%5D%2C%20%5B-96.336595%2C%20-73.616849%5D%2C%20%5B-95.043961%2C%20-73.4797%5D%2C%20%5B-93.672907%2C%20-73.283743%5D%2C%20%5B-92.439003%2C%20-73.166179%5D%2C%20%5B-91.420564%2C%20-73.401307%5D%2C%20%5B-90.088733%2C%20-73.322914%5D%2C%20%5B-89.226951%2C%20-72.558722%5D%2C%20%5B-88.423951%2C%20-73.009393%5D%2C%20%5B-87.268337%2C%20-73.185764%5D%2C%20%5B-86.014822%2C%20-73.087786%5D%2C%20%5B-85.192236%2C%20-73.4797%5D%2C%20%5B-83.879991%2C%20-73.518871%5D%2C%20%5B-82.665646%2C%20-73.636434%5D%2C%20%5B-81.470913%2C%20-73.851977%5D%2C%20%5B-80.687447%2C%20-73.4797%5D%2C%20%5B-80.295791%2C%20-73.126956%5D%2C%20%5B-79.296886%2C%20-73.518871%5D%2C%20%5B-77.925858%2C%20-73.420892%5D%2C%20%5B-76.907367%2C%20-73.636434%5D%2C%20%5B-76.221879%2C%20-73.969541%5D%2C%20%5B-74.890049%2C%20-73.871614%5D%2C%20%5B-73.852024%2C%20-73.65602%5D%2C%20%5B-72.833533%2C%20-73.401307%5D%2C%20%5B-71.619215%2C%20-73.264157%5D%2C%20%5B-70.209042%2C%20-73.146542%5D%2C%20%5B-68.935916%2C%20-73.009393%5D%2C%20%5B-67.956622%2C%20-72.79385%5D%2C%20%5B-67.369061%2C%20-72.480329%5D%2C%20%5B-67.134036%2C%20-72.049244%5D%2C%20%5B-67.251548%2C%20-71.637745%5D%2C%20%5B-67.56494%2C%20-71.245831%5D%2C%20%5B-67.917477%2C%20-70.853917%5D%2C%20%5B-68.230843%2C%20-70.462055%5D%2C%20%5B-68.485452%2C%20-70.109311%5D%2C%20%5B-68.544209%2C%20-69.717397%5D%2C%20%5B-68.446282%2C%20-69.325535%5D%2C%20%5B-67.976233%2C%20-68.953206%5D%2C%20%5B-67.5845%2C%20-68.541707%5D%2C%20%5B-67.427843%2C%20-68.149844%5D%2C%20%5B-67.62367%2C%20-67.718759%5D%2C%20%5B-67.741183%2C%20-67.326845%5D%2C%20%5B-67.251548%2C%20-66.876175%5D%2C%20%5B-66.703184%2C%20-66.58224%5D%2C%20%5B-66.056815%2C%20-66.209963%5D%2C%20%5B-65.371327%2C%20-65.89639%5D%2C%20%5B-64.568276%2C%20-65.602506%5D%2C%20%5B-64.176542%2C%20-65.171423%5D%2C%20%5B-63.628152%2C%20-64.897073%5D%2C%20%5B-63.001394%2C%20-64.642308%5D%2C%20%5B-62.041686%2C%20-64.583552%5D%2C%20%5B-61.414928%2C%20-64.270031%5D%2C%20%5B-60.709855%2C%20-64.074074%5D%2C%20%5B-59.887269%2C%20-63.95651%5D%2C%20%5B-59.162585%2C%20-63.701745%5D%2C%20%5B-58.594557%2C%20-63.388224%5D%2C%20%5B-57.811143%2C%20-63.27066%5D%2C%20%5B-57.223582%2C%20-63.525425%5D%2C%20%5B-57.59573%2C%20-63.858532%5D%2C%20%5B-58.614143%2C%20-64.152467%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22ATA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Antarctica%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B68.935%2C%20-48.625%5D%2C%20%5B69.58%2C%20-48.94%5D%2C%20%5B70.525%2C%20-49.065%5D%2C%20%5B70.56%2C%20-49.255%5D%2C%20%5B70.28%2C%20-49.71%5D%2C%20%5B68.745%2C%20-49.775%5D%2C%20%5B68.72%2C%20-49.2425%5D%2C%20%5B68.8675%2C%20-48.83%5D%2C%20%5B68.935%2C%20-48.625%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ATF%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22French%20Southern%20and%20Antarctic%20Lands%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B145.397978%2C%20-40.792549%5D%2C%20%5B146.364121%2C%20-41.137695%5D%2C%20%5B146.908584%2C%20-41.000546%5D%2C%20%5B147.689259%2C%20-40.808258%5D%2C%20%5B148.289068%2C%20-40.875438%5D%2C%20%5B148.359865%2C%20-42.062445%5D%2C%20%5B148.017301%2C%20-42.407024%5D%2C%20%5B147.914052%2C%20-43.211522%5D%2C%20%5B147.564564%2C%20-42.937689%5D%2C%20%5B146.870343%2C%20-43.634597%5D%2C%20%5B146.663327%2C%20-43.580854%5D%2C%20%5B146.048378%2C%20-43.549745%5D%2C%20%5B145.43193%2C%20-42.693776%5D%2C%20%5B145.29509%2C%20-42.03361%5D%2C%20%5B144.718071%2C%20-41.162552%5D%2C%20%5B144.743755%2C%20-40.703975%5D%2C%20%5B145.397978%2C%20-40.792549%5D%5D%5D%2C%20%5B%5B%5B143.561811%2C%20-13.763656%5D%2C%20%5B143.922099%2C%20-14.548311%5D%2C%20%5B144.563714%2C%20-14.171176%5D%2C%20%5B144.894908%2C%20-14.594458%5D%2C%20%5B145.374724%2C%20-14.984976%5D%2C%20%5B145.271991%2C%20-15.428205%5D%2C%20%5B145.48526%2C%20-16.285672%5D%2C%20%5B145.637033%2C%20-16.784918%5D%2C%20%5B145.888904%2C%20-16.906926%5D%2C%20%5B146.160309%2C%20-17.761655%5D%2C%20%5B146.063674%2C%20-18.280073%5D%2C%20%5B146.387478%2C%20-18.958274%5D%2C%20%5B147.471082%2C%20-19.480723%5D%2C%20%5B148.177602%2C%20-19.955939%5D%2C%20%5B148.848414%2C%20-20.39121%5D%2C%20%5B148.717465%2C%20-20.633469%5D%2C%20%5B149.28942%2C%20-21.260511%5D%2C%20%5B149.678337%2C%20-22.342512%5D%2C%20%5B150.077382%2C%20-22.122784%5D%2C%20%5B150.482939%2C%20-22.556142%5D%2C%20%5B150.727265%2C%20-22.402405%5D%2C%20%5B150.899554%2C%20-23.462237%5D%2C%20%5B151.609175%2C%20-24.076256%5D%2C%20%5B152.07354%2C%20-24.457887%5D%2C%20%5B152.855197%2C%20-25.267501%5D%2C%20%5B153.136162%2C%20-26.071173%5D%2C%20%5B153.161949%2C%20-26.641319%5D%2C%20%5B153.092909%2C%20-27.2603%5D%2C%20%5B153.569469%2C%20-28.110067%5D%2C%20%5B153.512108%2C%20-28.995077%5D%2C%20%5B153.339095%2C%20-29.458202%5D%2C%20%5B153.069241%2C%20-30.35024%5D%2C%20%5B153.089602%2C%20-30.923642%5D%2C%20%5B152.891578%2C%20-31.640446%5D%2C%20%5B152.450002%2C%20-32.550003%5D%2C%20%5B151.709117%2C%20-33.041342%5D%2C%20%5B151.343972%2C%20-33.816023%5D%2C%20%5B151.010555%2C%20-34.31036%5D%2C%20%5B150.714139%2C%20-35.17346%5D%2C%20%5B150.32822%2C%20-35.671879%5D%2C%20%5B150.075212%2C%20-36.420206%5D%2C%20%5B149.946124%2C%20-37.109052%5D%2C%20%5B149.997284%2C%20-37.425261%5D%2C%20%5B149.423882%2C%20-37.772681%5D%2C%20%5B148.304622%2C%20-37.809061%5D%2C%20%5B147.381733%2C%20-38.219217%5D%2C%20%5B146.922123%2C%20-38.606532%5D%2C%20%5B146.317922%2C%20-39.035757%5D%2C%20%5B145.489652%2C%20-38.593768%5D%2C%20%5B144.876976%2C%20-38.417448%5D%2C%20%5B145.032212%2C%20-37.896188%5D%2C%20%5B144.485682%2C%20-38.085324%5D%2C%20%5B143.609974%2C%20-38.809465%5D%2C%20%5B142.745427%2C%20-38.538268%5D%2C%20%5B142.17833%2C%20-38.380034%5D%2C%20%5B141.606582%2C%20-38.308514%5D%2C%20%5B140.638579%2C%20-38.019333%5D%2C%20%5B139.992158%2C%20-37.402936%5D%2C%20%5B139.806588%2C%20-36.643603%5D%2C%20%5B139.574148%2C%20-36.138362%5D%2C%20%5B139.082808%2C%20-35.732754%5D%2C%20%5B138.120748%2C%20-35.612296%5D%2C%20%5B138.449462%2C%20-35.127261%5D%2C%20%5B138.207564%2C%20-34.384723%5D%2C%20%5B137.71917%2C%20-35.076825%5D%2C%20%5B136.829406%2C%20-35.260535%5D%2C%20%5B137.352371%2C%20-34.707339%5D%2C%20%5B137.503886%2C%20-34.130268%5D%2C%20%5B137.890116%2C%20-33.640479%5D%2C%20%5B137.810328%2C%20-32.900007%5D%2C%20%5B136.996837%2C%20-33.752771%5D%2C%20%5B136.372069%2C%20-34.094766%5D%2C%20%5B135.989043%2C%20-34.890118%5D%2C%20%5B135.208213%2C%20-34.47867%5D%2C%20%5B135.239218%2C%20-33.947953%5D%2C%20%5B134.613417%2C%20-33.222778%5D%2C%20%5B134.085904%2C%20-32.848072%5D%2C%20%5B134.273903%2C%20-32.617234%5D%2C%20%5B132.990777%2C%20-32.011224%5D%2C%20%5B132.288081%2C%20-31.982647%5D%2C%20%5B131.326331%2C%20-31.495803%5D%2C%20%5B129.535794%2C%20-31.590423%5D%2C%20%5B128.240938%2C%20-31.948489%5D%2C%20%5B127.102867%2C%20-32.282267%5D%2C%20%5B126.148714%2C%20-32.215966%5D%2C%20%5B125.088623%2C%20-32.728751%5D%2C%20%5B124.221648%2C%20-32.959487%5D%2C%20%5B124.028947%2C%20-33.483847%5D%2C%20%5B123.659667%2C%20-33.890179%5D%2C%20%5B122.811036%2C%20-33.914467%5D%2C%20%5B122.183064%2C%20-34.003402%5D%2C%20%5B121.299191%2C%20-33.821036%5D%2C%20%5B120.580268%2C%20-33.930177%5D%2C%20%5B119.893695%2C%20-33.976065%5D%2C%20%5B119.298899%2C%20-34.509366%5D%2C%20%5B119.007341%2C%20-34.464149%5D%2C%20%5B118.505718%2C%20-34.746819%5D%2C%20%5B118.024972%2C%20-35.064733%5D%2C%20%5B117.295507%2C%20-35.025459%5D%2C%20%5B116.625109%2C%20-35.025097%5D%2C%20%5B115.564347%2C%20-34.386428%5D%2C%20%5B115.026809%2C%20-34.196517%5D%2C%20%5B115.048616%2C%20-33.623425%5D%2C%20%5B115.545123%2C%20-33.487258%5D%2C%20%5B115.714674%2C%20-33.259572%5D%2C%20%5B115.679379%2C%20-32.900369%5D%2C%20%5B115.801645%2C%20-32.205062%5D%2C%20%5B115.689611%2C%20-31.612437%5D%2C%20%5B115.160909%2C%20-30.601594%5D%2C%20%5B114.997043%2C%20-30.030725%5D%2C%20%5B115.040038%2C%20-29.461095%5D%2C%20%5B114.641974%2C%20-28.810231%5D%2C%20%5B114.616498%2C%20-28.516399%5D%2C%20%5B114.173579%2C%20-28.118077%5D%2C%20%5B114.048884%2C%20-27.334765%5D%2C%20%5B113.477498%2C%20-26.543134%5D%2C%20%5B113.338953%2C%20-26.116545%5D%2C%20%5B113.778358%2C%20-26.549025%5D%2C%20%5B113.440962%2C%20-25.621278%5D%2C%20%5B113.936901%2C%20-25.911235%5D%2C%20%5B114.232852%2C%20-26.298446%5D%2C%20%5B114.216161%2C%20-25.786281%5D%2C%20%5B113.721255%2C%20-24.998939%5D%2C%20%5B113.625344%2C%20-24.683971%5D%2C%20%5B113.393523%2C%20-24.384764%5D%2C%20%5B113.502044%2C%20-23.80635%5D%2C%20%5B113.706993%2C%20-23.560215%5D%2C%20%5B113.843418%2C%20-23.059987%5D%2C%20%5B113.736552%2C%20-22.475475%5D%2C%20%5B114.149756%2C%20-21.755881%5D%2C%20%5B114.225307%2C%20-22.517488%5D%2C%20%5B114.647762%2C%20-21.82952%5D%2C%20%5B115.460167%2C%20-21.495173%5D%2C%20%5B115.947373%2C%20-21.068688%5D%2C%20%5B116.711615%2C%20-20.701682%5D%2C%20%5B117.166316%2C%20-20.623599%5D%2C%20%5B117.441545%2C%20-20.746899%5D%2C%20%5B118.229559%2C%20-20.374208%5D%2C%20%5B118.836085%2C%20-20.263311%5D%2C%20%5B118.987807%2C%20-20.044203%5D%2C%20%5B119.252494%2C%20-19.952942%5D%2C%20%5B119.805225%2C%20-19.976506%5D%2C%20%5B120.85622%2C%20-19.683708%5D%2C%20%5B121.399856%2C%20-19.239756%5D%2C%20%5B121.655138%2C%20-18.705318%5D%2C%20%5B122.241665%2C%20-18.197649%5D%2C%20%5B122.286624%2C%20-17.798603%5D%2C%20%5B122.312772%2C%20-17.254967%5D%2C%20%5B123.012574%2C%20-16.4052%5D%2C%20%5B123.433789%2C%20-17.268558%5D%2C%20%5B123.859345%2C%20-17.069035%5D%2C%20%5B123.503242%2C%20-16.596506%5D%2C%20%5B123.817073%2C%20-16.111316%5D%2C%20%5B124.258287%2C%20-16.327944%5D%2C%20%5B124.379726%2C%20-15.56706%5D%2C%20%5B124.926153%2C%20-15.0751%5D%2C%20%5B125.167275%2C%20-14.680396%5D%2C%20%5B125.670087%2C%20-14.51007%5D%2C%20%5B125.685796%2C%20-14.230656%5D%2C%20%5B126.125149%2C%20-14.347341%5D%2C%20%5B126.142823%2C%20-14.095987%5D%2C%20%5B126.582589%2C%20-13.952791%5D%2C%20%5B127.065867%2C%20-13.817968%5D%2C%20%5B127.804633%2C%20-14.276906%5D%2C%20%5B128.35969%2C%20-14.86917%5D%2C%20%5B128.985543%2C%20-14.875991%5D%2C%20%5B129.621473%2C%20-14.969784%5D%2C%20%5B129.4096%2C%20-14.42067%5D%2C%20%5B129.888641%2C%20-13.618703%5D%2C%20%5B130.339466%2C%20-13.357376%5D%2C%20%5B130.183506%2C%20-13.10752%5D%2C%20%5B130.617795%2C%20-12.536392%5D%2C%20%5B131.223495%2C%20-12.183649%5D%2C%20%5B131.735091%2C%20-12.302453%5D%2C%20%5B132.575298%2C%20-12.114041%5D%2C%20%5B132.557212%2C%20-11.603012%5D%2C%20%5B131.824698%2C%20-11.273782%5D%2C%20%5B132.357224%2C%20-11.128519%5D%2C%20%5B133.019561%2C%20-11.376411%5D%2C%20%5B133.550846%2C%20-11.786515%5D%2C%20%5B134.393068%2C%20-12.042365%5D%2C%20%5B134.678632%2C%20-11.941183%5D%2C%20%5B135.298491%2C%20-12.248606%5D%2C%20%5B135.882693%2C%20-11.962267%5D%2C%20%5B136.258381%2C%20-12.049342%5D%2C%20%5B136.492475%2C%20-11.857209%5D%2C%20%5B136.95162%2C%20-12.351959%5D%2C%20%5B136.685125%2C%20-12.887223%5D%2C%20%5B136.305407%2C%20-13.29123%5D%2C%20%5B135.961758%2C%20-13.324509%5D%2C%20%5B136.077617%2C%20-13.724278%5D%2C%20%5B135.783836%2C%20-14.223989%5D%2C%20%5B135.428664%2C%20-14.715432%5D%2C%20%5B135.500184%2C%20-14.997741%5D%2C%20%5B136.295175%2C%20-15.550265%5D%2C%20%5B137.06536%2C%20-15.870762%5D%2C%20%5B137.580471%2C%20-16.215082%5D%2C%20%5B138.303217%2C%20-16.807604%5D%2C%20%5B138.585164%2C%20-16.806622%5D%2C%20%5B139.108543%2C%20-17.062679%5D%2C%20%5B139.260575%2C%20-17.371601%5D%2C%20%5B140.215245%2C%20-17.710805%5D%2C%20%5B140.875463%2C%20-17.369069%5D%2C%20%5B141.07111%2C%20-16.832047%5D%2C%20%5B141.274095%2C%20-16.38887%5D%2C%20%5B141.398222%2C%20-15.840532%5D%2C%20%5B141.702183%2C%20-15.044921%5D%2C%20%5B141.56338%2C%20-14.561333%5D%2C%20%5B141.63552%2C%20-14.270395%5D%2C%20%5B141.519869%2C%20-13.698078%5D%2C%20%5B141.65092%2C%20-12.944688%5D%2C%20%5B141.842691%2C%20-12.741548%5D%2C%20%5B141.68699%2C%20-12.407614%5D%2C%20%5B141.928629%2C%20-11.877466%5D%2C%20%5B142.118488%2C%20-11.328042%5D%2C%20%5B142.143706%2C%20-11.042737%5D%2C%20%5B142.51526%2C%20-10.668186%5D%2C%20%5B142.79731%2C%20-11.157355%5D%2C%20%5B142.866763%2C%20-11.784707%5D%2C%20%5B143.115947%2C%20-11.90563%5D%2C%20%5B143.158632%2C%20-12.325656%5D%2C%20%5B143.522124%2C%20-12.834358%5D%2C%20%5B143.597158%2C%20-13.400422%5D%2C%20%5B143.561811%2C%20-13.763656%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22AUS%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Australia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B16.979667%2C%2048.123497%5D%2C%20%5B16.903754%2C%2047.714866%5D%2C%20%5B16.340584%2C%2047.712902%5D%2C%20%5B16.534268%2C%2047.496171%5D%2C%20%5B16.202298%2C%2046.852386%5D%2C%20%5B16.011664%2C%2046.683611%5D%2C%20%5B15.137092%2C%2046.658703%5D%2C%20%5B14.632472%2C%2046.431817%5D%2C%20%5B13.806475%2C%2046.509306%5D%2C%20%5B12.376485%2C%2046.767559%5D%2C%20%5B12.153088%2C%2047.115393%5D%2C%20%5B11.164828%2C%2046.941579%5D%2C%20%5B11.048556%2C%2046.751359%5D%2C%20%5B10.442701%2C%2046.893546%5D%2C%20%5B9.932448%2C%2046.920728%5D%2C%20%5B9.47997%2C%2047.10281%5D%2C%20%5B9.632932%2C%2047.347601%5D%2C%20%5B9.594226%2C%2047.525058%5D%2C%20%5B9.896068%2C%2047.580197%5D%2C%20%5B10.402084%2C%2047.302488%5D%2C%20%5B10.544504%2C%2047.566399%5D%2C%20%5B11.426414%2C%2047.523766%5D%2C%20%5B12.141357%2C%2047.703083%5D%2C%20%5B12.62076%2C%2047.672388%5D%2C%20%5B12.932627%2C%2047.467646%5D%2C%20%5B13.025851%2C%2047.637584%5D%2C%20%5B12.884103%2C%2048.289146%5D%2C%20%5B13.243357%2C%2048.416115%5D%2C%20%5B13.595946%2C%2048.877172%5D%2C%20%5B14.338898%2C%2048.555305%5D%2C%20%5B14.901447%2C%2048.964402%5D%2C%20%5B15.253416%2C%2049.039074%5D%2C%20%5B16.029647%2C%2048.733899%5D%2C%20%5B16.499283%2C%2048.785808%5D%2C%20%5B16.960288%2C%2048.596982%5D%2C%20%5B16.879983%2C%2048.470013%5D%2C%20%5B16.979667%2C%2048.123497%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22AUT%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Austria%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B45.001987%2C%2039.740004%5D%2C%20%5B45.298145%2C%2039.471751%5D%2C%20%5B45.739978%2C%2039.473999%5D%2C%20%5B45.735379%2C%2039.319719%5D%2C%20%5B46.143623%2C%2038.741201%5D%2C%20%5B45.457722%2C%2038.874139%5D%2C%20%5B44.952688%2C%2039.335765%5D%2C%20%5B44.79399%2C%2039.713003%5D%2C%20%5B45.001987%2C%2039.740004%5D%5D%5D%2C%20%5B%5B%5B47.373315%2C%2041.219732%5D%2C%20%5B47.815666%2C%2041.151416%5D%2C%20%5B47.987283%2C%2041.405819%5D%2C%20%5B48.584353%2C%2041.80887%5D%2C%20%5B49.110264%2C%2041.282287%5D%2C%20%5B49.618915%2C%2040.572924%5D%2C%20%5B50.08483%2C%2040.526157%5D%2C%20%5B50.392821%2C%2040.256561%5D%2C%20%5B49.569202%2C%2040.176101%5D%2C%20%5B49.395259%2C%2039.399482%5D%2C%20%5B49.223228%2C%2039.049219%5D%2C%20%5B48.856532%2C%2038.815486%5D%2C%20%5B48.883249%2C%2038.320245%5D%2C%20%5B48.634375%2C%2038.270378%5D%2C%20%5B48.010744%2C%2038.794015%5D%2C%20%5B48.355529%2C%2039.288765%5D%2C%20%5B48.060095%2C%2039.582235%5D%2C%20%5B47.685079%2C%2039.508364%5D%2C%20%5B46.50572%2C%2038.770605%5D%2C%20%5B46.483499%2C%2039.464155%5D%2C%20%5B46.034534%2C%2039.628021%5D%2C%20%5B45.610012%2C%2039.899994%5D%2C%20%5B45.891907%2C%2040.218476%5D%2C%20%5B45.359175%2C%2040.561504%5D%2C%20%5B45.560351%2C%2040.81229%5D%2C%20%5B45.179496%2C%2040.985354%5D%2C%20%5B44.97248%2C%2041.248129%5D%2C%20%5B45.217426%2C%2041.411452%5D%2C%20%5B45.962601%2C%2041.123873%5D%2C%20%5B46.501637%2C%2041.064445%5D%2C%20%5B46.637908%2C%2041.181673%5D%2C%20%5B46.145432%2C%2041.722802%5D%2C%20%5B46.404951%2C%2041.860675%5D%2C%20%5B46.686071%2C%2041.827137%5D%2C%20%5B47.373315%2C%2041.219732%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22AZE%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Azerbaijan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B29.339998%2C%20-4.499983%5D%2C%20%5B29.276384%2C%20-3.293907%5D%2C%20%5B29.024926%2C%20-2.839258%5D%2C%20%5B29.632176%2C%20-2.917858%5D%2C%20%5B29.938359%2C%20-2.348487%5D%2C%20%5B30.469696%2C%20-2.413858%5D%2C%20%5B30.527677%2C%20-2.807632%5D%2C%20%5B30.743013%2C%20-3.034285%5D%2C%20%5B30.752263%2C%20-3.35933%5D%2C%20%5B30.50556%2C%20-3.568567%5D%2C%20%5B30.116333%2C%20-4.090138%5D%2C%20%5B29.753512%2C%20-4.452389%5D%2C%20%5B29.339998%2C%20-4.499983%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BDI%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Burundi%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B3.314971%2C%2051.345781%5D%2C%20%5B4.047071%2C%2051.267259%5D%2C%20%5B4.973991%2C%2051.475024%5D%2C%20%5B5.606976%2C%2051.037298%5D%2C%20%5B6.156658%2C%2050.803721%5D%2C%20%5B6.043073%2C%2050.128052%5D%2C%20%5B5.782417%2C%2050.090328%5D%2C%20%5B5.674052%2C%2049.529484%5D%2C%20%5B4.799222%2C%2049.985373%5D%2C%20%5B4.286023%2C%2049.907497%5D%2C%20%5B3.588184%2C%2050.378992%5D%2C%20%5B3.123252%2C%2050.780363%5D%2C%20%5B2.658422%2C%2050.796848%5D%2C%20%5B2.513573%2C%2051.148506%5D%2C%20%5B3.314971%2C%2051.345781%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BEL%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Belgium%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B2.691702%2C%206.258817%5D%2C%20%5B1.865241%2C%206.142158%5D%2C%20%5B1.618951%2C%206.832038%5D%2C%20%5B1.664478%2C%209.12859%5D%2C%20%5B1.463043%2C%209.334624%5D%2C%20%5B1.425061%2C%209.825395%5D%2C%20%5B1.077795%2C%2010.175607%5D%2C%20%5B0.772336%2C%2010.470808%5D%2C%20%5B0.899563%2C%2010.997339%5D%2C%20%5B1.24347%2C%2011.110511%5D%2C%20%5B1.447178%2C%2011.547719%5D%2C%20%5B1.935986%2C%2011.64115%5D%2C%20%5B2.154474%2C%2011.94015%5D%2C%20%5B2.490164%2C%2012.233052%5D%2C%20%5B2.848643%2C%2012.235636%5D%2C%20%5B3.61118%2C%2011.660167%5D%2C%20%5B3.572216%2C%2011.327939%5D%2C%20%5B3.797112%2C%2010.734746%5D%2C%20%5B3.60007%2C%2010.332186%5D%2C%20%5B3.705438%2C%2010.06321%5D%2C%20%5B3.220352%2C%209.444153%5D%2C%20%5B2.912308%2C%209.137608%5D%2C%20%5B2.723793%2C%208.506845%5D%2C%20%5B2.749063%2C%207.870734%5D%2C%20%5B2.691702%2C%206.258817%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BEN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Benin%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-2.827496%2C%209.642461%5D%2C%20%5B-3.511899%2C%209.900326%5D%2C%20%5B-3.980449%2C%209.862344%5D%2C%20%5B-4.330247%2C%209.610835%5D%2C%20%5B-4.779884%2C%209.821985%5D%2C%20%5B-4.954653%2C%2010.152714%5D%2C%20%5B-5.404342%2C%2010.370737%5D%2C%20%5B-5.470565%2C%2010.95127%5D%2C%20%5B-5.197843%2C%2011.375146%5D%2C%20%5B-5.220942%2C%2011.713859%5D%2C%20%5B-4.427166%2C%2012.542646%5D%2C%20%5B-4.280405%2C%2013.228444%5D%2C%20%5B-4.006391%2C%2013.472485%5D%2C%20%5B-3.522803%2C%2013.337662%5D%2C%20%5B-3.103707%2C%2013.541267%5D%2C%20%5B-2.967694%2C%2013.79815%5D%2C%20%5B-2.191825%2C%2014.246418%5D%2C%20%5B-2.001035%2C%2014.559008%5D%2C%20%5B-1.066363%2C%2014.973815%5D%2C%20%5B-0.515854%2C%2015.116158%5D%2C%20%5B-0.266257%2C%2014.924309%5D%2C%20%5B0.374892%2C%2014.928908%5D%2C%20%5B0.295646%2C%2014.444235%5D%2C%20%5B0.429928%2C%2013.988733%5D%2C%20%5B0.993046%2C%2013.33575%5D%2C%20%5B1.024103%2C%2012.851826%5D%2C%20%5B2.177108%2C%2012.625018%5D%2C%20%5B2.154474%2C%2011.94015%5D%2C%20%5B1.935986%2C%2011.64115%5D%2C%20%5B1.447178%2C%2011.547719%5D%2C%20%5B1.24347%2C%2011.110511%5D%2C%20%5B0.899563%2C%2010.997339%5D%2C%20%5B0.023803%2C%2011.018682%5D%2C%20%5B-0.438702%2C%2011.098341%5D%2C%20%5B-0.761576%2C%2010.93693%5D%2C%20%5B-1.203358%2C%2011.009819%5D%2C%20%5B-2.940409%2C%2010.96269%5D%2C%20%5B-2.963896%2C%2010.395335%5D%2C%20%5B-2.827496%2C%209.642461%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BFA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Burkina%20Faso%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B92.672721%2C%2022.041239%5D%2C%20%5B92.652257%2C%2021.324048%5D%2C%20%5B92.303234%2C%2021.475485%5D%2C%20%5B92.368554%2C%2020.670883%5D%2C%20%5B92.082886%2C%2021.192195%5D%2C%20%5B92.025215%2C%2021.70157%5D%2C%20%5B91.834891%2C%2022.182936%5D%2C%20%5B91.417087%2C%2022.765019%5D%2C%20%5B90.496006%2C%2022.805017%5D%2C%20%5B90.586957%2C%2022.392794%5D%2C%20%5B90.272971%2C%2021.836368%5D%2C%20%5B89.847467%2C%2022.039146%5D%2C%20%5B89.70205%2C%2021.857116%5D%2C%20%5B89.418863%2C%2021.966179%5D%2C%20%5B89.031961%2C%2022.055708%5D%2C%20%5B88.876312%2C%2022.879146%5D%2C%20%5B88.52977%2C%2023.631142%5D%2C%20%5B88.69994%2C%2024.233715%5D%2C%20%5B88.084422%2C%2024.501657%5D%2C%20%5B88.306373%2C%2024.866079%5D%2C%20%5B88.931554%2C%2025.238692%5D%2C%20%5B88.209789%2C%2025.768066%5D%2C%20%5B88.563049%2C%2026.446526%5D%2C%20%5B89.355094%2C%2026.014407%5D%2C%20%5B89.832481%2C%2025.965082%5D%2C%20%5B89.920693%2C%2025.26975%5D%2C%20%5B90.872211%2C%2025.132601%5D%2C%20%5B91.799596%2C%2025.147432%5D%2C%20%5B92.376202%2C%2024.976693%5D%2C%20%5B91.915093%2C%2024.130414%5D%2C%20%5B91.46773%2C%2024.072639%5D%2C%20%5B91.158963%2C%2023.503527%5D%2C%20%5B91.706475%2C%2022.985264%5D%2C%20%5B91.869928%2C%2023.624346%5D%2C%20%5B92.146035%2C%2023.627499%5D%2C%20%5B92.672721%2C%2022.041239%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BGD%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Bangladesh%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B22.65715%2C%2044.234923%5D%2C%20%5B22.944832%2C%2043.823785%5D%2C%20%5B23.332302%2C%2043.897011%5D%2C%20%5B24.100679%2C%2043.741051%5D%2C%20%5B25.569272%2C%2043.688445%5D%2C%20%5B26.065159%2C%2043.943494%5D%2C%20%5B27.2424%2C%2044.175986%5D%2C%20%5B27.970107%2C%2043.812468%5D%2C%20%5B28.558081%2C%2043.707462%5D%2C%20%5B28.039095%2C%2043.293172%5D%2C%20%5B27.673898%2C%2042.577892%5D%2C%20%5B27.99672%2C%2042.007359%5D%2C%20%5B27.135739%2C%2042.141485%5D%2C%20%5B26.117042%2C%2041.826905%5D%2C%20%5B26.106138%2C%2041.328899%5D%2C%20%5B25.197201%2C%2041.234486%5D%2C%20%5B24.492645%2C%2041.583896%5D%2C%20%5B23.692074%2C%2041.309081%5D%2C%20%5B22.952377%2C%2041.337994%5D%2C%20%5B22.881374%2C%2041.999297%5D%2C%20%5B22.380526%2C%2042.32026%5D%2C%20%5B22.545012%2C%2042.461362%5D%2C%20%5B22.436595%2C%2042.580321%5D%2C%20%5B22.604801%2C%2042.898519%5D%2C%20%5B22.986019%2C%2043.211161%5D%2C%20%5B22.500157%2C%2043.642814%5D%2C%20%5B22.410446%2C%2044.008063%5D%2C%20%5B22.65715%2C%2044.234923%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BGR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Bulgaria%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B-77.53466%2C%2023.75975%5D%2C%20%5B-77.78%2C%2023.71%5D%2C%20%5B-78.03405%2C%2024.28615%5D%2C%20%5B-78.40848%2C%2024.57564%5D%2C%20%5B-78.19087%2C%2025.2103%5D%2C%20%5B-77.89%2C%2025.17%5D%2C%20%5B-77.54%2C%2024.34%5D%2C%20%5B-77.53466%2C%2023.75975%5D%5D%5D%2C%20%5B%5B%5B-77.82%2C%2026.58%5D%2C%20%5B-78.91%2C%2026.42%5D%2C%20%5B-78.98%2C%2026.79%5D%2C%20%5B-78.51%2C%2026.87%5D%2C%20%5B-77.85%2C%2026.84%5D%2C%20%5B-77.82%2C%2026.58%5D%5D%5D%2C%20%5B%5B%5B-77%2C%2026.59%5D%2C%20%5B-77.17255%2C%2025.87918%5D%2C%20%5B-77.35641%2C%2026.00735%5D%2C%20%5B-77.34%2C%2026.53%5D%2C%20%5B-77.78802%2C%2026.92516%5D%2C%20%5B-77.79%2C%2027.04%5D%2C%20%5B-77%2C%2026.59%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22BHS%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22The%20Bahamas%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B19.005486%2C%2044.860234%5D%2C%20%5B19.36803%2C%2044.863%5D%2C%20%5B19.11761%2C%2044.42307%5D%2C%20%5B19.59976%2C%2044.03847%5D%2C%20%5B19.454%2C%2043.5681%5D%2C%20%5B19.21852%2C%2043.52384%5D%2C%20%5B19.03165%2C%2043.43253%5D%2C%20%5B18.70648%2C%2043.20011%5D%2C%20%5B18.56%2C%2042.65%5D%2C%20%5B17.674922%2C%2043.028563%5D%2C%20%5B17.297373%2C%2043.446341%5D%2C%20%5B16.916156%2C%2043.667722%5D%2C%20%5B16.456443%2C%2044.04124%5D%2C%20%5B16.23966%2C%2044.351143%5D%2C%20%5B15.750026%2C%2044.818712%5D%2C%20%5B15.959367%2C%2045.233777%5D%2C%20%5B16.318157%2C%2045.004127%5D%2C%20%5B16.534939%2C%2045.211608%5D%2C%20%5B17.002146%2C%2045.233777%5D%2C%20%5B17.861783%2C%2045.06774%5D%2C%20%5B18.553214%2C%2045.08159%5D%2C%20%5B19.005486%2C%2044.860234%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BIH%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Bosnia%20and%20Herzegovina%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B23.484128%2C%2053.912498%5D%2C%20%5B24.450684%2C%2053.905702%5D%2C%20%5B25.536354%2C%2054.282423%5D%2C%20%5B25.768433%2C%2054.846963%5D%2C%20%5B26.588279%2C%2055.167176%5D%2C%20%5B26.494331%2C%2055.615107%5D%2C%20%5B27.10246%2C%2055.783314%5D%2C%20%5B28.176709%2C%2056.16913%5D%2C%20%5B29.229513%2C%2055.918344%5D%2C%20%5B29.371572%2C%2055.670091%5D%2C%20%5B29.896294%2C%2055.789463%5D%2C%20%5B30.873909%2C%2055.550976%5D%2C%20%5B30.971836%2C%2055.081548%5D%2C%20%5B30.757534%2C%2054.811771%5D%2C%20%5B31.384472%2C%2054.157056%5D%2C%20%5B31.791424%2C%2053.974639%5D%2C%20%5B31.731273%2C%2053.794029%5D%2C%20%5B32.405599%2C%2053.618045%5D%2C%20%5B32.693643%2C%2053.351421%5D%2C%20%5B32.304519%2C%2053.132726%5D%2C%20%5B31.497644%2C%2053.167427%5D%2C%20%5B31.305201%2C%2053.073996%5D%2C%20%5B31.540018%2C%2052.742052%5D%2C%20%5B31.785998%2C%2052.101678%5D%2C%20%5B30.927549%2C%2052.042353%5D%2C%20%5B30.619454%2C%2051.822806%5D%2C%20%5B30.555117%2C%2051.319503%5D%2C%20%5B30.157364%2C%2051.416138%5D%2C%20%5B29.254938%2C%2051.368234%5D%2C%20%5B28.992835%2C%2051.602044%5D%2C%20%5B28.617613%2C%2051.427714%5D%2C%20%5B28.241615%2C%2051.572227%5D%2C%20%5B27.454066%2C%2051.592303%5D%2C%20%5B26.337959%2C%2051.832289%5D%2C%20%5B25.327788%2C%2051.910656%5D%2C%20%5B24.553106%2C%2051.888461%5D%2C%20%5B24.005078%2C%2051.617444%5D%2C%20%5B23.527071%2C%2051.578454%5D%2C%20%5B23.508002%2C%2052.023647%5D%2C%20%5B23.199494%2C%2052.486977%5D%2C%20%5B23.799199%2C%2052.691099%5D%2C%20%5B23.804935%2C%2053.089731%5D%2C%20%5B23.527536%2C%2053.470122%5D%2C%20%5B23.484128%2C%2053.912498%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BLR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Belarus%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-89.14308%2C%2017.808319%5D%2C%20%5B-89.150909%2C%2017.955468%5D%2C%20%5B-89.029857%2C%2018.001511%5D%2C%20%5B-88.848344%2C%2017.883198%5D%2C%20%5B-88.490123%2C%2018.486831%5D%2C%20%5B-88.300031%2C%2018.499982%5D%2C%20%5B-88.296336%2C%2018.353273%5D%2C%20%5B-88.106813%2C%2018.348674%5D%2C%20%5B-88.123479%2C%2018.076675%5D%2C%20%5B-88.285355%2C%2017.644143%5D%2C%20%5B-88.197867%2C%2017.489475%5D%2C%20%5B-88.302641%2C%2017.131694%5D%2C%20%5B-88.239518%2C%2017.036066%5D%2C%20%5B-88.355428%2C%2016.530774%5D%2C%20%5B-88.551825%2C%2016.265467%5D%2C%20%5B-88.732434%2C%2016.233635%5D%2C%20%5B-88.930613%2C%2015.887273%5D%2C%20%5B-89.229122%2C%2015.886938%5D%2C%20%5B-89.150806%2C%2017.015577%5D%2C%20%5B-89.14308%2C%2017.808319%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BLZ%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Belize%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-62.846468%2C%20-22.034985%5D%2C%20%5B-63.986838%2C%20-21.993644%5D%2C%20%5B-64.377021%2C%20-22.798091%5D%2C%20%5B-64.964892%2C%20-22.075862%5D%2C%20%5B-66.273339%2C%20-21.83231%5D%2C%20%5B-67.106674%2C%20-22.735925%5D%2C%20%5B-67.82818%2C%20-22.872919%5D%2C%20%5B-68.219913%2C%20-21.494347%5D%2C%20%5B-68.757167%2C%20-20.372658%5D%2C%20%5B-68.442225%2C%20-19.405068%5D%2C%20%5B-68.966818%2C%20-18.981683%5D%2C%20%5B-69.100247%2C%20-18.260125%5D%2C%20%5B-69.590424%2C%20-17.580012%5D%2C%20%5B-68.959635%2C%20-16.500698%5D%2C%20%5B-69.389764%2C%20-15.660129%5D%2C%20%5B-69.160347%2C%20-15.323974%5D%2C%20%5B-69.339535%2C%20-14.953195%5D%2C%20%5B-68.948887%2C%20-14.453639%5D%2C%20%5B-68.929224%2C%20-13.602684%5D%2C%20%5B-68.88008%2C%20-12.899729%5D%2C%20%5B-68.66508%2C%20-12.5613%5D%2C%20%5B-69.529678%2C%20-10.951734%5D%2C%20%5B-68.786158%2C%20-11.03638%5D%2C%20%5B-68.271254%2C%20-11.014521%5D%2C%20%5B-68.048192%2C%20-10.712059%5D%2C%20%5B-67.173801%2C%20-10.306812%5D%2C%20%5B-66.646908%2C%20-9.931331%5D%2C%20%5B-65.338435%2C%20-9.761988%5D%2C%20%5B-65.444837%2C%20-10.511451%5D%2C%20%5B-65.321899%2C%20-10.895872%5D%2C%20%5B-65.402281%2C%20-11.56627%5D%2C%20%5B-64.316353%2C%20-12.461978%5D%2C%20%5B-63.196499%2C%20-12.627033%5D%2C%20%5B-62.80306%2C%20-13.000653%5D%2C%20%5B-62.127081%2C%20-13.198781%5D%2C%20%5B-61.713204%2C%20-13.489202%5D%2C%20%5B-61.084121%2C%20-13.479384%5D%2C%20%5B-60.503304%2C%20-13.775955%5D%2C%20%5B-60.459198%2C%20-14.354007%5D%2C%20%5B-60.264326%2C%20-14.645979%5D%2C%20%5B-60.251149%2C%20-15.077219%5D%2C%20%5B-60.542966%2C%20-15.09391%5D%2C%20%5B-60.15839%2C%20-16.258284%5D%2C%20%5B-58.24122%2C%20-16.299573%5D%2C%20%5B-58.388058%2C%20-16.877109%5D%2C%20%5B-58.280804%2C%20-17.27171%5D%2C%20%5B-57.734558%2C%20-17.552468%5D%2C%20%5B-57.498371%2C%20-18.174188%5D%2C%20%5B-57.676009%2C%20-18.96184%5D%2C%20%5B-57.949997%2C%20-19.400004%5D%2C%20%5B-57.853802%2C%20-19.969995%5D%2C%20%5B-58.166392%2C%20-20.176701%5D%2C%20%5B-58.183471%2C%20-19.868399%5D%2C%20%5B-59.115042%2C%20-19.356906%5D%2C%20%5B-60.043565%2C%20-19.342747%5D%2C%20%5B-61.786326%2C%20-19.633737%5D%2C%20%5B-62.265961%2C%20-20.513735%5D%2C%20%5B-62.291179%2C%20-21.051635%5D%2C%20%5B-62.685057%2C%20-22.249029%5D%2C%20%5B-62.846468%2C%20-22.034985%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BOL%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Bolivia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-57.625133%2C%20-30.216295%5D%2C%20%5B-56.2909%2C%20-28.852761%5D%2C%20%5B-55.162286%2C%20-27.881915%5D%2C%20%5B-54.490725%2C%20-27.474757%5D%2C%20%5B-53.648735%2C%20-26.923473%5D%2C%20%5B-53.628349%2C%20-26.124865%5D%2C%20%5B-54.13005%2C%20-25.547639%5D%2C%20%5B-54.625291%2C%20-25.739255%5D%2C%20%5B-54.428946%2C%20-25.162185%5D%2C%20%5B-54.293476%2C%20-24.5708%5D%2C%20%5B-54.29296%2C%20-24.021014%5D%2C%20%5B-54.652834%2C%20-23.839578%5D%2C%20%5B-55.027902%2C%20-24.001274%5D%2C%20%5B-55.400747%2C%20-23.956935%5D%2C%20%5B-55.517639%2C%20-23.571998%5D%2C%20%5B-55.610683%2C%20-22.655619%5D%2C%20%5B-55.797958%2C%20-22.35693%5D%2C%20%5B-56.473317%2C%20-22.0863%5D%2C%20%5B-56.88151%2C%20-22.282154%5D%2C%20%5B-57.937156%2C%20-22.090176%5D%2C%20%5B-57.870674%2C%20-20.732688%5D%2C%20%5B-58.166392%2C%20-20.176701%5D%2C%20%5B-57.853802%2C%20-19.969995%5D%2C%20%5B-57.949997%2C%20-19.400004%5D%2C%20%5B-57.676009%2C%20-18.96184%5D%2C%20%5B-57.498371%2C%20-18.174188%5D%2C%20%5B-57.734558%2C%20-17.552468%5D%2C%20%5B-58.280804%2C%20-17.27171%5D%2C%20%5B-58.388058%2C%20-16.877109%5D%2C%20%5B-58.24122%2C%20-16.299573%5D%2C%20%5B-60.15839%2C%20-16.258284%5D%2C%20%5B-60.542966%2C%20-15.09391%5D%2C%20%5B-60.251149%2C%20-15.077219%5D%2C%20%5B-60.264326%2C%20-14.645979%5D%2C%20%5B-60.459198%2C%20-14.354007%5D%2C%20%5B-60.503304%2C%20-13.775955%5D%2C%20%5B-61.084121%2C%20-13.479384%5D%2C%20%5B-61.713204%2C%20-13.489202%5D%2C%20%5B-62.127081%2C%20-13.198781%5D%2C%20%5B-62.80306%2C%20-13.000653%5D%2C%20%5B-63.196499%2C%20-12.627033%5D%2C%20%5B-64.316353%2C%20-12.461978%5D%2C%20%5B-65.402281%2C%20-11.56627%5D%2C%20%5B-65.321899%2C%20-10.895872%5D%2C%20%5B-65.444837%2C%20-10.511451%5D%2C%20%5B-65.338435%2C%20-9.761988%5D%2C%20%5B-66.646908%2C%20-9.931331%5D%2C%20%5B-67.173801%2C%20-10.306812%5D%2C%20%5B-68.048192%2C%20-10.712059%5D%2C%20%5B-68.271254%2C%20-11.014521%5D%2C%20%5B-68.786158%2C%20-11.03638%5D%2C%20%5B-69.529678%2C%20-10.951734%5D%2C%20%5B-70.093752%2C%20-11.123972%5D%2C%20%5B-70.548686%2C%20-11.009147%5D%2C%20%5B-70.481894%2C%20-9.490118%5D%2C%20%5B-71.302412%2C%20-10.079436%5D%2C%20%5B-72.184891%2C%20-10.053598%5D%2C%20%5B-72.563033%2C%20-9.520194%5D%2C%20%5B-73.226713%2C%20-9.462213%5D%2C%20%5B-73.015383%2C%20-9.032833%5D%2C%20%5B-73.571059%2C%20-8.424447%5D%2C%20%5B-73.987235%2C%20-7.52383%5D%2C%20%5B-73.723401%2C%20-7.340999%5D%2C%20%5B-73.724487%2C%20-6.918595%5D%2C%20%5B-73.120027%2C%20-6.629931%5D%2C%20%5B-73.219711%2C%20-6.089189%5D%2C%20%5B-72.964507%2C%20-5.741251%5D%2C%20%5B-72.891928%2C%20-5.274561%5D%2C%20%5B-71.748406%2C%20-4.593983%5D%2C%20%5B-70.928843%2C%20-4.401591%5D%2C%20%5B-70.794769%2C%20-4.251265%5D%2C%20%5B-69.893635%2C%20-4.298187%5D%2C%20%5B-69.444102%2C%20-1.556287%5D%2C%20%5B-69.420486%2C%20-1.122619%5D%2C%20%5B-69.577065%2C%20-0.549992%5D%2C%20%5B-70.020656%2C%20-0.185156%5D%2C%20%5B-70.015566%2C%200.541414%5D%2C%20%5B-69.452396%2C%200.706159%5D%2C%20%5B-69.252434%2C%200.602651%5D%2C%20%5B-69.218638%2C%200.985677%5D%2C%20%5B-69.804597%2C%201.089081%5D%2C%20%5B-69.816973%2C%201.714805%5D%2C%20%5B-67.868565%2C%201.692455%5D%2C%20%5B-67.53781%2C%202.037163%5D%2C%20%5B-67.259998%2C%201.719999%5D%2C%20%5B-67.065048%2C%201.130112%5D%2C%20%5B-66.876326%2C%201.253361%5D%2C%20%5B-66.325765%2C%200.724452%5D%2C%20%5B-65.548267%2C%200.789254%5D%2C%20%5B-65.354713%2C%201.095282%5D%2C%20%5B-64.611012%2C%201.328731%5D%2C%20%5B-64.199306%2C%201.492855%5D%2C%20%5B-64.083085%2C%201.916369%5D%2C%20%5B-63.368788%2C%202.2009%5D%2C%20%5B-63.422867%2C%202.411068%5D%2C%20%5B-64.269999%2C%202.497006%5D%2C%20%5B-64.408828%2C%203.126786%5D%2C%20%5B-64.368494%2C%203.79721%5D%2C%20%5B-64.816064%2C%204.056445%5D%2C%20%5B-64.628659%2C%204.148481%5D%2C%20%5B-63.888343%2C%204.02053%5D%2C%20%5B-63.093198%2C%203.770571%5D%2C%20%5B-62.804533%2C%204.006965%5D%2C%20%5B-62.08543%2C%204.162124%5D%2C%20%5B-60.966893%2C%204.536468%5D%2C%20%5B-60.601179%2C%204.918098%5D%2C%20%5B-60.733574%2C%205.200277%5D%2C%20%5B-60.213683%2C%205.244486%5D%2C%20%5B-59.980959%2C%205.014061%5D%2C%20%5B-60.111002%2C%204.574967%5D%2C%20%5B-59.767406%2C%204.423503%5D%2C%20%5B-59.53804%2C%203.958803%5D%2C%20%5B-59.815413%2C%203.606499%5D%2C%20%5B-59.974525%2C%202.755233%5D%2C%20%5B-59.718546%2C%202.24963%5D%2C%20%5B-59.646044%2C%201.786894%5D%2C%20%5B-59.030862%2C%201.317698%5D%2C%20%5B-58.540013%2C%201.268088%5D%2C%20%5B-58.429477%2C%201.463942%5D%2C%20%5B-58.11345%2C%201.507195%5D%2C%20%5B-57.660971%2C%201.682585%5D%2C%20%5B-57.335823%2C%201.948538%5D%2C%20%5B-56.782704%2C%201.863711%5D%2C%20%5B-56.539386%2C%201.899523%5D%2C%20%5B-55.995698%2C%201.817667%5D%2C%20%5B-55.9056%2C%202.021996%5D%2C%20%5B-56.073342%2C%202.220795%5D%2C%20%5B-55.973322%2C%202.510364%5D%2C%20%5B-55.569755%2C%202.421506%5D%2C%20%5B-55.097587%2C%202.523748%5D%2C%20%5B-54.524754%2C%202.311849%5D%2C%20%5B-54.088063%2C%202.105557%5D%2C%20%5B-53.778521%2C%202.376703%5D%2C%20%5B-53.554839%2C%202.334897%5D%2C%20%5B-53.418465%2C%202.053389%5D%2C%20%5B-52.939657%2C%202.124858%5D%2C%20%5B-52.556425%2C%202.504705%5D%2C%20%5B-52.249338%2C%203.241094%5D%2C%20%5B-51.657797%2C%204.156232%5D%2C%20%5B-51.317146%2C%204.203491%5D%2C%20%5B-51.069771%2C%203.650398%5D%2C%20%5B-50.508875%2C%201.901564%5D%2C%20%5B-49.974076%2C%201.736483%5D%2C%20%5B-49.947101%2C%201.04619%5D%2C%20%5B-50.699251%2C%200.222984%5D%2C%20%5B-50.388211%2C%20-0.078445%5D%2C%20%5B-48.620567%2C%20-0.235489%5D%2C%20%5B-48.584497%2C%20-1.237805%5D%2C%20%5B-47.824956%2C%20-0.581618%5D%2C%20%5B-46.566584%2C%20-0.941028%5D%2C%20%5B-44.905703%2C%20-1.55174%5D%2C%20%5B-44.417619%2C%20-2.13775%5D%2C%20%5B-44.581589%2C%20-2.691308%5D%2C%20%5B-43.418791%2C%20-2.38311%5D%2C%20%5B-41.472657%2C%20-2.912018%5D%2C%20%5B-39.978665%2C%20-2.873054%5D%2C%20%5B-38.500383%2C%20-3.700652%5D%2C%20%5B-37.223252%2C%20-4.820946%5D%2C%20%5B-36.452937%2C%20-5.109404%5D%2C%20%5B-35.597796%2C%20-5.149504%5D%2C%20%5B-35.235389%2C%20-5.464937%5D%2C%20%5B-34.89603%2C%20-6.738193%5D%2C%20%5B-34.729993%2C%20-7.343221%5D%2C%20%5B-35.128212%2C%20-8.996401%5D%2C%20%5B-35.636967%2C%20-9.649282%5D%2C%20%5B-37.046519%2C%20-11.040721%5D%2C%20%5B-37.683612%2C%20-12.171195%5D%2C%20%5B-38.423877%2C%20-13.038119%5D%2C%20%5B-38.673887%2C%20-13.057652%5D%2C%20%5B-38.953276%2C%20-13.79337%5D%2C%20%5B-38.882298%2C%20-15.667054%5D%2C%20%5B-39.161092%2C%20-17.208407%5D%2C%20%5B-39.267339%2C%20-17.867746%5D%2C%20%5B-39.583521%2C%20-18.262296%5D%2C%20%5B-39.760823%2C%20-19.599113%5D%2C%20%5B-40.774741%2C%20-20.904512%5D%2C%20%5B-40.944756%2C%20-21.937317%5D%2C%20%5B-41.754164%2C%20-22.370676%5D%2C%20%5B-41.988284%2C%20-22.97007%5D%2C%20%5B-43.074704%2C%20-22.967693%5D%2C%20%5B-44.647812%2C%20-23.351959%5D%2C%20%5B-45.352136%2C%20-23.796842%5D%2C%20%5B-46.472093%2C%20-24.088969%5D%2C%20%5B-47.648972%2C%20-24.885199%5D%2C%20%5B-48.495458%2C%20-25.877025%5D%2C%20%5B-48.641005%2C%20-26.623698%5D%2C%20%5B-48.474736%2C%20-27.175912%5D%2C%20%5B-48.66152%2C%20-28.186135%5D%2C%20%5B-48.888457%2C%20-28.674115%5D%2C%20%5B-49.587329%2C%20-29.224469%5D%2C%20%5B-50.696874%2C%20-30.984465%5D%2C%20%5B-51.576226%2C%20-31.777698%5D%2C%20%5B-52.256081%2C%20-32.24537%5D%2C%20%5B-52.7121%2C%20-33.196578%5D%2C%20%5B-53.373662%2C%20-33.768378%5D%2C%20%5B-53.650544%2C%20-33.202004%5D%2C%20%5B-53.209589%2C%20-32.727666%5D%2C%20%5B-53.787952%2C%20-32.047243%5D%2C%20%5B-54.572452%2C%20-31.494511%5D%2C%20%5B-55.60151%2C%20-30.853879%5D%2C%20%5B-55.973245%2C%20-30.883076%5D%2C%20%5B-56.976026%2C%20-30.109686%5D%2C%20%5B-57.625133%2C%20-30.216295%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BRA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Brazil%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B114.204017%2C%204.525874%5D%2C%20%5B114.599961%2C%204.900011%5D%2C%20%5B115.45071%2C%205.44773%5D%2C%20%5B115.4057%2C%204.955228%5D%2C%20%5B115.347461%2C%204.316636%5D%2C%20%5B114.869557%2C%204.348314%5D%2C%20%5B114.659596%2C%204.007637%5D%2C%20%5B114.204017%2C%204.525874%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BRN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Brunei%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B91.696657%2C%2027.771742%5D%2C%20%5B92.103712%2C%2027.452614%5D%2C%20%5B92.033484%2C%2026.83831%5D%2C%20%5B91.217513%2C%2026.808648%5D%2C%20%5B90.373275%2C%2026.875724%5D%2C%20%5B89.744528%2C%2026.719403%5D%2C%20%5B88.835643%2C%2027.098966%5D%2C%20%5B88.814248%2C%2027.299316%5D%2C%20%5B89.47581%2C%2028.042759%5D%2C%20%5B90.015829%2C%2028.296439%5D%2C%20%5B90.730514%2C%2028.064954%5D%2C%20%5B91.258854%2C%2028.040614%5D%2C%20%5B91.696657%2C%2027.771742%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BTN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Bhutan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B25.649163%2C%20-18.536026%5D%2C%20%5B25.850391%2C%20-18.714413%5D%2C%20%5B26.164791%2C%20-19.293086%5D%2C%20%5B27.296505%2C%20-20.39152%5D%2C%20%5B27.724747%2C%20-20.499059%5D%2C%20%5B27.727228%2C%20-20.851802%5D%2C%20%5B28.02137%2C%20-21.485975%5D%2C%20%5B28.794656%2C%20-21.639454%5D%2C%20%5B29.432188%2C%20-22.091313%5D%2C%20%5B28.017236%2C%20-22.827754%5D%2C%20%5B27.11941%2C%20-23.574323%5D%2C%20%5B26.786407%2C%20-24.240691%5D%2C%20%5B26.485753%2C%20-24.616327%5D%2C%20%5B25.941652%2C%20-24.696373%5D%2C%20%5B25.765849%2C%20-25.174845%5D%2C%20%5B25.664666%2C%20-25.486816%5D%2C%20%5B25.025171%2C%20-25.71967%5D%2C%20%5B24.211267%2C%20-25.670216%5D%2C%20%5B23.73357%2C%20-25.390129%5D%2C%20%5B23.312097%2C%20-25.26869%5D%2C%20%5B22.824271%2C%20-25.500459%5D%2C%20%5B22.579532%2C%20-25.979448%5D%2C%20%5B22.105969%2C%20-26.280256%5D%2C%20%5B21.605896%2C%20-26.726534%5D%2C%20%5B20.889609%2C%20-26.828543%5D%2C%20%5B20.66647%2C%20-26.477453%5D%2C%20%5B20.758609%2C%20-25.868136%5D%2C%20%5B20.165726%2C%20-24.917962%5D%2C%20%5B19.895768%2C%20-24.76779%5D%2C%20%5B19.895458%2C%20-21.849157%5D%2C%20%5B20.881134%2C%20-21.814327%5D%2C%20%5B20.910641%2C%20-18.252219%5D%2C%20%5B21.65504%2C%20-18.219146%5D%2C%20%5B23.196858%2C%20-17.869038%5D%2C%20%5B23.579006%2C%20-18.281261%5D%2C%20%5B24.217365%2C%20-17.889347%5D%2C%20%5B24.520705%2C%20-17.887125%5D%2C%20%5B25.084443%2C%20-17.661816%5D%2C%20%5B25.264226%2C%20-17.73654%5D%2C%20%5B25.649163%2C%20-18.536026%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22BWA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Botswana%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B15.27946%2C%207.421925%5D%2C%20%5B16.106232%2C%207.497088%5D%2C%20%5B16.290562%2C%207.754307%5D%2C%20%5B16.456185%2C%207.734774%5D%2C%20%5B16.705988%2C%207.508328%5D%2C%20%5B17.96493%2C%207.890914%5D%2C%20%5B18.389555%2C%208.281304%5D%2C%20%5B18.911022%2C%208.630895%5D%2C%20%5B18.81201%2C%208.982915%5D%2C%20%5B19.094008%2C%209.074847%5D%2C%20%5B20.059685%2C%209.012706%5D%2C%20%5B21.000868%2C%209.475985%5D%2C%20%5B21.723822%2C%2010.567056%5D%2C%20%5B22.231129%2C%2010.971889%5D%2C%20%5B22.864165%2C%2011.142395%5D%2C%20%5B22.977544%2C%2010.714463%5D%2C%20%5B23.554304%2C%2010.089255%5D%2C%20%5B23.55725%2C%209.681218%5D%2C%20%5B23.394779%2C%209.265068%5D%2C%20%5B23.459013%2C%208.954286%5D%2C%20%5B23.805813%2C%208.666319%5D%2C%20%5B24.567369%2C%208.229188%5D%2C%20%5B25.114932%2C%207.825104%5D%2C%20%5B25.124131%2C%207.500085%5D%2C%20%5B25.796648%2C%206.979316%5D%2C%20%5B26.213418%2C%206.546603%5D%2C%20%5B26.465909%2C%205.946717%5D%2C%20%5B27.213409%2C%205.550953%5D%2C%20%5B27.374226%2C%205.233944%5D%2C%20%5B27.044065%2C%205.127853%5D%2C%20%5B26.402761%2C%205.150875%5D%2C%20%5B25.650455%2C%205.256088%5D%2C%20%5B25.278798%2C%205.170408%5D%2C%20%5B25.128833%2C%204.927245%5D%2C%20%5B24.805029%2C%204.897247%5D%2C%20%5B24.410531%2C%205.108784%5D%2C%20%5B23.297214%2C%204.609693%5D%2C%20%5B22.84148%2C%204.710126%5D%2C%20%5B22.704124%2C%204.633051%5D%2C%20%5B22.405124%2C%204.02916%5D%2C%20%5B21.659123%2C%204.224342%5D%2C%20%5B20.927591%2C%204.322786%5D%2C%20%5B20.290679%2C%204.691678%5D%2C%20%5B19.467784%2C%205.031528%5D%2C%20%5B18.932312%2C%204.709506%5D%2C%20%5B18.542982%2C%204.201785%5D%2C%20%5B18.453065%2C%203.504386%5D%2C%20%5B17.8099%2C%203.560196%5D%2C%20%5B17.133042%2C%203.728197%5D%2C%20%5B16.537058%2C%203.198255%5D%2C%20%5B16.012852%2C%202.26764%5D%2C%20%5B15.907381%2C%202.557389%5D%2C%20%5B15.862732%2C%203.013537%5D%2C%20%5B15.405396%2C%203.335301%5D%2C%20%5B15.03622%2C%203.851367%5D%2C%20%5B14.950953%2C%204.210389%5D%2C%20%5B14.478372%2C%204.732605%5D%2C%20%5B14.558936%2C%205.030598%5D%2C%20%5B14.459407%2C%205.451761%5D%2C%20%5B14.53656%2C%206.226959%5D%2C%20%5B14.776545%2C%206.408498%5D%2C%20%5B15.27946%2C%207.421925%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22CAF%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Central%20African%20Republic%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B-63.6645%2C%2046.55001%5D%2C%20%5B-62.9393%2C%2046.41587%5D%2C%20%5B-62.01208%2C%2046.44314%5D%2C%20%5B-62.50391%2C%2046.03339%5D%2C%20%5B-62.87433%2C%2045.96818%5D%2C%20%5B-64.1428%2C%2046.39265%5D%2C%20%5B-64.39261%2C%2046.72747%5D%2C%20%5B-64.01486%2C%2047.03601%5D%2C%20%5B-63.6645%2C%2046.55001%5D%5D%5D%2C%20%5B%5B%5B-61.806305%2C%2049.10506%5D%2C%20%5B-62.29318%2C%2049.08717%5D%2C%20%5B-63.58926%2C%2049.40069%5D%2C%20%5B-64.51912%2C%2049.87304%5D%2C%20%5B-64.17322%2C%2049.95718%5D%2C%20%5B-62.85829%2C%2049.70641%5D%2C%20%5B-61.835585%2C%2049.28855%5D%2C%20%5B-61.806305%2C%2049.10506%5D%5D%5D%2C%20%5B%5B%5B-123.510002%2C%2048.510011%5D%2C%20%5B-124.012891%2C%2048.370846%5D%2C%20%5B-125.655013%2C%2048.825005%5D%2C%20%5B-125.954994%2C%2049.179996%5D%2C%20%5B-126.850004%2C%2049.53%5D%2C%20%5B-127.029993%2C%2049.814996%5D%2C%20%5B-128.059336%2C%2049.994959%5D%2C%20%5B-128.444584%2C%2050.539138%5D%2C%20%5B-128.358414%2C%2050.770648%5D%2C%20%5B-127.308581%2C%2050.552574%5D%2C%20%5B-126.695001%2C%2050.400903%5D%2C%20%5B-125.755007%2C%2050.295018%5D%2C%20%5B-125.415002%2C%2049.950001%5D%2C%20%5B-124.920768%2C%2049.475275%5D%2C%20%5B-123.922509%2C%2049.062484%5D%2C%20%5B-123.510002%2C%2048.510011%5D%5D%5D%2C%20%5B%5B%5B-56.134036%2C%2050.68701%5D%2C%20%5B-56.795882%2C%2049.812309%5D%2C%20%5B-56.143105%2C%2050.150117%5D%2C%20%5B-55.471492%2C%2049.935815%5D%2C%20%5B-55.822401%2C%2049.587129%5D%2C%20%5B-54.935143%2C%2049.313011%5D%2C%20%5B-54.473775%2C%2049.556691%5D%2C%20%5B-53.476549%2C%2049.249139%5D%2C%20%5B-53.786014%2C%2048.516781%5D%2C%20%5B-53.086134%2C%2048.687804%5D%2C%20%5B-52.958648%2C%2048.157164%5D%2C%20%5B-52.648099%2C%2047.535548%5D%2C%20%5B-53.069158%2C%2046.655499%5D%2C%20%5B-53.521456%2C%2046.618292%5D%2C%20%5B-54.178936%2C%2046.807066%5D%2C%20%5B-53.961869%2C%2047.625207%5D%2C%20%5B-54.240482%2C%2047.752279%5D%2C%20%5B-55.400773%2C%2046.884994%5D%2C%20%5B-55.997481%2C%2046.91972%5D%2C%20%5B-55.291219%2C%2047.389562%5D%2C%20%5B-56.250799%2C%2047.632545%5D%2C%20%5B-57.325229%2C%2047.572807%5D%2C%20%5B-59.266015%2C%2047.603348%5D%2C%20%5B-59.419494%2C%2047.899454%5D%2C%20%5B-58.796586%2C%2048.251525%5D%2C%20%5B-59.231625%2C%2048.523188%5D%2C%20%5B-58.391805%2C%2049.125581%5D%2C%20%5B-57.35869%2C%2050.718274%5D%2C%20%5B-56.73865%2C%2051.287438%5D%2C%20%5B-55.870977%2C%2051.632094%5D%2C%20%5B-55.406974%2C%2051.588273%5D%2C%20%5B-55.600218%2C%2051.317075%5D%2C%20%5B-56.134036%2C%2050.68701%5D%5D%5D%2C%20%5B%5B%5B-132.710008%2C%2054.040009%5D%2C%20%5B-132.710009%2C%2054.040009%5D%2C%20%5B-132.710008%2C%2054.040009%5D%2C%20%5B-132.710008%2C%2054.040009%5D%2C%20%5B-131.74999%2C%2054.120004%5D%2C%20%5B-132.04948%2C%2052.984621%5D%2C%20%5B-131.179043%2C%2052.180433%5D%2C%20%5B-131.57783%2C%2052.182371%5D%2C%20%5B-132.180428%2C%2052.639707%5D%2C%20%5B-132.549992%2C%2053.100015%5D%2C%20%5B-133.054611%2C%2053.411469%5D%2C%20%5B-133.239664%2C%2053.85108%5D%2C%20%5B-133.180004%2C%2054.169975%5D%2C%20%5B-132.710008%2C%2054.040009%5D%5D%5D%2C%20%5B%5B%5B-79.26582%2C%2062.158675%5D%2C%20%5B-79.65752%2C%2061.63308%5D%2C%20%5B-80.09956%2C%2061.7181%5D%2C%20%5B-80.36215%2C%2062.01649%5D%2C%20%5B-80.315395%2C%2062.085565%5D%2C%20%5B-79.92939%2C%2062.3856%5D%2C%20%5B-79.52002%2C%2062.36371%5D%2C%20%5B-79.26582%2C%2062.158675%5D%5D%5D%2C%20%5B%5B%5B-81.89825%2C%2062.7108%5D%2C%20%5B-83.06857%2C%2062.15922%5D%2C%20%5B-83.77462%2C%2062.18231%5D%2C%20%5B-83.99367%2C%2062.4528%5D%2C%20%5B-83.25048%2C%2062.91409%5D%2C%20%5B-81.87699%2C%2062.90458%5D%2C%20%5B-81.89825%2C%2062.7108%5D%5D%5D%2C%20%5B%5B%5B-85.161308%2C%2065.657285%5D%2C%20%5B-84.975764%2C%2065.217518%5D%2C%20%5B-84.464012%2C%2065.371772%5D%2C%20%5B-83.882626%2C%2065.109618%5D%2C%20%5B-82.787577%2C%2064.766693%5D%2C%20%5B-81.642014%2C%2064.455136%5D%2C%20%5B-81.55344%2C%2063.979609%5D%2C%20%5B-80.817361%2C%2064.057486%5D%2C%20%5B-80.103451%2C%2063.725981%5D%2C%20%5B-80.99102%2C%2063.411246%5D%2C%20%5B-82.547178%2C%2063.651722%5D%2C%20%5B-83.108798%2C%2064.101876%5D%2C%20%5B-84.100417%2C%2063.569712%5D%2C%20%5B-85.523405%2C%2063.052379%5D%2C%20%5B-85.866769%2C%2063.637253%5D%2C%20%5B-87.221983%2C%2063.541238%5D%2C%20%5B-86.35276%2C%2064.035833%5D%2C%20%5B-86.224886%2C%2064.822917%5D%2C%20%5B-85.883848%2C%2065.738778%5D%2C%20%5B-85.161308%2C%2065.657285%5D%5D%5D%2C%20%5B%5B%5B-75.86588%2C%2067.14886%5D%2C%20%5B-76.98687%2C%2067.09873%5D%2C%20%5B-77.2364%2C%2067.58809%5D%2C%20%5B-76.81166%2C%2068.14856%5D%2C%20%5B-75.89521%2C%2068.28721%5D%2C%20%5B-75.1145%2C%2068.01036%5D%2C%20%5B-75.10333%2C%2067.58202%5D%2C%20%5B-75.21597%2C%2067.44425%5D%2C%20%5B-75.86588%2C%2067.14886%5D%5D%5D%2C%20%5B%5B%5B-95.647681%2C%2069.10769%5D%2C%20%5B-96.269521%2C%2068.75704%5D%2C%20%5B-97.617401%2C%2069.06003%5D%2C%20%5B-98.431801%2C%2068.9507%5D%2C%20%5B-99.797401%2C%2069.40003%5D%2C%20%5B-98.917401%2C%2069.71003%5D%2C%20%5B-98.218261%2C%2070.14354%5D%2C%20%5B-97.157401%2C%2069.86003%5D%2C%20%5B-96.557401%2C%2069.68003%5D%2C%20%5B-96.257401%2C%2069.49003%5D%2C%20%5B-95.647681%2C%2069.10769%5D%5D%5D%2C%20%5B%5B%5B-90.5471%2C%2069.49766%5D%2C%20%5B-90.55151%2C%2068.47499%5D%2C%20%5B-89.21515%2C%2069.25873%5D%2C%20%5B-88.01966%2C%2068.61508%5D%2C%20%5B-88.31749%2C%2067.87338%5D%2C%20%5B-87.35017%2C%2067.19872%5D%2C%20%5B-86.30607%2C%2067.92146%5D%2C%20%5B-85.57664%2C%2068.78456%5D%2C%20%5B-85.52197%2C%2069.88211%5D%2C%20%5B-84.10081%2C%2069.80539%5D%2C%20%5B-82.62258%2C%2069.65826%5D%2C%20%5B-81.28043%2C%2069.16202%5D%2C%20%5B-81.2202%2C%2068.66567%5D%2C%20%5B-81.96436%2C%2068.13253%5D%2C%20%5B-81.25928%2C%2067.59716%5D%2C%20%5B-81.38653%2C%2067.11078%5D%2C%20%5B-83.34456%2C%2066.41154%5D%2C%20%5B-84.73542%2C%2066.2573%5D%2C%20%5B-85.76943%2C%2066.55833%5D%2C%20%5B-86.0676%2C%2066.05625%5D%2C%20%5B-87.03143%2C%2065.21297%5D%2C%20%5B-87.32324%2C%2064.77563%5D%2C%20%5B-88.48296%2C%2064.09897%5D%2C%20%5B-89.91444%2C%2064.03273%5D%2C%20%5B-90.70398%2C%2063.61017%5D%2C%20%5B-90.77004%2C%2062.96021%5D%2C%20%5B-91.93342%2C%2062.83508%5D%2C%20%5B-93.15698%2C%2062.02469%5D%2C%20%5B-94.24153%2C%2060.89865%5D%2C%20%5B-94.62931%2C%2060.11021%5D%2C%20%5B-94.6846%2C%2058.94882%5D%2C%20%5B-93.21502%2C%2058.78212%5D%2C%20%5B-92.76462%2C%2057.84571%5D%2C%20%5B-92.29703%2C%2057.08709%5D%2C%20%5B-90.89769%2C%2057.28468%5D%2C%20%5B-89.03953%2C%2056.85172%5D%2C%20%5B-88.03978%2C%2056.47162%5D%2C%20%5B-87.32421%2C%2055.99914%5D%2C%20%5B-86.07121%2C%2055.72383%5D%2C%20%5B-85.01181%2C%2055.3026%5D%2C%20%5B-83.36055%2C%2055.24489%5D%2C%20%5B-82.27285%2C%2055.14832%5D%2C%20%5B-82.4362%2C%2054.28227%5D%2C%20%5B-82.12502%2C%2053.27703%5D%2C%20%5B-81.40075%2C%2052.15788%5D%2C%20%5B-79.91289%2C%2051.20842%5D%2C%20%5B-79.14301%2C%2051.53393%5D%2C%20%5B-78.60191%2C%2052.56208%5D%2C%20%5B-79.12421%2C%2054.14145%5D%2C%20%5B-79.82958%2C%2054.66772%5D%2C%20%5B-78.22874%2C%2055.13645%5D%2C%20%5B-77.0956%2C%2055.83741%5D%2C%20%5B-76.54137%2C%2056.53423%5D%2C%20%5B-76.62319%2C%2057.20263%5D%2C%20%5B-77.30226%2C%2058.05209%5D%2C%20%5B-78.51688%2C%2058.80458%5D%2C%20%5B-77.33676%2C%2059.85261%5D%2C%20%5B-77.77272%2C%2060.75788%5D%2C%20%5B-78.10687%2C%2062.31964%5D%2C%20%5B-77.41067%2C%2062.55053%5D%2C%20%5B-75.69621%2C%2062.2784%5D%2C%20%5B-74.6682%2C%2062.18111%5D%2C%20%5B-73.83988%2C%2062.4438%5D%2C%20%5B-72.90853%2C%2062.10507%5D%2C%20%5B-71.67708%2C%2061.52535%5D%2C%20%5B-71.37369%2C%2061.13717%5D%2C%20%5B-69.59042%2C%2061.06141%5D%2C%20%5B-69.62033%2C%2060.22125%5D%2C%20%5B-69.2879%2C%2058.95736%5D%2C%20%5B-68.37455%2C%2058.80106%5D%2C%20%5B-67.64976%2C%2058.21206%5D%2C%20%5B-66.20178%2C%2058.76731%5D%2C%20%5B-65.24517%2C%2059.87071%5D%2C%20%5B-64.58352%2C%2060.33558%5D%2C%20%5B-63.80475%2C%2059.4426%5D%2C%20%5B-62.50236%2C%2058.16708%5D%2C%20%5B-61.39655%2C%2056.96745%5D%2C%20%5B-61.79866%2C%2056.33945%5D%2C%20%5B-60.46853%2C%2055.77548%5D%2C%20%5B-59.56962%2C%2055.20407%5D%2C%20%5B-57.97508%2C%2054.94549%5D%2C%20%5B-57.3332%2C%2054.6265%5D%2C%20%5B-56.93689%2C%2053.78032%5D%2C%20%5B-56.15811%2C%2053.64749%5D%2C%20%5B-55.75632%2C%2053.27036%5D%2C%20%5B-55.68338%2C%2052.14664%5D%2C%20%5B-56.40916%2C%2051.7707%5D%2C%20%5B-57.12691%2C%2051.41972%5D%2C%20%5B-58.77482%2C%2051.0643%5D%2C%20%5B-60.03309%2C%2050.24277%5D%2C%20%5B-61.72366%2C%2050.08046%5D%2C%20%5B-63.86251%2C%2050.29099%5D%2C%20%5B-65.36331%2C%2050.2982%5D%2C%20%5B-66.39905%2C%2050.22897%5D%2C%20%5B-67.23631%2C%2049.51156%5D%2C%20%5B-68.51114%2C%2049.06836%5D%2C%20%5B-69.95362%2C%2047.74488%5D%2C%20%5B-71.10458%2C%2046.82171%5D%2C%20%5B-70.25522%2C%2046.98606%5D%2C%20%5B-68.65%2C%2048.3%5D%2C%20%5B-66.55243%2C%2049.1331%5D%2C%20%5B-65.05626%2C%2049.23278%5D%2C%20%5B-64.17099%2C%2048.74248%5D%2C%20%5B-65.11545%2C%2048.07085%5D%2C%20%5B-64.79854%2C%2046.99297%5D%2C%20%5B-64.47219%2C%2046.23849%5D%2C%20%5B-63.17329%2C%2045.73902%5D%2C%20%5B-61.52072%2C%2045.88377%5D%2C%20%5B-60.51815%2C%2047.00793%5D%2C%20%5B-60.4486%2C%2046.28264%5D%2C%20%5B-59.80287%2C%2045.9204%5D%2C%20%5B-61.03988%2C%2045.26525%5D%2C%20%5B-63.25471%2C%2044.67014%5D%2C%20%5B-64.24656%2C%2044.26553%5D%2C%20%5B-65.36406%2C%2043.54523%5D%2C%20%5B-66.1234%2C%2043.61867%5D%2C%20%5B-66.16173%2C%2044.46512%5D%2C%20%5B-64.42549%2C%2045.29204%5D%2C%20%5B-66.02605%2C%2045.25931%5D%2C%20%5B-67.13741%2C%2045.13753%5D%2C%20%5B-67.79134%2C%2045.70281%5D%2C%20%5B-67.79046%2C%2047.06636%5D%2C%20%5B-68.23444%2C%2047.35486%5D%2C%20%5B-68.905%2C%2047.185%5D%2C%20%5B-69.237216%2C%2047.447781%5D%2C%20%5B-69.99997%2C%2046.69307%5D%2C%20%5B-70.305%2C%2045.915%5D%2C%20%5B-70.66%2C%2045.46%5D%2C%20%5B-71.08482%2C%2045.30524%5D%2C%20%5B-71.405%2C%2045.255%5D%2C%20%5B-71.50506%2C%2045.0082%5D%2C%20%5B-73.34783%2C%2045.00738%5D%2C%20%5B-74.867%2C%2045.00048%5D%2C%20%5B-75.31821%2C%2044.81645%5D%2C%20%5B-76.375%2C%2044.09631%5D%2C%20%5B-76.5%2C%2044.018459%5D%2C%20%5B-76.820034%2C%2043.628784%5D%2C%20%5B-77.737885%2C%2043.629056%5D%2C%20%5B-78.72028%2C%2043.625089%5D%2C%20%5B-79.171674%2C%2043.466339%5D%2C%20%5B-79.01%2C%2043.27%5D%2C%20%5B-78.92%2C%2042.965%5D%2C%20%5B-78.939362%2C%2042.863611%5D%2C%20%5B-80.247448%2C%2042.3662%5D%2C%20%5B-81.277747%2C%2042.209026%5D%2C%20%5B-82.439278%2C%2041.675105%5D%2C%20%5B-82.690089%2C%2041.675105%5D%2C%20%5B-83.02981%2C%2041.832796%5D%2C%20%5B-83.142%2C%2041.975681%5D%2C%20%5B-83.12%2C%2042.08%5D%2C%20%5B-82.9%2C%2042.43%5D%2C%20%5B-82.43%2C%2042.98%5D%2C%20%5B-82.137642%2C%2043.571088%5D%2C%20%5B-82.337763%2C%2044.44%5D%2C%20%5B-82.550925%2C%2045.347517%5D%2C%20%5B-83.592851%2C%2045.816894%5D%2C%20%5B-83.469551%2C%2045.994686%5D%2C%20%5B-83.616131%2C%2046.116927%5D%2C%20%5B-83.890765%2C%2046.116927%5D%2C%20%5B-84.091851%2C%2046.275419%5D%2C%20%5B-84.14212%2C%2046.512226%5D%2C%20%5B-84.3367%2C%2046.40877%5D%2C%20%5B-84.6049%2C%2046.4396%5D%2C%20%5B-84.543749%2C%2046.538684%5D%2C%20%5B-84.779238%2C%2046.637102%5D%2C%20%5B-84.87608%2C%2046.900083%5D%2C%20%5B-85.652363%2C%2047.220219%5D%2C%20%5B-86.461991%2C%2047.553338%5D%2C%20%5B-87.439793%2C%2047.94%5D%2C%20%5B-88.378114%2C%2048.302918%5D%2C%20%5B-89.272917%2C%2048.019808%5D%2C%20%5B-89.6%2C%2048.01%5D%2C%20%5B-90.83%2C%2048.27%5D%2C%20%5B-91.64%2C%2048.14%5D%2C%20%5B-92.61%2C%2048.45%5D%2C%20%5B-93.63087%2C%2048.60926%5D%2C%20%5B-94.32914%2C%2048.67074%5D%2C%20%5B-94.64%2C%2048.84%5D%2C%20%5B-94.81758%2C%2049.38905%5D%2C%20%5B-95.15609%2C%2049.38425%5D%2C%20%5B-95.15907%2C%2049%5D%2C%20%5B-97.22872%2C%2049.0007%5D%2C%20%5B-100.65%2C%2049%5D%2C%20%5B-104.04826%2C%2048.99986%5D%2C%20%5B-107.05%2C%2049%5D%2C%20%5B-110.05%2C%2049%5D%2C%20%5B-113%2C%2049%5D%2C%20%5B-116.04818%2C%2049%5D%2C%20%5B-117.03121%2C%2049%5D%2C%20%5B-120%2C%2049%5D%2C%20%5B-122.84%2C%2049%5D%2C%20%5B-122.97421%2C%2049.002538%5D%2C%20%5B-124.91024%2C%2049.98456%5D%2C%20%5B-125.62461%2C%2050.41656%5D%2C%20%5B-127.43561%2C%2050.83061%5D%2C%20%5B-127.99276%2C%2051.71583%5D%2C%20%5B-127.85032%2C%2052.32961%5D%2C%20%5B-129.12979%2C%2052.75538%5D%2C%20%5B-129.30523%2C%2053.56159%5D%2C%20%5B-130.51497%2C%2054.28757%5D%2C%20%5B-130.53611%2C%2054.80278%5D%2C%20%5B-129.98%2C%2055.285%5D%2C%20%5B-130.00778%2C%2055.91583%5D%2C%20%5B-131.70781%2C%2056.55212%5D%2C%20%5B-132.73042%2C%2057.69289%5D%2C%20%5B-133.35556%2C%2058.41028%5D%2C%20%5B-134.27111%2C%2058.86111%5D%2C%20%5B-134.945%2C%2059.27056%5D%2C%20%5B-135.47583%2C%2059.78778%5D%2C%20%5B-136.47972%2C%2059.46389%5D%2C%20%5B-137.4525%2C%2058.905%5D%2C%20%5B-138.34089%2C%2059.56211%5D%2C%20%5B-139.039%2C%2060%5D%2C%20%5B-140.013%2C%2060.27682%5D%2C%20%5B-140.99778%2C%2060.30639%5D%2C%20%5B-140.9925%2C%2066.00003%5D%2C%20%5B-140.986%2C%2069.712%5D%2C%20%5B-139.12052%2C%2069.47102%5D%2C%20%5B-137.54636%2C%2068.99002%5D%2C%20%5B-136.50358%2C%2068.89804%5D%2C%20%5B-135.62576%2C%2069.31512%5D%2C%20%5B-134.41464%2C%2069.62743%5D%2C%20%5B-132.92925%2C%2069.50534%5D%2C%20%5B-131.43136%2C%2069.94451%5D%2C%20%5B-129.79471%2C%2070.19369%5D%2C%20%5B-129.10773%2C%2069.77927%5D%2C%20%5B-128.36156%2C%2070.01286%5D%2C%20%5B-128.13817%2C%2070.48384%5D%2C%20%5B-127.44712%2C%2070.37721%5D%2C%20%5B-125.75632%2C%2069.48058%5D%2C%20%5B-124.42483%2C%2070.1584%5D%2C%20%5B-124.28968%2C%2069.39969%5D%2C%20%5B-123.06108%2C%2069.56372%5D%2C%20%5B-122.6835%2C%2069.85553%5D%2C%20%5B-121.47226%2C%2069.79778%5D%2C%20%5B-119.94288%2C%2069.37786%5D%2C%20%5B-117.60268%2C%2069.01128%5D%2C%20%5B-116.22643%2C%2068.84151%5D%2C%20%5B-115.2469%2C%2068.90591%5D%2C%20%5B-113.89794%2C%2068.3989%5D%2C%20%5B-115.30489%2C%2067.90261%5D%2C%20%5B-113.49727%2C%2067.68815%5D%2C%20%5B-110.798%2C%2067.80612%5D%2C%20%5B-109.94619%2C%2067.98104%5D%2C%20%5B-108.8802%2C%2067.38144%5D%2C%20%5B-107.79239%2C%2067.88736%5D%2C%20%5B-108.81299%2C%2068.31164%5D%2C%20%5B-108.16721%2C%2068.65392%5D%2C%20%5B-106.95%2C%2068.7%5D%2C%20%5B-106.15%2C%2068.8%5D%2C%20%5B-105.34282%2C%2068.56122%5D%2C%20%5B-104.33791%2C%2068.018%5D%2C%20%5B-103.22115%2C%2068.09775%5D%2C%20%5B-101.45433%2C%2067.64689%5D%2C%20%5B-99.90195%2C%2067.80566%5D%2C%20%5B-98.4432%2C%2067.78165%5D%2C%20%5B-98.5586%2C%2068.40394%5D%2C%20%5B-97.66948%2C%2068.57864%5D%2C%20%5B-96.11991%2C%2068.23939%5D%2C%20%5B-96.12588%2C%2067.29338%5D%2C%20%5B-95.48943%2C%2068.0907%5D%2C%20%5B-94.685%2C%2068.06383%5D%2C%20%5B-94.23282%2C%2069.06903%5D%2C%20%5B-95.30408%2C%2069.68571%5D%2C%20%5B-96.47131%2C%2070.08976%5D%2C%20%5B-96.39115%2C%2071.19482%5D%2C%20%5B-95.2088%2C%2071.92053%5D%2C%20%5B-93.88997%2C%2071.76015%5D%2C%20%5B-92.87818%2C%2071.31869%5D%2C%20%5B-91.51964%2C%2070.19129%5D%2C%20%5B-92.40692%2C%2069.69997%5D%2C%20%5B-90.5471%2C%2069.49766%5D%5D%5D%2C%20%5B%5B%5B-114.16717%2C%2073.12145%5D%2C%20%5B-114.66634%2C%2072.65277%5D%2C%20%5B-112.44102%2C%2072.9554%5D%2C%20%5B-111.05039%2C%2072.4504%5D%2C%20%5B-109.92035%2C%2072.96113%5D%2C%20%5B-109.00654%2C%2072.63335%5D%2C%20%5B-108.18835%2C%2071.65089%5D%2C%20%5B-107.68599%2C%2072.06548%5D%2C%20%5B-108.39639%2C%2073.08953%5D%2C%20%5B-107.51645%2C%2073.23598%5D%2C%20%5B-106.52259%2C%2073.07601%5D%2C%20%5B-105.40246%2C%2072.67259%5D%2C%20%5B-104.77484%2C%2071.6984%5D%2C%20%5B-104.46476%2C%2070.99297%5D%2C%20%5B-102.78537%2C%2070.49776%5D%2C%20%5B-100.98078%2C%2070.02432%5D%2C%20%5B-101.08929%2C%2069.58447%5D%2C%20%5B-102.73116%2C%2069.50402%5D%2C%20%5B-102.09329%2C%2069.11962%5D%2C%20%5B-102.43024%2C%2068.75282%5D%2C%20%5B-104.24%2C%2068.91%5D%2C%20%5B-105.96%2C%2069.18%5D%2C%20%5B-107.12254%2C%2069.11922%5D%2C%20%5B-109%2C%2068.78%5D%2C%20%5B-111.534149%2C%2068.630059%5D%2C%20%5B-113.3132%2C%2068.53554%5D%2C%20%5B-113.85496%2C%2069.00744%5D%2C%20%5B-115.22%2C%2069.28%5D%2C%20%5B-116.10794%2C%2069.16821%5D%2C%20%5B-117.34%2C%2069.96%5D%2C%20%5B-116.67473%2C%2070.06655%5D%2C%20%5B-115.13112%2C%2070.2373%5D%2C%20%5B-113.72141%2C%2070.19237%5D%2C%20%5B-112.4161%2C%2070.36638%5D%2C%20%5B-114.35%2C%2070.6%5D%2C%20%5B-116.48684%2C%2070.52045%5D%2C%20%5B-117.9048%2C%2070.54056%5D%2C%20%5B-118.43238%2C%2070.9092%5D%2C%20%5B-116.11311%2C%2071.30918%5D%2C%20%5B-117.65568%2C%2071.2952%5D%2C%20%5B-119.40199%2C%2071.55859%5D%2C%20%5B-118.56267%2C%2072.30785%5D%2C%20%5B-117.86642%2C%2072.70594%5D%2C%20%5B-115.18909%2C%2073.31459%5D%2C%20%5B-114.16717%2C%2073.12145%5D%5D%5D%2C%20%5B%5B%5B-104.5%2C%2073.42%5D%2C%20%5B-105.38%2C%2072.76%5D%2C%20%5B-106.94%2C%2073.46%5D%2C%20%5B-106.6%2C%2073.6%5D%2C%20%5B-105.26%2C%2073.64%5D%2C%20%5B-104.5%2C%2073.42%5D%5D%5D%2C%20%5B%5B%5B-76.34%2C%2073.102685%5D%2C%20%5B-76.251404%2C%2072.826385%5D%2C%20%5B-77.314438%2C%2072.855545%5D%2C%20%5B-78.39167%2C%2072.876656%5D%2C%20%5B-79.486252%2C%2072.742203%5D%2C%20%5B-79.775833%2C%2072.802902%5D%2C%20%5B-80.876099%2C%2073.333183%5D%2C%20%5B-80.833885%2C%2073.693184%5D%2C%20%5B-80.353058%2C%2073.75972%5D%2C%20%5B-78.064438%2C%2073.651932%5D%2C%20%5B-76.34%2C%2073.102685%5D%5D%5D%2C%20%5B%5B%5B-86.562179%2C%2073.157447%5D%2C%20%5B-85.774371%2C%2072.534126%5D%2C%20%5B-84.850112%2C%2073.340278%5D%2C%20%5B-82.31559%2C%2073.750951%5D%2C%20%5B-80.600088%2C%2072.716544%5D%2C%20%5B-80.748942%2C%2072.061907%5D%2C%20%5B-78.770639%2C%2072.352173%5D%2C%20%5B-77.824624%2C%2072.749617%5D%2C%20%5B-75.605845%2C%2072.243678%5D%2C%20%5B-74.228616%2C%2071.767144%5D%2C%20%5B-74.099141%2C%2071.33084%5D%2C%20%5B-72.242226%2C%2071.556925%5D%2C%20%5B-71.200015%2C%2070.920013%5D%2C%20%5B-68.786054%2C%2070.525024%5D%2C%20%5B-67.91497%2C%2070.121948%5D%2C%20%5B-66.969033%2C%2069.186087%5D%2C%20%5B-68.805123%2C%2068.720198%5D%2C%20%5B-66.449866%2C%2068.067163%5D%2C%20%5B-64.862314%2C%2067.847539%5D%2C%20%5B-63.424934%2C%2066.928473%5D%2C%20%5B-61.851981%2C%2066.862121%5D%2C%20%5B-62.163177%2C%2066.160251%5D%2C%20%5B-63.918444%2C%2064.998669%5D%2C%20%5B-65.14886%2C%2065.426033%5D%2C%20%5B-66.721219%2C%2066.388041%5D%2C%20%5B-68.015016%2C%2066.262726%5D%2C%20%5B-68.141287%2C%2065.689789%5D%2C%20%5B-67.089646%2C%2065.108455%5D%2C%20%5B-65.73208%2C%2064.648406%5D%2C%20%5B-65.320168%2C%2064.382737%5D%2C%20%5B-64.669406%2C%2063.392927%5D%2C%20%5B-65.013804%2C%2062.674185%5D%2C%20%5B-66.275045%2C%2062.945099%5D%2C%20%5B-68.783186%2C%2063.74567%5D%2C%20%5B-67.369681%2C%2062.883966%5D%2C%20%5B-66.328297%2C%2062.280075%5D%2C%20%5B-66.165568%2C%2061.930897%5D%2C%20%5B-68.877367%2C%2062.330149%5D%2C%20%5B-71.023437%2C%2062.910708%5D%2C%20%5B-72.235379%2C%2063.397836%5D%2C%20%5B-71.886278%2C%2063.679989%5D%2C%20%5B-73.378306%2C%2064.193963%5D%2C%20%5B-74.834419%2C%2064.679076%5D%2C%20%5B-74.818503%2C%2064.389093%5D%2C%20%5B-77.70998%2C%2064.229542%5D%2C%20%5B-78.555949%2C%2064.572906%5D%2C%20%5B-77.897281%2C%2065.309192%5D%2C%20%5B-76.018274%2C%2065.326969%5D%2C%20%5B-73.959795%2C%2065.454765%5D%2C%20%5B-74.293883%2C%2065.811771%5D%2C%20%5B-73.944912%2C%2066.310578%5D%2C%20%5B-72.651167%2C%2067.284576%5D%2C%20%5B-72.92606%2C%2067.726926%5D%2C%20%5B-73.311618%2C%2068.069437%5D%2C%20%5B-74.843307%2C%2068.554627%5D%2C%20%5B-76.869101%2C%2068.894736%5D%2C%20%5B-76.228649%2C%2069.147769%5D%2C%20%5B-77.28737%2C%2069.76954%5D%2C%20%5B-78.168634%2C%2069.826488%5D%2C%20%5B-78.957242%2C%2070.16688%5D%2C%20%5B-79.492455%2C%2069.871808%5D%2C%20%5B-81.305471%2C%2069.743185%5D%2C%20%5B-84.944706%2C%2069.966634%5D%2C%20%5B-87.060003%2C%2070.260001%5D%2C%20%5B-88.681713%2C%2070.410741%5D%2C%20%5B-89.51342%2C%2070.762038%5D%2C%20%5B-88.467721%2C%2071.218186%5D%2C%20%5B-89.888151%2C%2071.222552%5D%2C%20%5B-90.20516%2C%2072.235074%5D%2C%20%5B-89.436577%2C%2073.129464%5D%2C%20%5B-88.408242%2C%2073.537889%5D%2C%20%5B-85.826151%2C%2073.803816%5D%2C%20%5B-86.562179%2C%2073.157447%5D%5D%5D%2C%20%5B%5B%5B-100.35642%2C%2073.84389%5D%2C%20%5B-99.16387%2C%2073.63339%5D%2C%20%5B-97.38%2C%2073.76%5D%2C%20%5B-97.12%2C%2073.47%5D%2C%20%5B-98.05359%2C%2072.99052%5D%2C%20%5B-96.54%2C%2072.56%5D%2C%20%5B-96.72%2C%2071.66%5D%2C%20%5B-98.35966%2C%2071.27285%5D%2C%20%5B-99.32286%2C%2071.35639%5D%2C%20%5B-100.01482%2C%2071.73827%5D%2C%20%5B-102.5%2C%2072.51%5D%2C%20%5B-102.48%2C%2072.83%5D%2C%20%5B-100.43836%2C%2072.70588%5D%2C%20%5B-101.54%2C%2073.36%5D%2C%20%5B-100.35642%2C%2073.84389%5D%5D%5D%2C%20%5B%5B%5B-93.196296%2C%2072.771992%5D%2C%20%5B-94.269047%2C%2072.024596%5D%2C%20%5B-95.409856%2C%2072.061881%5D%2C%20%5B-96.033745%2C%2072.940277%5D%2C%20%5B-96.018268%2C%2073.43743%5D%2C%20%5B-95.495793%2C%2073.862417%5D%2C%20%5B-94.503658%2C%2074.134907%5D%2C%20%5B-92.420012%2C%2074.100025%5D%2C%20%5B-90.509793%2C%2073.856732%5D%2C%20%5B-92.003965%2C%2072.966244%5D%2C%20%5B-93.196296%2C%2072.771992%5D%5D%5D%2C%20%5B%5B%5B-120.46%2C%2071.383602%5D%2C%20%5B-123.09219%2C%2070.90164%5D%2C%20%5B-123.62%2C%2071.34%5D%2C%20%5B-125.928949%2C%2071.868688%5D%2C%20%5B-125.5%2C%2072.292261%5D%2C%20%5B-124.80729%2C%2073.02256%5D%2C%20%5B-123.94%2C%2073.68%5D%2C%20%5B-124.91775%2C%2074.29275%5D%2C%20%5B-121.53788%2C%2074.44893%5D%2C%20%5B-120.10978%2C%2074.24135%5D%2C%20%5B-117.55564%2C%2074.18577%5D%2C%20%5B-116.58442%2C%2073.89607%5D%2C%20%5B-115.51081%2C%2073.47519%5D%2C%20%5B-116.76794%2C%2073.22292%5D%2C%20%5B-119.22%2C%2072.52%5D%2C%20%5B-120.46%2C%2071.82%5D%2C%20%5B-120.46%2C%2071.383602%5D%5D%5D%2C%20%5B%5B%5B-93.612756%2C%2074.979997%5D%2C%20%5B-94.156909%2C%2074.592347%5D%2C%20%5B-95.608681%2C%2074.666864%5D%2C%20%5B-96.820932%2C%2074.927623%5D%2C%20%5B-96.288587%2C%2075.377828%5D%2C%20%5B-94.85082%2C%2075.647218%5D%2C%20%5B-93.977747%2C%2075.29649%5D%2C%20%5B-93.612756%2C%2074.979997%5D%5D%5D%2C%20%5B%5B%5B-98.5%2C%2076.72%5D%2C%20%5B-97.735585%2C%2076.25656%5D%2C%20%5B-97.704415%2C%2075.74344%5D%2C%20%5B-98.16%2C%2075%5D%2C%20%5B-99.80874%2C%2074.89744%5D%2C%20%5B-100.88366%2C%2075.05736%5D%2C%20%5B-100.86292%2C%2075.64075%5D%2C%20%5B-102.50209%2C%2075.5638%5D%2C%20%5B-102.56552%2C%2076.3366%5D%2C%20%5B-101.48973%2C%2076.30537%5D%2C%20%5B-99.98349%2C%2076.64634%5D%2C%20%5B-98.57699%2C%2076.58859%5D%2C%20%5B-98.5%2C%2076.72%5D%5D%5D%2C%20%5B%5B%5B-108.21141%2C%2076.20168%5D%2C%20%5B-107.81943%2C%2075.84552%5D%2C%20%5B-106.92893%2C%2076.01282%5D%2C%20%5B-105.881%2C%2075.9694%5D%2C%20%5B-105.70498%2C%2075.47951%5D%2C%20%5B-106.31347%2C%2075.00527%5D%2C%20%5B-109.7%2C%2074.85%5D%2C%20%5B-112.22307%2C%2074.41696%5D%2C%20%5B-113.74381%2C%2074.39427%5D%2C%20%5B-113.87135%2C%2074.72029%5D%2C%20%5B-111.79421%2C%2075.1625%5D%2C%20%5B-116.31221%2C%2075.04343%5D%2C%20%5B-117.7104%2C%2075.2222%5D%2C%20%5B-116.34602%2C%2076.19903%5D%2C%20%5B-115.40487%2C%2076.47887%5D%2C%20%5B-112.59056%2C%2076.14134%5D%2C%20%5B-110.81422%2C%2075.54919%5D%2C%20%5B-109.0671%2C%2075.47321%5D%2C%20%5B-110.49726%2C%2076.42982%5D%2C%20%5B-109.5811%2C%2076.79417%5D%2C%20%5B-108.54859%2C%2076.67832%5D%2C%20%5B-108.21141%2C%2076.20168%5D%5D%5D%2C%20%5B%5B%5B-94.684086%2C%2077.097878%5D%2C%20%5B-93.573921%2C%2076.776296%5D%2C%20%5B-91.605023%2C%2076.778518%5D%2C%20%5B-90.741846%2C%2076.449597%5D%2C%20%5B-90.969661%2C%2076.074013%5D%2C%20%5B-89.822238%2C%2075.847774%5D%2C%20%5B-89.187083%2C%2075.610166%5D%2C%20%5B-87.838276%2C%2075.566189%5D%2C%20%5B-86.379192%2C%2075.482421%5D%2C%20%5B-84.789625%2C%2075.699204%5D%2C%20%5B-82.753445%2C%2075.784315%5D%2C%20%5B-81.128531%2C%2075.713983%5D%2C%20%5B-80.057511%2C%2075.336849%5D%2C%20%5B-79.833933%2C%2074.923127%5D%2C%20%5B-80.457771%2C%2074.657304%5D%2C%20%5B-81.948843%2C%2074.442459%5D%2C%20%5B-83.228894%2C%2074.564028%5D%2C%20%5B-86.097452%2C%2074.410032%5D%2C%20%5B-88.15035%2C%2074.392307%5D%2C%20%5B-89.764722%2C%2074.515555%5D%2C%20%5B-92.422441%2C%2074.837758%5D%2C%20%5B-92.768285%2C%2075.38682%5D%2C%20%5B-92.889906%2C%2075.882655%5D%2C%20%5B-93.893824%2C%2076.319244%5D%2C%20%5B-95.962457%2C%2076.441381%5D%2C%20%5B-97.121379%2C%2076.751078%5D%2C%20%5B-96.745123%2C%2077.161389%5D%2C%20%5B-94.684086%2C%2077.097878%5D%5D%5D%2C%20%5B%5B%5B-116.198587%2C%2077.645287%5D%2C%20%5B-116.335813%2C%2076.876962%5D%2C%20%5B-117.106051%2C%2076.530032%5D%2C%20%5B-118.040412%2C%2076.481172%5D%2C%20%5B-119.899318%2C%2076.053213%5D%2C%20%5B-121.499995%2C%2075.900019%5D%2C%20%5B-122.854924%2C%2076.116543%5D%2C%20%5B-122.854925%2C%2076.116543%5D%2C%20%5B-121.157535%2C%2076.864508%5D%2C%20%5B-119.103939%2C%2077.51222%5D%2C%20%5B-117.570131%2C%2077.498319%5D%2C%20%5B-116.198587%2C%2077.645287%5D%5D%5D%2C%20%5B%5B%5B-93.840003%2C%2077.519997%5D%2C%20%5B-94.295608%2C%2077.491343%5D%2C%20%5B-96.169654%2C%2077.555111%5D%2C%20%5B-96.436304%2C%2077.834629%5D%2C%20%5B-94.422577%2C%2077.820005%5D%2C%20%5B-93.720656%2C%2077.634331%5D%2C%20%5B-93.840003%2C%2077.519997%5D%5D%5D%2C%20%5B%5B%5B-110.186938%2C%2077.697015%5D%2C%20%5B-112.051191%2C%2077.409229%5D%2C%20%5B-113.534279%2C%2077.732207%5D%2C%20%5B-112.724587%2C%2078.05105%5D%2C%20%5B-111.264443%2C%2078.152956%5D%2C%20%5B-109.854452%2C%2077.996325%5D%2C%20%5B-110.186938%2C%2077.697015%5D%5D%5D%2C%20%5B%5B%5B-109.663146%2C%2078.601973%5D%2C%20%5B-110.881314%2C%2078.40692%5D%2C%20%5B-112.542091%2C%2078.407902%5D%2C%20%5B-112.525891%2C%2078.550555%5D%2C%20%5B-111.50001%2C%2078.849994%5D%2C%20%5B-110.963661%2C%2078.804441%5D%2C%20%5B-109.663146%2C%2078.601973%5D%5D%5D%2C%20%5B%5B%5B-95.830295%2C%2078.056941%5D%2C%20%5B-97.309843%2C%2077.850597%5D%2C%20%5B-98.124289%2C%2078.082857%5D%2C%20%5B-98.552868%2C%2078.458105%5D%2C%20%5B-98.631984%2C%2078.87193%5D%2C%20%5B-97.337231%2C%2078.831984%5D%2C%20%5B-96.754399%2C%2078.765813%5D%2C%20%5B-95.559278%2C%2078.418315%5D%2C%20%5B-95.830295%2C%2078.056941%5D%5D%5D%2C%20%5B%5B%5B-100.060192%2C%2078.324754%5D%2C%20%5B-99.670939%2C%2077.907545%5D%2C%20%5B-101.30394%2C%2078.018985%5D%2C%20%5B-102.949809%2C%2078.343229%5D%2C%20%5B-105.176133%2C%2078.380332%5D%2C%20%5B-104.210429%2C%2078.67742%5D%2C%20%5B-105.41958%2C%2078.918336%5D%2C%20%5B-105.492289%2C%2079.301594%5D%2C%20%5B-103.529282%2C%2079.165349%5D%2C%20%5B-100.825158%2C%2078.800462%5D%2C%20%5B-100.060192%2C%2078.324754%5D%5D%5D%2C%20%5B%5B%5B-87.02%2C%2079.66%5D%2C%20%5B-85.81435%2C%2079.3369%5D%2C%20%5B-87.18756%2C%2079.0393%5D%2C%20%5B-89.03535%2C%2078.28723%5D%2C%20%5B-90.80436%2C%2078.21533%5D%2C%20%5B-92.87669%2C%2078.34333%5D%2C%20%5B-93.95116%2C%2078.75099%5D%2C%20%5B-93.93574%2C%2079.11373%5D%2C%20%5B-93.14524%2C%2079.3801%5D%2C%20%5B-94.974%2C%2079.37248%5D%2C%20%5B-96.07614%2C%2079.70502%5D%2C%20%5B-96.70972%2C%2080.15777%5D%2C%20%5B-96.01644%2C%2080.60233%5D%2C%20%5B-95.32345%2C%2080.90729%5D%2C%20%5B-94.29843%2C%2080.97727%5D%2C%20%5B-94.73542%2C%2081.20646%5D%2C%20%5B-92.40984%2C%2081.25739%5D%2C%20%5B-91.13289%2C%2080.72345%5D%2C%20%5B-89.45%2C%2080.509322%5D%2C%20%5B-87.81%2C%2080.32%5D%2C%20%5B-87.02%2C%2079.66%5D%5D%5D%2C%20%5B%5B%5B-68.5%2C%2083.106322%5D%2C%20%5B-65.82735%2C%2083.02801%5D%2C%20%5B-63.68%2C%2082.9%5D%2C%20%5B-61.85%2C%2082.6286%5D%2C%20%5B-61.89388%2C%2082.36165%5D%2C%20%5B-64.334%2C%2081.92775%5D%2C%20%5B-66.75342%2C%2081.72527%5D%2C%20%5B-67.65755%2C%2081.50141%5D%2C%20%5B-65.48031%2C%2081.50657%5D%2C%20%5B-67.84%2C%2080.9%5D%2C%20%5B-69.4697%2C%2080.61683%5D%2C%20%5B-71.18%2C%2079.8%5D%2C%20%5B-73.2428%2C%2079.63415%5D%2C%20%5B-73.88%2C%2079.430162%5D%2C%20%5B-76.90773%2C%2079.32309%5D%2C%20%5B-75.52924%2C%2079.19766%5D%2C%20%5B-76.22046%2C%2079.01907%5D%2C%20%5B-75.39345%2C%2078.52581%5D%2C%20%5B-76.34354%2C%2078.18296%5D%2C%20%5B-77.88851%2C%2077.89991%5D%2C%20%5B-78.36269%2C%2077.50859%5D%2C%20%5B-79.75951%2C%2077.20968%5D%2C%20%5B-79.61965%2C%2076.98336%5D%2C%20%5B-77.91089%2C%2077.022045%5D%2C%20%5B-77.88911%2C%2076.777955%5D%2C%20%5B-80.56125%2C%2076.17812%5D%2C%20%5B-83.17439%2C%2076.45403%5D%2C%20%5B-86.11184%2C%2076.29901%5D%2C%20%5B-87.6%2C%2076.42%5D%2C%20%5B-89.49068%2C%2076.47239%5D%2C%20%5B-89.6161%2C%2076.95213%5D%2C%20%5B-87.76739%2C%2077.17833%5D%2C%20%5B-88.26%2C%2077.9%5D%2C%20%5B-87.65%2C%2077.970222%5D%2C%20%5B-84.97634%2C%2077.53873%5D%2C%20%5B-86.34%2C%2078.18%5D%2C%20%5B-87.96192%2C%2078.37181%5D%2C%20%5B-87.15198%2C%2078.75867%5D%2C%20%5B-85.37868%2C%2078.9969%5D%2C%20%5B-85.09495%2C%2079.34543%5D%2C%20%5B-86.50734%2C%2079.73624%5D%2C%20%5B-86.93179%2C%2080.25145%5D%2C%20%5B-84.19844%2C%2080.20836%5D%2C%20%5B-83.408696%2C%2080.1%5D%2C%20%5B-81.84823%2C%2080.46442%5D%2C%20%5B-84.1%2C%2080.58%5D%2C%20%5B-87.59895%2C%2080.51627%5D%2C%20%5B-89.36663%2C%2080.85569%5D%2C%20%5B-90.2%2C%2081.26%5D%2C%20%5B-91.36786%2C%2081.5531%5D%2C%20%5B-91.58702%2C%2081.89429%5D%2C%20%5B-90.1%2C%2082.085%5D%2C%20%5B-88.93227%2C%2082.11751%5D%2C%20%5B-86.97024%2C%2082.27961%5D%2C%20%5B-85.5%2C%2082.652273%5D%2C%20%5B-84.260005%2C%2082.6%5D%2C%20%5B-83.18%2C%2082.32%5D%2C%20%5B-82.42%2C%2082.86%5D%2C%20%5B-81.1%2C%2083.02%5D%2C%20%5B-79.30664%2C%2083.13056%5D%2C%20%5B-76.25%2C%2083.172059%5D%2C%20%5B-75.71878%2C%2083.06404%5D%2C%20%5B-72.83153%2C%2083.23324%5D%2C%20%5B-70.665765%2C%2083.169781%5D%2C%20%5B-68.5%2C%2083.106322%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22CAN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Canada%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B9.594226%2C%2047.525058%5D%2C%20%5B9.632932%2C%2047.347601%5D%2C%20%5B9.47997%2C%2047.10281%5D%2C%20%5B9.932448%2C%2046.920728%5D%2C%20%5B10.442701%2C%2046.893546%5D%2C%20%5B10.363378%2C%2046.483571%5D%2C%20%5B9.922837%2C%2046.314899%5D%2C%20%5B9.182882%2C%2046.440215%5D%2C%20%5B8.966306%2C%2046.036932%5D%2C%20%5B8.489952%2C%2046.005151%5D%2C%20%5B8.31663%2C%2046.163642%5D%2C%20%5B7.755992%2C%2045.82449%5D%2C%20%5B7.273851%2C%2045.776948%5D%2C%20%5B6.843593%2C%2045.991147%5D%2C%20%5B6.5001%2C%2046.429673%5D%2C%20%5B6.022609%2C%2046.27299%5D%2C%20%5B6.037389%2C%2046.725779%5D%2C%20%5B6.768714%2C%2047.287708%5D%2C%20%5B6.736571%2C%2047.541801%5D%2C%20%5B7.192202%2C%2047.449766%5D%2C%20%5B7.466759%2C%2047.620582%5D%2C%20%5B8.317301%2C%2047.61358%5D%2C%20%5B8.522612%2C%2047.830828%5D%2C%20%5B9.594226%2C%2047.525058%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22CHE%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Switzerland%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B-68.63401%2C%20-52.63637%5D%2C%20%5B-68.63335%2C%20-54.8695%5D%2C%20%5B-67.56244%2C%20-54.87001%5D%2C%20%5B-66.95992%2C%20-54.89681%5D%2C%20%5B-67.29103%2C%20-55.30124%5D%2C%20%5B-68.14863%2C%20-55.61183%5D%2C%20%5B-68.639991%2C%20-55.580018%5D%2C%20%5B-69.2321%2C%20-55.49906%5D%2C%20%5B-69.95809%2C%20-55.19843%5D%2C%20%5B-71.00568%2C%20-55.05383%5D%2C%20%5B-72.2639%2C%20-54.49514%5D%2C%20%5B-73.2852%2C%20-53.95752%5D%2C%20%5B-74.66253%2C%20-52.83749%5D%2C%20%5B-73.8381%2C%20-53.04743%5D%2C%20%5B-72.43418%2C%20-53.7154%5D%2C%20%5B-71.10773%2C%20-54.07433%5D%2C%20%5B-70.59178%2C%20-53.61583%5D%2C%20%5B-70.26748%2C%20-52.93123%5D%2C%20%5B-69.34565%2C%20-52.5183%5D%2C%20%5B-68.63401%2C%20-52.63637%5D%5D%5D%2C%20%5B%5B%5B-68.219913%2C%20-21.494347%5D%2C%20%5B-67.82818%2C%20-22.872919%5D%2C%20%5B-67.106674%2C%20-22.735925%5D%2C%20%5B-66.985234%2C%20-22.986349%5D%2C%20%5B-67.328443%2C%20-24.025303%5D%2C%20%5B-68.417653%2C%20-24.518555%5D%2C%20%5B-68.386001%2C%20-26.185016%5D%2C%20%5B-68.5948%2C%20-26.506909%5D%2C%20%5B-68.295542%2C%20-26.89934%5D%2C%20%5B-69.001235%2C%20-27.521214%5D%2C%20%5B-69.65613%2C%20-28.459141%5D%2C%20%5B-70.01355%2C%20-29.367923%5D%2C%20%5B-69.919008%2C%20-30.336339%5D%2C%20%5B-70.535069%2C%20-31.36501%5D%2C%20%5B-70.074399%2C%20-33.09121%5D%2C%20%5B-69.814777%2C%20-33.273886%5D%2C%20%5B-69.817309%2C%20-34.193571%5D%2C%20%5B-70.388049%2C%20-35.169688%5D%2C%20%5B-70.364769%2C%20-36.005089%5D%2C%20%5B-71.121881%2C%20-36.658124%5D%2C%20%5B-71.118625%2C%20-37.576827%5D%2C%20%5B-70.814664%2C%20-38.552995%5D%2C%20%5B-71.413517%2C%20-38.916022%5D%2C%20%5B-71.680761%2C%20-39.808164%5D%2C%20%5B-71.915734%2C%20-40.832339%5D%2C%20%5B-71.746804%2C%20-42.051386%5D%2C%20%5B-72.148898%2C%20-42.254888%5D%2C%20%5B-71.915424%2C%20-43.408565%5D%2C%20%5B-71.464056%2C%20-43.787611%5D%2C%20%5B-71.793623%2C%20-44.207172%5D%2C%20%5B-71.329801%2C%20-44.407522%5D%2C%20%5B-71.222779%2C%20-44.784243%5D%2C%20%5B-71.659316%2C%20-44.973689%5D%2C%20%5B-71.552009%2C%20-45.560733%5D%2C%20%5B-71.917258%2C%20-46.884838%5D%2C%20%5B-72.447355%2C%20-47.738533%5D%2C%20%5B-72.331161%2C%20-48.244238%5D%2C%20%5B-72.648247%2C%20-48.878618%5D%2C%20%5B-73.415436%2C%20-49.318436%5D%2C%20%5B-73.328051%2C%20-50.378785%5D%2C%20%5B-72.975747%2C%20-50.74145%5D%2C%20%5B-72.309974%2C%20-50.67701%5D%2C%20%5B-72.329404%2C%20-51.425956%5D%2C%20%5B-71.914804%2C%20-52.009022%5D%2C%20%5B-69.498362%2C%20-52.142761%5D%2C%20%5B-68.571545%2C%20-52.299444%5D%2C%20%5B-69.461284%2C%20-52.291951%5D%2C%20%5B-69.94278%2C%20-52.537931%5D%2C%20%5B-70.845102%2C%20-52.899201%5D%2C%20%5B-71.006332%2C%20-53.833252%5D%2C%20%5B-71.429795%2C%20-53.856455%5D%2C%20%5B-72.557943%2C%20-53.53141%5D%2C%20%5B-73.702757%2C%20-52.835069%5D%2C%20%5B-73.702757%2C%20-52.83507%5D%2C%20%5B-74.946763%2C%20-52.262754%5D%2C%20%5B-75.260026%2C%20-51.629355%5D%2C%20%5B-74.976632%2C%20-51.043396%5D%2C%20%5B-75.479754%2C%20-50.378372%5D%2C%20%5B-75.608015%2C%20-48.673773%5D%2C%20%5B-75.18277%2C%20-47.711919%5D%2C%20%5B-74.126581%2C%20-46.939253%5D%2C%20%5B-75.644395%2C%20-46.647643%5D%2C%20%5B-74.692154%2C%20-45.763976%5D%2C%20%5B-74.351709%2C%20-44.103044%5D%2C%20%5B-73.240356%2C%20-44.454961%5D%2C%20%5B-72.717804%2C%20-42.383356%5D%2C%20%5B-73.3889%2C%20-42.117532%5D%2C%20%5B-73.701336%2C%20-43.365776%5D%2C%20%5B-74.331943%2C%20-43.224958%5D%2C%20%5B-74.017957%2C%20-41.794813%5D%2C%20%5B-73.677099%2C%20-39.942213%5D%2C%20%5B-73.217593%2C%20-39.258689%5D%2C%20%5B-73.505559%2C%20-38.282883%5D%2C%20%5B-73.588061%2C%20-37.156285%5D%2C%20%5B-73.166717%2C%20-37.12378%5D%2C%20%5B-72.553137%2C%20-35.50884%5D%2C%20%5B-71.861732%2C%20-33.909093%5D%2C%20%5B-71.43845%2C%20-32.418899%5D%2C%20%5B-71.668721%2C%20-30.920645%5D%2C%20%5B-71.370083%2C%20-30.095682%5D%2C%20%5B-71.489894%2C%20-28.861442%5D%2C%20%5B-70.905124%2C%20-27.64038%5D%2C%20%5B-70.724954%2C%20-25.705924%5D%2C%20%5B-70.403966%2C%20-23.628997%5D%2C%20%5B-70.091246%2C%20-21.393319%5D%2C%20%5B-70.16442%2C%20-19.756468%5D%2C%20%5B-70.372572%2C%20-18.347975%5D%2C%20%5B-69.858444%2C%20-18.092694%5D%2C%20%5B-69.590424%2C%20-17.580012%5D%2C%20%5B-69.100247%2C%20-18.260125%5D%2C%20%5B-68.966818%2C%20-18.981683%5D%2C%20%5B-68.442225%2C%20-19.405068%5D%2C%20%5B-68.757167%2C%20-20.372658%5D%2C%20%5B-68.219913%2C%20-21.494347%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22CHL%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Chile%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B110.339188%2C%2018.678395%5D%2C%20%5B109.47521%2C%2018.197701%5D%2C%20%5B108.655208%2C%2018.507682%5D%2C%20%5B108.626217%2C%2019.367888%5D%2C%20%5B109.119056%2C%2019.821039%5D%2C%20%5B110.211599%2C%2020.101254%5D%2C%20%5B110.786551%2C%2020.077534%5D%2C%20%5B111.010051%2C%2019.69593%5D%2C%20%5B110.570647%2C%2019.255879%5D%2C%20%5B110.339188%2C%2018.678395%5D%5D%5D%2C%20%5B%5B%5B127.657407%2C%2049.76027%5D%2C%20%5B129.397818%2C%2049.4406%5D%2C%20%5B130.582293%2C%2048.729687%5D%2C%20%5B130.987282%2C%2047.790132%5D%2C%20%5B132.506672%2C%2047.78897%5D%2C%20%5B133.373596%2C%2048.183442%5D%2C%20%5B135.026311%2C%2048.47823%5D%2C%20%5B134.500814%2C%2047.57844%5D%2C%20%5B134.112362%2C%2047.212467%5D%2C%20%5B133.769644%2C%2046.116927%5D%2C%20%5B133.097127%2C%2045.144066%5D%2C%20%5B131.883454%2C%2045.321162%5D%2C%20%5B131.025212%2C%2044.967953%5D%2C%20%5B131.288555%2C%2044.11152%5D%2C%20%5B131.144688%2C%2042.92999%5D%2C%20%5B130.633866%2C%2042.903015%5D%2C%20%5B130.640016%2C%2042.395009%5D%2C%20%5B129.994267%2C%2042.985387%5D%2C%20%5B129.596669%2C%2042.424982%5D%2C%20%5B128.052215%2C%2041.994285%5D%2C%20%5B128.208433%2C%2041.466772%5D%2C%20%5B127.343783%2C%2041.503152%5D%2C%20%5B126.869083%2C%2041.816569%5D%2C%20%5B126.182045%2C%2041.107336%5D%2C%20%5B125.079942%2C%2040.569824%5D%2C%20%5B124.265625%2C%2039.928493%5D%2C%20%5B122.86757%2C%2039.637788%5D%2C%20%5B122.131388%2C%2039.170452%5D%2C%20%5B121.054554%2C%2038.897471%5D%2C%20%5B121.585995%2C%2039.360854%5D%2C%20%5B121.376757%2C%2039.750261%5D%2C%20%5B122.168595%2C%2040.422443%5D%2C%20%5B121.640359%2C%2040.94639%5D%2C%20%5B120.768629%2C%2040.593388%5D%2C%20%5B119.639602%2C%2039.898056%5D%2C%20%5B119.023464%2C%2039.252333%5D%2C%20%5B118.042749%2C%2039.204274%5D%2C%20%5B117.532702%2C%2038.737636%5D%2C%20%5B118.059699%2C%2038.061476%5D%2C%20%5B118.87815%2C%2037.897325%5D%2C%20%5B118.911636%2C%2037.448464%5D%2C%20%5B119.702802%2C%2037.156389%5D%2C%20%5B120.823457%2C%2037.870428%5D%2C%20%5B121.711259%2C%2037.481123%5D%2C%20%5B122.357937%2C%2037.454484%5D%2C%20%5B122.519995%2C%2036.930614%5D%2C%20%5B121.104164%2C%2036.651329%5D%2C%20%5B120.637009%2C%2036.11144%5D%2C%20%5B119.664562%2C%2035.609791%5D%2C%20%5B119.151208%2C%2034.909859%5D%2C%20%5B120.227525%2C%2034.360332%5D%2C%20%5B120.620369%2C%2033.376723%5D%2C%20%5B121.229014%2C%2032.460319%5D%2C%20%5B121.908146%2C%2031.692174%5D%2C%20%5B121.891919%2C%2030.949352%5D%2C%20%5B121.264257%2C%2030.676267%5D%2C%20%5B121.503519%2C%2030.142915%5D%2C%20%5B122.092114%2C%2029.83252%5D%2C%20%5B121.938428%2C%2029.018022%5D%2C%20%5B121.684439%2C%2028.225513%5D%2C%20%5B121.125661%2C%2028.135673%5D%2C%20%5B120.395473%2C%2027.053207%5D%2C%20%5B119.585497%2C%2025.740781%5D%2C%20%5B118.656871%2C%2024.547391%5D%2C%20%5B117.281606%2C%2023.624501%5D%2C%20%5B115.890735%2C%2022.782873%5D%2C%20%5B114.763827%2C%2022.668074%5D%2C%20%5B114.152547%2C%2022.22376%5D%2C%20%5B113.80678%2C%2022.54834%5D%2C%20%5B113.241078%2C%2022.051367%5D%2C%20%5B111.843592%2C%2021.550494%5D%2C%20%5B110.785466%2C%2021.397144%5D%2C%20%5B110.444039%2C%2020.341033%5D%2C%20%5B109.889861%2C%2020.282457%5D%2C%20%5B109.627655%2C%2021.008227%5D%2C%20%5B109.864488%2C%2021.395051%5D%2C%20%5B108.522813%2C%2021.715212%5D%2C%20%5B108.05018%2C%2021.55238%5D%2C%20%5B107.04342%2C%2021.811899%5D%2C%20%5B106.567273%2C%2022.218205%5D%2C%20%5B106.725403%2C%2022.794268%5D%2C%20%5B105.811247%2C%2022.976892%5D%2C%20%5B105.329209%2C%2023.352063%5D%2C%20%5B104.476858%2C%2022.81915%5D%2C%20%5B103.504515%2C%2022.703757%5D%2C%20%5B102.706992%2C%2022.708795%5D%2C%20%5B102.170436%2C%2022.464753%5D%2C%20%5B101.652018%2C%2022.318199%5D%2C%20%5B101.80312%2C%2021.174367%5D%2C%20%5B101.270026%2C%2021.201652%5D%2C%20%5B101.180005%2C%2021.436573%5D%2C%20%5B101.150033%2C%2021.849984%5D%2C%20%5B100.416538%2C%2021.558839%5D%2C%20%5B99.983489%2C%2021.742937%5D%2C%20%5B99.240899%2C%2022.118314%5D%2C%20%5B99.531992%2C%2022.949039%5D%2C%20%5B98.898749%2C%2023.142722%5D%2C%20%5B98.660262%2C%2024.063286%5D%2C%20%5B97.60472%2C%2023.897405%5D%2C%20%5B97.724609%2C%2025.083637%5D%2C%20%5B98.671838%2C%2025.918703%5D%2C%20%5B98.712094%2C%2026.743536%5D%2C%20%5B98.68269%2C%2027.508812%5D%2C%20%5B98.246231%2C%2027.747221%5D%2C%20%5B97.911988%2C%2028.335945%5D%2C%20%5B97.327114%2C%2028.261583%5D%2C%20%5B96.248833%2C%2028.411031%5D%2C%20%5B96.586591%2C%2028.83098%5D%2C%20%5B96.117679%2C%2029.452802%5D%2C%20%5B95.404802%2C%2029.031717%5D%2C%20%5B94.56599%2C%2029.277438%5D%2C%20%5B93.413348%2C%2028.640629%5D%2C%20%5B92.503119%2C%2027.896876%5D%2C%20%5B91.696657%2C%2027.771742%5D%2C%20%5B91.258854%2C%2028.040614%5D%2C%20%5B90.730514%2C%2028.064954%5D%2C%20%5B90.015829%2C%2028.296439%5D%2C%20%5B89.47581%2C%2028.042759%5D%2C%20%5B88.814248%2C%2027.299316%5D%2C%20%5B88.730326%2C%2028.086865%5D%2C%20%5B88.120441%2C%2027.876542%5D%2C%20%5B86.954517%2C%2027.974262%5D%2C%20%5B85.82332%2C%2028.203576%5D%2C%20%5B85.011638%2C%2028.642774%5D%2C%20%5B84.23458%2C%2028.839894%5D%2C%20%5B83.898993%2C%2029.320226%5D%2C%20%5B83.337115%2C%2029.463732%5D%2C%20%5B82.327513%2C%2030.115268%5D%2C%20%5B81.525804%2C%2030.422717%5D%2C%20%5B81.111256%2C%2030.183481%5D%2C%20%5B79.721367%2C%2030.882715%5D%2C%20%5B78.738894%2C%2031.515906%5D%2C%20%5B78.458446%2C%2032.618164%5D%2C%20%5B79.176129%2C%2032.48378%5D%2C%20%5B79.208892%2C%2032.994395%5D%2C%20%5B78.811086%2C%2033.506198%5D%2C%20%5B78.912269%2C%2034.321936%5D%2C%20%5B77.837451%2C%2035.49401%5D%2C%20%5B76.192848%2C%2035.898403%5D%2C%20%5B75.896897%2C%2036.666806%5D%2C%20%5B75.158028%2C%2037.133031%5D%2C%20%5B74.980002%2C%2037.41999%5D%2C%20%5B74.829986%2C%2037.990007%5D%2C%20%5B74.864816%2C%2038.378846%5D%2C%20%5B74.257514%2C%2038.606507%5D%2C%20%5B73.928852%2C%2038.505815%5D%2C%20%5B73.675379%2C%2039.431237%5D%2C%20%5B73.960013%2C%2039.660008%5D%2C%20%5B73.822244%2C%2039.893973%5D%2C%20%5B74.776862%2C%2040.366425%5D%2C%20%5B75.467828%2C%2040.562072%5D%2C%20%5B76.526368%2C%2040.427946%5D%2C%20%5B76.904484%2C%2041.066486%5D%2C%20%5B78.187197%2C%2041.185316%5D%2C%20%5B78.543661%2C%2041.582243%5D%2C%20%5B80.11943%2C%2042.123941%5D%2C%20%5B80.25999%2C%2042.349999%5D%2C%20%5B80.18015%2C%2042.920068%5D%2C%20%5B80.866206%2C%2043.180362%5D%2C%20%5B79.966106%2C%2044.917517%5D%2C%20%5B81.947071%2C%2045.317027%5D%2C%20%5B82.458926%2C%2045.53965%5D%2C%20%5B83.180484%2C%2047.330031%5D%2C%20%5B85.16429%2C%2047.000956%5D%2C%20%5B85.720484%2C%2047.452969%5D%2C%20%5B85.768233%2C%2048.455751%5D%2C%20%5B86.598776%2C%2048.549182%5D%2C%20%5B87.35997%2C%2049.214981%5D%2C%20%5B87.751264%2C%2049.297198%5D%2C%20%5B88.013832%2C%2048.599463%5D%2C%20%5B88.854298%2C%2048.069082%5D%2C%20%5B90.280826%2C%2047.693549%5D%2C%20%5B90.970809%2C%2046.888146%5D%2C%20%5B90.585768%2C%2045.719716%5D%2C%20%5B90.94554%2C%2045.286073%5D%2C%20%5B92.133891%2C%2045.115076%5D%2C%20%5B93.480734%2C%2044.975472%5D%2C%20%5B94.688929%2C%2044.352332%5D%2C%20%5B95.306875%2C%2044.241331%5D%2C%20%5B95.762455%2C%2043.319449%5D%2C%20%5B96.349396%2C%2042.725635%5D%2C%20%5B97.451757%2C%2042.74889%5D%2C%20%5B99.515817%2C%2042.524691%5D%2C%20%5B100.845866%2C%2042.663804%5D%2C%20%5B101.83304%2C%2042.514873%5D%2C%20%5B103.312278%2C%2041.907468%5D%2C%20%5B104.522282%2C%2041.908347%5D%2C%20%5B104.964994%2C%2041.59741%5D%2C%20%5B106.129316%2C%2042.134328%5D%2C%20%5B107.744773%2C%2042.481516%5D%2C%20%5B109.243596%2C%2042.519446%5D%2C%20%5B110.412103%2C%2042.871234%5D%2C%20%5B111.129682%2C%2043.406834%5D%2C%20%5B111.829588%2C%2043.743118%5D%2C%20%5B111.667737%2C%2044.073176%5D%2C%20%5B111.348377%2C%2044.457442%5D%2C%20%5B111.873306%2C%2045.102079%5D%2C%20%5B112.436062%2C%2045.011646%5D%2C%20%5B113.463907%2C%2044.808893%5D%2C%20%5B114.460332%2C%2045.339817%5D%2C%20%5B115.985096%2C%2045.727235%5D%2C%20%5B116.717868%2C%2046.388202%5D%2C%20%5B117.421701%2C%2046.672733%5D%2C%20%5B118.874326%2C%2046.805412%5D%2C%20%5B119.66327%2C%2046.69268%5D%2C%20%5B119.772824%2C%2047.048059%5D%2C%20%5B118.866574%2C%2047.74706%5D%2C%20%5B118.064143%2C%2048.06673%5D%2C%20%5B117.295507%2C%2047.697709%5D%2C%20%5B116.308953%2C%2047.85341%5D%2C%20%5B115.742837%2C%2047.726545%5D%2C%20%5B115.485282%2C%2048.135383%5D%2C%20%5B116.191802%2C%2049.134598%5D%2C%20%5B116.678801%2C%2049.888531%5D%2C%20%5B117.879244%2C%2049.510983%5D%2C%20%5B119.288461%2C%2050.142883%5D%2C%20%5B119.279366%2C%2050.582908%5D%2C%20%5B120.18205%2C%2051.643566%5D%2C%20%5B120.738191%2C%2051.964115%5D%2C%20%5B120.725789%2C%2052.516226%5D%2C%20%5B120.177089%2C%2052.753886%5D%2C%20%5B121.003085%2C%2053.251401%5D%2C%20%5B122.245748%2C%2053.431726%5D%2C%20%5B123.571507%2C%2053.458804%5D%2C%20%5B125.068211%2C%2053.161045%5D%2C%20%5B125.946349%2C%2052.792799%5D%2C%20%5B126.564399%2C%2051.784255%5D%2C%20%5B126.939157%2C%2051.353894%5D%2C%20%5B127.287456%2C%2050.739797%5D%2C%20%5B127.657407%2C%2049.76027%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22CHN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22China%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-2.856125%2C%204.994476%5D%2C%20%5B-3.311084%2C%204.984296%5D%2C%20%5B-4.00882%2C%205.179813%5D%2C%20%5B-4.649917%2C%205.168264%5D%2C%20%5B-5.834496%2C%204.993701%5D%2C%20%5B-6.528769%2C%204.705088%5D%2C%20%5B-7.518941%2C%204.338288%5D%2C%20%5B-7.712159%2C%204.364566%5D%2C%20%5B-7.635368%2C%205.188159%5D%2C%20%5B-7.539715%2C%205.313345%5D%2C%20%5B-7.570153%2C%205.707352%5D%2C%20%5B-7.993693%2C%206.12619%5D%2C%20%5B-8.311348%2C%206.193033%5D%2C%20%5B-8.60288%2C%206.467564%5D%2C%20%5B-8.385452%2C%206.911801%5D%2C%20%5B-8.485446%2C%207.395208%5D%2C%20%5B-8.439298%2C%207.686043%5D%2C%20%5B-8.280703%2C%207.68718%5D%2C%20%5B-8.221792%2C%208.123329%5D%2C%20%5B-8.299049%2C%208.316444%5D%2C%20%5B-8.203499%2C%208.455453%5D%2C%20%5B-7.8321%2C%208.575704%5D%2C%20%5B-8.079114%2C%209.376224%5D%2C%20%5B-8.309616%2C%209.789532%5D%2C%20%5B-8.229337%2C%2010.12902%5D%2C%20%5B-8.029944%2C%2010.206535%5D%2C%20%5B-7.89959%2C%2010.297382%5D%2C%20%5B-7.622759%2C%2010.147236%5D%2C%20%5B-6.850507%2C%2010.138994%5D%2C%20%5B-6.666461%2C%2010.430811%5D%2C%20%5B-6.493965%2C%2010.411303%5D%2C%20%5B-6.205223%2C%2010.524061%5D%2C%20%5B-6.050452%2C%2010.096361%5D%2C%20%5B-5.816926%2C%2010.222555%5D%2C%20%5B-5.404342%2C%2010.370737%5D%2C%20%5B-4.954653%2C%2010.152714%5D%2C%20%5B-4.779884%2C%209.821985%5D%2C%20%5B-4.330247%2C%209.610835%5D%2C%20%5B-3.980449%2C%209.862344%5D%2C%20%5B-3.511899%2C%209.900326%5D%2C%20%5B-2.827496%2C%209.642461%5D%2C%20%5B-2.56219%2C%208.219628%5D%2C%20%5B-2.983585%2C%207.379705%5D%2C%20%5B-3.24437%2C%206.250472%5D%2C%20%5B-2.810701%2C%205.389051%5D%2C%20%5B-2.856125%2C%204.994476%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22CIV%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Ivory%20Coast%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B13.075822%2C%202.267097%5D%2C%20%5B12.951334%2C%202.321616%5D%2C%20%5B12.35938%2C%202.192812%5D%2C%20%5B11.751665%2C%202.326758%5D%2C%20%5B11.276449%2C%202.261051%5D%2C%20%5B9.649158%2C%202.283866%5D%2C%20%5B9.795196%2C%203.073404%5D%2C%20%5B9.404367%2C%203.734527%5D%2C%20%5B8.948116%2C%203.904129%5D%2C%20%5B8.744924%2C%204.352215%5D%2C%20%5B8.488816%2C%204.495617%5D%2C%20%5B8.500288%2C%204.771983%5D%2C%20%5B8.757533%2C%205.479666%5D%2C%20%5B9.233163%2C%206.444491%5D%2C%20%5B9.522706%2C%206.453482%5D%2C%20%5B10.118277%2C%207.03877%5D%2C%20%5B10.497375%2C%207.055358%5D%2C%20%5B11.058788%2C%206.644427%5D%2C%20%5B11.745774%2C%206.981383%5D%2C%20%5B11.839309%2C%207.397042%5D%2C%20%5B12.063946%2C%207.799808%5D%2C%20%5B12.218872%2C%208.305824%5D%2C%20%5B12.753672%2C%208.717763%5D%2C%20%5B12.955468%2C%209.417772%5D%2C%20%5B13.1676%2C%209.640626%5D%2C%20%5B13.308676%2C%2010.160362%5D%2C%20%5B13.57295%2C%2010.798566%5D%2C%20%5B14.415379%2C%2011.572369%5D%2C%20%5B14.468192%2C%2011.904752%5D%2C%20%5B14.577178%2C%2012.085361%5D%2C%20%5B14.181336%2C%2012.483657%5D%2C%20%5B14.213531%2C%2012.802035%5D%2C%20%5B14.495787%2C%2012.859396%5D%2C%20%5B14.893386%2C%2012.219048%5D%2C%20%5B14.960152%2C%2011.555574%5D%2C%20%5B14.923565%2C%2010.891325%5D%2C%20%5B15.467873%2C%209.982337%5D%2C%20%5B14.909354%2C%209.992129%5D%2C%20%5B14.627201%2C%209.920919%5D%2C%20%5B14.171466%2C%2010.021378%5D%2C%20%5B13.954218%2C%209.549495%5D%2C%20%5B14.544467%2C%208.965861%5D%2C%20%5B14.979996%2C%208.796104%5D%2C%20%5B15.120866%2C%208.38215%5D%2C%20%5B15.436092%2C%207.692812%5D%2C%20%5B15.27946%2C%207.421925%5D%2C%20%5B14.776545%2C%206.408498%5D%2C%20%5B14.53656%2C%206.226959%5D%2C%20%5B14.459407%2C%205.451761%5D%2C%20%5B14.558936%2C%205.030598%5D%2C%20%5B14.478372%2C%204.732605%5D%2C%20%5B14.950953%2C%204.210389%5D%2C%20%5B15.03622%2C%203.851367%5D%2C%20%5B15.405396%2C%203.335301%5D%2C%20%5B15.862732%2C%203.013537%5D%2C%20%5B15.907381%2C%202.557389%5D%2C%20%5B16.012852%2C%202.26764%5D%2C%20%5B15.940919%2C%201.727673%5D%2C%20%5B15.146342%2C%201.964015%5D%2C%20%5B14.337813%2C%202.227875%5D%2C%20%5B13.075822%2C%202.267097%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22CMR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Cameroon%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B30.83386%2C%203.509166%5D%2C%20%5B30.773347%2C%202.339883%5D%2C%20%5B31.174149%2C%202.204465%5D%2C%20%5B30.85267%2C%201.849396%5D%2C%20%5B30.468508%2C%201.583805%5D%2C%20%5B30.086154%2C%201.062313%5D%2C%20%5B29.875779%2C%200.59738%5D%2C%20%5B29.819503%2C%20-0.20531%5D%2C%20%5B29.587838%2C%20-0.587406%5D%2C%20%5B29.579466%2C%20-1.341313%5D%2C%20%5B29.291887%2C%20-1.620056%5D%2C%20%5B29.254835%2C%20-2.21511%5D%2C%20%5B29.117479%2C%20-2.292211%5D%2C%20%5B29.024926%2C%20-2.839258%5D%2C%20%5B29.276384%2C%20-3.293907%5D%2C%20%5B29.339998%2C%20-4.499983%5D%2C%20%5B29.519987%2C%20-5.419979%5D%2C%20%5B29.419993%2C%20-5.939999%5D%2C%20%5B29.620032%2C%20-6.520015%5D%2C%20%5B30.199997%2C%20-7.079981%5D%2C%20%5B30.740015%2C%20-8.340007%5D%2C%20%5B30.346086%2C%20-8.238257%5D%2C%20%5B29.002912%2C%20-8.407032%5D%2C%20%5B28.734867%2C%20-8.526559%5D%2C%20%5B28.449871%2C%20-9.164918%5D%2C%20%5B28.673682%2C%20-9.605925%5D%2C%20%5B28.49607%2C%20-10.789884%5D%2C%20%5B28.372253%2C%20-11.793647%5D%2C%20%5B28.642417%2C%20-11.971569%5D%2C%20%5B29.341548%2C%20-12.360744%5D%2C%20%5B29.616001%2C%20-12.178895%5D%2C%20%5B29.699614%2C%20-13.257227%5D%2C%20%5B28.934286%2C%20-13.248958%5D%2C%20%5B28.523562%2C%20-12.698604%5D%2C%20%5B28.155109%2C%20-12.272481%5D%2C%20%5B27.388799%2C%20-12.132747%5D%2C%20%5B27.16442%2C%20-11.608748%5D%2C%20%5B26.553088%2C%20-11.92444%5D%2C%20%5B25.75231%2C%20-11.784965%5D%2C%20%5B25.418118%2C%20-11.330936%5D%2C%20%5B24.78317%2C%20-11.238694%5D%2C%20%5B24.314516%2C%20-11.262826%5D%2C%20%5B24.257155%2C%20-10.951993%5D%2C%20%5B23.912215%2C%20-10.926826%5D%2C%20%5B23.456791%2C%20-10.867863%5D%2C%20%5B22.837345%2C%20-11.017622%5D%2C%20%5B22.402798%2C%20-10.993075%5D%2C%20%5B22.155268%2C%20-11.084801%5D%2C%20%5B22.208753%2C%20-9.894796%5D%2C%20%5B21.875182%2C%20-9.523708%5D%2C%20%5B21.801801%2C%20-8.908707%5D%2C%20%5B21.949131%2C%20-8.305901%5D%2C%20%5B21.746456%2C%20-7.920085%5D%2C%20%5B21.728111%2C%20-7.290872%5D%2C%20%5B20.514748%2C%20-7.299606%5D%2C%20%5B20.601823%2C%20-6.939318%5D%2C%20%5B20.091622%2C%20-6.94309%5D%2C%20%5B20.037723%2C%20-7.116361%5D%2C%20%5B19.417502%2C%20-7.155429%5D%2C%20%5B19.166613%2C%20-7.738184%5D%2C%20%5B19.016752%2C%20-7.988246%5D%2C%20%5B18.464176%2C%20-7.847014%5D%2C%20%5B18.134222%2C%20-7.987678%5D%2C%20%5B17.47297%2C%20-8.068551%5D%2C%20%5B17.089996%2C%20-7.545689%5D%2C%20%5B16.860191%2C%20-7.222298%5D%2C%20%5B16.57318%2C%20-6.622645%5D%2C%20%5B16.326528%2C%20-5.87747%5D%2C%20%5B13.375597%2C%20-5.864241%5D%2C%20%5B13.024869%2C%20-5.984389%5D%2C%20%5B12.735171%2C%20-5.965682%5D%2C%20%5B12.322432%2C%20-6.100092%5D%2C%20%5B12.182337%2C%20-5.789931%5D%2C%20%5B12.436688%2C%20-5.684304%5D%2C%20%5B12.468004%2C%20-5.248362%5D%2C%20%5B12.631612%2C%20-4.991271%5D%2C%20%5B12.995517%2C%20-4.781103%5D%2C%20%5B13.25824%2C%20-4.882957%5D%2C%20%5B13.600235%2C%20-4.500138%5D%2C%20%5B14.144956%2C%20-4.510009%5D%2C%20%5B14.209035%2C%20-4.793092%5D%2C%20%5B14.582604%2C%20-4.970239%5D%2C%20%5B15.170992%2C%20-4.343507%5D%2C%20%5B15.75354%2C%20-3.855165%5D%2C%20%5B16.00629%2C%20-3.535133%5D%2C%20%5B15.972803%2C%20-2.712392%5D%2C%20%5B16.407092%2C%20-1.740927%5D%2C%20%5B16.865307%2C%20-1.225816%5D%2C%20%5B17.523716%2C%20-0.74383%5D%2C%20%5B17.638645%2C%20-0.424832%5D%2C%20%5B17.663553%2C%20-0.058084%5D%2C%20%5B17.82654%2C%200.288923%5D%2C%20%5B17.774192%2C%200.855659%5D%2C%20%5B17.898835%2C%201.741832%5D%2C%20%5B18.094276%2C%202.365722%5D%2C%20%5B18.393792%2C%202.900443%5D%2C%20%5B18.453065%2C%203.504386%5D%2C%20%5B18.542982%2C%204.201785%5D%2C%20%5B18.932312%2C%204.709506%5D%2C%20%5B19.467784%2C%205.031528%5D%2C%20%5B20.290679%2C%204.691678%5D%2C%20%5B20.927591%2C%204.322786%5D%2C%20%5B21.659123%2C%204.224342%5D%2C%20%5B22.405124%2C%204.02916%5D%2C%20%5B22.704124%2C%204.633051%5D%2C%20%5B22.84148%2C%204.710126%5D%2C%20%5B23.297214%2C%204.609693%5D%2C%20%5B24.410531%2C%205.108784%5D%2C%20%5B24.805029%2C%204.897247%5D%2C%20%5B25.128833%2C%204.927245%5D%2C%20%5B25.278798%2C%205.170408%5D%2C%20%5B25.650455%2C%205.256088%5D%2C%20%5B26.402761%2C%205.150875%5D%2C%20%5B27.044065%2C%205.127853%5D%2C%20%5B27.374226%2C%205.233944%5D%2C%20%5B27.979977%2C%204.408413%5D%2C%20%5B28.428994%2C%204.287155%5D%2C%20%5B28.696678%2C%204.455077%5D%2C%20%5B29.159078%2C%204.389267%5D%2C%20%5B29.715995%2C%204.600805%5D%2C%20%5B29.9535%2C%204.173699%5D%2C%20%5B30.83386%2C%203.509166%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22COD%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Democratic%20Republic%20of%20the%20Congo%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B12.995517%2C%20-4.781103%5D%2C%20%5B12.62076%2C%20-4.438023%5D%2C%20%5B12.318608%2C%20-4.60623%5D%2C%20%5B11.914963%2C%20-5.037987%5D%2C%20%5B11.093773%2C%20-3.978827%5D%2C%20%5B11.855122%2C%20-3.426871%5D%2C%20%5B11.478039%2C%20-2.765619%5D%2C%20%5B11.820964%2C%20-2.514161%5D%2C%20%5B12.495703%2C%20-2.391688%5D%2C%20%5B12.575284%2C%20-1.948511%5D%2C%20%5B13.109619%2C%20-2.42874%5D%2C%20%5B13.992407%2C%20-2.470805%5D%2C%20%5B14.29921%2C%20-1.998276%5D%2C%20%5B14.425456%2C%20-1.333407%5D%2C%20%5B14.316418%2C%20-0.552627%5D%2C%20%5B13.843321%2C%200.038758%5D%2C%20%5B14.276266%2C%201.19693%5D%2C%20%5B14.026669%2C%201.395677%5D%2C%20%5B13.282631%2C%201.314184%5D%2C%20%5B13.003114%2C%201.830896%5D%2C%20%5B13.075822%2C%202.267097%5D%2C%20%5B14.337813%2C%202.227875%5D%2C%20%5B15.146342%2C%201.964015%5D%2C%20%5B15.940919%2C%201.727673%5D%2C%20%5B16.012852%2C%202.26764%5D%2C%20%5B16.537058%2C%203.198255%5D%2C%20%5B17.133042%2C%203.728197%5D%2C%20%5B17.8099%2C%203.560196%5D%2C%20%5B18.453065%2C%203.504386%5D%2C%20%5B18.393792%2C%202.900443%5D%2C%20%5B18.094276%2C%202.365722%5D%2C%20%5B17.898835%2C%201.741832%5D%2C%20%5B17.774192%2C%200.855659%5D%2C%20%5B17.82654%2C%200.288923%5D%2C%20%5B17.663553%2C%20-0.058084%5D%2C%20%5B17.638645%2C%20-0.424832%5D%2C%20%5B17.523716%2C%20-0.74383%5D%2C%20%5B16.865307%2C%20-1.225816%5D%2C%20%5B16.407092%2C%20-1.740927%5D%2C%20%5B15.972803%2C%20-2.712392%5D%2C%20%5B16.00629%2C%20-3.535133%5D%2C%20%5B15.75354%2C%20-3.855165%5D%2C%20%5B15.170992%2C%20-4.343507%5D%2C%20%5B14.582604%2C%20-4.970239%5D%2C%20%5B14.209035%2C%20-4.793092%5D%2C%20%5B14.144956%2C%20-4.510009%5D%2C%20%5B13.600235%2C%20-4.500138%5D%2C%20%5B13.25824%2C%20-4.882957%5D%2C%20%5B12.995517%2C%20-4.781103%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22COG%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Republic%20of%20the%20Congo%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-75.373223%2C%20-0.152032%5D%2C%20%5B-75.801466%2C%200.084801%5D%2C%20%5B-76.292314%2C%200.416047%5D%2C%20%5B-76.57638%2C%200.256936%5D%2C%20%5B-77.424984%2C%200.395687%5D%2C%20%5B-77.668613%2C%200.825893%5D%2C%20%5B-77.855061%2C%200.809925%5D%2C%20%5B-78.855259%2C%201.380924%5D%2C%20%5B-78.990935%2C%201.69137%5D%2C%20%5B-78.617831%2C%201.766404%5D%2C%20%5B-78.662118%2C%202.267355%5D%2C%20%5B-78.42761%2C%202.629556%5D%2C%20%5B-77.931543%2C%202.696606%5D%2C%20%5B-77.510431%2C%203.325017%5D%2C%20%5B-77.12769%2C%203.849636%5D%2C%20%5B-77.496272%2C%204.087606%5D%2C%20%5B-77.307601%2C%204.667984%5D%2C%20%5B-77.533221%2C%205.582812%5D%2C%20%5B-77.318815%2C%205.845354%5D%2C%20%5B-77.476661%2C%206.691116%5D%2C%20%5B-77.881571%2C%207.223771%5D%2C%20%5B-77.753414%2C%207.70984%5D%2C%20%5B-77.431108%2C%207.638061%5D%2C%20%5B-77.242566%2C%207.935278%5D%2C%20%5B-77.474723%2C%208.524286%5D%2C%20%5B-77.353361%2C%208.670505%5D%2C%20%5B-76.836674%2C%208.638749%5D%2C%20%5B-76.086384%2C%209.336821%5D%2C%20%5B-75.6746%2C%209.443248%5D%2C%20%5B-75.664704%2C%209.774003%5D%2C%20%5B-75.480426%2C%2010.61899%5D%2C%20%5B-74.906895%2C%2011.083045%5D%2C%20%5B-74.276753%2C%2011.102036%5D%2C%20%5B-74.197223%2C%2011.310473%5D%2C%20%5B-73.414764%2C%2011.227015%5D%2C%20%5B-72.627835%2C%2011.731972%5D%2C%20%5B-72.238195%2C%2011.95555%5D%2C%20%5B-71.75409%2C%2012.437303%5D%2C%20%5B-71.399822%2C%2012.376041%5D%2C%20%5B-71.137461%2C%2012.112982%5D%2C%20%5B-71.331584%2C%2011.776284%5D%2C%20%5B-71.973922%2C%2011.608672%5D%2C%20%5B-72.227575%2C%2011.108702%5D%2C%20%5B-72.614658%2C%2010.821975%5D%2C%20%5B-72.905286%2C%2010.450344%5D%2C%20%5B-73.027604%2C%209.73677%5D%2C%20%5B-73.304952%2C%209.152%5D%2C%20%5B-72.78873%2C%209.085027%5D%2C%20%5B-72.660495%2C%208.625288%5D%2C%20%5B-72.439862%2C%208.405275%5D%2C%20%5B-72.360901%2C%208.002638%5D%2C%20%5B-72.479679%2C%207.632506%5D%2C%20%5B-72.444487%2C%207.423785%5D%2C%20%5B-72.198352%2C%207.340431%5D%2C%20%5B-71.960176%2C%206.991615%5D%2C%20%5B-70.674234%2C%207.087785%5D%2C%20%5B-70.093313%2C%206.960376%5D%2C%20%5B-69.38948%2C%206.099861%5D%2C%20%5B-68.985319%2C%206.206805%5D%2C%20%5B-68.265052%2C%206.153268%5D%2C%20%5B-67.695087%2C%206.267318%5D%2C%20%5B-67.34144%2C%206.095468%5D%2C%20%5B-67.521532%2C%205.55687%5D%2C%20%5B-67.744697%2C%205.221129%5D%2C%20%5B-67.823012%2C%204.503937%5D%2C%20%5B-67.621836%2C%203.839482%5D%2C%20%5B-67.337564%2C%203.542342%5D%2C%20%5B-67.303173%2C%203.318454%5D%2C%20%5B-67.809938%2C%202.820655%5D%2C%20%5B-67.447092%2C%202.600281%5D%2C%20%5B-67.181294%2C%202.250638%5D%2C%20%5B-66.876326%2C%201.253361%5D%2C%20%5B-67.065048%2C%201.130112%5D%2C%20%5B-67.259998%2C%201.719999%5D%2C%20%5B-67.53781%2C%202.037163%5D%2C%20%5B-67.868565%2C%201.692455%5D%2C%20%5B-69.816973%2C%201.714805%5D%2C%20%5B-69.804597%2C%201.089081%5D%2C%20%5B-69.218638%2C%200.985677%5D%2C%20%5B-69.252434%2C%200.602651%5D%2C%20%5B-69.452396%2C%200.706159%5D%2C%20%5B-70.015566%2C%200.541414%5D%2C%20%5B-70.020656%2C%20-0.185156%5D%2C%20%5B-69.577065%2C%20-0.549992%5D%2C%20%5B-69.420486%2C%20-1.122619%5D%2C%20%5B-69.444102%2C%20-1.556287%5D%2C%20%5B-69.893635%2C%20-4.298187%5D%2C%20%5B-70.394044%2C%20-3.766591%5D%2C%20%5B-70.692682%2C%20-3.742872%5D%2C%20%5B-70.047709%2C%20-2.725156%5D%2C%20%5B-70.813476%2C%20-2.256865%5D%2C%20%5B-71.413646%2C%20-2.342802%5D%2C%20%5B-71.774761%2C%20-2.16979%5D%2C%20%5B-72.325787%2C%20-2.434218%5D%2C%20%5B-73.070392%2C%20-2.308954%5D%2C%20%5B-73.659504%2C%20-1.260491%5D%2C%20%5B-74.122395%2C%20-1.002833%5D%2C%20%5B-74.441601%2C%20-0.53082%5D%2C%20%5B-75.106625%2C%20-0.057205%5D%2C%20%5B-75.373223%2C%20-0.152032%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22COL%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Colombia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-82.965783%2C%208.225028%5D%2C%20%5B-83.508437%2C%208.446927%5D%2C%20%5B-83.711474%2C%208.656836%5D%2C%20%5B-83.596313%2C%208.830443%5D%2C%20%5B-83.632642%2C%209.051386%5D%2C%20%5B-83.909886%2C%209.290803%5D%2C%20%5B-84.303402%2C%209.487354%5D%2C%20%5B-84.647644%2C%209.615537%5D%2C%20%5B-84.713351%2C%209.908052%5D%2C%20%5B-84.97566%2C%2010.086723%5D%2C%20%5B-84.911375%2C%209.795992%5D%2C%20%5B-85.110923%2C%209.55704%5D%2C%20%5B-85.339488%2C%209.834542%5D%2C%20%5B-85.660787%2C%209.933347%5D%2C%20%5B-85.797445%2C%2010.134886%5D%2C%20%5B-85.791709%2C%2010.439337%5D%2C%20%5B-85.659314%2C%2010.754331%5D%2C%20%5B-85.941725%2C%2010.895278%5D%2C%20%5B-85.71254%2C%2011.088445%5D%2C%20%5B-85.561852%2C%2011.217119%5D%2C%20%5B-84.903003%2C%2010.952303%5D%2C%20%5B-84.673069%2C%2011.082657%5D%2C%20%5B-84.355931%2C%2010.999226%5D%2C%20%5B-84.190179%2C%2010.79345%5D%2C%20%5B-83.895054%2C%2010.726839%5D%2C%20%5B-83.655612%2C%2010.938764%5D%2C%20%5B-83.40232%2C%2010.395438%5D%2C%20%5B-83.015677%2C%209.992982%5D%2C%20%5B-82.546196%2C%209.566135%5D%2C%20%5B-82.932891%2C%209.476812%5D%2C%20%5B-82.927155%2C%209.07433%5D%2C%20%5B-82.719183%2C%208.925709%5D%2C%20%5B-82.868657%2C%208.807266%5D%2C%20%5B-82.829771%2C%208.626295%5D%2C%20%5B-82.913176%2C%208.423517%5D%2C%20%5B-82.965783%2C%208.225028%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22CRI%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Costa%20Rica%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-82.268151%2C%2023.188611%5D%2C%20%5B-81.404457%2C%2023.117271%5D%2C%20%5B-80.618769%2C%2023.10598%5D%2C%20%5B-79.679524%2C%2022.765303%5D%2C%20%5B-79.281486%2C%2022.399202%5D%2C%20%5B-78.347434%2C%2022.512166%5D%2C%20%5B-77.993296%2C%2022.277194%5D%2C%20%5B-77.146422%2C%2021.657851%5D%2C%20%5B-76.523825%2C%2021.20682%5D%2C%20%5B-76.19462%2C%2021.220565%5D%2C%20%5B-75.598222%2C%2021.016624%5D%2C%20%5B-75.67106%2C%2020.735091%5D%2C%20%5B-74.933896%2C%2020.693905%5D%2C%20%5B-74.178025%2C%2020.284628%5D%2C%20%5B-74.296648%2C%2020.050379%5D%2C%20%5B-74.961595%2C%2019.923435%5D%2C%20%5B-75.63468%2C%2019.873774%5D%2C%20%5B-76.323656%2C%2019.952891%5D%2C%20%5B-77.755481%2C%2019.855481%5D%2C%20%5B-77.085108%2C%2020.413354%5D%2C%20%5B-77.492655%2C%2020.673105%5D%2C%20%5B-78.137292%2C%2020.739949%5D%2C%20%5B-78.482827%2C%2021.028613%5D%2C%20%5B-78.719867%2C%2021.598114%5D%2C%20%5B-79.285%2C%2021.559175%5D%2C%20%5B-80.217475%2C%2021.827324%5D%2C%20%5B-80.517535%2C%2022.037079%5D%2C%20%5B-81.820943%2C%2022.192057%5D%2C%20%5B-82.169992%2C%2022.387109%5D%2C%20%5B-81.795002%2C%2022.636965%5D%2C%20%5B-82.775898%2C%2022.68815%5D%2C%20%5B-83.494459%2C%2022.168518%5D%2C%20%5B-83.9088%2C%2022.154565%5D%2C%20%5B-84.052151%2C%2021.910575%5D%2C%20%5B-84.54703%2C%2021.801228%5D%2C%20%5B-84.974911%2C%2021.896028%5D%2C%20%5B-84.447062%2C%2022.20495%5D%2C%20%5B-84.230357%2C%2022.565755%5D%2C%20%5B-83.77824%2C%2022.788118%5D%2C%20%5B-83.267548%2C%2022.983042%5D%2C%20%5B-82.510436%2C%2023.078747%5D%2C%20%5B-82.268151%2C%2023.188611%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22CUB%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Cuba%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B32.73178%2C%2035.140026%5D%2C%20%5B32.802474%2C%2035.145504%5D%2C%20%5B32.946961%2C%2035.386703%5D%2C%20%5B33.667227%2C%2035.373216%5D%2C%20%5B34.576474%2C%2035.671596%5D%2C%20%5B33.900804%2C%2035.245756%5D%2C%20%5B33.973617%2C%2035.058506%5D%2C%20%5B33.86644%2C%2035.093595%5D%2C%20%5B33.675392%2C%2035.017863%5D%2C%20%5B33.525685%2C%2035.038688%5D%2C%20%5B33.475817%2C%2035.000345%5D%2C%20%5B33.455922%2C%2035.101424%5D%2C%20%5B33.383833%2C%2035.162712%5D%2C%20%5B33.190977%2C%2035.173125%5D%2C%20%5B32.919572%2C%2035.087833%5D%2C%20%5B32.73178%2C%2035.140026%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22-99%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Northern%20Cyprus%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B33.973617%2C%2035.058506%5D%2C%20%5B34.004881%2C%2034.978098%5D%2C%20%5B32.979827%2C%2034.571869%5D%2C%20%5B32.490296%2C%2034.701655%5D%2C%20%5B32.256667%2C%2035.103232%5D%2C%20%5B32.73178%2C%2035.140026%5D%2C%20%5B32.919572%2C%2035.087833%5D%2C%20%5B33.190977%2C%2035.173125%5D%2C%20%5B33.383833%2C%2035.162712%5D%2C%20%5B33.455922%2C%2035.101424%5D%2C%20%5B33.475817%2C%2035.000345%5D%2C%20%5B33.525685%2C%2035.038688%5D%2C%20%5B33.675392%2C%2035.017863%5D%2C%20%5B33.86644%2C%2035.093595%5D%2C%20%5B33.973617%2C%2035.058506%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22CYP%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Cyprus%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B16.960288%2C%2048.596982%5D%2C%20%5B16.499283%2C%2048.785808%5D%2C%20%5B16.029647%2C%2048.733899%5D%2C%20%5B15.253416%2C%2049.039074%5D%2C%20%5B14.901447%2C%2048.964402%5D%2C%20%5B14.338898%2C%2048.555305%5D%2C%20%5B13.595946%2C%2048.877172%5D%2C%20%5B13.031329%2C%2049.307068%5D%2C%20%5B12.521024%2C%2049.547415%5D%2C%20%5B12.415191%2C%2049.969121%5D%2C%20%5B12.240111%2C%2050.266338%5D%2C%20%5B12.966837%2C%2050.484076%5D%2C%20%5B13.338132%2C%2050.733234%5D%2C%20%5B14.056228%2C%2050.926918%5D%2C%20%5B14.307013%2C%2051.117268%5D%2C%20%5B14.570718%2C%2051.002339%5D%2C%20%5B15.016996%2C%2051.106674%5D%2C%20%5B15.490972%2C%2050.78473%5D%2C%20%5B16.238627%2C%2050.697733%5D%2C%20%5B16.176253%2C%2050.422607%5D%2C%20%5B16.719476%2C%2050.215747%5D%2C%20%5B16.868769%2C%2050.473974%5D%2C%20%5B17.554567%2C%2050.362146%5D%2C%20%5B17.649445%2C%2050.049038%5D%2C%20%5B18.392914%2C%2049.988629%5D%2C%20%5B18.853144%2C%2049.49623%5D%2C%20%5B18.554971%2C%2049.495015%5D%2C%20%5B18.399994%2C%2049.315001%5D%2C%20%5B18.170498%2C%2049.271515%5D%2C%20%5B18.104973%2C%2049.043983%5D%2C%20%5B17.913512%2C%2048.996493%5D%2C%20%5B17.886485%2C%2048.903475%5D%2C%20%5B17.545007%2C%2048.800019%5D%2C%20%5B17.101985%2C%2048.816969%5D%2C%20%5B16.960288%2C%2048.596982%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22CZE%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Czech%20Republic%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B9.921906%2C%2054.983104%5D%2C%20%5B9.93958%2C%2054.596642%5D%2C%20%5B10.950112%2C%2054.363607%5D%2C%20%5B10.939467%2C%2054.008693%5D%2C%20%5B11.956252%2C%2054.196486%5D%2C%20%5B12.51844%2C%2054.470371%5D%2C%20%5B13.647467%2C%2054.075511%5D%2C%20%5B14.119686%2C%2053.757029%5D%2C%20%5B14.353315%2C%2053.248171%5D%2C%20%5B14.074521%2C%2052.981263%5D%2C%20%5B14.4376%2C%2052.62485%5D%2C%20%5B14.685026%2C%2052.089947%5D%2C%20%5B14.607098%2C%2051.745188%5D%2C%20%5B15.016996%2C%2051.106674%5D%2C%20%5B14.570718%2C%2051.002339%5D%2C%20%5B14.307013%2C%2051.117268%5D%2C%20%5B14.056228%2C%2050.926918%5D%2C%20%5B13.338132%2C%2050.733234%5D%2C%20%5B12.966837%2C%2050.484076%5D%2C%20%5B12.240111%2C%2050.266338%5D%2C%20%5B12.415191%2C%2049.969121%5D%2C%20%5B12.521024%2C%2049.547415%5D%2C%20%5B13.031329%2C%2049.307068%5D%2C%20%5B13.595946%2C%2048.877172%5D%2C%20%5B13.243357%2C%2048.416115%5D%2C%20%5B12.884103%2C%2048.289146%5D%2C%20%5B13.025851%2C%2047.637584%5D%2C%20%5B12.932627%2C%2047.467646%5D%2C%20%5B12.62076%2C%2047.672388%5D%2C%20%5B12.141357%2C%2047.703083%5D%2C%20%5B11.426414%2C%2047.523766%5D%2C%20%5B10.544504%2C%2047.566399%5D%2C%20%5B10.402084%2C%2047.302488%5D%2C%20%5B9.896068%2C%2047.580197%5D%2C%20%5B9.594226%2C%2047.525058%5D%2C%20%5B8.522612%2C%2047.830828%5D%2C%20%5B8.317301%2C%2047.61358%5D%2C%20%5B7.466759%2C%2047.620582%5D%2C%20%5B7.593676%2C%2048.333019%5D%2C%20%5B8.099279%2C%2049.017784%5D%2C%20%5B6.65823%2C%2049.201958%5D%2C%20%5B6.18632%2C%2049.463803%5D%2C%20%5B6.242751%2C%2049.902226%5D%2C%20%5B6.043073%2C%2050.128052%5D%2C%20%5B6.156658%2C%2050.803721%5D%2C%20%5B5.988658%2C%2051.851616%5D%2C%20%5B6.589397%2C%2051.852029%5D%2C%20%5B6.84287%2C%2052.22844%5D%2C%20%5B7.092053%2C%2053.144043%5D%2C%20%5B6.90514%2C%2053.482162%5D%2C%20%5B7.100425%2C%2053.693932%5D%2C%20%5B7.936239%2C%2053.748296%5D%2C%20%5B8.121706%2C%2053.527792%5D%2C%20%5B8.800734%2C%2054.020786%5D%2C%20%5B8.572118%2C%2054.395646%5D%2C%20%5B8.526229%2C%2054.962744%5D%2C%20%5B9.282049%2C%2054.830865%5D%2C%20%5B9.921906%2C%2054.983104%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22DEU%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Germany%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B43.081226%2C%2012.699639%5D%2C%20%5B43.317852%2C%2012.390148%5D%2C%20%5B43.286381%2C%2011.974928%5D%2C%20%5B42.715874%2C%2011.735641%5D%2C%20%5B43.145305%2C%2011.46204%5D%2C%20%5B42.776852%2C%2010.926879%5D%2C%20%5B42.55493%2C%2011.10511%5D%2C%20%5B42.31414%2C%2011.0342%5D%2C%20%5B41.75557%2C%2011.05091%5D%2C%20%5B41.73959%2C%2011.35511%5D%2C%20%5B41.66176%2C%2011.6312%5D%2C%20%5B42%2C%2012.1%5D%2C%20%5B42.35156%2C%2012.54223%5D%2C%20%5B42.779642%2C%2012.455416%5D%2C%20%5B43.081226%2C%2012.699639%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22DJI%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Djibouti%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B12.690006%2C%2055.609991%5D%2C%20%5B12.089991%2C%2054.800015%5D%2C%20%5B11.043543%2C%2055.364864%5D%2C%20%5B10.903914%2C%2055.779955%5D%2C%20%5B12.370904%2C%2056.111407%5D%2C%20%5B12.690006%2C%2055.609991%5D%5D%5D%2C%20%5B%5B%5B10.912182%2C%2056.458621%5D%2C%20%5B10.667804%2C%2056.081383%5D%2C%20%5B10.369993%2C%2056.190007%5D%2C%20%5B9.649985%2C%2055.469999%5D%2C%20%5B9.921906%2C%2054.983104%5D%2C%20%5B9.282049%2C%2054.830865%5D%2C%20%5B8.526229%2C%2054.962744%5D%2C%20%5B8.120311%2C%2055.517723%5D%2C%20%5B8.089977%2C%2056.540012%5D%2C%20%5B8.256582%2C%2056.809969%5D%2C%20%5B8.543438%2C%2057.110003%5D%2C%20%5B9.424469%2C%2057.172066%5D%2C%20%5B9.775559%2C%2057.447941%5D%2C%20%5B10.580006%2C%2057.730017%5D%2C%20%5B10.546106%2C%2057.215733%5D%2C%20%5B10.25%2C%2056.890016%5D%2C%20%5B10.369993%2C%2056.609982%5D%2C%20%5B10.912182%2C%2056.458621%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22DNK%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Denmark%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-71.712361%2C%2019.714456%5D%2C%20%5B-71.587304%2C%2019.884911%5D%2C%20%5B-70.806706%2C%2019.880286%5D%2C%20%5B-70.214365%2C%2019.622885%5D%2C%20%5B-69.950815%2C%2019.648%5D%2C%20%5B-69.76925%2C%2019.293267%5D%2C%20%5B-69.222126%2C%2019.313214%5D%2C%20%5B-69.254346%2C%2019.015196%5D%2C%20%5B-68.809412%2C%2018.979074%5D%2C%20%5B-68.317943%2C%2018.612198%5D%2C%20%5B-68.689316%2C%2018.205142%5D%2C%20%5B-69.164946%2C%2018.422648%5D%2C%20%5B-69.623988%2C%2018.380713%5D%2C%20%5B-69.952934%2C%2018.428307%5D%2C%20%5B-70.133233%2C%2018.245915%5D%2C%20%5B-70.517137%2C%2018.184291%5D%2C%20%5B-70.669298%2C%2018.426886%5D%2C%20%5B-70.99995%2C%2018.283329%5D%2C%20%5B-71.40021%2C%2017.598564%5D%2C%20%5B-71.657662%2C%2017.757573%5D%2C%20%5B-71.708305%2C%2018.044997%5D%2C%20%5B-71.687738%2C%2018.31666%5D%2C%20%5B-71.945112%2C%2018.6169%5D%2C%20%5B-71.701303%2C%2018.785417%5D%2C%20%5B-71.624873%2C%2019.169838%5D%2C%20%5B-71.712361%2C%2019.714456%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22DOM%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Dominican%20Republic%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B11.999506%2C%2023.471668%5D%2C%20%5B8.572893%2C%2021.565661%5D%2C%20%5B5.677566%2C%2019.601207%5D%2C%20%5B4.267419%2C%2019.155265%5D%2C%20%5B3.158133%2C%2019.057364%5D%2C%20%5B3.146661%2C%2019.693579%5D%2C%20%5B2.683588%2C%2019.85623%5D%2C%20%5B2.060991%2C%2020.142233%5D%2C%20%5B1.823228%2C%2020.610809%5D%2C%20%5B-1.550055%2C%2022.792666%5D%2C%20%5B-4.923337%2C%2024.974574%5D%2C%20%5B-8.6844%2C%2027.395744%5D%2C%20%5B-8.665124%2C%2027.589479%5D%2C%20%5B-8.66559%2C%2027.656426%5D%2C%20%5B-8.674116%2C%2028.841289%5D%2C%20%5B-7.059228%2C%2029.579228%5D%2C%20%5B-6.060632%2C%2029.7317%5D%2C%20%5B-5.242129%2C%2030.000443%5D%2C%20%5B-4.859646%2C%2030.501188%5D%2C%20%5B-3.690441%2C%2030.896952%5D%2C%20%5B-3.647498%2C%2031.637294%5D%2C%20%5B-3.06898%2C%2031.724498%5D%2C%20%5B-2.616605%2C%2032.094346%5D%2C%20%5B-1.307899%2C%2032.262889%5D%2C%20%5B-1.124551%2C%2032.651522%5D%2C%20%5B-1.388049%2C%2032.864015%5D%2C%20%5B-1.733455%2C%2033.919713%5D%2C%20%5B-1.792986%2C%2034.527919%5D%2C%20%5B-2.169914%2C%2035.168396%5D%2C%20%5B-1.208603%2C%2035.714849%5D%2C%20%5B-0.127454%2C%2035.888662%5D%2C%20%5B0.503877%2C%2036.301273%5D%2C%20%5B1.466919%2C%2036.605647%5D%2C%20%5B3.161699%2C%2036.783905%5D%2C%20%5B4.815758%2C%2036.865037%5D%2C%20%5B5.32012%2C%2036.716519%5D%2C%20%5B6.26182%2C%2037.110655%5D%2C%20%5B7.330385%2C%2037.118381%5D%2C%20%5B7.737078%2C%2036.885708%5D%2C%20%5B8.420964%2C%2036.946427%5D%2C%20%5B8.217824%2C%2036.433177%5D%2C%20%5B8.376368%2C%2035.479876%5D%2C%20%5B8.140981%2C%2034.655146%5D%2C%20%5B7.524482%2C%2034.097376%5D%2C%20%5B7.612642%2C%2033.344115%5D%2C%20%5B8.430473%2C%2032.748337%5D%2C%20%5B8.439103%2C%2032.506285%5D%2C%20%5B9.055603%2C%2032.102692%5D%2C%20%5B9.48214%2C%2030.307556%5D%2C%20%5B9.805634%2C%2029.424638%5D%2C%20%5B9.859998%2C%2028.95999%5D%2C%20%5B9.683885%2C%2028.144174%5D%2C%20%5B9.756128%2C%2027.688259%5D%2C%20%5B9.629056%2C%2027.140953%5D%2C%20%5B9.716286%2C%2026.512206%5D%2C%20%5B9.319411%2C%2026.094325%5D%2C%20%5B9.910693%2C%2025.365455%5D%2C%20%5B9.948261%2C%2024.936954%5D%2C%20%5B10.303847%2C%2024.379313%5D%2C%20%5B10.771364%2C%2024.562532%5D%2C%20%5B11.560669%2C%2024.097909%5D%2C%20%5B11.999506%2C%2023.471668%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22DZA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Algeria%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-80.302561%2C%20-3.404856%5D%2C%20%5B-79.770293%2C%20-2.657512%5D%2C%20%5B-79.986559%2C%20-2.220794%5D%2C%20%5B-80.368784%2C%20-2.685159%5D%2C%20%5B-80.967765%2C%20-2.246943%5D%2C%20%5B-80.764806%2C%20-1.965048%5D%2C%20%5B-80.933659%2C%20-1.057455%5D%2C%20%5B-80.58337%2C%20-0.906663%5D%2C%20%5B-80.399325%2C%20-0.283703%5D%2C%20%5B-80.020898%2C%200.36034%5D%2C%20%5B-80.09061%2C%200.768429%5D%2C%20%5B-79.542762%2C%200.982938%5D%2C%20%5B-78.855259%2C%201.380924%5D%2C%20%5B-77.855061%2C%200.809925%5D%2C%20%5B-77.668613%2C%200.825893%5D%2C%20%5B-77.424984%2C%200.395687%5D%2C%20%5B-76.57638%2C%200.256936%5D%2C%20%5B-76.292314%2C%200.416047%5D%2C%20%5B-75.801466%2C%200.084801%5D%2C%20%5B-75.373223%2C%20-0.152032%5D%2C%20%5B-75.233723%2C%20-0.911417%5D%2C%20%5B-75.544996%2C%20-1.56161%5D%2C%20%5B-76.635394%2C%20-2.608678%5D%2C%20%5B-77.837905%2C%20-3.003021%5D%2C%20%5B-78.450684%2C%20-3.873097%5D%2C%20%5B-78.639897%2C%20-4.547784%5D%2C%20%5B-79.205289%2C%20-4.959129%5D%2C%20%5B-79.624979%2C%20-4.454198%5D%2C%20%5B-80.028908%2C%20-4.346091%5D%2C%20%5B-80.442242%2C%20-4.425724%5D%2C%20%5B-80.469295%2C%20-4.059287%5D%2C%20%5B-80.184015%2C%20-3.821162%5D%2C%20%5B-80.302561%2C%20-3.404856%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ECU%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Ecuador%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B34.9226%2C%2029.50133%5D%2C%20%5B34.64174%2C%2029.09942%5D%2C%20%5B34.42655%2C%2028.34399%5D%2C%20%5B34.15451%2C%2027.8233%5D%2C%20%5B33.92136%2C%2027.6487%5D%2C%20%5B33.58811%2C%2027.97136%5D%2C%20%5B33.13676%2C%2028.41765%5D%2C%20%5B32.42323%2C%2029.85108%5D%2C%20%5B32.32046%2C%2029.76043%5D%2C%20%5B32.73482%2C%2028.70523%5D%2C%20%5B33.34876%2C%2027.69989%5D%2C%20%5B34.10455%2C%2026.14227%5D%2C%20%5B34.47387%2C%2025.59856%5D%2C%20%5B34.79507%2C%2025.03375%5D%2C%20%5B35.69241%2C%2023.92671%5D%2C%20%5B35.49372%2C%2023.75237%5D%2C%20%5B35.52598%2C%2023.10244%5D%2C%20%5B36.69069%2C%2022.20485%5D%2C%20%5B36.86623%2C%2022%5D%2C%20%5B32.9%2C%2022%5D%2C%20%5B29.02%2C%2022%5D%2C%20%5B25%2C%2022%5D%2C%20%5B25%2C%2025.6825%5D%2C%20%5B25%2C%2029.238655%5D%2C%20%5B24.70007%2C%2030.04419%5D%2C%20%5B24.95762%2C%2030.6616%5D%2C%20%5B24.80287%2C%2031.08929%5D%2C%20%5B25.16482%2C%2031.56915%5D%2C%20%5B26.49533%2C%2031.58568%5D%2C%20%5B27.45762%2C%2031.32126%5D%2C%20%5B28.45048%2C%2031.02577%5D%2C%20%5B28.91353%2C%2030.87005%5D%2C%20%5B29.68342%2C%2031.18686%5D%2C%20%5B30.09503%2C%2031.4734%5D%2C%20%5B30.97693%2C%2031.55586%5D%2C%20%5B31.68796%2C%2031.4296%5D%2C%20%5B31.96041%2C%2030.9336%5D%2C%20%5B32.19247%2C%2031.26034%5D%2C%20%5B32.99392%2C%2031.02407%5D%2C%20%5B33.7734%2C%2030.96746%5D%2C%20%5B34.26544%2C%2031.21936%5D%2C%20%5B34.9226%2C%2029.50133%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22EGY%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Egypt%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B42.35156%2C%2012.54223%5D%2C%20%5B42.00975%2C%2012.86582%5D%2C%20%5B41.59856%2C%2013.45209%5D%2C%20%5B41.155194%2C%2013.77332%5D%2C%20%5B40.8966%2C%2014.11864%5D%2C%20%5B40.026219%2C%2014.519579%5D%2C%20%5B39.34061%2C%2014.53155%5D%2C%20%5B39.0994%2C%2014.74064%5D%2C%20%5B38.51295%2C%2014.50547%5D%2C%20%5B37.90607%2C%2014.95943%5D%2C%20%5B37.59377%2C%2014.2131%5D%2C%20%5B36.42951%2C%2014.42211%5D%2C%20%5B36.323189%2C%2014.822481%5D%2C%20%5B36.75386%2C%2016.291874%5D%2C%20%5B36.85253%2C%2016.95655%5D%2C%20%5B37.16747%2C%2017.26314%5D%2C%20%5B37.904%2C%2017.42754%5D%2C%20%5B38.41009%2C%2017.998307%5D%2C%20%5B38.990623%2C%2016.840626%5D%2C%20%5B39.26611%2C%2015.922723%5D%2C%20%5B39.814294%2C%2015.435647%5D%2C%20%5B41.179275%2C%2014.49108%5D%2C%20%5B41.734952%2C%2013.921037%5D%2C%20%5B42.276831%2C%2013.343992%5D%2C%20%5B42.589576%2C%2013.000421%5D%2C%20%5B43.081226%2C%2012.699639%5D%2C%20%5B42.779642%2C%2012.455416%5D%2C%20%5B42.35156%2C%2012.54223%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ERI%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Eritrea%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-9.034818%2C%2041.880571%5D%2C%20%5B-8.984433%2C%2042.592775%5D%2C%20%5B-9.392884%2C%2043.026625%5D%2C%20%5B-7.97819%2C%2043.748338%5D%2C%20%5B-6.754492%2C%2043.567909%5D%2C%20%5B-5.411886%2C%2043.57424%5D%2C%20%5B-4.347843%2C%2043.403449%5D%2C%20%5B-3.517532%2C%2043.455901%5D%2C%20%5B-1.901351%2C%2043.422802%5D%2C%20%5B-1.502771%2C%2043.034014%5D%2C%20%5B0.338047%2C%2042.579546%5D%2C%20%5B0.701591%2C%2042.795734%5D%2C%20%5B1.826793%2C%2042.343385%5D%2C%20%5B2.985999%2C%2042.473015%5D%2C%20%5B3.039484%2C%2041.89212%5D%2C%20%5B2.091842%2C%2041.226089%5D%2C%20%5B0.810525%2C%2041.014732%5D%2C%20%5B0.721331%2C%2040.678318%5D%2C%20%5B0.106692%2C%2040.123934%5D%2C%20%5B-0.278711%2C%2039.309978%5D%2C%20%5B0.111291%2C%2038.738514%5D%2C%20%5B-0.467124%2C%2038.292366%5D%2C%20%5B-0.683389%2C%2037.642354%5D%2C%20%5B-1.438382%2C%2037.443064%5D%2C%20%5B-2.146453%2C%2036.674144%5D%2C%20%5B-3.415781%2C%2036.6589%5D%2C%20%5B-4.368901%2C%2036.677839%5D%2C%20%5B-4.995219%2C%2036.324708%5D%2C%20%5B-5.37716%2C%2035.94685%5D%2C%20%5B-5.866432%2C%2036.029817%5D%2C%20%5B-6.236694%2C%2036.367677%5D%2C%20%5B-6.520191%2C%2036.942913%5D%2C%20%5B-7.453726%2C%2037.097788%5D%2C%20%5B-7.537105%2C%2037.428904%5D%2C%20%5B-7.166508%2C%2037.803894%5D%2C%20%5B-7.029281%2C%2038.075764%5D%2C%20%5B-7.374092%2C%2038.373059%5D%2C%20%5B-7.098037%2C%2039.030073%5D%2C%20%5B-7.498632%2C%2039.629571%5D%2C%20%5B-7.066592%2C%2039.711892%5D%2C%20%5B-7.026413%2C%2040.184524%5D%2C%20%5B-6.86402%2C%2040.330872%5D%2C%20%5B-6.851127%2C%2041.111083%5D%2C%20%5B-6.389088%2C%2041.381815%5D%2C%20%5B-6.668606%2C%2041.883387%5D%2C%20%5B-7.251309%2C%2041.918346%5D%2C%20%5B-7.422513%2C%2041.792075%5D%2C%20%5B-8.013175%2C%2041.790886%5D%2C%20%5B-8.263857%2C%2042.280469%5D%2C%20%5B-8.671946%2C%2042.134689%5D%2C%20%5B-9.034818%2C%2041.880571%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ESP%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Spain%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B24.312863%2C%2057.793424%5D%2C%20%5B24.428928%2C%2058.383413%5D%2C%20%5B24.061198%2C%2058.257375%5D%2C%20%5B23.42656%2C%2058.612753%5D%2C%20%5B23.339795%2C%2059.18724%5D%2C%20%5B24.604214%2C%2059.465854%5D%2C%20%5B25.864189%2C%2059.61109%5D%2C%20%5B26.949136%2C%2059.445803%5D%2C%20%5B27.981114%2C%2059.475388%5D%2C%20%5B28.131699%2C%2059.300825%5D%2C%20%5B27.420166%2C%2058.724581%5D%2C%20%5B27.716686%2C%2057.791899%5D%2C%20%5B27.288185%2C%2057.474528%5D%2C%20%5B26.463532%2C%2057.476389%5D%2C%20%5B25.60281%2C%2057.847529%5D%2C%20%5B25.164594%2C%2057.970157%5D%2C%20%5B24.312863%2C%2057.793424%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22EST%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Estonia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B37.90607%2C%2014.95943%5D%2C%20%5B38.51295%2C%2014.50547%5D%2C%20%5B39.0994%2C%2014.74064%5D%2C%20%5B39.34061%2C%2014.53155%5D%2C%20%5B40.02625%2C%2014.51959%5D%2C%20%5B40.8966%2C%2014.11864%5D%2C%20%5B41.1552%2C%2013.77333%5D%2C%20%5B41.59856%2C%2013.45209%5D%2C%20%5B42.00975%2C%2012.86582%5D%2C%20%5B42.35156%2C%2012.54223%5D%2C%20%5B42%2C%2012.1%5D%2C%20%5B41.66176%2C%2011.6312%5D%2C%20%5B41.73959%2C%2011.35511%5D%2C%20%5B41.75557%2C%2011.05091%5D%2C%20%5B42.31414%2C%2011.0342%5D%2C%20%5B42.55493%2C%2011.10511%5D%2C%20%5B42.776852%2C%2010.926879%5D%2C%20%5B42.55876%2C%2010.57258%5D%2C%20%5B42.92812%2C%2010.02194%5D%2C%20%5B43.29699%2C%209.54048%5D%2C%20%5B43.67875%2C%209.18358%5D%2C%20%5B46.94834%2C%207.99688%5D%2C%20%5B47.78942%2C%208.003%5D%2C%20%5B44.9636%2C%205.00162%5D%2C%20%5B43.66087%2C%204.95755%5D%2C%20%5B42.76967%2C%204.25259%5D%2C%20%5B42.12861%2C%204.23413%5D%2C%20%5B41.855083%2C%203.918912%5D%2C%20%5B41.1718%2C%203.91909%5D%2C%20%5B40.76848%2C%204.25702%5D%2C%20%5B39.85494%2C%203.83879%5D%2C%20%5B39.559384%2C%203.42206%5D%2C%20%5B38.89251%2C%203.50074%5D%2C%20%5B38.67114%2C%203.61607%5D%2C%20%5B38.43697%2C%203.58851%5D%2C%20%5B38.120915%2C%203.598605%5D%2C%20%5B36.855093%2C%204.447864%5D%2C%20%5B36.159079%2C%204.447864%5D%2C%20%5B35.817448%2C%204.776966%5D%2C%20%5B35.817448%2C%205.338232%5D%2C%20%5B35.298007%2C%205.506%5D%2C%20%5B34.70702%2C%206.59422%5D%2C%20%5B34.25032%2C%206.82607%5D%2C%20%5B34.0751%2C%207.22595%5D%2C%20%5B33.56829%2C%207.71334%5D%2C%20%5B32.95418%2C%207.78497%5D%2C%20%5B33.2948%2C%208.35458%5D%2C%20%5B33.8255%2C%208.37916%5D%2C%20%5B33.97498%2C%208.68456%5D%2C%20%5B33.96162%2C%209.58358%5D%2C%20%5B34.25745%2C%2010.63009%5D%2C%20%5B34.73115%2C%2010.91017%5D%2C%20%5B34.83163%2C%2011.31896%5D%2C%20%5B35.26049%2C%2012.08286%5D%2C%20%5B35.86363%2C%2012.57828%5D%2C%20%5B36.27022%2C%2013.56333%5D%2C%20%5B36.42951%2C%2014.42211%5D%2C%20%5B37.59377%2C%2014.2131%5D%2C%20%5B37.90607%2C%2014.95943%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ETH%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Ethiopia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B28.59193%2C%2069.064777%5D%2C%20%5B28.445944%2C%2068.364613%5D%2C%20%5B29.977426%2C%2067.698297%5D%2C%20%5B29.054589%2C%2066.944286%5D%2C%20%5B30.21765%2C%2065.80598%5D%2C%20%5B29.54443%2C%2064.948672%5D%2C%20%5B30.444685%2C%2064.204453%5D%2C%20%5B30.035872%2C%2063.552814%5D%2C%20%5B31.516092%2C%2062.867687%5D%2C%20%5B31.139991%2C%2062.357693%5D%2C%20%5B30.211107%2C%2061.780028%5D%2C%20%5B28.069998%2C%2060.503517%5D%2C%20%5B26.255173%2C%2060.423961%5D%2C%20%5B24.496624%2C%2060.057316%5D%2C%20%5B22.869695%2C%2059.846373%5D%2C%20%5B22.290764%2C%2060.391921%5D%2C%20%5B21.322244%2C%2060.72017%5D%2C%20%5B21.544866%2C%2061.705329%5D%2C%20%5B21.059211%2C%2062.607393%5D%2C%20%5B21.536029%2C%2063.189735%5D%2C%20%5B22.442744%2C%2063.81781%5D%2C%20%5B24.730512%2C%2064.902344%5D%2C%20%5B25.398068%2C%2065.111427%5D%2C%20%5B25.294043%2C%2065.534346%5D%2C%20%5B23.903379%2C%2066.006927%5D%2C%20%5B23.56588%2C%2066.396051%5D%2C%20%5B23.539473%2C%2067.936009%5D%2C%20%5B21.978535%2C%2068.616846%5D%2C%20%5B20.645593%2C%2069.106247%5D%2C%20%5B21.244936%2C%2069.370443%5D%2C%20%5B22.356238%2C%2068.841741%5D%2C%20%5B23.66205%2C%2068.891247%5D%2C%20%5B24.735679%2C%2068.649557%5D%2C%20%5B25.689213%2C%2069.092114%5D%2C%20%5B26.179622%2C%2069.825299%5D%2C%20%5B27.732292%2C%2070.164193%5D%2C%20%5B29.015573%2C%2069.766491%5D%2C%20%5B28.59193%2C%2069.064777%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22FIN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Finland%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B178.3736%2C%20-17.33992%5D%2C%20%5B178.71806%2C%20-17.62846%5D%2C%20%5B178.55271%2C%20-18.15059%5D%2C%20%5B177.93266%2C%20-18.28799%5D%2C%20%5B177.38146%2C%20-18.16432%5D%2C%20%5B177.28504%2C%20-17.72465%5D%2C%20%5B177.67087%2C%20-17.38114%5D%2C%20%5B178.12557%2C%20-17.50481%5D%2C%20%5B178.3736%2C%20-17.33992%5D%5D%5D%2C%20%5B%5B%5B179.364143%2C%20-16.801354%5D%2C%20%5B178.725059%2C%20-17.012042%5D%2C%20%5B178.596839%2C%20-16.63915%5D%2C%20%5B179.096609%2C%20-16.433984%5D%2C%20%5B179.413509%2C%20-16.379054%5D%2C%20%5B180%2C%20-16.067133%5D%2C%20%5B180%2C%20-16.555217%5D%2C%20%5B179.364143%2C%20-16.801354%5D%5D%5D%2C%20%5B%5B%5B-179.917369%2C%20-16.501783%5D%2C%20%5B-180%2C%20-16.555217%5D%2C%20%5B-180%2C%20-16.067133%5D%2C%20%5B-179.79332%2C%20-16.020882%5D%2C%20%5B-179.917369%2C%20-16.501783%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22FJI%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Fiji%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-61.2%2C%20-51.85%5D%2C%20%5B-60%2C%20-51.25%5D%2C%20%5B-59.15%2C%20-51.5%5D%2C%20%5B-58.55%2C%20-51.1%5D%2C%20%5B-57.75%2C%20-51.55%5D%2C%20%5B-58.05%2C%20-51.9%5D%2C%20%5B-59.4%2C%20-52.2%5D%2C%20%5B-59.85%2C%20-51.85%5D%2C%20%5B-60.7%2C%20-52.3%5D%2C%20%5B-61.2%2C%20-51.85%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22FLK%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Falkland%20Islands%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B-52.556425%2C%202.504705%5D%2C%20%5B-52.939657%2C%202.124858%5D%2C%20%5B-53.418465%2C%202.053389%5D%2C%20%5B-53.554839%2C%202.334897%5D%2C%20%5B-53.778521%2C%202.376703%5D%2C%20%5B-54.088063%2C%202.105557%5D%2C%20%5B-54.524754%2C%202.311849%5D%2C%20%5B-54.27123%2C%202.738748%5D%2C%20%5B-54.184284%2C%203.194172%5D%2C%20%5B-54.011504%2C%203.62257%5D%2C%20%5B-54.399542%2C%204.212611%5D%2C%20%5B-54.478633%2C%204.896756%5D%2C%20%5B-53.958045%2C%205.756548%5D%2C%20%5B-53.618453%2C%205.646529%5D%2C%20%5B-52.882141%2C%205.409851%5D%2C%20%5B-51.823343%2C%204.565768%5D%2C%20%5B-51.657797%2C%204.156232%5D%2C%20%5B-52.249338%2C%203.241094%5D%2C%20%5B-52.556425%2C%202.504705%5D%5D%5D%2C%20%5B%5B%5B9.560016%2C%2042.152492%5D%2C%20%5B9.229752%2C%2041.380007%5D%2C%20%5B8.775723%2C%2041.583612%5D%2C%20%5B8.544213%2C%2042.256517%5D%2C%20%5B8.746009%2C%2042.628122%5D%2C%20%5B9.390001%2C%2043.009985%5D%2C%20%5B9.560016%2C%2042.152492%5D%5D%5D%2C%20%5B%5B%5B3.588184%2C%2050.378992%5D%2C%20%5B4.286023%2C%2049.907497%5D%2C%20%5B4.799222%2C%2049.985373%5D%2C%20%5B5.674052%2C%2049.529484%5D%2C%20%5B5.897759%2C%2049.442667%5D%2C%20%5B6.18632%2C%2049.463803%5D%2C%20%5B6.65823%2C%2049.201958%5D%2C%20%5B8.099279%2C%2049.017784%5D%2C%20%5B7.593676%2C%2048.333019%5D%2C%20%5B7.466759%2C%2047.620582%5D%2C%20%5B7.192202%2C%2047.449766%5D%2C%20%5B6.736571%2C%2047.541801%5D%2C%20%5B6.768714%2C%2047.287708%5D%2C%20%5B6.037389%2C%2046.725779%5D%2C%20%5B6.022609%2C%2046.27299%5D%2C%20%5B6.5001%2C%2046.429673%5D%2C%20%5B6.843593%2C%2045.991147%5D%2C%20%5B6.802355%2C%2045.70858%5D%2C%20%5B7.096652%2C%2045.333099%5D%2C%20%5B6.749955%2C%2045.028518%5D%2C%20%5B7.007562%2C%2044.254767%5D%2C%20%5B7.549596%2C%2044.127901%5D%2C%20%5B7.435185%2C%2043.693845%5D%2C%20%5B6.529245%2C%2043.128892%5D%2C%20%5B4.556963%2C%2043.399651%5D%2C%20%5B3.100411%2C%2043.075201%5D%2C%20%5B2.985999%2C%2042.473015%5D%2C%20%5B1.826793%2C%2042.343385%5D%2C%20%5B0.701591%2C%2042.795734%5D%2C%20%5B0.338047%2C%2042.579546%5D%2C%20%5B-1.502771%2C%2043.034014%5D%2C%20%5B-1.901351%2C%2043.422802%5D%2C%20%5B-1.384225%2C%2044.02261%5D%2C%20%5B-1.193798%2C%2046.014918%5D%2C%20%5B-2.225724%2C%2047.064363%5D%2C%20%5B-2.963276%2C%2047.570327%5D%2C%20%5B-4.491555%2C%2047.954954%5D%2C%20%5B-4.59235%2C%2048.68416%5D%2C%20%5B-3.295814%2C%2048.901692%5D%2C%20%5B-1.616511%2C%2048.644421%5D%2C%20%5B-1.933494%2C%2049.776342%5D%2C%20%5B-0.989469%2C%2049.347376%5D%2C%20%5B1.338761%2C%2050.127173%5D%2C%20%5B1.639001%2C%2050.946606%5D%2C%20%5B2.513573%2C%2051.148506%5D%2C%20%5B2.658422%2C%2050.796848%5D%2C%20%5B3.123252%2C%2050.780363%5D%2C%20%5B3.588184%2C%2050.378992%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22FRA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22France%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B11.093773%2C%20-3.978827%5D%2C%20%5B10.066135%2C%20-2.969483%5D%2C%20%5B9.405245%2C%20-2.144313%5D%2C%20%5B8.797996%2C%20-1.111301%5D%2C%20%5B8.830087%2C%20-0.779074%5D%2C%20%5B9.04842%2C%20-0.459351%5D%2C%20%5B9.291351%2C%200.268666%5D%2C%20%5B9.492889%2C%201.01012%5D%2C%20%5B9.830284%2C%201.067894%5D%2C%20%5B11.285079%2C%201.057662%5D%2C%20%5B11.276449%2C%202.261051%5D%2C%20%5B11.751665%2C%202.326758%5D%2C%20%5B12.35938%2C%202.192812%5D%2C%20%5B12.951334%2C%202.321616%5D%2C%20%5B13.075822%2C%202.267097%5D%2C%20%5B13.003114%2C%201.830896%5D%2C%20%5B13.282631%2C%201.314184%5D%2C%20%5B14.026669%2C%201.395677%5D%2C%20%5B14.276266%2C%201.19693%5D%2C%20%5B13.843321%2C%200.038758%5D%2C%20%5B14.316418%2C%20-0.552627%5D%2C%20%5B14.425456%2C%20-1.333407%5D%2C%20%5B14.29921%2C%20-1.998276%5D%2C%20%5B13.992407%2C%20-2.470805%5D%2C%20%5B13.109619%2C%20-2.42874%5D%2C%20%5B12.575284%2C%20-1.948511%5D%2C%20%5B12.495703%2C%20-2.391688%5D%2C%20%5B11.820964%2C%20-2.514161%5D%2C%20%5B11.478039%2C%20-2.765619%5D%2C%20%5B11.855122%2C%20-3.426871%5D%2C%20%5B11.093773%2C%20-3.978827%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22GAB%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Gabon%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B-5.661949%2C%2054.554603%5D%2C%20%5B-6.197885%2C%2053.867565%5D%2C%20%5B-6.95373%2C%2054.073702%5D%2C%20%5B-7.572168%2C%2054.059956%5D%2C%20%5B-7.366031%2C%2054.595841%5D%2C%20%5B-7.572168%2C%2055.131622%5D%2C%20%5B-6.733847%2C%2055.17286%5D%2C%20%5B-5.661949%2C%2054.554603%5D%5D%5D%2C%20%5B%5B%5B-3.005005%2C%2058.635%5D%2C%20%5B-4.073828%2C%2057.553025%5D%2C%20%5B-3.055002%2C%2057.690019%5D%2C%20%5B-1.959281%2C%2057.6848%5D%2C%20%5B-2.219988%2C%2056.870017%5D%2C%20%5B-3.119003%2C%2055.973793%5D%2C%20%5B-2.085009%2C%2055.909998%5D%2C%20%5B-2.005676%2C%2055.804903%5D%2C%20%5B-1.114991%2C%2054.624986%5D%2C%20%5B-0.430485%2C%2054.464376%5D%2C%20%5B0.184981%2C%2053.325014%5D%2C%20%5B0.469977%2C%2052.929999%5D%2C%20%5B1.681531%2C%2052.73952%5D%2C%20%5B1.559988%2C%2052.099998%5D%2C%20%5B1.050562%2C%2051.806761%5D%2C%20%5B1.449865%2C%2051.289428%5D%2C%20%5B0.550334%2C%2050.765739%5D%2C%20%5B-0.787517%2C%2050.774989%5D%2C%20%5B-2.489998%2C%2050.500019%5D%2C%20%5B-2.956274%2C%2050.69688%5D%2C%20%5B-3.617448%2C%2050.228356%5D%2C%20%5B-4.542508%2C%2050.341837%5D%2C%20%5B-5.245023%2C%2049.96%5D%2C%20%5B-5.776567%2C%2050.159678%5D%2C%20%5B-4.30999%2C%2051.210001%5D%2C%20%5B-3.414851%2C%2051.426009%5D%2C%20%5B-3.422719%2C%2051.426848%5D%2C%20%5B-4.984367%2C%2051.593466%5D%2C%20%5B-5.267296%2C%2051.9914%5D%2C%20%5B-4.222347%2C%2052.301356%5D%2C%20%5B-4.770013%2C%2052.840005%5D%2C%20%5B-4.579999%2C%2053.495004%5D%2C%20%5B-3.093831%2C%2053.404547%5D%2C%20%5B-3.09208%2C%2053.404441%5D%2C%20%5B-2.945009%2C%2053.985%5D%2C%20%5B-3.614701%2C%2054.600937%5D%2C%20%5B-3.630005%2C%2054.615013%5D%2C%20%5B-4.844169%2C%2054.790971%5D%2C%20%5B-5.082527%2C%2055.061601%5D%2C%20%5B-4.719112%2C%2055.508473%5D%2C%20%5B-5.047981%2C%2055.783986%5D%2C%20%5B-5.586398%2C%2055.311146%5D%2C%20%5B-5.644999%2C%2056.275015%5D%2C%20%5B-6.149981%2C%2056.78501%5D%2C%20%5B-5.786825%2C%2057.818848%5D%2C%20%5B-5.009999%2C%2058.630013%5D%2C%20%5B-4.211495%2C%2058.550845%5D%2C%20%5B-3.005005%2C%2058.635%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22GBR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22United%20Kingdom%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B41.554084%2C%2041.535656%5D%2C%20%5B41.703171%2C%2041.962943%5D%2C%20%5B41.45347%2C%2042.645123%5D%2C%20%5B40.875469%2C%2043.013628%5D%2C%20%5B40.321394%2C%2043.128634%5D%2C%20%5B39.955009%2C%2043.434998%5D%2C%20%5B40.076965%2C%2043.553104%5D%2C%20%5B40.922185%2C%2043.382159%5D%2C%20%5B42.394395%2C%2043.220308%5D%2C%20%5B43.756017%2C%2042.740828%5D%2C%20%5B43.9312%2C%2042.554974%5D%2C%20%5B44.537623%2C%2042.711993%5D%2C%20%5B45.470279%2C%2042.502781%5D%2C%20%5B45.77641%2C%2042.092444%5D%2C%20%5B46.404951%2C%2041.860675%5D%2C%20%5B46.145432%2C%2041.722802%5D%2C%20%5B46.637908%2C%2041.181673%5D%2C%20%5B46.501637%2C%2041.064445%5D%2C%20%5B45.962601%2C%2041.123873%5D%2C%20%5B45.217426%2C%2041.411452%5D%2C%20%5B44.97248%2C%2041.248129%5D%2C%20%5B43.582746%2C%2041.092143%5D%2C%20%5B42.619549%2C%2041.583173%5D%2C%20%5B41.554084%2C%2041.535656%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22GEO%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Georgia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B1.060122%2C%205.928837%5D%2C%20%5B-0.507638%2C%205.343473%5D%2C%20%5B-1.063625%2C%205.000548%5D%2C%20%5B-1.964707%2C%204.710462%5D%2C%20%5B-2.856125%2C%204.994476%5D%2C%20%5B-2.810701%2C%205.389051%5D%2C%20%5B-3.24437%2C%206.250472%5D%2C%20%5B-2.983585%2C%207.379705%5D%2C%20%5B-2.56219%2C%208.219628%5D%2C%20%5B-2.827496%2C%209.642461%5D%2C%20%5B-2.963896%2C%2010.395335%5D%2C%20%5B-2.940409%2C%2010.96269%5D%2C%20%5B-1.203358%2C%2011.009819%5D%2C%20%5B-0.761576%2C%2010.93693%5D%2C%20%5B-0.438702%2C%2011.098341%5D%2C%20%5B0.023803%2C%2011.018682%5D%2C%20%5B-0.049785%2C%2010.706918%5D%2C%20%5B0.36758%2C%2010.191213%5D%2C%20%5B0.365901%2C%209.465004%5D%2C%20%5B0.461192%2C%208.677223%5D%2C%20%5B0.712029%2C%208.312465%5D%2C%20%5B0.490957%2C%207.411744%5D%2C%20%5B0.570384%2C%206.914359%5D%2C%20%5B0.836931%2C%206.279979%5D%2C%20%5B1.060122%2C%205.928837%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22GHA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Ghana%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-8.439298%2C%207.686043%5D%2C%20%5B-8.722124%2C%207.711674%5D%2C%20%5B-8.926065%2C%207.309037%5D%2C%20%5B-9.208786%2C%207.313921%5D%2C%20%5B-9.403348%2C%207.526905%5D%2C%20%5B-9.33728%2C%207.928534%5D%2C%20%5B-9.755342%2C%208.541055%5D%2C%20%5B-10.016567%2C%208.428504%5D%2C%20%5B-10.230094%2C%208.406206%5D%2C%20%5B-10.505477%2C%208.348896%5D%2C%20%5B-10.494315%2C%208.715541%5D%2C%20%5B-10.65477%2C%208.977178%5D%2C%20%5B-10.622395%2C%209.26791%5D%2C%20%5B-10.839152%2C%209.688246%5D%2C%20%5B-11.117481%2C%2010.045873%5D%2C%20%5B-11.917277%2C%2010.046984%5D%2C%20%5B-12.150338%2C%209.858572%5D%2C%20%5B-12.425929%2C%209.835834%5D%2C%20%5B-12.596719%2C%209.620188%5D%2C%20%5B-12.711958%2C%209.342712%5D%2C%20%5B-13.24655%2C%208.903049%5D%2C%20%5B-13.685154%2C%209.494744%5D%2C%20%5B-14.074045%2C%209.886167%5D%2C%20%5B-14.330076%2C%2010.01572%5D%2C%20%5B-14.579699%2C%2010.214467%5D%2C%20%5B-14.693232%2C%2010.656301%5D%2C%20%5B-14.839554%2C%2010.876572%5D%2C%20%5B-15.130311%2C%2011.040412%5D%2C%20%5B-14.685687%2C%2011.527824%5D%2C%20%5B-14.382192%2C%2011.509272%5D%2C%20%5B-14.121406%2C%2011.677117%5D%2C%20%5B-13.9008%2C%2011.678719%5D%2C%20%5B-13.743161%2C%2011.811269%5D%2C%20%5B-13.828272%2C%2012.142644%5D%2C%20%5B-13.718744%2C%2012.247186%5D%2C%20%5B-13.700476%2C%2012.586183%5D%2C%20%5B-13.217818%2C%2012.575874%5D%2C%20%5B-12.499051%2C%2012.33209%5D%2C%20%5B-12.278599%2C%2012.35444%5D%2C%20%5B-12.203565%2C%2012.465648%5D%2C%20%5B-11.658301%2C%2012.386583%5D%2C%20%5B-11.513943%2C%2012.442988%5D%2C%20%5B-11.456169%2C%2012.076834%5D%2C%20%5B-11.297574%2C%2012.077971%5D%2C%20%5B-11.036556%2C%2012.211245%5D%2C%20%5B-10.87083%2C%2012.177887%5D%2C%20%5B-10.593224%2C%2011.923975%5D%2C%20%5B-10.165214%2C%2011.844084%5D%2C%20%5B-9.890993%2C%2012.060479%5D%2C%20%5B-9.567912%2C%2012.194243%5D%2C%20%5B-9.327616%2C%2012.334286%5D%2C%20%5B-9.127474%2C%2012.30806%5D%2C%20%5B-8.905265%2C%2012.088358%5D%2C%20%5B-8.786099%2C%2011.812561%5D%2C%20%5B-8.376305%2C%2011.393646%5D%2C%20%5B-8.581305%2C%2011.136246%5D%2C%20%5B-8.620321%2C%2010.810891%5D%2C%20%5B-8.407311%2C%2010.909257%5D%2C%20%5B-8.282357%2C%2010.792597%5D%2C%20%5B-8.335377%2C%2010.494812%5D%2C%20%5B-8.029944%2C%2010.206535%5D%2C%20%5B-8.229337%2C%2010.12902%5D%2C%20%5B-8.309616%2C%209.789532%5D%2C%20%5B-8.079114%2C%209.376224%5D%2C%20%5B-7.8321%2C%208.575704%5D%2C%20%5B-8.203499%2C%208.455453%5D%2C%20%5B-8.299049%2C%208.316444%5D%2C%20%5B-8.221792%2C%208.123329%5D%2C%20%5B-8.280703%2C%207.68718%5D%2C%20%5B-8.439298%2C%207.686043%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22GIN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Guinea%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-16.841525%2C%2013.151394%5D%2C%20%5B-16.713729%2C%2013.594959%5D%2C%20%5B-15.624596%2C%2013.623587%5D%2C%20%5B-15.39877%2C%2013.860369%5D%2C%20%5B-15.081735%2C%2013.876492%5D%2C%20%5B-14.687031%2C%2013.630357%5D%2C%20%5B-14.376714%2C%2013.62568%5D%2C%20%5B-14.046992%2C%2013.794068%5D%2C%20%5B-13.844963%2C%2013.505042%5D%2C%20%5B-14.277702%2C%2013.280585%5D%2C%20%5B-14.712197%2C%2013.298207%5D%2C%20%5B-15.141163%2C%2013.509512%5D%2C%20%5B-15.511813%2C%2013.27857%5D%2C%20%5B-15.691001%2C%2013.270353%5D%2C%20%5B-15.931296%2C%2013.130284%5D%2C%20%5B-16.841525%2C%2013.151394%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22GMB%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Gambia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-15.130311%2C%2011.040412%5D%2C%20%5B-15.66418%2C%2011.458474%5D%2C%20%5B-16.085214%2C%2011.524594%5D%2C%20%5B-16.314787%2C%2011.806515%5D%2C%20%5B-16.308947%2C%2011.958702%5D%2C%20%5B-16.613838%2C%2012.170911%5D%2C%20%5B-16.677452%2C%2012.384852%5D%2C%20%5B-16.147717%2C%2012.547762%5D%2C%20%5B-15.816574%2C%2012.515567%5D%2C%20%5B-15.548477%2C%2012.62817%5D%2C%20%5B-13.700476%2C%2012.586183%5D%2C%20%5B-13.718744%2C%2012.247186%5D%2C%20%5B-13.828272%2C%2012.142644%5D%2C%20%5B-13.743161%2C%2011.811269%5D%2C%20%5B-13.9008%2C%2011.678719%5D%2C%20%5B-14.121406%2C%2011.677117%5D%2C%20%5B-14.382192%2C%2011.509272%5D%2C%20%5B-14.685687%2C%2011.527824%5D%2C%20%5B-15.130311%2C%2011.040412%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22GNB%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Guinea%20Bissau%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B9.492889%2C%201.01012%5D%2C%20%5B9.305613%2C%201.160911%5D%2C%20%5B9.649158%2C%202.283866%5D%2C%20%5B11.276449%2C%202.261051%5D%2C%20%5B11.285079%2C%201.057662%5D%2C%20%5B9.830284%2C%201.067894%5D%2C%20%5B9.492889%2C%201.01012%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22GNQ%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Equatorial%20Guinea%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B23.69998%2C%2035.705004%5D%2C%20%5B24.246665%2C%2035.368022%5D%2C%20%5B25.025015%2C%2035.424996%5D%2C%20%5B25.769208%2C%2035.354018%5D%2C%20%5B25.745023%2C%2035.179998%5D%2C%20%5B26.290003%2C%2035.29999%5D%2C%20%5B26.164998%2C%2035.004995%5D%2C%20%5B24.724982%2C%2034.919988%5D%2C%20%5B24.735007%2C%2035.084991%5D%2C%20%5B23.514978%2C%2035.279992%5D%2C%20%5B23.69998%2C%2035.705004%5D%5D%5D%2C%20%5B%5B%5B26.604196%2C%2041.562115%5D%2C%20%5B26.294602%2C%2040.936261%5D%2C%20%5B26.056942%2C%2040.824123%5D%2C%20%5B25.447677%2C%2040.852545%5D%2C%20%5B24.925848%2C%2040.947062%5D%2C%20%5B23.714811%2C%2040.687129%5D%2C%20%5B24.407999%2C%2040.124993%5D%2C%20%5B23.899968%2C%2039.962006%5D%2C%20%5B23.342999%2C%2039.960998%5D%2C%20%5B22.813988%2C%2040.476005%5D%2C%20%5B22.626299%2C%2040.256561%5D%2C%20%5B22.849748%2C%2039.659311%5D%2C%20%5B23.350027%2C%2039.190011%5D%2C%20%5B22.973099%2C%2038.970903%5D%2C%20%5B23.530016%2C%2038.510001%5D%2C%20%5B24.025025%2C%2038.219993%5D%2C%20%5B24.040011%2C%2037.655015%5D%2C%20%5B23.115003%2C%2037.920011%5D%2C%20%5B23.409972%2C%2037.409991%5D%2C%20%5B22.774972%2C%2037.30501%5D%2C%20%5B23.154225%2C%2036.422506%5D%2C%20%5B22.490028%2C%2036.41%5D%2C%20%5B21.670026%2C%2036.844986%5D%2C%20%5B21.295011%2C%2037.644989%5D%2C%20%5B21.120034%2C%2038.310323%5D%2C%20%5B20.730032%2C%2038.769985%5D%2C%20%5B20.217712%2C%2039.340235%5D%2C%20%5B20.150016%2C%2039.624998%5D%2C%20%5B20.615%2C%2040.110007%5D%2C%20%5B20.674997%2C%2040.435%5D%2C%20%5B20.99999%2C%2040.580004%5D%2C%20%5B21.02004%2C%2040.842727%5D%2C%20%5B21.674161%2C%2040.931275%5D%2C%20%5B22.055378%2C%2041.149866%5D%2C%20%5B22.597308%2C%2041.130487%5D%2C%20%5B22.76177%2C%2041.3048%5D%2C%20%5B22.952377%2C%2041.337994%5D%2C%20%5B23.692074%2C%2041.309081%5D%2C%20%5B24.492645%2C%2041.583896%5D%2C%20%5B25.197201%2C%2041.234486%5D%2C%20%5B26.106138%2C%2041.328899%5D%2C%20%5B26.117042%2C%2041.826905%5D%2C%20%5B26.604196%2C%2041.562115%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22GRC%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Greece%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-46.76379%2C%2082.62796%5D%2C%20%5B-43.40644%2C%2083.22516%5D%2C%20%5B-39.89753%2C%2083.18018%5D%2C%20%5B-38.62214%2C%2083.54905%5D%2C%20%5B-35.08787%2C%2083.64513%5D%2C%20%5B-27.10046%2C%2083.51966%5D%2C%20%5B-20.84539%2C%2082.72669%5D%2C%20%5B-22.69182%2C%2082.34165%5D%2C%20%5B-26.51753%2C%2082.29765%5D%2C%20%5B-31.9%2C%2082.2%5D%2C%20%5B-31.39646%2C%2082.02154%5D%2C%20%5B-27.85666%2C%2082.13178%5D%2C%20%5B-24.84448%2C%2081.78697%5D%2C%20%5B-22.90328%2C%2082.09317%5D%2C%20%5B-22.07175%2C%2081.73449%5D%2C%20%5B-23.16961%2C%2081.15271%5D%2C%20%5B-20.62363%2C%2081.52462%5D%2C%20%5B-15.76818%2C%2081.91245%5D%2C%20%5B-12.77018%2C%2081.71885%5D%2C%20%5B-12.20855%2C%2081.29154%5D%2C%20%5B-16.28533%2C%2080.58004%5D%2C%20%5B-16.85%2C%2080.35%5D%2C%20%5B-20.04624%2C%2080.17708%5D%2C%20%5B-17.73035%2C%2080.12912%5D%2C%20%5B-18.9%2C%2079.4%5D%2C%20%5B-19.70499%2C%2078.75128%5D%2C%20%5B-19.67353%2C%2077.63859%5D%2C%20%5B-18.47285%2C%2076.98565%5D%2C%20%5B-20.03503%2C%2076.94434%5D%2C%20%5B-21.67944%2C%2076.62795%5D%2C%20%5B-19.83407%2C%2076.09808%5D%2C%20%5B-19.59896%2C%2075.24838%5D%2C%20%5B-20.66818%2C%2075.15585%5D%2C%20%5B-19.37281%2C%2074.29561%5D%2C%20%5B-21.59422%2C%2074.22382%5D%2C%20%5B-20.43454%2C%2073.81713%5D%2C%20%5B-20.76234%2C%2073.46436%5D%2C%20%5B-22.17221%2C%2073.30955%5D%2C%20%5B-23.56593%2C%2073.30663%5D%2C%20%5B-22.31311%2C%2072.62928%5D%2C%20%5B-22.29954%2C%2072.18409%5D%2C%20%5B-24.27834%2C%2072.59788%5D%2C%20%5B-24.79296%2C%2072.3302%5D%2C%20%5B-23.44296%2C%2072.08016%5D%2C%20%5B-22.13281%2C%2071.46898%5D%2C%20%5B-21.75356%2C%2070.66369%5D%2C%20%5B-23.53603%2C%2070.471%5D%2C%20%5B-24.30702%2C%2070.85649%5D%2C%20%5B-25.54341%2C%2071.43094%5D%2C%20%5B-25.20135%2C%2070.75226%5D%2C%20%5B-26.36276%2C%2070.22646%5D%2C%20%5B-23.72742%2C%2070.18401%5D%2C%20%5B-22.34902%2C%2070.12946%5D%2C%20%5B-25.02927%2C%2069.2588%5D%2C%20%5B-27.74737%2C%2068.47046%5D%2C%20%5B-30.67371%2C%2068.12503%5D%2C%20%5B-31.77665%2C%2068.12078%5D%2C%20%5B-32.81105%2C%2067.73547%5D%2C%20%5B-34.20196%2C%2066.67974%5D%2C%20%5B-36.35284%2C%2065.9789%5D%2C%20%5B-37.04378%2C%2065.93768%5D%2C%20%5B-38.37505%2C%2065.69213%5D%2C%20%5B-39.81222%2C%2065.45848%5D%2C%20%5B-40.66899%2C%2064.83997%5D%2C%20%5B-40.68281%2C%2064.13902%5D%2C%20%5B-41.1887%2C%2063.48246%5D%2C%20%5B-42.81938%2C%2062.68233%5D%2C%20%5B-42.41666%2C%2061.90093%5D%2C%20%5B-42.86619%2C%2061.07404%5D%2C%20%5B-43.3784%2C%2060.09772%5D%2C%20%5B-44.7875%2C%2060.03676%5D%2C%20%5B-46.26364%2C%2060.85328%5D%2C%20%5B-48.26294%2C%2060.85843%5D%2C%20%5B-49.23308%2C%2061.40681%5D%2C%20%5B-49.90039%2C%2062.38336%5D%2C%20%5B-51.63325%2C%2063.62691%5D%2C%20%5B-52.14014%2C%2064.27842%5D%2C%20%5B-52.27659%2C%2065.1767%5D%2C%20%5B-53.66166%2C%2066.09957%5D%2C%20%5B-53.30161%2C%2066.8365%5D%2C%20%5B-53.96911%2C%2067.18899%5D%2C%20%5B-52.9804%2C%2068.35759%5D%2C%20%5B-51.47536%2C%2068.72958%5D%2C%20%5B-51.08041%2C%2069.14781%5D%2C%20%5B-50.87122%2C%2069.9291%5D%2C%20%5B-52.013585%2C%2069.574925%5D%2C%20%5B-52.55792%2C%2069.42616%5D%2C%20%5B-53.45629%2C%2069.283625%5D%2C%20%5B-54.68336%2C%2069.61003%5D%2C%20%5B-54.75001%2C%2070.28932%5D%2C%20%5B-54.35884%2C%2070.821315%5D%2C%20%5B-53.431315%2C%2070.835755%5D%2C%20%5B-51.39014%2C%2070.56978%5D%2C%20%5B-53.10937%2C%2071.20485%5D%2C%20%5B-54.00422%2C%2071.54719%5D%2C%20%5B-55%2C%2071.406537%5D%2C%20%5B-55.83468%2C%2071.65444%5D%2C%20%5B-54.71819%2C%2072.58625%5D%2C%20%5B-55.32634%2C%2072.95861%5D%2C%20%5B-56.12003%2C%2073.64977%5D%2C%20%5B-57.32363%2C%2074.71026%5D%2C%20%5B-58.59679%2C%2075.09861%5D%2C%20%5B-58.58516%2C%2075.51727%5D%2C%20%5B-61.26861%2C%2076.10238%5D%2C%20%5B-63.39165%2C%2076.1752%5D%2C%20%5B-66.06427%2C%2076.13486%5D%2C%20%5B-68.50438%2C%2076.06141%5D%2C%20%5B-69.66485%2C%2076.37975%5D%2C%20%5B-71.40257%2C%2077.00857%5D%2C%20%5B-68.77671%2C%2077.32312%5D%2C%20%5B-66.76397%2C%2077.37595%5D%2C%20%5B-71.04293%2C%2077.63595%5D%2C%20%5B-73.297%2C%2078.04419%5D%2C%20%5B-73.15938%2C%2078.43271%5D%2C%20%5B-69.37345%2C%2078.91388%5D%2C%20%5B-65.7107%2C%2079.39436%5D%2C%20%5B-65.3239%2C%2079.75814%5D%2C%20%5B-68.02298%2C%2080.11721%5D%2C%20%5B-67.15129%2C%2080.51582%5D%2C%20%5B-63.68925%2C%2081.21396%5D%2C%20%5B-62.23444%2C%2081.3211%5D%2C%20%5B-62.65116%2C%2081.77042%5D%2C%20%5B-60.28249%2C%2082.03363%5D%2C%20%5B-57.20744%2C%2082.19074%5D%2C%20%5B-54.13442%2C%2082.19962%5D%2C%20%5B-53.04328%2C%2081.88833%5D%2C%20%5B-50.39061%2C%2082.43883%5D%2C%20%5B-48.00386%2C%2082.06481%5D%2C%20%5B-46.59984%2C%2081.985945%5D%2C%20%5B-44.523%2C%2081.6607%5D%2C%20%5B-46.9007%2C%2082.19979%5D%2C%20%5B-46.76379%2C%2082.62796%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22GRL%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Greenland%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-90.095555%2C%2013.735338%5D%2C%20%5B-90.608624%2C%2013.909771%5D%2C%20%5B-91.23241%2C%2013.927832%5D%2C%20%5B-91.689747%2C%2014.126218%5D%2C%20%5B-92.22775%2C%2014.538829%5D%2C%20%5B-92.20323%2C%2014.830103%5D%2C%20%5B-92.087216%2C%2015.064585%5D%2C%20%5B-92.229249%2C%2015.251447%5D%2C%20%5B-91.74796%2C%2016.066565%5D%2C%20%5B-90.464473%2C%2016.069562%5D%2C%20%5B-90.438867%2C%2016.41011%5D%2C%20%5B-90.600847%2C%2016.470778%5D%2C%20%5B-90.711822%2C%2016.687483%5D%2C%20%5B-91.08167%2C%2016.918477%5D%2C%20%5B-91.453921%2C%2017.252177%5D%2C%20%5B-91.002269%2C%2017.254658%5D%2C%20%5B-91.00152%2C%2017.817595%5D%2C%20%5B-90.067934%2C%2017.819326%5D%2C%20%5B-89.14308%2C%2017.808319%5D%2C%20%5B-89.150806%2C%2017.015577%5D%2C%20%5B-89.229122%2C%2015.886938%5D%2C%20%5B-88.930613%2C%2015.887273%5D%2C%20%5B-88.604586%2C%2015.70638%5D%2C%20%5B-88.518364%2C%2015.855389%5D%2C%20%5B-88.225023%2C%2015.727722%5D%2C%20%5B-88.68068%2C%2015.346247%5D%2C%20%5B-89.154811%2C%2015.066419%5D%2C%20%5B-89.22522%2C%2014.874286%5D%2C%20%5B-89.145535%2C%2014.678019%5D%2C%20%5B-89.353326%2C%2014.424133%5D%2C%20%5B-89.587343%2C%2014.362586%5D%2C%20%5B-89.534219%2C%2014.244816%5D%2C%20%5B-89.721934%2C%2014.134228%5D%2C%20%5B-90.064678%2C%2013.88197%5D%2C%20%5B-90.095555%2C%2013.735338%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22GTM%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Guatemala%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-59.758285%2C%208.367035%5D%2C%20%5B-59.101684%2C%207.999202%5D%2C%20%5B-58.482962%2C%207.347691%5D%2C%20%5B-58.454876%2C%206.832787%5D%2C%20%5B-58.078103%2C%206.809094%5D%2C%20%5B-57.542219%2C%206.321268%5D%2C%20%5B-57.147436%2C%205.97315%5D%2C%20%5B-57.307246%2C%205.073567%5D%2C%20%5B-57.914289%2C%204.812626%5D%2C%20%5B-57.86021%2C%204.576801%5D%2C%20%5B-58.044694%2C%204.060864%5D%2C%20%5B-57.601569%2C%203.334655%5D%2C%20%5B-57.281433%2C%203.333492%5D%2C%20%5B-57.150098%2C%202.768927%5D%2C%20%5B-56.539386%2C%201.899523%5D%2C%20%5B-56.782704%2C%201.863711%5D%2C%20%5B-57.335823%2C%201.948538%5D%2C%20%5B-57.660971%2C%201.682585%5D%2C%20%5B-58.11345%2C%201.507195%5D%2C%20%5B-58.429477%2C%201.463942%5D%2C%20%5B-58.540013%2C%201.268088%5D%2C%20%5B-59.030862%2C%201.317698%5D%2C%20%5B-59.646044%2C%201.786894%5D%2C%20%5B-59.718546%2C%202.24963%5D%2C%20%5B-59.974525%2C%202.755233%5D%2C%20%5B-59.815413%2C%203.606499%5D%2C%20%5B-59.53804%2C%203.958803%5D%2C%20%5B-59.767406%2C%204.423503%5D%2C%20%5B-60.111002%2C%204.574967%5D%2C%20%5B-59.980959%2C%205.014061%5D%2C%20%5B-60.213683%2C%205.244486%5D%2C%20%5B-60.733574%2C%205.200277%5D%2C%20%5B-61.410303%2C%205.959068%5D%2C%20%5B-61.139415%2C%206.234297%5D%2C%20%5B-61.159336%2C%206.696077%5D%2C%20%5B-60.543999%2C%206.856584%5D%2C%20%5B-60.295668%2C%207.043911%5D%2C%20%5B-60.637973%2C%207.415%5D%2C%20%5B-60.550588%2C%207.779603%5D%2C%20%5B-59.758285%2C%208.367035%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22GUY%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Guyana%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-87.316654%2C%2012.984686%5D%2C%20%5B-87.489409%2C%2013.297535%5D%2C%20%5B-87.793111%2C%2013.38448%5D%2C%20%5B-87.723503%2C%2013.78505%5D%2C%20%5B-87.859515%2C%2013.893312%5D%2C%20%5B-88.065343%2C%2013.964626%5D%2C%20%5B-88.503998%2C%2013.845486%5D%2C%20%5B-88.541231%2C%2013.980155%5D%2C%20%5B-88.843073%2C%2014.140507%5D%2C%20%5B-89.058512%2C%2014.340029%5D%2C%20%5B-89.353326%2C%2014.424133%5D%2C%20%5B-89.145535%2C%2014.678019%5D%2C%20%5B-89.22522%2C%2014.874286%5D%2C%20%5B-89.154811%2C%2015.066419%5D%2C%20%5B-88.68068%2C%2015.346247%5D%2C%20%5B-88.225023%2C%2015.727722%5D%2C%20%5B-88.121153%2C%2015.688655%5D%2C%20%5B-87.901813%2C%2015.864458%5D%2C%20%5B-87.61568%2C%2015.878799%5D%2C%20%5B-87.522921%2C%2015.797279%5D%2C%20%5B-87.367762%2C%2015.84694%5D%2C%20%5B-86.903191%2C%2015.756713%5D%2C%20%5B-86.440946%2C%2015.782835%5D%2C%20%5B-86.119234%2C%2015.893449%5D%2C%20%5B-86.001954%2C%2016.005406%5D%2C%20%5B-85.683317%2C%2015.953652%5D%2C%20%5B-85.444004%2C%2015.885749%5D%2C%20%5B-85.182444%2C%2015.909158%5D%2C%20%5B-84.983722%2C%2015.995923%5D%2C%20%5B-84.52698%2C%2015.857224%5D%2C%20%5B-84.368256%2C%2015.835158%5D%2C%20%5B-84.063055%2C%2015.648244%5D%2C%20%5B-83.773977%2C%2015.424072%5D%2C%20%5B-83.410381%2C%2015.270903%5D%2C%20%5B-83.147219%2C%2014.995829%5D%2C%20%5B-83.489989%2C%2015.016267%5D%2C%20%5B-83.628585%2C%2014.880074%5D%2C%20%5B-83.975721%2C%2014.749436%5D%2C%20%5B-84.228342%2C%2014.748764%5D%2C%20%5B-84.449336%2C%2014.621614%5D%2C%20%5B-84.649582%2C%2014.666805%5D%2C%20%5B-84.820037%2C%2014.819587%5D%2C%20%5B-84.924501%2C%2014.790493%5D%2C%20%5B-85.052787%2C%2014.551541%5D%2C%20%5B-85.148751%2C%2014.560197%5D%2C%20%5B-85.165365%2C%2014.35437%5D%2C%20%5B-85.514413%2C%2014.079012%5D%2C%20%5B-85.698665%2C%2013.960078%5D%2C%20%5B-85.801295%2C%2013.836055%5D%2C%20%5B-86.096264%2C%2014.038187%5D%2C%20%5B-86.312142%2C%2013.771356%5D%2C%20%5B-86.520708%2C%2013.778487%5D%2C%20%5B-86.755087%2C%2013.754845%5D%2C%20%5B-86.733822%2C%2013.263093%5D%2C%20%5B-86.880557%2C%2013.254204%5D%2C%20%5B-87.005769%2C%2013.025794%5D%2C%20%5B-87.316654%2C%2012.984686%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22HND%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Honduras%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B18.829838%2C%2045.908878%5D%2C%20%5B19.072769%2C%2045.521511%5D%2C%20%5B19.390476%2C%2045.236516%5D%2C%20%5B19.005486%2C%2044.860234%5D%2C%20%5B18.553214%2C%2045.08159%5D%2C%20%5B17.861783%2C%2045.06774%5D%2C%20%5B17.002146%2C%2045.233777%5D%2C%20%5B16.534939%2C%2045.211608%5D%2C%20%5B16.318157%2C%2045.004127%5D%2C%20%5B15.959367%2C%2045.233777%5D%2C%20%5B15.750026%2C%2044.818712%5D%2C%20%5B16.23966%2C%2044.351143%5D%2C%20%5B16.456443%2C%2044.04124%5D%2C%20%5B16.916156%2C%2043.667722%5D%2C%20%5B17.297373%2C%2043.446341%5D%2C%20%5B17.674922%2C%2043.028563%5D%2C%20%5B18.56%2C%2042.65%5D%2C%20%5B18.450016%2C%2042.479991%5D%2C%20%5B17.50997%2C%2042.849995%5D%2C%20%5B16.930006%2C%2043.209998%5D%2C%20%5B16.015385%2C%2043.507215%5D%2C%20%5B15.174454%2C%2044.243191%5D%2C%20%5B15.37625%2C%2044.317915%5D%2C%20%5B14.920309%2C%2044.738484%5D%2C%20%5B14.901602%2C%2045.07606%5D%2C%20%5B14.258748%2C%2045.233777%5D%2C%20%5B13.952255%2C%2044.802124%5D%2C%20%5B13.656976%2C%2045.136935%5D%2C%20%5B13.679403%2C%2045.484149%5D%2C%20%5B13.71506%2C%2045.500324%5D%2C%20%5B14.411968%2C%2045.466166%5D%2C%20%5B14.595109%2C%2045.634941%5D%2C%20%5B14.935244%2C%2045.471695%5D%2C%20%5B15.327675%2C%2045.452316%5D%2C%20%5B15.323954%2C%2045.731783%5D%2C%20%5B15.67153%2C%2045.834154%5D%2C%20%5B15.768733%2C%2046.238108%5D%2C%20%5B16.564808%2C%2046.503751%5D%2C%20%5B16.882515%2C%2046.380632%5D%2C%20%5B17.630066%2C%2045.951769%5D%2C%20%5B18.456062%2C%2045.759481%5D%2C%20%5B18.829838%2C%2045.908878%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22HRV%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Croatia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-73.189791%2C%2019.915684%5D%2C%20%5B-72.579673%2C%2019.871501%5D%2C%20%5B-71.712361%2C%2019.714456%5D%2C%20%5B-71.624873%2C%2019.169838%5D%2C%20%5B-71.701303%2C%2018.785417%5D%2C%20%5B-71.945112%2C%2018.6169%5D%2C%20%5B-71.687738%2C%2018.31666%5D%2C%20%5B-71.708305%2C%2018.044997%5D%2C%20%5B-72.372476%2C%2018.214961%5D%2C%20%5B-72.844411%2C%2018.145611%5D%2C%20%5B-73.454555%2C%2018.217906%5D%2C%20%5B-73.922433%2C%2018.030993%5D%2C%20%5B-74.458034%2C%2018.34255%5D%2C%20%5B-74.369925%2C%2018.664908%5D%2C%20%5B-73.449542%2C%2018.526053%5D%2C%20%5B-72.694937%2C%2018.445799%5D%2C%20%5B-72.334882%2C%2018.668422%5D%2C%20%5B-72.79165%2C%2019.101625%5D%2C%20%5B-72.784105%2C%2019.483591%5D%2C%20%5B-73.415022%2C%2019.639551%5D%2C%20%5B-73.189791%2C%2019.915684%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22HTI%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Haiti%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B16.202298%2C%2046.852386%5D%2C%20%5B16.534268%2C%2047.496171%5D%2C%20%5B16.340584%2C%2047.712902%5D%2C%20%5B16.903754%2C%2047.714866%5D%2C%20%5B16.979667%2C%2048.123497%5D%2C%20%5B17.488473%2C%2047.867466%5D%2C%20%5B17.857133%2C%2047.758429%5D%2C%20%5B18.696513%2C%2047.880954%5D%2C%20%5B18.777025%2C%2048.081768%5D%2C%20%5B19.174365%2C%2048.111379%5D%2C%20%5B19.661364%2C%2048.266615%5D%2C%20%5B19.769471%2C%2048.202691%5D%2C%20%5B20.239054%2C%2048.327567%5D%2C%20%5B20.473562%2C%2048.56285%5D%2C%20%5B20.801294%2C%2048.623854%5D%2C%20%5B21.872236%2C%2048.319971%5D%2C%20%5B22.085608%2C%2048.422264%5D%2C%20%5B22.64082%2C%2048.15024%5D%2C%20%5B22.710531%2C%2047.882194%5D%2C%20%5B22.099768%2C%2047.672439%5D%2C%20%5B21.626515%2C%2046.994238%5D%2C%20%5B21.021952%2C%2046.316088%5D%2C%20%5B20.220192%2C%2046.127469%5D%2C%20%5B19.596045%2C%2046.17173%5D%2C%20%5B18.829838%2C%2045.908878%5D%2C%20%5B18.456062%2C%2045.759481%5D%2C%20%5B17.630066%2C%2045.951769%5D%2C%20%5B16.882515%2C%2046.380632%5D%2C%20%5B16.564808%2C%2046.503751%5D%2C%20%5B16.370505%2C%2046.841327%5D%2C%20%5B16.202298%2C%2046.852386%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22HUN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Hungary%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B120.715609%2C%20-10.239581%5D%2C%20%5B120.295014%2C%20-10.25865%5D%2C%20%5B118.967808%2C%20-9.557969%5D%2C%20%5B119.90031%2C%20-9.36134%5D%2C%20%5B120.425756%2C%20-9.665921%5D%2C%20%5B120.775502%2C%20-9.969675%5D%2C%20%5B120.715609%2C%20-10.239581%5D%5D%5D%2C%20%5B%5B%5B124.43595%2C%20-10.140001%5D%2C%20%5B123.579982%2C%20-10.359987%5D%2C%20%5B123.459989%2C%20-10.239995%5D%2C%20%5B123.550009%2C%20-9.900016%5D%2C%20%5B123.980009%2C%20-9.290027%5D%2C%20%5B124.968682%2C%20-8.89279%5D%2C%20%5B125.07002%2C%20-9.089987%5D%2C%20%5B125.08852%2C%20-9.393173%5D%2C%20%5B124.43595%2C%20-10.140001%5D%5D%5D%2C%20%5B%5B%5B117.900018%2C%20-8.095681%5D%2C%20%5B118.260616%2C%20-8.362383%5D%2C%20%5B118.87846%2C%20-8.280683%5D%2C%20%5B119.126507%2C%20-8.705825%5D%2C%20%5B117.970402%2C%20-8.906639%5D%2C%20%5B117.277731%2C%20-9.040895%5D%2C%20%5B116.740141%2C%20-9.032937%5D%2C%20%5B117.083737%2C%20-8.457158%5D%2C%20%5B117.632024%2C%20-8.449303%5D%2C%20%5B117.900018%2C%20-8.095681%5D%5D%5D%2C%20%5B%5B%5B122.903537%2C%20-8.094234%5D%2C%20%5B122.756983%2C%20-8.649808%5D%2C%20%5B121.254491%2C%20-8.933666%5D%2C%20%5B119.924391%2C%20-8.810418%5D%2C%20%5B119.920929%2C%20-8.444859%5D%2C%20%5B120.715092%2C%20-8.236965%5D%2C%20%5B121.341669%2C%20-8.53674%5D%2C%20%5B122.007365%2C%20-8.46062%5D%2C%20%5B122.903537%2C%20-8.094234%5D%5D%5D%2C%20%5B%5B%5B108.623479%2C%20-6.777674%5D%2C%20%5B110.539227%2C%20-6.877358%5D%2C%20%5B110.759576%2C%20-6.465186%5D%2C%20%5B112.614811%2C%20-6.946036%5D%2C%20%5B112.978768%2C%20-7.594213%5D%2C%20%5B114.478935%2C%20-7.776528%5D%2C%20%5B115.705527%2C%20-8.370807%5D%2C%20%5B114.564511%2C%20-8.751817%5D%2C%20%5B113.464734%2C%20-8.348947%5D%2C%20%5B112.559672%2C%20-8.376181%5D%2C%20%5B111.522061%2C%20-8.302129%5D%2C%20%5B110.58615%2C%20-8.122605%5D%2C%20%5B109.427667%2C%20-7.740664%5D%2C%20%5B108.693655%2C%20-7.6416%5D%2C%20%5B108.277763%2C%20-7.766657%5D%2C%20%5B106.454102%2C%20-7.3549%5D%2C%20%5B106.280624%2C%20-6.9249%5D%2C%20%5B105.365486%2C%20-6.851416%5D%2C%20%5B106.051646%2C%20-5.895919%5D%2C%20%5B107.265009%2C%20-5.954985%5D%2C%20%5B108.072091%2C%20-6.345762%5D%2C%20%5B108.486846%2C%20-6.421985%5D%2C%20%5B108.623479%2C%20-6.777674%5D%5D%5D%2C%20%5B%5B%5B134.724624%2C%20-6.214401%5D%2C%20%5B134.210134%2C%20-6.895238%5D%2C%20%5B134.112776%2C%20-6.142467%5D%2C%20%5B134.290336%2C%20-5.783058%5D%2C%20%5B134.499625%2C%20-5.445042%5D%2C%20%5B134.727002%2C%20-5.737582%5D%2C%20%5B134.724624%2C%20-6.214401%5D%5D%5D%2C%20%5B%5B%5B127.249215%2C%20-3.459065%5D%2C%20%5B126.874923%2C%20-3.790983%5D%2C%20%5B126.183802%2C%20-3.607376%5D%2C%20%5B125.989034%2C%20-3.177273%5D%2C%20%5B127.000651%2C%20-3.129318%5D%2C%20%5B127.249215%2C%20-3.459065%5D%5D%5D%2C%20%5B%5B%5B130.471344%2C%20-3.093764%5D%2C%20%5B130.834836%2C%20-3.858472%5D%2C%20%5B129.990547%2C%20-3.446301%5D%2C%20%5B129.155249%2C%20-3.362637%5D%2C%20%5B128.590684%2C%20-3.428679%5D%2C%20%5B127.898891%2C%20-3.393436%5D%2C%20%5B128.135879%2C%20-2.84365%5D%2C%20%5B129.370998%2C%20-2.802154%5D%2C%20%5B130.471344%2C%20-3.093764%5D%5D%5D%2C%20%5B%5B%5B134.143368%2C%20-1.151867%5D%2C%20%5B134.422627%2C%20-2.769185%5D%2C%20%5B135.457603%2C%20-3.367753%5D%2C%20%5B136.293314%2C%20-2.307042%5D%2C%20%5B137.440738%2C%20-1.703513%5D%2C%20%5B138.329727%2C%20-1.702686%5D%2C%20%5B139.184921%2C%20-2.051296%5D%2C%20%5B139.926684%2C%20-2.409052%5D%2C%20%5B141.00021%2C%20-2.600151%5D%2C%20%5B141.017057%2C%20-5.859022%5D%2C%20%5B141.033852%2C%20-9.117893%5D%2C%20%5B140.143415%2C%20-8.297168%5D%2C%20%5B139.127767%2C%20-8.096043%5D%2C%20%5B138.881477%2C%20-8.380935%5D%2C%20%5B137.614474%2C%20-8.411683%5D%2C%20%5B138.039099%2C%20-7.597882%5D%2C%20%5B138.668621%2C%20-7.320225%5D%2C%20%5B138.407914%2C%20-6.232849%5D%2C%20%5B137.92784%2C%20-5.393366%5D%2C%20%5B135.98925%2C%20-4.546544%5D%2C%20%5B135.164598%2C%20-4.462931%5D%2C%20%5B133.66288%2C%20-3.538853%5D%2C%20%5B133.367705%2C%20-4.024819%5D%2C%20%5B132.983956%2C%20-4.112979%5D%2C%20%5B132.756941%2C%20-3.746283%5D%2C%20%5B132.753789%2C%20-3.311787%5D%2C%20%5B131.989804%2C%20-2.820551%5D%2C%20%5B133.066845%2C%20-2.460418%5D%2C%20%5B133.780031%2C%20-2.479848%5D%2C%20%5B133.696212%2C%20-2.214542%5D%2C%20%5B132.232373%2C%20-2.212526%5D%2C%20%5B131.836222%2C%20-1.617162%5D%2C%20%5B130.94284%2C%20-1.432522%5D%2C%20%5B130.519558%2C%20-0.93772%5D%2C%20%5B131.867538%2C%20-0.695461%5D%2C%20%5B132.380116%2C%20-0.369538%5D%2C%20%5B133.985548%2C%20-0.78021%5D%2C%20%5B134.143368%2C%20-1.151867%5D%5D%5D%2C%20%5B%5B%5B125.240501%2C%201.419836%5D%2C%20%5B124.437035%2C%200.427881%5D%2C%20%5B123.685505%2C%200.235593%5D%2C%20%5B122.723083%2C%200.431137%5D%2C%20%5B121.056725%2C%200.381217%5D%2C%20%5B120.183083%2C%200.237247%5D%2C%20%5B120.04087%2C%20-0.519658%5D%2C%20%5B120.935905%2C%20-1.408906%5D%2C%20%5B121.475821%2C%20-0.955962%5D%2C%20%5B123.340565%2C%20-0.615673%5D%2C%20%5B123.258399%2C%20-1.076213%5D%2C%20%5B122.822715%2C%20-0.930951%5D%2C%20%5B122.38853%2C%20-1.516858%5D%2C%20%5B121.508274%2C%20-1.904483%5D%2C%20%5B122.454572%2C%20-3.186058%5D%2C%20%5B122.271896%2C%20-3.5295%5D%2C%20%5B123.170963%2C%20-4.683693%5D%2C%20%5B123.162333%2C%20-5.340604%5D%2C%20%5B122.628515%2C%20-5.634591%5D%2C%20%5B122.236394%2C%20-5.282933%5D%2C%20%5B122.719569%2C%20-4.464172%5D%2C%20%5B121.738234%2C%20-4.851331%5D%2C%20%5B121.489463%2C%20-4.574553%5D%2C%20%5B121.619171%2C%20-4.188478%5D%2C%20%5B120.898182%2C%20-3.602105%5D%2C%20%5B120.972389%2C%20-2.627643%5D%2C%20%5B120.305453%2C%20-2.931604%5D%2C%20%5B120.390047%2C%20-4.097579%5D%2C%20%5B120.430717%2C%20-5.528241%5D%2C%20%5B119.796543%2C%20-5.6734%5D%2C%20%5B119.366906%2C%20-5.379878%5D%2C%20%5B119.653606%2C%20-4.459417%5D%2C%20%5B119.498835%2C%20-3.494412%5D%2C%20%5B119.078344%2C%20-3.487022%5D%2C%20%5B118.767769%2C%20-2.801999%5D%2C%20%5B119.180974%2C%20-2.147104%5D%2C%20%5B119.323394%2C%20-1.353147%5D%2C%20%5B119.825999%2C%200.154254%5D%2C%20%5B120.035702%2C%200.566477%5D%2C%20%5B120.885779%2C%201.309223%5D%2C%20%5B121.666817%2C%201.013944%5D%2C%20%5B122.927567%2C%200.875192%5D%2C%20%5B124.077522%2C%200.917102%5D%2C%20%5B125.065989%2C%201.643259%5D%2C%20%5B125.240501%2C%201.419836%5D%5D%5D%2C%20%5B%5B%5B128.688249%2C%201.132386%5D%2C%20%5B128.635952%2C%200.258486%5D%2C%20%5B128.12017%2C%200.356413%5D%2C%20%5B127.968034%2C%20-0.252077%5D%2C%20%5B128.379999%2C%20-0.780004%5D%2C%20%5B128.100016%2C%20-0.899996%5D%2C%20%5B127.696475%2C%20-0.266598%5D%2C%20%5B127.39949%2C%201.011722%5D%2C%20%5B127.600512%2C%201.810691%5D%2C%20%5B127.932378%2C%202.174596%5D%2C%20%5B128.004156%2C%201.628531%5D%2C%20%5B128.594559%2C%201.540811%5D%2C%20%5B128.688249%2C%201.132386%5D%5D%5D%2C%20%5B%5B%5B117.875627%2C%201.827641%5D%2C%20%5B118.996747%2C%200.902219%5D%2C%20%5B117.811858%2C%200.784242%5D%2C%20%5B117.478339%2C%200.102475%5D%2C%20%5B117.521644%2C%20-0.803723%5D%2C%20%5B116.560048%2C%20-1.487661%5D%2C%20%5B116.533797%2C%20-2.483517%5D%2C%20%5B116.148084%2C%20-4.012726%5D%2C%20%5B116.000858%2C%20-3.657037%5D%2C%20%5B114.864803%2C%20-4.106984%5D%2C%20%5B114.468652%2C%20-3.495704%5D%2C%20%5B113.755672%2C%20-3.43917%5D%2C%20%5B113.256994%2C%20-3.118776%5D%2C%20%5B112.068126%2C%20-3.478392%5D%2C%20%5B111.703291%2C%20-2.994442%5D%2C%20%5B111.04824%2C%20-3.049426%5D%2C%20%5B110.223846%2C%20-2.934032%5D%2C%20%5B110.070936%2C%20-1.592874%5D%2C%20%5B109.571948%2C%20-1.314907%5D%2C%20%5B109.091874%2C%20-0.459507%5D%2C%20%5B108.952658%2C%200.415375%5D%2C%20%5B109.069136%2C%201.341934%5D%2C%20%5B109.66326%2C%202.006467%5D%2C%20%5B109.830227%2C%201.338136%5D%2C%20%5B110.514061%2C%200.773131%5D%2C%20%5B111.159138%2C%200.976478%5D%2C%20%5B111.797548%2C%200.904441%5D%2C%20%5B112.380252%2C%201.410121%5D%2C%20%5B112.859809%2C%201.49779%5D%2C%20%5B113.80585%2C%201.217549%5D%2C%20%5B114.621355%2C%201.430688%5D%2C%20%5B115.134037%2C%202.821482%5D%2C%20%5B115.519078%2C%203.169238%5D%2C%20%5B115.865517%2C%204.306559%5D%2C%20%5B117.015214%2C%204.306094%5D%2C%20%5B117.882035%2C%204.137551%5D%2C%20%5B117.313232%2C%203.234428%5D%2C%20%5B118.04833%2C%202.28769%5D%2C%20%5B117.875627%2C%201.827641%5D%5D%5D%2C%20%5B%5B%5B105.817655%2C%20-5.852356%5D%2C%20%5B104.710384%2C%20-5.873285%5D%2C%20%5B103.868213%2C%20-5.037315%5D%2C%20%5B102.584261%2C%20-4.220259%5D%2C%20%5B102.156173%2C%20-3.614146%5D%2C%20%5B101.399113%2C%20-2.799777%5D%2C%20%5B100.902503%2C%20-2.050262%5D%2C%20%5B100.141981%2C%20-0.650348%5D%2C%20%5B99.26374%2C%200.183142%5D%2C%20%5B98.970011%2C%201.042882%5D%2C%20%5B98.601351%2C%201.823507%5D%2C%20%5B97.699598%2C%202.453184%5D%2C%20%5B97.176942%2C%203.308791%5D%2C%20%5B96.424017%2C%203.86886%5D%2C%20%5B95.380876%2C%204.970782%5D%2C%20%5B95.293026%2C%205.479821%5D%2C%20%5B95.936863%2C%205.439513%5D%2C%20%5B97.484882%2C%205.246321%5D%2C%20%5B98.369169%2C%204.26837%5D%2C%20%5B99.142559%2C%203.59035%5D%2C%20%5B99.693998%2C%203.174329%5D%2C%20%5B100.641434%2C%202.099381%5D%2C%20%5B101.658012%2C%202.083697%5D%2C%20%5B102.498271%2C%201.3987%5D%2C%20%5B103.07684%2C%200.561361%5D%2C%20%5B103.838396%2C%200.104542%5D%2C%20%5B103.437645%2C%20-0.711946%5D%2C%20%5B104.010789%2C%20-1.059212%5D%2C%20%5B104.369991%2C%20-1.084843%5D%2C%20%5B104.53949%2C%20-1.782372%5D%2C%20%5B104.887893%2C%20-2.340425%5D%2C%20%5B105.622111%2C%20-2.428844%5D%2C%20%5B106.108593%2C%20-3.061777%5D%2C%20%5B105.857446%2C%20-4.305525%5D%2C%20%5B105.817655%2C%20-5.852356%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22IDN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Indonesia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B77.837451%2C%2035.49401%5D%2C%20%5B78.912269%2C%2034.321936%5D%2C%20%5B78.811086%2C%2033.506198%5D%2C%20%5B79.208892%2C%2032.994395%5D%2C%20%5B79.176129%2C%2032.48378%5D%2C%20%5B78.458446%2C%2032.618164%5D%2C%20%5B78.738894%2C%2031.515906%5D%2C%20%5B79.721367%2C%2030.882715%5D%2C%20%5B81.111256%2C%2030.183481%5D%2C%20%5B80.476721%2C%2029.729865%5D%2C%20%5B80.088425%2C%2028.79447%5D%2C%20%5B81.057203%2C%2028.416095%5D%2C%20%5B81.999987%2C%2027.925479%5D%2C%20%5B83.304249%2C%2027.364506%5D%2C%20%5B84.675018%2C%2027.234901%5D%2C%20%5B85.251779%2C%2026.726198%5D%2C%20%5B86.024393%2C%2026.630985%5D%2C%20%5B87.227472%2C%2026.397898%5D%2C%20%5B88.060238%2C%2026.414615%5D%2C%20%5B88.174804%2C%2026.810405%5D%2C%20%5B88.043133%2C%2027.445819%5D%2C%20%5B88.120441%2C%2027.876542%5D%2C%20%5B88.730326%2C%2028.086865%5D%2C%20%5B88.814248%2C%2027.299316%5D%2C%20%5B88.835643%2C%2027.098966%5D%2C%20%5B89.744528%2C%2026.719403%5D%2C%20%5B90.373275%2C%2026.875724%5D%2C%20%5B91.217513%2C%2026.808648%5D%2C%20%5B92.033484%2C%2026.83831%5D%2C%20%5B92.103712%2C%2027.452614%5D%2C%20%5B91.696657%2C%2027.771742%5D%2C%20%5B92.503119%2C%2027.896876%5D%2C%20%5B93.413348%2C%2028.640629%5D%2C%20%5B94.56599%2C%2029.277438%5D%2C%20%5B95.404802%2C%2029.031717%5D%2C%20%5B96.117679%2C%2029.452802%5D%2C%20%5B96.586591%2C%2028.83098%5D%2C%20%5B96.248833%2C%2028.411031%5D%2C%20%5B97.327114%2C%2028.261583%5D%2C%20%5B97.402561%2C%2027.882536%5D%2C%20%5B97.051989%2C%2027.699059%5D%2C%20%5B97.133999%2C%2027.083774%5D%2C%20%5B96.419366%2C%2027.264589%5D%2C%20%5B95.124768%2C%2026.573572%5D%2C%20%5B95.155153%2C%2026.001307%5D%2C%20%5B94.603249%2C%2025.162495%5D%2C%20%5B94.552658%2C%2024.675238%5D%2C%20%5B94.106742%2C%2023.850741%5D%2C%20%5B93.325188%2C%2024.078556%5D%2C%20%5B93.286327%2C%2023.043658%5D%2C%20%5B93.060294%2C%2022.703111%5D%2C%20%5B93.166128%2C%2022.27846%5D%2C%20%5B92.672721%2C%2022.041239%5D%2C%20%5B92.146035%2C%2023.627499%5D%2C%20%5B91.869928%2C%2023.624346%5D%2C%20%5B91.706475%2C%2022.985264%5D%2C%20%5B91.158963%2C%2023.503527%5D%2C%20%5B91.46773%2C%2024.072639%5D%2C%20%5B91.915093%2C%2024.130414%5D%2C%20%5B92.376202%2C%2024.976693%5D%2C%20%5B91.799596%2C%2025.147432%5D%2C%20%5B90.872211%2C%2025.132601%5D%2C%20%5B89.920693%2C%2025.26975%5D%2C%20%5B89.832481%2C%2025.965082%5D%2C%20%5B89.355094%2C%2026.014407%5D%2C%20%5B88.563049%2C%2026.446526%5D%2C%20%5B88.209789%2C%2025.768066%5D%2C%20%5B88.931554%2C%2025.238692%5D%2C%20%5B88.306373%2C%2024.866079%5D%2C%20%5B88.084422%2C%2024.501657%5D%2C%20%5B88.69994%2C%2024.233715%5D%2C%20%5B88.52977%2C%2023.631142%5D%2C%20%5B88.876312%2C%2022.879146%5D%2C%20%5B89.031961%2C%2022.055708%5D%2C%20%5B88.888766%2C%2021.690588%5D%2C%20%5B88.208497%2C%2021.703172%5D%2C%20%5B86.975704%2C%2021.495562%5D%2C%20%5B87.033169%2C%2020.743308%5D%2C%20%5B86.499351%2C%2020.151638%5D%2C%20%5B85.060266%2C%2019.478579%5D%2C%20%5B83.941006%2C%2018.30201%5D%2C%20%5B83.189217%2C%2017.671221%5D%2C%20%5B82.192792%2C%2017.016636%5D%2C%20%5B82.191242%2C%2016.556664%5D%2C%20%5B81.692719%2C%2016.310219%5D%2C%20%5B80.791999%2C%2015.951972%5D%2C%20%5B80.324896%2C%2015.899185%5D%2C%20%5B80.025069%2C%2015.136415%5D%2C%20%5B80.233274%2C%2013.835771%5D%2C%20%5B80.286294%2C%2013.006261%5D%2C%20%5B79.862547%2C%2012.056215%5D%2C%20%5B79.857999%2C%2010.357275%5D%2C%20%5B79.340512%2C%2010.308854%5D%2C%20%5B78.885345%2C%209.546136%5D%2C%20%5B79.18972%2C%209.216544%5D%2C%20%5B78.277941%2C%208.933047%5D%2C%20%5B77.941165%2C%208.252959%5D%2C%20%5B77.539898%2C%207.965535%5D%2C%20%5B76.592979%2C%208.899276%5D%2C%20%5B76.130061%2C%2010.29963%5D%2C%20%5B75.746467%2C%2011.308251%5D%2C%20%5B75.396101%2C%2011.781245%5D%2C%20%5B74.864816%2C%2012.741936%5D%2C%20%5B74.616717%2C%2013.992583%5D%2C%20%5B74.443859%2C%2014.617222%5D%2C%20%5B73.534199%2C%2015.990652%5D%2C%20%5B73.119909%2C%2017.92857%5D%2C%20%5B72.820909%2C%2019.208234%5D%2C%20%5B72.824475%2C%2020.419503%5D%2C%20%5B72.630533%2C%2021.356009%5D%2C%20%5B71.175273%2C%2020.757441%5D%2C%20%5B70.470459%2C%2020.877331%5D%2C%20%5B69.16413%2C%2022.089298%5D%2C%20%5B69.644928%2C%2022.450775%5D%2C%20%5B69.349597%2C%2022.84318%5D%2C%20%5B68.176645%2C%2023.691965%5D%2C%20%5B68.842599%2C%2024.359134%5D%2C%20%5B71.04324%2C%2024.356524%5D%2C%20%5B70.844699%2C%2025.215102%5D%2C%20%5B70.282873%2C%2025.722229%5D%2C%20%5B70.168927%2C%2026.491872%5D%2C%20%5B69.514393%2C%2026.940966%5D%2C%20%5B70.616496%2C%2027.989196%5D%2C%20%5B71.777666%2C%2027.91318%5D%2C%20%5B72.823752%2C%2028.961592%5D%2C%20%5B73.450638%2C%2029.976413%5D%2C%20%5B74.42138%2C%2030.979815%5D%2C%20%5B74.405929%2C%2031.692639%5D%2C%20%5B75.258642%2C%2032.271105%5D%2C%20%5B74.451559%2C%2032.7649%5D%2C%20%5B74.104294%2C%2033.441473%5D%2C%20%5B73.749948%2C%2034.317699%5D%2C%20%5B74.240203%2C%2034.748887%5D%2C%20%5B75.757061%2C%2034.504923%5D%2C%20%5B76.871722%2C%2034.653544%5D%2C%20%5B77.837451%2C%2035.49401%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22IND%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22India%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-6.197885%2C%2053.867565%5D%2C%20%5B-6.032985%2C%2053.153164%5D%2C%20%5B-6.788857%2C%2052.260118%5D%2C%20%5B-8.561617%2C%2051.669301%5D%2C%20%5B-9.977086%2C%2051.820455%5D%2C%20%5B-9.166283%2C%2052.864629%5D%2C%20%5B-9.688525%2C%2053.881363%5D%2C%20%5B-8.327987%2C%2054.664519%5D%2C%20%5B-7.572168%2C%2055.131622%5D%2C%20%5B-7.366031%2C%2054.595841%5D%2C%20%5B-7.572168%2C%2054.059956%5D%2C%20%5B-6.95373%2C%2054.073702%5D%2C%20%5B-6.197885%2C%2053.867565%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22IRL%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Ireland%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B53.921598%2C%2037.198918%5D%2C%20%5B54.800304%2C%2037.392421%5D%2C%20%5B55.511578%2C%2037.964117%5D%2C%20%5B56.180375%2C%2037.935127%5D%2C%20%5B56.619366%2C%2038.121394%5D%2C%20%5B57.330434%2C%2038.029229%5D%2C%20%5B58.436154%2C%2037.522309%5D%2C%20%5B59.234762%2C%2037.412988%5D%2C%20%5B60.377638%2C%2036.527383%5D%2C%20%5B61.123071%2C%2036.491597%5D%2C%20%5B61.210817%2C%2035.650072%5D%2C%20%5B60.803193%2C%2034.404102%5D%2C%20%5B60.52843%2C%2033.676446%5D%2C%20%5B60.9637%2C%2033.528832%5D%2C%20%5B60.536078%2C%2032.981269%5D%2C%20%5B60.863655%2C%2032.18292%5D%2C%20%5B60.941945%2C%2031.548075%5D%2C%20%5B61.699314%2C%2031.379506%5D%2C%20%5B61.781222%2C%2030.73585%5D%2C%20%5B60.874248%2C%2029.829239%5D%2C%20%5B61.369309%2C%2029.303276%5D%2C%20%5B61.771868%2C%2028.699334%5D%2C%20%5B62.72783%2C%2028.259645%5D%2C%20%5B62.755426%2C%2027.378923%5D%2C%20%5B63.233898%2C%2027.217047%5D%2C%20%5B63.316632%2C%2026.756532%5D%2C%20%5B61.874187%2C%2026.239975%5D%2C%20%5B61.497363%2C%2025.078237%5D%2C%20%5B59.616134%2C%2025.380157%5D%2C%20%5B58.525761%2C%2025.609962%5D%2C%20%5B57.397251%2C%2025.739902%5D%2C%20%5B56.970766%2C%2026.966106%5D%2C%20%5B56.492139%2C%2027.143305%5D%2C%20%5B55.72371%2C%2026.964633%5D%2C%20%5B54.71509%2C%2026.480658%5D%2C%20%5B53.493097%2C%2026.812369%5D%2C%20%5B52.483598%2C%2027.580849%5D%2C%20%5B51.520763%2C%2027.86569%5D%2C%20%5B50.852948%2C%2028.814521%5D%2C%20%5B50.115009%2C%2030.147773%5D%2C%20%5B49.57685%2C%2029.985715%5D%2C%20%5B48.941333%2C%2030.31709%5D%2C%20%5B48.567971%2C%2029.926778%5D%2C%20%5B48.014568%2C%2030.452457%5D%2C%20%5B48.004698%2C%2030.985137%5D%2C%20%5B47.685286%2C%2030.984853%5D%2C%20%5B47.849204%2C%2031.709176%5D%2C%20%5B47.334661%2C%2032.469155%5D%2C%20%5B46.109362%2C%2033.017287%5D%2C%20%5B45.416691%2C%2033.967798%5D%2C%20%5B45.64846%2C%2034.748138%5D%2C%20%5B46.151788%2C%2035.093259%5D%2C%20%5B46.07634%2C%2035.677383%5D%2C%20%5B45.420618%2C%2035.977546%5D%2C%20%5B44.77267%2C%2037.17045%5D%2C%20%5B44.225756%2C%2037.971584%5D%2C%20%5B44.421403%2C%2038.281281%5D%2C%20%5B44.109225%2C%2039.428136%5D%2C%20%5B44.79399%2C%2039.713003%5D%2C%20%5B44.952688%2C%2039.335765%5D%2C%20%5B45.457722%2C%2038.874139%5D%2C%20%5B46.143623%2C%2038.741201%5D%2C%20%5B46.50572%2C%2038.770605%5D%2C%20%5B47.685079%2C%2039.508364%5D%2C%20%5B48.060095%2C%2039.582235%5D%2C%20%5B48.355529%2C%2039.288765%5D%2C%20%5B48.010744%2C%2038.794015%5D%2C%20%5B48.634375%2C%2038.270378%5D%2C%20%5B48.883249%2C%2038.320245%5D%2C%20%5B49.199612%2C%2037.582874%5D%2C%20%5B50.147771%2C%2037.374567%5D%2C%20%5B50.842354%2C%2036.872814%5D%2C%20%5B52.264025%2C%2036.700422%5D%2C%20%5B53.82579%2C%2036.965031%5D%2C%20%5B53.921598%2C%2037.198918%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22IRN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Iran%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B45.420618%2C%2035.977546%5D%2C%20%5B46.07634%2C%2035.677383%5D%2C%20%5B46.151788%2C%2035.093259%5D%2C%20%5B45.64846%2C%2034.748138%5D%2C%20%5B45.416691%2C%2033.967798%5D%2C%20%5B46.109362%2C%2033.017287%5D%2C%20%5B47.334661%2C%2032.469155%5D%2C%20%5B47.849204%2C%2031.709176%5D%2C%20%5B47.685286%2C%2030.984853%5D%2C%20%5B48.004698%2C%2030.985137%5D%2C%20%5B48.014568%2C%2030.452457%5D%2C%20%5B48.567971%2C%2029.926778%5D%2C%20%5B47.974519%2C%2029.975819%5D%2C%20%5B47.302622%2C%2030.05907%5D%2C%20%5B46.568713%2C%2029.099025%5D%2C%20%5B44.709499%2C%2029.178891%5D%2C%20%5B41.889981%2C%2031.190009%5D%2C%20%5B40.399994%2C%2031.889992%5D%2C%20%5B39.195468%2C%2032.161009%5D%2C%20%5B38.792341%2C%2033.378686%5D%2C%20%5B41.006159%2C%2034.419372%5D%2C%20%5B41.383965%2C%2035.628317%5D%2C%20%5B41.289707%2C%2036.358815%5D%2C%20%5B41.837064%2C%2036.605854%5D%2C%20%5B42.349591%2C%2037.229873%5D%2C%20%5B42.779126%2C%2037.385264%5D%2C%20%5B43.942259%2C%2037.256228%5D%2C%20%5B44.293452%2C%2037.001514%5D%2C%20%5B44.772699%2C%2037.170445%5D%2C%20%5B45.420618%2C%2035.977546%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22IRQ%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Iraq%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-14.508695%2C%2066.455892%5D%2C%20%5B-14.739637%2C%2065.808748%5D%2C%20%5B-13.609732%2C%2065.126671%5D%2C%20%5B-14.909834%2C%2064.364082%5D%2C%20%5B-17.794438%2C%2063.678749%5D%2C%20%5B-18.656246%2C%2063.496383%5D%2C%20%5B-19.972755%2C%2063.643635%5D%2C%20%5B-22.762972%2C%2063.960179%5D%2C%20%5B-21.778484%2C%2064.402116%5D%2C%20%5B-23.955044%2C%2064.89113%5D%2C%20%5B-22.184403%2C%2065.084968%5D%2C%20%5B-22.227423%2C%2065.378594%5D%2C%20%5B-24.326184%2C%2065.611189%5D%2C%20%5B-23.650515%2C%2066.262519%5D%2C%20%5B-22.134922%2C%2066.410469%5D%2C%20%5B-20.576284%2C%2065.732112%5D%2C%20%5B-19.056842%2C%2066.276601%5D%2C%20%5B-17.798624%2C%2065.993853%5D%2C%20%5B-16.167819%2C%2066.526792%5D%2C%20%5B-14.508695%2C%2066.455892%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ISL%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Iceland%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B35.719918%2C%2032.709192%5D%2C%20%5B35.545665%2C%2032.393992%5D%2C%20%5B35.18393%2C%2032.532511%5D%2C%20%5B34.974641%2C%2031.866582%5D%2C%20%5B35.225892%2C%2031.754341%5D%2C%20%5B34.970507%2C%2031.616778%5D%2C%20%5B34.927408%2C%2031.353435%5D%2C%20%5B35.397561%2C%2031.489086%5D%2C%20%5B35.420918%2C%2031.100066%5D%2C%20%5B34.922603%2C%2029.501326%5D%2C%20%5B34.265433%2C%2031.219361%5D%2C%20%5B34.556372%2C%2031.548824%5D%2C%20%5B34.488107%2C%2031.605539%5D%2C%20%5B34.752587%2C%2032.072926%5D%2C%20%5B34.955417%2C%2032.827376%5D%2C%20%5B35.098457%2C%2033.080539%5D%2C%20%5B35.126053%2C%2033.0909%5D%2C%20%5B35.460709%2C%2033.08904%5D%2C%20%5B35.552797%2C%2033.264275%5D%2C%20%5B35.821101%2C%2033.277426%5D%2C%20%5B35.836397%2C%2032.868123%5D%2C%20%5B35.700798%2C%2032.716014%5D%2C%20%5B35.719918%2C%2032.709192%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ISR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Israel%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B15.520376%2C%2038.231155%5D%2C%20%5B15.160243%2C%2037.444046%5D%2C%20%5B15.309898%2C%2037.134219%5D%2C%20%5B15.099988%2C%2036.619987%5D%2C%20%5B14.335229%2C%2036.996631%5D%2C%20%5B13.826733%2C%2037.104531%5D%2C%20%5B12.431004%2C%2037.61295%5D%2C%20%5B12.570944%2C%2038.126381%5D%2C%20%5B13.741156%2C%2038.034966%5D%2C%20%5B14.761249%2C%2038.143874%5D%2C%20%5B15.520376%2C%2038.231155%5D%5D%5D%2C%20%5B%5B%5B9.210012%2C%2041.209991%5D%2C%20%5B9.809975%2C%2040.500009%5D%2C%20%5B9.669519%2C%2039.177376%5D%2C%20%5B9.214818%2C%2039.240473%5D%2C%20%5B8.806936%2C%2038.906618%5D%2C%20%5B8.428302%2C%2039.171847%5D%2C%20%5B8.388253%2C%2040.378311%5D%2C%20%5B8.159998%2C%2040.950007%5D%2C%20%5B8.709991%2C%2040.899984%5D%2C%20%5B9.210012%2C%2041.209991%5D%5D%5D%2C%20%5B%5B%5B12.376485%2C%2046.767559%5D%2C%20%5B13.806475%2C%2046.509306%5D%2C%20%5B13.69811%2C%2046.016778%5D%2C%20%5B13.93763%2C%2045.591016%5D%2C%20%5B13.141606%2C%2045.736692%5D%2C%20%5B12.328581%2C%2045.381778%5D%2C%20%5B12.383875%2C%2044.885374%5D%2C%20%5B12.261453%2C%2044.600482%5D%2C%20%5B12.589237%2C%2044.091366%5D%2C%20%5B13.526906%2C%2043.587727%5D%2C%20%5B14.029821%2C%2042.761008%5D%2C%20%5B15.14257%2C%2041.95514%5D%2C%20%5B15.926191%2C%2041.961315%5D%2C%20%5B16.169897%2C%2041.740295%5D%2C%20%5B15.889346%2C%2041.541082%5D%2C%20%5B16.785002%2C%2041.179606%5D%2C%20%5B17.519169%2C%2040.877143%5D%2C%20%5B18.376687%2C%2040.355625%5D%2C%20%5B18.480247%2C%2040.168866%5D%2C%20%5B18.293385%2C%2039.810774%5D%2C%20%5B17.73838%2C%2040.277671%5D%2C%20%5B16.869596%2C%2040.442235%5D%2C%20%5B16.448743%2C%2039.795401%5D%2C%20%5B17.17149%2C%2039.4247%5D%2C%20%5B17.052841%2C%2038.902871%5D%2C%20%5B16.635088%2C%2038.843572%5D%2C%20%5B16.100961%2C%2037.985899%5D%2C%20%5B15.684087%2C%2037.908849%5D%2C%20%5B15.687963%2C%2038.214593%5D%2C%20%5B15.891981%2C%2038.750942%5D%2C%20%5B16.109332%2C%2038.964547%5D%2C%20%5B15.718814%2C%2039.544072%5D%2C%20%5B15.413613%2C%2040.048357%5D%2C%20%5B14.998496%2C%2040.172949%5D%2C%20%5B14.703268%2C%2040.60455%5D%2C%20%5B14.060672%2C%2040.786348%5D%2C%20%5B13.627985%2C%2041.188287%5D%2C%20%5B12.888082%2C%2041.25309%5D%2C%20%5B12.106683%2C%2041.704535%5D%2C%20%5B11.191906%2C%2042.355425%5D%2C%20%5B10.511948%2C%2042.931463%5D%2C%20%5B10.200029%2C%2043.920007%5D%2C%20%5B9.702488%2C%2044.036279%5D%2C%20%5B8.888946%2C%2044.366336%5D%2C%20%5B8.428561%2C%2044.231228%5D%2C%20%5B7.850767%2C%2043.767148%5D%2C%20%5B7.435185%2C%2043.693845%5D%2C%20%5B7.549596%2C%2044.127901%5D%2C%20%5B7.007562%2C%2044.254767%5D%2C%20%5B6.749955%2C%2045.028518%5D%2C%20%5B7.096652%2C%2045.333099%5D%2C%20%5B6.802355%2C%2045.70858%5D%2C%20%5B6.843593%2C%2045.991147%5D%2C%20%5B7.273851%2C%2045.776948%5D%2C%20%5B7.755992%2C%2045.82449%5D%2C%20%5B8.31663%2C%2046.163642%5D%2C%20%5B8.489952%2C%2046.005151%5D%2C%20%5B8.966306%2C%2046.036932%5D%2C%20%5B9.182882%2C%2046.440215%5D%2C%20%5B9.922837%2C%2046.314899%5D%2C%20%5B10.363378%2C%2046.483571%5D%2C%20%5B10.442701%2C%2046.893546%5D%2C%20%5B11.048556%2C%2046.751359%5D%2C%20%5B11.164828%2C%2046.941579%5D%2C%20%5B12.153088%2C%2047.115393%5D%2C%20%5B12.376485%2C%2046.767559%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22ITA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Italy%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-77.569601%2C%2018.490525%5D%2C%20%5B-76.896619%2C%2018.400867%5D%2C%20%5B-76.365359%2C%2018.160701%5D%2C%20%5B-76.199659%2C%2017.886867%5D%2C%20%5B-76.902561%2C%2017.868238%5D%2C%20%5B-77.206341%2C%2017.701116%5D%2C%20%5B-77.766023%2C%2017.861597%5D%2C%20%5B-78.337719%2C%2018.225968%5D%2C%20%5B-78.217727%2C%2018.454533%5D%2C%20%5B-77.797365%2C%2018.524218%5D%2C%20%5B-77.569601%2C%2018.490525%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22JAM%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Jamaica%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B35.545665%2C%2032.393992%5D%2C%20%5B35.719918%2C%2032.709192%5D%2C%20%5B36.834062%2C%2032.312938%5D%2C%20%5B38.792341%2C%2033.378686%5D%2C%20%5B39.195468%2C%2032.161009%5D%2C%20%5B39.004886%2C%2032.010217%5D%2C%20%5B37.002166%2C%2031.508413%5D%2C%20%5B37.998849%2C%2030.5085%5D%2C%20%5B37.66812%2C%2030.338665%5D%2C%20%5B37.503582%2C%2030.003776%5D%2C%20%5B36.740528%2C%2029.865283%5D%2C%20%5B36.501214%2C%2029.505254%5D%2C%20%5B36.068941%2C%2029.197495%5D%2C%20%5B34.956037%2C%2029.356555%5D%2C%20%5B34.922603%2C%2029.501326%5D%2C%20%5B35.420918%2C%2031.100066%5D%2C%20%5B35.397561%2C%2031.489086%5D%2C%20%5B35.545252%2C%2031.782505%5D%2C%20%5B35.545665%2C%2032.393992%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22JOR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Jordan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B134.638428%2C%2034.149234%5D%2C%20%5B134.766379%2C%2033.806335%5D%2C%20%5B134.203416%2C%2033.201178%5D%2C%20%5B133.79295%2C%2033.521985%5D%2C%20%5B133.280268%2C%2033.28957%5D%2C%20%5B133.014858%2C%2032.704567%5D%2C%20%5B132.363115%2C%2032.989382%5D%2C%20%5B132.371176%2C%2033.463642%5D%2C%20%5B132.924373%2C%2034.060299%5D%2C%20%5B133.492968%2C%2033.944621%5D%2C%20%5B133.904106%2C%2034.364931%5D%2C%20%5B134.638428%2C%2034.149234%5D%5D%5D%2C%20%5B%5B%5B140.976388%2C%2037.142074%5D%2C%20%5B140.59977%2C%2036.343983%5D%2C%20%5B140.774074%2C%2035.842877%5D%2C%20%5B140.253279%2C%2035.138114%5D%2C%20%5B138.975528%2C%2034.6676%5D%2C%20%5B137.217599%2C%2034.606286%5D%2C%20%5B135.792983%2C%2033.464805%5D%2C%20%5B135.120983%2C%2033.849071%5D%2C%20%5B135.079435%2C%2034.596545%5D%2C%20%5B133.340316%2C%2034.375938%5D%2C%20%5B132.156771%2C%2033.904933%5D%2C%20%5B130.986145%2C%2033.885761%5D%2C%20%5B132.000036%2C%2033.149992%5D%2C%20%5B131.33279%2C%2031.450355%5D%2C%20%5B130.686318%2C%2031.029579%5D%2C%20%5B130.20242%2C%2031.418238%5D%2C%20%5B130.447676%2C%2032.319475%5D%2C%20%5B129.814692%2C%2032.61031%5D%2C%20%5B129.408463%2C%2033.296056%5D%2C%20%5B130.353935%2C%2033.604151%5D%2C%20%5B130.878451%2C%2034.232743%5D%2C%20%5B131.884229%2C%2034.749714%5D%2C%20%5B132.617673%2C%2035.433393%5D%2C%20%5B134.608301%2C%2035.731618%5D%2C%20%5B135.677538%2C%2035.527134%5D%2C%20%5B136.723831%2C%2037.304984%5D%2C%20%5B137.390612%2C%2036.827391%5D%2C%20%5B138.857602%2C%2037.827485%5D%2C%20%5B139.426405%2C%2038.215962%5D%2C%20%5B140.05479%2C%2039.438807%5D%2C%20%5B139.883379%2C%2040.563312%5D%2C%20%5B140.305783%2C%2041.195005%5D%2C%20%5B141.368973%2C%2041.37856%5D%2C%20%5B141.914263%2C%2039.991616%5D%2C%20%5B141.884601%2C%2039.180865%5D%2C%20%5B140.959489%2C%2038.174001%5D%2C%20%5B140.976388%2C%2037.142074%5D%5D%5D%2C%20%5B%5B%5B143.910162%2C%2044.1741%5D%2C%20%5B144.613427%2C%2043.960883%5D%2C%20%5B145.320825%2C%2044.384733%5D%2C%20%5B145.543137%2C%2043.262088%5D%2C%20%5B144.059662%2C%2042.988358%5D%2C%20%5B143.18385%2C%2041.995215%5D%2C%20%5B141.611491%2C%2042.678791%5D%2C%20%5B141.067286%2C%2041.584594%5D%2C%20%5B139.955106%2C%2041.569556%5D%2C%20%5B139.817544%2C%2042.563759%5D%2C%20%5B140.312087%2C%2043.333273%5D%2C%20%5B141.380549%2C%2043.388825%5D%2C%20%5B141.671952%2C%2044.772125%5D%2C%20%5B141.967645%2C%2045.551483%5D%2C%20%5B143.14287%2C%2044.510358%5D%2C%20%5B143.910162%2C%2044.1741%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22JPN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Japan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B70.962315%2C%2042.266154%5D%2C%20%5B70.388965%2C%2042.081308%5D%2C%20%5B69.070027%2C%2041.384244%5D%2C%20%5B68.632483%2C%2040.668681%5D%2C%20%5B68.259896%2C%2040.662325%5D%2C%20%5B67.985856%2C%2041.135991%5D%2C%20%5B66.714047%2C%2041.168444%5D%2C%20%5B66.510649%2C%2041.987644%5D%2C%20%5B66.023392%2C%2041.994646%5D%2C%20%5B66.098012%2C%2042.99766%5D%2C%20%5B64.900824%2C%2043.728081%5D%2C%20%5B63.185787%2C%2043.650075%5D%2C%20%5B62.0133%2C%2043.504477%5D%2C%20%5B61.05832%2C%2044.405817%5D%2C%20%5B60.239972%2C%2044.784037%5D%2C%20%5B58.689989%2C%2045.500014%5D%2C%20%5B58.503127%2C%2045.586804%5D%2C%20%5B55.928917%2C%2044.995858%5D%2C%20%5B55.968191%2C%2041.308642%5D%2C%20%5B55.455251%2C%2041.259859%5D%2C%20%5B54.755345%2C%2042.043971%5D%2C%20%5B54.079418%2C%2042.324109%5D%2C%20%5B52.944293%2C%2042.116034%5D%2C%20%5B52.50246%2C%2041.783316%5D%2C%20%5B52.446339%2C%2042.027151%5D%2C%20%5B52.692112%2C%2042.443895%5D%2C%20%5B52.501426%2C%2042.792298%5D%2C%20%5B51.342427%2C%2043.132975%5D%2C%20%5B50.891292%2C%2044.031034%5D%2C%20%5B50.339129%2C%2044.284016%5D%2C%20%5B50.305643%2C%2044.609836%5D%2C%20%5B51.278503%2C%2044.514854%5D%2C%20%5B51.316899%2C%2045.245998%5D%2C%20%5B52.16739%2C%2045.408391%5D%2C%20%5B53.040876%2C%2045.259047%5D%2C%20%5B53.220866%2C%2046.234646%5D%2C%20%5B53.042737%2C%2046.853006%5D%2C%20%5B52.042023%2C%2046.804637%5D%2C%20%5B51.191945%2C%2047.048705%5D%2C%20%5B50.034083%2C%2046.60899%5D%2C%20%5B49.10116%2C%2046.39933%5D%2C%20%5B48.593241%2C%2046.561034%5D%2C%20%5B48.694734%2C%2047.075628%5D%2C%20%5B48.057253%2C%2047.743753%5D%2C%20%5B47.315231%2C%2047.715847%5D%2C%20%5B46.466446%2C%2048.394152%5D%2C%20%5B47.043672%2C%2049.152039%5D%2C%20%5B46.751596%2C%2049.356006%5D%2C%20%5B47.54948%2C%2050.454698%5D%2C%20%5B48.577841%2C%2049.87476%5D%2C%20%5B48.702382%2C%2050.605128%5D%2C%20%5B50.766648%2C%2051.692762%5D%2C%20%5B52.328724%2C%2051.718652%5D%2C%20%5B54.532878%2C%2051.02624%5D%2C%20%5B55.716941%2C%2050.621717%5D%2C%20%5B56.777961%2C%2051.043551%5D%2C%20%5B58.363291%2C%2051.063653%5D%2C%20%5B59.642282%2C%2050.545442%5D%2C%20%5B59.932807%2C%2050.842194%5D%2C%20%5B61.337424%2C%2050.79907%5D%2C%20%5B61.588003%2C%2051.272659%5D%2C%20%5B59.967534%2C%2051.96042%5D%2C%20%5B60.927269%2C%2052.447548%5D%2C%20%5B60.739993%2C%2052.719986%5D%2C%20%5B61.699986%2C%2052.979996%5D%2C%20%5B60.978066%2C%2053.664993%5D%2C%20%5B61.436591%2C%2054.006265%5D%2C%20%5B65.178534%2C%2054.354228%5D%2C%20%5B65.666876%2C%2054.601267%5D%2C%20%5B68.1691%2C%2054.970392%5D%2C%20%5B69.068167%2C%2055.38525%5D%2C%20%5B70.865267%2C%2055.169734%5D%2C%20%5B71.180131%2C%2054.133285%5D%2C%20%5B72.22415%2C%2054.376655%5D%2C%20%5B73.508516%2C%2054.035617%5D%2C%20%5B73.425679%2C%2053.48981%5D%2C%20%5B74.384845%2C%2053.546861%5D%2C%20%5B76.8911%2C%2054.490524%5D%2C%20%5B76.525179%2C%2054.177003%5D%2C%20%5B77.800916%2C%2053.404415%5D%2C%20%5B80.03556%2C%2050.864751%5D%2C%20%5B80.568447%2C%2051.388336%5D%2C%20%5B81.945986%2C%2050.812196%5D%2C%20%5B83.383004%2C%2051.069183%5D%2C%20%5B83.935115%2C%2050.889246%5D%2C%20%5B84.416377%2C%2050.3114%5D%2C%20%5B85.11556%2C%2050.117303%5D%2C%20%5B85.54127%2C%2049.692859%5D%2C%20%5B86.829357%2C%2049.826675%5D%2C%20%5B87.35997%2C%2049.214981%5D%2C%20%5B86.598776%2C%2048.549182%5D%2C%20%5B85.768233%2C%2048.455751%5D%2C%20%5B85.720484%2C%2047.452969%5D%2C%20%5B85.16429%2C%2047.000956%5D%2C%20%5B83.180484%2C%2047.330031%5D%2C%20%5B82.458926%2C%2045.53965%5D%2C%20%5B81.947071%2C%2045.317027%5D%2C%20%5B79.966106%2C%2044.917517%5D%2C%20%5B80.866206%2C%2043.180362%5D%2C%20%5B80.18015%2C%2042.920068%5D%2C%20%5B80.25999%2C%2042.349999%5D%2C%20%5B79.643645%2C%2042.496683%5D%2C%20%5B79.142177%2C%2042.856092%5D%2C%20%5B77.658392%2C%2042.960686%5D%2C%20%5B76.000354%2C%2042.988022%5D%2C%20%5B75.636965%2C%2042.8779%5D%2C%20%5B74.212866%2C%2043.298339%5D%2C%20%5B73.645304%2C%2043.091272%5D%2C%20%5B73.489758%2C%2042.500894%5D%2C%20%5B71.844638%2C%2042.845395%5D%2C%20%5B71.186281%2C%2042.704293%5D%2C%20%5B70.962315%2C%2042.266154%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22KAZ%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Kazakhstan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B40.993%2C%20-0.85829%5D%2C%20%5B41.58513%2C%20-1.68325%5D%2C%20%5B40.88477%2C%20-2.08255%5D%2C%20%5B40.63785%2C%20-2.49979%5D%2C%20%5B40.26304%2C%20-2.57309%5D%2C%20%5B40.12119%2C%20-3.27768%5D%2C%20%5B39.80006%2C%20-3.68116%5D%2C%20%5B39.60489%2C%20-4.34653%5D%2C%20%5B39.20222%2C%20-4.67677%5D%2C%20%5B37.7669%2C%20-3.67712%5D%2C%20%5B37.69869%2C%20-3.09699%5D%2C%20%5B34.07262%2C%20-1.05982%5D%2C%20%5B33.903711%2C%20-0.95%5D%2C%20%5B33.893569%2C%200.109814%5D%2C%20%5B34.18%2C%200.515%5D%2C%20%5B34.6721%2C%201.17694%5D%2C%20%5B35.03599%2C%201.90584%5D%2C%20%5B34.59607%2C%203.05374%5D%2C%20%5B34.47913%2C%203.5556%5D%2C%20%5B34.005%2C%204.249885%5D%2C%20%5B34.620196%2C%204.847123%5D%2C%20%5B35.298007%2C%205.506%5D%2C%20%5B35.817448%2C%205.338232%5D%2C%20%5B35.817448%2C%204.776966%5D%2C%20%5B36.159079%2C%204.447864%5D%2C%20%5B36.855093%2C%204.447864%5D%2C%20%5B38.120915%2C%203.598605%5D%2C%20%5B38.43697%2C%203.58851%5D%2C%20%5B38.67114%2C%203.61607%5D%2C%20%5B38.89251%2C%203.50074%5D%2C%20%5B39.559384%2C%203.42206%5D%2C%20%5B39.85494%2C%203.83879%5D%2C%20%5B40.76848%2C%204.25702%5D%2C%20%5B41.1718%2C%203.91909%5D%2C%20%5B41.855083%2C%203.918912%5D%2C%20%5B40.98105%2C%202.78452%5D%2C%20%5B40.993%2C%20-0.85829%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22KEN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Kenya%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B70.962315%2C%2042.266154%5D%2C%20%5B71.186281%2C%2042.704293%5D%2C%20%5B71.844638%2C%2042.845395%5D%2C%20%5B73.489758%2C%2042.500894%5D%2C%20%5B73.645304%2C%2043.091272%5D%2C%20%5B74.212866%2C%2043.298339%5D%2C%20%5B75.636965%2C%2042.8779%5D%2C%20%5B76.000354%2C%2042.988022%5D%2C%20%5B77.658392%2C%2042.960686%5D%2C%20%5B79.142177%2C%2042.856092%5D%2C%20%5B79.643645%2C%2042.496683%5D%2C%20%5B80.25999%2C%2042.349999%5D%2C%20%5B80.11943%2C%2042.123941%5D%2C%20%5B78.543661%2C%2041.582243%5D%2C%20%5B78.187197%2C%2041.185316%5D%2C%20%5B76.904484%2C%2041.066486%5D%2C%20%5B76.526368%2C%2040.427946%5D%2C%20%5B75.467828%2C%2040.562072%5D%2C%20%5B74.776862%2C%2040.366425%5D%2C%20%5B73.822244%2C%2039.893973%5D%2C%20%5B73.960013%2C%2039.660008%5D%2C%20%5B73.675379%2C%2039.431237%5D%2C%20%5B71.784694%2C%2039.279463%5D%2C%20%5B70.549162%2C%2039.604198%5D%2C%20%5B69.464887%2C%2039.526683%5D%2C%20%5B69.55961%2C%2040.103211%5D%2C%20%5B70.648019%2C%2039.935754%5D%2C%20%5B71.014198%2C%2040.244366%5D%2C%20%5B71.774875%2C%2040.145844%5D%2C%20%5B73.055417%2C%2040.866033%5D%2C%20%5B71.870115%2C%2041.3929%5D%2C%20%5B71.157859%2C%2041.143587%5D%2C%20%5B70.420022%2C%2041.519998%5D%2C%20%5B71.259248%2C%2042.167711%5D%2C%20%5B70.962315%2C%2042.266154%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22KGZ%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Kyrgyzstan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B103.49728%2C%2010.632555%5D%2C%20%5B103.09069%2C%2011.153661%5D%2C%20%5B102.584932%2C%2012.186595%5D%2C%20%5B102.348099%2C%2013.394247%5D%2C%20%5B102.988422%2C%2014.225721%5D%2C%20%5B104.281418%2C%2014.416743%5D%2C%20%5B105.218777%2C%2014.273212%5D%2C%20%5B106.043946%2C%2013.881091%5D%2C%20%5B106.496373%2C%2014.570584%5D%2C%20%5B107.382727%2C%2014.202441%5D%2C%20%5B107.614548%2C%2013.535531%5D%2C%20%5B107.491403%2C%2012.337206%5D%2C%20%5B105.810524%2C%2011.567615%5D%2C%20%5B106.24967%2C%2010.961812%5D%2C%20%5B105.199915%2C%2010.88931%5D%2C%20%5B104.334335%2C%2010.486544%5D%2C%20%5B103.49728%2C%2010.632555%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22KHM%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Cambodia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B128.349716%2C%2038.612243%5D%2C%20%5B129.21292%2C%2037.432392%5D%2C%20%5B129.46045%2C%2036.784189%5D%2C%20%5B129.468304%2C%2035.632141%5D%2C%20%5B129.091377%2C%2035.082484%5D%2C%20%5B128.18585%2C%2034.890377%5D%2C%20%5B127.386519%2C%2034.475674%5D%2C%20%5B126.485748%2C%2034.390046%5D%2C%20%5B126.37392%2C%2034.93456%5D%2C%20%5B126.559231%2C%2035.684541%5D%2C%20%5B126.117398%2C%2036.725485%5D%2C%20%5B126.860143%2C%2036.893924%5D%2C%20%5B126.174759%2C%2037.749686%5D%2C%20%5B126.237339%2C%2037.840378%5D%2C%20%5B126.68372%2C%2037.804773%5D%2C%20%5B127.073309%2C%2038.256115%5D%2C%20%5B127.780035%2C%2038.304536%5D%2C%20%5B128.205746%2C%2038.370397%5D%2C%20%5B128.349716%2C%2038.612243%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22KOR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22South%20Korea%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B20.76216%2C%2042.05186%5D%2C%20%5B20.71731%2C%2041.84711%5D%2C%20%5B20.59023%2C%2041.85541%5D%2C%20%5B20.52295%2C%2042.21787%5D%2C%20%5B20.28374%2C%2042.32025%5D%2C%20%5B20.0707%2C%2042.58863%5D%2C%20%5B20.25758%2C%2042.81275%5D%2C%20%5B20.49679%2C%2042.88469%5D%2C%20%5B20.63508%2C%2043.21671%5D%2C%20%5B20.81448%2C%2043.27205%5D%2C%20%5B20.95651%2C%2043.13094%5D%2C%20%5B21.143395%2C%2043.068685%5D%2C%20%5B21.27421%2C%2042.90959%5D%2C%20%5B21.43866%2C%2042.86255%5D%2C%20%5B21.63302%2C%2042.67717%5D%2C%20%5B21.77505%2C%2042.6827%5D%2C%20%5B21.66292%2C%2042.43922%5D%2C%20%5B21.54332%2C%2042.32025%5D%2C%20%5B21.576636%2C%2042.245224%5D%2C%20%5B21.3527%2C%2042.2068%5D%2C%20%5B20.76216%2C%2042.05186%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22-99%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Kosovo%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B47.974519%2C%2029.975819%5D%2C%20%5B48.183189%2C%2029.534477%5D%2C%20%5B48.093943%2C%2029.306299%5D%2C%20%5B48.416094%2C%2028.552004%5D%2C%20%5B47.708851%2C%2028.526063%5D%2C%20%5B47.459822%2C%2029.002519%5D%2C%20%5B46.568713%2C%2029.099025%5D%2C%20%5B47.302622%2C%2030.05907%5D%2C%20%5B47.974519%2C%2029.975819%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22KWT%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Kuwait%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B105.218777%2C%2014.273212%5D%2C%20%5B105.544338%2C%2014.723934%5D%2C%20%5B105.589039%2C%2015.570316%5D%2C%20%5B104.779321%2C%2016.441865%5D%2C%20%5B104.716947%2C%2017.428859%5D%2C%20%5B103.956477%2C%2018.240954%5D%2C%20%5B103.200192%2C%2018.309632%5D%2C%20%5B102.998706%2C%2017.961695%5D%2C%20%5B102.413005%2C%2017.932782%5D%2C%20%5B102.113592%2C%2018.109102%5D%2C%20%5B101.059548%2C%2017.512497%5D%2C%20%5B101.035931%2C%2018.408928%5D%2C%20%5B101.282015%2C%2019.462585%5D%2C%20%5B100.606294%2C%2019.508344%5D%2C%20%5B100.548881%2C%2020.109238%5D%2C%20%5B100.115988%2C%2020.41785%5D%2C%20%5B100.329101%2C%2020.786122%5D%2C%20%5B101.180005%2C%2021.436573%5D%2C%20%5B101.270026%2C%2021.201652%5D%2C%20%5B101.80312%2C%2021.174367%5D%2C%20%5B101.652018%2C%2022.318199%5D%2C%20%5B102.170436%2C%2022.464753%5D%2C%20%5B102.754896%2C%2021.675137%5D%2C%20%5B103.203861%2C%2020.766562%5D%2C%20%5B104.435%2C%2020.758733%5D%2C%20%5B104.822574%2C%2019.886642%5D%2C%20%5B104.183388%2C%2019.624668%5D%2C%20%5B103.896532%2C%2019.265181%5D%2C%20%5B105.094598%2C%2018.666975%5D%2C%20%5B105.925762%2C%2017.485315%5D%2C%20%5B106.556008%2C%2016.604284%5D%2C%20%5B107.312706%2C%2015.908538%5D%2C%20%5B107.564525%2C%2015.202173%5D%2C%20%5B107.382727%2C%2014.202441%5D%2C%20%5B106.496373%2C%2014.570584%5D%2C%20%5B106.043946%2C%2013.881091%5D%2C%20%5B105.218777%2C%2014.273212%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22LAO%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Laos%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B35.821101%2C%2033.277426%5D%2C%20%5B35.552797%2C%2033.264275%5D%2C%20%5B35.460709%2C%2033.08904%5D%2C%20%5B35.126053%2C%2033.0909%5D%2C%20%5B35.482207%2C%2033.90545%5D%2C%20%5B35.979592%2C%2034.610058%5D%2C%20%5B35.998403%2C%2034.644914%5D%2C%20%5B36.448194%2C%2034.593935%5D%2C%20%5B36.61175%2C%2034.201789%5D%2C%20%5B36.06646%2C%2033.824912%5D%2C%20%5B35.821101%2C%2033.277426%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22LBN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Lebanon%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-7.712159%2C%204.364566%5D%2C%20%5B-7.974107%2C%204.355755%5D%2C%20%5B-9.004794%2C%204.832419%5D%2C%20%5B-9.91342%2C%205.593561%5D%2C%20%5B-10.765384%2C%206.140711%5D%2C%20%5B-11.438779%2C%206.785917%5D%2C%20%5B-11.199802%2C%207.105846%5D%2C%20%5B-11.146704%2C%207.396706%5D%2C%20%5B-10.695595%2C%207.939464%5D%2C%20%5B-10.230094%2C%208.406206%5D%2C%20%5B-10.016567%2C%208.428504%5D%2C%20%5B-9.755342%2C%208.541055%5D%2C%20%5B-9.33728%2C%207.928534%5D%2C%20%5B-9.403348%2C%207.526905%5D%2C%20%5B-9.208786%2C%207.313921%5D%2C%20%5B-8.926065%2C%207.309037%5D%2C%20%5B-8.722124%2C%207.711674%5D%2C%20%5B-8.439298%2C%207.686043%5D%2C%20%5B-8.485446%2C%207.395208%5D%2C%20%5B-8.385452%2C%206.911801%5D%2C%20%5B-8.60288%2C%206.467564%5D%2C%20%5B-8.311348%2C%206.193033%5D%2C%20%5B-7.993693%2C%206.12619%5D%2C%20%5B-7.570153%2C%205.707352%5D%2C%20%5B-7.539715%2C%205.313345%5D%2C%20%5B-7.635368%2C%205.188159%5D%2C%20%5B-7.712159%2C%204.364566%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22LBR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Liberia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B14.8513%2C%2022.86295%5D%2C%20%5B14.143871%2C%2022.491289%5D%2C%20%5B13.581425%2C%2023.040506%5D%2C%20%5B11.999506%2C%2023.471668%5D%2C%20%5B11.560669%2C%2024.097909%5D%2C%20%5B10.771364%2C%2024.562532%5D%2C%20%5B10.303847%2C%2024.379313%5D%2C%20%5B9.948261%2C%2024.936954%5D%2C%20%5B9.910693%2C%2025.365455%5D%2C%20%5B9.319411%2C%2026.094325%5D%2C%20%5B9.716286%2C%2026.512206%5D%2C%20%5B9.629056%2C%2027.140953%5D%2C%20%5B9.756128%2C%2027.688259%5D%2C%20%5B9.683885%2C%2028.144174%5D%2C%20%5B9.859998%2C%2028.95999%5D%2C%20%5B9.805634%2C%2029.424638%5D%2C%20%5B9.48214%2C%2030.307556%5D%2C%20%5B9.970017%2C%2030.539325%5D%2C%20%5B10.056575%2C%2030.961831%5D%2C%20%5B9.950225%2C%2031.37607%5D%2C%20%5B10.636901%2C%2031.761421%5D%2C%20%5B10.94479%2C%2032.081815%5D%2C%20%5B11.432253%2C%2032.368903%5D%2C%20%5B11.488787%2C%2033.136996%5D%2C%20%5B12.66331%2C%2032.79278%5D%2C%20%5B13.08326%2C%2032.87882%5D%2C%20%5B13.91868%2C%2032.71196%5D%2C%20%5B15.24563%2C%2032.26508%5D%2C%20%5B15.71394%2C%2031.37626%5D%2C%20%5B16.61162%2C%2031.18218%5D%2C%20%5B18.02109%2C%2030.76357%5D%2C%20%5B19.08641%2C%2030.26639%5D%2C%20%5B19.57404%2C%2030.52582%5D%2C%20%5B20.05335%2C%2030.98576%5D%2C%20%5B19.82033%2C%2031.75179%5D%2C%20%5B20.13397%2C%2032.2382%5D%2C%20%5B20.85452%2C%2032.7068%5D%2C%20%5B21.54298%2C%2032.8432%5D%2C%20%5B22.89576%2C%2032.63858%5D%2C%20%5B23.2368%2C%2032.19149%5D%2C%20%5B23.60913%2C%2032.18726%5D%2C%20%5B23.9275%2C%2032.01667%5D%2C%20%5B24.92114%2C%2031.89936%5D%2C%20%5B25.16482%2C%2031.56915%5D%2C%20%5B24.80287%2C%2031.08929%5D%2C%20%5B24.95762%2C%2030.6616%5D%2C%20%5B24.70007%2C%2030.04419%5D%2C%20%5B25%2C%2029.238655%5D%2C%20%5B25%2C%2025.6825%5D%2C%20%5B25%2C%2022%5D%2C%20%5B25%2C%2020.00304%5D%2C%20%5B23.85%2C%2020%5D%2C%20%5B23.83766%2C%2019.58047%5D%2C%20%5B19.84926%2C%2021.49509%5D%2C%20%5B15.86085%2C%2023.40972%5D%2C%20%5B14.8513%2C%2022.86295%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22LBY%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Libya%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B81.787959%2C%207.523055%5D%2C%20%5B81.637322%2C%206.481775%5D%2C%20%5B81.21802%2C%206.197141%5D%2C%20%5B80.348357%2C%205.96837%5D%2C%20%5B79.872469%2C%206.763463%5D%2C%20%5B79.695167%2C%208.200843%5D%2C%20%5B80.147801%2C%209.824078%5D%2C%20%5B80.838818%2C%209.268427%5D%2C%20%5B81.304319%2C%208.564206%5D%2C%20%5B81.787959%2C%207.523055%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22LKA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Sri%20Lanka%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B28.978263%2C%20-28.955597%5D%2C%20%5B29.325166%2C%20-29.257387%5D%2C%20%5B29.018415%2C%20-29.743766%5D%2C%20%5B28.8484%2C%20-30.070051%5D%2C%20%5B28.291069%2C%20-30.226217%5D%2C%20%5B28.107205%2C%20-30.545732%5D%2C%20%5B27.749397%2C%20-30.645106%5D%2C%20%5B26.999262%2C%20-29.875954%5D%2C%20%5B27.532511%2C%20-29.242711%5D%2C%20%5B28.074338%2C%20-28.851469%5D%2C%20%5B28.5417%2C%20-28.647502%5D%2C%20%5B28.978263%2C%20-28.955597%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22LSO%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Lesotho%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B22.731099%2C%2054.327537%5D%2C%20%5B22.651052%2C%2054.582741%5D%2C%20%5B22.757764%2C%2054.856574%5D%2C%20%5B22.315724%2C%2055.015299%5D%2C%20%5B21.268449%2C%2055.190482%5D%2C%20%5B21.0558%2C%2056.031076%5D%2C%20%5B22.201157%2C%2056.337802%5D%2C%20%5B23.878264%2C%2056.273671%5D%2C%20%5B24.860684%2C%2056.372528%5D%2C%20%5B25.000934%2C%2056.164531%5D%2C%20%5B25.533047%2C%2056.100297%5D%2C%20%5B26.494331%2C%2055.615107%5D%2C%20%5B26.588279%2C%2055.167176%5D%2C%20%5B25.768433%2C%2054.846963%5D%2C%20%5B25.536354%2C%2054.282423%5D%2C%20%5B24.450684%2C%2053.905702%5D%2C%20%5B23.484128%2C%2053.912498%5D%2C%20%5B23.243987%2C%2054.220567%5D%2C%20%5B22.731099%2C%2054.327537%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22LTU%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Lithuania%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B6.043073%2C%2050.128052%5D%2C%20%5B6.242751%2C%2049.902226%5D%2C%20%5B6.18632%2C%2049.463803%5D%2C%20%5B5.897759%2C%2049.442667%5D%2C%20%5B5.674052%2C%2049.529484%5D%2C%20%5B5.782417%2C%2050.090328%5D%2C%20%5B6.043073%2C%2050.128052%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22LUX%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Luxembourg%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B21.0558%2C%2056.031076%5D%2C%20%5B21.090424%2C%2056.783873%5D%2C%20%5B21.581866%2C%2057.411871%5D%2C%20%5B22.524341%2C%2057.753374%5D%2C%20%5B23.318453%2C%2057.006236%5D%2C%20%5B24.12073%2C%2057.025693%5D%2C%20%5B24.312863%2C%2057.793424%5D%2C%20%5B25.164594%2C%2057.970157%5D%2C%20%5B25.60281%2C%2057.847529%5D%2C%20%5B26.463532%2C%2057.476389%5D%2C%20%5B27.288185%2C%2057.474528%5D%2C%20%5B27.770016%2C%2057.244258%5D%2C%20%5B27.855282%2C%2056.759326%5D%2C%20%5B28.176709%2C%2056.16913%5D%2C%20%5B27.10246%2C%2055.783314%5D%2C%20%5B26.494331%2C%2055.615107%5D%2C%20%5B25.533047%2C%2056.100297%5D%2C%20%5B25.000934%2C%2056.164531%5D%2C%20%5B24.860684%2C%2056.372528%5D%2C%20%5B23.878264%2C%2056.273671%5D%2C%20%5B22.201157%2C%2056.337802%5D%2C%20%5B21.0558%2C%2056.031076%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22LVA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Latvia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-5.193863%2C%2035.755182%5D%2C%20%5B-4.591006%2C%2035.330712%5D%2C%20%5B-3.640057%2C%2035.399855%5D%2C%20%5B-2.604306%2C%2035.179093%5D%2C%20%5B-2.169914%2C%2035.168396%5D%2C%20%5B-1.792986%2C%2034.527919%5D%2C%20%5B-1.733455%2C%2033.919713%5D%2C%20%5B-1.388049%2C%2032.864015%5D%2C%20%5B-1.124551%2C%2032.651522%5D%2C%20%5B-1.307899%2C%2032.262889%5D%2C%20%5B-2.616605%2C%2032.094346%5D%2C%20%5B-3.06898%2C%2031.724498%5D%2C%20%5B-3.647498%2C%2031.637294%5D%2C%20%5B-3.690441%2C%2030.896952%5D%2C%20%5B-4.859646%2C%2030.501188%5D%2C%20%5B-5.242129%2C%2030.000443%5D%2C%20%5B-6.060632%2C%2029.7317%5D%2C%20%5B-7.059228%2C%2029.579228%5D%2C%20%5B-8.674116%2C%2028.841289%5D%2C%20%5B-8.66559%2C%2027.656426%5D%2C%20%5B-8.817809%2C%2027.656426%5D%2C%20%5B-8.817828%2C%2027.656426%5D%2C%20%5B-8.794884%2C%2027.120696%5D%2C%20%5B-9.413037%2C%2027.088476%5D%2C%20%5B-9.735343%2C%2026.860945%5D%2C%20%5B-10.189424%2C%2026.860945%5D%2C%20%5B-10.551263%2C%2026.990808%5D%2C%20%5B-11.392555%2C%2026.883424%5D%2C%20%5B-11.71822%2C%2026.104092%5D%2C%20%5B-12.030759%2C%2026.030866%5D%2C%20%5B-12.500963%2C%2024.770116%5D%2C%20%5B-13.89111%2C%2023.691009%5D%2C%20%5B-14.221168%2C%2022.310163%5D%2C%20%5B-14.630833%2C%2021.86094%5D%2C%20%5B-14.750955%2C%2021.5006%5D%2C%20%5B-17.002962%2C%2021.420734%5D%2C%20%5B-17.020428%2C%2021.42231%5D%2C%20%5B-16.973248%2C%2021.885745%5D%2C%20%5B-16.589137%2C%2022.158234%5D%2C%20%5B-16.261922%2C%2022.67934%5D%2C%20%5B-16.326414%2C%2023.017768%5D%2C%20%5B-15.982611%2C%2023.723358%5D%2C%20%5B-15.426004%2C%2024.359134%5D%2C%20%5B-15.089332%2C%2024.520261%5D%2C%20%5B-14.824645%2C%2025.103533%5D%2C%20%5B-14.800926%2C%2025.636265%5D%2C%20%5B-14.43994%2C%2026.254418%5D%2C%20%5B-13.773805%2C%2026.618892%5D%2C%20%5B-13.139942%2C%2027.640148%5D%2C%20%5B-13.121613%2C%2027.654148%5D%2C%20%5B-12.618837%2C%2028.038186%5D%2C%20%5B-11.688919%2C%2028.148644%5D%2C%20%5B-10.900957%2C%2028.832142%5D%2C%20%5B-10.399592%2C%2029.098586%5D%2C%20%5B-9.564811%2C%2029.933574%5D%2C%20%5B-9.814718%2C%2031.177736%5D%2C%20%5B-9.434793%2C%2032.038096%5D%2C%20%5B-9.300693%2C%2032.564679%5D%2C%20%5B-8.657476%2C%2033.240245%5D%2C%20%5B-7.654178%2C%2033.697065%5D%2C%20%5B-6.912544%2C%2034.110476%5D%2C%20%5B-6.244342%2C%2035.145865%5D%2C%20%5B-5.929994%2C%2035.759988%5D%2C%20%5B-5.193863%2C%2035.755182%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22MAR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Morocco%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B26.619337%2C%2048.220726%5D%2C%20%5B26.857824%2C%2048.368211%5D%2C%20%5B27.522537%2C%2048.467119%5D%2C%20%5B28.259547%2C%2048.155562%5D%2C%20%5B28.670891%2C%2048.118149%5D%2C%20%5B29.122698%2C%2047.849095%5D%2C%20%5B29.050868%2C%2047.510227%5D%2C%20%5B29.415135%2C%2047.346645%5D%2C%20%5B29.559674%2C%2046.928583%5D%2C%20%5B29.908852%2C%2046.674361%5D%2C%20%5B29.83821%2C%2046.525326%5D%2C%20%5B30.024659%2C%2046.423937%5D%2C%20%5B29.759972%2C%2046.349988%5D%2C%20%5B29.170654%2C%2046.379262%5D%2C%20%5B29.072107%2C%2046.517678%5D%2C%20%5B28.862972%2C%2046.437889%5D%2C%20%5B28.933717%2C%2046.25883%5D%2C%20%5B28.659987%2C%2045.939987%5D%2C%20%5B28.485269%2C%2045.596907%5D%2C%20%5B28.233554%2C%2045.488283%5D%2C%20%5B28.054443%2C%2045.944586%5D%2C%20%5B28.160018%2C%2046.371563%5D%2C%20%5B28.12803%2C%2046.810476%5D%2C%20%5B27.551166%2C%2047.405117%5D%2C%20%5B27.233873%2C%2047.826771%5D%2C%20%5B26.924176%2C%2048.123264%5D%2C%20%5B26.619337%2C%2048.220726%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22MDA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Moldova%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B49.543519%2C%20-12.469833%5D%2C%20%5B49.808981%2C%20-12.895285%5D%2C%20%5B50.056511%2C%20-13.555761%5D%2C%20%5B50.217431%2C%20-14.758789%5D%2C%20%5B50.476537%2C%20-15.226512%5D%2C%20%5B50.377111%2C%20-15.706069%5D%2C%20%5B50.200275%2C%20-16.000263%5D%2C%20%5B49.860606%2C%20-15.414253%5D%2C%20%5B49.672607%2C%20-15.710204%5D%2C%20%5B49.863344%2C%20-16.451037%5D%2C%20%5B49.774564%2C%20-16.875042%5D%2C%20%5B49.498612%2C%20-17.106036%5D%2C%20%5B49.435619%2C%20-17.953064%5D%2C%20%5B49.041792%2C%20-19.118781%5D%2C%20%5B48.548541%2C%20-20.496888%5D%2C%20%5B47.930749%2C%20-22.391501%5D%2C%20%5B47.547723%2C%20-23.781959%5D%2C%20%5B47.095761%2C%20-24.94163%5D%2C%20%5B46.282478%2C%20-25.178463%5D%2C%20%5B45.409508%2C%20-25.601434%5D%2C%20%5B44.833574%2C%20-25.346101%5D%2C%20%5B44.03972%2C%20-24.988345%5D%2C%20%5B43.763768%2C%20-24.460677%5D%2C%20%5B43.697778%2C%20-23.574116%5D%2C%20%5B43.345654%2C%20-22.776904%5D%2C%20%5B43.254187%2C%20-22.057413%5D%2C%20%5B43.433298%2C%20-21.336475%5D%2C%20%5B43.893683%2C%20-21.163307%5D%2C%20%5B43.89637%2C%20-20.830459%5D%2C%20%5B44.374325%2C%20-20.072366%5D%2C%20%5B44.464397%2C%20-19.435454%5D%2C%20%5B44.232422%2C%20-18.961995%5D%2C%20%5B44.042976%2C%20-18.331387%5D%2C%20%5B43.963084%2C%20-17.409945%5D%2C%20%5B44.312469%2C%20-16.850496%5D%2C%20%5B44.446517%2C%20-16.216219%5D%2C%20%5B44.944937%2C%20-16.179374%5D%2C%20%5B45.502732%2C%20-15.974373%5D%2C%20%5B45.872994%2C%20-15.793454%5D%2C%20%5B46.312243%2C%20-15.780018%5D%2C%20%5B46.882183%2C%20-15.210182%5D%2C%20%5B47.70513%2C%20-14.594303%5D%2C%20%5B48.005215%2C%20-14.091233%5D%2C%20%5B47.869047%2C%20-13.663869%5D%2C%20%5B48.293828%2C%20-13.784068%5D%2C%20%5B48.84506%2C%20-13.089175%5D%2C%20%5B48.863509%2C%20-12.487868%5D%2C%20%5B49.194651%2C%20-12.040557%5D%2C%20%5B49.543519%2C%20-12.469833%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22MDG%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Madagascar%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-97.140008%2C%2025.869997%5D%2C%20%5B-97.528072%2C%2024.992144%5D%2C%20%5B-97.702946%2C%2024.272343%5D%2C%20%5B-97.776042%2C%2022.93258%5D%2C%20%5B-97.872367%2C%2022.444212%5D%2C%20%5B-97.699044%2C%2021.898689%5D%2C%20%5B-97.38896%2C%2021.411019%5D%2C%20%5B-97.189333%2C%2020.635433%5D%2C%20%5B-96.525576%2C%2019.890931%5D%2C%20%5B-96.292127%2C%2019.320371%5D%2C%20%5B-95.900885%2C%2018.828024%5D%2C%20%5B-94.839063%2C%2018.562717%5D%2C%20%5B-94.42573%2C%2018.144371%5D%2C%20%5B-93.548651%2C%2018.423837%5D%2C%20%5B-92.786114%2C%2018.524839%5D%2C%20%5B-92.037348%2C%2018.704569%5D%2C%20%5B-91.407903%2C%2018.876083%5D%2C%20%5B-90.77187%2C%2019.28412%5D%2C%20%5B-90.53359%2C%2019.867418%5D%2C%20%5B-90.451476%2C%2020.707522%5D%2C%20%5B-90.278618%2C%2020.999855%5D%2C%20%5B-89.601321%2C%2021.261726%5D%2C%20%5B-88.543866%2C%2021.493675%5D%2C%20%5B-87.658417%2C%2021.458846%5D%2C%20%5B-87.05189%2C%2021.543543%5D%2C%20%5B-86.811982%2C%2021.331515%5D%2C%20%5B-86.845908%2C%2020.849865%5D%2C%20%5B-87.383291%2C%2020.255405%5D%2C%20%5B-87.621054%2C%2019.646553%5D%2C%20%5B-87.43675%2C%2019.472403%5D%2C%20%5B-87.58656%2C%2019.04013%5D%2C%20%5B-87.837191%2C%2018.259816%5D%2C%20%5B-88.090664%2C%2018.516648%5D%2C%20%5B-88.300031%2C%2018.499982%5D%2C%20%5B-88.490123%2C%2018.486831%5D%2C%20%5B-88.848344%2C%2017.883198%5D%2C%20%5B-89.029857%2C%2018.001511%5D%2C%20%5B-89.150909%2C%2017.955468%5D%2C%20%5B-89.14308%2C%2017.808319%5D%2C%20%5B-90.067934%2C%2017.819326%5D%2C%20%5B-91.00152%2C%2017.817595%5D%2C%20%5B-91.002269%2C%2017.254658%5D%2C%20%5B-91.453921%2C%2017.252177%5D%2C%20%5B-91.08167%2C%2016.918477%5D%2C%20%5B-90.711822%2C%2016.687483%5D%2C%20%5B-90.600847%2C%2016.470778%5D%2C%20%5B-90.438867%2C%2016.41011%5D%2C%20%5B-90.464473%2C%2016.069562%5D%2C%20%5B-91.74796%2C%2016.066565%5D%2C%20%5B-92.229249%2C%2015.251447%5D%2C%20%5B-92.087216%2C%2015.064585%5D%2C%20%5B-92.20323%2C%2014.830103%5D%2C%20%5B-92.22775%2C%2014.538829%5D%2C%20%5B-93.359464%2C%2015.61543%5D%2C%20%5B-93.875169%2C%2015.940164%5D%2C%20%5B-94.691656%2C%2016.200975%5D%2C%20%5B-95.250227%2C%2016.128318%5D%2C%20%5B-96.053382%2C%2015.752088%5D%2C%20%5B-96.557434%2C%2015.653515%5D%2C%20%5B-97.263592%2C%2015.917065%5D%2C%20%5B-98.01303%2C%2016.107312%5D%2C%20%5B-98.947676%2C%2016.566043%5D%2C%20%5B-99.697397%2C%2016.706164%5D%2C%20%5B-100.829499%2C%2017.171071%5D%2C%20%5B-101.666089%2C%2017.649026%5D%2C%20%5B-101.918528%2C%2017.91609%5D%2C%20%5B-102.478132%2C%2017.975751%5D%2C%20%5B-103.50099%2C%2018.292295%5D%2C%20%5B-103.917527%2C%2018.748572%5D%2C%20%5B-104.99201%2C%2019.316134%5D%2C%20%5B-105.493038%2C%2019.946767%5D%2C%20%5B-105.731396%2C%2020.434102%5D%2C%20%5B-105.397773%2C%2020.531719%5D%2C%20%5B-105.500661%2C%2020.816895%5D%2C%20%5B-105.270752%2C%2021.076285%5D%2C%20%5B-105.265817%2C%2021.422104%5D%2C%20%5B-105.603161%2C%2021.871146%5D%2C%20%5B-105.693414%2C%2022.26908%5D%2C%20%5B-106.028716%2C%2022.773752%5D%2C%20%5B-106.90998%2C%2023.767774%5D%2C%20%5B-107.915449%2C%2024.548915%5D%2C%20%5B-108.401905%2C%2025.172314%5D%2C%20%5B-109.260199%2C%2025.580609%5D%2C%20%5B-109.444089%2C%2025.824884%5D%2C%20%5B-109.291644%2C%2026.442934%5D%2C%20%5B-109.801458%2C%2026.676176%5D%2C%20%5B-110.391732%2C%2027.162115%5D%2C%20%5B-110.641019%2C%2027.859876%5D%2C%20%5B-111.178919%2C%2027.941241%5D%2C%20%5B-111.759607%2C%2028.467953%5D%2C%20%5B-112.228235%2C%2028.954409%5D%2C%20%5B-112.271824%2C%2029.266844%5D%2C%20%5B-112.809594%2C%2030.021114%5D%2C%20%5B-113.163811%2C%2030.786881%5D%2C%20%5B-113.148669%2C%2031.170966%5D%2C%20%5B-113.871881%2C%2031.567608%5D%2C%20%5B-114.205737%2C%2031.524045%5D%2C%20%5B-114.776451%2C%2031.799532%5D%2C%20%5B-114.9367%2C%2031.393485%5D%2C%20%5B-114.771232%2C%2030.913617%5D%2C%20%5B-114.673899%2C%2030.162681%5D%2C%20%5B-114.330974%2C%2029.750432%5D%2C%20%5B-113.588875%2C%2029.061611%5D%2C%20%5B-113.424053%2C%2028.826174%5D%2C%20%5B-113.271969%2C%2028.754783%5D%2C%20%5B-113.140039%2C%2028.411289%5D%2C%20%5B-112.962298%2C%2028.42519%5D%2C%20%5B-112.761587%2C%2027.780217%5D%2C%20%5B-112.457911%2C%2027.525814%5D%2C%20%5B-112.244952%2C%2027.171727%5D%2C%20%5B-111.616489%2C%2026.662817%5D%2C%20%5B-111.284675%2C%2025.73259%5D%2C%20%5B-110.987819%2C%2025.294606%5D%2C%20%5B-110.710007%2C%2024.826004%5D%2C%20%5B-110.655049%2C%2024.298595%5D%2C%20%5B-110.172856%2C%2024.265548%5D%2C%20%5B-109.771847%2C%2023.811183%5D%2C%20%5B-109.409104%2C%2023.364672%5D%2C%20%5B-109.433392%2C%2023.185588%5D%2C%20%5B-109.854219%2C%2022.818272%5D%2C%20%5B-110.031392%2C%2022.823078%5D%2C%20%5B-110.295071%2C%2023.430973%5D%2C%20%5B-110.949501%2C%2024.000964%5D%2C%20%5B-111.670568%2C%2024.484423%5D%2C%20%5B-112.182036%2C%2024.738413%5D%2C%20%5B-112.148989%2C%2025.470125%5D%2C%20%5B-112.300711%2C%2026.012004%5D%2C%20%5B-112.777297%2C%2026.32196%5D%2C%20%5B-113.464671%2C%2026.768186%5D%2C%20%5B-113.59673%2C%2026.63946%5D%2C%20%5B-113.848937%2C%2026.900064%5D%2C%20%5B-114.465747%2C%2027.14209%5D%2C%20%5B-115.055142%2C%2027.722727%5D%2C%20%5B-114.982253%2C%2027.7982%5D%2C%20%5B-114.570366%2C%2027.741485%5D%2C%20%5B-114.199329%2C%2028.115003%5D%2C%20%5B-114.162018%2C%2028.566112%5D%2C%20%5B-114.931842%2C%2029.279479%5D%2C%20%5B-115.518654%2C%2029.556362%5D%2C%20%5B-115.887365%2C%2030.180794%5D%2C%20%5B-116.25835%2C%2030.836464%5D%2C%20%5B-116.721526%2C%2031.635744%5D%2C%20%5B-117.12776%2C%2032.53534%5D%2C%20%5B-115.99135%2C%2032.61239%5D%2C%20%5B-114.72139%2C%2032.72083%5D%2C%20%5B-114.815%2C%2032.52528%5D%2C%20%5B-113.30498%2C%2032.03914%5D%2C%20%5B-111.02361%2C%2031.33472%5D%2C%20%5B-109.035%2C%2031.34194%5D%2C%20%5B-108.24194%2C%2031.34222%5D%2C%20%5B-108.24%2C%2031.754854%5D%2C%20%5B-106.50759%2C%2031.75452%5D%2C%20%5B-106.1429%2C%2031.39995%5D%2C%20%5B-105.63159%2C%2031.08383%5D%2C%20%5B-105.03737%2C%2030.64402%5D%2C%20%5B-104.70575%2C%2030.12173%5D%2C%20%5B-104.45697%2C%2029.57196%5D%2C%20%5B-103.94%2C%2029.27%5D%2C%20%5B-103.11%2C%2028.97%5D%2C%20%5B-102.48%2C%2029.76%5D%2C%20%5B-101.6624%2C%2029.7793%5D%2C%20%5B-100.9576%2C%2029.38071%5D%2C%20%5B-100.45584%2C%2028.69612%5D%2C%20%5B-100.11%2C%2028.11%5D%2C%20%5B-99.52%2C%2027.54%5D%2C%20%5B-99.3%2C%2026.84%5D%2C%20%5B-99.02%2C%2026.37%5D%2C%20%5B-98.24%2C%2026.06%5D%2C%20%5B-97.53%2C%2025.84%5D%2C%20%5B-97.140008%2C%2025.869997%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22MEX%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Mexico%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B20.59023%2C%2041.85541%5D%2C%20%5B20.71731%2C%2041.84711%5D%2C%20%5B20.76216%2C%2042.05186%5D%2C%20%5B21.3527%2C%2042.2068%5D%2C%20%5B21.576636%2C%2042.245224%5D%2C%20%5B21.91708%2C%2042.30364%5D%2C%20%5B22.380526%2C%2042.32026%5D%2C%20%5B22.881374%2C%2041.999297%5D%2C%20%5B22.952377%2C%2041.337994%5D%2C%20%5B22.76177%2C%2041.3048%5D%2C%20%5B22.597308%2C%2041.130487%5D%2C%20%5B22.055378%2C%2041.149866%5D%2C%20%5B21.674161%2C%2040.931275%5D%2C%20%5B21.02004%2C%2040.842727%5D%2C%20%5B20.60518%2C%2041.08622%5D%2C%20%5B20.46315%2C%2041.51509%5D%2C%20%5B20.59023%2C%2041.85541%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22MKD%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Macedonia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-12.17075%2C%2014.616834%5D%2C%20%5B-11.834208%2C%2014.799097%5D%2C%20%5B-11.666078%2C%2015.388208%5D%2C%20%5B-11.349095%2C%2015.411256%5D%2C%20%5B-10.650791%2C%2015.132746%5D%2C%20%5B-10.086846%2C%2015.330486%5D%2C%20%5B-9.700255%2C%2015.264107%5D%2C%20%5B-9.550238%2C%2015.486497%5D%2C%20%5B-5.537744%2C%2015.50169%5D%2C%20%5B-5.315277%2C%2016.201854%5D%2C%20%5B-5.488523%2C%2016.325102%5D%2C%20%5B-5.971129%2C%2020.640833%5D%2C%20%5B-6.453787%2C%2024.956591%5D%2C%20%5B-4.923337%2C%2024.974574%5D%2C%20%5B-1.550055%2C%2022.792666%5D%2C%20%5B1.823228%2C%2020.610809%5D%2C%20%5B2.060991%2C%2020.142233%5D%2C%20%5B2.683588%2C%2019.85623%5D%2C%20%5B3.146661%2C%2019.693579%5D%2C%20%5B3.158133%2C%2019.057364%5D%2C%20%5B4.267419%2C%2019.155265%5D%2C%20%5B4.27021%2C%2016.852227%5D%2C%20%5B3.723422%2C%2016.184284%5D%2C%20%5B3.638259%2C%2015.56812%5D%2C%20%5B2.749993%2C%2015.409525%5D%2C%20%5B1.385528%2C%2015.323561%5D%2C%20%5B1.015783%2C%2014.968182%5D%2C%20%5B0.374892%2C%2014.928908%5D%2C%20%5B-0.266257%2C%2014.924309%5D%2C%20%5B-0.515854%2C%2015.116158%5D%2C%20%5B-1.066363%2C%2014.973815%5D%2C%20%5B-2.001035%2C%2014.559008%5D%2C%20%5B-2.191825%2C%2014.246418%5D%2C%20%5B-2.967694%2C%2013.79815%5D%2C%20%5B-3.103707%2C%2013.541267%5D%2C%20%5B-3.522803%2C%2013.337662%5D%2C%20%5B-4.006391%2C%2013.472485%5D%2C%20%5B-4.280405%2C%2013.228444%5D%2C%20%5B-4.427166%2C%2012.542646%5D%2C%20%5B-5.220942%2C%2011.713859%5D%2C%20%5B-5.197843%2C%2011.375146%5D%2C%20%5B-5.470565%2C%2010.95127%5D%2C%20%5B-5.404342%2C%2010.370737%5D%2C%20%5B-5.816926%2C%2010.222555%5D%2C%20%5B-6.050452%2C%2010.096361%5D%2C%20%5B-6.205223%2C%2010.524061%5D%2C%20%5B-6.493965%2C%2010.411303%5D%2C%20%5B-6.666461%2C%2010.430811%5D%2C%20%5B-6.850507%2C%2010.138994%5D%2C%20%5B-7.622759%2C%2010.147236%5D%2C%20%5B-7.89959%2C%2010.297382%5D%2C%20%5B-8.029944%2C%2010.206535%5D%2C%20%5B-8.335377%2C%2010.494812%5D%2C%20%5B-8.282357%2C%2010.792597%5D%2C%20%5B-8.407311%2C%2010.909257%5D%2C%20%5B-8.620321%2C%2010.810891%5D%2C%20%5B-8.581305%2C%2011.136246%5D%2C%20%5B-8.376305%2C%2011.393646%5D%2C%20%5B-8.786099%2C%2011.812561%5D%2C%20%5B-8.905265%2C%2012.088358%5D%2C%20%5B-9.127474%2C%2012.30806%5D%2C%20%5B-9.327616%2C%2012.334286%5D%2C%20%5B-9.567912%2C%2012.194243%5D%2C%20%5B-9.890993%2C%2012.060479%5D%2C%20%5B-10.165214%2C%2011.844084%5D%2C%20%5B-10.593224%2C%2011.923975%5D%2C%20%5B-10.87083%2C%2012.177887%5D%2C%20%5B-11.036556%2C%2012.211245%5D%2C%20%5B-11.297574%2C%2012.077971%5D%2C%20%5B-11.456169%2C%2012.076834%5D%2C%20%5B-11.513943%2C%2012.442988%5D%2C%20%5B-11.467899%2C%2012.754519%5D%2C%20%5B-11.553398%2C%2013.141214%5D%2C%20%5B-11.927716%2C%2013.422075%5D%2C%20%5B-12.124887%2C%2013.994727%5D%2C%20%5B-12.17075%2C%2014.616834%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22MLI%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Mali%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B99.543309%2C%2020.186598%5D%2C%20%5B98.959676%2C%2019.752981%5D%2C%20%5B98.253724%2C%2019.708203%5D%2C%20%5B97.797783%2C%2018.62708%5D%2C%20%5B97.375896%2C%2018.445438%5D%2C%20%5B97.859123%2C%2017.567946%5D%2C%20%5B98.493761%2C%2016.837836%5D%2C%20%5B98.903348%2C%2016.177824%5D%2C%20%5B98.537376%2C%2015.308497%5D%2C%20%5B98.192074%2C%2015.123703%5D%2C%20%5B98.430819%2C%2014.622028%5D%2C%20%5B99.097755%2C%2013.827503%5D%2C%20%5B99.212012%2C%2013.269294%5D%2C%20%5B99.196354%2C%2012.804748%5D%2C%20%5B99.587286%2C%2011.892763%5D%2C%20%5B99.038121%2C%2010.960546%5D%2C%20%5B98.553551%2C%209.93296%5D%2C%20%5B98.457174%2C%2010.675266%5D%2C%20%5B98.764546%2C%2011.441292%5D%2C%20%5B98.428339%2C%2012.032987%5D%2C%20%5B98.509574%2C%2013.122378%5D%2C%20%5B98.103604%2C%2013.64046%5D%2C%20%5B97.777732%2C%2014.837286%5D%2C%20%5B97.597072%2C%2016.100568%5D%2C%20%5B97.16454%2C%2016.928734%5D%2C%20%5B96.505769%2C%2016.427241%5D%2C%20%5B95.369352%2C%2015.71439%5D%2C%20%5B94.808405%2C%2015.803454%5D%2C%20%5B94.188804%2C%2016.037936%5D%2C%20%5B94.533486%2C%2017.27724%5D%2C%20%5B94.324817%2C%2018.213514%5D%2C%20%5B93.540988%2C%2019.366493%5D%2C%20%5B93.663255%2C%2019.726962%5D%2C%20%5B93.078278%2C%2019.855145%5D%2C%20%5B92.368554%2C%2020.670883%5D%2C%20%5B92.303234%2C%2021.475485%5D%2C%20%5B92.652257%2C%2021.324048%5D%2C%20%5B92.672721%2C%2022.041239%5D%2C%20%5B93.166128%2C%2022.27846%5D%2C%20%5B93.060294%2C%2022.703111%5D%2C%20%5B93.286327%2C%2023.043658%5D%2C%20%5B93.325188%2C%2024.078556%5D%2C%20%5B94.106742%2C%2023.850741%5D%2C%20%5B94.552658%2C%2024.675238%5D%2C%20%5B94.603249%2C%2025.162495%5D%2C%20%5B95.155153%2C%2026.001307%5D%2C%20%5B95.124768%2C%2026.573572%5D%2C%20%5B96.419366%2C%2027.264589%5D%2C%20%5B97.133999%2C%2027.083774%5D%2C%20%5B97.051989%2C%2027.699059%5D%2C%20%5B97.402561%2C%2027.882536%5D%2C%20%5B97.327114%2C%2028.261583%5D%2C%20%5B97.911988%2C%2028.335945%5D%2C%20%5B98.246231%2C%2027.747221%5D%2C%20%5B98.68269%2C%2027.508812%5D%2C%20%5B98.712094%2C%2026.743536%5D%2C%20%5B98.671838%2C%2025.918703%5D%2C%20%5B97.724609%2C%2025.083637%5D%2C%20%5B97.60472%2C%2023.897405%5D%2C%20%5B98.660262%2C%2024.063286%5D%2C%20%5B98.898749%2C%2023.142722%5D%2C%20%5B99.531992%2C%2022.949039%5D%2C%20%5B99.240899%2C%2022.118314%5D%2C%20%5B99.983489%2C%2021.742937%5D%2C%20%5B100.416538%2C%2021.558839%5D%2C%20%5B101.150033%2C%2021.849984%5D%2C%20%5B101.180005%2C%2021.436573%5D%2C%20%5B100.329101%2C%2020.786122%5D%2C%20%5B100.115988%2C%2020.41785%5D%2C%20%5B99.543309%2C%2020.186598%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22MMR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Myanmar%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B19.801613%2C%2042.500093%5D%2C%20%5B19.738051%2C%2042.688247%5D%2C%20%5B19.30449%2C%2042.19574%5D%2C%20%5B19.37177%2C%2041.87755%5D%2C%20%5B19.16246%2C%2041.95502%5D%2C%20%5B18.88214%2C%2042.28151%5D%2C%20%5B18.45%2C%2042.48%5D%2C%20%5B18.56%2C%2042.65%5D%2C%20%5B18.70648%2C%2043.20011%5D%2C%20%5B19.03165%2C%2043.43253%5D%2C%20%5B19.21852%2C%2043.52384%5D%2C%20%5B19.48389%2C%2043.35229%5D%2C%20%5B19.63%2C%2043.21378%5D%2C%20%5B19.95857%2C%2043.10604%5D%2C%20%5B20.3398%2C%2042.89852%5D%2C%20%5B20.25758%2C%2042.81275%5D%2C%20%5B20.0707%2C%2042.58863%5D%2C%20%5B19.801613%2C%2042.500093%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22MNE%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Montenegro%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B87.751264%2C%2049.297198%5D%2C%20%5B88.805567%2C%2049.470521%5D%2C%20%5B90.713667%2C%2050.331812%5D%2C%20%5B92.234712%2C%2050.802171%5D%2C%20%5B93.104219%2C%2050.49529%5D%2C%20%5B94.147566%2C%2050.480537%5D%2C%20%5B94.815949%2C%2050.013433%5D%2C%20%5B95.814028%2C%2049.977467%5D%2C%20%5B97.259728%2C%2049.726061%5D%2C%20%5B98.231762%2C%2050.422401%5D%2C%20%5B97.82574%2C%2051.010995%5D%2C%20%5B98.861491%2C%2052.047366%5D%2C%20%5B99.981732%2C%2051.634006%5D%2C%20%5B100.88948%2C%2051.516856%5D%2C%20%5B102.065223%2C%2051.259921%5D%2C%20%5B102.255909%2C%2050.510561%5D%2C%20%5B103.676545%2C%2050.089966%5D%2C%20%5B104.621552%2C%2050.275329%5D%2C%20%5B105.886591%2C%2050.406019%5D%2C%20%5B106.888804%2C%2050.274296%5D%2C%20%5B107.868176%2C%2049.793705%5D%2C%20%5B108.475167%2C%2049.282548%5D%2C%20%5B109.402449%2C%2049.292961%5D%2C%20%5B110.662011%2C%2049.130128%5D%2C%20%5B111.581231%2C%2049.377968%5D%2C%20%5B112.89774%2C%2049.543565%5D%2C%20%5B114.362456%2C%2050.248303%5D%2C%20%5B114.96211%2C%2050.140247%5D%2C%20%5B115.485695%2C%2049.805177%5D%2C%20%5B116.678801%2C%2049.888531%5D%2C%20%5B116.191802%2C%2049.134598%5D%2C%20%5B115.485282%2C%2048.135383%5D%2C%20%5B115.742837%2C%2047.726545%5D%2C%20%5B116.308953%2C%2047.85341%5D%2C%20%5B117.295507%2C%2047.697709%5D%2C%20%5B118.064143%2C%2048.06673%5D%2C%20%5B118.866574%2C%2047.74706%5D%2C%20%5B119.772824%2C%2047.048059%5D%2C%20%5B119.66327%2C%2046.69268%5D%2C%20%5B118.874326%2C%2046.805412%5D%2C%20%5B117.421701%2C%2046.672733%5D%2C%20%5B116.717868%2C%2046.388202%5D%2C%20%5B115.985096%2C%2045.727235%5D%2C%20%5B114.460332%2C%2045.339817%5D%2C%20%5B113.463907%2C%2044.808893%5D%2C%20%5B112.436062%2C%2045.011646%5D%2C%20%5B111.873306%2C%2045.102079%5D%2C%20%5B111.348377%2C%2044.457442%5D%2C%20%5B111.667737%2C%2044.073176%5D%2C%20%5B111.829588%2C%2043.743118%5D%2C%20%5B111.129682%2C%2043.406834%5D%2C%20%5B110.412103%2C%2042.871234%5D%2C%20%5B109.243596%2C%2042.519446%5D%2C%20%5B107.744773%2C%2042.481516%5D%2C%20%5B106.129316%2C%2042.134328%5D%2C%20%5B104.964994%2C%2041.59741%5D%2C%20%5B104.522282%2C%2041.908347%5D%2C%20%5B103.312278%2C%2041.907468%5D%2C%20%5B101.83304%2C%2042.514873%5D%2C%20%5B100.845866%2C%2042.663804%5D%2C%20%5B99.515817%2C%2042.524691%5D%2C%20%5B97.451757%2C%2042.74889%5D%2C%20%5B96.349396%2C%2042.725635%5D%2C%20%5B95.762455%2C%2043.319449%5D%2C%20%5B95.306875%2C%2044.241331%5D%2C%20%5B94.688929%2C%2044.352332%5D%2C%20%5B93.480734%2C%2044.975472%5D%2C%20%5B92.133891%2C%2045.115076%5D%2C%20%5B90.94554%2C%2045.286073%5D%2C%20%5B90.585768%2C%2045.719716%5D%2C%20%5B90.970809%2C%2046.888146%5D%2C%20%5B90.280826%2C%2047.693549%5D%2C%20%5B88.854298%2C%2048.069082%5D%2C%20%5B88.013832%2C%2048.599463%5D%2C%20%5B87.751264%2C%2049.297198%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22MNG%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Mongolia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B34.559989%2C%20-11.52002%5D%2C%20%5B35.312398%2C%20-11.439146%5D%2C%20%5B36.514082%2C%20-11.720938%5D%2C%20%5B36.775151%2C%20-11.594537%5D%2C%20%5B37.471284%2C%20-11.568751%5D%2C%20%5B37.827645%2C%20-11.268769%5D%2C%20%5B38.427557%2C%20-11.285202%5D%2C%20%5B39.52103%2C%20-10.896854%5D%2C%20%5B40.316589%2C%20-10.317096%5D%2C%20%5B40.478387%2C%20-10.765441%5D%2C%20%5B40.437253%2C%20-11.761711%5D%2C%20%5B40.560811%2C%20-12.639177%5D%2C%20%5B40.59962%2C%20-14.201975%5D%2C%20%5B40.775475%2C%20-14.691764%5D%2C%20%5B40.477251%2C%20-15.406294%5D%2C%20%5B40.089264%2C%20-16.100774%5D%2C%20%5B39.452559%2C%20-16.720891%5D%2C%20%5B38.538351%2C%20-17.101023%5D%2C%20%5B37.411133%2C%20-17.586368%5D%2C%20%5B36.281279%2C%20-18.659688%5D%2C%20%5B35.896497%2C%20-18.84226%5D%2C%20%5B35.1984%2C%20-19.552811%5D%2C%20%5B34.786383%2C%20-19.784012%5D%2C%20%5B34.701893%2C%20-20.497043%5D%2C%20%5B35.176127%2C%20-21.254361%5D%2C%20%5B35.373428%2C%20-21.840837%5D%2C%20%5B35.385848%2C%20-22.14%5D%2C%20%5B35.562546%2C%20-22.09%5D%2C%20%5B35.533935%2C%20-23.070788%5D%2C%20%5B35.371774%2C%20-23.535359%5D%2C%20%5B35.60747%2C%20-23.706563%5D%2C%20%5B35.458746%2C%20-24.12261%5D%2C%20%5B35.040735%2C%20-24.478351%5D%2C%20%5B34.215824%2C%20-24.816314%5D%2C%20%5B33.01321%2C%20-25.357573%5D%2C%20%5B32.574632%2C%20-25.727318%5D%2C%20%5B32.660363%2C%20-26.148584%5D%2C%20%5B32.915955%2C%20-26.215867%5D%2C%20%5B32.83012%2C%20-26.742192%5D%2C%20%5B32.071665%2C%20-26.73382%5D%2C%20%5B31.985779%2C%20-26.29178%5D%2C%20%5B31.837778%2C%20-25.843332%5D%2C%20%5B31.752408%2C%20-25.484284%5D%2C%20%5B31.930589%2C%20-24.369417%5D%2C%20%5B31.670398%2C%20-23.658969%5D%2C%20%5B31.191409%2C%20-22.25151%5D%2C%20%5B32.244988%2C%20-21.116489%5D%2C%20%5B32.508693%2C%20-20.395292%5D%2C%20%5B32.659743%2C%20-20.30429%5D%2C%20%5B32.772708%2C%20-19.715592%5D%2C%20%5B32.611994%2C%20-19.419383%5D%2C%20%5B32.654886%2C%20-18.67209%5D%2C%20%5B32.849861%2C%20-17.979057%5D%2C%20%5B32.847639%2C%20-16.713398%5D%2C%20%5B32.328239%2C%20-16.392074%5D%2C%20%5B31.852041%2C%20-16.319417%5D%2C%20%5B31.636498%2C%20-16.07199%5D%2C%20%5B31.173064%2C%20-15.860944%5D%2C%20%5B30.338955%2C%20-15.880839%5D%2C%20%5B30.274256%2C%20-15.507787%5D%2C%20%5B30.179481%2C%20-14.796099%5D%2C%20%5B33.214025%2C%20-13.97186%5D%2C%20%5B33.7897%2C%20-14.451831%5D%2C%20%5B34.064825%2C%20-14.35995%5D%2C%20%5B34.459633%2C%20-14.61301%5D%2C%20%5B34.517666%2C%20-15.013709%5D%2C%20%5B34.307291%2C%20-15.478641%5D%2C%20%5B34.381292%2C%20-16.18356%5D%2C%20%5B35.03381%2C%20-16.8013%5D%2C%20%5B35.339063%2C%20-16.10744%5D%2C%20%5B35.771905%2C%20-15.896859%5D%2C%20%5B35.686845%2C%20-14.611046%5D%2C%20%5B35.267956%2C%20-13.887834%5D%2C%20%5B34.907151%2C%20-13.565425%5D%2C%20%5B34.559989%2C%20-13.579998%5D%2C%20%5B34.280006%2C%20-12.280025%5D%2C%20%5B34.559989%2C%20-11.52002%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22MOZ%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Mozambique%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-12.17075%2C%2014.616834%5D%2C%20%5B-12.830658%2C%2015.303692%5D%2C%20%5B-13.435738%2C%2016.039383%5D%2C%20%5B-14.099521%2C%2016.304302%5D%2C%20%5B-14.577348%2C%2016.598264%5D%2C%20%5B-15.135737%2C%2016.587282%5D%2C%20%5B-15.623666%2C%2016.369337%5D%2C%20%5B-16.12069%2C%2016.455663%5D%2C%20%5B-16.463098%2C%2016.135036%5D%2C%20%5B-16.549708%2C%2016.673892%5D%2C%20%5B-16.270552%2C%2017.166963%5D%2C%20%5B-16.146347%2C%2018.108482%5D%2C%20%5B-16.256883%2C%2019.096716%5D%2C%20%5B-16.377651%2C%2019.593817%5D%2C%20%5B-16.277838%2C%2020.092521%5D%2C%20%5B-16.536324%2C%2020.567866%5D%2C%20%5B-17.063423%2C%2020.999752%5D%2C%20%5B-16.845194%2C%2021.333323%5D%2C%20%5B-12.929102%2C%2021.327071%5D%2C%20%5B-13.118754%2C%2022.77122%5D%2C%20%5B-12.874222%2C%2023.284832%5D%2C%20%5B-11.937224%2C%2023.374594%5D%2C%20%5B-11.969419%2C%2025.933353%5D%2C%20%5B-8.687294%2C%2025.881056%5D%2C%20%5B-8.6844%2C%2027.395744%5D%2C%20%5B-4.923337%2C%2024.974574%5D%2C%20%5B-6.453787%2C%2024.956591%5D%2C%20%5B-5.971129%2C%2020.640833%5D%2C%20%5B-5.488523%2C%2016.325102%5D%2C%20%5B-5.315277%2C%2016.201854%5D%2C%20%5B-5.537744%2C%2015.50169%5D%2C%20%5B-9.550238%2C%2015.486497%5D%2C%20%5B-9.700255%2C%2015.264107%5D%2C%20%5B-10.086846%2C%2015.330486%5D%2C%20%5B-10.650791%2C%2015.132746%5D%2C%20%5B-11.349095%2C%2015.411256%5D%2C%20%5B-11.666078%2C%2015.388208%5D%2C%20%5B-11.834208%2C%2014.799097%5D%2C%20%5B-12.17075%2C%2014.616834%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22MRT%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Mauritania%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B34.559989%2C%20-11.52002%5D%2C%20%5B34.280006%2C%20-12.280025%5D%2C%20%5B34.559989%2C%20-13.579998%5D%2C%20%5B34.907151%2C%20-13.565425%5D%2C%20%5B35.267956%2C%20-13.887834%5D%2C%20%5B35.686845%2C%20-14.611046%5D%2C%20%5B35.771905%2C%20-15.896859%5D%2C%20%5B35.339063%2C%20-16.10744%5D%2C%20%5B35.03381%2C%20-16.8013%5D%2C%20%5B34.381292%2C%20-16.18356%5D%2C%20%5B34.307291%2C%20-15.478641%5D%2C%20%5B34.517666%2C%20-15.013709%5D%2C%20%5B34.459633%2C%20-14.61301%5D%2C%20%5B34.064825%2C%20-14.35995%5D%2C%20%5B33.7897%2C%20-14.451831%5D%2C%20%5B33.214025%2C%20-13.97186%5D%2C%20%5B32.688165%2C%20-13.712858%5D%2C%20%5B32.991764%2C%20-12.783871%5D%2C%20%5B33.306422%2C%20-12.435778%5D%2C%20%5B33.114289%2C%20-11.607198%5D%2C%20%5B33.31531%2C%20-10.79655%5D%2C%20%5B33.485688%2C%20-10.525559%5D%2C%20%5B33.231388%2C%20-9.676722%5D%2C%20%5B32.759375%2C%20-9.230599%5D%2C%20%5B33.739729%2C%20-9.417151%5D%2C%20%5B33.940838%2C%20-9.693674%5D%2C%20%5B34.280006%2C%20-10.16%5D%2C%20%5B34.559989%2C%20-11.52002%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22MWI%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Malawi%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B101.075516%2C%206.204867%5D%2C%20%5B101.154219%2C%205.691384%5D%2C%20%5B101.814282%2C%205.810808%5D%2C%20%5B102.141187%2C%206.221636%5D%2C%20%5B102.371147%2C%206.128205%5D%2C%20%5B102.961705%2C%205.524495%5D%2C%20%5B103.381215%2C%204.855001%5D%2C%20%5B103.438575%2C%204.181606%5D%2C%20%5B103.332122%2C%203.726698%5D%2C%20%5B103.429429%2C%203.382869%5D%2C%20%5B103.502448%2C%202.791019%5D%2C%20%5B103.854674%2C%202.515454%5D%2C%20%5B104.247932%2C%201.631141%5D%2C%20%5B104.228811%2C%201.293048%5D%2C%20%5B103.519707%2C%201.226334%5D%2C%20%5B102.573615%2C%201.967115%5D%2C%20%5B101.390638%2C%202.760814%5D%2C%20%5B101.27354%2C%203.270292%5D%2C%20%5B100.695435%2C%203.93914%5D%2C%20%5B100.557408%2C%204.76728%5D%2C%20%5B100.196706%2C%205.312493%5D%2C%20%5B100.30626%2C%206.040562%5D%2C%20%5B100.085757%2C%206.464489%5D%2C%20%5B100.259596%2C%206.642825%5D%2C%20%5B101.075516%2C%206.204867%5D%5D%5D%2C%20%5B%5B%5B118.618321%2C%204.478202%5D%2C%20%5B117.882035%2C%204.137551%5D%2C%20%5B117.015214%2C%204.306094%5D%2C%20%5B115.865517%2C%204.306559%5D%2C%20%5B115.519078%2C%203.169238%5D%2C%20%5B115.134037%2C%202.821482%5D%2C%20%5B114.621355%2C%201.430688%5D%2C%20%5B113.80585%2C%201.217549%5D%2C%20%5B112.859809%2C%201.49779%5D%2C%20%5B112.380252%2C%201.410121%5D%2C%20%5B111.797548%2C%200.904441%5D%2C%20%5B111.159138%2C%200.976478%5D%2C%20%5B110.514061%2C%200.773131%5D%2C%20%5B109.830227%2C%201.338136%5D%2C%20%5B109.66326%2C%202.006467%5D%2C%20%5B110.396135%2C%201.663775%5D%2C%20%5B111.168853%2C%201.850637%5D%2C%20%5B111.370081%2C%202.697303%5D%2C%20%5B111.796928%2C%202.885897%5D%2C%20%5B112.995615%2C%203.102395%5D%2C%20%5B113.712935%2C%203.893509%5D%2C%20%5B114.204017%2C%204.525874%5D%2C%20%5B114.659596%2C%204.007637%5D%2C%20%5B114.869557%2C%204.348314%5D%2C%20%5B115.347461%2C%204.316636%5D%2C%20%5B115.4057%2C%204.955228%5D%2C%20%5B115.45071%2C%205.44773%5D%2C%20%5B116.220741%2C%206.143191%5D%2C%20%5B116.725103%2C%206.924771%5D%2C%20%5B117.129626%2C%206.928053%5D%2C%20%5B117.643393%2C%206.422166%5D%2C%20%5B117.689075%2C%205.98749%5D%2C%20%5B118.347691%2C%205.708696%5D%2C%20%5B119.181904%2C%205.407836%5D%2C%20%5B119.110694%2C%205.016128%5D%2C%20%5B118.439727%2C%204.966519%5D%2C%20%5B118.618321%2C%204.478202%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22MYS%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Malaysia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B16.344977%2C%20-28.576705%5D%2C%20%5B15.601818%2C%20-27.821247%5D%2C%20%5B15.210472%2C%20-27.090956%5D%2C%20%5B14.989711%2C%20-26.117372%5D%2C%20%5B14.743214%2C%20-25.39292%5D%2C%20%5B14.408144%2C%20-23.853014%5D%2C%20%5B14.385717%2C%20-22.656653%5D%2C%20%5B14.257714%2C%20-22.111208%5D%2C%20%5B13.868642%2C%20-21.699037%5D%2C%20%5B13.352498%2C%20-20.872834%5D%2C%20%5B12.826845%2C%20-19.673166%5D%2C%20%5B12.608564%2C%20-19.045349%5D%2C%20%5B11.794919%2C%20-18.069129%5D%2C%20%5B11.734199%2C%20-17.301889%5D%2C%20%5B12.215461%2C%20-17.111668%5D%2C%20%5B12.814081%2C%20-16.941343%5D%2C%20%5B13.462362%2C%20-16.971212%5D%2C%20%5B14.058501%2C%20-17.423381%5D%2C%20%5B14.209707%2C%20-17.353101%5D%2C%20%5B18.263309%2C%20-17.309951%5D%2C%20%5B18.956187%2C%20-17.789095%5D%2C%20%5B21.377176%2C%20-17.930636%5D%2C%20%5B23.215048%2C%20-17.523116%5D%2C%20%5B24.033862%2C%20-17.295843%5D%2C%20%5B24.682349%2C%20-17.353411%5D%2C%20%5B25.07695%2C%20-17.578823%5D%2C%20%5B25.084443%2C%20-17.661816%5D%2C%20%5B24.520705%2C%20-17.887125%5D%2C%20%5B24.217365%2C%20-17.889347%5D%2C%20%5B23.579006%2C%20-18.281261%5D%2C%20%5B23.196858%2C%20-17.869038%5D%2C%20%5B21.65504%2C%20-18.219146%5D%2C%20%5B20.910641%2C%20-18.252219%5D%2C%20%5B20.881134%2C%20-21.814327%5D%2C%20%5B19.895458%2C%20-21.849157%5D%2C%20%5B19.895768%2C%20-24.76779%5D%2C%20%5B19.894734%2C%20-28.461105%5D%2C%20%5B19.002127%2C%20-28.972443%5D%2C%20%5B18.464899%2C%20-29.045462%5D%2C%20%5B17.836152%2C%20-28.856378%5D%2C%20%5B17.387497%2C%20-28.783514%5D%2C%20%5B17.218929%2C%20-28.355943%5D%2C%20%5B16.824017%2C%20-28.082162%5D%2C%20%5B16.344977%2C%20-28.576705%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22NAM%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Namibia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B165.77999%2C%20-21.080005%5D%2C%20%5B166.599991%2C%20-21.700019%5D%2C%20%5B167.120011%2C%20-22.159991%5D%2C%20%5B166.740035%2C%20-22.399976%5D%2C%20%5B166.189732%2C%20-22.129708%5D%2C%20%5B165.474375%2C%20-21.679607%5D%2C%20%5B164.829815%2C%20-21.14982%5D%2C%20%5B164.167995%2C%20-20.444747%5D%2C%20%5B164.029606%2C%20-20.105646%5D%2C%20%5B164.459967%2C%20-20.120012%5D%2C%20%5B165.020036%2C%20-20.459991%5D%2C%20%5B165.460009%2C%20-20.800022%5D%2C%20%5B165.77999%2C%20-21.080005%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22NCL%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22New%20Caledonia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B2.154474%2C%2011.94015%5D%2C%20%5B2.177108%2C%2012.625018%5D%2C%20%5B1.024103%2C%2012.851826%5D%2C%20%5B0.993046%2C%2013.33575%5D%2C%20%5B0.429928%2C%2013.988733%5D%2C%20%5B0.295646%2C%2014.444235%5D%2C%20%5B0.374892%2C%2014.928908%5D%2C%20%5B1.015783%2C%2014.968182%5D%2C%20%5B1.385528%2C%2015.323561%5D%2C%20%5B2.749993%2C%2015.409525%5D%2C%20%5B3.638259%2C%2015.56812%5D%2C%20%5B3.723422%2C%2016.184284%5D%2C%20%5B4.27021%2C%2016.852227%5D%2C%20%5B4.267419%2C%2019.155265%5D%2C%20%5B5.677566%2C%2019.601207%5D%2C%20%5B8.572893%2C%2021.565661%5D%2C%20%5B11.999506%2C%2023.471668%5D%2C%20%5B13.581425%2C%2023.040506%5D%2C%20%5B14.143871%2C%2022.491289%5D%2C%20%5B14.8513%2C%2022.86295%5D%2C%20%5B15.096888%2C%2021.308519%5D%2C%20%5B15.471077%2C%2021.048457%5D%2C%20%5B15.487148%2C%2020.730415%5D%2C%20%5B15.903247%2C%2020.387619%5D%2C%20%5B15.685741%2C%2019.95718%5D%2C%20%5B15.300441%2C%2017.92795%5D%2C%20%5B15.247731%2C%2016.627306%5D%2C%20%5B13.972202%2C%2015.684366%5D%2C%20%5B13.540394%2C%2014.367134%5D%2C%20%5B13.956699%2C%2013.996691%5D%2C%20%5B13.954477%2C%2013.353449%5D%2C%20%5B14.595781%2C%2013.330427%5D%2C%20%5B14.495787%2C%2012.859396%5D%2C%20%5B14.213531%2C%2012.802035%5D%2C%20%5B14.181336%2C%2012.483657%5D%2C%20%5B13.995353%2C%2012.461565%5D%2C%20%5B13.318702%2C%2013.556356%5D%2C%20%5B13.083987%2C%2013.596147%5D%2C%20%5B12.302071%2C%2013.037189%5D%2C%20%5B11.527803%2C%2013.32898%5D%2C%20%5B10.989593%2C%2013.387323%5D%2C%20%5B10.701032%2C%2013.246918%5D%2C%20%5B10.114814%2C%2013.277252%5D%2C%20%5B9.524928%2C%2012.851102%5D%2C%20%5B9.014933%2C%2012.826659%5D%2C%20%5B7.804671%2C%2013.343527%5D%2C%20%5B7.330747%2C%2013.098038%5D%2C%20%5B6.820442%2C%2013.115091%5D%2C%20%5B6.445426%2C%2013.492768%5D%2C%20%5B5.443058%2C%2013.865924%5D%2C%20%5B4.368344%2C%2013.747482%5D%2C%20%5B4.107946%2C%2013.531216%5D%2C%20%5B3.967283%2C%2012.956109%5D%2C%20%5B3.680634%2C%2012.552903%5D%2C%20%5B3.61118%2C%2011.660167%5D%2C%20%5B2.848643%2C%2012.235636%5D%2C%20%5B2.490164%2C%2012.233052%5D%2C%20%5B2.154474%2C%2011.94015%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22NER%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Niger%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B8.500288%2C%204.771983%5D%2C%20%5B7.462108%2C%204.412108%5D%2C%20%5B7.082596%2C%204.464689%5D%2C%20%5B6.698072%2C%204.240594%5D%2C%20%5B5.898173%2C%204.262453%5D%2C%20%5B5.362805%2C%204.887971%5D%2C%20%5B5.033574%2C%205.611802%5D%2C%20%5B4.325607%2C%206.270651%5D%2C%20%5B3.57418%2C%206.2583%5D%2C%20%5B2.691702%2C%206.258817%5D%2C%20%5B2.749063%2C%207.870734%5D%2C%20%5B2.723793%2C%208.506845%5D%2C%20%5B2.912308%2C%209.137608%5D%2C%20%5B3.220352%2C%209.444153%5D%2C%20%5B3.705438%2C%2010.06321%5D%2C%20%5B3.60007%2C%2010.332186%5D%2C%20%5B3.797112%2C%2010.734746%5D%2C%20%5B3.572216%2C%2011.327939%5D%2C%20%5B3.61118%2C%2011.660167%5D%2C%20%5B3.680634%2C%2012.552903%5D%2C%20%5B3.967283%2C%2012.956109%5D%2C%20%5B4.107946%2C%2013.531216%5D%2C%20%5B4.368344%2C%2013.747482%5D%2C%20%5B5.443058%2C%2013.865924%5D%2C%20%5B6.445426%2C%2013.492768%5D%2C%20%5B6.820442%2C%2013.115091%5D%2C%20%5B7.330747%2C%2013.098038%5D%2C%20%5B7.804671%2C%2013.343527%5D%2C%20%5B9.014933%2C%2012.826659%5D%2C%20%5B9.524928%2C%2012.851102%5D%2C%20%5B10.114814%2C%2013.277252%5D%2C%20%5B10.701032%2C%2013.246918%5D%2C%20%5B10.989593%2C%2013.387323%5D%2C%20%5B11.527803%2C%2013.32898%5D%2C%20%5B12.302071%2C%2013.037189%5D%2C%20%5B13.083987%2C%2013.596147%5D%2C%20%5B13.318702%2C%2013.556356%5D%2C%20%5B13.995353%2C%2012.461565%5D%2C%20%5B14.181336%2C%2012.483657%5D%2C%20%5B14.577178%2C%2012.085361%5D%2C%20%5B14.468192%2C%2011.904752%5D%2C%20%5B14.415379%2C%2011.572369%5D%2C%20%5B13.57295%2C%2010.798566%5D%2C%20%5B13.308676%2C%2010.160362%5D%2C%20%5B13.1676%2C%209.640626%5D%2C%20%5B12.955468%2C%209.417772%5D%2C%20%5B12.753672%2C%208.717763%5D%2C%20%5B12.218872%2C%208.305824%5D%2C%20%5B12.063946%2C%207.799808%5D%2C%20%5B11.839309%2C%207.397042%5D%2C%20%5B11.745774%2C%206.981383%5D%2C%20%5B11.058788%2C%206.644427%5D%2C%20%5B10.497375%2C%207.055358%5D%2C%20%5B10.118277%2C%207.03877%5D%2C%20%5B9.522706%2C%206.453482%5D%2C%20%5B9.233163%2C%206.444491%5D%2C%20%5B8.757533%2C%205.479666%5D%2C%20%5B8.500288%2C%204.771983%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22NGA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Nigeria%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-85.71254%2C%2011.088445%5D%2C%20%5B-86.058488%2C%2011.403439%5D%2C%20%5B-86.52585%2C%2011.806877%5D%2C%20%5B-86.745992%2C%2012.143962%5D%2C%20%5B-87.167516%2C%2012.458258%5D%2C%20%5B-87.668493%2C%2012.90991%5D%2C%20%5B-87.557467%2C%2013.064552%5D%2C%20%5B-87.392386%2C%2012.914018%5D%2C%20%5B-87.316654%2C%2012.984686%5D%2C%20%5B-87.005769%2C%2013.025794%5D%2C%20%5B-86.880557%2C%2013.254204%5D%2C%20%5B-86.733822%2C%2013.263093%5D%2C%20%5B-86.755087%2C%2013.754845%5D%2C%20%5B-86.520708%2C%2013.778487%5D%2C%20%5B-86.312142%2C%2013.771356%5D%2C%20%5B-86.096264%2C%2014.038187%5D%2C%20%5B-85.801295%2C%2013.836055%5D%2C%20%5B-85.698665%2C%2013.960078%5D%2C%20%5B-85.514413%2C%2014.079012%5D%2C%20%5B-85.165365%2C%2014.35437%5D%2C%20%5B-85.148751%2C%2014.560197%5D%2C%20%5B-85.052787%2C%2014.551541%5D%2C%20%5B-84.924501%2C%2014.790493%5D%2C%20%5B-84.820037%2C%2014.819587%5D%2C%20%5B-84.649582%2C%2014.666805%5D%2C%20%5B-84.449336%2C%2014.621614%5D%2C%20%5B-84.228342%2C%2014.748764%5D%2C%20%5B-83.975721%2C%2014.749436%5D%2C%20%5B-83.628585%2C%2014.880074%5D%2C%20%5B-83.489989%2C%2015.016267%5D%2C%20%5B-83.147219%2C%2014.995829%5D%2C%20%5B-83.233234%2C%2014.899866%5D%2C%20%5B-83.284162%2C%2014.676624%5D%2C%20%5B-83.182126%2C%2014.310703%5D%2C%20%5B-83.4125%2C%2013.970078%5D%2C%20%5B-83.519832%2C%2013.567699%5D%2C%20%5B-83.552207%2C%2013.127054%5D%2C%20%5B-83.498515%2C%2012.869292%5D%2C%20%5B-83.473323%2C%2012.419087%5D%2C%20%5B-83.626104%2C%2012.32085%5D%2C%20%5B-83.719613%2C%2011.893124%5D%2C%20%5B-83.650858%2C%2011.629032%5D%2C%20%5B-83.85547%2C%2011.373311%5D%2C%20%5B-83.808936%2C%2011.103044%5D%2C%20%5B-83.655612%2C%2010.938764%5D%2C%20%5B-83.895054%2C%2010.726839%5D%2C%20%5B-84.190179%2C%2010.79345%5D%2C%20%5B-84.355931%2C%2010.999226%5D%2C%20%5B-84.673069%2C%2011.082657%5D%2C%20%5B-84.903003%2C%2010.952303%5D%2C%20%5B-85.561852%2C%2011.217119%5D%2C%20%5B-85.71254%2C%2011.088445%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22NIC%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Nicaragua%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B6.074183%2C%2053.510403%5D%2C%20%5B6.90514%2C%2053.482162%5D%2C%20%5B7.092053%2C%2053.144043%5D%2C%20%5B6.84287%2C%2052.22844%5D%2C%20%5B6.589397%2C%2051.852029%5D%2C%20%5B5.988658%2C%2051.851616%5D%2C%20%5B6.156658%2C%2050.803721%5D%2C%20%5B5.606976%2C%2051.037298%5D%2C%20%5B4.973991%2C%2051.475024%5D%2C%20%5B4.047071%2C%2051.267259%5D%2C%20%5B3.314971%2C%2051.345755%5D%2C%20%5B3.830289%2C%2051.620545%5D%2C%20%5B4.705997%2C%2053.091798%5D%2C%20%5B6.074183%2C%2053.510403%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22NLD%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Netherlands%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B28.165547%2C%2071.185474%5D%2C%20%5B31.293418%2C%2070.453788%5D%2C%20%5B30.005435%2C%2070.186259%5D%2C%20%5B31.101079%2C%2069.55808%5D%2C%20%5B29.399581%2C%2069.156916%5D%2C%20%5B28.59193%2C%2069.064777%5D%2C%20%5B29.015573%2C%2069.766491%5D%2C%20%5B27.732292%2C%2070.164193%5D%2C%20%5B26.179622%2C%2069.825299%5D%2C%20%5B25.689213%2C%2069.092114%5D%2C%20%5B24.735679%2C%2068.649557%5D%2C%20%5B23.66205%2C%2068.891247%5D%2C%20%5B22.356238%2C%2068.841741%5D%2C%20%5B21.244936%2C%2069.370443%5D%2C%20%5B20.645593%2C%2069.106247%5D%2C%20%5B20.025269%2C%2069.065139%5D%2C%20%5B19.87856%2C%2068.407194%5D%2C%20%5B17.993868%2C%2068.567391%5D%2C%20%5B17.729182%2C%2068.010552%5D%2C%20%5B16.768879%2C%2068.013937%5D%2C%20%5B16.108712%2C%2067.302456%5D%2C%20%5B15.108411%2C%2066.193867%5D%2C%20%5B13.55569%2C%2064.787028%5D%2C%20%5B13.919905%2C%2064.445421%5D%2C%20%5B13.571916%2C%2064.049114%5D%2C%20%5B12.579935%2C%2064.066219%5D%2C%20%5B11.930569%2C%2063.128318%5D%2C%20%5B11.992064%2C%2061.800362%5D%2C%20%5B12.631147%2C%2061.293572%5D%2C%20%5B12.300366%2C%2060.117933%5D%2C%20%5B11.468272%2C%2059.432393%5D%2C%20%5B11.027369%2C%2058.856149%5D%2C%20%5B10.356557%2C%2059.469807%5D%2C%20%5B8.382%2C%2058.313288%5D%2C%20%5B7.048748%2C%2058.078884%5D%2C%20%5B5.665835%2C%2058.588155%5D%2C%20%5B5.308234%2C%2059.663232%5D%2C%20%5B4.992078%2C%2061.970998%5D%2C%20%5B5.9129%2C%2062.614473%5D%2C%20%5B8.553411%2C%2063.454008%5D%2C%20%5B10.527709%2C%2064.486038%5D%2C%20%5B12.358347%2C%2065.879726%5D%2C%20%5B14.761146%2C%2067.810642%5D%2C%20%5B16.435927%2C%2068.563205%5D%2C%20%5B19.184028%2C%2069.817444%5D%2C%20%5B21.378416%2C%2070.255169%5D%2C%20%5B23.023742%2C%2070.202072%5D%2C%20%5B24.546543%2C%2071.030497%5D%2C%20%5B26.37005%2C%2070.986262%5D%2C%20%5B28.165547%2C%2071.185474%5D%5D%5D%2C%20%5B%5B%5B24.72412%2C%2077.85385%5D%2C%20%5B22.49032%2C%2077.44493%5D%2C%20%5B20.72601%2C%2077.67704%5D%2C%20%5B21.41611%2C%2077.93504%5D%2C%20%5B20.8119%2C%2078.25463%5D%2C%20%5B22.88426%2C%2078.45494%5D%2C%20%5B23.28134%2C%2078.07954%5D%2C%20%5B24.72412%2C%2077.85385%5D%5D%5D%2C%20%5B%5B%5B18.25183%2C%2079.70175%5D%2C%20%5B21.54383%2C%2078.95611%5D%2C%20%5B19.02737%2C%2078.5626%5D%2C%20%5B18.47172%2C%2077.82669%5D%2C%20%5B17.59441%2C%2077.63796%5D%2C%20%5B17.1182%2C%2076.80941%5D%2C%20%5B15.91315%2C%2076.77045%5D%2C%20%5B13.76259%2C%2077.38035%5D%2C%20%5B14.66956%2C%2077.73565%5D%2C%20%5B13.1706%2C%2078.02493%5D%2C%20%5B11.22231%2C%2078.8693%5D%2C%20%5B10.44453%2C%2079.65239%5D%2C%20%5B13.17077%2C%2080.01046%5D%2C%20%5B13.71852%2C%2079.66039%5D%2C%20%5B15.14282%2C%2079.67431%5D%2C%20%5B15.52255%2C%2080.01608%5D%2C%20%5B16.99085%2C%2080.05086%5D%2C%20%5B18.25183%2C%2079.70175%5D%5D%5D%2C%20%5B%5B%5B25.447625%2C%2080.40734%5D%2C%20%5B27.407506%2C%2080.056406%5D%2C%20%5B25.924651%2C%2079.517834%5D%2C%20%5B23.024466%2C%2079.400012%5D%2C%20%5B20.075188%2C%2079.566823%5D%2C%20%5B19.897266%2C%2079.842362%5D%2C%20%5B18.462264%2C%2079.85988%5D%2C%20%5B17.368015%2C%2080.318896%5D%2C%20%5B20.455992%2C%2080.598156%5D%2C%20%5B21.907945%2C%2080.357679%5D%2C%20%5B22.919253%2C%2080.657144%5D%2C%20%5B25.447625%2C%2080.40734%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22NOR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Norway%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B88.120441%2C%2027.876542%5D%2C%20%5B88.043133%2C%2027.445819%5D%2C%20%5B88.174804%2C%2026.810405%5D%2C%20%5B88.060238%2C%2026.414615%5D%2C%20%5B87.227472%2C%2026.397898%5D%2C%20%5B86.024393%2C%2026.630985%5D%2C%20%5B85.251779%2C%2026.726198%5D%2C%20%5B84.675018%2C%2027.234901%5D%2C%20%5B83.304249%2C%2027.364506%5D%2C%20%5B81.999987%2C%2027.925479%5D%2C%20%5B81.057203%2C%2028.416095%5D%2C%20%5B80.088425%2C%2028.79447%5D%2C%20%5B80.476721%2C%2029.729865%5D%2C%20%5B81.111256%2C%2030.183481%5D%2C%20%5B81.525804%2C%2030.422717%5D%2C%20%5B82.327513%2C%2030.115268%5D%2C%20%5B83.337115%2C%2029.463732%5D%2C%20%5B83.898993%2C%2029.320226%5D%2C%20%5B84.23458%2C%2028.839894%5D%2C%20%5B85.011638%2C%2028.642774%5D%2C%20%5B85.82332%2C%2028.203576%5D%2C%20%5B86.954517%2C%2027.974262%5D%2C%20%5B88.120441%2C%2027.876542%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22NPL%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Nepal%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B173.020375%2C%20-40.919052%5D%2C%20%5B173.247234%2C%20-41.331999%5D%2C%20%5B173.958405%2C%20-40.926701%5D%2C%20%5B174.247587%2C%20-41.349155%5D%2C%20%5B174.248517%2C%20-41.770008%5D%2C%20%5B173.876447%2C%20-42.233184%5D%2C%20%5B173.22274%2C%20-42.970038%5D%2C%20%5B172.711246%2C%20-43.372288%5D%2C%20%5B173.080113%2C%20-43.853344%5D%2C%20%5B172.308584%2C%20-43.865694%5D%2C%20%5B171.452925%2C%20-44.242519%5D%2C%20%5B171.185138%2C%20-44.897104%5D%2C%20%5B170.616697%2C%20-45.908929%5D%2C%20%5B169.831422%2C%20-46.355775%5D%2C%20%5B169.332331%2C%20-46.641235%5D%2C%20%5B168.411354%2C%20-46.619945%5D%2C%20%5B167.763745%2C%20-46.290197%5D%2C%20%5B166.676886%2C%20-46.219917%5D%2C%20%5B166.509144%2C%20-45.852705%5D%2C%20%5B167.046424%2C%20-45.110941%5D%2C%20%5B168.303763%2C%20-44.123973%5D%2C%20%5B168.949409%2C%20-43.935819%5D%2C%20%5B169.667815%2C%20-43.555326%5D%2C%20%5B170.52492%2C%20-43.031688%5D%2C%20%5B171.12509%2C%20-42.512754%5D%2C%20%5B171.569714%2C%20-41.767424%5D%2C%20%5B171.948709%2C%20-41.514417%5D%2C%20%5B172.097227%2C%20-40.956104%5D%2C%20%5B172.79858%2C%20-40.493962%5D%2C%20%5B173.020375%2C%20-40.919052%5D%5D%5D%2C%20%5B%5B%5B174.612009%2C%20-36.156397%5D%2C%20%5B175.336616%2C%20-37.209098%5D%2C%20%5B175.357596%2C%20-36.526194%5D%2C%20%5B175.808887%2C%20-36.798942%5D%2C%20%5B175.95849%2C%20-37.555382%5D%2C%20%5B176.763195%2C%20-37.881253%5D%2C%20%5B177.438813%2C%20-37.961248%5D%2C%20%5B178.010354%2C%20-37.579825%5D%2C%20%5B178.517094%2C%20-37.695373%5D%2C%20%5B178.274731%2C%20-38.582813%5D%2C%20%5B177.97046%2C%20-39.166343%5D%2C%20%5B177.206993%2C%20-39.145776%5D%2C%20%5B176.939981%2C%20-39.449736%5D%2C%20%5B177.032946%2C%20-39.879943%5D%2C%20%5B176.885824%2C%20-40.065978%5D%2C%20%5B176.508017%2C%20-40.604808%5D%2C%20%5B176.01244%2C%20-41.289624%5D%2C%20%5B175.239567%2C%20-41.688308%5D%2C%20%5B175.067898%2C%20-41.425895%5D%2C%20%5B174.650973%2C%20-41.281821%5D%2C%20%5B175.22763%2C%20-40.459236%5D%2C%20%5B174.900157%2C%20-39.908933%5D%2C%20%5B173.824047%2C%20-39.508854%5D%2C%20%5B173.852262%2C%20-39.146602%5D%2C%20%5B174.574802%2C%20-38.797683%5D%2C%20%5B174.743474%2C%20-38.027808%5D%2C%20%5B174.697017%2C%20-37.381129%5D%2C%20%5B174.292028%2C%20-36.711092%5D%2C%20%5B174.319004%2C%20-36.534824%5D%2C%20%5B173.840997%2C%20-36.121981%5D%2C%20%5B173.054171%2C%20-35.237125%5D%2C%20%5B172.636005%2C%20-34.529107%5D%2C%20%5B173.007042%2C%20-34.450662%5D%2C%20%5B173.551298%2C%20-35.006183%5D%2C%20%5B174.32939%2C%20-35.265496%5D%2C%20%5B174.612009%2C%20-36.156397%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22NZL%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22New%20Zealand%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B58.861141%2C%2021.114035%5D%2C%20%5B58.487986%2C%2020.428986%5D%2C%20%5B58.034318%2C%2020.481437%5D%2C%20%5B57.826373%2C%2020.243002%5D%2C%20%5B57.665762%2C%2019.736005%5D%2C%20%5B57.7887%2C%2019.06757%5D%2C%20%5B57.694391%2C%2018.94471%5D%2C%20%5B57.234264%2C%2018.947991%5D%2C%20%5B56.609651%2C%2018.574267%5D%2C%20%5B56.512189%2C%2018.087113%5D%2C%20%5B56.283521%2C%2017.876067%5D%2C%20%5B55.661492%2C%2017.884128%5D%2C%20%5B55.269939%2C%2017.632309%5D%2C%20%5B55.2749%2C%2017.228354%5D%2C%20%5B54.791002%2C%2016.950697%5D%2C%20%5B54.239253%2C%2017.044981%5D%2C%20%5B53.570508%2C%2016.707663%5D%2C%20%5B53.108573%2C%2016.651051%5D%2C%20%5B52.782184%2C%2017.349742%5D%2C%20%5B52.00001%2C%2019.000003%5D%2C%20%5B54.999982%2C%2019.999994%5D%2C%20%5B55.666659%2C%2022.000001%5D%2C%20%5B55.208341%2C%2022.70833%5D%2C%20%5B55.234489%2C%2023.110993%5D%2C%20%5B55.525841%2C%2023.524869%5D%2C%20%5B55.528632%2C%2023.933604%5D%2C%20%5B55.981214%2C%2024.130543%5D%2C%20%5B55.804119%2C%2024.269604%5D%2C%20%5B55.886233%2C%2024.920831%5D%2C%20%5B56.396847%2C%2024.924732%5D%2C%20%5B56.84514%2C%2024.241673%5D%2C%20%5B57.403453%2C%2023.878594%5D%2C%20%5B58.136948%2C%2023.747931%5D%2C%20%5B58.729211%2C%2023.565668%5D%2C%20%5B59.180502%2C%2022.992395%5D%2C%20%5B59.450098%2C%2022.660271%5D%2C%20%5B59.80806%2C%2022.533612%5D%2C%20%5B59.806148%2C%2022.310525%5D%2C%20%5B59.442191%2C%2021.714541%5D%2C%20%5B59.282408%2C%2021.433886%5D%2C%20%5B58.861141%2C%2021.114035%5D%5D%5D%2C%20%5B%5B%5B56.391421%2C%2025.895991%5D%2C%20%5B56.261042%2C%2025.714606%5D%2C%20%5B56.070821%2C%2026.055464%5D%2C%20%5B56.362017%2C%2026.395934%5D%2C%20%5B56.485679%2C%2026.309118%5D%2C%20%5B56.391421%2C%2025.895991%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22OMN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Oman%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B75.158028%2C%2037.133031%5D%2C%20%5B75.896897%2C%2036.666806%5D%2C%20%5B76.192848%2C%2035.898403%5D%2C%20%5B77.837451%2C%2035.49401%5D%2C%20%5B76.871722%2C%2034.653544%5D%2C%20%5B75.757061%2C%2034.504923%5D%2C%20%5B74.240203%2C%2034.748887%5D%2C%20%5B73.749948%2C%2034.317699%5D%2C%20%5B74.104294%2C%2033.441473%5D%2C%20%5B74.451559%2C%2032.7649%5D%2C%20%5B75.258642%2C%2032.271105%5D%2C%20%5B74.405929%2C%2031.692639%5D%2C%20%5B74.42138%2C%2030.979815%5D%2C%20%5B73.450638%2C%2029.976413%5D%2C%20%5B72.823752%2C%2028.961592%5D%2C%20%5B71.777666%2C%2027.91318%5D%2C%20%5B70.616496%2C%2027.989196%5D%2C%20%5B69.514393%2C%2026.940966%5D%2C%20%5B70.168927%2C%2026.491872%5D%2C%20%5B70.282873%2C%2025.722229%5D%2C%20%5B70.844699%2C%2025.215102%5D%2C%20%5B71.04324%2C%2024.356524%5D%2C%20%5B68.842599%2C%2024.359134%5D%2C%20%5B68.176645%2C%2023.691965%5D%2C%20%5B67.443667%2C%2023.944844%5D%2C%20%5B67.145442%2C%2024.663611%5D%2C%20%5B66.372828%2C%2025.425141%5D%2C%20%5B64.530408%2C%2025.237039%5D%2C%20%5B62.905701%2C%2025.218409%5D%2C%20%5B61.497363%2C%2025.078237%5D%2C%20%5B61.874187%2C%2026.239975%5D%2C%20%5B63.316632%2C%2026.756532%5D%2C%20%5B63.233898%2C%2027.217047%5D%2C%20%5B62.755426%2C%2027.378923%5D%2C%20%5B62.72783%2C%2028.259645%5D%2C%20%5B61.771868%2C%2028.699334%5D%2C%20%5B61.369309%2C%2029.303276%5D%2C%20%5B60.874248%2C%2029.829239%5D%2C%20%5B62.549857%2C%2029.318572%5D%2C%20%5B63.550261%2C%2029.468331%5D%2C%20%5B64.148002%2C%2029.340819%5D%2C%20%5B64.350419%2C%2029.560031%5D%2C%20%5B65.046862%2C%2029.472181%5D%2C%20%5B66.346473%2C%2029.887943%5D%2C%20%5B66.381458%2C%2030.738899%5D%2C%20%5B66.938891%2C%2031.304911%5D%2C%20%5B67.683394%2C%2031.303154%5D%2C%20%5B67.792689%2C%2031.58293%5D%2C%20%5B68.556932%2C%2031.71331%5D%2C%20%5B68.926677%2C%2031.620189%5D%2C%20%5B69.317764%2C%2031.901412%5D%2C%20%5B69.262522%2C%2032.501944%5D%2C%20%5B69.687147%2C%2033.105499%5D%2C%20%5B70.323594%2C%2033.358533%5D%2C%20%5B69.930543%2C%2034.02012%5D%2C%20%5B70.881803%2C%2033.988856%5D%2C%20%5B71.156773%2C%2034.348911%5D%2C%20%5B71.115019%2C%2034.733126%5D%2C%20%5B71.613076%2C%2035.153203%5D%2C%20%5B71.498768%2C%2035.650563%5D%2C%20%5B71.262348%2C%2036.074388%5D%2C%20%5B71.846292%2C%2036.509942%5D%2C%20%5B72.920025%2C%2036.720007%5D%2C%20%5B74.067552%2C%2036.836176%5D%2C%20%5B74.575893%2C%2037.020841%5D%2C%20%5B75.158028%2C%2037.133031%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22PAK%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Pakistan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-77.881571%2C%207.223771%5D%2C%20%5B-78.214936%2C%207.512255%5D%2C%20%5B-78.429161%2C%208.052041%5D%2C%20%5B-78.182096%2C%208.319182%5D%2C%20%5B-78.435465%2C%208.387705%5D%2C%20%5B-78.622121%2C%208.718124%5D%2C%20%5B-79.120307%2C%208.996092%5D%2C%20%5B-79.557877%2C%208.932375%5D%2C%20%5B-79.760578%2C%208.584515%5D%2C%20%5B-80.164481%2C%208.333316%5D%2C%20%5B-80.382659%2C%208.298409%5D%2C%20%5B-80.480689%2C%208.090308%5D%2C%20%5B-80.00369%2C%207.547524%5D%2C%20%5B-80.276671%2C%207.419754%5D%2C%20%5B-80.421158%2C%207.271572%5D%2C%20%5B-80.886401%2C%207.220541%5D%2C%20%5B-81.059543%2C%207.817921%5D%2C%20%5B-81.189716%2C%207.647906%5D%2C%20%5B-81.519515%2C%207.70661%5D%2C%20%5B-81.721311%2C%208.108963%5D%2C%20%5B-82.131441%2C%208.175393%5D%2C%20%5B-82.390934%2C%208.292362%5D%2C%20%5B-82.820081%2C%208.290864%5D%2C%20%5B-82.850958%2C%208.073823%5D%2C%20%5B-82.965783%2C%208.225028%5D%2C%20%5B-82.913176%2C%208.423517%5D%2C%20%5B-82.829771%2C%208.626295%5D%2C%20%5B-82.868657%2C%208.807266%5D%2C%20%5B-82.719183%2C%208.925709%5D%2C%20%5B-82.927155%2C%209.07433%5D%2C%20%5B-82.932891%2C%209.476812%5D%2C%20%5B-82.546196%2C%209.566135%5D%2C%20%5B-82.187123%2C%209.207449%5D%2C%20%5B-82.207586%2C%208.995575%5D%2C%20%5B-81.808567%2C%208.950617%5D%2C%20%5B-81.714154%2C%209.031955%5D%2C%20%5B-81.439287%2C%208.786234%5D%2C%20%5B-80.947302%2C%208.858504%5D%2C%20%5B-80.521901%2C%209.111072%5D%2C%20%5B-79.9146%2C%209.312765%5D%2C%20%5B-79.573303%2C%209.61161%5D%2C%20%5B-79.021192%2C%209.552931%5D%2C%20%5B-79.05845%2C%209.454565%5D%2C%20%5B-78.500888%2C%209.420459%5D%2C%20%5B-78.055928%2C%209.24773%5D%2C%20%5B-77.729514%2C%208.946844%5D%2C%20%5B-77.353361%2C%208.670505%5D%2C%20%5B-77.474723%2C%208.524286%5D%2C%20%5B-77.242566%2C%207.935278%5D%2C%20%5B-77.431108%2C%207.638061%5D%2C%20%5B-77.753414%2C%207.70984%5D%2C%20%5B-77.881571%2C%207.223771%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22PAN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Panama%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-69.590424%2C%20-17.580012%5D%2C%20%5B-69.858444%2C%20-18.092694%5D%2C%20%5B-70.372572%2C%20-18.347975%5D%2C%20%5B-71.37525%2C%20-17.773799%5D%2C%20%5B-71.462041%2C%20-17.363488%5D%2C%20%5B-73.44453%2C%20-16.359363%5D%2C%20%5B-75.237883%2C%20-15.265683%5D%2C%20%5B-76.009205%2C%20-14.649286%5D%2C%20%5B-76.423469%2C%20-13.823187%5D%2C%20%5B-76.259242%2C%20-13.535039%5D%2C%20%5B-77.106192%2C%20-12.222716%5D%2C%20%5B-78.092153%2C%20-10.377712%5D%2C%20%5B-79.036953%2C%20-8.386568%5D%2C%20%5B-79.44592%2C%20-7.930833%5D%2C%20%5B-79.760578%2C%20-7.194341%5D%2C%20%5B-80.537482%2C%20-6.541668%5D%2C%20%5B-81.249996%2C%20-6.136834%5D%2C%20%5B-80.926347%2C%20-5.690557%5D%2C%20%5B-81.410943%2C%20-4.736765%5D%2C%20%5B-81.09967%2C%20-4.036394%5D%2C%20%5B-80.302561%2C%20-3.404856%5D%2C%20%5B-80.184015%2C%20-3.821162%5D%2C%20%5B-80.469295%2C%20-4.059287%5D%2C%20%5B-80.442242%2C%20-4.425724%5D%2C%20%5B-80.028908%2C%20-4.346091%5D%2C%20%5B-79.624979%2C%20-4.454198%5D%2C%20%5B-79.205289%2C%20-4.959129%5D%2C%20%5B-78.639897%2C%20-4.547784%5D%2C%20%5B-78.450684%2C%20-3.873097%5D%2C%20%5B-77.837905%2C%20-3.003021%5D%2C%20%5B-76.635394%2C%20-2.608678%5D%2C%20%5B-75.544996%2C%20-1.56161%5D%2C%20%5B-75.233723%2C%20-0.911417%5D%2C%20%5B-75.373223%2C%20-0.152032%5D%2C%20%5B-75.106625%2C%20-0.057205%5D%2C%20%5B-74.441601%2C%20-0.53082%5D%2C%20%5B-74.122395%2C%20-1.002833%5D%2C%20%5B-73.659504%2C%20-1.260491%5D%2C%20%5B-73.070392%2C%20-2.308954%5D%2C%20%5B-72.325787%2C%20-2.434218%5D%2C%20%5B-71.774761%2C%20-2.16979%5D%2C%20%5B-71.413646%2C%20-2.342802%5D%2C%20%5B-70.813476%2C%20-2.256865%5D%2C%20%5B-70.047709%2C%20-2.725156%5D%2C%20%5B-70.692682%2C%20-3.742872%5D%2C%20%5B-70.394044%2C%20-3.766591%5D%2C%20%5B-69.893635%2C%20-4.298187%5D%2C%20%5B-70.794769%2C%20-4.251265%5D%2C%20%5B-70.928843%2C%20-4.401591%5D%2C%20%5B-71.748406%2C%20-4.593983%5D%2C%20%5B-72.891928%2C%20-5.274561%5D%2C%20%5B-72.964507%2C%20-5.741251%5D%2C%20%5B-73.219711%2C%20-6.089189%5D%2C%20%5B-73.120027%2C%20-6.629931%5D%2C%20%5B-73.724487%2C%20-6.918595%5D%2C%20%5B-73.723401%2C%20-7.340999%5D%2C%20%5B-73.987235%2C%20-7.52383%5D%2C%20%5B-73.571059%2C%20-8.424447%5D%2C%20%5B-73.015383%2C%20-9.032833%5D%2C%20%5B-73.226713%2C%20-9.462213%5D%2C%20%5B-72.563033%2C%20-9.520194%5D%2C%20%5B-72.184891%2C%20-10.053598%5D%2C%20%5B-71.302412%2C%20-10.079436%5D%2C%20%5B-70.481894%2C%20-9.490118%5D%2C%20%5B-70.548686%2C%20-11.009147%5D%2C%20%5B-70.093752%2C%20-11.123972%5D%2C%20%5B-69.529678%2C%20-10.951734%5D%2C%20%5B-68.66508%2C%20-12.5613%5D%2C%20%5B-68.88008%2C%20-12.899729%5D%2C%20%5B-68.929224%2C%20-13.602684%5D%2C%20%5B-68.948887%2C%20-14.453639%5D%2C%20%5B-69.339535%2C%20-14.953195%5D%2C%20%5B-69.160347%2C%20-15.323974%5D%2C%20%5B-69.389764%2C%20-15.660129%5D%2C%20%5B-68.959635%2C%20-16.500698%5D%2C%20%5B-69.590424%2C%20-17.580012%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22PER%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Peru%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B126.376814%2C%208.414706%5D%2C%20%5B126.478513%2C%207.750354%5D%2C%20%5B126.537424%2C%207.189381%5D%2C%20%5B126.196773%2C%206.274294%5D%2C%20%5B125.831421%2C%207.293715%5D%2C%20%5B125.363852%2C%206.786485%5D%2C%20%5B125.683161%2C%206.049657%5D%2C%20%5B125.396512%2C%205.581003%5D%2C%20%5B124.219788%2C%206.161355%5D%2C%20%5B123.93872%2C%206.885136%5D%2C%20%5B124.243662%2C%207.36061%5D%2C%20%5B123.610212%2C%207.833527%5D%2C%20%5B123.296071%2C%207.418876%5D%2C%20%5B122.825506%2C%207.457375%5D%2C%20%5B122.085499%2C%206.899424%5D%2C%20%5B121.919928%2C%207.192119%5D%2C%20%5B122.312359%2C%208.034962%5D%2C%20%5B122.942398%2C%208.316237%5D%2C%20%5B123.487688%2C%208.69301%5D%2C%20%5B123.841154%2C%208.240324%5D%2C%20%5B124.60147%2C%208.514158%5D%2C%20%5B124.764612%2C%208.960409%5D%2C%20%5B125.471391%2C%208.986997%5D%2C%20%5B125.412118%2C%209.760335%5D%2C%20%5B126.222714%2C%209.286074%5D%2C%20%5B126.306637%2C%208.782487%5D%2C%20%5B126.376814%2C%208.414706%5D%5D%5D%2C%20%5B%5B%5B123.982438%2C%2010.278779%5D%2C%20%5B123.623183%2C%209.950091%5D%2C%20%5B123.309921%2C%209.318269%5D%2C%20%5B122.995883%2C%209.022189%5D%2C%20%5B122.380055%2C%209.713361%5D%2C%20%5B122.586089%2C%209.981045%5D%2C%20%5B122.837081%2C%2010.261157%5D%2C%20%5B122.947411%2C%2010.881868%5D%2C%20%5B123.49885%2C%2010.940624%5D%2C%20%5B123.337774%2C%2010.267384%5D%2C%20%5B124.077936%2C%2011.232726%5D%2C%20%5B123.982438%2C%2010.278779%5D%5D%5D%2C%20%5B%5B%5B118.504581%2C%209.316383%5D%2C%20%5B117.174275%2C%208.3675%5D%2C%20%5B117.664477%2C%209.066889%5D%2C%20%5B118.386914%2C%209.6845%5D%2C%20%5B118.987342%2C%2010.376292%5D%2C%20%5B119.511496%2C%2011.369668%5D%2C%20%5B119.689677%2C%2010.554291%5D%2C%20%5B119.029458%2C%2010.003653%5D%2C%20%5B118.504581%2C%209.316383%5D%5D%5D%2C%20%5B%5B%5B121.883548%2C%2011.891755%5D%2C%20%5B122.483821%2C%2011.582187%5D%2C%20%5B123.120217%2C%2011.58366%5D%2C%20%5B123.100838%2C%2011.165934%5D%2C%20%5B122.637714%2C%2010.741308%5D%2C%20%5B122.00261%2C%2010.441017%5D%2C%20%5B121.967367%2C%2010.905691%5D%2C%20%5B122.03837%2C%2011.415841%5D%2C%20%5B121.883548%2C%2011.891755%5D%5D%5D%2C%20%5B%5B%5B125.502552%2C%2012.162695%5D%2C%20%5B125.783465%2C%2011.046122%5D%2C%20%5B125.011884%2C%2011.311455%5D%2C%20%5B125.032761%2C%2010.975816%5D%2C%20%5B125.277449%2C%2010.358722%5D%2C%20%5B124.801819%2C%2010.134679%5D%2C%20%5B124.760168%2C%2010.837995%5D%2C%20%5B124.459101%2C%2010.88993%5D%2C%20%5B124.302522%2C%2011.495371%5D%2C%20%5B124.891013%2C%2011.415583%5D%2C%20%5B124.87799%2C%2011.79419%5D%2C%20%5B124.266762%2C%2012.557761%5D%2C%20%5B125.227116%2C%2012.535721%5D%2C%20%5B125.502552%2C%2012.162695%5D%5D%5D%2C%20%5B%5B%5B121.527394%2C%2013.06959%5D%2C%20%5B121.26219%2C%2012.20556%5D%2C%20%5B120.833896%2C%2012.704496%5D%2C%20%5B120.323436%2C%2013.466413%5D%2C%20%5B121.180128%2C%2013.429697%5D%2C%20%5B121.527394%2C%2013.06959%5D%5D%5D%2C%20%5B%5B%5B121.321308%2C%2018.504065%5D%2C%20%5B121.937601%2C%2018.218552%5D%2C%20%5B122.246006%2C%2018.47895%5D%2C%20%5B122.336957%2C%2018.224883%5D%2C%20%5B122.174279%2C%2017.810283%5D%2C%20%5B122.515654%2C%2017.093505%5D%2C%20%5B122.252311%2C%2016.262444%5D%2C%20%5B121.662786%2C%2015.931018%5D%2C%20%5B121.50507%2C%2015.124814%5D%2C%20%5B121.728829%2C%2014.328376%5D%2C%20%5B122.258925%2C%2014.218202%5D%2C%20%5B122.701276%2C%2014.336541%5D%2C%20%5B123.950295%2C%2013.782131%5D%2C%20%5B123.855107%2C%2013.237771%5D%2C%20%5B124.181289%2C%2012.997527%5D%2C%20%5B124.077419%2C%2012.536677%5D%2C%20%5B123.298035%2C%2013.027526%5D%2C%20%5B122.928652%2C%2013.55292%5D%2C%20%5B122.671355%2C%2013.185836%5D%2C%20%5B122.03465%2C%2013.784482%5D%2C%20%5B121.126385%2C%2013.636687%5D%2C%20%5B120.628637%2C%2013.857656%5D%2C%20%5B120.679384%2C%2014.271016%5D%2C%20%5B120.991819%2C%2014.525393%5D%2C%20%5B120.693336%2C%2014.756671%5D%2C%20%5B120.564145%2C%2014.396279%5D%2C%20%5B120.070429%2C%2014.970869%5D%2C%20%5B119.920929%2C%2015.406347%5D%2C%20%5B119.883773%2C%2016.363704%5D%2C%20%5B120.286488%2C%2016.034629%5D%2C%20%5B120.390047%2C%2017.599081%5D%2C%20%5B120.715867%2C%2018.505227%5D%2C%20%5B121.321308%2C%2018.504065%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22PHL%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Philippines%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B155.880026%2C%20-6.819997%5D%2C%20%5B155.599991%2C%20-6.919991%5D%2C%20%5B155.166994%2C%20-6.535931%5D%2C%20%5B154.729192%2C%20-5.900828%5D%2C%20%5B154.514114%2C%20-5.139118%5D%2C%20%5B154.652504%2C%20-5.042431%5D%2C%20%5B154.759991%2C%20-5.339984%5D%2C%20%5B155.062918%2C%20-5.566792%5D%2C%20%5B155.547746%2C%20-6.200655%5D%2C%20%5B156.019965%2C%20-6.540014%5D%2C%20%5B155.880026%2C%20-6.819997%5D%5D%5D%2C%20%5B%5B%5B151.982796%2C%20-5.478063%5D%2C%20%5B151.459107%2C%20-5.56028%5D%2C%20%5B151.30139%2C%20-5.840728%5D%2C%20%5B150.754447%2C%20-6.083763%5D%2C%20%5B150.241197%2C%20-6.317754%5D%2C%20%5B149.709963%2C%20-6.316513%5D%2C%20%5B148.890065%2C%20-6.02604%5D%2C%20%5B148.318937%2C%20-5.747142%5D%2C%20%5B148.401826%2C%20-5.437756%5D%2C%20%5B149.298412%2C%20-5.583742%5D%2C%20%5B149.845562%2C%20-5.505503%5D%2C%20%5B149.99625%2C%20-5.026101%5D%2C%20%5B150.139756%2C%20-5.001348%5D%2C%20%5B150.236908%2C%20-5.53222%5D%2C%20%5B150.807467%2C%20-5.455842%5D%2C%20%5B151.089672%2C%20-5.113693%5D%2C%20%5B151.647881%2C%20-4.757074%5D%2C%20%5B151.537862%2C%20-4.167807%5D%2C%20%5B152.136792%2C%20-4.14879%5D%2C%20%5B152.338743%2C%20-4.312966%5D%2C%20%5B152.318693%2C%20-4.867661%5D%2C%20%5B151.982796%2C%20-5.478063%5D%5D%5D%2C%20%5B%5B%5B147.191874%2C%20-7.388024%5D%2C%20%5B148.084636%2C%20-8.044108%5D%2C%20%5B148.734105%2C%20-9.104664%5D%2C%20%5B149.306835%2C%20-9.071436%5D%2C%20%5B149.266631%2C%20-9.514406%5D%2C%20%5B150.038728%2C%20-9.684318%5D%2C%20%5B149.738798%2C%20-9.872937%5D%2C%20%5B150.801628%2C%20-10.293687%5D%2C%20%5B150.690575%2C%20-10.582713%5D%2C%20%5B150.028393%2C%20-10.652476%5D%2C%20%5B149.78231%2C%20-10.393267%5D%2C%20%5B148.923138%2C%20-10.280923%5D%2C%20%5B147.913018%2C%20-10.130441%5D%2C%20%5B147.135443%2C%20-9.492444%5D%2C%20%5B146.567881%2C%20-8.942555%5D%2C%20%5B146.048481%2C%20-8.067414%5D%2C%20%5B144.744168%2C%20-7.630128%5D%2C%20%5B143.897088%2C%20-7.91533%5D%2C%20%5B143.286376%2C%20-8.245491%5D%2C%20%5B143.413913%2C%20-8.983069%5D%2C%20%5B142.628431%2C%20-9.326821%5D%2C%20%5B142.068259%2C%20-9.159596%5D%2C%20%5B141.033852%2C%20-9.117893%5D%2C%20%5B141.017057%2C%20-5.859022%5D%2C%20%5B141.00021%2C%20-2.600151%5D%2C%20%5B142.735247%2C%20-3.289153%5D%2C%20%5B144.583971%2C%20-3.861418%5D%2C%20%5B145.27318%2C%20-4.373738%5D%2C%20%5B145.829786%2C%20-4.876498%5D%2C%20%5B145.981922%2C%20-5.465609%5D%2C%20%5B147.648073%2C%20-6.083659%5D%2C%20%5B147.891108%2C%20-6.614015%5D%2C%20%5B146.970905%2C%20-6.721657%5D%2C%20%5B147.191874%2C%20-7.388024%5D%5D%5D%2C%20%5B%5B%5B153.140038%2C%20-4.499983%5D%2C%20%5B152.827292%2C%20-4.766427%5D%2C%20%5B152.638673%2C%20-4.176127%5D%2C%20%5B152.406026%2C%20-3.789743%5D%2C%20%5B151.953237%2C%20-3.462062%5D%2C%20%5B151.384279%2C%20-3.035422%5D%2C%20%5B150.66205%2C%20-2.741486%5D%2C%20%5B150.939965%2C%20-2.500002%5D%2C%20%5B151.479984%2C%20-2.779985%5D%2C%20%5B151.820015%2C%20-2.999972%5D%2C%20%5B152.239989%2C%20-3.240009%5D%2C%20%5B152.640017%2C%20-3.659983%5D%2C%20%5B153.019994%2C%20-3.980015%5D%2C%20%5B153.140038%2C%20-4.499983%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22PNG%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Papua%20New%20Guinea%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B15.016996%2C%2051.106674%5D%2C%20%5B14.607098%2C%2051.745188%5D%2C%20%5B14.685026%2C%2052.089947%5D%2C%20%5B14.4376%2C%2052.62485%5D%2C%20%5B14.074521%2C%2052.981263%5D%2C%20%5B14.353315%2C%2053.248171%5D%2C%20%5B14.119686%2C%2053.757029%5D%2C%20%5B14.8029%2C%2054.050706%5D%2C%20%5B16.363477%2C%2054.513159%5D%2C%20%5B17.622832%2C%2054.851536%5D%2C%20%5B18.620859%2C%2054.682606%5D%2C%20%5B18.696255%2C%2054.438719%5D%2C%20%5B19.66064%2C%2054.426084%5D%2C%20%5B20.892245%2C%2054.312525%5D%2C%20%5B22.731099%2C%2054.327537%5D%2C%20%5B23.243987%2C%2054.220567%5D%2C%20%5B23.484128%2C%2053.912498%5D%2C%20%5B23.527536%2C%2053.470122%5D%2C%20%5B23.804935%2C%2053.089731%5D%2C%20%5B23.799199%2C%2052.691099%5D%2C%20%5B23.199494%2C%2052.486977%5D%2C%20%5B23.508002%2C%2052.023647%5D%2C%20%5B23.527071%2C%2051.578454%5D%2C%20%5B24.029986%2C%2050.705407%5D%2C%20%5B23.922757%2C%2050.424881%5D%2C%20%5B23.426508%2C%2050.308506%5D%2C%20%5B22.51845%2C%2049.476774%5D%2C%20%5B22.776419%2C%2049.027395%5D%2C%20%5B22.558138%2C%2049.085738%5D%2C%20%5B21.607808%2C%2049.470107%5D%2C%20%5B20.887955%2C%2049.328772%5D%2C%20%5B20.415839%2C%2049.431453%5D%2C%20%5B19.825023%2C%2049.217125%5D%2C%20%5B19.320713%2C%2049.571574%5D%2C%20%5B18.909575%2C%2049.435846%5D%2C%20%5B18.853144%2C%2049.49623%5D%2C%20%5B18.392914%2C%2049.988629%5D%2C%20%5B17.649445%2C%2050.049038%5D%2C%20%5B17.554567%2C%2050.362146%5D%2C%20%5B16.868769%2C%2050.473974%5D%2C%20%5B16.719476%2C%2050.215747%5D%2C%20%5B16.176253%2C%2050.422607%5D%2C%20%5B16.238627%2C%2050.697733%5D%2C%20%5B15.490972%2C%2050.78473%5D%2C%20%5B15.016996%2C%2051.106674%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22POL%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Poland%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-66.282434%2C%2018.514762%5D%2C%20%5B-65.771303%2C%2018.426679%5D%2C%20%5B-65.591004%2C%2018.228035%5D%2C%20%5B-65.847164%2C%2017.975906%5D%2C%20%5B-66.599934%2C%2017.981823%5D%2C%20%5B-67.184162%2C%2017.946553%5D%2C%20%5B-67.242428%2C%2018.37446%5D%2C%20%5B-67.100679%2C%2018.520601%5D%2C%20%5B-66.282434%2C%2018.514762%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22PRI%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Puerto%20Rico%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B130.640016%2C%2042.395009%5D%2C%20%5B130.780007%2C%2042.220007%5D%2C%20%5B130.400031%2C%2042.280004%5D%2C%20%5B129.965949%2C%2041.941368%5D%2C%20%5B129.667362%2C%2041.601104%5D%2C%20%5B129.705189%2C%2040.882828%5D%2C%20%5B129.188115%2C%2040.661808%5D%2C%20%5B129.0104%2C%2040.485436%5D%2C%20%5B128.633368%2C%2040.189847%5D%2C%20%5B127.967414%2C%2040.025413%5D%2C%20%5B127.533436%2C%2039.75685%5D%2C%20%5B127.50212%2C%2039.323931%5D%2C%20%5B127.385434%2C%2039.213472%5D%2C%20%5B127.783343%2C%2039.050898%5D%2C%20%5B128.349716%2C%2038.612243%5D%2C%20%5B128.205746%2C%2038.370397%5D%2C%20%5B127.780035%2C%2038.304536%5D%2C%20%5B127.073309%2C%2038.256115%5D%2C%20%5B126.68372%2C%2037.804773%5D%2C%20%5B126.237339%2C%2037.840378%5D%2C%20%5B126.174759%2C%2037.749686%5D%2C%20%5B125.689104%2C%2037.94001%5D%2C%20%5B125.568439%2C%2037.752089%5D%2C%20%5B125.27533%2C%2037.669071%5D%2C%20%5B125.240087%2C%2037.857224%5D%2C%20%5B124.981033%2C%2037.948821%5D%2C%20%5B124.712161%2C%2038.108346%5D%2C%20%5B124.985994%2C%2038.548474%5D%2C%20%5B125.221949%2C%2038.665857%5D%2C%20%5B125.132859%2C%2038.848559%5D%2C%20%5B125.38659%2C%2039.387958%5D%2C%20%5B125.321116%2C%2039.551385%5D%2C%20%5B124.737482%2C%2039.660344%5D%2C%20%5B124.265625%2C%2039.928493%5D%2C%20%5B125.079942%2C%2040.569824%5D%2C%20%5B126.182045%2C%2041.107336%5D%2C%20%5B126.869083%2C%2041.816569%5D%2C%20%5B127.343783%2C%2041.503152%5D%2C%20%5B128.208433%2C%2041.466772%5D%2C%20%5B128.052215%2C%2041.994285%5D%2C%20%5B129.596669%2C%2042.424982%5D%2C%20%5B129.994267%2C%2042.985387%5D%2C%20%5B130.640016%2C%2042.395009%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22PRK%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22North%20Korea%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-9.034818%2C%2041.880571%5D%2C%20%5B-8.671946%2C%2042.134689%5D%2C%20%5B-8.263857%2C%2042.280469%5D%2C%20%5B-8.013175%2C%2041.790886%5D%2C%20%5B-7.422513%2C%2041.792075%5D%2C%20%5B-7.251309%2C%2041.918346%5D%2C%20%5B-6.668606%2C%2041.883387%5D%2C%20%5B-6.389088%2C%2041.381815%5D%2C%20%5B-6.851127%2C%2041.111083%5D%2C%20%5B-6.86402%2C%2040.330872%5D%2C%20%5B-7.026413%2C%2040.184524%5D%2C%20%5B-7.066592%2C%2039.711892%5D%2C%20%5B-7.498632%2C%2039.629571%5D%2C%20%5B-7.098037%2C%2039.030073%5D%2C%20%5B-7.374092%2C%2038.373059%5D%2C%20%5B-7.029281%2C%2038.075764%5D%2C%20%5B-7.166508%2C%2037.803894%5D%2C%20%5B-7.537105%2C%2037.428904%5D%2C%20%5B-7.453726%2C%2037.097788%5D%2C%20%5B-7.855613%2C%2036.838269%5D%2C%20%5B-8.382816%2C%2036.97888%5D%2C%20%5B-8.898857%2C%2036.868809%5D%2C%20%5B-8.746101%2C%2037.651346%5D%2C%20%5B-8.839998%2C%2038.266243%5D%2C%20%5B-9.287464%2C%2038.358486%5D%2C%20%5B-9.526571%2C%2038.737429%5D%2C%20%5B-9.446989%2C%2039.392066%5D%2C%20%5B-9.048305%2C%2039.755093%5D%2C%20%5B-8.977353%2C%2040.159306%5D%2C%20%5B-8.768684%2C%2040.760639%5D%2C%20%5B-8.790853%2C%2041.184334%5D%2C%20%5B-8.990789%2C%2041.543459%5D%2C%20%5B-9.034818%2C%2041.880571%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22PRT%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Portugal%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-62.685057%2C%20-22.249029%5D%2C%20%5B-62.291179%2C%20-21.051635%5D%2C%20%5B-62.265961%2C%20-20.513735%5D%2C%20%5B-61.786326%2C%20-19.633737%5D%2C%20%5B-60.043565%2C%20-19.342747%5D%2C%20%5B-59.115042%2C%20-19.356906%5D%2C%20%5B-58.183471%2C%20-19.868399%5D%2C%20%5B-58.166392%2C%20-20.176701%5D%2C%20%5B-57.870674%2C%20-20.732688%5D%2C%20%5B-57.937156%2C%20-22.090176%5D%2C%20%5B-56.88151%2C%20-22.282154%5D%2C%20%5B-56.473317%2C%20-22.0863%5D%2C%20%5B-55.797958%2C%20-22.35693%5D%2C%20%5B-55.610683%2C%20-22.655619%5D%2C%20%5B-55.517639%2C%20-23.571998%5D%2C%20%5B-55.400747%2C%20-23.956935%5D%2C%20%5B-55.027902%2C%20-24.001274%5D%2C%20%5B-54.652834%2C%20-23.839578%5D%2C%20%5B-54.29296%2C%20-24.021014%5D%2C%20%5B-54.293476%2C%20-24.5708%5D%2C%20%5B-54.428946%2C%20-25.162185%5D%2C%20%5B-54.625291%2C%20-25.739255%5D%2C%20%5B-54.788795%2C%20-26.621786%5D%2C%20%5B-55.695846%2C%20-27.387837%5D%2C%20%5B-56.486702%2C%20-27.548499%5D%2C%20%5B-57.60976%2C%20-27.395899%5D%2C%20%5B-58.618174%2C%20-27.123719%5D%2C%20%5B-57.63366%2C%20-25.603657%5D%2C%20%5B-57.777217%2C%20-25.16234%5D%2C%20%5B-58.807128%2C%20-24.771459%5D%2C%20%5B-60.028966%2C%20-24.032796%5D%2C%20%5B-60.846565%2C%20-23.880713%5D%2C%20%5B-62.685057%2C%20-22.249029%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22PRY%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Paraguay%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B50.810108%2C%2024.754743%5D%2C%20%5B50.743911%2C%2025.482424%5D%2C%20%5B51.013352%2C%2026.006992%5D%2C%20%5B51.286462%2C%2026.114582%5D%2C%20%5B51.589079%2C%2025.801113%5D%2C%20%5B51.6067%2C%2025.21567%5D%2C%20%5B51.389608%2C%2024.627386%5D%2C%20%5B51.112415%2C%2024.556331%5D%2C%20%5B50.810108%2C%2024.754743%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22QAT%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Qatar%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B22.710531%2C%2047.882194%5D%2C%20%5B23.142236%2C%2048.096341%5D%2C%20%5B23.760958%2C%2047.985598%5D%2C%20%5B24.402056%2C%2047.981878%5D%2C%20%5B24.866317%2C%2047.737526%5D%2C%20%5B25.207743%2C%2047.891056%5D%2C%20%5B25.945941%2C%2047.987149%5D%2C%20%5B26.19745%2C%2048.220881%5D%2C%20%5B26.619337%2C%2048.220726%5D%2C%20%5B26.924176%2C%2048.123264%5D%2C%20%5B27.233873%2C%2047.826771%5D%2C%20%5B27.551166%2C%2047.405117%5D%2C%20%5B28.12803%2C%2046.810476%5D%2C%20%5B28.160018%2C%2046.371563%5D%2C%20%5B28.054443%2C%2045.944586%5D%2C%20%5B28.233554%2C%2045.488283%5D%2C%20%5B28.679779%2C%2045.304031%5D%2C%20%5B29.149725%2C%2045.464925%5D%2C%20%5B29.603289%2C%2045.293308%5D%2C%20%5B29.626543%2C%2045.035391%5D%2C%20%5B29.141612%2C%2044.82021%5D%2C%20%5B28.837858%2C%2044.913874%5D%2C%20%5B28.558081%2C%2043.707462%5D%2C%20%5B27.970107%2C%2043.812468%5D%2C%20%5B27.2424%2C%2044.175986%5D%2C%20%5B26.065159%2C%2043.943494%5D%2C%20%5B25.569272%2C%2043.688445%5D%2C%20%5B24.100679%2C%2043.741051%5D%2C%20%5B23.332302%2C%2043.897011%5D%2C%20%5B22.944832%2C%2043.823785%5D%2C%20%5B22.65715%2C%2044.234923%5D%2C%20%5B22.474008%2C%2044.409228%5D%2C%20%5B22.705726%2C%2044.578003%5D%2C%20%5B22.459022%2C%2044.702517%5D%2C%20%5B22.145088%2C%2044.478422%5D%2C%20%5B21.562023%2C%2044.768947%5D%2C%20%5B21.483526%2C%2045.18117%5D%2C%20%5B20.874313%2C%2045.416375%5D%2C%20%5B20.762175%2C%2045.734573%5D%2C%20%5B20.220192%2C%2046.127469%5D%2C%20%5B21.021952%2C%2046.316088%5D%2C%20%5B21.626515%2C%2046.994238%5D%2C%20%5B22.099768%2C%2047.672439%5D%2C%20%5B22.710531%2C%2047.882194%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ROU%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Romania%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B143.648007%2C%2050.7476%5D%2C%20%5B144.654148%2C%2048.976391%5D%2C%20%5B143.173928%2C%2049.306551%5D%2C%20%5B142.558668%2C%2047.861575%5D%2C%20%5B143.533492%2C%2046.836728%5D%2C%20%5B143.505277%2C%2046.137908%5D%2C%20%5B142.747701%2C%2046.740765%5D%2C%20%5B142.09203%2C%2045.966755%5D%2C%20%5B141.906925%2C%2046.805929%5D%2C%20%5B142.018443%2C%2047.780133%5D%2C%20%5B141.904445%2C%2048.859189%5D%2C%20%5B142.1358%2C%2049.615163%5D%2C%20%5B142.179983%2C%2050.952342%5D%2C%20%5B141.594076%2C%2051.935435%5D%2C%20%5B141.682546%2C%2053.301966%5D%2C%20%5B142.606934%2C%2053.762145%5D%2C%20%5B142.209749%2C%2054.225476%5D%2C%20%5B142.654786%2C%2054.365881%5D%2C%20%5B142.914616%2C%2053.704578%5D%2C%20%5B143.260848%2C%2052.74076%5D%2C%20%5B143.235268%2C%2051.75666%5D%2C%20%5B143.648007%2C%2050.7476%5D%5D%5D%2C%20%5B%5B%5B22.731099%2C%2054.327537%5D%2C%20%5B20.892245%2C%2054.312525%5D%2C%20%5B19.66064%2C%2054.426084%5D%2C%20%5B19.888481%2C%2054.86616%5D%2C%20%5B21.268449%2C%2055.190482%5D%2C%20%5B22.315724%2C%2055.015299%5D%2C%20%5B22.757764%2C%2054.856574%5D%2C%20%5B22.651052%2C%2054.582741%5D%2C%20%5B22.731099%2C%2054.327537%5D%5D%5D%2C%20%5B%5B%5B-175.01425%2C%2066.58435%5D%2C%20%5B-174.33983%2C%2066.33556%5D%2C%20%5B-174.57182%2C%2067.06219%5D%2C%20%5B-171.85731%2C%2066.91308%5D%2C%20%5B-169.89958%2C%2065.97724%5D%2C%20%5B-170.89107%2C%2065.54139%5D%2C%20%5B-172.53025%2C%2065.43791%5D%2C%20%5B-172.555%2C%2064.46079%5D%2C%20%5B-172.95533%2C%2064.25269%5D%2C%20%5B-173.89184%2C%2064.2826%5D%2C%20%5B-174.65392%2C%2064.63125%5D%2C%20%5B-175.98353%2C%2064.92288%5D%2C%20%5B-176.20716%2C%2065.35667%5D%2C%20%5B-177.22266%2C%2065.52024%5D%2C%20%5B-178.35993%2C%2065.39052%5D%2C%20%5B-178.90332%2C%2065.74044%5D%2C%20%5B-178.68611%2C%2066.11211%5D%2C%20%5B-179.88377%2C%2065.87456%5D%2C%20%5B-179.43268%2C%2065.40411%5D%2C%20%5B-180%2C%2064.979709%5D%2C%20%5B-180%2C%2068.963636%5D%2C%20%5B-177.55%2C%2068.2%5D%2C%20%5B-174.92825%2C%2067.20589%5D%2C%20%5B-175.01425%2C%2066.58435%5D%5D%5D%2C%20%5B%5B%5B180%2C%2070.832199%5D%2C%20%5B178.903425%2C%2070.78114%5D%2C%20%5B178.7253%2C%2071.0988%5D%2C%20%5B180%2C%2071.515714%5D%2C%20%5B180%2C%2070.832199%5D%5D%5D%2C%20%5B%5B%5B-178.69378%2C%2070.89302%5D%2C%20%5B-180%2C%2070.832199%5D%2C%20%5B-180%2C%2071.515714%5D%2C%20%5B-179.871875%2C%2071.55762%5D%2C%20%5B-179.02433%2C%2071.55553%5D%2C%20%5B-177.577945%2C%2071.26948%5D%2C%20%5B-177.663575%2C%2071.13277%5D%2C%20%5B-178.69378%2C%2070.89302%5D%5D%5D%2C%20%5B%5B%5B143.60385%2C%2073.21244%5D%2C%20%5B142.08763%2C%2073.20544%5D%2C%20%5B140.038155%2C%2073.31692%5D%2C%20%5B139.86312%2C%2073.36983%5D%2C%20%5B140.81171%2C%2073.76506%5D%2C%20%5B142.06207%2C%2073.85758%5D%2C%20%5B143.48283%2C%2073.47525%5D%2C%20%5B143.60385%2C%2073.21244%5D%5D%5D%2C%20%5B%5B%5B150.73167%2C%2075.08406%5D%2C%20%5B149.575925%2C%2074.68892%5D%2C%20%5B147.977465%2C%2074.778355%5D%2C%20%5B146.11919%2C%2075.17298%5D%2C%20%5B146.358485%2C%2075.49682%5D%2C%20%5B148.22223%2C%2075.345845%5D%2C%20%5B150.73167%2C%2075.08406%5D%5D%5D%2C%20%5B%5B%5B145.086285%2C%2075.562625%5D%2C%20%5B144.3%2C%2074.82%5D%2C%20%5B140.61381%2C%2074.84768%5D%2C%20%5B138.95544%2C%2074.61148%5D%2C%20%5B136.97439%2C%2075.26167%5D%2C%20%5B137.51176%2C%2075.94917%5D%2C%20%5B138.831075%2C%2076.13676%5D%2C%20%5B141.471615%2C%2076.09289%5D%2C%20%5B145.086285%2C%2075.562625%5D%5D%5D%2C%20%5B%5B%5B57.535693%2C%2070.720464%5D%2C%20%5B56.944979%2C%2070.632743%5D%2C%20%5B53.677375%2C%2070.762658%5D%2C%20%5B53.412017%2C%2071.206662%5D%2C%20%5B51.601895%2C%2071.474759%5D%2C%20%5B51.455754%2C%2072.014881%5D%2C%20%5B52.478275%2C%2072.229442%5D%2C%20%5B52.444169%2C%2072.774731%5D%2C%20%5B54.427614%2C%2073.627548%5D%2C%20%5B53.50829%2C%2073.749814%5D%2C%20%5B55.902459%2C%2074.627486%5D%2C%20%5B55.631933%2C%2075.081412%5D%2C%20%5B57.868644%2C%2075.60939%5D%2C%20%5B61.170044%2C%2076.251883%5D%2C%20%5B64.498368%2C%2076.439055%5D%2C%20%5B66.210977%2C%2076.809782%5D%2C%20%5B68.15706%2C%2076.939697%5D%2C%20%5B68.852211%2C%2076.544811%5D%2C%20%5B68.180573%2C%2076.233642%5D%2C%20%5B64.637326%2C%2075.737755%5D%2C%20%5B61.583508%2C%2075.260885%5D%2C%20%5B58.477082%2C%2074.309056%5D%2C%20%5B56.986786%2C%2073.333044%5D%2C%20%5B55.419336%2C%2072.371268%5D%2C%20%5B55.622838%2C%2071.540595%5D%2C%20%5B57.535693%2C%2070.720464%5D%5D%5D%2C%20%5B%5B%5B106.97013%2C%2076.97419%5D%2C%20%5B107.24%2C%2076.48%5D%2C%20%5B108.1538%2C%2076.72335%5D%2C%20%5B111.07726%2C%2076.71%5D%2C%20%5B113.33151%2C%2076.22224%5D%2C%20%5B114.13417%2C%2075.84764%5D%2C%20%5B113.88539%2C%2075.32779%5D%2C%20%5B112.77918%2C%2075.03186%5D%2C%20%5B110.15125%2C%2074.47673%5D%2C%20%5B109.4%2C%2074.18%5D%2C%20%5B110.64%2C%2074.04%5D%2C%20%5B112.11919%2C%2073.78774%5D%2C%20%5B113.01954%2C%2073.97693%5D%2C%20%5B113.52958%2C%2073.33505%5D%2C%20%5B113.96881%2C%2073.59488%5D%2C%20%5B115.56782%2C%2073.75285%5D%2C%20%5B118.77633%2C%2073.58772%5D%2C%20%5B119.02%2C%2073.12%5D%2C%20%5B123.20066%2C%2072.97122%5D%2C%20%5B123.25777%2C%2073.73503%5D%2C%20%5B125.38%2C%2073.56%5D%2C%20%5B126.97644%2C%2073.56549%5D%2C%20%5B128.59126%2C%2073.03871%5D%2C%20%5B129.05157%2C%2072.39872%5D%2C%20%5B128.46%2C%2071.98%5D%2C%20%5B129.71599%2C%2071.19304%5D%2C%20%5B131.28858%2C%2070.78699%5D%2C%20%5B132.2535%2C%2071.8363%5D%2C%20%5B133.85766%2C%2071.38642%5D%2C%20%5B135.56193%2C%2071.65525%5D%2C%20%5B137.49755%2C%2071.34763%5D%2C%20%5B138.23409%2C%2071.62803%5D%2C%20%5B139.86983%2C%2071.48783%5D%2C%20%5B139.14791%2C%2072.41619%5D%2C%20%5B140.46817%2C%2072.84941%5D%2C%20%5B149.5%2C%2072.2%5D%2C%20%5B150.35118%2C%2071.60643%5D%2C%20%5B152.9689%2C%2070.84222%5D%2C%20%5B157.00688%2C%2071.03141%5D%2C%20%5B158.99779%2C%2070.86672%5D%2C%20%5B159.83031%2C%2070.45324%5D%2C%20%5B159.70866%2C%2069.72198%5D%2C%20%5B160.94053%2C%2069.43728%5D%2C%20%5B162.27907%2C%2069.64204%5D%2C%20%5B164.05248%2C%2069.66823%5D%2C%20%5B165.94037%2C%2069.47199%5D%2C%20%5B167.83567%2C%2069.58269%5D%2C%20%5B169.57763%2C%2068.6938%5D%2C%20%5B170.81688%2C%2069.01363%5D%2C%20%5B170.0082%2C%2069.65276%5D%2C%20%5B170.45345%2C%2070.09703%5D%2C%20%5B173.64391%2C%2069.81743%5D%2C%20%5B175.72403%2C%2069.87725%5D%2C%20%5B178.6%2C%2069.4%5D%2C%20%5B180%2C%2068.963636%5D%2C%20%5B180%2C%2064.979709%5D%2C%20%5B179.99281%2C%2064.97433%5D%2C%20%5B178.7072%2C%2064.53493%5D%2C%20%5B177.41128%2C%2064.60821%5D%2C%20%5B178.313%2C%2064.07593%5D%2C%20%5B178.90825%2C%2063.25197%5D%2C%20%5B179.37034%2C%2062.98262%5D%2C%20%5B179.48636%2C%2062.56894%5D%2C%20%5B179.22825%2C%2062.3041%5D%2C%20%5B177.3643%2C%2062.5219%5D%2C%20%5B174.56929%2C%2061.76915%5D%2C%20%5B173.68013%2C%2061.65261%5D%2C%20%5B172.15%2C%2060.95%5D%2C%20%5B170.6985%2C%2060.33618%5D%2C%20%5B170.33085%2C%2059.88177%5D%2C%20%5B168.90046%2C%2060.57355%5D%2C%20%5B166.29498%2C%2059.78855%5D%2C%20%5B165.84%2C%2060.16%5D%2C%20%5B164.87674%2C%2059.7316%5D%2C%20%5B163.53929%2C%2059.86871%5D%2C%20%5B163.21711%2C%2059.21101%5D%2C%20%5B162.01733%2C%2058.24328%5D%2C%20%5B162.05297%2C%2057.83912%5D%2C%20%5B163.19191%2C%2057.61503%5D%2C%20%5B163.05794%2C%2056.15924%5D%2C%20%5B162.12958%2C%2056.12219%5D%2C%20%5B161.70146%2C%2055.28568%5D%2C%20%5B162.11749%2C%2054.85514%5D%2C%20%5B160.36877%2C%2054.34433%5D%2C%20%5B160.02173%2C%2053.20257%5D%2C%20%5B158.53094%2C%2052.95868%5D%2C%20%5B158.23118%2C%2051.94269%5D%2C%20%5B156.78979%2C%2051.01105%5D%2C%20%5B156.42%2C%2051.7%5D%2C%20%5B155.99182%2C%2053.15895%5D%2C%20%5B155.43366%2C%2055.38103%5D%2C%20%5B155.91442%2C%2056.76792%5D%2C%20%5B156.75815%2C%2057.3647%5D%2C%20%5B156.81035%2C%2057.83204%5D%2C%20%5B158.36433%2C%2058.05575%5D%2C%20%5B160.15064%2C%2059.31477%5D%2C%20%5B161.87204%2C%2060.343%5D%2C%20%5B163.66969%2C%2061.1409%5D%2C%20%5B164.47355%2C%2062.55061%5D%2C%20%5B163.25842%2C%2062.46627%5D%2C%20%5B162.65791%2C%2061.6425%5D%2C%20%5B160.12148%2C%2060.54423%5D%2C%20%5B159.30232%2C%2061.77396%5D%2C%20%5B156.72068%2C%2061.43442%5D%2C%20%5B154.21806%2C%2059.75818%5D%2C%20%5B155.04375%2C%2059.14495%5D%2C%20%5B152.81185%2C%2058.88385%5D%2C%20%5B151.26573%2C%2058.78089%5D%2C%20%5B151.33815%2C%2059.50396%5D%2C%20%5B149.78371%2C%2059.65573%5D%2C%20%5B148.54481%2C%2059.16448%5D%2C%20%5B145.48722%2C%2059.33637%5D%2C%20%5B142.19782%2C%2059.03998%5D%2C%20%5B138.95848%2C%2057.08805%5D%2C%20%5B135.12619%2C%2054.72959%5D%2C%20%5B136.70171%2C%2054.60355%5D%2C%20%5B137.19342%2C%2053.97732%5D%2C%20%5B138.1647%2C%2053.75501%5D%2C%20%5B138.80463%2C%2054.25455%5D%2C%20%5B139.90151%2C%2054.18968%5D%2C%20%5B141.34531%2C%2053.08957%5D%2C%20%5B141.37923%2C%2052.23877%5D%2C%20%5B140.59742%2C%2051.23967%5D%2C%20%5B140.51308%2C%2050.04553%5D%2C%20%5B140.06193%2C%2048.44671%5D%2C%20%5B138.55472%2C%2046.99965%5D%2C%20%5B138.21971%2C%2046.30795%5D%2C%20%5B136.86232%2C%2045.1435%5D%2C%20%5B135.51535%2C%2043.989%5D%2C%20%5B134.86939%2C%2043.39821%5D%2C%20%5B133.53687%2C%2042.81147%5D%2C%20%5B132.90627%2C%2042.79849%5D%2C%20%5B132.27807%2C%2043.28456%5D%2C%20%5B130.93587%2C%2042.55274%5D%2C%20%5B130.78%2C%2042.22%5D%2C%20%5B130.64%2C%2042.395%5D%2C%20%5B130.633866%2C%2042.903015%5D%2C%20%5B131.144688%2C%2042.92999%5D%2C%20%5B131.288555%2C%2044.11152%5D%2C%20%5B131.02519%2C%2044.96796%5D%2C%20%5B131.883454%2C%2045.321162%5D%2C%20%5B133.09712%2C%2045.14409%5D%2C%20%5B133.769644%2C%2046.116927%5D%2C%20%5B134.11235%2C%2047.21248%5D%2C%20%5B134.50081%2C%2047.57845%5D%2C%20%5B135.026311%2C%2048.47823%5D%2C%20%5B133.373596%2C%2048.183442%5D%2C%20%5B132.50669%2C%2047.78896%5D%2C%20%5B130.98726%2C%2047.79013%5D%2C%20%5B130.582293%2C%2048.729687%5D%2C%20%5B129.397818%2C%2049.4406%5D%2C%20%5B127.6574%2C%2049.76027%5D%2C%20%5B127.287456%2C%2050.739797%5D%2C%20%5B126.939157%2C%2051.353894%5D%2C%20%5B126.564399%2C%2051.784255%5D%2C%20%5B125.946349%2C%2052.792799%5D%2C%20%5B125.068211%2C%2053.161045%5D%2C%20%5B123.57147%2C%2053.4588%5D%2C%20%5B122.245748%2C%2053.431726%5D%2C%20%5B121.003085%2C%2053.251401%5D%2C%20%5B120.177089%2C%2052.753886%5D%2C%20%5B120.725789%2C%2052.516226%5D%2C%20%5B120.7382%2C%2051.96411%5D%2C%20%5B120.18208%2C%2051.64355%5D%2C%20%5B119.27939%2C%2050.58292%5D%2C%20%5B119.288461%2C%2050.142883%5D%2C%20%5B117.879244%2C%2049.510983%5D%2C%20%5B116.678801%2C%2049.888531%5D%2C%20%5B115.485695%2C%2049.805177%5D%2C%20%5B114.96211%2C%2050.140247%5D%2C%20%5B114.362456%2C%2050.248303%5D%2C%20%5B112.89774%2C%2049.543565%5D%2C%20%5B111.581231%2C%2049.377968%5D%2C%20%5B110.662011%2C%2049.130128%5D%2C%20%5B109.402449%2C%2049.292961%5D%2C%20%5B108.475167%2C%2049.282548%5D%2C%20%5B107.868176%2C%2049.793705%5D%2C%20%5B106.888804%2C%2050.274296%5D%2C%20%5B105.886591%2C%2050.406019%5D%2C%20%5B104.62158%2C%2050.27532%5D%2C%20%5B103.676545%2C%2050.089966%5D%2C%20%5B102.25589%2C%2050.51056%5D%2C%20%5B102.06521%2C%2051.25991%5D%2C%20%5B100.88948%2C%2051.516856%5D%2C%20%5B99.981732%2C%2051.634006%5D%2C%20%5B98.861491%2C%2052.047366%5D%2C%20%5B97.82574%2C%2051.010995%5D%2C%20%5B98.231762%2C%2050.422401%5D%2C%20%5B97.25976%2C%2049.72605%5D%2C%20%5B95.81402%2C%2049.97746%5D%2C%20%5B94.815949%2C%2050.013433%5D%2C%20%5B94.147566%2C%2050.480537%5D%2C%20%5B93.10421%2C%2050.49529%5D%2C%20%5B92.234712%2C%2050.802171%5D%2C%20%5B90.713667%2C%2050.331812%5D%2C%20%5B88.805567%2C%2049.470521%5D%2C%20%5B87.751264%2C%2049.297198%5D%2C%20%5B87.35997%2C%2049.214981%5D%2C%20%5B86.829357%2C%2049.826675%5D%2C%20%5B85.54127%2C%2049.692859%5D%2C%20%5B85.11556%2C%2050.117303%5D%2C%20%5B84.416377%2C%2050.3114%5D%2C%20%5B83.935115%2C%2050.889246%5D%2C%20%5B83.383004%2C%2051.069183%5D%2C%20%5B81.945986%2C%2050.812196%5D%2C%20%5B80.568447%2C%2051.388336%5D%2C%20%5B80.03556%2C%2050.864751%5D%2C%20%5B77.800916%2C%2053.404415%5D%2C%20%5B76.525179%2C%2054.177003%5D%2C%20%5B76.8911%2C%2054.490524%5D%2C%20%5B74.38482%2C%2053.54685%5D%2C%20%5B73.425679%2C%2053.48981%5D%2C%20%5B73.508516%2C%2054.035617%5D%2C%20%5B72.22415%2C%2054.376655%5D%2C%20%5B71.180131%2C%2054.133285%5D%2C%20%5B70.865267%2C%2055.169734%5D%2C%20%5B69.068167%2C%2055.38525%5D%2C%20%5B68.1691%2C%2054.970392%5D%2C%20%5B65.66687%2C%2054.60125%5D%2C%20%5B65.178534%2C%2054.354228%5D%2C%20%5B61.4366%2C%2054.00625%5D%2C%20%5B60.978066%2C%2053.664993%5D%2C%20%5B61.699986%2C%2052.979996%5D%2C%20%5B60.739993%2C%2052.719986%5D%2C%20%5B60.927269%2C%2052.447548%5D%2C%20%5B59.967534%2C%2051.96042%5D%2C%20%5B61.588003%2C%2051.272659%5D%2C%20%5B61.337424%2C%2050.79907%5D%2C%20%5B59.932807%2C%2050.842194%5D%2C%20%5B59.642282%2C%2050.545442%5D%2C%20%5B58.36332%2C%2051.06364%5D%2C%20%5B56.77798%2C%2051.04355%5D%2C%20%5B55.71694%2C%2050.62171%5D%2C%20%5B54.532878%2C%2051.02624%5D%2C%20%5B52.328724%2C%2051.718652%5D%2C%20%5B50.766648%2C%2051.692762%5D%2C%20%5B48.702382%2C%2050.605128%5D%2C%20%5B48.577841%2C%2049.87476%5D%2C%20%5B47.54948%2C%2050.454698%5D%2C%20%5B46.751596%2C%2049.356006%5D%2C%20%5B47.043672%2C%2049.152039%5D%2C%20%5B46.466446%2C%2048.394152%5D%2C%20%5B47.31524%2C%2047.71585%5D%2C%20%5B48.05725%2C%2047.74377%5D%2C%20%5B48.694734%2C%2047.075628%5D%2C%20%5B48.59325%2C%2046.56104%5D%2C%20%5B49.10116%2C%2046.39933%5D%2C%20%5B48.64541%2C%2045.80629%5D%2C%20%5B47.67591%2C%2045.64149%5D%2C%20%5B46.68201%2C%2044.6092%5D%2C%20%5B47.59094%2C%2043.66016%5D%2C%20%5B47.49252%2C%2042.98658%5D%2C%20%5B48.58437%2C%2041.80888%5D%2C%20%5B47.987283%2C%2041.405819%5D%2C%20%5B47.815666%2C%2041.151416%5D%2C%20%5B47.373315%2C%2041.219732%5D%2C%20%5B46.686071%2C%2041.827137%5D%2C%20%5B46.404951%2C%2041.860675%5D%2C%20%5B45.7764%2C%2042.09244%5D%2C%20%5B45.470279%2C%2042.502781%5D%2C%20%5B44.537623%2C%2042.711993%5D%2C%20%5B43.93121%2C%2042.55496%5D%2C%20%5B43.75599%2C%2042.74083%5D%2C%20%5B42.3944%2C%2043.2203%5D%2C%20%5B40.92219%2C%2043.38215%5D%2C%20%5B40.076965%2C%2043.553104%5D%2C%20%5B39.955009%2C%2043.434998%5D%2C%20%5B38.68%2C%2044.28%5D%2C%20%5B37.53912%2C%2044.65721%5D%2C%20%5B36.67546%2C%2045.24469%5D%2C%20%5B37.40317%2C%2045.40451%5D%2C%20%5B38.23295%2C%2046.24087%5D%2C%20%5B37.67372%2C%2046.63657%5D%2C%20%5B39.14767%2C%2047.04475%5D%2C%20%5B39.1212%2C%2047.26336%5D%2C%20%5B38.223538%2C%2047.10219%5D%2C%20%5B38.255112%2C%2047.5464%5D%2C%20%5B38.77057%2C%2047.82562%5D%2C%20%5B39.738278%2C%2047.898937%5D%2C%20%5B39.89562%2C%2048.23241%5D%2C%20%5B39.67465%2C%2048.78382%5D%2C%20%5B40.080789%2C%2049.30743%5D%2C%20%5B40.06904%2C%2049.60105%5D%2C%20%5B38.594988%2C%2049.926462%5D%2C%20%5B38.010631%2C%2049.915662%5D%2C%20%5B37.39346%2C%2050.383953%5D%2C%20%5B36.626168%2C%2050.225591%5D%2C%20%5B35.356116%2C%2050.577197%5D%2C%20%5B35.37791%2C%2050.77394%5D%2C%20%5B35.022183%2C%2051.207572%5D%2C%20%5B34.224816%2C%2051.255993%5D%2C%20%5B34.141978%2C%2051.566413%5D%2C%20%5B34.391731%2C%2051.768882%5D%2C%20%5B33.7527%2C%2052.335075%5D%2C%20%5B32.715761%2C%2052.238465%5D%2C%20%5B32.412058%2C%2052.288695%5D%2C%20%5B32.15944%2C%2052.06125%5D%2C%20%5B31.78597%2C%2052.10168%5D%2C%20%5B31.540018%2C%2052.742052%5D%2C%20%5B31.305201%2C%2053.073996%5D%2C%20%5B31.49764%2C%2053.16743%5D%2C%20%5B32.304519%2C%2053.132726%5D%2C%20%5B32.693643%2C%2053.351421%5D%2C%20%5B32.405599%2C%2053.618045%5D%2C%20%5B31.731273%2C%2053.794029%5D%2C%20%5B31.791424%2C%2053.974639%5D%2C%20%5B31.384472%2C%2054.157056%5D%2C%20%5B30.757534%2C%2054.811771%5D%2C%20%5B30.971836%2C%2055.081548%5D%2C%20%5B30.873909%2C%2055.550976%5D%2C%20%5B29.896294%2C%2055.789463%5D%2C%20%5B29.371572%2C%2055.670091%5D%2C%20%5B29.229513%2C%2055.918344%5D%2C%20%5B28.176709%2C%2056.16913%5D%2C%20%5B27.855282%2C%2056.759326%5D%2C%20%5B27.770016%2C%2057.244258%5D%2C%20%5B27.288185%2C%2057.474528%5D%2C%20%5B27.716686%2C%2057.791899%5D%2C%20%5B27.42015%2C%2058.72457%5D%2C%20%5B28.131699%2C%2059.300825%5D%2C%20%5B27.98112%2C%2059.47537%5D%2C%20%5B29.1177%2C%2060.02805%5D%2C%20%5B28.07%2C%2060.50352%5D%2C%20%5B30.211107%2C%2061.780028%5D%2C%20%5B31.139991%2C%2062.357693%5D%2C%20%5B31.516092%2C%2062.867687%5D%2C%20%5B30.035872%2C%2063.552814%5D%2C%20%5B30.444685%2C%2064.204453%5D%2C%20%5B29.54443%2C%2064.948672%5D%2C%20%5B30.21765%2C%2065.80598%5D%2C%20%5B29.054589%2C%2066.944286%5D%2C%20%5B29.977426%2C%2067.698297%5D%2C%20%5B28.445944%2C%2068.364613%5D%2C%20%5B28.59193%2C%2069.064777%5D%2C%20%5B29.39955%2C%2069.15692%5D%2C%20%5B31.10108%2C%2069.55811%5D%2C%20%5B32.13272%2C%2069.90595%5D%2C%20%5B33.77547%2C%2069.30142%5D%2C%20%5B36.51396%2C%2069.06342%5D%2C%20%5B40.29234%2C%2067.9324%5D%2C%20%5B41.05987%2C%2067.45713%5D%2C%20%5B41.12595%2C%2066.79158%5D%2C%20%5B40.01583%2C%2066.26618%5D%2C%20%5B38.38295%2C%2065.99953%5D%2C%20%5B33.91871%2C%2066.75961%5D%2C%20%5B33.18444%2C%2066.63253%5D%2C%20%5B34.81477%2C%2065.90015%5D%2C%20%5B34.878574%2C%2065.436213%5D%2C%20%5B34.94391%2C%2064.41437%5D%2C%20%5B36.23129%2C%2064.10945%5D%2C%20%5B37.01273%2C%2063.84983%5D%2C%20%5B37.14197%2C%2064.33471%5D%2C%20%5B36.539579%2C%2064.76446%5D%2C%20%5B37.17604%2C%2065.14322%5D%2C%20%5B39.59345%2C%2064.52079%5D%2C%20%5B40.4356%2C%2064.76446%5D%2C%20%5B39.7626%2C%2065.49682%5D%2C%20%5B42.09309%2C%2066.47623%5D%2C%20%5B43.01604%2C%2066.41858%5D%2C%20%5B43.94975%2C%2066.06908%5D%2C%20%5B44.53226%2C%2066.75634%5D%2C%20%5B43.69839%2C%2067.35245%5D%2C%20%5B44.18795%2C%2067.95051%5D%2C%20%5B43.45282%2C%2068.57079%5D%2C%20%5B46.25%2C%2068.25%5D%2C%20%5B46.82134%2C%2067.68997%5D%2C%20%5B45.55517%2C%2067.56652%5D%2C%20%5B45.56202%2C%2067.01005%5D%2C%20%5B46.34915%2C%2066.66767%5D%2C%20%5B47.89416%2C%2066.88455%5D%2C%20%5B48.13876%2C%2067.52238%5D%2C%20%5B50.22766%2C%2067.99867%5D%2C%20%5B53.71743%2C%2068.85738%5D%2C%20%5B54.47171%2C%2068.80815%5D%2C%20%5B53.48582%2C%2068.20131%5D%2C%20%5B54.72628%2C%2068.09702%5D%2C%20%5B55.44268%2C%2068.43866%5D%2C%20%5B57.31702%2C%2068.46628%5D%2C%20%5B58.802%2C%2068.88082%5D%2C%20%5B59.94142%2C%2068.27844%5D%2C%20%5B61.07784%2C%2068.94069%5D%2C%20%5B60.03%2C%2069.52%5D%2C%20%5B60.55%2C%2069.85%5D%2C%20%5B63.504%2C%2069.54739%5D%2C%20%5B64.888115%2C%2069.234835%5D%2C%20%5B68.51216%2C%2068.09233%5D%2C%20%5B69.18068%2C%2068.61563%5D%2C%20%5B68.16444%2C%2069.14436%5D%2C%20%5B68.13522%2C%2069.35649%5D%2C%20%5B66.93008%2C%2069.45461%5D%2C%20%5B67.25976%2C%2069.92873%5D%2C%20%5B66.72492%2C%2070.70889%5D%2C%20%5B66.69466%2C%2071.02897%5D%2C%20%5B68.54006%2C%2071.9345%5D%2C%20%5B69.19636%2C%2072.84336%5D%2C%20%5B69.94%2C%2073.04%5D%2C%20%5B72.58754%2C%2072.77629%5D%2C%20%5B72.79603%2C%2072.22006%5D%2C%20%5B71.84811%2C%2071.40898%5D%2C%20%5B72.47011%2C%2071.09019%5D%2C%20%5B72.79188%2C%2070.39114%5D%2C%20%5B72.5647%2C%2069.02085%5D%2C%20%5B73.66787%2C%2068.4079%5D%2C%20%5B73.2387%2C%2067.7404%5D%2C%20%5B71.28%2C%2066.32%5D%2C%20%5B72.42301%2C%2066.17267%5D%2C%20%5B72.82077%2C%2066.53267%5D%2C%20%5B73.92099%2C%2066.78946%5D%2C%20%5B74.18651%2C%2067.28429%5D%2C%20%5B75.052%2C%2067.76047%5D%2C%20%5B74.46926%2C%2068.32899%5D%2C%20%5B74.93584%2C%2068.98918%5D%2C%20%5B73.84236%2C%2069.07146%5D%2C%20%5B73.60187%2C%2069.62763%5D%2C%20%5B74.3998%2C%2070.63175%5D%2C%20%5B73.1011%2C%2071.44717%5D%2C%20%5B74.89082%2C%2072.12119%5D%2C%20%5B74.65926%2C%2072.83227%5D%2C%20%5B75.15801%2C%2072.85497%5D%2C%20%5B75.68351%2C%2072.30056%5D%2C%20%5B75.28898%2C%2071.33556%5D%2C%20%5B76.35911%2C%2071.15287%5D%2C%20%5B75.90313%2C%2071.87401%5D%2C%20%5B77.57665%2C%2072.26717%5D%2C%20%5B79.65202%2C%2072.32011%5D%2C%20%5B81.5%2C%2071.75%5D%2C%20%5B80.61071%2C%2072.58285%5D%2C%20%5B80.51109%2C%2073.6482%5D%2C%20%5B82.25%2C%2073.85%5D%2C%20%5B84.65526%2C%2073.80591%5D%2C%20%5B86.8223%2C%2073.93688%5D%2C%20%5B86.00956%2C%2074.45967%5D%2C%20%5B87.16682%2C%2075.11643%5D%2C%20%5B88.31571%2C%2075.14393%5D%2C%20%5B90.26%2C%2075.64%5D%2C%20%5B92.90058%2C%2075.77333%5D%2C%20%5B93.23421%2C%2076.0472%5D%2C%20%5B95.86%2C%2076.14%5D%2C%20%5B96.67821%2C%2075.91548%5D%2C%20%5B98.92254%2C%2076.44689%5D%2C%20%5B100.75967%2C%2076.43028%5D%2C%20%5B101.03532%2C%2076.86189%5D%2C%20%5B101.99084%2C%2077.28754%5D%2C%20%5B104.3516%2C%2077.69792%5D%2C%20%5B106.06664%2C%2077.37389%5D%2C%20%5B104.705%2C%2077.1274%5D%2C%20%5B106.97013%2C%2076.97419%5D%5D%5D%2C%20%5B%5B%5B105.07547%2C%2078.30689%5D%2C%20%5B99.43814%2C%2077.921%5D%2C%20%5B101.2649%2C%2079.23399%5D%2C%20%5B102.08635%2C%2079.34641%5D%2C%20%5B102.837815%2C%2079.28129%5D%2C%20%5B105.37243%2C%2078.71334%5D%2C%20%5B105.07547%2C%2078.30689%5D%5D%5D%2C%20%5B%5B%5B51.136187%2C%2080.54728%5D%2C%20%5B49.793685%2C%2080.415428%5D%2C%20%5B48.894411%2C%2080.339567%5D%2C%20%5B48.754937%2C%2080.175468%5D%2C%20%5B47.586119%2C%2080.010181%5D%2C%20%5B46.502826%2C%2080.247247%5D%2C%20%5B47.072455%2C%2080.559424%5D%2C%20%5B44.846958%2C%2080.58981%5D%2C%20%5B46.799139%2C%2080.771918%5D%2C%20%5B48.318477%2C%2080.78401%5D%2C%20%5B48.522806%2C%2080.514569%5D%2C%20%5B49.09719%2C%2080.753986%5D%2C%20%5B50.039768%2C%2080.918885%5D%2C%20%5B51.522933%2C%2080.699726%5D%2C%20%5B51.136187%2C%2080.54728%5D%5D%5D%2C%20%5B%5B%5B99.93976%2C%2078.88094%5D%2C%20%5B97.75794%2C%2078.7562%5D%2C%20%5B94.97259%2C%2079.044745%5D%2C%20%5B93.31288%2C%2079.4265%5D%2C%20%5B92.5454%2C%2080.14379%5D%2C%20%5B91.18107%2C%2080.34146%5D%2C%20%5B93.77766%2C%2081.0246%5D%2C%20%5B95.940895%2C%2081.2504%5D%2C%20%5B97.88385%2C%2080.746975%5D%2C%20%5B100.186655%2C%2079.780135%5D%2C%20%5B99.93976%2C%2078.88094%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22RUS%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Russia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B30.419105%2C%20-1.134659%5D%2C%20%5B30.816135%2C%20-1.698914%5D%2C%20%5B30.758309%2C%20-2.28725%5D%2C%20%5B30.469696%2C%20-2.413858%5D%2C%20%5B29.938359%2C%20-2.348487%5D%2C%20%5B29.632176%2C%20-2.917858%5D%2C%20%5B29.024926%2C%20-2.839258%5D%2C%20%5B29.117479%2C%20-2.292211%5D%2C%20%5B29.254835%2C%20-2.21511%5D%2C%20%5B29.291887%2C%20-1.620056%5D%2C%20%5B29.579466%2C%20-1.341313%5D%2C%20%5B29.821519%2C%20-1.443322%5D%2C%20%5B30.419105%2C%20-1.134659%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22RWA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Rwanda%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-8.794884%2C%2027.120696%5D%2C%20%5B-8.817828%2C%2027.656426%5D%2C%20%5B-8.66559%2C%2027.656426%5D%2C%20%5B-8.665124%2C%2027.589479%5D%2C%20%5B-8.6844%2C%2027.395744%5D%2C%20%5B-8.687294%2C%2025.881056%5D%2C%20%5B-11.969419%2C%2025.933353%5D%2C%20%5B-11.937224%2C%2023.374594%5D%2C%20%5B-12.874222%2C%2023.284832%5D%2C%20%5B-13.118754%2C%2022.77122%5D%2C%20%5B-12.929102%2C%2021.327071%5D%2C%20%5B-16.845194%2C%2021.333323%5D%2C%20%5B-17.063423%2C%2020.999752%5D%2C%20%5B-17.020428%2C%2021.42231%5D%2C%20%5B-17.002962%2C%2021.420734%5D%2C%20%5B-14.750955%2C%2021.5006%5D%2C%20%5B-14.630833%2C%2021.86094%5D%2C%20%5B-14.221168%2C%2022.310163%5D%2C%20%5B-13.89111%2C%2023.691009%5D%2C%20%5B-12.500963%2C%2024.770116%5D%2C%20%5B-12.030759%2C%2026.030866%5D%2C%20%5B-11.71822%2C%2026.104092%5D%2C%20%5B-11.392555%2C%2026.883424%5D%2C%20%5B-10.551263%2C%2026.990808%5D%2C%20%5B-10.189424%2C%2026.860945%5D%2C%20%5B-9.735343%2C%2026.860945%5D%2C%20%5B-9.413037%2C%2027.088476%5D%2C%20%5B-8.794884%2C%2027.120696%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22-99%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Western%20Sahara%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B42.779332%2C%2016.347891%5D%2C%20%5B42.649573%2C%2016.774635%5D%2C%20%5B42.347989%2C%2017.075806%5D%2C%20%5B42.270888%2C%2017.474722%5D%2C%20%5B41.754382%2C%2017.833046%5D%2C%20%5B41.221391%2C%2018.6716%5D%2C%20%5B40.939341%2C%2019.486485%5D%2C%20%5B40.247652%2C%2020.174635%5D%2C%20%5B39.801685%2C%2020.338862%5D%2C%20%5B39.139399%2C%2021.291905%5D%2C%20%5B39.023696%2C%2021.986875%5D%2C%20%5B39.066329%2C%2022.579656%5D%2C%20%5B38.492772%2C%2023.688451%5D%2C%20%5B38.02386%2C%2024.078686%5D%2C%20%5B37.483635%2C%2024.285495%5D%2C%20%5B37.154818%2C%2024.858483%5D%2C%20%5B37.209491%2C%2025.084542%5D%2C%20%5B36.931627%2C%2025.602959%5D%2C%20%5B36.639604%2C%2025.826228%5D%2C%20%5B36.249137%2C%2026.570136%5D%2C%20%5B35.640182%2C%2027.37652%5D%2C%20%5B35.130187%2C%2028.063352%5D%2C%20%5B34.632336%2C%2028.058546%5D%2C%20%5B34.787779%2C%2028.607427%5D%2C%20%5B34.83222%2C%2028.957483%5D%2C%20%5B34.956037%2C%2029.356555%5D%2C%20%5B36.068941%2C%2029.197495%5D%2C%20%5B36.501214%2C%2029.505254%5D%2C%20%5B36.740528%2C%2029.865283%5D%2C%20%5B37.503582%2C%2030.003776%5D%2C%20%5B37.66812%2C%2030.338665%5D%2C%20%5B37.998849%2C%2030.5085%5D%2C%20%5B37.002166%2C%2031.508413%5D%2C%20%5B39.004886%2C%2032.010217%5D%2C%20%5B39.195468%2C%2032.161009%5D%2C%20%5B40.399994%2C%2031.889992%5D%2C%20%5B41.889981%2C%2031.190009%5D%2C%20%5B44.709499%2C%2029.178891%5D%2C%20%5B46.568713%2C%2029.099025%5D%2C%20%5B47.459822%2C%2029.002519%5D%2C%20%5B47.708851%2C%2028.526063%5D%2C%20%5B48.416094%2C%2028.552004%5D%2C%20%5B48.807595%2C%2027.689628%5D%2C%20%5B49.299554%2C%2027.461218%5D%2C%20%5B49.470914%2C%2027.109999%5D%2C%20%5B50.152422%2C%2026.689663%5D%2C%20%5B50.212935%2C%2026.277027%5D%2C%20%5B50.113303%2C%2025.943972%5D%2C%20%5B50.239859%2C%2025.60805%5D%2C%20%5B50.527387%2C%2025.327808%5D%2C%20%5B50.660557%2C%2024.999896%5D%2C%20%5B50.810108%2C%2024.754743%5D%2C%20%5B51.112415%2C%2024.556331%5D%2C%20%5B51.389608%2C%2024.627386%5D%2C%20%5B51.579519%2C%2024.245497%5D%2C%20%5B51.617708%2C%2024.014219%5D%2C%20%5B52.000733%2C%2023.001154%5D%2C%20%5B55.006803%2C%2022.496948%5D%2C%20%5B55.208341%2C%2022.70833%5D%2C%20%5B55.666659%2C%2022.000001%5D%2C%20%5B54.999982%2C%2019.999994%5D%2C%20%5B52.00001%2C%2019.000003%5D%2C%20%5B49.116672%2C%2018.616668%5D%2C%20%5B48.183344%2C%2018.166669%5D%2C%20%5B47.466695%2C%2017.116682%5D%2C%20%5B47.000005%2C%2016.949999%5D%2C%20%5B46.749994%2C%2017.283338%5D%2C%20%5B46.366659%2C%2017.233315%5D%2C%20%5B45.399999%2C%2017.333335%5D%2C%20%5B45.216651%2C%2017.433329%5D%2C%20%5B44.062613%2C%2017.410359%5D%2C%20%5B43.791519%2C%2017.319977%5D%2C%20%5B43.380794%2C%2017.579987%5D%2C%20%5B43.115798%2C%2017.08844%5D%2C%20%5B43.218375%2C%2016.66689%5D%2C%20%5B42.779332%2C%2016.347891%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SAU%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Saudi%20Arabia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B33.963393%2C%209.464285%5D%2C%20%5B33.824963%2C%209.484061%5D%2C%20%5B33.842131%2C%209.981915%5D%2C%20%5B33.721959%2C%2010.325262%5D%2C%20%5B33.206938%2C%2010.720112%5D%2C%20%5B33.086766%2C%2011.441141%5D%2C%20%5B33.206938%2C%2012.179338%5D%2C%20%5B32.743419%2C%2012.248008%5D%2C%20%5B32.67475%2C%2012.024832%5D%2C%20%5B32.073892%2C%2011.97333%5D%2C%20%5B32.314235%2C%2011.681484%5D%2C%20%5B32.400072%2C%2011.080626%5D%2C%20%5B31.850716%2C%2010.531271%5D%2C%20%5B31.352862%2C%209.810241%5D%2C%20%5B30.837841%2C%209.707237%5D%2C%20%5B29.996639%2C%2010.290927%5D%2C%20%5B29.618957%2C%2010.084919%5D%2C%20%5B29.515953%2C%209.793074%5D%2C%20%5B29.000932%2C%209.604232%5D%2C%20%5B28.966597%2C%209.398224%5D%2C%20%5B27.97089%2C%209.398224%5D%2C%20%5B27.833551%2C%209.604232%5D%2C%20%5B27.112521%2C%209.638567%5D%2C%20%5B26.752006%2C%209.466893%5D%2C%20%5B26.477328%2C%209.55273%5D%2C%20%5B25.962307%2C%2010.136421%5D%2C%20%5B25.790633%2C%2010.411099%5D%2C%20%5B25.069604%2C%2010.27376%5D%2C%20%5B24.794926%2C%209.810241%5D%2C%20%5B24.537415%2C%208.917538%5D%2C%20%5B24.194068%2C%208.728696%5D%2C%20%5B23.88698%2C%208.61973%5D%2C%20%5B23.805813%2C%208.666319%5D%2C%20%5B23.459013%2C%208.954286%5D%2C%20%5B23.394779%2C%209.265068%5D%2C%20%5B23.55725%2C%209.681218%5D%2C%20%5B23.554304%2C%2010.089255%5D%2C%20%5B22.977544%2C%2010.714463%5D%2C%20%5B22.864165%2C%2011.142395%5D%2C%20%5B22.87622%2C%2011.38461%5D%2C%20%5B22.50869%2C%2011.67936%5D%2C%20%5B22.49762%2C%2012.26024%5D%2C%20%5B22.28801%2C%2012.64605%5D%2C%20%5B21.93681%2C%2012.58818%5D%2C%20%5B22.03759%2C%2012.95546%5D%2C%20%5B22.29658%2C%2013.37232%5D%2C%20%5B22.18329%2C%2013.78648%5D%2C%20%5B22.51202%2C%2014.09318%5D%2C%20%5B22.30351%2C%2014.32682%5D%2C%20%5B22.56795%2C%2014.94429%5D%2C%20%5B23.02459%2C%2015.68072%5D%2C%20%5B23.88689%2C%2015.61084%5D%2C%20%5B23.83766%2C%2019.58047%5D%2C%20%5B23.85%2C%2020%5D%2C%20%5B25%2C%2020.00304%5D%2C%20%5B25%2C%2022%5D%2C%20%5B29.02%2C%2022%5D%2C%20%5B32.9%2C%2022%5D%2C%20%5B36.86623%2C%2022%5D%2C%20%5B37.18872%2C%2021.01885%5D%2C%20%5B36.96941%2C%2020.83744%5D%2C%20%5B37.1147%2C%2019.80796%5D%2C%20%5B37.48179%2C%2018.61409%5D%2C%20%5B37.86276%2C%2018.36786%5D%2C%20%5B38.41009%2C%2017.998307%5D%2C%20%5B37.904%2C%2017.42754%5D%2C%20%5B37.16747%2C%2017.26314%5D%2C%20%5B36.85253%2C%2016.95655%5D%2C%20%5B36.75389%2C%2016.29186%5D%2C%20%5B36.32322%2C%2014.82249%5D%2C%20%5B36.42951%2C%2014.42211%5D%2C%20%5B36.27022%2C%2013.56333%5D%2C%20%5B35.86363%2C%2012.57828%5D%2C%20%5B35.26049%2C%2012.08286%5D%2C%20%5B34.83163%2C%2011.31896%5D%2C%20%5B34.73115%2C%2010.91017%5D%2C%20%5B34.25745%2C%2010.63009%5D%2C%20%5B33.96162%2C%209.58358%5D%2C%20%5B33.963393%2C%209.464285%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SDN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Sudan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B33.963393%2C%209.464285%5D%2C%20%5B33.97498%2C%208.68456%5D%2C%20%5B33.8255%2C%208.37916%5D%2C%20%5B33.2948%2C%208.35458%5D%2C%20%5B32.95418%2C%207.78497%5D%2C%20%5B33.56829%2C%207.71334%5D%2C%20%5B34.0751%2C%207.22595%5D%2C%20%5B34.25032%2C%206.82607%5D%2C%20%5B34.70702%2C%206.59422%5D%2C%20%5B35.298007%2C%205.506%5D%2C%20%5B34.620196%2C%204.847123%5D%2C%20%5B34.005%2C%204.249885%5D%2C%20%5B33.39%2C%203.79%5D%2C%20%5B32.68642%2C%203.79232%5D%2C%20%5B31.88145%2C%203.55827%5D%2C%20%5B31.24556%2C%203.7819%5D%2C%20%5B30.83385%2C%203.50917%5D%2C%20%5B29.95349%2C%204.1737%5D%2C%20%5B29.715995%2C%204.600805%5D%2C%20%5B29.159078%2C%204.389267%5D%2C%20%5B28.696678%2C%204.455077%5D%2C%20%5B28.428994%2C%204.287155%5D%2C%20%5B27.979977%2C%204.408413%5D%2C%20%5B27.374226%2C%205.233944%5D%2C%20%5B27.213409%2C%205.550953%5D%2C%20%5B26.465909%2C%205.946717%5D%2C%20%5B26.213418%2C%206.546603%5D%2C%20%5B25.796648%2C%206.979316%5D%2C%20%5B25.124131%2C%207.500085%5D%2C%20%5B25.114932%2C%207.825104%5D%2C%20%5B24.567369%2C%208.229188%5D%2C%20%5B23.88698%2C%208.61973%5D%2C%20%5B24.194068%2C%208.728696%5D%2C%20%5B24.537415%2C%208.917538%5D%2C%20%5B24.794926%2C%209.810241%5D%2C%20%5B25.069604%2C%2010.27376%5D%2C%20%5B25.790633%2C%2010.411099%5D%2C%20%5B25.962307%2C%2010.136421%5D%2C%20%5B26.477328%2C%209.55273%5D%2C%20%5B26.752006%2C%209.466893%5D%2C%20%5B27.112521%2C%209.638567%5D%2C%20%5B27.833551%2C%209.604232%5D%2C%20%5B27.97089%2C%209.398224%5D%2C%20%5B28.966597%2C%209.398224%5D%2C%20%5B29.000932%2C%209.604232%5D%2C%20%5B29.515953%2C%209.793074%5D%2C%20%5B29.618957%2C%2010.084919%5D%2C%20%5B29.996639%2C%2010.290927%5D%2C%20%5B30.837841%2C%209.707237%5D%2C%20%5B31.352862%2C%209.810241%5D%2C%20%5B31.850716%2C%2010.531271%5D%2C%20%5B32.400072%2C%2011.080626%5D%2C%20%5B32.314235%2C%2011.681484%5D%2C%20%5B32.073892%2C%2011.97333%5D%2C%20%5B32.67475%2C%2012.024832%5D%2C%20%5B32.743419%2C%2012.248008%5D%2C%20%5B33.206938%2C%2012.179338%5D%2C%20%5B33.086766%2C%2011.441141%5D%2C%20%5B33.206938%2C%2010.720112%5D%2C%20%5B33.721959%2C%2010.325262%5D%2C%20%5B33.842131%2C%209.981915%5D%2C%20%5B33.824963%2C%209.484061%5D%2C%20%5B33.963393%2C%209.464285%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SDS%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22South%20Sudan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-16.713729%2C%2013.594959%5D%2C%20%5B-17.126107%2C%2014.373516%5D%2C%20%5B-17.625043%2C%2014.729541%5D%2C%20%5B-17.185173%2C%2014.919477%5D%2C%20%5B-16.700706%2C%2015.621527%5D%2C%20%5B-16.463098%2C%2016.135036%5D%2C%20%5B-16.12069%2C%2016.455663%5D%2C%20%5B-15.623666%2C%2016.369337%5D%2C%20%5B-15.135737%2C%2016.587282%5D%2C%20%5B-14.577348%2C%2016.598264%5D%2C%20%5B-14.099521%2C%2016.304302%5D%2C%20%5B-13.435738%2C%2016.039383%5D%2C%20%5B-12.830658%2C%2015.303692%5D%2C%20%5B-12.17075%2C%2014.616834%5D%2C%20%5B-12.124887%2C%2013.994727%5D%2C%20%5B-11.927716%2C%2013.422075%5D%2C%20%5B-11.553398%2C%2013.141214%5D%2C%20%5B-11.467899%2C%2012.754519%5D%2C%20%5B-11.513943%2C%2012.442988%5D%2C%20%5B-11.658301%2C%2012.386583%5D%2C%20%5B-12.203565%2C%2012.465648%5D%2C%20%5B-12.278599%2C%2012.35444%5D%2C%20%5B-12.499051%2C%2012.33209%5D%2C%20%5B-13.217818%2C%2012.575874%5D%2C%20%5B-13.700476%2C%2012.586183%5D%2C%20%5B-15.548477%2C%2012.62817%5D%2C%20%5B-15.816574%2C%2012.515567%5D%2C%20%5B-16.147717%2C%2012.547762%5D%2C%20%5B-16.677452%2C%2012.384852%5D%2C%20%5B-16.841525%2C%2013.151394%5D%2C%20%5B-15.931296%2C%2013.130284%5D%2C%20%5B-15.691001%2C%2013.270353%5D%2C%20%5B-15.511813%2C%2013.27857%5D%2C%20%5B-15.141163%2C%2013.509512%5D%2C%20%5B-14.712197%2C%2013.298207%5D%2C%20%5B-14.277702%2C%2013.280585%5D%2C%20%5B-13.844963%2C%2013.505042%5D%2C%20%5B-14.046992%2C%2013.794068%5D%2C%20%5B-14.376714%2C%2013.62568%5D%2C%20%5B-14.687031%2C%2013.630357%5D%2C%20%5B-15.081735%2C%2013.876492%5D%2C%20%5B-15.39877%2C%2013.860369%5D%2C%20%5B-15.624596%2C%2013.623587%5D%2C%20%5B-16.713729%2C%2013.594959%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SEN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Senegal%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B162.119025%2C%20-10.482719%5D%2C%20%5B162.398646%2C%20-10.826367%5D%2C%20%5B161.700032%2C%20-10.820011%5D%2C%20%5B161.319797%2C%20-10.204751%5D%2C%20%5B161.917383%2C%20-10.446701%5D%2C%20%5B162.119025%2C%20-10.482719%5D%5D%5D%2C%20%5B%5B%5B160.852229%2C%20-9.872937%5D%2C%20%5B160.462588%2C%20-9.89521%5D%2C%20%5B159.849447%2C%20-9.794027%5D%2C%20%5B159.640003%2C%20-9.63998%5D%2C%20%5B159.702945%2C%20-9.24295%5D%2C%20%5B160.362956%2C%20-9.400304%5D%2C%20%5B160.688518%2C%20-9.610162%5D%2C%20%5B160.852229%2C%20-9.872937%5D%5D%5D%2C%20%5B%5B%5B161.679982%2C%20-9.599982%5D%2C%20%5B161.529397%2C%20-9.784312%5D%2C%20%5B160.788253%2C%20-8.917543%5D%2C%20%5B160.579997%2C%20-8.320009%5D%2C%20%5B160.920028%2C%20-8.320009%5D%2C%20%5B161.280006%2C%20-9.120011%5D%2C%20%5B161.679982%2C%20-9.599982%5D%5D%5D%2C%20%5B%5B%5B159.875027%2C%20-8.33732%5D%2C%20%5B159.917402%2C%20-8.53829%5D%2C%20%5B159.133677%2C%20-8.114181%5D%2C%20%5B158.586114%2C%20-7.754824%5D%2C%20%5B158.21115%2C%20-7.421872%5D%2C%20%5B158.359978%2C%20-7.320018%5D%2C%20%5B158.820001%2C%20-7.560003%5D%2C%20%5B159.640003%2C%20-8.020027%5D%2C%20%5B159.875027%2C%20-8.33732%5D%5D%5D%2C%20%5B%5B%5B157.538426%2C%20-7.34782%5D%2C%20%5B157.33942%2C%20-7.404767%5D%2C%20%5B156.90203%2C%20-7.176874%5D%2C%20%5B156.491358%2C%20-6.765943%5D%2C%20%5B156.542828%2C%20-6.599338%5D%2C%20%5B157.14%2C%20-7.021638%5D%2C%20%5B157.538426%2C%20-7.34782%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22SLB%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Solomon%20Islands%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-11.438779%2C%206.785917%5D%2C%20%5B-11.708195%2C%206.860098%5D%2C%20%5B-12.428099%2C%207.262942%5D%2C%20%5B-12.949049%2C%207.798646%5D%2C%20%5B-13.124025%2C%208.163946%5D%2C%20%5B-13.24655%2C%208.903049%5D%2C%20%5B-12.711958%2C%209.342712%5D%2C%20%5B-12.596719%2C%209.620188%5D%2C%20%5B-12.425929%2C%209.835834%5D%2C%20%5B-12.150338%2C%209.858572%5D%2C%20%5B-11.917277%2C%2010.046984%5D%2C%20%5B-11.117481%2C%2010.045873%5D%2C%20%5B-10.839152%2C%209.688246%5D%2C%20%5B-10.622395%2C%209.26791%5D%2C%20%5B-10.65477%2C%208.977178%5D%2C%20%5B-10.494315%2C%208.715541%5D%2C%20%5B-10.505477%2C%208.348896%5D%2C%20%5B-10.230094%2C%208.406206%5D%2C%20%5B-10.695595%2C%207.939464%5D%2C%20%5B-11.146704%2C%207.396706%5D%2C%20%5B-11.199802%2C%207.105846%5D%2C%20%5B-11.438779%2C%206.785917%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SLE%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Sierra%20Leone%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-87.793111%2C%2013.38448%5D%2C%20%5B-87.904112%2C%2013.149017%5D%2C%20%5B-88.483302%2C%2013.163951%5D%2C%20%5B-88.843228%2C%2013.259734%5D%2C%20%5B-89.256743%2C%2013.458533%5D%2C%20%5B-89.812394%2C%2013.520622%5D%2C%20%5B-90.095555%2C%2013.735338%5D%2C%20%5B-90.064678%2C%2013.88197%5D%2C%20%5B-89.721934%2C%2014.134228%5D%2C%20%5B-89.534219%2C%2014.244816%5D%2C%20%5B-89.587343%2C%2014.362586%5D%2C%20%5B-89.353326%2C%2014.424133%5D%2C%20%5B-89.058512%2C%2014.340029%5D%2C%20%5B-88.843073%2C%2014.140507%5D%2C%20%5B-88.541231%2C%2013.980155%5D%2C%20%5B-88.503998%2C%2013.845486%5D%2C%20%5B-88.065343%2C%2013.964626%5D%2C%20%5B-87.859515%2C%2013.893312%5D%2C%20%5B-87.723503%2C%2013.78505%5D%2C%20%5B-87.793111%2C%2013.38448%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SLV%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22El%20Salvador%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B48.93813%2C%209.451749%5D%2C%20%5B48.486736%2C%208.837626%5D%2C%20%5B47.78942%2C%208.003%5D%2C%20%5B46.948328%2C%207.996877%5D%2C%20%5B43.67875%2C%209.18358%5D%2C%20%5B43.296975%2C%209.540477%5D%2C%20%5B42.92812%2C%2010.02194%5D%2C%20%5B42.55876%2C%2010.57258%5D%2C%20%5B42.776852%2C%2010.926879%5D%2C%20%5B43.145305%2C%2011.46204%5D%2C%20%5B43.47066%2C%2011.27771%5D%2C%20%5B43.666668%2C%2010.864169%5D%2C%20%5B44.117804%2C%2010.445538%5D%2C%20%5B44.614259%2C%2010.442205%5D%2C%20%5B45.556941%2C%2010.698029%5D%2C%20%5B46.645401%2C%2010.816549%5D%2C%20%5B47.525658%2C%2011.127228%5D%2C%20%5B48.021596%2C%2011.193064%5D%2C%20%5B48.378784%2C%2011.375482%5D%2C%20%5B48.948206%2C%2011.410622%5D%2C%20%5B48.942005%2C%2011.394266%5D%2C%20%5B48.938491%2C%2010.982327%5D%2C%20%5B48.938233%2C%209.9735%5D%2C%20%5B48.93813%2C%209.451749%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22-99%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Somaliland%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B49.72862%2C%2011.5789%5D%2C%20%5B50.25878%2C%2011.67957%5D%2C%20%5B50.73202%2C%2012.0219%5D%2C%20%5B51.1112%2C%2012.02464%5D%2C%20%5B51.13387%2C%2011.74815%5D%2C%20%5B51.04153%2C%2011.16651%5D%2C%20%5B51.04531%2C%2010.6409%5D%2C%20%5B50.83418%2C%2010.27972%5D%2C%20%5B50.55239%2C%209.19874%5D%2C%20%5B50.07092%2C%208.08173%5D%2C%20%5B49.4527%2C%206.80466%5D%2C%20%5B48.59455%2C%205.33911%5D%2C%20%5B47.74079%2C%204.2194%5D%2C%20%5B46.56476%2C%202.85529%5D%2C%20%5B45.56399%2C%202.04576%5D%2C%20%5B44.06815%2C%201.05283%5D%2C%20%5B43.13597%2C%200.2922%5D%2C%20%5B42.04157%2C%20-0.91916%5D%2C%20%5B41.81095%2C%20-1.44647%5D%2C%20%5B41.58513%2C%20-1.68325%5D%2C%20%5B40.993%2C%20-0.85829%5D%2C%20%5B40.98105%2C%202.78452%5D%2C%20%5B41.855083%2C%203.918912%5D%2C%20%5B42.12861%2C%204.23413%5D%2C%20%5B42.76967%2C%204.25259%5D%2C%20%5B43.66087%2C%204.95755%5D%2C%20%5B44.9636%2C%205.00162%5D%2C%20%5B47.78942%2C%208.003%5D%2C%20%5B48.486736%2C%208.837626%5D%2C%20%5B48.93813%2C%209.451749%5D%2C%20%5B48.938233%2C%209.9735%5D%2C%20%5B48.938491%2C%2010.982327%5D%2C%20%5B48.942005%2C%2011.394266%5D%2C%20%5B48.948205%2C%2011.410617%5D%2C%20%5B49.26776%2C%2011.43033%5D%2C%20%5B49.72862%2C%2011.5789%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SOM%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Somalia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B20.874313%2C%2045.416375%5D%2C%20%5B21.483526%2C%2045.18117%5D%2C%20%5B21.562023%2C%2044.768947%5D%2C%20%5B22.145088%2C%2044.478422%5D%2C%20%5B22.459022%2C%2044.702517%5D%2C%20%5B22.705726%2C%2044.578003%5D%2C%20%5B22.474008%2C%2044.409228%5D%2C%20%5B22.65715%2C%2044.234923%5D%2C%20%5B22.410446%2C%2044.008063%5D%2C%20%5B22.500157%2C%2043.642814%5D%2C%20%5B22.986019%2C%2043.211161%5D%2C%20%5B22.604801%2C%2042.898519%5D%2C%20%5B22.436595%2C%2042.580321%5D%2C%20%5B22.545012%2C%2042.461362%5D%2C%20%5B22.380526%2C%2042.32026%5D%2C%20%5B21.91708%2C%2042.30364%5D%2C%20%5B21.576636%2C%2042.245224%5D%2C%20%5B21.54332%2C%2042.32025%5D%2C%20%5B21.66292%2C%2042.43922%5D%2C%20%5B21.77505%2C%2042.6827%5D%2C%20%5B21.63302%2C%2042.67717%5D%2C%20%5B21.43866%2C%2042.86255%5D%2C%20%5B21.27421%2C%2042.90959%5D%2C%20%5B21.143395%2C%2043.068685%5D%2C%20%5B20.95651%2C%2043.13094%5D%2C%20%5B20.81448%2C%2043.27205%5D%2C%20%5B20.63508%2C%2043.21671%5D%2C%20%5B20.49679%2C%2042.88469%5D%2C%20%5B20.25758%2C%2042.81275%5D%2C%20%5B20.3398%2C%2042.89852%5D%2C%20%5B19.95857%2C%2043.10604%5D%2C%20%5B19.63%2C%2043.21378%5D%2C%20%5B19.48389%2C%2043.35229%5D%2C%20%5B19.21852%2C%2043.52384%5D%2C%20%5B19.454%2C%2043.5681%5D%2C%20%5B19.59976%2C%2044.03847%5D%2C%20%5B19.11761%2C%2044.42307%5D%2C%20%5B19.36803%2C%2044.863%5D%2C%20%5B19.00548%2C%2044.86023%5D%2C%20%5B19.390476%2C%2045.236516%5D%2C%20%5B19.072769%2C%2045.521511%5D%2C%20%5B18.82982%2C%2045.90888%5D%2C%20%5B19.596045%2C%2046.17173%5D%2C%20%5B20.220192%2C%2046.127469%5D%2C%20%5B20.762175%2C%2045.734573%5D%2C%20%5B20.874313%2C%2045.416375%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SRB%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Republic%20of%20Serbia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-57.147436%2C%205.97315%5D%2C%20%5B-55.949318%2C%205.772878%5D%2C%20%5B-55.84178%2C%205.953125%5D%2C%20%5B-55.03325%2C%206.025291%5D%2C%20%5B-53.958045%2C%205.756548%5D%2C%20%5B-54.478633%2C%204.896756%5D%2C%20%5B-54.399542%2C%204.212611%5D%2C%20%5B-54.006931%2C%203.620038%5D%2C%20%5B-54.181726%2C%203.18978%5D%2C%20%5B-54.269705%2C%202.732392%5D%2C%20%5B-54.524754%2C%202.311849%5D%2C%20%5B-55.097587%2C%202.523748%5D%2C%20%5B-55.569755%2C%202.421506%5D%2C%20%5B-55.973322%2C%202.510364%5D%2C%20%5B-56.073342%2C%202.220795%5D%2C%20%5B-55.9056%2C%202.021996%5D%2C%20%5B-55.995698%2C%201.817667%5D%2C%20%5B-56.539386%2C%201.899523%5D%2C%20%5B-57.150098%2C%202.768927%5D%2C%20%5B-57.281433%2C%203.333492%5D%2C%20%5B-57.601569%2C%203.334655%5D%2C%20%5B-58.044694%2C%204.060864%5D%2C%20%5B-57.86021%2C%204.576801%5D%2C%20%5B-57.914289%2C%204.812626%5D%2C%20%5B-57.307246%2C%205.073567%5D%2C%20%5B-57.147436%2C%205.97315%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SUR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Suriname%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B18.853144%2C%2049.49623%5D%2C%20%5B18.909575%2C%2049.435846%5D%2C%20%5B19.320713%2C%2049.571574%5D%2C%20%5B19.825023%2C%2049.217125%5D%2C%20%5B20.415839%2C%2049.431453%5D%2C%20%5B20.887955%2C%2049.328772%5D%2C%20%5B21.607808%2C%2049.470107%5D%2C%20%5B22.558138%2C%2049.085738%5D%2C%20%5B22.280842%2C%2048.825392%5D%2C%20%5B22.085608%2C%2048.422264%5D%2C%20%5B21.872236%2C%2048.319971%5D%2C%20%5B20.801294%2C%2048.623854%5D%2C%20%5B20.473562%2C%2048.56285%5D%2C%20%5B20.239054%2C%2048.327567%5D%2C%20%5B19.769471%2C%2048.202691%5D%2C%20%5B19.661364%2C%2048.266615%5D%2C%20%5B19.174365%2C%2048.111379%5D%2C%20%5B18.777025%2C%2048.081768%5D%2C%20%5B18.696513%2C%2047.880954%5D%2C%20%5B17.857133%2C%2047.758429%5D%2C%20%5B17.488473%2C%2047.867466%5D%2C%20%5B16.979667%2C%2048.123497%5D%2C%20%5B16.879983%2C%2048.470013%5D%2C%20%5B16.960288%2C%2048.596982%5D%2C%20%5B17.101985%2C%2048.816969%5D%2C%20%5B17.545007%2C%2048.800019%5D%2C%20%5B17.886485%2C%2048.903475%5D%2C%20%5B17.913512%2C%2048.996493%5D%2C%20%5B18.104973%2C%2049.043983%5D%2C%20%5B18.170498%2C%2049.271515%5D%2C%20%5B18.399994%2C%2049.315001%5D%2C%20%5B18.554971%2C%2049.495015%5D%2C%20%5B18.853144%2C%2049.49623%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SVK%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Slovakia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B13.806475%2C%2046.509306%5D%2C%20%5B14.632472%2C%2046.431817%5D%2C%20%5B15.137092%2C%2046.658703%5D%2C%20%5B16.011664%2C%2046.683611%5D%2C%20%5B16.202298%2C%2046.852386%5D%2C%20%5B16.370505%2C%2046.841327%5D%2C%20%5B16.564808%2C%2046.503751%5D%2C%20%5B15.768733%2C%2046.238108%5D%2C%20%5B15.67153%2C%2045.834154%5D%2C%20%5B15.323954%2C%2045.731783%5D%2C%20%5B15.327675%2C%2045.452316%5D%2C%20%5B14.935244%2C%2045.471695%5D%2C%20%5B14.595109%2C%2045.634941%5D%2C%20%5B14.411968%2C%2045.466166%5D%2C%20%5B13.71506%2C%2045.500324%5D%2C%20%5B13.93763%2C%2045.591016%5D%2C%20%5B13.69811%2C%2046.016778%5D%2C%20%5B13.806475%2C%2046.509306%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SVN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Slovenia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B22.183173%2C%2065.723741%5D%2C%20%5B21.213517%2C%2065.026005%5D%2C%20%5B21.369631%2C%2064.413588%5D%2C%20%5B19.778876%2C%2063.609554%5D%2C%20%5B17.847779%2C%2062.7494%5D%2C%20%5B17.119555%2C%2061.341166%5D%2C%20%5B17.831346%2C%2060.636583%5D%2C%20%5B18.787722%2C%2060.081914%5D%2C%20%5B17.869225%2C%2058.953766%5D%2C%20%5B16.829185%2C%2058.719827%5D%2C%20%5B16.44771%2C%2057.041118%5D%2C%20%5B15.879786%2C%2056.104302%5D%2C%20%5B14.666681%2C%2056.200885%5D%2C%20%5B14.100721%2C%2055.407781%5D%2C%20%5B12.942911%2C%2055.361737%5D%2C%20%5B12.625101%2C%2056.30708%5D%2C%20%5B11.787942%2C%2057.441817%5D%2C%20%5B11.027369%2C%2058.856149%5D%2C%20%5B11.468272%2C%2059.432393%5D%2C%20%5B12.300366%2C%2060.117933%5D%2C%20%5B12.631147%2C%2061.293572%5D%2C%20%5B11.992064%2C%2061.800362%5D%2C%20%5B11.930569%2C%2063.128318%5D%2C%20%5B12.579935%2C%2064.066219%5D%2C%20%5B13.571916%2C%2064.049114%5D%2C%20%5B13.919905%2C%2064.445421%5D%2C%20%5B13.55569%2C%2064.787028%5D%2C%20%5B15.108411%2C%2066.193867%5D%2C%20%5B16.108712%2C%2067.302456%5D%2C%20%5B16.768879%2C%2068.013937%5D%2C%20%5B17.729182%2C%2068.010552%5D%2C%20%5B17.993868%2C%2068.567391%5D%2C%20%5B19.87856%2C%2068.407194%5D%2C%20%5B20.025269%2C%2069.065139%5D%2C%20%5B20.645593%2C%2069.106247%5D%2C%20%5B21.978535%2C%2068.616846%5D%2C%20%5B23.539473%2C%2067.936009%5D%2C%20%5B23.56588%2C%2066.396051%5D%2C%20%5B23.903379%2C%2066.006927%5D%2C%20%5B22.183173%2C%2065.723741%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SWE%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Sweden%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B32.071665%2C%20-26.73382%5D%2C%20%5B31.86806%2C%20-27.177927%5D%2C%20%5B31.282773%2C%20-27.285879%5D%2C%20%5B30.685962%2C%20-26.743845%5D%2C%20%5B30.676609%2C%20-26.398078%5D%2C%20%5B30.949667%2C%20-26.022649%5D%2C%20%5B31.04408%2C%20-25.731452%5D%2C%20%5B31.333158%2C%20-25.660191%5D%2C%20%5B31.837778%2C%20-25.843332%5D%2C%20%5B31.985779%2C%20-26.29178%5D%2C%20%5B32.071665%2C%20-26.73382%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SWZ%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Swaziland%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B38.792341%2C%2033.378686%5D%2C%20%5B36.834062%2C%2032.312938%5D%2C%20%5B35.719918%2C%2032.709192%5D%2C%20%5B35.700798%2C%2032.716014%5D%2C%20%5B35.836397%2C%2032.868123%5D%2C%20%5B35.821101%2C%2033.277426%5D%2C%20%5B36.06646%2C%2033.824912%5D%2C%20%5B36.61175%2C%2034.201789%5D%2C%20%5B36.448194%2C%2034.593935%5D%2C%20%5B35.998403%2C%2034.644914%5D%2C%20%5B35.905023%2C%2035.410009%5D%2C%20%5B36.149763%2C%2035.821535%5D%2C%20%5B36.41755%2C%2036.040617%5D%2C%20%5B36.685389%2C%2036.259699%5D%2C%20%5B36.739494%2C%2036.81752%5D%2C%20%5B37.066761%2C%2036.623036%5D%2C%20%5B38.167727%2C%2036.90121%5D%2C%20%5B38.699891%2C%2036.712927%5D%2C%20%5B39.52258%2C%2036.716054%5D%2C%20%5B40.673259%2C%2037.091276%5D%2C%20%5B41.212089%2C%2037.074352%5D%2C%20%5B42.349591%2C%2037.229873%5D%2C%20%5B41.837064%2C%2036.605854%5D%2C%20%5B41.289707%2C%2036.358815%5D%2C%20%5B41.383965%2C%2035.628317%5D%2C%20%5B41.006159%2C%2034.419372%5D%2C%20%5B38.792341%2C%2033.378686%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22SYR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Syria%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B14.495787%2C%2012.859396%5D%2C%20%5B14.595781%2C%2013.330427%5D%2C%20%5B13.954477%2C%2013.353449%5D%2C%20%5B13.956699%2C%2013.996691%5D%2C%20%5B13.540394%2C%2014.367134%5D%2C%20%5B13.97217%2C%2015.68437%5D%2C%20%5B15.247731%2C%2016.627306%5D%2C%20%5B15.300441%2C%2017.92795%5D%2C%20%5B15.685741%2C%2019.95718%5D%2C%20%5B15.903247%2C%2020.387619%5D%2C%20%5B15.487148%2C%2020.730415%5D%2C%20%5B15.47106%2C%2021.04845%5D%2C%20%5B15.096888%2C%2021.308519%5D%2C%20%5B14.8513%2C%2022.86295%5D%2C%20%5B15.86085%2C%2023.40972%5D%2C%20%5B19.84926%2C%2021.49509%5D%2C%20%5B23.83766%2C%2019.58047%5D%2C%20%5B23.88689%2C%2015.61084%5D%2C%20%5B23.02459%2C%2015.68072%5D%2C%20%5B22.56795%2C%2014.94429%5D%2C%20%5B22.30351%2C%2014.32682%5D%2C%20%5B22.51202%2C%2014.09318%5D%2C%20%5B22.18329%2C%2013.78648%5D%2C%20%5B22.29658%2C%2013.37232%5D%2C%20%5B22.03759%2C%2012.95546%5D%2C%20%5B21.93681%2C%2012.58818%5D%2C%20%5B22.28801%2C%2012.64605%5D%2C%20%5B22.49762%2C%2012.26024%5D%2C%20%5B22.50869%2C%2011.67936%5D%2C%20%5B22.87622%2C%2011.38461%5D%2C%20%5B22.864165%2C%2011.142395%5D%2C%20%5B22.231129%2C%2010.971889%5D%2C%20%5B21.723822%2C%2010.567056%5D%2C%20%5B21.000868%2C%209.475985%5D%2C%20%5B20.059685%2C%209.012706%5D%2C%20%5B19.094008%2C%209.074847%5D%2C%20%5B18.81201%2C%208.982915%5D%2C%20%5B18.911022%2C%208.630895%5D%2C%20%5B18.389555%2C%208.281304%5D%2C%20%5B17.96493%2C%207.890914%5D%2C%20%5B16.705988%2C%207.508328%5D%2C%20%5B16.456185%2C%207.734774%5D%2C%20%5B16.290562%2C%207.754307%5D%2C%20%5B16.106232%2C%207.497088%5D%2C%20%5B15.27946%2C%207.421925%5D%2C%20%5B15.436092%2C%207.692812%5D%2C%20%5B15.120866%2C%208.38215%5D%2C%20%5B14.979996%2C%208.796104%5D%2C%20%5B14.544467%2C%208.965861%5D%2C%20%5B13.954218%2C%209.549495%5D%2C%20%5B14.171466%2C%2010.021378%5D%2C%20%5B14.627201%2C%209.920919%5D%2C%20%5B14.909354%2C%209.992129%5D%2C%20%5B15.467873%2C%209.982337%5D%2C%20%5B14.923565%2C%2010.891325%5D%2C%20%5B14.960152%2C%2011.555574%5D%2C%20%5B14.89336%2C%2012.21905%5D%2C%20%5B14.495787%2C%2012.859396%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22TCD%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Chad%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B1.865241%2C%206.142158%5D%2C%20%5B1.060122%2C%205.928837%5D%2C%20%5B0.836931%2C%206.279979%5D%2C%20%5B0.570384%2C%206.914359%5D%2C%20%5B0.490957%2C%207.411744%5D%2C%20%5B0.712029%2C%208.312465%5D%2C%20%5B0.461192%2C%208.677223%5D%2C%20%5B0.365901%2C%209.465004%5D%2C%20%5B0.36758%2C%2010.191213%5D%2C%20%5B-0.049785%2C%2010.706918%5D%2C%20%5B0.023803%2C%2011.018682%5D%2C%20%5B0.899563%2C%2010.997339%5D%2C%20%5B0.772336%2C%2010.470808%5D%2C%20%5B1.077795%2C%2010.175607%5D%2C%20%5B1.425061%2C%209.825395%5D%2C%20%5B1.463043%2C%209.334624%5D%2C%20%5B1.664478%2C%209.12859%5D%2C%20%5B1.618951%2C%206.832038%5D%2C%20%5B1.865241%2C%206.142158%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22TGO%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Togo%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B102.584932%2C%2012.186595%5D%2C%20%5B101.687158%2C%2012.64574%5D%2C%20%5B100.83181%2C%2012.627085%5D%2C%20%5B100.978467%2C%2013.412722%5D%2C%20%5B100.097797%2C%2013.406856%5D%2C%20%5B100.018733%2C%2012.307001%5D%2C%20%5B99.478921%2C%2010.846367%5D%2C%20%5B99.153772%2C%209.963061%5D%2C%20%5B99.222399%2C%209.239255%5D%2C%20%5B99.873832%2C%209.207862%5D%2C%20%5B100.279647%2C%208.295153%5D%2C%20%5B100.459274%2C%207.429573%5D%2C%20%5B101.017328%2C%206.856869%5D%2C%20%5B101.623079%2C%206.740622%5D%2C%20%5B102.141187%2C%206.221636%5D%2C%20%5B101.814282%2C%205.810808%5D%2C%20%5B101.154219%2C%205.691384%5D%2C%20%5B101.075516%2C%206.204867%5D%2C%20%5B100.259596%2C%206.642825%5D%2C%20%5B100.085757%2C%206.464489%5D%2C%20%5B99.690691%2C%206.848213%5D%2C%20%5B99.519642%2C%207.343454%5D%2C%20%5B98.988253%2C%207.907993%5D%2C%20%5B98.503786%2C%208.382305%5D%2C%20%5B98.339662%2C%207.794512%5D%2C%20%5B98.150009%2C%208.350007%5D%2C%20%5B98.25915%2C%208.973923%5D%2C%20%5B98.553551%2C%209.93296%5D%2C%20%5B99.038121%2C%2010.960546%5D%2C%20%5B99.587286%2C%2011.892763%5D%2C%20%5B99.196354%2C%2012.804748%5D%2C%20%5B99.212012%2C%2013.269294%5D%2C%20%5B99.097755%2C%2013.827503%5D%2C%20%5B98.430819%2C%2014.622028%5D%2C%20%5B98.192074%2C%2015.123703%5D%2C%20%5B98.537376%2C%2015.308497%5D%2C%20%5B98.903348%2C%2016.177824%5D%2C%20%5B98.493761%2C%2016.837836%5D%2C%20%5B97.859123%2C%2017.567946%5D%2C%20%5B97.375896%2C%2018.445438%5D%2C%20%5B97.797783%2C%2018.62708%5D%2C%20%5B98.253724%2C%2019.708203%5D%2C%20%5B98.959676%2C%2019.752981%5D%2C%20%5B99.543309%2C%2020.186598%5D%2C%20%5B100.115988%2C%2020.41785%5D%2C%20%5B100.548881%2C%2020.109238%5D%2C%20%5B100.606294%2C%2019.508344%5D%2C%20%5B101.282015%2C%2019.462585%5D%2C%20%5B101.035931%2C%2018.408928%5D%2C%20%5B101.059548%2C%2017.512497%5D%2C%20%5B102.113592%2C%2018.109102%5D%2C%20%5B102.413005%2C%2017.932782%5D%2C%20%5B102.998706%2C%2017.961695%5D%2C%20%5B103.200192%2C%2018.309632%5D%2C%20%5B103.956477%2C%2018.240954%5D%2C%20%5B104.716947%2C%2017.428859%5D%2C%20%5B104.779321%2C%2016.441865%5D%2C%20%5B105.589039%2C%2015.570316%5D%2C%20%5B105.544338%2C%2014.723934%5D%2C%20%5B105.218777%2C%2014.273212%5D%2C%20%5B104.281418%2C%2014.416743%5D%2C%20%5B102.988422%2C%2014.225721%5D%2C%20%5B102.348099%2C%2013.394247%5D%2C%20%5B102.584932%2C%2012.186595%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22THA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Thailand%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B71.014198%2C%2040.244366%5D%2C%20%5B70.648019%2C%2039.935754%5D%2C%20%5B69.55961%2C%2040.103211%5D%2C%20%5B69.464887%2C%2039.526683%5D%2C%20%5B70.549162%2C%2039.604198%5D%2C%20%5B71.784694%2C%2039.279463%5D%2C%20%5B73.675379%2C%2039.431237%5D%2C%20%5B73.928852%2C%2038.505815%5D%2C%20%5B74.257514%2C%2038.606507%5D%2C%20%5B74.864816%2C%2038.378846%5D%2C%20%5B74.829986%2C%2037.990007%5D%2C%20%5B74.980002%2C%2037.41999%5D%2C%20%5B73.948696%2C%2037.421566%5D%2C%20%5B73.260056%2C%2037.495257%5D%2C%20%5B72.63689%2C%2037.047558%5D%2C%20%5B72.193041%2C%2036.948288%5D%2C%20%5B71.844638%2C%2036.738171%5D%2C%20%5B71.448693%2C%2037.065645%5D%2C%20%5B71.541918%2C%2037.905774%5D%2C%20%5B71.239404%2C%2037.953265%5D%2C%20%5B71.348131%2C%2038.258905%5D%2C%20%5B70.806821%2C%2038.486282%5D%2C%20%5B70.376304%2C%2038.138396%5D%2C%20%5B70.270574%2C%2037.735165%5D%2C%20%5B70.116578%2C%2037.588223%5D%2C%20%5B69.518785%2C%2037.608997%5D%2C%20%5B69.196273%2C%2037.151144%5D%2C%20%5B68.859446%2C%2037.344336%5D%2C%20%5B68.135562%2C%2037.023115%5D%2C%20%5B67.83%2C%2037.144994%5D%2C%20%5B68.392033%2C%2038.157025%5D%2C%20%5B68.176025%2C%2038.901553%5D%2C%20%5B67.44222%2C%2039.140144%5D%2C%20%5B67.701429%2C%2039.580478%5D%2C%20%5B68.536416%2C%2039.533453%5D%2C%20%5B69.011633%2C%2040.086158%5D%2C%20%5B69.329495%2C%2040.727824%5D%2C%20%5B70.666622%2C%2040.960213%5D%2C%20%5B70.45816%2C%2040.496495%5D%2C%20%5B70.601407%2C%2040.218527%5D%2C%20%5B71.014198%2C%2040.244366%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22TJK%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Tajikistan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B61.210817%2C%2035.650072%5D%2C%20%5B61.123071%2C%2036.491597%5D%2C%20%5B60.377638%2C%2036.527383%5D%2C%20%5B59.234762%2C%2037.412988%5D%2C%20%5B58.436154%2C%2037.522309%5D%2C%20%5B57.330434%2C%2038.029229%5D%2C%20%5B56.619366%2C%2038.121394%5D%2C%20%5B56.180375%2C%2037.935127%5D%2C%20%5B55.511578%2C%2037.964117%5D%2C%20%5B54.800304%2C%2037.392421%5D%2C%20%5B53.921598%2C%2037.198918%5D%2C%20%5B53.735511%2C%2037.906136%5D%2C%20%5B53.880929%2C%2038.952093%5D%2C%20%5B53.101028%2C%2039.290574%5D%2C%20%5B53.357808%2C%2039.975286%5D%2C%20%5B52.693973%2C%2040.033629%5D%2C%20%5B52.915251%2C%2040.876523%5D%2C%20%5B53.858139%2C%2040.631034%5D%2C%20%5B54.736845%2C%2040.951015%5D%2C%20%5B54.008311%2C%2041.551211%5D%2C%20%5B53.721713%2C%2042.123191%5D%2C%20%5B52.91675%2C%2041.868117%5D%2C%20%5B52.814689%2C%2041.135371%5D%2C%20%5B52.50246%2C%2041.783316%5D%2C%20%5B52.944293%2C%2042.116034%5D%2C%20%5B54.079418%2C%2042.324109%5D%2C%20%5B54.755345%2C%2042.043971%5D%2C%20%5B55.455251%2C%2041.259859%5D%2C%20%5B55.968191%2C%2041.308642%5D%2C%20%5B57.096391%2C%2041.32231%5D%2C%20%5B56.932215%2C%2041.826026%5D%2C%20%5B57.78653%2C%2042.170553%5D%2C%20%5B58.629011%2C%2042.751551%5D%2C%20%5B59.976422%2C%2042.223082%5D%2C%20%5B60.083341%2C%2041.425146%5D%2C%20%5B60.465953%2C%2041.220327%5D%2C%20%5B61.547179%2C%2041.26637%5D%2C%20%5B61.882714%2C%2041.084857%5D%2C%20%5B62.37426%2C%2040.053886%5D%2C%20%5B63.518015%2C%2039.363257%5D%2C%20%5B64.170223%2C%2038.892407%5D%2C%20%5B65.215999%2C%2038.402695%5D%2C%20%5B66.54615%2C%2037.974685%5D%2C%20%5B66.518607%2C%2037.362784%5D%2C%20%5B66.217385%2C%2037.39379%5D%2C%20%5B65.745631%2C%2037.661164%5D%2C%20%5B65.588948%2C%2037.305217%5D%2C%20%5B64.746105%2C%2037.111818%5D%2C%20%5B64.546479%2C%2036.312073%5D%2C%20%5B63.982896%2C%2036.007957%5D%2C%20%5B63.193538%2C%2035.857166%5D%2C%20%5B62.984662%2C%2035.404041%5D%2C%20%5B62.230651%2C%2035.270664%5D%2C%20%5B61.210817%2C%2035.650072%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22TKM%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Turkmenistan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B124.968682%2C%20-8.89279%5D%2C%20%5B125.086246%2C%20-8.656887%5D%2C%20%5B125.947072%2C%20-8.432095%5D%2C%20%5B126.644704%2C%20-8.398247%5D%2C%20%5B126.957243%2C%20-8.273345%5D%2C%20%5B127.335928%2C%20-8.397317%5D%2C%20%5B126.967992%2C%20-8.668256%5D%2C%20%5B125.925885%2C%20-9.106007%5D%2C%20%5B125.08852%2C%20-9.393173%5D%2C%20%5B125.07002%2C%20-9.089987%5D%2C%20%5B124.968682%2C%20-8.89279%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22TLS%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22East%20Timor%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-61.68%2C%2010.76%5D%2C%20%5B-61.105%2C%2010.89%5D%2C%20%5B-60.895%2C%2010.855%5D%2C%20%5B-60.935%2C%2010.11%5D%2C%20%5B-61.77%2C%2010%5D%2C%20%5B-61.95%2C%2010.09%5D%2C%20%5B-61.66%2C%2010.365%5D%2C%20%5B-61.68%2C%2010.76%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22TTO%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Trinidad%20and%20Tobago%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B9.48214%2C%2030.307556%5D%2C%20%5B9.055603%2C%2032.102692%5D%2C%20%5B8.439103%2C%2032.506285%5D%2C%20%5B8.430473%2C%2032.748337%5D%2C%20%5B7.612642%2C%2033.344115%5D%2C%20%5B7.524482%2C%2034.097376%5D%2C%20%5B8.140981%2C%2034.655146%5D%2C%20%5B8.376368%2C%2035.479876%5D%2C%20%5B8.217824%2C%2036.433177%5D%2C%20%5B8.420964%2C%2036.946427%5D%2C%20%5B9.509994%2C%2037.349994%5D%2C%20%5B10.210002%2C%2037.230002%5D%2C%20%5B10.18065%2C%2036.724038%5D%2C%20%5B11.028867%2C%2037.092103%5D%2C%20%5B11.100026%2C%2036.899996%5D%2C%20%5B10.600005%2C%2036.41%5D%2C%20%5B10.593287%2C%2035.947444%5D%2C%20%5B10.939519%2C%2035.698984%5D%2C%20%5B10.807847%2C%2034.833507%5D%2C%20%5B10.149593%2C%2034.330773%5D%2C%20%5B10.339659%2C%2033.785742%5D%2C%20%5B10.856836%2C%2033.76874%5D%2C%20%5B11.108501%2C%2033.293343%5D%2C%20%5B11.488787%2C%2033.136996%5D%2C%20%5B11.432253%2C%2032.368903%5D%2C%20%5B10.94479%2C%2032.081815%5D%2C%20%5B10.636901%2C%2031.761421%5D%2C%20%5B9.950225%2C%2031.37607%5D%2C%20%5B10.056575%2C%2030.961831%5D%2C%20%5B9.970017%2C%2030.539325%5D%2C%20%5B9.48214%2C%2030.307556%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22TUN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Tunisia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B36.913127%2C%2041.335358%5D%2C%20%5B38.347665%2C%2040.948586%5D%2C%20%5B39.512607%2C%2041.102763%5D%2C%20%5B40.373433%2C%2041.013673%5D%2C%20%5B41.554084%2C%2041.535656%5D%2C%20%5B42.619549%2C%2041.583173%5D%2C%20%5B43.582746%2C%2041.092143%5D%2C%20%5B43.752658%2C%2040.740201%5D%2C%20%5B43.656436%2C%2040.253564%5D%2C%20%5B44.400009%2C%2040.005%5D%2C%20%5B44.79399%2C%2039.713003%5D%2C%20%5B44.109225%2C%2039.428136%5D%2C%20%5B44.421403%2C%2038.281281%5D%2C%20%5B44.225756%2C%2037.971584%5D%2C%20%5B44.772699%2C%2037.170445%5D%2C%20%5B44.293452%2C%2037.001514%5D%2C%20%5B43.942259%2C%2037.256228%5D%2C%20%5B42.779126%2C%2037.385264%5D%2C%20%5B42.349591%2C%2037.229873%5D%2C%20%5B41.212089%2C%2037.074352%5D%2C%20%5B40.673259%2C%2037.091276%5D%2C%20%5B39.52258%2C%2036.716054%5D%2C%20%5B38.699891%2C%2036.712927%5D%2C%20%5B38.167727%2C%2036.90121%5D%2C%20%5B37.066761%2C%2036.623036%5D%2C%20%5B36.739494%2C%2036.81752%5D%2C%20%5B36.685389%2C%2036.259699%5D%2C%20%5B36.41755%2C%2036.040617%5D%2C%20%5B36.149763%2C%2035.821535%5D%2C%20%5B35.782085%2C%2036.274995%5D%2C%20%5B36.160822%2C%2036.650606%5D%2C%20%5B35.550936%2C%2036.565443%5D%2C%20%5B34.714553%2C%2036.795532%5D%2C%20%5B34.026895%2C%2036.21996%5D%2C%20%5B32.509158%2C%2036.107564%5D%2C%20%5B31.699595%2C%2036.644275%5D%2C%20%5B30.621625%2C%2036.677865%5D%2C%20%5B30.391096%2C%2036.262981%5D%2C%20%5B29.699976%2C%2036.144357%5D%2C%20%5B28.732903%2C%2036.676831%5D%2C%20%5B27.641187%2C%2036.658822%5D%2C%20%5B27.048768%2C%2037.653361%5D%2C%20%5B26.318218%2C%2038.208133%5D%2C%20%5B26.8047%2C%2038.98576%5D%2C%20%5B26.170785%2C%2039.463612%5D%2C%20%5B27.28002%2C%2040.420014%5D%2C%20%5B28.819978%2C%2040.460011%5D%2C%20%5B29.240004%2C%2041.219991%5D%2C%20%5B31.145934%2C%2041.087622%5D%2C%20%5B32.347979%2C%2041.736264%5D%2C%20%5B33.513283%2C%2042.01896%5D%2C%20%5B35.167704%2C%2042.040225%5D%2C%20%5B36.913127%2C%2041.335358%5D%5D%5D%2C%20%5B%5B%5B27.192377%2C%2040.690566%5D%2C%20%5B26.358009%2C%2040.151994%5D%2C%20%5B26.043351%2C%2040.617754%5D%2C%20%5B26.056942%2C%2040.824123%5D%2C%20%5B26.294602%2C%2040.936261%5D%2C%20%5B26.604196%2C%2041.562115%5D%2C%20%5B26.117042%2C%2041.826905%5D%2C%20%5B27.135739%2C%2042.141485%5D%2C%20%5B27.99672%2C%2042.007359%5D%2C%20%5B28.115525%2C%2041.622886%5D%2C%20%5B28.988443%2C%2041.299934%5D%2C%20%5B28.806438%2C%2041.054962%5D%2C%20%5B27.619017%2C%2040.999823%5D%2C%20%5B27.192377%2C%2040.690566%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22TUR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Turkey%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B121.777818%2C%2024.394274%5D%2C%20%5B121.175632%2C%2022.790857%5D%2C%20%5B120.74708%2C%2021.970571%5D%2C%20%5B120.220083%2C%2022.814861%5D%2C%20%5B120.106189%2C%2023.556263%5D%2C%20%5B120.69468%2C%2024.538451%5D%2C%20%5B121.495044%2C%2025.295459%5D%2C%20%5B121.951244%2C%2024.997596%5D%2C%20%5B121.777818%2C%2024.394274%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22TWN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Taiwan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B33.903711%2C%20-0.95%5D%2C%20%5B34.07262%2C%20-1.05982%5D%2C%20%5B37.69869%2C%20-3.09699%5D%2C%20%5B37.7669%2C%20-3.67712%5D%2C%20%5B39.20222%2C%20-4.67677%5D%2C%20%5B38.74054%2C%20-5.90895%5D%2C%20%5B38.79977%2C%20-6.47566%5D%2C%20%5B39.44%2C%20-6.84%5D%2C%20%5B39.47%2C%20-7.1%5D%2C%20%5B39.19469%2C%20-7.7039%5D%2C%20%5B39.25203%2C%20-8.00781%5D%2C%20%5B39.18652%2C%20-8.48551%5D%2C%20%5B39.53574%2C%20-9.11237%5D%2C%20%5B39.9496%2C%20-10.0984%5D%2C%20%5B40.31659%2C%20-10.3171%5D%2C%20%5B39.521%2C%20-10.89688%5D%2C%20%5B38.427557%2C%20-11.285202%5D%2C%20%5B37.82764%2C%20-11.26879%5D%2C%20%5B37.47129%2C%20-11.56876%5D%2C%20%5B36.775151%2C%20-11.594537%5D%2C%20%5B36.514082%2C%20-11.720938%5D%2C%20%5B35.312398%2C%20-11.439146%5D%2C%20%5B34.559989%2C%20-11.52002%5D%2C%20%5B34.28%2C%20-10.16%5D%2C%20%5B33.940838%2C%20-9.693674%5D%2C%20%5B33.73972%2C%20-9.41715%5D%2C%20%5B32.759375%2C%20-9.230599%5D%2C%20%5B32.191865%2C%20-8.930359%5D%2C%20%5B31.556348%2C%20-8.762049%5D%2C%20%5B31.157751%2C%20-8.594579%5D%2C%20%5B30.74%2C%20-8.34%5D%2C%20%5B30.2%2C%20-7.08%5D%2C%20%5B29.62%2C%20-6.52%5D%2C%20%5B29.419993%2C%20-5.939999%5D%2C%20%5B29.519987%2C%20-5.419979%5D%2C%20%5B29.339998%2C%20-4.499983%5D%2C%20%5B29.753512%2C%20-4.452389%5D%2C%20%5B30.11632%2C%20-4.09012%5D%2C%20%5B30.50554%2C%20-3.56858%5D%2C%20%5B30.75224%2C%20-3.35931%5D%2C%20%5B30.74301%2C%20-3.03431%5D%2C%20%5B30.52766%2C%20-2.80762%5D%2C%20%5B30.46967%2C%20-2.41383%5D%2C%20%5B30.758309%2C%20-2.28725%5D%2C%20%5B30.816135%2C%20-1.698914%5D%2C%20%5B30.419105%2C%20-1.134659%5D%2C%20%5B30.76986%2C%20-1.01455%5D%2C%20%5B31.86617%2C%20-1.02736%5D%2C%20%5B33.903711%2C%20-0.95%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22TZA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22United%20Republic%20of%20Tanzania%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B31.86617%2C%20-1.02736%5D%2C%20%5B30.76986%2C%20-1.01455%5D%2C%20%5B30.419105%2C%20-1.134659%5D%2C%20%5B29.821519%2C%20-1.443322%5D%2C%20%5B29.579466%2C%20-1.341313%5D%2C%20%5B29.587838%2C%20-0.587406%5D%2C%20%5B29.8195%2C%20-0.2053%5D%2C%20%5B29.875779%2C%200.59738%5D%2C%20%5B30.086154%2C%201.062313%5D%2C%20%5B30.468508%2C%201.583805%5D%2C%20%5B30.85267%2C%201.849396%5D%2C%20%5B31.174149%2C%202.204465%5D%2C%20%5B30.77332%2C%202.33989%5D%2C%20%5B30.83385%2C%203.50917%5D%2C%20%5B31.24556%2C%203.7819%5D%2C%20%5B31.88145%2C%203.55827%5D%2C%20%5B32.68642%2C%203.79232%5D%2C%20%5B33.39%2C%203.79%5D%2C%20%5B34.005%2C%204.249885%5D%2C%20%5B34.47913%2C%203.5556%5D%2C%20%5B34.59607%2C%203.05374%5D%2C%20%5B35.03599%2C%201.90584%5D%2C%20%5B34.6721%2C%201.17694%5D%2C%20%5B34.18%2C%200.515%5D%2C%20%5B33.893569%2C%200.109814%5D%2C%20%5B33.903711%2C%20-0.95%5D%2C%20%5B31.86617%2C%20-1.02736%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22UGA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Uganda%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B31.785998%2C%2052.101678%5D%2C%20%5B32.159412%2C%2052.061267%5D%2C%20%5B32.412058%2C%2052.288695%5D%2C%20%5B32.715761%2C%2052.238465%5D%2C%20%5B33.7527%2C%2052.335075%5D%2C%20%5B34.391731%2C%2051.768882%5D%2C%20%5B34.141978%2C%2051.566413%5D%2C%20%5B34.224816%2C%2051.255993%5D%2C%20%5B35.022183%2C%2051.207572%5D%2C%20%5B35.377924%2C%2050.773955%5D%2C%20%5B35.356116%2C%2050.577197%5D%2C%20%5B36.626168%2C%2050.225591%5D%2C%20%5B37.39346%2C%2050.383953%5D%2C%20%5B38.010631%2C%2049.915662%5D%2C%20%5B38.594988%2C%2049.926462%5D%2C%20%5B40.069058%2C%2049.601055%5D%2C%20%5B40.080789%2C%2049.30743%5D%2C%20%5B39.674664%2C%2048.783818%5D%2C%20%5B39.895632%2C%2048.232405%5D%2C%20%5B39.738278%2C%2047.898937%5D%2C%20%5B38.770585%2C%2047.825608%5D%2C%20%5B38.255112%2C%2047.5464%5D%2C%20%5B38.223538%2C%2047.10219%5D%2C%20%5B37.425137%2C%2047.022221%5D%2C%20%5B36.759855%2C%2046.6987%5D%2C%20%5B35.823685%2C%2046.645964%5D%2C%20%5B34.962342%2C%2046.273197%5D%2C%20%5B35.020788%2C%2045.651219%5D%2C%20%5B35.510009%2C%2045.409993%5D%2C%20%5B36.529998%2C%2045.46999%5D%2C%20%5B36.334713%2C%2045.113216%5D%2C%20%5B35.239999%2C%2044.939996%5D%2C%20%5B33.882511%2C%2044.361479%5D%2C%20%5B33.326421%2C%2044.564877%5D%2C%20%5B33.546924%2C%2045.034771%5D%2C%20%5B32.454174%2C%2045.327466%5D%2C%20%5B32.630804%2C%2045.519186%5D%2C%20%5B33.588162%2C%2045.851569%5D%2C%20%5B33.298567%2C%2046.080598%5D%2C%20%5B31.74414%2C%2046.333348%5D%2C%20%5B31.675307%2C%2046.706245%5D%2C%20%5B30.748749%2C%2046.5831%5D%2C%20%5B30.377609%2C%2046.03241%5D%2C%20%5B29.603289%2C%2045.293308%5D%2C%20%5B29.149725%2C%2045.464925%5D%2C%20%5B28.679779%2C%2045.304031%5D%2C%20%5B28.233554%2C%2045.488283%5D%2C%20%5B28.485269%2C%2045.596907%5D%2C%20%5B28.659987%2C%2045.939987%5D%2C%20%5B28.933717%2C%2046.25883%5D%2C%20%5B28.862972%2C%2046.437889%5D%2C%20%5B29.072107%2C%2046.517678%5D%2C%20%5B29.170654%2C%2046.379262%5D%2C%20%5B29.759972%2C%2046.349988%5D%2C%20%5B30.024659%2C%2046.423937%5D%2C%20%5B29.83821%2C%2046.525326%5D%2C%20%5B29.908852%2C%2046.674361%5D%2C%20%5B29.559674%2C%2046.928583%5D%2C%20%5B29.415135%2C%2047.346645%5D%2C%20%5B29.050868%2C%2047.510227%5D%2C%20%5B29.122698%2C%2047.849095%5D%2C%20%5B28.670891%2C%2048.118149%5D%2C%20%5B28.259547%2C%2048.155562%5D%2C%20%5B27.522537%2C%2048.467119%5D%2C%20%5B26.857824%2C%2048.368211%5D%2C%20%5B26.619337%2C%2048.220726%5D%2C%20%5B26.19745%2C%2048.220881%5D%2C%20%5B25.945941%2C%2047.987149%5D%2C%20%5B25.207743%2C%2047.891056%5D%2C%20%5B24.866317%2C%2047.737526%5D%2C%20%5B24.402056%2C%2047.981878%5D%2C%20%5B23.760958%2C%2047.985598%5D%2C%20%5B23.142236%2C%2048.096341%5D%2C%20%5B22.710531%2C%2047.882194%5D%2C%20%5B22.64082%2C%2048.15024%5D%2C%20%5B22.085608%2C%2048.422264%5D%2C%20%5B22.280842%2C%2048.825392%5D%2C%20%5B22.558138%2C%2049.085738%5D%2C%20%5B22.776419%2C%2049.027395%5D%2C%20%5B22.51845%2C%2049.476774%5D%2C%20%5B23.426508%2C%2050.308506%5D%2C%20%5B23.922757%2C%2050.424881%5D%2C%20%5B24.029986%2C%2050.705407%5D%2C%20%5B23.527071%2C%2051.578454%5D%2C%20%5B24.005078%2C%2051.617444%5D%2C%20%5B24.553106%2C%2051.888461%5D%2C%20%5B25.327788%2C%2051.910656%5D%2C%20%5B26.337959%2C%2051.832289%5D%2C%20%5B27.454066%2C%2051.592303%5D%2C%20%5B28.241615%2C%2051.572227%5D%2C%20%5B28.617613%2C%2051.427714%5D%2C%20%5B28.992835%2C%2051.602044%5D%2C%20%5B29.254938%2C%2051.368234%5D%2C%20%5B30.157364%2C%2051.416138%5D%2C%20%5B30.555117%2C%2051.319503%5D%2C%20%5B30.619454%2C%2051.822806%5D%2C%20%5B30.927549%2C%2052.042353%5D%2C%20%5B31.785998%2C%2052.101678%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22UKR%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Ukraine%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-57.625133%2C%20-30.216295%5D%2C%20%5B-56.976026%2C%20-30.109686%5D%2C%20%5B-55.973245%2C%20-30.883076%5D%2C%20%5B-55.60151%2C%20-30.853879%5D%2C%20%5B-54.572452%2C%20-31.494511%5D%2C%20%5B-53.787952%2C%20-32.047243%5D%2C%20%5B-53.209589%2C%20-32.727666%5D%2C%20%5B-53.650544%2C%20-33.202004%5D%2C%20%5B-53.373662%2C%20-33.768378%5D%2C%20%5B-53.806426%2C%20-34.396815%5D%2C%20%5B-54.935866%2C%20-34.952647%5D%2C%20%5B-55.67409%2C%20-34.752659%5D%2C%20%5B-56.215297%2C%20-34.859836%5D%2C%20%5B-57.139685%2C%20-34.430456%5D%2C%20%5B-57.817861%2C%20-34.462547%5D%2C%20%5B-58.427074%2C%20-33.909454%5D%2C%20%5B-58.349611%2C%20-33.263189%5D%2C%20%5B-58.132648%2C%20-33.040567%5D%2C%20%5B-58.14244%2C%20-32.044504%5D%2C%20%5B-57.874937%2C%20-31.016556%5D%2C%20%5B-57.625133%2C%20-30.216295%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22URY%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Uruguay%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B-155.54211%2C%2019.08348%5D%2C%20%5B-155.68817%2C%2018.91619%5D%2C%20%5B-155.93665%2C%2019.05939%5D%2C%20%5B-155.90806%2C%2019.33888%5D%2C%20%5B-156.07347%2C%2019.70294%5D%2C%20%5B-156.02368%2C%2019.81422%5D%2C%20%5B-155.85008%2C%2019.97729%5D%2C%20%5B-155.91907%2C%2020.17395%5D%2C%20%5B-155.86108%2C%2020.26721%5D%2C%20%5B-155.78505%2C%2020.2487%5D%2C%20%5B-155.40214%2C%2020.07975%5D%2C%20%5B-155.22452%2C%2019.99302%5D%2C%20%5B-155.06226%2C%2019.8591%5D%2C%20%5B-154.80741%2C%2019.50871%5D%2C%20%5B-154.83147%2C%2019.45328%5D%2C%20%5B-155.22217%2C%2019.23972%5D%2C%20%5B-155.54211%2C%2019.08348%5D%5D%5D%2C%20%5B%5B%5B-156.07926%2C%2020.64397%5D%2C%20%5B-156.41445%2C%2020.57241%5D%2C%20%5B-156.58673%2C%2020.783%5D%2C%20%5B-156.70167%2C%2020.8643%5D%2C%20%5B-156.71055%2C%2020.92676%5D%2C%20%5B-156.61258%2C%2021.01249%5D%2C%20%5B-156.25711%2C%2020.91745%5D%2C%20%5B-155.99566%2C%2020.76404%5D%2C%20%5B-156.07926%2C%2020.64397%5D%5D%5D%2C%20%5B%5B%5B-156.75824%2C%2021.17684%5D%2C%20%5B-156.78933%2C%2021.06873%5D%2C%20%5B-157.32521%2C%2021.09777%5D%2C%20%5B-157.25027%2C%2021.21958%5D%2C%20%5B-156.75824%2C%2021.17684%5D%5D%5D%2C%20%5B%5B%5B-157.65283%2C%2021.32217%5D%2C%20%5B-157.70703%2C%2021.26442%5D%2C%20%5B-157.7786%2C%2021.27729%5D%2C%20%5B-158.12667%2C%2021.31244%5D%2C%20%5B-158.2538%2C%2021.53919%5D%2C%20%5B-158.29265%2C%2021.57912%5D%2C%20%5B-158.0252%2C%2021.71696%5D%2C%20%5B-157.94161%2C%2021.65272%5D%2C%20%5B-157.65283%2C%2021.32217%5D%5D%5D%2C%20%5B%5B%5B-159.34512%2C%2021.982%5D%2C%20%5B-159.46372%2C%2021.88299%5D%2C%20%5B-159.80051%2C%2022.06533%5D%2C%20%5B-159.74877%2C%2022.1382%5D%2C%20%5B-159.5962%2C%2022.23618%5D%2C%20%5B-159.36569%2C%2022.21494%5D%2C%20%5B-159.34512%2C%2021.982%5D%5D%5D%2C%20%5B%5B%5B-94.81758%2C%2049.38905%5D%2C%20%5B-94.64%2C%2048.84%5D%2C%20%5B-94.32914%2C%2048.67074%5D%2C%20%5B-93.63087%2C%2048.60926%5D%2C%20%5B-92.61%2C%2048.45%5D%2C%20%5B-91.64%2C%2048.14%5D%2C%20%5B-90.83%2C%2048.27%5D%2C%20%5B-89.6%2C%2048.01%5D%2C%20%5B-89.272917%2C%2048.019808%5D%2C%20%5B-88.378114%2C%2048.302918%5D%2C%20%5B-87.439793%2C%2047.94%5D%2C%20%5B-86.461991%2C%2047.553338%5D%2C%20%5B-85.652363%2C%2047.220219%5D%2C%20%5B-84.87608%2C%2046.900083%5D%2C%20%5B-84.779238%2C%2046.637102%5D%2C%20%5B-84.543749%2C%2046.538684%5D%2C%20%5B-84.6049%2C%2046.4396%5D%2C%20%5B-84.3367%2C%2046.40877%5D%2C%20%5B-84.14212%2C%2046.512226%5D%2C%20%5B-84.091851%2C%2046.275419%5D%2C%20%5B-83.890765%2C%2046.116927%5D%2C%20%5B-83.616131%2C%2046.116927%5D%2C%20%5B-83.469551%2C%2045.994686%5D%2C%20%5B-83.592851%2C%2045.816894%5D%2C%20%5B-82.550925%2C%2045.347517%5D%2C%20%5B-82.337763%2C%2044.44%5D%2C%20%5B-82.137642%2C%2043.571088%5D%2C%20%5B-82.43%2C%2042.98%5D%2C%20%5B-82.9%2C%2042.43%5D%2C%20%5B-83.12%2C%2042.08%5D%2C%20%5B-83.142%2C%2041.975681%5D%2C%20%5B-83.02981%2C%2041.832796%5D%2C%20%5B-82.690089%2C%2041.675105%5D%2C%20%5B-82.439278%2C%2041.675105%5D%2C%20%5B-81.277747%2C%2042.209026%5D%2C%20%5B-80.247448%2C%2042.3662%5D%2C%20%5B-78.939362%2C%2042.863611%5D%2C%20%5B-78.92%2C%2042.965%5D%2C%20%5B-79.01%2C%2043.27%5D%2C%20%5B-79.171674%2C%2043.466339%5D%2C%20%5B-78.72028%2C%2043.625089%5D%2C%20%5B-77.737885%2C%2043.629056%5D%2C%20%5B-76.820034%2C%2043.628784%5D%2C%20%5B-76.5%2C%2044.018459%5D%2C%20%5B-76.375%2C%2044.09631%5D%2C%20%5B-75.31821%2C%2044.81645%5D%2C%20%5B-74.867%2C%2045.00048%5D%2C%20%5B-73.34783%2C%2045.00738%5D%2C%20%5B-71.50506%2C%2045.0082%5D%2C%20%5B-71.405%2C%2045.255%5D%2C%20%5B-71.08482%2C%2045.30524%5D%2C%20%5B-70.66%2C%2045.46%5D%2C%20%5B-70.305%2C%2045.915%5D%2C%20%5B-69.99997%2C%2046.69307%5D%2C%20%5B-69.237216%2C%2047.447781%5D%2C%20%5B-68.905%2C%2047.185%5D%2C%20%5B-68.23444%2C%2047.35486%5D%2C%20%5B-67.79046%2C%2047.06636%5D%2C%20%5B-67.79134%2C%2045.70281%5D%2C%20%5B-67.13741%2C%2045.13753%5D%2C%20%5B-66.96466%2C%2044.8097%5D%2C%20%5B-68.03252%2C%2044.3252%5D%2C%20%5B-69.06%2C%2043.98%5D%2C%20%5B-70.11617%2C%2043.68405%5D%2C%20%5B-70.645476%2C%2043.090238%5D%2C%20%5B-70.81489%2C%2042.8653%5D%2C%20%5B-70.825%2C%2042.335%5D%2C%20%5B-70.495%2C%2041.805%5D%2C%20%5B-70.08%2C%2041.78%5D%2C%20%5B-70.185%2C%2042.145%5D%2C%20%5B-69.88497%2C%2041.92283%5D%2C%20%5B-69.96503%2C%2041.63717%5D%2C%20%5B-70.64%2C%2041.475%5D%2C%20%5B-71.12039%2C%2041.49445%5D%2C%20%5B-71.86%2C%2041.32%5D%2C%20%5B-72.295%2C%2041.27%5D%2C%20%5B-72.87643%2C%2041.22065%5D%2C%20%5B-73.71%2C%2040.931102%5D%2C%20%5B-72.24126%2C%2041.11948%5D%2C%20%5B-71.945%2C%2040.93%5D%2C%20%5B-73.345%2C%2040.63%5D%2C%20%5B-73.982%2C%2040.628%5D%2C%20%5B-73.952325%2C%2040.75075%5D%2C%20%5B-74.25671%2C%2040.47351%5D%2C%20%5B-73.96244%2C%2040.42763%5D%2C%20%5B-74.17838%2C%2039.70926%5D%2C%20%5B-74.90604%2C%2038.93954%5D%2C%20%5B-74.98041%2C%2039.1964%5D%2C%20%5B-75.20002%2C%2039.24845%5D%2C%20%5B-75.52805%2C%2039.4985%5D%2C%20%5B-75.32%2C%2038.96%5D%2C%20%5B-75.071835%2C%2038.782032%5D%2C%20%5B-75.05673%2C%2038.40412%5D%2C%20%5B-75.37747%2C%2038.01551%5D%2C%20%5B-75.94023%2C%2037.21689%5D%2C%20%5B-76.03127%2C%2037.2566%5D%2C%20%5B-75.72205%2C%2037.93705%5D%2C%20%5B-76.23287%2C%2038.319215%5D%2C%20%5B-76.35%2C%2039.15%5D%2C%20%5B-76.542725%2C%2038.717615%5D%2C%20%5B-76.32933%2C%2038.08326%5D%2C%20%5B-76.989998%2C%2038.239992%5D%2C%20%5B-76.30162%2C%2037.917945%5D%2C%20%5B-76.25874%2C%2036.9664%5D%2C%20%5B-75.9718%2C%2036.89726%5D%2C%20%5B-75.86804%2C%2036.55125%5D%2C%20%5B-75.72749%2C%2035.55074%5D%2C%20%5B-76.36318%2C%2034.80854%5D%2C%20%5B-77.397635%2C%2034.51201%5D%2C%20%5B-78.05496%2C%2033.92547%5D%2C%20%5B-78.55435%2C%2033.86133%5D%2C%20%5B-79.06067%2C%2033.49395%5D%2C%20%5B-79.20357%2C%2033.15839%5D%2C%20%5B-80.301325%2C%2032.509355%5D%2C%20%5B-80.86498%2C%2032.0333%5D%2C%20%5B-81.33629%2C%2031.44049%5D%2C%20%5B-81.49042%2C%2030.72999%5D%2C%20%5B-81.31371%2C%2030.03552%5D%2C%20%5B-80.98%2C%2029.18%5D%2C%20%5B-80.535585%2C%2028.47213%5D%2C%20%5B-80.53%2C%2028.04%5D%2C%20%5B-80.056539%2C%2026.88%5D%2C%20%5B-80.088015%2C%2026.205765%5D%2C%20%5B-80.13156%2C%2025.816775%5D%2C%20%5B-80.38103%2C%2025.20616%5D%2C%20%5B-80.68%2C%2025.08%5D%2C%20%5B-81.17213%2C%2025.20126%5D%2C%20%5B-81.33%2C%2025.64%5D%2C%20%5B-81.71%2C%2025.87%5D%2C%20%5B-82.24%2C%2026.73%5D%2C%20%5B-82.70515%2C%2027.49504%5D%2C%20%5B-82.85526%2C%2027.88624%5D%2C%20%5B-82.65%2C%2028.55%5D%2C%20%5B-82.93%2C%2029.1%5D%2C%20%5B-83.70959%2C%2029.93656%5D%2C%20%5B-84.1%2C%2030.09%5D%2C%20%5B-85.10882%2C%2029.63615%5D%2C%20%5B-85.28784%2C%2029.68612%5D%2C%20%5B-85.7731%2C%2030.15261%5D%2C%20%5B-86.4%2C%2030.4%5D%2C%20%5B-87.53036%2C%2030.27433%5D%2C%20%5B-88.41782%2C%2030.3849%5D%2C%20%5B-89.18049%2C%2030.31598%5D%2C%20%5B-89.593831%2C%2030.159994%5D%2C%20%5B-89.413735%2C%2029.89419%5D%2C%20%5B-89.43%2C%2029.48864%5D%2C%20%5B-89.21767%2C%2029.29108%5D%2C%20%5B-89.40823%2C%2029.15961%5D%2C%20%5B-89.77928%2C%2029.30714%5D%2C%20%5B-90.15463%2C%2029.11743%5D%2C%20%5B-90.880225%2C%2029.148535%5D%2C%20%5B-91.626785%2C%2029.677%5D%2C%20%5B-92.49906%2C%2029.5523%5D%2C%20%5B-93.22637%2C%2029.78375%5D%2C%20%5B-93.84842%2C%2029.71363%5D%2C%20%5B-94.69%2C%2029.48%5D%2C%20%5B-95.60026%2C%2028.73863%5D%2C%20%5B-96.59404%2C%2028.30748%5D%2C%20%5B-97.14%2C%2027.83%5D%2C%20%5B-97.37%2C%2027.38%5D%2C%20%5B-97.38%2C%2026.69%5D%2C%20%5B-97.33%2C%2026.21%5D%2C%20%5B-97.14%2C%2025.87%5D%2C%20%5B-97.53%2C%2025.84%5D%2C%20%5B-98.24%2C%2026.06%5D%2C%20%5B-99.02%2C%2026.37%5D%2C%20%5B-99.3%2C%2026.84%5D%2C%20%5B-99.52%2C%2027.54%5D%2C%20%5B-100.11%2C%2028.11%5D%2C%20%5B-100.45584%2C%2028.69612%5D%2C%20%5B-100.9576%2C%2029.38071%5D%2C%20%5B-101.6624%2C%2029.7793%5D%2C%20%5B-102.48%2C%2029.76%5D%2C%20%5B-103.11%2C%2028.97%5D%2C%20%5B-103.94%2C%2029.27%5D%2C%20%5B-104.45697%2C%2029.57196%5D%2C%20%5B-104.70575%2C%2030.12173%5D%2C%20%5B-105.03737%2C%2030.64402%5D%2C%20%5B-105.63159%2C%2031.08383%5D%2C%20%5B-106.1429%2C%2031.39995%5D%2C%20%5B-106.50759%2C%2031.75452%5D%2C%20%5B-108.24%2C%2031.754854%5D%2C%20%5B-108.24194%2C%2031.34222%5D%2C%20%5B-109.035%2C%2031.34194%5D%2C%20%5B-111.02361%2C%2031.33472%5D%2C%20%5B-113.30498%2C%2032.03914%5D%2C%20%5B-114.815%2C%2032.52528%5D%2C%20%5B-114.72139%2C%2032.72083%5D%2C%20%5B-115.99135%2C%2032.61239%5D%2C%20%5B-117.12776%2C%2032.53534%5D%2C%20%5B-117.295938%2C%2033.046225%5D%2C%20%5B-117.944%2C%2033.621236%5D%2C%20%5B-118.410602%2C%2033.740909%5D%2C%20%5B-118.519895%2C%2034.027782%5D%2C%20%5B-119.081%2C%2034.078%5D%2C%20%5B-119.438841%2C%2034.348477%5D%2C%20%5B-120.36778%2C%2034.44711%5D%2C%20%5B-120.62286%2C%2034.60855%5D%2C%20%5B-120.74433%2C%2035.15686%5D%2C%20%5B-121.71457%2C%2036.16153%5D%2C%20%5B-122.54747%2C%2037.55176%5D%2C%20%5B-122.51201%2C%2037.78339%5D%2C%20%5B-122.95319%2C%2038.11371%5D%2C%20%5B-123.7272%2C%2038.95166%5D%2C%20%5B-123.86517%2C%2039.76699%5D%2C%20%5B-124.39807%2C%2040.3132%5D%2C%20%5B-124.17886%2C%2041.14202%5D%2C%20%5B-124.2137%2C%2041.99964%5D%2C%20%5B-124.53284%2C%2042.76599%5D%2C%20%5B-124.14214%2C%2043.70838%5D%2C%20%5B-124.020535%2C%2044.615895%5D%2C%20%5B-123.89893%2C%2045.52341%5D%2C%20%5B-124.079635%2C%2046.86475%5D%2C%20%5B-124.39567%2C%2047.72017%5D%2C%20%5B-124.68721%2C%2048.184433%5D%2C%20%5B-124.566101%2C%2048.379715%5D%2C%20%5B-123.12%2C%2048.04%5D%2C%20%5B-122.58736%2C%2047.096%5D%2C%20%5B-122.34%2C%2047.36%5D%2C%20%5B-122.5%2C%2048.18%5D%2C%20%5B-122.84%2C%2049%5D%2C%20%5B-120%2C%2049%5D%2C%20%5B-117.03121%2C%2049%5D%2C%20%5B-116.04818%2C%2049%5D%2C%20%5B-113%2C%2049%5D%2C%20%5B-110.05%2C%2049%5D%2C%20%5B-107.05%2C%2049%5D%2C%20%5B-104.04826%2C%2048.99986%5D%2C%20%5B-100.65%2C%2049%5D%2C%20%5B-97.22872%2C%2049.0007%5D%2C%20%5B-95.15907%2C%2049%5D%2C%20%5B-95.15609%2C%2049.38425%5D%2C%20%5B-94.81758%2C%2049.38905%5D%5D%5D%2C%20%5B%5B%5B-153.006314%2C%2057.115842%5D%2C%20%5B-154.00509%2C%2056.734677%5D%2C%20%5B-154.516403%2C%2056.992749%5D%2C%20%5B-154.670993%2C%2057.461196%5D%2C%20%5B-153.76278%2C%2057.816575%5D%2C%20%5B-153.228729%2C%2057.968968%5D%2C%20%5B-152.564791%2C%2057.901427%5D%2C%20%5B-152.141147%2C%2057.591059%5D%2C%20%5B-153.006314%2C%2057.115842%5D%5D%5D%2C%20%5B%5B%5B-165.579164%2C%2059.909987%5D%2C%20%5B-166.19277%2C%2059.754441%5D%2C%20%5B-166.848337%2C%2059.941406%5D%2C%20%5B-167.455277%2C%2060.213069%5D%2C%20%5B-166.467792%2C%2060.38417%5D%2C%20%5B-165.67443%2C%2060.293607%5D%2C%20%5B-165.579164%2C%2059.909987%5D%5D%5D%2C%20%5B%5B%5B-171.731657%2C%2063.782515%5D%2C%20%5B-171.114434%2C%2063.592191%5D%2C%20%5B-170.491112%2C%2063.694975%5D%2C%20%5B-169.682505%2C%2063.431116%5D%2C%20%5B-168.689439%2C%2063.297506%5D%2C%20%5B-168.771941%2C%2063.188598%5D%2C%20%5B-169.52944%2C%2062.976931%5D%2C%20%5B-170.290556%2C%2063.194438%5D%2C%20%5B-170.671386%2C%2063.375822%5D%2C%20%5B-171.553063%2C%2063.317789%5D%2C%20%5B-171.791111%2C%2063.405846%5D%2C%20%5B-171.731657%2C%2063.782515%5D%5D%5D%2C%20%5B%5B%5B-155.06779%2C%2071.147776%5D%2C%20%5B-154.344165%2C%2070.696409%5D%2C%20%5B-153.900006%2C%2070.889989%5D%2C%20%5B-152.210006%2C%2070.829992%5D%2C%20%5B-152.270002%2C%2070.600006%5D%2C%20%5B-150.739992%2C%2070.430017%5D%2C%20%5B-149.720003%2C%2070.53001%5D%2C%20%5B-147.613362%2C%2070.214035%5D%2C%20%5B-145.68999%2C%2070.12001%5D%2C%20%5B-144.920011%2C%2069.989992%5D%2C%20%5B-143.589446%2C%2070.152514%5D%2C%20%5B-142.07251%2C%2069.851938%5D%2C%20%5B-140.985988%2C%2069.711998%5D%2C%20%5B-140.985988%2C%2069.711998%5D%2C%20%5B-140.992499%2C%2066.000029%5D%2C%20%5B-140.99777%2C%2060.306397%5D%2C%20%5B-140.012998%2C%2060.276838%5D%2C%20%5B-139.039%2C%2060.000007%5D%2C%20%5B-138.34089%2C%2059.56211%5D%2C%20%5B-137.4525%2C%2058.905%5D%2C%20%5B-136.47972%2C%2059.46389%5D%2C%20%5B-135.47583%2C%2059.78778%5D%2C%20%5B-134.945%2C%2059.27056%5D%2C%20%5B-134.27111%2C%2058.86111%5D%2C%20%5B-133.355549%2C%2058.410285%5D%2C%20%5B-132.73042%2C%2057.69289%5D%2C%20%5B-131.70781%2C%2056.55212%5D%2C%20%5B-130.00778%2C%2055.91583%5D%2C%20%5B-129.979994%2C%2055.284998%5D%2C%20%5B-130.53611%2C%2054.802753%5D%2C%20%5B-131.085818%2C%2055.178906%5D%2C%20%5B-131.967211%2C%2055.497776%5D%2C%20%5B-132.250011%2C%2056.369996%5D%2C%20%5B-133.539181%2C%2057.178887%5D%2C%20%5B-134.078063%2C%2058.123068%5D%2C%20%5B-135.038211%2C%2058.187715%5D%2C%20%5B-136.628062%2C%2058.212209%5D%2C%20%5B-137.800006%2C%2058.499995%5D%2C%20%5B-139.867787%2C%2059.537762%5D%2C%20%5B-140.825274%2C%2059.727517%5D%2C%20%5B-142.574444%2C%2060.084447%5D%2C%20%5B-143.958881%2C%2059.99918%5D%2C%20%5B-145.925557%2C%2060.45861%5D%2C%20%5B-147.114374%2C%2060.884656%5D%2C%20%5B-148.224306%2C%2060.672989%5D%2C%20%5B-148.018066%2C%2059.978329%5D%2C%20%5B-148.570823%2C%2059.914173%5D%2C%20%5B-149.727858%2C%2059.705658%5D%2C%20%5B-150.608243%2C%2059.368211%5D%2C%20%5B-151.716393%2C%2059.155821%5D%2C%20%5B-151.859433%2C%2059.744984%5D%2C%20%5B-151.409719%2C%2060.725803%5D%2C%20%5B-150.346941%2C%2061.033588%5D%2C%20%5B-150.621111%2C%2061.284425%5D%2C%20%5B-151.895839%2C%2060.727198%5D%2C%20%5B-152.57833%2C%2060.061657%5D%2C%20%5B-154.019172%2C%2059.350279%5D%2C%20%5B-153.287511%2C%2058.864728%5D%2C%20%5B-154.232492%2C%2058.146374%5D%2C%20%5B-155.307491%2C%2057.727795%5D%2C%20%5B-156.308335%2C%2057.422774%5D%2C%20%5B-156.556097%2C%2056.979985%5D%2C%20%5B-158.117217%2C%2056.463608%5D%2C%20%5B-158.433321%2C%2055.994154%5D%2C%20%5B-159.603327%2C%2055.566686%5D%2C%20%5B-160.28972%2C%2055.643581%5D%2C%20%5B-161.223048%2C%2055.364735%5D%2C%20%5B-162.237766%2C%2055.024187%5D%2C%20%5B-163.069447%2C%2054.689737%5D%2C%20%5B-164.785569%2C%2054.404173%5D%2C%20%5B-164.942226%2C%2054.572225%5D%2C%20%5B-163.84834%2C%2055.039431%5D%2C%20%5B-162.870001%2C%2055.348043%5D%2C%20%5B-161.804175%2C%2055.894986%5D%2C%20%5B-160.563605%2C%2056.008055%5D%2C%20%5B-160.07056%2C%2056.418055%5D%2C%20%5B-158.684443%2C%2057.016675%5D%2C%20%5B-158.461097%2C%2057.216921%5D%2C%20%5B-157.72277%2C%2057.570001%5D%2C%20%5B-157.550274%2C%2058.328326%5D%2C%20%5B-157.041675%2C%2058.918885%5D%2C%20%5B-158.194731%2C%2058.615802%5D%2C%20%5B-158.517218%2C%2058.787781%5D%2C%20%5B-159.058606%2C%2058.424186%5D%2C%20%5B-159.711667%2C%2058.93139%5D%2C%20%5B-159.981289%2C%2058.572549%5D%2C%20%5B-160.355271%2C%2059.071123%5D%2C%20%5B-161.355003%2C%2058.670838%5D%2C%20%5B-161.968894%2C%2058.671665%5D%2C%20%5B-162.054987%2C%2059.266925%5D%2C%20%5B-161.874171%2C%2059.633621%5D%2C%20%5B-162.518059%2C%2059.989724%5D%2C%20%5B-163.818341%2C%2059.798056%5D%2C%20%5B-164.662218%2C%2060.267484%5D%2C%20%5B-165.346388%2C%2060.507496%5D%2C%20%5B-165.350832%2C%2061.073895%5D%2C%20%5B-166.121379%2C%2061.500019%5D%2C%20%5B-165.734452%2C%2062.074997%5D%2C%20%5B-164.919179%2C%2062.633076%5D%2C%20%5B-164.562508%2C%2063.146378%5D%2C%20%5B-163.753332%2C%2063.219449%5D%2C%20%5B-163.067224%2C%2063.059459%5D%2C%20%5B-162.260555%2C%2063.541936%5D%2C%20%5B-161.53445%2C%2063.455817%5D%2C%20%5B-160.772507%2C%2063.766108%5D%2C%20%5B-160.958335%2C%2064.222799%5D%2C%20%5B-161.518068%2C%2064.402788%5D%2C%20%5B-160.777778%2C%2064.788604%5D%2C%20%5B-161.391926%2C%2064.777235%5D%2C%20%5B-162.45305%2C%2064.559445%5D%2C%20%5B-162.757786%2C%2064.338605%5D%2C%20%5B-163.546394%2C%2064.55916%5D%2C%20%5B-164.96083%2C%2064.446945%5D%2C%20%5B-166.425288%2C%2064.686672%5D%2C%20%5B-166.845004%2C%2065.088896%5D%2C%20%5B-168.11056%2C%2065.669997%5D%2C%20%5B-166.705271%2C%2066.088318%5D%2C%20%5B-164.47471%2C%2066.57666%5D%2C%20%5B-163.652512%2C%2066.57666%5D%2C%20%5B-163.788602%2C%2066.077207%5D%2C%20%5B-161.677774%2C%2066.11612%5D%2C%20%5B-162.489715%2C%2066.735565%5D%2C%20%5B-163.719717%2C%2067.116395%5D%2C%20%5B-164.430991%2C%2067.616338%5D%2C%20%5B-165.390287%2C%2068.042772%5D%2C%20%5B-166.764441%2C%2068.358877%5D%2C%20%5B-166.204707%2C%2068.883031%5D%2C%20%5B-164.430811%2C%2068.915535%5D%2C%20%5B-163.168614%2C%2069.371115%5D%2C%20%5B-162.930566%2C%2069.858062%5D%2C%20%5B-161.908897%2C%2070.33333%5D%2C%20%5B-160.934797%2C%2070.44769%5D%2C%20%5B-159.039176%2C%2070.891642%5D%2C%20%5B-158.119723%2C%2070.824721%5D%2C%20%5B-156.580825%2C%2071.357764%5D%2C%20%5B-155.06779%2C%2071.147776%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22USA%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22United%20States%20of%20America%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B66.518607%2C%2037.362784%5D%2C%20%5B66.54615%2C%2037.974685%5D%2C%20%5B65.215999%2C%2038.402695%5D%2C%20%5B64.170223%2C%2038.892407%5D%2C%20%5B63.518015%2C%2039.363257%5D%2C%20%5B62.37426%2C%2040.053886%5D%2C%20%5B61.882714%2C%2041.084857%5D%2C%20%5B61.547179%2C%2041.26637%5D%2C%20%5B60.465953%2C%2041.220327%5D%2C%20%5B60.083341%2C%2041.425146%5D%2C%20%5B59.976422%2C%2042.223082%5D%2C%20%5B58.629011%2C%2042.751551%5D%2C%20%5B57.78653%2C%2042.170553%5D%2C%20%5B56.932215%2C%2041.826026%5D%2C%20%5B57.096391%2C%2041.32231%5D%2C%20%5B55.968191%2C%2041.308642%5D%2C%20%5B55.928917%2C%2044.995858%5D%2C%20%5B58.503127%2C%2045.586804%5D%2C%20%5B58.689989%2C%2045.500014%5D%2C%20%5B60.239972%2C%2044.784037%5D%2C%20%5B61.05832%2C%2044.405817%5D%2C%20%5B62.0133%2C%2043.504477%5D%2C%20%5B63.185787%2C%2043.650075%5D%2C%20%5B64.900824%2C%2043.728081%5D%2C%20%5B66.098012%2C%2042.99766%5D%2C%20%5B66.023392%2C%2041.994646%5D%2C%20%5B66.510649%2C%2041.987644%5D%2C%20%5B66.714047%2C%2041.168444%5D%2C%20%5B67.985856%2C%2041.135991%5D%2C%20%5B68.259896%2C%2040.662325%5D%2C%20%5B68.632483%2C%2040.668681%5D%2C%20%5B69.070027%2C%2041.384244%5D%2C%20%5B70.388965%2C%2042.081308%5D%2C%20%5B70.962315%2C%2042.266154%5D%2C%20%5B71.259248%2C%2042.167711%5D%2C%20%5B70.420022%2C%2041.519998%5D%2C%20%5B71.157859%2C%2041.143587%5D%2C%20%5B71.870115%2C%2041.3929%5D%2C%20%5B73.055417%2C%2040.866033%5D%2C%20%5B71.774875%2C%2040.145844%5D%2C%20%5B71.014198%2C%2040.244366%5D%2C%20%5B70.601407%2C%2040.218527%5D%2C%20%5B70.45816%2C%2040.496495%5D%2C%20%5B70.666622%2C%2040.960213%5D%2C%20%5B69.329495%2C%2040.727824%5D%2C%20%5B69.011633%2C%2040.086158%5D%2C%20%5B68.536416%2C%2039.533453%5D%2C%20%5B67.701429%2C%2039.580478%5D%2C%20%5B67.44222%2C%2039.140144%5D%2C%20%5B68.176025%2C%2038.901553%5D%2C%20%5B68.392033%2C%2038.157025%5D%2C%20%5B67.83%2C%2037.144994%5D%2C%20%5B67.075782%2C%2037.356144%5D%2C%20%5B66.518607%2C%2037.362784%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22UZB%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Uzbekistan%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B-71.331584%2C%2011.776284%5D%2C%20%5B-71.360006%2C%2011.539994%5D%2C%20%5B-71.94705%2C%2011.423282%5D%2C%20%5B-71.620868%2C%2010.96946%5D%2C%20%5B-71.633064%2C%2010.446494%5D%2C%20%5B-72.074174%2C%209.865651%5D%2C%20%5B-71.695644%2C%209.072263%5D%2C%20%5B-71.264559%2C%209.137195%5D%2C%20%5B-71.039999%2C%209.859993%5D%2C%20%5B-71.350084%2C%2010.211935%5D%2C%20%5B-71.400623%2C%2010.968969%5D%2C%20%5B-70.155299%2C%2011.375482%5D%2C%20%5B-70.293843%2C%2011.846822%5D%2C%20%5B-69.943245%2C%2012.162307%5D%2C%20%5B-69.5843%2C%2011.459611%5D%2C%20%5B-68.882999%2C%2011.443385%5D%2C%20%5B-68.233271%2C%2010.885744%5D%2C%20%5B-68.194127%2C%2010.554653%5D%2C%20%5B-67.296249%2C%2010.545868%5D%2C%20%5B-66.227864%2C%2010.648627%5D%2C%20%5B-65.655238%2C%2010.200799%5D%2C%20%5B-64.890452%2C%2010.077215%5D%2C%20%5B-64.329479%2C%2010.389599%5D%2C%20%5B-64.318007%2C%2010.641418%5D%2C%20%5B-63.079322%2C%2010.701724%5D%2C%20%5B-61.880946%2C%2010.715625%5D%2C%20%5B-62.730119%2C%2010.420269%5D%2C%20%5B-62.388512%2C%209.948204%5D%2C%20%5B-61.588767%2C%209.873067%5D%2C%20%5B-60.830597%2C%209.38134%5D%2C%20%5B-60.671252%2C%208.580174%5D%2C%20%5B-60.150096%2C%208.602757%5D%2C%20%5B-59.758285%2C%208.367035%5D%2C%20%5B-60.550588%2C%207.779603%5D%2C%20%5B-60.637973%2C%207.415%5D%2C%20%5B-60.295668%2C%207.043911%5D%2C%20%5B-60.543999%2C%206.856584%5D%2C%20%5B-61.159336%2C%206.696077%5D%2C%20%5B-61.139415%2C%206.234297%5D%2C%20%5B-61.410303%2C%205.959068%5D%2C%20%5B-60.733574%2C%205.200277%5D%2C%20%5B-60.601179%2C%204.918098%5D%2C%20%5B-60.966893%2C%204.536468%5D%2C%20%5B-62.08543%2C%204.162124%5D%2C%20%5B-62.804533%2C%204.006965%5D%2C%20%5B-63.093198%2C%203.770571%5D%2C%20%5B-63.888343%2C%204.02053%5D%2C%20%5B-64.628659%2C%204.148481%5D%2C%20%5B-64.816064%2C%204.056445%5D%2C%20%5B-64.368494%2C%203.79721%5D%2C%20%5B-64.408828%2C%203.126786%5D%2C%20%5B-64.269999%2C%202.497006%5D%2C%20%5B-63.422867%2C%202.411068%5D%2C%20%5B-63.368788%2C%202.2009%5D%2C%20%5B-64.083085%2C%201.916369%5D%2C%20%5B-64.199306%2C%201.492855%5D%2C%20%5B-64.611012%2C%201.328731%5D%2C%20%5B-65.354713%2C%201.095282%5D%2C%20%5B-65.548267%2C%200.789254%5D%2C%20%5B-66.325765%2C%200.724452%5D%2C%20%5B-66.876326%2C%201.253361%5D%2C%20%5B-67.181294%2C%202.250638%5D%2C%20%5B-67.447092%2C%202.600281%5D%2C%20%5B-67.809938%2C%202.820655%5D%2C%20%5B-67.303173%2C%203.318454%5D%2C%20%5B-67.337564%2C%203.542342%5D%2C%20%5B-67.621836%2C%203.839482%5D%2C%20%5B-67.823012%2C%204.503937%5D%2C%20%5B-67.744697%2C%205.221129%5D%2C%20%5B-67.521532%2C%205.55687%5D%2C%20%5B-67.34144%2C%206.095468%5D%2C%20%5B-67.695087%2C%206.267318%5D%2C%20%5B-68.265052%2C%206.153268%5D%2C%20%5B-68.985319%2C%206.206805%5D%2C%20%5B-69.38948%2C%206.099861%5D%2C%20%5B-70.093313%2C%206.960376%5D%2C%20%5B-70.674234%2C%207.087785%5D%2C%20%5B-71.960176%2C%206.991615%5D%2C%20%5B-72.198352%2C%207.340431%5D%2C%20%5B-72.444487%2C%207.423785%5D%2C%20%5B-72.479679%2C%207.632506%5D%2C%20%5B-72.360901%2C%208.002638%5D%2C%20%5B-72.439862%2C%208.405275%5D%2C%20%5B-72.660495%2C%208.625288%5D%2C%20%5B-72.78873%2C%209.085027%5D%2C%20%5B-73.304952%2C%209.152%5D%2C%20%5B-73.027604%2C%209.73677%5D%2C%20%5B-72.905286%2C%2010.450344%5D%2C%20%5B-72.614658%2C%2010.821975%5D%2C%20%5B-72.227575%2C%2011.108702%5D%2C%20%5B-71.973922%2C%2011.608672%5D%2C%20%5B-71.331584%2C%2011.776284%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22VEN%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Venezuela%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B108.05018%2C%2021.55238%5D%2C%20%5B106.715068%2C%2020.696851%5D%2C%20%5B105.881682%2C%2019.75205%5D%2C%20%5B105.662006%2C%2019.058165%5D%2C%20%5B106.426817%2C%2018.004121%5D%2C%20%5B107.361954%2C%2016.697457%5D%2C%20%5B108.269495%2C%2016.079742%5D%2C%20%5B108.877107%2C%2015.276691%5D%2C%20%5B109.33527%2C%2013.426028%5D%2C%20%5B109.200136%2C%2011.666859%5D%2C%20%5B108.36613%2C%2011.008321%5D%2C%20%5B107.220929%2C%2010.364484%5D%2C%20%5B106.405113%2C%209.53084%5D%2C%20%5B105.158264%2C%208.59976%5D%2C%20%5B104.795185%2C%209.241038%5D%2C%20%5B105.076202%2C%209.918491%5D%2C%20%5B104.334335%2C%2010.486544%5D%2C%20%5B105.199915%2C%2010.88931%5D%2C%20%5B106.24967%2C%2010.961812%5D%2C%20%5B105.810524%2C%2011.567615%5D%2C%20%5B107.491403%2C%2012.337206%5D%2C%20%5B107.614548%2C%2013.535531%5D%2C%20%5B107.382727%2C%2014.202441%5D%2C%20%5B107.564525%2C%2015.202173%5D%2C%20%5B107.312706%2C%2015.908538%5D%2C%20%5B106.556008%2C%2016.604284%5D%2C%20%5B105.925762%2C%2017.485315%5D%2C%20%5B105.094598%2C%2018.666975%5D%2C%20%5B103.896532%2C%2019.265181%5D%2C%20%5B104.183388%2C%2019.624668%5D%2C%20%5B104.822574%2C%2019.886642%5D%2C%20%5B104.435%2C%2020.758733%5D%2C%20%5B103.203861%2C%2020.766562%5D%2C%20%5B102.754896%2C%2021.675137%5D%2C%20%5B102.170436%2C%2022.464753%5D%2C%20%5B102.706992%2C%2022.708795%5D%2C%20%5B103.504515%2C%2022.703757%5D%2C%20%5B104.476858%2C%2022.81915%5D%2C%20%5B105.329209%2C%2023.352063%5D%2C%20%5B105.811247%2C%2022.976892%5D%2C%20%5B106.725403%2C%2022.794268%5D%2C%20%5B106.567273%2C%2022.218205%5D%2C%20%5B107.04342%2C%2021.811899%5D%2C%20%5B108.05018%2C%2021.55238%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22VNM%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Vietnam%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B%5B167.844877%2C%20-16.466333%5D%2C%20%5B167.515181%2C%20-16.59785%5D%2C%20%5B167.180008%2C%20-16.159995%5D%2C%20%5B167.216801%2C%20-15.891846%5D%2C%20%5B167.844877%2C%20-16.466333%5D%5D%5D%2C%20%5B%5B%5B167.107712%2C%20-14.93392%5D%2C%20%5B167.270028%2C%20-15.740021%5D%2C%20%5B167.001207%2C%20-15.614602%5D%2C%20%5B166.793158%2C%20-15.668811%5D%2C%20%5B166.649859%2C%20-15.392704%5D%2C%20%5B166.629137%2C%20-14.626497%5D%2C%20%5B167.107712%2C%20-14.93392%5D%5D%5D%5D%2C%20%22type%22%3A%20%22MultiPolygon%22%7D%2C%20%22id%22%3A%20%22VUT%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Vanuatu%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B35.545665%2C%2032.393992%5D%2C%20%5B35.545252%2C%2031.782505%5D%2C%20%5B35.397561%2C%2031.489086%5D%2C%20%5B34.927408%2C%2031.353435%5D%2C%20%5B34.970507%2C%2031.616778%5D%2C%20%5B35.225892%2C%2031.754341%5D%2C%20%5B34.974641%2C%2031.866582%5D%2C%20%5B35.18393%2C%2032.532511%5D%2C%20%5B35.545665%2C%2032.393992%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22PSE%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22West%20Bank%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B53.108573%2C%2016.651051%5D%2C%20%5B52.385206%2C%2016.382411%5D%2C%20%5B52.191729%2C%2015.938433%5D%2C%20%5B52.168165%2C%2015.59742%5D%2C%20%5B51.172515%2C%2015.17525%5D%2C%20%5B49.574576%2C%2014.708767%5D%2C%20%5B48.679231%2C%2014.003202%5D%2C%20%5B48.238947%2C%2013.94809%5D%2C%20%5B47.938914%2C%2014.007233%5D%2C%20%5B47.354454%2C%2013.59222%5D%2C%20%5B46.717076%2C%2013.399699%5D%2C%20%5B45.877593%2C%2013.347764%5D%2C%20%5B45.62505%2C%2013.290946%5D%2C%20%5B45.406459%2C%2013.026905%5D%2C%20%5B45.144356%2C%2012.953938%5D%2C%20%5B44.989533%2C%2012.699587%5D%2C%20%5B44.494576%2C%2012.721653%5D%2C%20%5B44.175113%2C%2012.58595%5D%2C%20%5B43.482959%2C%2012.6368%5D%2C%20%5B43.222871%2C%2013.22095%5D%2C%20%5B43.251448%2C%2013.767584%5D%2C%20%5B43.087944%2C%2014.06263%5D%2C%20%5B42.892245%2C%2014.802249%5D%2C%20%5B42.604873%2C%2015.213335%5D%2C%20%5B42.805015%2C%2015.261963%5D%2C%20%5B42.702438%2C%2015.718886%5D%2C%20%5B42.823671%2C%2015.911742%5D%2C%20%5B42.779332%2C%2016.347891%5D%2C%20%5B43.218375%2C%2016.66689%5D%2C%20%5B43.115798%2C%2017.08844%5D%2C%20%5B43.380794%2C%2017.579987%5D%2C%20%5B43.791519%2C%2017.319977%5D%2C%20%5B44.062613%2C%2017.410359%5D%2C%20%5B45.216651%2C%2017.433329%5D%2C%20%5B45.399999%2C%2017.333335%5D%2C%20%5B46.366659%2C%2017.233315%5D%2C%20%5B46.749994%2C%2017.283338%5D%2C%20%5B47.000005%2C%2016.949999%5D%2C%20%5B47.466695%2C%2017.116682%5D%2C%20%5B48.183344%2C%2018.166669%5D%2C%20%5B49.116672%2C%2018.616668%5D%2C%20%5B52.00001%2C%2019.000003%5D%2C%20%5B52.782184%2C%2017.349742%5D%2C%20%5B53.108573%2C%2016.651051%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22YEM%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Yemen%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B31.521001%2C%20-29.257387%5D%2C%20%5B31.325561%2C%20-29.401978%5D%2C%20%5B30.901763%2C%20-29.909957%5D%2C%20%5B30.622813%2C%20-30.423776%5D%2C%20%5B30.055716%2C%20-31.140269%5D%2C%20%5B28.925553%2C%20-32.172041%5D%2C%20%5B28.219756%2C%20-32.771953%5D%2C%20%5B27.464608%2C%20-33.226964%5D%2C%20%5B26.419452%2C%20-33.61495%5D%2C%20%5B25.909664%2C%20-33.66704%5D%2C%20%5B25.780628%2C%20-33.944646%5D%2C%20%5B25.172862%2C%20-33.796851%5D%2C%20%5B24.677853%2C%20-33.987176%5D%2C%20%5B23.594043%2C%20-33.794474%5D%2C%20%5B22.988189%2C%20-33.916431%5D%2C%20%5B22.574157%2C%20-33.864083%5D%2C%20%5B21.542799%2C%20-34.258839%5D%2C%20%5B20.689053%2C%20-34.417175%5D%2C%20%5B20.071261%2C%20-34.795137%5D%2C%20%5B19.616405%2C%20-34.819166%5D%2C%20%5B19.193278%2C%20-34.462599%5D%2C%20%5B18.855315%2C%20-34.444306%5D%2C%20%5B18.424643%2C%20-33.997873%5D%2C%20%5B18.377411%2C%20-34.136521%5D%2C%20%5B18.244499%2C%20-33.867752%5D%2C%20%5B18.25008%2C%20-33.281431%5D%2C%20%5B17.92519%2C%20-32.611291%5D%2C%20%5B18.24791%2C%20-32.429131%5D%2C%20%5B18.221762%2C%20-31.661633%5D%2C%20%5B17.566918%2C%20-30.725721%5D%2C%20%5B17.064416%2C%20-29.878641%5D%2C%20%5B17.062918%2C%20-29.875954%5D%2C%20%5B16.344977%2C%20-28.576705%5D%2C%20%5B16.824017%2C%20-28.082162%5D%2C%20%5B17.218929%2C%20-28.355943%5D%2C%20%5B17.387497%2C%20-28.783514%5D%2C%20%5B17.836152%2C%20-28.856378%5D%2C%20%5B18.464899%2C%20-29.045462%5D%2C%20%5B19.002127%2C%20-28.972443%5D%2C%20%5B19.894734%2C%20-28.461105%5D%2C%20%5B19.895768%2C%20-24.76779%5D%2C%20%5B20.165726%2C%20-24.917962%5D%2C%20%5B20.758609%2C%20-25.868136%5D%2C%20%5B20.66647%2C%20-26.477453%5D%2C%20%5B20.889609%2C%20-26.828543%5D%2C%20%5B21.605896%2C%20-26.726534%5D%2C%20%5B22.105969%2C%20-26.280256%5D%2C%20%5B22.579532%2C%20-25.979448%5D%2C%20%5B22.824271%2C%20-25.500459%5D%2C%20%5B23.312097%2C%20-25.26869%5D%2C%20%5B23.73357%2C%20-25.390129%5D%2C%20%5B24.211267%2C%20-25.670216%5D%2C%20%5B25.025171%2C%20-25.71967%5D%2C%20%5B25.664666%2C%20-25.486816%5D%2C%20%5B25.765849%2C%20-25.174845%5D%2C%20%5B25.941652%2C%20-24.696373%5D%2C%20%5B26.485753%2C%20-24.616327%5D%2C%20%5B26.786407%2C%20-24.240691%5D%2C%20%5B27.11941%2C%20-23.574323%5D%2C%20%5B28.017236%2C%20-22.827754%5D%2C%20%5B29.432188%2C%20-22.091313%5D%2C%20%5B29.839037%2C%20-22.102216%5D%2C%20%5B30.322883%2C%20-22.271612%5D%2C%20%5B30.659865%2C%20-22.151567%5D%2C%20%5B31.191409%2C%20-22.25151%5D%2C%20%5B31.670398%2C%20-23.658969%5D%2C%20%5B31.930589%2C%20-24.369417%5D%2C%20%5B31.752408%2C%20-25.484284%5D%2C%20%5B31.837778%2C%20-25.843332%5D%2C%20%5B31.333158%2C%20-25.660191%5D%2C%20%5B31.04408%2C%20-25.731452%5D%2C%20%5B30.949667%2C%20-26.022649%5D%2C%20%5B30.676609%2C%20-26.398078%5D%2C%20%5B30.685962%2C%20-26.743845%5D%2C%20%5B31.282773%2C%20-27.285879%5D%2C%20%5B31.86806%2C%20-27.177927%5D%2C%20%5B32.071665%2C%20-26.73382%5D%2C%20%5B32.83012%2C%20-26.742192%5D%2C%20%5B32.580265%2C%20-27.470158%5D%2C%20%5B32.462133%2C%20-28.301011%5D%2C%20%5B32.203389%2C%20-28.752405%5D%2C%20%5B31.521001%2C%20-29.257387%5D%5D%2C%20%5B%5B28.978263%2C%20-28.955597%5D%2C%20%5B28.5417%2C%20-28.647502%5D%2C%20%5B28.074338%2C%20-28.851469%5D%2C%20%5B27.532511%2C%20-29.242711%5D%2C%20%5B26.999262%2C%20-29.875954%5D%2C%20%5B27.749397%2C%20-30.645106%5D%2C%20%5B28.107205%2C%20-30.545732%5D%2C%20%5B28.291069%2C%20-30.226217%5D%2C%20%5B28.8484%2C%20-30.070051%5D%2C%20%5B29.018415%2C%20-29.743766%5D%2C%20%5B29.325166%2C%20-29.257387%5D%2C%20%5B28.978263%2C%20-28.955597%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ZAF%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22South%20Africa%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B32.759375%2C%20-9.230599%5D%2C%20%5B33.231388%2C%20-9.676722%5D%2C%20%5B33.485688%2C%20-10.525559%5D%2C%20%5B33.31531%2C%20-10.79655%5D%2C%20%5B33.114289%2C%20-11.607198%5D%2C%20%5B33.306422%2C%20-12.435778%5D%2C%20%5B32.991764%2C%20-12.783871%5D%2C%20%5B32.688165%2C%20-13.712858%5D%2C%20%5B33.214025%2C%20-13.97186%5D%2C%20%5B30.179481%2C%20-14.796099%5D%2C%20%5B30.274256%2C%20-15.507787%5D%2C%20%5B29.516834%2C%20-15.644678%5D%2C%20%5B28.947463%2C%20-16.043051%5D%2C%20%5B28.825869%2C%20-16.389749%5D%2C%20%5B28.467906%2C%20-16.4684%5D%2C%20%5B27.598243%2C%20-17.290831%5D%2C%20%5B27.044427%2C%20-17.938026%5D%2C%20%5B26.706773%2C%20-17.961229%5D%2C%20%5B26.381935%2C%20-17.846042%5D%2C%20%5B25.264226%2C%20-17.73654%5D%2C%20%5B25.084443%2C%20-17.661816%5D%2C%20%5B25.07695%2C%20-17.578823%5D%2C%20%5B24.682349%2C%20-17.353411%5D%2C%20%5B24.033862%2C%20-17.295843%5D%2C%20%5B23.215048%2C%20-17.523116%5D%2C%20%5B22.562478%2C%20-16.898451%5D%2C%20%5B21.887843%2C%20-16.08031%5D%2C%20%5B21.933886%2C%20-12.898437%5D%2C%20%5B24.016137%2C%20-12.911046%5D%2C%20%5B23.930922%2C%20-12.565848%5D%2C%20%5B24.079905%2C%20-12.191297%5D%2C%20%5B23.904154%2C%20-11.722282%5D%2C%20%5B24.017894%2C%20-11.237298%5D%2C%20%5B23.912215%2C%20-10.926826%5D%2C%20%5B24.257155%2C%20-10.951993%5D%2C%20%5B24.314516%2C%20-11.262826%5D%2C%20%5B24.78317%2C%20-11.238694%5D%2C%20%5B25.418118%2C%20-11.330936%5D%2C%20%5B25.75231%2C%20-11.784965%5D%2C%20%5B26.553088%2C%20-11.92444%5D%2C%20%5B27.16442%2C%20-11.608748%5D%2C%20%5B27.388799%2C%20-12.132747%5D%2C%20%5B28.155109%2C%20-12.272481%5D%2C%20%5B28.523562%2C%20-12.698604%5D%2C%20%5B28.934286%2C%20-13.248958%5D%2C%20%5B29.699614%2C%20-13.257227%5D%2C%20%5B29.616001%2C%20-12.178895%5D%2C%20%5B29.341548%2C%20-12.360744%5D%2C%20%5B28.642417%2C%20-11.971569%5D%2C%20%5B28.372253%2C%20-11.793647%5D%2C%20%5B28.49607%2C%20-10.789884%5D%2C%20%5B28.673682%2C%20-9.605925%5D%2C%20%5B28.449871%2C%20-9.164918%5D%2C%20%5B28.734867%2C%20-8.526559%5D%2C%20%5B29.002912%2C%20-8.407032%5D%2C%20%5B30.346086%2C%20-8.238257%5D%2C%20%5B30.740015%2C%20-8.340007%5D%2C%20%5B31.157751%2C%20-8.594579%5D%2C%20%5B31.556348%2C%20-8.762049%5D%2C%20%5B32.191865%2C%20-8.930359%5D%2C%20%5B32.759375%2C%20-9.230599%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ZMB%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Zambia%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%2C%20%7B%22geometry%22%3A%20%7B%22coordinates%22%3A%20%5B%5B%5B31.191409%2C%20-22.25151%5D%2C%20%5B30.659865%2C%20-22.151567%5D%2C%20%5B30.322883%2C%20-22.271612%5D%2C%20%5B29.839037%2C%20-22.102216%5D%2C%20%5B29.432188%2C%20-22.091313%5D%2C%20%5B28.794656%2C%20-21.639454%5D%2C%20%5B28.02137%2C%20-21.485975%5D%2C%20%5B27.727228%2C%20-20.851802%5D%2C%20%5B27.724747%2C%20-20.499059%5D%2C%20%5B27.296505%2C%20-20.39152%5D%2C%20%5B26.164791%2C%20-19.293086%5D%2C%20%5B25.850391%2C%20-18.714413%5D%2C%20%5B25.649163%2C%20-18.536026%5D%2C%20%5B25.264226%2C%20-17.73654%5D%2C%20%5B26.381935%2C%20-17.846042%5D%2C%20%5B26.706773%2C%20-17.961229%5D%2C%20%5B27.044427%2C%20-17.938026%5D%2C%20%5B27.598243%2C%20-17.290831%5D%2C%20%5B28.467906%2C%20-16.4684%5D%2C%20%5B28.825869%2C%20-16.389749%5D%2C%20%5B28.947463%2C%20-16.043051%5D%2C%20%5B29.516834%2C%20-15.644678%5D%2C%20%5B30.274256%2C%20-15.507787%5D%2C%20%5B30.338955%2C%20-15.880839%5D%2C%20%5B31.173064%2C%20-15.860944%5D%2C%20%5B31.636498%2C%20-16.07199%5D%2C%20%5B31.852041%2C%20-16.319417%5D%2C%20%5B32.328239%2C%20-16.392074%5D%2C%20%5B32.847639%2C%20-16.713398%5D%2C%20%5B32.849861%2C%20-17.979057%5D%2C%20%5B32.654886%2C%20-18.67209%5D%2C%20%5B32.611994%2C%20-19.419383%5D%2C%20%5B32.772708%2C%20-19.715592%5D%2C%20%5B32.659743%2C%20-20.30429%5D%2C%20%5B32.508693%2C%20-20.395292%5D%2C%20%5B32.244988%2C%20-21.116489%5D%2C%20%5B31.191409%2C%20-22.25151%5D%5D%5D%2C%20%22type%22%3A%20%22Polygon%22%7D%2C%20%22id%22%3A%20%22ZWE%22%2C%20%22properties%22%3A%20%7B%22name%22%3A%20%22Zimbabwe%22%7D%2C%20%22type%22%3A%20%22Feature%22%7D%5D%2C%20%22type%22%3A%20%22FeatureCollection%22%7D%29%3B%0A%0A%20%20%20%20%20%20%20%20%0A%20%20%20%20%0A%20%20%20%20geo_json_70014295e18e4bfc98d118a4cf48986b.bindTooltip%28%0A%20%20%20%20function%28layer%29%7B%0A%20%20%20%20let%20div%20%3D%20L.DomUtil.create%28%27div%27%29%3B%0A%20%20%20%20%0A%20%20%20%20let%20handleObject%20%3D%20feature%3D%3Etypeof%28feature%29%3D%3D%27object%27%20%3F%20JSON.stringify%28feature%29%20%3A%20feature%3B%0A%20%20%20%20let%20fields%20%3D%20%5B%22name%22%5D%3B%0A%20%20%20%20let%20aliases%20%3D%20%5B%22name%22%5D%3B%0A%20%20%20%20let%20table%20%3D%20%27%3Ctable%3E%27%20%2B%0A%20%20%20%20%20%20%20%20String%28%0A%20%20%20%20%20%20%20%20fields.map%28%0A%20%20%20%20%20%20%20%20%28v%2Ci%29%3D%3E%0A%20%20%20%20%20%20%20%20%60%3Ctr%3E%0A%20%20%20%20%20%20%20%20%20%20%20%20%3Ctd%3E%24%7BhandleObject%28layer.feature.properties%5Bv%5D%29%7D%3C/td%3E%0A%20%20%20%20%20%20%20%20%3C/tr%3E%60%29.join%28%27%27%29%29%0A%20%20%20%20%2B%27%3C/table%3E%27%3B%0A%20%20%20%20div.innerHTML%3Dtable%3B%0A%20%20%20%20%0A%20%20%20%20return%20div%0A%20%20%20%20%7D%0A%20%20%20%20%2C%7B%22className%22%3A%20%22foliumtooltip%22%2C%20%22sticky%22%3A%20true%7D%29%3B%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%0A%20%20%20%20%0A%20%20%20%20var%20color_map_8e9309acf8b2421c8c361164966cf52d%20%3D%20%7B%7D%3B%0A%0A%20%20%20%20%0A%20%20%20%20color_map_8e9309acf8b2421c8c361164966cf52d.color%20%3D%20d3.scale.threshold%28%29%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20.domain%28%5B1.0%2C%201.0761523046092185%2C%201.1523046092184368%2C%201.2284569138276553%2C%201.3046092184368738%2C%201.3807615230460921%2C%201.4569138276553106%2C%201.533066132264529%2C%201.6092184368737477%2C%201.685370741482966%2C%201.7615230460921842%2C%201.8376753507014028%2C%201.9138276553106213%2C%201.9899799599198396%2C%202.066132264529058%2C%202.1422845691382766%2C%202.2184368737474953%2C%202.2945891783567136%2C%202.370741482965932%2C%202.44689378757515%2C%202.5230460921843685%2C%202.599198396793587%2C%202.6753507014028055%2C%202.7515030060120242%2C%202.8276553106212425%2C%202.903807615230461%2C%202.979959919839679%2C%203.056112224448898%2C%203.132264529058116%2C%203.208416833667335%2C%203.284569138276553%2C%203.3607214428857715%2C%203.43687374749499%2C%203.5130260521042085%2C%203.5891783567134268%2C%203.6653306613226455%2C%203.741482965931864%2C%203.817635270541082%2C%203.8937875751503004%2C%203.969939879759519%2C%204.046092184368737%2C%204.122244488977955%2C%204.198396793587174%2C%204.274549098196393%2C%204.350701402805611%2C%204.42685370741483%2C%204.5030060120240485%2C%204.579158316633267%2C%204.655310621242485%2C%204.731462925851703%2C%204.807615230460922%2C%204.88376753507014%2C%204.959919839679358%2C%205.036072144288577%2C%205.112224448897796%2C%205.188376753507014%2C%205.264529058116232%2C%205.340681362725451%2C%205.41683366733467%2C%205.492985971943888%2C%205.569138276553106%2C%205.645290581162325%2C%205.721442885771543%2C%205.797595190380761%2C%205.87374749498998%2C%205.949899799599199%2C%206.026052104208417%2C%206.102204408817635%2C%206.1783567134268536%2C%206.254509018036072%2C%206.330661322645291%2C%206.406813627254509%2C%206.482965931863728%2C%206.559118236472946%2C%206.635270541082164%2C%206.7114228456913825%2C%206.787575150300601%2C%206.86372745490982%2C%206.939879759519038%2C%207.0160320641282565%2C%207.092184368737475%2C%207.168336673346693%2C%207.244488977955911%2C%207.320641282565131%2C%207.396793587174349%2C%207.472945891783567%2C%207.5490981963927855%2C%207.625250501002004%2C%207.701402805611222%2C%207.777555110220441%2C%207.8537074148296595%2C%207.929859719438878%2C%208.006012024048097%2C%208.082164328657313%2C%208.158316633266534%2C%208.234468937875752%2C%208.31062124248497%2C%208.386773547094188%2C%208.462925851703407%2C%208.539078156312625%2C%208.615230460921843%2C%208.691382765531063%2C%208.76753507014028%2C%208.8436873747495%2C%208.919839679358716%2C%208.995991983967937%2C%209.072144288577155%2C%209.148296593186373%2C%209.224448897795591%2C%209.30060120240481%2C%209.376753507014028%2C%209.452905811623246%2C%209.529058116232465%2C%209.605210420841683%2C%209.681362725450901%2C%209.75751503006012%2C%209.83366733466934%2C%209.909819639278558%2C%209.985971943887776%2C%2010.062124248496994%2C%2010.138276553106213%2C%2010.214428857715431%2C%2010.29058116232465%2C%2010.366733466933868%2C%2010.442885771543086%2C%2010.519038076152304%2C%2010.595190380761522%2C%2010.67134268537074%2C%2010.74749498997996%2C%2010.823647294589179%2C%2010.899799599198397%2C%2010.975951903807616%2C%2011.052104208416834%2C%2011.128256513026052%2C%2011.20440881763527%2C%2011.280561122244489%2C%2011.356713426853707%2C%2011.432865731462925%2C%2011.509018036072144%2C%2011.585170340681362%2C%2011.661322645290582%2C%2011.7374749498998%2C%2011.813627254509019%2C%2011.889779559118237%2C%2011.965931863727455%2C%2012.042084168336673%2C%2012.118236472945892%2C%2012.19438877755511%2C%2012.270541082164328%2C%2012.346693386773547%2C%2012.422845691382765%2C%2012.498997995991983%2C%2012.575150300601202%2C%2012.651302605210422%2C%2012.72745490981964%2C%2012.803607214428858%2C%2012.879759519038076%2C%2012.955911823647295%2C%2013.032064128256513%2C%2013.108216432865731%2C%2013.18436873747495%2C%2013.260521042084168%2C%2013.336673346693386%2C%2013.412825651302605%2C%2013.488977955911823%2C%2013.565130260521043%2C%2013.641282565130261%2C%2013.71743486973948%2C%2013.793587174348698%2C%2013.869739478957916%2C%2013.945891783567134%2C%2014.022044088176353%2C%2014.098196392785571%2C%2014.17434869739479%2C%2014.250501002004007%2C%2014.326653306613226%2C%2014.402805611222444%2C%2014.478957915831664%2C%2014.555110220440882%2C%2014.6312625250501%2C%2014.707414829659319%2C%2014.783567134268537%2C%2014.859719438877756%2C%2014.935871743486974%2C%2015.012024048096192%2C%2015.08817635270541%2C%2015.164328657314629%2C%2015.240480961923847%2C%2015.316633266533065%2C%2015.392785571142285%2C%2015.468937875751504%2C%2015.545090180360722%2C%2015.62124248496994%2C%2015.697394789579159%2C%2015.773547094188377%2C%2015.849699398797595%2C%2015.925851703406813%2C%2016.00200400801603%2C%2016.07815631262525%2C%2016.15430861723447%2C%2016.230460921843687%2C%2016.306613226452907%2C%2016.382765531062127%2C%2016.458917835671343%2C%2016.53507014028056%2C%2016.61122244488978%2C%2016.687374749499%2C%2016.763527054108216%2C%2016.839679358717433%2C%2016.915831663326653%2C%2016.991983967935873%2C%2017.06813627254509%2C%2017.14428857715431%2C%2017.220440881763526%2C%2017.296593186372746%2C%2017.372745490981963%2C%2017.448897795591183%2C%2017.5250501002004%2C%2017.60120240480962%2C%2017.677354709418836%2C%2017.753507014028056%2C%2017.829659318637276%2C%2017.905811623246493%2C%2017.981963927855713%2C%2018.05811623246493%2C%2018.13426853707415%2C%2018.210420841683366%2C%2018.286573146292586%2C%2018.362725450901802%2C%2018.438877755511022%2C%2018.51503006012024%2C%2018.59118236472946%2C%2018.66733466933868%2C%2018.743486973947896%2C%2018.819639278557116%2C%2018.895791583166332%2C%2018.971943887775552%2C%2019.04809619238477%2C%2019.12424849699399%2C%2019.200400801603205%2C%2019.276553106212425%2C%2019.352705410821642%2C%2019.428857715430862%2C%2019.50501002004008%2C%2019.5811623246493%2C%2019.65731462925852%2C%2019.733466933867735%2C%2019.809619238476955%2C%2019.88577154308617%2C%2019.96192384769539%2C%2020.03807615230461%2C%2020.11422845691383%2C%2020.190380761523045%2C%2020.266533066132265%2C%2020.34268537074148%2C%2020.4188376753507%2C%2020.49498997995992%2C%2020.571142284569138%2C%2020.647294589178358%2C%2020.723446893787575%2C%2020.799599198396795%2C%2020.87575150300601%2C%2020.95190380761523%2C%2021.028056112224448%2C%2021.104208416833668%2C%2021.180360721442884%2C%2021.256513026052104%2C%2021.33266533066132%2C%2021.40881763527054%2C%2021.48496993987976%2C%2021.561122244488978%2C%2021.637274549098198%2C%2021.713426853707414%2C%2021.789579158316634%2C%2021.86573146292585%2C%2021.94188376753507%2C%2022.018036072144287%2C%2022.094188376753507%2C%2022.170340681362724%2C%2022.246492985971944%2C%2022.322645290581164%2C%2022.39879759519038%2C%2022.4749498997996%2C%2022.551102204408817%2C%2022.627254509018037%2C%2022.703406813627254%2C%2022.779559118236474%2C%2022.85571142284569%2C%2022.93186372745491%2C%2023.008016032064127%2C%2023.084168336673347%2C%2023.160320641282564%2C%2023.236472945891784%2C%2023.312625250501004%2C%2023.38877755511022%2C%2023.46492985971944%2C%2023.541082164328657%2C%2023.617234468937877%2C%2023.693386773547093%2C%2023.769539078156313%2C%2023.84569138276553%2C%2023.92184368737475%2C%2023.997995991983966%2C%2024.074148296593187%2C%2024.150300601202403%2C%2024.226452905811623%2C%2024.302605210420843%2C%2024.37875751503006%2C%2024.45490981963928%2C%2024.531062124248496%2C%2024.607214428857716%2C%2024.683366733466933%2C%2024.759519038076153%2C%2024.83567134268537%2C%2024.91182364729459%2C%2024.987975951903806%2C%2025.064128256513026%2C%2025.140280561122246%2C%2025.216432865731463%2C%2025.292585170340683%2C%2025.3687374749499%2C%2025.44488977955912%2C%2025.521042084168336%2C%2025.597194388777556%2C%2025.673346693386772%2C%2025.749498997995993%2C%2025.82565130260521%2C%2025.90180360721443%2C%2025.977955911823646%2C%2026.054108216432866%2C%2026.130260521042086%2C%2026.206412825651302%2C%2026.282565130260522%2C%2026.35871743486974%2C%2026.43486973947896%2C%2026.511022044088175%2C%2026.587174348697395%2C%2026.663326653306612%2C%2026.739478957915832%2C%2026.81563126252505%2C%2026.89178356713427%2C%2026.96793587174349%2C%2027.044088176352705%2C%2027.120240480961925%2C%2027.196392785571142%2C%2027.272545090180362%2C%2027.34869739478958%2C%2027.4248496993988%2C%2027.501002004008015%2C%2027.577154308617235%2C%2027.65330661322645%2C%2027.72945891783567%2C%2027.805611222444888%2C%2027.881763527054108%2C%2027.95791583166333%2C%2028.034068136272545%2C%2028.110220440881765%2C%2028.18637274549098%2C%2028.2625250501002%2C%2028.338677354709418%2C%2028.414829659318638%2C%2028.490981963927855%2C%2028.567134268537075%2C%2028.64328657314629%2C%2028.71943887775551%2C%2028.795591182364728%2C%2028.871743486973948%2C%2028.947895791583168%2C%2029.024048096192384%2C%2029.100200400801604%2C%2029.17635270541082%2C%2029.25250501002004%2C%2029.328657314629258%2C%2029.404809619238478%2C%2029.480961923847694%2C%2029.557114228456914%2C%2029.63326653306613%2C%2029.70941883767535%2C%2029.78557114228457%2C%2029.861723446893787%2C%2029.937875751503007%2C%2030.014028056112224%2C%2030.090180360721444%2C%2030.16633266533066%2C%2030.24248496993988%2C%2030.318637274549097%2C%2030.394789579158317%2C%2030.470941883767534%2C%2030.547094188376754%2C%2030.62324649298597%2C%2030.69939879759519%2C%2030.77555110220441%2C%2030.851703406813627%2C%2030.927855711422847%2C%2031.004008016032063%2C%2031.080160320641284%2C%2031.1563126252505%2C%2031.23246492985972%2C%2031.308617234468937%2C%2031.384769539078157%2C%2031.460921843687373%2C%2031.537074148296593%2C%2031.613226452905813%2C%2031.68937875751503%2C%2031.76553106212425%2C%2031.841683366733466%2C%2031.917835671342687%2C%2031.993987975951903%2C%2032.07014028056112%2C%2032.14629258517034%2C%2032.22244488977956%2C%2032.298597194388776%2C%2032.374749498998%2C%2032.45090180360721%2C%2032.52705410821643%2C%2032.60320641282566%2C%2032.679358717434866%2C%2032.75551102204409%2C%2032.831663326653306%2C%2032.90781563126252%2C%2032.983967935871746%2C%2033.06012024048096%2C%2033.13627254509018%2C%2033.212424849699396%2C%2033.28857715430862%2C%2033.364729458917836%2C%2033.44088176352705%2C%2033.517034068136276%2C%2033.59318637274549%2C%2033.66933867735471%2C%2033.745490981963925%2C%2033.82164328657315%2C%2033.897795591182366%2C%2033.97394789579158%2C%2034.0501002004008%2C%2034.12625250501002%2C%2034.20240480961924%2C%2034.278557114228455%2C%2034.35470941883767%2C%2034.430861723446895%2C%2034.50701402805611%2C%2034.58316633266533%2C%2034.65931863727455%2C%2034.73547094188377%2C%2034.811623246492985%2C%2034.8877755511022%2C%2034.963927855711425%2C%2035.04008016032064%2C%2035.11623246492986%2C%2035.192384769539075%2C%2035.2685370741483%2C%2035.344689378757515%2C%2035.42084168336673%2C%2035.496993987975955%2C%2035.57314629258517%2C%2035.64929859719439%2C%2035.725450901803605%2C%2035.80160320641283%2C%2035.877755511022045%2C%2035.95390781563126%2C%2036.03006012024048%2C%2036.1062124248497%2C%2036.18236472945892%2C%2036.258517034068134%2C%2036.33466933867736%2C%2036.410821643286575%2C%2036.48697394789579%2C%2036.56312625250501%2C%2036.63927855711423%2C%2036.71543086172345%2C%2036.791583166332664%2C%2036.86773547094188%2C%2036.943887775551104%2C%2037.02004008016032%2C%2037.09619238476954%2C%2037.17234468937876%2C%2037.24849699398798%2C%2037.324649298597194%2C%2037.40080160320641%2C%2037.476953907815634%2C%2037.55310621242485%2C%2037.62925851703407%2C%2037.705410821643284%2C%2037.78156312625251%2C%2037.857715430861724%2C%2037.93386773547094%2C%2038.01002004008016%2C%2038.08617234468938%2C%2038.1623246492986%2C%2038.23847695390781%2C%2038.31462925851704%2C%2038.390781563126254%2C%2038.46693386773547%2C%2038.54308617234469%2C%2038.61923847695391%2C%2038.69539078156313%2C%2038.77154308617234%2C%2038.84769539078156%2C%2038.92384769539078%2C%2039.0%5D%29%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20.range%28%5B%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23ffffb2ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23fed976ff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23feb24cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23fd8d3cff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23f03b20ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%2C%20%27%23bd0026ff%27%5D%29%3B%0A%20%20%20%20%0A%0A%20%20%20%20color_map_8e9309acf8b2421c8c361164966cf52d.x%20%3D%20d3.scale.linear%28%29%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20.domain%28%5B1.0%2C%2039.0%5D%29%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20.range%28%5B0%2C%20400%5D%29%3B%0A%0A%20%20%20%20color_map_8e9309acf8b2421c8c361164966cf52d.legend%20%3D%20L.control%28%7Bposition%3A%20%27topright%27%7D%29%3B%0A%20%20%20%20color_map_8e9309acf8b2421c8c361164966cf52d.legend.onAdd%20%3D%20function%20%28map%29%20%7Bvar%20div%20%3D%20L.DomUtil.create%28%27div%27%2C%20%27legend%27%29%3B%20return%20div%7D%3B%0A%20%20%20%20color_map_8e9309acf8b2421c8c361164966cf52d.legend.addTo%28map_aa62a99e890e45728843666414ba6b9f%29%3B%0A%0A%20%20%20%20color_map_8e9309acf8b2421c8c361164966cf52d.xAxis%20%3D%20d3.svg.axis%28%29%0A%20%20%20%20%20%20%20%20.scale%28color_map_8e9309acf8b2421c8c361164966cf52d.x%29%0A%20%20%20%20%20%20%20%20.orient%28%22top%22%29%0A%20%20%20%20%20%20%20%20.tickSize%281%29%0A%20%20%20%20%20%20%20%20.tickValues%28%5B1.0%2C%207.333333333333333%2C%2013.666666666666666%2C%2020.0%2C%2026.333333333333332%2C%2032.666666666666664%2C%2039.0%5D%29%3B%0A%0A%20%20%20%20color_map_8e9309acf8b2421c8c361164966cf52d.svg%20%3D%20d3.select%28%22.legend.leaflet-control%22%29.append%28%22svg%22%29%0A%20%20%20%20%20%20%20%20.attr%28%22id%22%2C%20%27legend%27%29%0A%20%20%20%20%20%20%20%20.attr%28%22width%22%2C%20450%29%0A%20%20%20%20%20%20%20%20.attr%28%22height%22%2C%2040%29%3B%0A%0A%20%20%20%20color_map_8e9309acf8b2421c8c361164966cf52d.g%20%3D%20color_map_8e9309acf8b2421c8c361164966cf52d.svg.append%28%22g%22%29%0A%20%20%20%20%20%20%20%20.attr%28%22class%22%2C%20%22key%22%29%0A%20%20%20%20%20%20%20%20.attr%28%22transform%22%2C%20%22translate%2825%2C16%29%22%29%3B%0A%0A%20%20%20%20color_map_8e9309acf8b2421c8c361164966cf52d.g.selectAll%28%22rect%22%29%0A%20%20%20%20%20%20%20%20.data%28color_map_8e9309acf8b2421c8c361164966cf52d.color.range%28%29.map%28function%28d%2C%20i%29%20%7B%0A%20%20%20%20%20%20%20%20%20%20return%20%7B%0A%20%20%20%20%20%20%20%20%20%20%20%20x0%3A%20i%20%3F%20color_map_8e9309acf8b2421c8c361164966cf52d.x%28color_map_8e9309acf8b2421c8c361164966cf52d.color.domain%28%29%5Bi%20-%201%5D%29%20%3A%20color_map_8e9309acf8b2421c8c361164966cf52d.x.range%28%29%5B0%5D%2C%0A%20%20%20%20%20%20%20%20%20%20%20%20x1%3A%20i%20%3C%20color_map_8e9309acf8b2421c8c361164966cf52d.color.domain%28%29.length%20%3F%20color_map_8e9309acf8b2421c8c361164966cf52d.x%28color_map_8e9309acf8b2421c8c361164966cf52d.color.domain%28%29%5Bi%5D%29%20%3A%20color_map_8e9309acf8b2421c8c361164966cf52d.x.range%28%29%5B1%5D%2C%0A%20%20%20%20%20%20%20%20%20%20%20%20z%3A%20d%0A%20%20%20%20%20%20%20%20%20%20%7D%3B%0A%20%20%20%20%20%20%20%20%7D%29%29%0A%20%20%20%20%20%20.enter%28%29.append%28%22rect%22%29%0A%20%20%20%20%20%20%20%20.attr%28%22height%22%2C%2010%29%0A%20%20%20%20%20%20%20%20.attr%28%22x%22%2C%20function%28d%29%20%7B%20return%20d.x0%3B%20%7D%29%0A%20%20%20%20%20%20%20%20.attr%28%22width%22%2C%20function%28d%29%20%7B%20return%20d.x1%20-%20d.x0%3B%20%7D%29%0A%20%20%20%20%20%20%20%20.style%28%22fill%22%2C%20function%28d%29%20%7B%20return%20d.z%3B%20%7D%29%3B%0A%0A%20%20%20%20color_map_8e9309acf8b2421c8c361164966cf52d.g.call%28color_map_8e9309acf8b2421c8c361164966cf52d.xAxis%29.append%28%22text%22%29%0A%20%20%20%20%20%20%20%20.attr%28%22class%22%2C%20%22caption%22%29%0A%20%20%20%20%20%20%20%20.attr%28%22y%22%2C%2021%29%0A%20%20%20%20%20%20%20%20.text%28%27COVID19%20Vaccine%20Clinical%20Trials%27%29%3B%0A%3C/script%3E onload=\"this.contentDocument.open();this.contentDocument.write(    decodeURIComponent(this.getAttribute('data-html')));this.contentDocument.close();\" allowfullscreen webkitallowfullscreen mozallowfullscreen></iframe></div></div>"
      ],
      "text/plain": [
       "<folium.folium.Map at 0x7feddcc52cd0>"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# plot the clinical trials on a map\n",
    "map_ = folium.Map(location=[30, 0], zoom_start=1.5, tiles = 'cartodbpositron')\n",
    "\n",
    "choro = folium.Choropleth(geo_data=wc,\n",
    "                data=country_count,\n",
    "                columns=['LocationCountry', 'Count'],\n",
    "                key_on='feature.properties.name',\n",
    "                fill_color='YlOrRd',\n",
    "                fill_opacity=0.8,\n",
    "                line_opacity=0.2,\n",
    "                nan_fill_opacity = 0,\n",
    "                legend_name='COVID19 Vaccine Clinical Trials'\n",
    "                ).add_to(map_)\n",
    "choro.geojson.add_child(folium.features.GeoJsonTooltip(fields = ['name', ], labels=False))\n",
    "\n",
    "map_"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "_*Countries without coloring: there's no clinical trials related to COVID19 vaccines, or the data is unavailable on clinicaltrials.gov._\n",
    "\n",
    "It can be found that US has the larget number of trials for COVID19 vaccine. However, the result can be biased as the source data was taken from clinicaltrials.gov, which is governed under US National Institutes of Health. It is not compulsory for clinical trials to be registered on this website in the States, and the clinical trials conducted purely outside of the States have an even lower probability of registration.\n",
    "\n",
    "## 4. Conclusion\n",
    "\n",
    "As shown in the previous sections, since the pandemic has striken last year, clinical trials on COVID19 vaccine has been conducted actively around the globe. Few vaccines have been approved and launched since Q4 2020, thanks to the good result from these clinical trials. With the large number of trials in mid-to-late phase of the clinical trial cycle, it is promising that more vaccines will be launched in the future with a wider accessibility to the population globally."
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
